data_2f52_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2f52 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.452 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 59.6 mt . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 78.1 mt-10 -130.62 143.52 50.81 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.283 -0.886 . . . . 0.0 109.203 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.524 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -152.06 156.09 26.5 Favored Glycine 0 N--CA 1.488 2.123 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -100.99 135.21 42.81 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.312 -1.111 . . . . 0.0 108.744 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.407 HG11 ' HA ' ' A' ' 43' ' ' GLU . 33.9 t -66.55 119.22 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.123 -0.986 . . . . 0.0 110.01 -179.424 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.502 ' N ' ' O ' ' A' ' 17' ' ' PHE . 5.9 tptm -79.48 -40.96 28.53 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.425 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.652 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -159.98 166.95 29.03 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 179.785 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.643 ' N ' ' CD2' ' A' ' 8' ' ' TRP . 17.1 p90 -158.76 147.39 18.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.943 -1.098 . . . . 0.0 110.574 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.622 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 13.9 t-20 . . . . . 0 N--CA 1.491 1.618 0 O-C-N 121.412 -0.805 . . . . 0.0 109.353 179.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.621 ' CE1' ' HB3' ' A' ' 10' ' ' ASN . 3.1 p90 . . . . . 0 N--CA 1.488 1.452 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.652 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -161.07 160.86 32.45 Favored Glycine 0 N--CA 1.486 2.018 0 C-N-CA 119.598 -1.286 . . . . 0.0 110.044 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.504 ' CD1' ' HB2' ' A' ' 27' ' ' PHE . 98.0 m-85 -90.74 139.37 30.79 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.488 -1.007 . . . . 0.0 108.719 179.492 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.583 ' CD1' ' CG2' ' A' ' 47' ' ' VAL . 19.7 mt -113.25 159.28 13.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.582 -0.699 . . . . 0.0 109.222 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.467 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 65.7 tt0 -114.27 109.52 18.51 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.225 -0.922 . . . . 0.0 109.464 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.439 HG22 HG23 ' A' ' 26' ' ' VAL . 2.7 t -90.74 109.48 20.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.199 -0.938 . . . . 0.0 109.206 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 74.3 mm-40 -59.22 108.87 0.75 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.214 -0.929 . . . . 0.0 109.267 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.9 -35.62 3.48 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.496 ' OE1' HD13 ' A' ' 51' ' ' ILE . 46.7 mt-30 -117.95 160.92 20.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -1.155 . . . . 0.0 109.362 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.447 ' O ' ' O ' ' A' ' 23' ' ' GLN . 44.5 m-20 -52.92 -174.19 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.253 -0.904 . . . . 0.0 109.514 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.479 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 80.8 m-20 -74.31 139.45 44.21 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.299 -0.876 . . . . 0.0 109.647 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.439 HG23 HG22 ' A' ' 20' ' ' VAL . 91.8 t -114.39 119.87 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.306 -0.871 . . . . 0.0 109.529 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.514 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.0 OUTLIER -77.17 155.75 32.05 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.111 -0.993 . . . . 0.0 109.396 -179.965 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.561 ' O ' ' HB2' ' A' ' 15' ' ' PHE . 10.8 t -131.09 138.5 53.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.294 -0.879 . . . . 0.0 109.434 -179.652 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.58 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 12.9 t-80 -112.21 149.93 31.58 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.094 -1.004 . . . . 0.0 109.581 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.699 ' CG ' ' N ' ' A' ' 31' ' ' SER . 1.2 p90 -46.88 -53.99 10.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.152 -0.968 . . . . 0.0 109.672 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.699 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 21.0 t -59.56 -20.85 58.58 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.024 -1.048 . . . . 0.0 109.907 -179.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.551 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -77.77 -12.66 60.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.157 -0.964 . . . . 0.0 109.414 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.656 ' CG2' HG13 ' A' ' 63' ' ' VAL . 3.0 mt . . . . . 0 N--CA 1.489 1.491 0 O-C-N 121.435 -0.79 . . . . 0.0 109.82 -179.66 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.613 ' CD1' ' CD1' ' A' ' 33' ' ' ILE . 4.3 mp . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.331 0.586 . . . . 0.0 109.84 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.451 ' O ' ' C ' ' A' ' 43' ' ' GLU . 58.5 tt0 -93.91 119.72 33.21 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.407 -0.808 . . . . 0.0 109.084 179.629 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.451 ' C ' ' O ' ' A' ' 42' ' ' GLU . 53.4 tt0 -41.13 131.38 2.65 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.284 -0.885 . . . . 0.0 109.553 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 89.69 -3.95 83.47 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 52.1 tt0 -80.81 128.18 33.37 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.171 -1.194 . . . . 0.0 109.466 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.503 ' O ' HG11 ' A' ' 47' ' ' VAL . . . -79.9 143.36 34.33 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.27 -0.894 . . . . 0.0 109.055 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.583 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 28.9 m -147.84 171.41 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.196 -0.94 . . . . 0.0 109.678 -179.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.64 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 34.7 t -116.3 156.46 26.61 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.308 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.583 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 17.0 p90 172.81 166.78 0.13 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.894 -1.129 . . . . 0.0 110.488 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -108.82 154.28 22.32 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.496 HD13 ' OE1' ' A' ' 23' ' ' GLN . 1.9 mt -87.73 122.85 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 120.863 -1.148 . . . . 0.0 110.069 -179.433 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.608 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 26.8 m -110.72 128.29 67.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 178.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -68.63 120.05 14.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.084 -1.01 . . . . 0.0 109.838 -179.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -128.02 162.57 21.81 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.761 -1.335 . . . . 0.0 109.761 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -51.78 -60.22 3.42 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.241 -1.153 . . . . 0.0 109.493 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 82.2 mtp180 -51.0 -33.16 23.65 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.274 -0.891 . . . . 0.0 109.184 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 144.84 -146.12 16.18 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.434 -1.466 . . . . 0.0 109.434 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.479 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 45.8 Cg_endo -69.35 127.99 15.74 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.781 2.321 . . . . 0.0 111.793 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.608 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 84.8 mt-30 -121.99 156.21 33.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.188 -0.945 . . . . 0.0 109.265 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.464 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -88.35 127.76 35.49 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.159 -0.963 . . . . 0.0 110.088 -179.336 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.515 ' HB3' ' CG1' ' A' ' 52' ' ' VAL . . . -108.71 150.47 27.52 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.322 -0.861 . . . . 0.0 108.887 179.37 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.487 ' C ' ' O ' ' A' ' 61' ' ' ALA . 36.8 t-20 40.64 67.22 0.53 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.213 -0.93 . . . . 0.0 109.013 -179.67 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.656 HG13 ' CG2' ' A' ' 33' ' ' ILE . 1.2 t -82.14 127.25 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.329 -0.857 . . . . 0.0 110.21 -179.175 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 35.3 m -115.63 117.56 30.63 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.146 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.483 ' HA ' HG11 ' A' ' 47' ' ' VAL . 18.1 mttm -65.34 117.01 7.26 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.279 -0.888 . . . . 0.0 109.663 -179.66 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 82.8 mt-10 -108.87 167.67 9.91 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.375 -0.828 . . . . 0.0 109.661 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.506 -179.956 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.606 ' CD1' ' N ' ' A' ' 2' ' ' LEU . 5.1 mp . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.479 ' O ' HG12 ' A' ' 20' ' ' VAL . 2.7 tt0 -127.68 140.27 52.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.227 -0.921 . . . . 0.0 109.208 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.0 155.22 24.91 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.784 -1.326 . . . . 0.0 109.784 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.476 ' HE3' ' OE2' ' A' ' 21' ' ' GLU . 54.5 mttt -108.88 137.86 46.13 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.406 -1.055 . . . . 0.0 108.645 179.46 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.521 ' HB ' ' O ' ' A' ' 42' ' ' GLU . 15.0 t -70.16 112.56 5.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.054 -1.029 . . . . 0.0 109.983 -179.301 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.475 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 14.7 tttm -78.5 -40.87 34.04 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.592 ' O ' ' CE3' ' A' ' 8' ' ' TRP . 0.0 OUTLIER -161.44 155.78 22.73 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.923 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.434 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 11.0 p90 -154.31 139.77 17.76 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.054 -1.029 . . . . 0.0 109.07 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.411 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 3.1 t-20 . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.052 -1.03 . . . . 0.0 109.869 -179.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.58 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 0.8 OUTLIER . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 . . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.533 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -148.57 173.85 28.41 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.564 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 29.2 m-85 -113.25 132.3 55.58 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.402 -1.058 . . . . 0.0 109.011 179.767 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.603 ' CD1' ' CG2' ' A' ' 28' ' ' VAL . 58.8 mt -119.07 149.5 21.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.239 -0.913 . . . . 0.0 109.681 -179.615 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.47 ' N ' HG23 ' A' ' 18' ' ' ILE . 46.8 tt0 -112.09 122.15 46.95 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.353 -0.842 . . . . 0.0 109.415 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.521 HG23 ' CG2' ' A' ' 26' ' ' VAL . 3.2 t -91.32 124.88 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.246 -0.909 . . . . 0.0 109.647 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.476 ' OE2' ' HE3' ' A' ' 5' ' ' LYS . 91.6 mt-10 -70.4 103.76 2.52 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.236 -0.915 . . . . 0.0 109.367 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 120.83 -19.13 8.99 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 49.0 mt-30 -129.82 162.6 28.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.263 -1.139 . . . . 0.0 109.578 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -54.46 -176.44 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.317 -0.864 . . . . 0.0 109.689 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.494 ' OD1' ' N ' ' A' ' 25' ' ' ASP . 11.3 p30 -73.39 136.32 44.33 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.29 -0.881 . . . . 0.0 109.413 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.521 ' CG2' HG23 ' A' ' 20' ' ' VAL . 72.3 t -113.03 122.31 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.235 -0.916 . . . . 0.0 109.569 -179.753 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.518 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.4 OUTLIER -78.12 157.29 29.51 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.164 -0.96 . . . . 0.0 109.223 179.837 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.603 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 21.9 t -132.27 131.24 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.296 -0.877 . . . . 0.0 109.243 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.679 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 13.9 t-80 -105.83 154.64 20.25 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.124 -0.985 . . . . 0.0 109.267 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.685 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -46.52 -53.46 11.26 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.159 -0.963 . . . . 0.0 109.246 -179.683 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.685 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 86.7 p -55.96 -24.37 37.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.096 -1.003 . . . . 0.0 109.979 -179.692 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.493 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -66.32 -19.97 65.96 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.114 -0.991 . . . . 0.0 109.577 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.553 HD13 ' CD1' ' A' ' 41' ' ' LEU . 2.9 mp . . . . . 0 N--CA 1.489 1.49 0 O-C-N 121.229 -0.92 . . . . 0.0 109.443 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.553 ' CD1' HD13 ' A' ' 33' ' ' ILE . 5.2 mp . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.364 0.602 . . . . 0.0 109.629 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.521 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 84.9 tt0 -116.11 149.26 39.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.297 -0.877 . . . . 0.0 109.008 179.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.478 ' HA ' HG13 ' A' ' 6' ' ' VAL . 77.5 tt0 -71.0 124.46 24.41 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.15 -0.969 . . . . 0.0 109.769 -179.788 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 92.01 -6.88 79.15 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.901 -1.28 . . . . 0.0 109.901 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.463 ' HB2' ' HB3' ' A' ' 42' ' ' GLU . 48.6 tp60 -82.04 133.19 35.27 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.131 -1.217 . . . . 0.0 109.732 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.485 ' O ' HG12 ' A' ' 47' ' ' VAL . . . -84.34 144.95 28.51 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.899 . . . . 0.0 109.415 179.8 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.594 ' CG2' HD11 ' A' ' 18' ' ' ILE . 23.2 m -144.78 163.61 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.232 -0.917 . . . . 0.0 109.795 -179.725 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.498 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 1.0 OUTLIER -108.19 153.23 23.48 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 179.342 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.516 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 7.8 p90 174.63 165.82 0.25 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.99 -1.069 . . . . 0.0 110.055 -179.76 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -102.84 165.14 11.21 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.14 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.0 mt -102.44 125.74 56.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 120.936 -1.102 . . . . 0.0 109.854 -179.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.569 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 32.0 m -114.3 126.29 71.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.413 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 178.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -66.18 118.64 10.2 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.158 -0.964 . . . . 0.0 109.727 -179.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -122.07 157.44 16.8 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.496 ' CG ' ' N ' ' A' ' 56' ' ' ARG . 7.9 p30 -48.05 -49.66 30.6 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.319 -1.106 . . . . 0.0 109.654 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.496 ' N ' ' CG ' ' A' ' 55' ' ' ASN . 84.0 mtp180 -64.47 -25.23 67.91 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.109 -0.994 . . . . 0.0 109.012 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 142.63 -152.63 23.99 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.475 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 49.2 Cg_endo -70.72 137.25 32.28 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.631 2.22 . . . . 0.0 111.782 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.569 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 79.1 mt-30 -127.53 163.83 23.29 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.228 -0.92 . . . . 0.0 109.207 179.641 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -96.6 142.65 28.4 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.154 -0.966 . . . . 0.0 110.103 -179.324 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.514 ' HB3' HG12 ' A' ' 52' ' ' VAL . . . -124.65 154.06 41.34 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.387 -0.821 . . . . 0.0 108.881 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.476 ' C ' ' O ' ' A' ' 61' ' ' ALA . 58.3 t30 42.54 64.24 1.2 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.103 -0.998 . . . . 0.0 108.784 -179.65 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.564 HG21 ' CG1' ' A' ' 28' ' ' VAL . 1.8 t -78.38 128.91 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.337 -0.852 . . . . 0.0 109.944 -179.122 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.467 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 93.4 m -119.56 126.32 50.95 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.484 -0.76 . . . . 0.0 109.082 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.468 ' NZ ' HG21 ' A' ' 33' ' ' ILE . 38.2 mttp -73.39 114.78 12.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.219 -0.925 . . . . 0.0 109.771 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.439 ' HG3' ' HA ' ' A' ' 47' ' ' VAL . 97.1 mt-10 -92.44 161.98 14.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.251 -0.905 . . . . 0.0 109.452 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.392 179.884 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.432 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 57.5 mt . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.483 ' O ' HG12 ' A' ' 20' ' ' VAL . 3.5 tt0 -128.43 137.76 51.99 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.266 -0.896 . . . . 0.0 109.208 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.05 154.33 24.41 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.776 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.448 ' O ' HG21 ' A' ' 18' ' ' ILE . 58.0 mttp -104.16 140.46 37.77 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.434 -1.039 . . . . 0.0 108.829 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.46 HG11 ' HA ' ' A' ' 43' ' ' GLU . 18.8 t -72.85 114.36 11.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.009 -1.057 . . . . 0.0 109.963 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 10.7 tptt -78.76 -42.24 28.54 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.581 ' O ' ' CE3' ' A' ' 8' ' ' TRP . 0.0 OUTLIER -160.1 156.12 26.3 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.452 -0.78 . . . . 0.0 109.009 179.96 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.498 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 10.4 p90 -154.96 139.08 16.5 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.124 -0.985 . . . . 0.0 109.021 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.422 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.7 t-20 . . . . . 0 N--CA 1.491 1.597 0 O-C-N 121.01 -1.056 . . . . 0.0 109.836 -179.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.584 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 . . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.566 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -145.12 175.4 24.73 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.564 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 32.8 m-85 -115.54 133.29 56.18 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.265 -1.138 . . . . 0.0 109.022 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.617 HD13 ' CG2' ' A' ' 47' ' ' VAL . 20.2 mt -119.88 155.08 22.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.226 -0.921 . . . . 0.0 109.402 -179.807 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 32.4 tp10 -117.83 123.92 47.1 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.315 -0.866 . . . . 0.0 109.588 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.483 HG12 ' O ' ' A' ' 3' ' ' GLU . 2.3 t -97.94 119.98 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.314 -0.866 . . . . 0.0 109.47 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -69.11 109.61 4.11 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.27 -0.894 . . . . 0.0 109.556 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 126.46 -30.68 4.19 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.491 ' OE1' ' CD1' ' A' ' 51' ' ' ILE . 57.1 mt-30 -128.6 166.85 18.07 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.322 -1.105 . . . . 0.0 109.41 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.46 ' O ' ' O ' ' A' ' 23' ' ' GLN . 55.4 m-20 -51.13 -177.38 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.251 -0.906 . . . . 0.0 109.411 179.898 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.493 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 20.3 p30 -75.27 147.28 40.37 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.232 -0.917 . . . . 0.0 109.308 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.455 HG21 HG23 ' A' ' 20' ' ' VAL . 81.6 t -118.14 120.44 64.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.121 -0.987 . . . . 0.0 109.676 -179.556 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.529 ' CE1' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER -76.81 158.27 30.96 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.127 -0.983 . . . . 0.0 109.11 179.696 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.582 ' CG2' HD12 ' A' ' 18' ' ' ILE . 7.7 t -131.64 134.08 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.187 -0.946 . . . . 0.0 109.299 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.632 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 12.9 t-80 -109.32 152.63 25.01 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.193 -0.942 . . . . 0.0 109.15 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.682 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.9 OUTLIER -45.43 -53.04 9.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.199 -0.938 . . . . 0.0 109.176 -179.592 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.682 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 22.7 t -54.96 -28.94 55.31 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.243 -0.911 . . . . 0.0 110.051 -179.587 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.487 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -62.83 -21.58 66.03 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.048 -1.032 . . . . 0.0 109.352 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.527 ' CD1' HD11 ' A' ' 41' ' ' LEU . 3.3 mp . . . . . 0 N--CA 1.488 1.474 0 O-C-N 121.298 -0.876 . . . . 0.0 109.256 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.527 HD11 ' CD1' ' A' ' 33' ' ' ILE . 5.4 mp . . . . . 0 N--CA 1.489 1.501 0 CA-C-O 121.397 0.617 . . . . 0.0 109.699 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.49 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 85.2 tt0 -117.57 152.07 35.87 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.415 -0.803 . . . . 0.0 109.042 179.546 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.46 ' HA ' HG11 ' A' ' 6' ' ' VAL . 67.4 tt0 -72.85 124.57 25.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.207 -0.933 . . . . 0.0 109.6 -179.729 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.7 -4.44 79.17 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.49 ' HB2' ' HB3' ' A' ' 42' ' ' GLU . 55.9 tp60 -82.05 132.81 35.26 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.189 -1.183 . . . . 0.0 109.877 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.489 ' O ' HG13 ' A' ' 47' ' ' VAL . . . -80.45 141.06 35.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.289 -0.882 . . . . 0.0 109.169 179.669 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.617 ' CG2' HD13 ' A' ' 18' ' ' ILE . 30.1 m -141.69 159.04 21.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 109.902 -179.614 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.499 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 28.9 t -109.66 153.11 24.7 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.048 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.527 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 8.5 p90 173.39 165.67 0.16 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.913 -1.117 . . . . 0.0 110.178 -179.764 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -100.05 162.89 12.69 Favored 'General case' 0 N--CA 1.487 1.382 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.491 ' CD1' ' OE1' ' A' ' 23' ' ' GLN . 0.9 OUTLIER -102.25 125.46 56.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 120.927 -1.108 . . . . 0.0 110.022 -179.571 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.6 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 26.7 m -109.9 121.98 63.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.7 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.418 ' OE2' ' HB3' ' A' ' 58' ' ' PRO . 39.9 mm-40 -91.47 89.9 7.42 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.144 -0.973 . . . . 0.0 109.945 -179.001 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.05 -169.96 32.23 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 56' ' ' ARG . 4.1 t30 -58.05 -66.17 0.52 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.236 -1.155 . . . . 0.0 109.837 -179.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.428 ' C ' ' O ' ' A' ' 55' ' ' ASN . 15.2 mtm180 -41.82 -46.29 3.88 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.282 -0.886 . . . . 0.0 109.501 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 150.65 -153.97 25.34 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.493 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 47.9 Cg_endo -69.64 129.42 17.69 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.682 2.255 . . . . 0.0 112.024 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.6 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 61.2 mt-30 -127.19 161.14 29.23 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.334 -0.854 . . . . 0.0 108.976 179.506 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.422 ' N ' ' O ' ' A' ' 27' ' ' PHE . . . -90.02 136.52 32.99 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.032 -1.043 . . . . 0.0 110.296 -179.154 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.521 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -118.79 149.57 41.28 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 179.442 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.488 ' C ' ' O ' ' A' ' 61' ' ' ALA . 38.6 t-20 41.34 67.77 0.51 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.033 -1.042 . . . . 0.0 108.875 -179.57 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.527 ' HA ' ' HB3' ' A' ' 49' ' ' PHE . 2.1 t -81.57 127.85 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.404 -0.81 . . . . 0.0 110.161 -179.176 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 91.8 m -118.1 123.84 46.57 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.472 -0.768 . . . . 0.0 109.082 179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.469 ' HE2' ' HA ' ' A' ' 41' ' ' LEU . 74.1 mttt -70.75 112.63 7.11 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.199 -0.938 . . . . 0.0 109.737 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -92.75 162.7 14.02 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.326 -0.859 . . . . 0.0 109.584 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.995 -1.002 . . . . 0.0 109.491 179.997 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.628 ' CD1' ' N ' ' A' ' 2' ' ' LEU . 4.6 mp . . . . . 0 N--CA 1.488 1.475 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.477 ' O ' HG12 ' A' ' 20' ' ' VAL . 2.4 tt0 -128.73 143.67 50.98 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.205 -0.935 . . . . 0.0 109.163 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -144.34 157.08 27.07 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.428 ' C ' HG21 ' A' ' 18' ' ' ILE . 43.2 mttm -108.23 137.1 46.79 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.423 -1.045 . . . . 0.0 108.576 179.383 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.417 ' HA ' HG12 ' A' ' 18' ' ' ILE . 16.1 t -68.28 114.45 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.128 -0.983 . . . . 0.0 109.85 -179.341 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.46 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 29.7 tttt -79.33 -38.07 36.03 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 179.601 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.608 ' CZ3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -166.37 157.39 12.89 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.476 -0.765 . . . . 0.0 109.035 -179.893 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.432 ' N ' ' CG ' ' A' ' 8' ' ' TRP . 16.1 p90 -152.75 139.89 19.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.203 -0.936 . . . . 0.0 108.847 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.464 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 55.1 t-20 . . . . . 0 N--CA 1.49 1.534 0 O-C-N 121.045 -1.034 . . . . 0.0 109.971 -179.408 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.597 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.29 0.567 . . . . 0.0 109.529 . . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.516 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -145.3 172.17 26.16 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.679 -1.368 . . . . 0.0 109.679 -179.834 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.608 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 28.4 m-85 -114.79 131.94 56.64 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.22 -1.164 . . . . 0.0 109.021 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.606 HD13 ' CG2' ' A' ' 47' ' ' VAL . 37.3 mt -119.25 149.54 21.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.146 -0.971 . . . . 0.0 109.647 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 46.3 tt0 -112.28 120.3 41.27 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.406 -0.809 . . . . 0.0 109.413 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.484 HG22 ' CG2' ' A' ' 26' ' ' VAL . 2.6 t -90.85 125.1 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.312 -0.868 . . . . 0.0 109.428 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.459 ' HA ' ' OE1' ' A' ' 21' ' ' GLU . 67.0 mm-40 -73.57 106.05 5.18 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.318 -0.864 . . . . 0.0 109.25 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.53 -17.54 8.89 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 46.5 mt-30 -133.9 164.62 26.86 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.276 -1.132 . . . . 0.0 109.648 -179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 50.5 m-20 -55.02 -176.6 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.207 -0.933 . . . . 0.0 109.607 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.499 ' OD1' ' N ' ' A' ' 25' ' ' ASP . 11.4 p30 -73.33 139.96 46.39 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.29 -0.881 . . . . 0.0 109.477 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.484 ' CG2' HG22 ' A' ' 20' ' ' VAL . 56.1 t -115.74 122.02 68.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.196 -0.94 . . . . 0.0 109.44 -179.796 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.503 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.3 OUTLIER -79.78 157.53 27.06 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.13 -0.981 . . . . 0.0 109.192 179.977 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.602 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 13.0 t -132.31 130.18 60.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.303 -0.873 . . . . 0.0 109.373 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.667 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 13.4 t-80 -103.65 154.41 19.55 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.148 -0.97 . . . . 0.0 109.089 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.689 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.7 OUTLIER -45.98 -53.44 10.02 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.082 -1.011 . . . . 0.0 109.188 -179.682 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.689 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 93.0 p -55.55 -30.26 60.45 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.154 -0.966 . . . . 0.0 110.236 -179.555 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.03 -27.9 63.99 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.996 -1.065 . . . . 0.0 109.331 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.621 HG12 HD11 ' A' ' 41' ' ' LEU . 2.6 mp . . . . . 0 C--N 1.302 -1.462 0 O-C-N 121.355 -0.841 . . . . 0.0 109.52 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.621 HD11 HG12 ' A' ' 33' ' ' ILE . 4.4 mp . . . . . 0 N--CA 1.489 1.519 0 CA-C-O 121.489 0.661 . . . . 0.0 109.837 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.433 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.5 tt0 -91.75 134.4 34.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.43 -0.794 . . . . 0.0 109.401 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.46 ' HG3' ' O ' ' A' ' 7' ' ' LYS . 76.1 tt0 -59.44 128.28 36.27 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.239 -0.913 . . . . 0.0 109.638 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.406 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 91.99 -5.13 78.8 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.726 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.433 ' HB2' ' HB3' ' A' ' 42' ' ' GLU . 63.3 tt0 -81.37 131.48 35.29 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.269 -1.136 . . . . 0.0 109.758 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.465 ' O ' HG12 ' A' ' 47' ' ' VAL . . . -79.14 141.4 37.29 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.247 -0.908 . . . . 0.0 109.22 179.681 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.606 ' CG2' HD13 ' A' ' 18' ' ' ILE . 33.2 m -141.83 159.19 21.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.127 -0.983 . . . . 0.0 109.907 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.495 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 27.5 t -106.08 151.26 24.91 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 179.017 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.578 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 11.7 p90 175.13 165.39 0.29 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.943 -1.098 . . . . 0.0 110.317 -179.707 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -100.05 166.26 11.12 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 178.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.415 HG12 HG21 ' A' ' 26' ' ' VAL . 0.6 OUTLIER -104.16 125.72 58.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.917 -1.114 . . . . 0.0 109.804 -179.66 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.59 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 33.1 m -114.03 125.57 71.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.173 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.446 ' HA ' ' HA ' ' A' ' 58' ' ' PRO . 19.8 mt-10 -96.66 93.61 6.84 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.196 -0.94 . . . . 0.0 109.923 -179.35 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.61 -176.62 44.33 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.407 ' CG ' ' N ' ' A' ' 56' ' ' ARG . 18.5 p-10 -53.17 -50.77 63.92 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.219 -1.165 . . . . 0.0 109.715 -179.674 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.407 ' N ' ' CG ' ' A' ' 55' ' ' ASN . 20.1 mtm180 -58.96 -37.5 76.93 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.081 -1.012 . . . . 0.0 109.381 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.05 -159.21 28.07 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.446 ' HA ' ' HA ' ' A' ' 53' ' ' GLU . 53.7 Cg_endo -72.59 142.28 35.99 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.728 2.285 . . . . 0.0 111.903 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.59 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 72.8 mt-30 -138.97 169.89 16.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.384 -0.822 . . . . 0.0 108.945 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.427 ' HB2' HG11 ' A' ' 26' ' ' VAL . . . -95.03 138.17 33.11 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.047 -1.033 . . . . 0.0 110.383 -179.132 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.578 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -125.42 156.33 39.01 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.34 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 73.5 m-20 45.39 69.18 0.47 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.893 -1.13 . . . . 0.0 108.665 -179.647 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.56 ' CG1' ' CG1' ' A' ' 33' ' ' ILE . 2.2 t -88.14 125.83 41.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.326 -0.859 . . . . 0.0 110.17 -179.033 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 98.1 m -118.16 121.23 39.99 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.505 -0.747 . . . . 0.0 109.025 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.494 ' HE3' HD13 ' A' ' 41' ' ' LEU . 28.7 mttp -71.49 112.26 7.47 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.229 -0.919 . . . . 0.0 109.361 -179.805 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.461 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 96.2 mt-10 -94.03 166.89 11.93 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.313 -0.867 . . . . 0.0 109.642 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . 0.414 ' O ' ' O ' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 117.998 -1.001 . . . . 0.0 109.548 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.614 ' CD1' ' N ' ' A' ' 2' ' ' LEU . 3.6 mp . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.481 ' O ' HG11 ' A' ' 20' ' ' VAL . 83.0 mt-10 -127.96 144.27 51.1 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.274 -0.891 . . . . 0.0 109.185 179.671 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.475 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -140.06 153.43 23.32 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.485 ' N ' HG21 ' A' ' 18' ' ' ILE . 58.4 mttm -104.03 139.26 39.39 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.315 -1.109 . . . . 0.0 108.841 179.482 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.554 ' CG1' ' HA ' ' A' ' 43' ' ' GLU . 38.7 t -71.63 109.94 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.166 -0.958 . . . . 0.0 109.899 -179.43 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.67 -32.83 27.94 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.371 -0.831 . . . . 0.0 108.977 179.42 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.686 ' CE3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -158.63 159.28 35.22 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 -179.837 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.505 ' N ' ' CG ' ' A' ' 8' ' ' TRP . 22.4 p90 -161.16 132.5 5.5 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.029 -1.044 . . . . 0.0 109.283 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.498 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.1 t-20 . . . . . 0 N--CA 1.49 1.536 0 O-C-N 121.197 -0.939 . . . . 0.0 109.539 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.703 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.654 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 . . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.598 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -136.96 172.57 22.56 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.686 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 17.0 m-85 -119.37 133.74 55.56 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.226 -1.161 . . . . 0.0 109.306 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.574 ' CD1' ' CG2' ' A' ' 28' ' ' VAL . 15.4 mt -120.82 154.41 24.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.342 -0.849 . . . . 0.0 109.46 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.455 ' N ' HG22 ' A' ' 18' ' ' ILE . 24.9 tp10 -117.65 122.91 44.82 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.307 -0.871 . . . . 0.0 109.38 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.526 HG23 ' CG2' ' A' ' 26' ' ' VAL . 2.9 t -93.58 120.16 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.228 -0.92 . . . . 0.0 109.553 -179.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -67.14 109.18 2.94 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.295 -0.878 . . . . 0.0 109.286 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.22 -23.1 7.75 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.533 ' OE1' ' CD1' ' A' ' 51' ' ' ILE . 65.0 mt-30 -130.79 164.79 24.38 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.304 -1.115 . . . . 0.0 109.51 -179.77 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 41.0 m-20 -55.28 -175.02 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.33 -0.856 . . . . 0.0 109.924 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 25' ' ' ASP . 15.2 p30 -74.18 141.99 45.46 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.301 -0.875 . . . . 0.0 109.737 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.526 ' CG2' HG23 ' A' ' 20' ' ' VAL . 90.6 t -117.87 118.13 57.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.207 -0.933 . . . . 0.0 109.353 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.452 ' CE1' ' HB3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -75.13 156.06 36.37 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.231 -0.918 . . . . 0.0 109.021 179.771 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.574 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 6.9 t -133.57 139.95 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.89 . . . . 0.0 109.607 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.703 ' HA ' ' HB3' ' A' ' 15' ' ' PHE . 13.6 t-80 -114.42 150.3 34.91 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.26 -0.9 . . . . 0.0 109.25 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.668 ' CG ' ' N ' ' A' ' 31' ' ' SER . 1.0 OUTLIER -43.75 -52.66 6.44 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.174 -0.954 . . . . 0.0 109.396 -179.642 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.668 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 22.8 t -57.61 -20.84 35.51 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.17 -0.956 . . . . 0.0 109.863 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.465 ' N ' ' O ' ' A' ' 29' ' ' HIS . . . -69.42 -22.75 63.66 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.115 -0.991 . . . . 0.0 109.735 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.594 ' CG1' ' CG1' ' A' ' 63' ' ' VAL . 2.9 mp . . . . . 0 N--CA 1.488 1.465 0 O-C-N 121.207 -0.933 . . . . 0.0 109.716 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.567 HD11 HG12 ' A' ' 33' ' ' ILE . 5.5 mp . . . . . 0 N--CA 1.489 1.493 0 CA-C-O 121.334 0.587 . . . . 0.0 109.787 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.426 ' O ' ' CB ' ' A' ' 6' ' ' VAL . 94.5 mt-10 -105.47 146.29 29.73 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.44 -0.787 . . . . 0.0 109.36 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.554 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 52.6 tt0 -70.06 130.72 42.91 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.184 -0.947 . . . . 0.0 109.613 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 93.11 -5.96 75.75 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.726 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.403 ' HB3' HG23 ' A' ' 6' ' ' VAL . 60.2 tp60 -81.86 125.68 30.99 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.26 -1.141 . . . . 0.0 109.73 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -73.25 143.94 46.88 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.199 -0.938 . . . . 0.0 109.223 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.567 ' CG2' HD12 ' A' ' 18' ' ' ILE . 33.4 m -145.39 158.92 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.109 -0.994 . . . . 0.0 110.188 -179.576 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.523 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 4.6 p -110.49 154.53 23.52 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.115 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.566 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 7.9 p90 171.29 167.66 0.08 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.93 -1.106 . . . . 0.0 110.035 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -103.67 165.09 11.25 Favored 'General case' 0 C--N 1.303 -1.436 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.212 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.533 ' CD1' ' OE1' ' A' ' 23' ' ' GLN . 3.9 mt -106.25 132.22 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 120.997 -1.064 . . . . 0.0 109.685 -179.897 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.54 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 20.5 m -121.28 133.12 68.87 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.557 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 -84.97 82.66 8.35 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.213 -0.929 . . . . 0.0 109.604 -179.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -84.32 176.64 51.56 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 20.2 p-10 -49.47 -51.69 34.13 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.241 -1.152 . . . . 0.0 109.65 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 23.2 mtm180 -62.38 -31.98 72.72 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.095 -1.003 . . . . 0.0 109.549 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 142.93 -148.22 19.89 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 50.0 Cg_endo -71.24 133.59 23.17 Favored 'Trans proline' 0 C--O 1.214 -0.688 0 C-N-CA 122.802 2.334 . . . . 0.0 112.034 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.54 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 42.6 mt-30 -127.87 161.32 29.34 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.38 -0.825 . . . . 0.0 109.359 179.726 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -92.16 110.49 21.87 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.217 -0.927 . . . . 0.0 110.134 -179.508 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.559 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -93.48 152.07 19.31 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.327 -0.858 . . . . 0.0 109.061 179.633 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.494 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 79.0 m-20 43.63 78.23 0.06 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.043 -1.036 . . . . 0.0 109.029 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.594 ' CG1' ' CG1' ' A' ' 33' ' ' ILE . 2.1 t -92.87 125.87 45.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.182 -0.949 . . . . 0.0 110.003 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.457 HG23 ' OE2' ' A' ' 66' ' ' GLU . 56.9 m -120.48 130.22 54.19 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.655 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.413 ' NZ ' ' CD1' ' A' ' 41' ' ' LEU . 44.3 mttp -76.81 114.04 15.13 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.277 -0.889 . . . . 0.0 109.72 -179.697 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.457 ' OE2' HG23 ' A' ' 64' ' ' THR . 57.5 mm-40 -101.02 172.02 7.28 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.284 -0.885 . . . . 0.0 109.635 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 117.993 -1.003 . . . . 0.0 109.471 179.893 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.604 ' CD1' ' N ' ' A' ' 2' ' ' LEU . 5.2 mp . . . . . 0 N--CA 1.489 1.502 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.485 ' O ' HG11 ' A' ' 20' ' ' VAL . 2.4 tt0 -132.39 139.99 48.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.179 -0.951 . . . . 0.0 109.461 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -140.4 158.75 26.09 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.507 ' O ' HG23 ' A' ' 18' ' ' ILE . 85.6 mttt -106.96 139.69 40.97 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.32 -1.106 . . . . 0.0 108.895 179.78 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.485 ' HB ' ' O ' ' A' ' 42' ' ' GLU . 22.6 t -72.88 111.56 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.109 -0.994 . . . . 0.0 110.127 -179.34 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 19.1 tttt -79.16 -40.6 30.52 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.615 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.7 154.76 26.88 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.765 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.436 ' N ' ' CG ' ' A' ' 8' ' ' TRP . 13.6 p90 -154.9 141.0 18.43 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.058 -1.026 . . . . 0.0 109.424 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.46 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.7 t-20 . . . . . 0 N--CA 1.489 1.517 0 O-C-N 121.253 -0.904 . . . . 0.0 109.677 -179.746 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.535 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 5.6 p90 . . . . . 0 N--CA 1.494 1.734 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.615 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -138.43 172.11 23.15 Favored Glycine 0 N--CA 1.49 2.27 0 C-N-CA 119.634 -1.27 . . . . 0.0 110.024 -179.452 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.514 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 27.1 m-85 -115.17 133.0 56.42 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.339 -1.095 . . . . 0.0 108.789 179.569 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.595 HD13 ' CG2' ' A' ' 47' ' ' VAL . 13.1 mt -120.92 155.29 24.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.151 -0.968 . . . . 0.0 109.873 -179.518 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.4 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 23.4 tp10 -116.92 123.47 47.06 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.398 -0.814 . . . . 0.0 109.369 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.485 HG11 ' O ' ' A' ' 3' ' ' GLU . 2.3 t -98.15 123.0 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.17 -0.956 . . . . 0.0 109.317 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.455 ' HA ' ' OE1' ' A' ' 21' ' ' GLU . 68.7 mm-40 -72.24 108.83 5.6 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 0.0 109.3 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 125.44 -22.68 6.17 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.226 -1.55 . . . . 0.0 109.226 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.538 ' OE1' ' CD1' ' A' ' 51' ' ' ILE . 73.1 mt-30 -135.73 167.54 20.96 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.28 -1.13 . . . . 0.0 109.548 -179.78 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -53.52 -177.12 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.262 -0.899 . . . . 0.0 109.587 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.479 ' OD1' ' N ' ' A' ' 25' ' ' ASP . 11.8 p30 -74.61 143.18 44.48 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.937 . . . . 0.0 109.426 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.472 HG21 HG21 ' A' ' 20' ' ' VAL . 97.9 t -116.33 119.36 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.16 -0.962 . . . . 0.0 109.425 -179.813 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.518 ' CG ' ' N ' ' A' ' 28' ' ' VAL . 0.4 OUTLIER -77.84 158.8 29.32 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.172 -0.955 . . . . 0.0 109.207 179.916 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.583 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 4.4 t -133.09 125.71 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.476 -0.765 . . . . 0.0 109.144 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.676 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 14.6 t-80 -98.46 153.93 18.24 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.355 -0.84 . . . . 0.0 109.091 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.687 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -45.13 -53.68 7.75 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.07 -1.019 . . . . 0.0 109.203 -179.65 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.687 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 62.8 p -54.27 -25.13 21.69 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.189 -0.945 . . . . 0.0 109.921 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.461 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -62.34 -24.52 67.38 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.126 -0.984 . . . . 0.0 109.439 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.538 ' CD1' HD12 ' A' ' 41' ' ' LEU . 3.0 mp . . . . . 0 N--CA 1.488 1.474 0 O-C-N 121.238 -0.914 . . . . 0.0 109.544 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.538 HD12 ' CD1' ' A' ' 33' ' ' ILE . 5.1 mp . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.396 0.617 . . . . 0.0 109.788 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.485 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 20.5 tt0 -116.42 140.24 49.56 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.391 -0.818 . . . . 0.0 109.057 179.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.462 ' HA ' HG13 ' A' ' 6' ' ' VAL . 76.6 tt0 -62.35 125.35 23.6 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.264 -0.898 . . . . 0.0 109.618 -179.76 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 90.67 -7.1 81.82 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.462 ' OE1' ' HB3' ' A' ' 42' ' ' GLU . 66.7 tt0 -81.76 134.39 35.44 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.24 -1.153 . . . . 0.0 109.72 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.459 ' O ' HG13 ' A' ' 47' ' ' VAL . . . -80.07 140.16 36.6 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.271 -0.893 . . . . 0.0 109.155 179.675 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.595 ' CG2' HD13 ' A' ' 18' ' ' ILE . 26.4 m -140.57 151.73 20.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.227 -0.921 . . . . 0.0 109.745 -179.464 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.511 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 33.0 t -100.56 148.94 24.24 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.053 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.581 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 7.2 p90 176.28 164.7 0.42 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.903 -1.123 . . . . 0.0 110.105 -179.63 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -103.54 161.41 13.9 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.247 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.538 ' CD1' ' OE1' ' A' ' 23' ' ' GLN . 7.2 mt -104.61 135.78 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.969 -1.082 . . . . 0.0 109.783 -179.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.494 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 32.7 m -122.23 131.41 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.481 -0.762 . . . . 0.0 109.11 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -86.8 84.22 7.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.185 -0.947 . . . . 0.0 109.634 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -85.84 177.16 49.55 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.3 t30 -50.34 -54.33 22.35 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.196 -1.179 . . . . 0.0 109.608 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 71.3 mtm180 -57.38 -35.46 70.01 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.241 -0.912 . . . . 0.0 109.498 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 145.2 -153.28 25.17 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -70.37 137.31 33.41 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.734 2.289 . . . . 0.0 111.987 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.494 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 92.2 mt-30 -135.19 165.99 24.14 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.342 -0.849 . . . . 0.0 109.275 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -94.58 137.15 34.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.198 -0.938 . . . . 0.0 109.777 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.581 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -123.96 155.04 38.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.365 -0.834 . . . . 0.0 108.843 179.717 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.476 ' C ' ' O ' ' A' ' 61' ' ' ALA . 85.8 m-20 43.19 73.91 0.13 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.897 -1.127 . . . . 0.0 108.706 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.543 HG22 ' CG1' ' A' ' 28' ' ' VAL . 2.7 t -89.65 126.96 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.212 -0.93 . . . . 0.0 109.99 -179.108 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.401 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 70.3 m -118.45 124.29 47.27 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.47 ' HE2' ' HA ' ' A' ' 41' ' ' LEU . 55.5 mttt -71.73 111.03 6.67 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.181 -0.95 . . . . 0.0 109.528 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -89.78 164.1 14.79 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.364 -0.835 . . . . 0.0 109.566 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.461 -179.922 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.587 ' CD1' ' N ' ' A' ' 2' ' ' LEU . 4.6 mp . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.474 ' O ' HG11 ' A' ' 20' ' ' VAL . 96.1 mt-10 -129.48 147.36 51.29 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.167 -0.958 . . . . 0.0 109.295 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.45 ' HA3' HG22 ' A' ' 18' ' ' ILE . . . -143.1 153.46 24.77 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.451 ' C ' HG23 ' A' ' 18' ' ' ILE . 27.6 mttp -102.48 141.38 35.39 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.284 -1.127 . . . . 0.0 108.839 179.557 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.517 ' CG1' ' HA ' ' A' ' 43' ' ' GLU . 33.7 t -73.8 110.58 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.247 -0.908 . . . . 0.0 110.126 -179.392 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.471 ' NZ ' ' HB3' ' A' ' 17' ' ' PHE . 2.9 pttt -79.89 -36.46 36.5 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.618 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -159.74 154.26 24.04 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.962 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.627 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 17.0 p90 -156.03 140.33 16.64 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.075 -1.016 . . . . 0.0 109.496 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.423 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 55.1 t-20 . . . . . 0 N--CA 1.489 1.489 0 O-C-N 121.224 -0.923 . . . . 0.0 109.521 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.556 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 2.8 p90 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.618 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -136.07 177.22 19.72 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.652 -1.261 . . . . 0.0 110.05 -179.366 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.562 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 19.4 m-85 -119.2 135.49 54.65 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.384 -1.068 . . . . 0.0 109.078 179.834 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.569 HG21 ' N ' ' A' ' 19' ' ' GLU . 37.9 mt -122.34 148.41 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.168 -0.958 . . . . 0.0 109.507 -179.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.569 ' N ' HG21 ' A' ' 18' ' ' ILE . 23.3 tp10 -110.98 121.05 44.37 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.342 -0.849 . . . . 0.0 109.332 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.484 HG23 HG21 ' A' ' 26' ' ' VAL . 2.6 t -91.46 120.59 40.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.211 -0.931 . . . . 0.0 109.664 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.404 ' OE1' ' HA ' ' A' ' 21' ' ' GLU . 73.2 mm-40 -71.9 110.64 6.54 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.202 -0.936 . . . . 0.0 109.246 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.57 -18.38 8.18 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.513 ' OE1' ' CD1' ' A' ' 51' ' ' ILE . 63.9 mt-30 -140.04 170.35 16.01 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.353 -1.086 . . . . 0.0 109.495 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 60.2 m-20 -55.31 -178.35 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.291 -0.88 . . . . 0.0 109.654 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 22.6 p30 -75.01 146.46 41.61 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.236 -0.915 . . . . 0.0 109.438 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.484 HG21 HG23 ' A' ' 20' ' ' VAL . 58.1 t -118.35 119.07 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.242 -0.911 . . . . 0.0 109.401 -179.67 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.54 ' CD1' ' C ' ' A' ' 27' ' ' PHE . 0.0 OUTLIER -76.61 156.31 32.84 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.205 -0.934 . . . . 0.0 109.148 179.855 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.558 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 14.7 t -133.45 132.97 57.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.383 -0.823 . . . . 0.0 109.399 -179.762 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.68 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 15.3 t-80 -111.18 153.5 25.7 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.354 -0.841 . . . . 0.0 109.053 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.682 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -44.47 -53.85 6.55 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.126 -0.984 . . . . 0.0 109.347 -179.605 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.682 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 32.3 t -57.04 -22.81 41.78 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.115 -0.991 . . . . 0.0 110.014 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.413 ' N ' ' O ' ' A' ' 29' ' ' HIS . . . -66.43 -27.53 67.91 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.09 -1.006 . . . . 0.0 109.458 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.589 ' CG1' ' CG1' ' A' ' 63' ' ' VAL . 2.4 mp . . . . . 0 N--CA 1.489 1.483 0 O-C-N 121.258 -0.901 . . . . 0.0 109.677 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.627 ' O ' ' CD2' ' A' ' 9' ' ' PHE . 3.1 mp . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 121.2 0.524 . . . . 0.0 109.672 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.468 ' O ' ' CB ' ' A' ' 6' ' ' VAL . 96.0 mt-10 -100.7 149.15 24.09 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.324 -0.86 . . . . 0.0 109.484 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.517 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 69.8 tt0 -71.91 130.01 39.97 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.348 -0.845 . . . . 0.0 109.625 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.463 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 90.52 -4.26 82.17 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.421 ' OE1' ' HG2' ' A' ' 65' ' ' LYS . 49.8 tt0 -80.8 129.57 34.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.271 -1.135 . . . . 0.0 109.638 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.499 ' O ' HG13 ' A' ' 47' ' ' VAL . . . -76.48 139.75 40.94 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.268 -0.895 . . . . 0.0 109.065 179.702 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.544 ' CG2' HD12 ' A' ' 18' ' ' ILE . 31.8 m -142.28 162.24 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.029 -1.044 . . . . 0.0 109.959 -179.651 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.524 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 63.8 m -112.44 153.38 27.47 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.61 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 5.8 p90 172.75 168.56 0.12 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.033 -1.042 . . . . 0.0 109.978 -179.833 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.496 ' HB2' ' HB1' ' A' ' 61' ' ' ALA . 95.1 mt-10 -103.5 160.88 14.34 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.513 ' CD1' ' OE1' ' A' ' 23' ' ' GLN . 3.9 mt -103.5 134.47 44.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.116 -0.99 . . . . 0.0 109.616 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.529 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 33.9 m -122.74 131.74 72.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -85.7 87.2 7.37 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.102 -0.999 . . . . 0.0 109.677 -179.724 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.62 178.07 43.96 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.9 t30 -50.24 -56.75 9.82 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.23 -1.159 . . . . 0.0 109.514 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 21.6 mtm180 -57.11 -34.07 67.96 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.262 -0.898 . . . . 0.0 109.417 -179.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 144.53 -152.18 24.15 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.434 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 51.0 Cg_endo -70.46 136.98 32.43 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.835 2.357 . . . . 0.0 112.052 -179.869 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.529 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 89.9 mt-30 -132.85 165.3 24.93 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.443 -0.786 . . . . 0.0 109.263 179.796 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.435 ' N ' ' CG1' ' A' ' 26' ' ' VAL . . . -90.13 132.19 35.58 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.16 -0.963 . . . . 0.0 109.789 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.529 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -113.7 147.76 37.61 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.528 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.484 ' C ' ' O ' ' A' ' 61' ' ' ALA . 23.9 t-20 41.27 74.41 0.11 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.141 -0.975 . . . . 0.0 108.778 -179.497 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.61 ' HA ' ' HB3' ' A' ' 49' ' ' PHE . 1.4 t -84.38 127.94 39.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.387 -0.821 . . . . 0.0 110.159 -179.068 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 27.7 m -119.68 126.61 51.53 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 179.333 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.421 ' HG2' ' OE1' ' A' ' 45' ' ' GLN . 57.7 mttt -73.72 108.78 6.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.162 -0.961 . . . . 0.0 109.511 -179.614 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 45.9 mm-40 -99.08 175.8 5.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.338 -0.852 . . . . 0.0 109.689 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.479 179.922 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.621 ' CD1' ' N ' ' A' ' 2' ' ' LEU . 5.1 mp . . . . . 0 N--CA 1.488 1.468 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.468 ' O ' HG11 ' A' ' 20' ' ' VAL . 2.1 tt0 -124.74 140.45 52.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.276 -0.89 . . . . 0.0 108.993 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -144.63 149.87 21.98 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 19.4 mttm -99.52 139.53 35.05 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.38 -1.071 . . . . 0.0 108.539 179.295 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.469 HG21 ' O ' ' A' ' 45' ' ' GLN . 20.7 t -69.91 115.22 8.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.039 -1.038 . . . . 0.0 109.776 -179.464 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.436 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 40.7 tttt -78.76 -42.13 28.81 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.726 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.63 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -160.14 154.93 24.28 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.43 -0.794 . . . . 0.0 108.888 179.976 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.46 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 11.3 p90 -154.25 141.74 19.76 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.101 -0.999 . . . . 0.0 109.193 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.456 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 57.9 t-20 . . . . . 0 N--CA 1.489 1.507 0 O-C-N 121.151 -0.968 . . . . 0.0 109.832 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.509 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 4.0 p90 . . . . . 0 N--CA 1.491 1.61 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.63 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -138.63 175.21 21.61 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 119.625 -1.274 . . . . 0.0 109.97 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.483 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 37.6 m-85 -116.7 132.49 56.67 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.404 -1.057 . . . . 0.0 109.014 179.696 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.583 ' CD1' ' CG2' ' A' ' 28' ' ' VAL . 37.1 mt -116.89 148.7 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.141 -0.974 . . . . 0.0 109.528 -179.827 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 30.6 tp10 -110.29 121.31 44.98 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.332 -0.855 . . . . 0.0 109.448 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.468 HG11 ' O ' ' A' ' 3' ' ' GLU . 2.4 t -96.22 120.02 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.163 -0.961 . . . . 0.0 109.471 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 47.1 mp0 -71.75 109.01 5.36 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.273 -0.892 . . . . 0.0 109.36 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.426 ' C ' ' HG3' ' A' ' 23' ' ' GLN . . . 125.28 -20.46 6.61 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.783 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.426 ' HG3' ' C ' ' A' ' 22' ' ' GLY . 37.3 mt-30 -138.83 169.62 17.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.317 -1.107 . . . . 0.0 109.695 -179.811 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -53.54 -177.4 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.32 -0.862 . . . . 0.0 109.665 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' A' ' 25' ' ' ASP . 11.0 p30 -75.97 143.54 41.49 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.287 -0.883 . . . . 0.0 109.661 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.468 HG21 HG21 ' A' ' 20' ' ' VAL . 79.7 t -116.92 120.87 66.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.23 -0.919 . . . . 0.0 109.527 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.553 ' CG ' ' N ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER -80.26 161.11 25.3 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.373 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.583 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 15.0 t -135.7 125.02 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.428 -0.795 . . . . 0.0 109.4 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.688 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 15.1 t-80 -96.2 154.35 17.3 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.231 -0.918 . . . . 0.0 109.14 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.688 ' CD2' ' CE1' ' A' ' 29' ' ' HIS . 0.7 OUTLIER -45.8 -53.41 9.66 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.105 -0.997 . . . . 0.0 109.245 -179.616 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.685 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 86.8 p -55.66 -27.24 48.84 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.171 -0.956 . . . . 0.0 109.982 -179.618 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -64.41 -35.94 82.52 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.995 -1.066 . . . . 0.0 109.159 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 5.1 mt . . . . . 0 N--CA 1.488 1.47 0 O-C-N 121.228 -0.92 . . . . 0.0 109.349 179.777 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.48 HD23 HG12 ' A' ' 47' ' ' VAL . 1.1 mt . . . . . 0 N--CA 1.488 1.474 0 CA-C-O 121.243 0.544 . . . . 0.0 109.575 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.465 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 46.3 tp10 -123.18 147.13 47.18 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.203 -0.936 . . . . 0.0 109.56 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.466 ' HA ' HG11 ' A' ' 6' ' ' VAL . 76.0 tt0 -73.35 126.01 29.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.196 -0.94 . . . . 0.0 109.739 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.75 -5.45 79.62 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.469 ' O ' HG21 ' A' ' 6' ' ' VAL . 48.4 tp60 -81.22 124.4 29.26 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.196 -1.179 . . . . 0.0 109.601 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.455 ' O ' HG11 ' A' ' 47' ' ' VAL . . . -75.09 144.61 42.84 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.263 -0.898 . . . . 0.0 109.154 179.63 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.546 ' CG2' HD11 ' A' ' 18' ' ' ILE . 21.7 m -148.36 168.11 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.177 -0.952 . . . . 0.0 109.827 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.528 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 4.1 p -112.48 152.76 28.37 Favored 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.325 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.558 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 14.4 p90 175.83 164.42 0.36 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.979 -1.076 . . . . 0.0 110.141 -179.781 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -100.36 164.6 11.86 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 179.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.459 HG12 HG22 ' A' ' 26' ' ' VAL . 0.4 OUTLIER -101.77 124.36 55.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 120.851 -1.156 . . . . 0.0 109.422 -179.903 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.558 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.1 m -111.1 123.57 67.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.401 -0.812 . . . . 0.0 109.011 179.764 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.41 ' HA ' ' HA ' ' A' ' 58' ' ' PRO . 10.2 mt-10 -94.97 91.12 6.23 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.177 -0.952 . . . . 0.0 109.948 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.08 -174.88 42.37 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 179.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -54.37 -62.39 1.69 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.171 -1.194 . . . . 0.0 109.546 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 18.8 mtm180 -46.66 -41.23 14.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.157 -0.964 . . . . 0.0 109.194 179.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 152.99 -161.53 29.65 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.486 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 53.6 Cg_endo -72.09 144.12 41.65 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.712 2.275 . . . . 0.0 111.752 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.558 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 78.8 mt-30 -141.82 172.36 12.79 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.289 -0.882 . . . . 0.0 109.048 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.415 ' N ' ' O ' ' A' ' 27' ' ' PHE . . . -94.23 142.55 27.28 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.139 -0.976 . . . . 0.0 110.236 -179.234 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.512 ' O ' ' C ' ' A' ' 62' ' ' ASN . . . -124.43 152.85 42.77 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.434 -0.791 . . . . 0.0 108.903 179.578 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.512 ' C ' ' O ' ' A' ' 61' ' ' ALA . 44.8 t30 38.62 73.91 0.1 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.07 -1.019 . . . . 0.0 109.186 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.558 ' HA ' ' HB3' ' A' ' 49' ' ' PHE . 1.5 t -86.97 129.22 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.245 -0.909 . . . . 0.0 109.96 -179.313 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.436 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 65.3 m -115.44 119.53 36.54 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.35 -0.843 . . . . 0.0 109.116 179.645 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.507 ' HA ' HG11 ' A' ' 47' ' ' VAL . 35.9 mttt -69.73 108.17 3.79 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 109.286 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.437 ' HG3' ' HA ' ' A' ' 47' ' ' VAL . 97.2 mt-10 -87.4 164.09 16.4 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.272 -0.892 . . . . 0.0 109.725 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.562 0 CA-C-O 117.989 -1.005 . . . . 0.0 109.58 -179.955 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 45.5 mt . . . . . 0 N--CA 1.489 1.498 0 CA-C-O 121.291 0.567 . . . . 0.0 109.541 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.465 ' O ' HG12 ' A' ' 20' ' ' VAL . 89.1 mt-10 -136.13 136.54 40.17 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.241 -0.912 . . . . 0.0 109.26 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -133.78 159.42 23.7 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.463 ' C ' HG21 ' A' ' 18' ' ' ILE . 77.9 mttt -103.34 140.84 36.9 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.409 -1.053 . . . . 0.0 108.824 179.41 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.487 ' HB ' ' O ' ' A' ' 42' ' ' GLU . 18.9 t -73.73 114.2 12.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.116 -0.99 . . . . 0.0 110.241 -179.111 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.4 tttt -78.44 -41.45 32.79 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.664 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.78 153.89 25.32 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.553 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.629 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 6.2 p90 -156.05 141.65 17.8 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.986 -1.071 . . . . 0.0 109.764 -179.61 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.412 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 50.4 t-20 . . . . . 0 N--CA 1.488 1.456 0 O-C-N 121.276 -0.89 . . . . 0.0 108.992 179.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.592 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 50.2 p90 . . . . . 0 N--CA 1.491 1.621 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.664 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -149.53 174.96 28.92 Favored Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.53 -1.319 . . . . 0.0 110.206 -179.477 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.437 ' CE1' ' HB2' ' A' ' 27' ' ' PHE . 49.6 m-85 -111.9 133.75 53.9 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.446 -1.032 . . . . 0.0 108.834 179.644 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.61 ' CD1' ' CG2' ' A' ' 28' ' ' VAL . 19.7 mt -120.4 149.43 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.207 -0.933 . . . . 0.0 109.489 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.55 ' N ' HG22 ' A' ' 18' ' ' ILE . 20.7 tp10 -113.28 122.44 47.44 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.351 -0.843 . . . . 0.0 109.332 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.532 HG23 ' CG2' ' A' ' 26' ' ' VAL . 2.8 t -91.75 121.9 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.253 -0.904 . . . . 0.0 109.525 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -69.36 108.5 3.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.333 -0.854 . . . . 0.0 109.325 179.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.07 -19.72 8.7 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.469 ' OE1' HD12 ' A' ' 51' ' ' ILE . 49.0 mt-30 -133.47 166.18 23.14 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.289 -1.124 . . . . 0.0 109.487 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 59.5 m-20 -54.79 -175.74 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.235 -0.916 . . . . 0.0 109.45 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.493 ' OD1' ' N ' ' A' ' 25' ' ' ASP . 11.2 p30 -75.84 143.78 41.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.291 -0.881 . . . . 0.0 109.577 -179.832 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.532 ' CG2' HG23 ' A' ' 20' ' ' VAL . 79.3 t -118.85 121.42 66.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.184 -0.947 . . . . 0.0 109.374 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.504 ' O ' ' N ' ' A' ' 60' ' ' ALA . 0.1 OUTLIER -79.03 158.26 27.93 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.266 -0.896 . . . . 0.0 109.392 -179.984 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.61 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 17.3 t -132.85 132.38 59.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.428 -0.795 . . . . 0.0 109.165 -179.76 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.678 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 14.6 t-80 -104.61 154.89 19.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.256 -0.903 . . . . 0.0 109.277 -179.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.693 ' CD1' ' N ' ' A' ' 31' ' ' SER . 0.6 OUTLIER -46.3 -53.01 11.56 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.215 -0.928 . . . . 0.0 109.361 -179.696 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.693 ' N ' ' CD1' ' A' ' 30' ' ' PHE . 91.4 p -60.16 -21.19 61.35 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.095 -1.003 . . . . 0.0 110.025 -179.631 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.466 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -63.19 -23.6 67.5 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.042 -1.036 . . . . 0.0 109.468 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.553 HD11 ' CD1' ' A' ' 41' ' ' LEU . 3.5 mp . . . . . 0 N--CA 1.489 1.477 0 O-C-N 121.206 -0.934 . . . . 0.0 109.605 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.629 ' O ' ' CD2' ' A' ' 9' ' ' PHE . 3.0 mp . . . . . 0 N--CA 1.489 1.486 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.495 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.1 tt0 -121.61 150.63 41.42 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.26 -0.9 . . . . 0.0 109.338 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 61.5 tt0 -67.44 124.23 22.62 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.23 -0.919 . . . . 0.0 109.538 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 90.96 -3.58 80.93 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 179.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.495 ' HB2' ' HB3' ' A' ' 42' ' ' GLU . 61.4 tp60 -81.71 131.6 35.27 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.18 -1.189 . . . . 0.0 109.603 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.467 ' O ' HG12 ' A' ' 47' ' ' VAL . . . -76.54 140.16 41.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.187 -0.946 . . . . 0.0 109.204 179.741 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.589 ' CG2' HD12 ' A' ' 18' ' ' ILE . 33.8 m -141.26 159.96 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.151 -0.968 . . . . 0.0 109.532 -179.84 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.511 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 43.4 m -112.86 155.62 24.36 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.385 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.563 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 3.7 p90 171.69 166.48 0.09 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.037 -1.039 . . . . 0.0 110.144 -179.692 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -97.82 157.53 16.02 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.729 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.469 HD12 ' OE1' ' A' ' 23' ' ' GLN . 1.4 mt -98.12 128.1 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.985 -1.072 . . . . 0.0 110.006 -179.473 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.552 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 0.3 OUTLIER -110.07 119.68 59.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.366 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -89.01 91.44 8.83 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.203 -0.936 . . . . 0.0 109.872 -179.446 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -97.23 -176.2 34.58 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -53.57 -61.59 2.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.178 -1.189 . . . . 0.0 109.663 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 61.3 mtp180 -47.9 -38.88 17.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.232 -0.917 . . . . 0.0 109.049 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.86 -157.3 27.3 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -71.06 140.78 38.54 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.719 2.279 . . . . 0.0 111.692 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.552 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 91.8 mt-30 -135.51 167.78 20.44 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.21 -0.931 . . . . 0.0 109.232 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.504 ' N ' ' O ' ' A' ' 27' ' ' PHE . . . -96.42 137.58 35.28 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.18 -0.95 . . . . 0.0 110.158 -179.354 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.563 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -125.18 156.67 38.06 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.466 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.524 ' C ' ' O ' ' A' ' 61' ' ' ALA . 80.7 m-20 38.68 74.56 0.09 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.075 -1.016 . . . . 0.0 108.927 -179.765 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.541 ' CG1' HG13 ' A' ' 33' ' ' ILE . 2.4 t -89.32 129.62 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.234 -0.916 . . . . 0.0 110.307 -178.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.446 HG21 ' OE2' ' A' ' 66' ' ' GLU . 60.8 m -118.54 124.66 48.07 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.513 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 53.2 mttt -67.18 107.37 2.31 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.245 -0.91 . . . . 0.0 109.281 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.446 ' OE2' HG21 ' A' ' 64' ' ' THR . 59.4 mm-40 -97.09 170.58 9.03 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.157 -0.964 . . . . 0.0 109.622 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.406 179.989 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.477 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 71.6 mt . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 121.256 0.55 . . . . 0.0 109.539 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.414 ' O ' HG12 ' A' ' 20' ' ' VAL . 1.4 tt0 -130.75 140.89 50.35 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.34 -0.85 . . . . 0.0 109.329 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.49 155.06 25.05 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.474 ' O ' HG22 ' A' ' 18' ' ' ILE . 84.5 mttt -104.14 139.51 39.09 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.317 -1.108 . . . . 0.0 108.764 179.553 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.496 ' HB ' ' O ' ' A' ' 42' ' ' GLU . 16.0 t -72.22 113.16 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.097 -1.002 . . . . 0.0 110.085 -179.223 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.3 tttt -78.85 -40.87 31.49 Favored 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 179.546 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.604 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.96 154.41 25.82 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.812 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.601 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 8.2 p90 -155.59 141.27 17.95 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.026 -1.046 . . . . 0.0 109.315 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.436 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 63.2 t-20 . . . . . 0 N--CA 1.49 1.545 0 O-C-N 121.166 -0.959 . . . . 0.0 109.777 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.526 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 5.6 p90 . . . . . 0 N--CA 1.492 1.673 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.604 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -134.71 174.54 21.0 Favored Glycine 0 N--CA 1.491 2.349 0 C-N-CA 119.708 -1.234 . . . . 0.0 110.087 -179.438 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.49 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 26.1 m-85 -115.75 137.94 51.6 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.463 -1.022 . . . . 0.0 109.215 179.755 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.6 ' CD1' ' CG2' ' A' ' 28' ' ' VAL . 12.5 mt -123.69 154.06 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.161 -0.962 . . . . 0.0 109.491 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.46 ' N ' HG23 ' A' ' 18' ' ' ILE . 6.9 tt0 -117.98 116.06 26.15 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.313 -0.867 . . . . 0.0 109.503 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.524 HG23 ' CG2' ' A' ' 26' ' ' VAL . 2.4 t -85.33 118.4 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.276 -0.89 . . . . 0.0 109.353 179.789 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 85.4 mt-10 -68.43 111.08 4.45 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.196 -0.94 . . . . 0.0 109.243 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.444 ' C ' ' HG3' ' A' ' 23' ' ' GLN . . . 120.93 -15.66 9.51 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.444 ' HG3' ' C ' ' A' ' 22' ' ' GLY . 49.5 mt-30 -140.68 169.75 17.05 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.222 -1.164 . . . . 0.0 109.622 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 60.5 m-20 -54.75 -179.21 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.254 -0.904 . . . . 0.0 109.681 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.461 ' OD1' ' N ' ' A' ' 25' ' ' ASP . 18.4 p30 -75.41 144.0 42.44 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.307 -0.871 . . . . 0.0 109.706 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.524 ' CG2' HG23 ' A' ' 20' ' ' VAL . 86.4 t -118.38 118.8 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.224 -0.923 . . . . 0.0 109.263 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.586 ' CD1' ' N ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER -77.31 159.0 29.88 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.152 -0.967 . . . . 0.0 109.154 -179.935 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.6 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 13.6 t -134.08 131.43 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.356 -0.84 . . . . 0.0 109.393 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.664 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 17.4 t-80 -106.97 154.64 20.79 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.313 -0.867 . . . . 0.0 109.027 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.676 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -46.47 -53.36 11.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.023 -1.048 . . . . 0.0 109.205 -179.631 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.676 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 54.6 p -53.91 -30.75 47.57 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.155 -0.966 . . . . 0.0 110.347 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.475 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -61.83 -21.24 64.47 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.029 -1.045 . . . . 0.0 109.465 -179.856 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.536 ' CD1' HD11 ' A' ' 41' ' ' LEU . 3.2 mp . . . . . 0 N--CA 1.489 1.479 0 O-C-N 121.204 -0.935 . . . . 0.0 109.506 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.601 ' O ' ' CD2' ' A' ' 9' ' ' PHE . 5.3 mp . . . . . 0 N--CA 1.488 1.441 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.496 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 84.7 tt0 -117.31 149.78 39.9 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.181 -0.949 . . . . 0.0 109.055 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.437 ' HA ' HG13 ' A' ' 6' ' ' VAL . 62.8 tt0 -70.52 123.97 23.08 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.253 -0.904 . . . . 0.0 109.584 -179.778 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 92.89 -3.41 73.79 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 179.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.49 ' HB2' ' HB3' ' A' ' 42' ' ' GLU . 60.7 tt0 -82.74 134.95 35.12 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.119 -1.224 . . . . 0.0 109.906 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.485 ' O ' HG12 ' A' ' 47' ' ' VAL . . . -81.1 141.56 34.17 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.399 -0.813 . . . . 0.0 109.067 179.501 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.591 ' CG2' HD13 ' A' ' 18' ' ' ILE . 28.1 m -141.51 159.57 21.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.131 -0.981 . . . . 0.0 109.922 -179.529 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.503 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 23.0 t -110.89 154.06 24.58 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.424 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.541 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 5.6 p90 172.26 166.14 0.11 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.01 -1.056 . . . . 0.0 110.077 -179.746 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -98.98 160.55 14.18 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.435 HD12 ' OE1' ' A' ' 23' ' ' GLN . 0.8 OUTLIER -97.94 125.41 51.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 120.933 -1.105 . . . . 0.0 109.781 -179.436 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.582 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 0.1 OUTLIER -107.85 118.95 56.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.473 -0.767 . . . . 0.0 109.076 179.852 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -86.76 84.78 7.3 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.314 -0.866 . . . . 0.0 109.704 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.43 -177.31 41.61 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.3 t30 -54.2 -61.98 1.96 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.219 -1.165 . . . . 0.0 109.563 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 39.7 mtp180 -48.32 -39.36 21.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.285 -0.884 . . . . 0.0 109.135 179.794 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 148.81 -158.86 27.82 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.532 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 49.8 Cg_endo -70.23 140.44 40.92 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.686 2.257 . . . . 0.0 111.716 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.582 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 8.5 mt-30 -133.88 166.25 23.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.318 -0.864 . . . . 0.0 109.37 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -87.58 128.4 35.26 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.308 -0.87 . . . . 0.0 109.871 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.541 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -112.74 146.45 38.74 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.35 -0.844 . . . . 0.0 108.812 179.457 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.472 ' C ' ' O ' ' A' ' 61' ' ' ALA . 62.5 t30 42.82 71.9 0.2 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.046 -1.034 . . . . 0.0 108.776 -179.615 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.53 HG12 ' CG1' ' A' ' 33' ' ' ILE . 2.0 t -83.82 127.1 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.365 -0.834 . . . . 0.0 110.162 -178.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 93.9 m -119.79 127.04 52.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.449 -0.782 . . . . 0.0 109.016 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.509 ' HE3' ' HA ' ' A' ' 41' ' ' LEU . 55.1 mttp -77.46 112.78 14.57 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.172 -0.955 . . . . 0.0 109.726 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -89.82 165.11 14.34 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.902 . . . . 0.0 109.428 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 118.009 -0.996 . . . . 0.0 109.41 -179.999 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.499 ' CD1' ' N ' ' A' ' 2' ' ' LEU . 6.2 mp . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.476 ' HG2' ' O ' ' A' ' 47' ' ' VAL . 3.0 tt0 -133.39 132.53 41.3 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.306 -0.871 . . . . 0.0 109.217 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.515 ' C ' ' CG2' ' A' ' 18' ' ' ILE . . . -135.63 167.6 24.19 Favored Glycine 0 N--CA 1.491 2.342 0 C-N-CA 119.632 -1.27 . . . . 0.0 110.229 -179.602 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.514 ' O ' ' HA ' ' A' ' 18' ' ' ILE . 44.0 mmtm -110.39 135.63 50.81 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.544 -0.974 . . . . 0.0 108.693 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.561 ' HA ' HG12 ' A' ' 18' ' ' ILE . 17.6 t -68.5 116.14 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.19 -0.944 . . . . 0.0 109.973 -179.556 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.422 ' N ' ' O ' ' A' ' 17' ' ' PHE . 11.5 tttm -80.38 -33.69 37.0 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.303 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.671 ' CD2' ' N ' ' A' ' 9' ' ' PHE . 0.4 OUTLIER -162.57 166.41 24.74 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 179.671 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.671 ' N ' ' CD2' ' A' ' 8' ' ' TRP . 9.9 p90 -164.47 145.93 8.32 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.94 -1.1 . . . . 0.0 110.601 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.633 ' HB3' ' CE1' ' A' ' 15' ' ' PHE . 38.0 t-20 . . . . . 0 N--CA 1.493 1.679 0 O-C-N 121.391 -0.818 . . . . 0.0 109.615 179.741 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.633 ' CE1' ' HB3' ' A' ' 10' ' ' ASN . 1.4 p90 . . . . . 0 N--CA 1.488 1.458 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.598 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -176.75 151.18 10.99 Favored Glycine 0 N--CA 1.487 2.076 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.026 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.46 ' HB3' ' OD2' ' A' ' 25' ' ' ASP . 89.4 m-85 -79.08 143.18 35.8 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.369 -1.077 . . . . 0.0 108.803 179.596 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.643 HG21 ' N ' ' A' ' 19' ' ' GLU . 73.3 mt -121.84 149.17 25.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 -179.786 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.643 ' N ' HG21 ' A' ' 18' ' ' ILE . 44.5 tt0 -103.7 118.49 36.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.199 -0.938 . . . . 0.0 109.529 -179.852 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.498 HG21 ' CG2' ' A' ' 26' ' ' VAL . 3.4 t -94.32 123.51 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.255 -0.903 . . . . 0.0 109.417 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -59.08 99.93 0.06 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.303 -0.873 . . . . 0.0 109.674 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.25 -29.04 3.54 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 179.623 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.431 ' OE1' HD11 ' A' ' 51' ' ' ILE . 15.0 mt-30 -127.05 169.86 12.93 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.133 -1.216 . . . . 0.0 109.739 -179.814 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.533 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -60.24 -163.41 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.237 -0.914 . . . . 0.0 109.553 179.753 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.46 ' OD2' ' HB3' ' A' ' 17' ' ' PHE . 2.9 t70 -77.53 143.64 38.25 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.285 -0.884 . . . . 0.0 109.713 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.498 ' CG2' HG21 ' A' ' 20' ' ' VAL . 88.4 t -115.95 127.14 73.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.371 -0.831 . . . . 0.0 109.367 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.523 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.1 OUTLIER -76.47 148.23 37.35 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.118 -0.988 . . . . 0.0 109.636 -179.791 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.606 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 16.5 t -131.14 131.44 63.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 -179.79 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.672 ' CE1' ' CE2' ' A' ' 30' ' ' PHE . 12.1 t-80 -102.68 148.33 25.72 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.083 -1.011 . . . . 0.0 109.924 -179.529 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.672 ' CE2' ' CE1' ' A' ' 29' ' ' HIS . 1.1 p90 -43.57 -51.83 6.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.307 -0.871 . . . . 0.0 109.519 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.672 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 46.5 p -61.27 -13.58 19.9 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.168 -0.957 . . . . 0.0 109.801 -179.701 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.517 ' N ' ' O ' ' A' ' 29' ' ' HIS . . . -66.68 -25.23 66.45 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.265 -0.897 . . . . 0.0 109.642 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.562 HG13 ' CG1' ' A' ' 63' ' ' VAL . 2.2 mp . . . . . 0 N--CA 1.491 1.607 0 O-C-N 121.257 -0.902 . . . . 0.0 109.725 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.536 ' CD1' HD11 ' A' ' 33' ' ' ILE . 1.1 mt . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.279 0.562 . . . . 0.0 109.614 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.461 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 80.2 tt0 -117.42 150.76 38.35 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.341 -0.85 . . . . 0.0 109.249 179.84 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 68.4 tt0 -68.33 128.07 35.25 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.914 . . . . 0.0 109.571 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 86.77 -2.94 87.33 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 179.733 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.461 ' HB2' ' HB3' ' A' ' 42' ' ' GLU . 51.8 tt0 -80.44 134.62 36.01 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.203 -1.175 . . . . 0.0 109.715 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.514 ' O ' HG13 ' A' ' 47' ' ' VAL . . . -87.55 142.52 27.79 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.299 -0.876 . . . . 0.0 109.169 179.689 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.626 ' CG2' HD11 ' A' ' 18' ' ' ILE . 32.9 m -147.06 167.06 5.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.232 -0.918 . . . . 0.0 109.864 -179.734 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.575 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 24.0 t -109.15 154.77 21.87 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 178.838 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.569 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 8.1 p90 172.15 168.59 0.11 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.003 -1.061 . . . . 0.0 110.034 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 90.2 mt-10 -105.99 169.24 8.61 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 179.173 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.431 HD11 ' OE1' ' A' ' 23' ' ' GLN . 4.2 mt -111.02 136.87 45.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.022 -1.049 . . . . 0.0 109.546 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.416 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 33.7 m -123.04 134.36 66.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.465 -0.772 . . . . 0.0 108.942 179.727 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -90.49 79.64 6.18 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.139 -0.975 . . . . 0.0 109.613 -179.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -81.3 -179.5 53.04 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -52.45 -57.15 10.79 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.177 -1.19 . . . . 0.0 109.559 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 82.1 mtm180 -54.19 -38.17 65.32 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.163 -0.96 . . . . 0.0 109.599 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.08 -153.34 25.29 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.416 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 50.9 Cg_endo -70.76 133.76 24.41 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.867 2.378 . . . . 0.0 112.146 -179.825 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 83.7 mt-30 -133.53 164.66 26.65 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.356 -0.84 . . . . 0.0 109.032 179.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -92.72 136.93 32.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.119 -0.988 . . . . 0.0 110.104 -179.506 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.569 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -121.14 153.06 38.01 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 179.376 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.499 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 85.0 m-20 43.86 79.41 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.962 -1.086 . . . . 0.0 108.702 -179.557 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.575 ' HA ' ' O ' ' A' ' 48' ' ' SER . 2.1 t -94.63 124.34 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.161 -0.962 . . . . 0.0 110.195 -179.059 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.475 ' HB ' ' HB3' ' A' ' 48' ' ' SER . 97.1 m -114.16 114.96 26.74 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.49 -0.756 . . . . 0.0 109.055 179.576 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.485 ' HA ' HG13 ' A' ' 47' ' ' VAL . 56.5 mttt -65.02 118.4 9.07 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.335 -0.853 . . . . 0.0 109.426 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 67.1 mm-40 -102.38 162.56 12.82 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.378 -0.826 . . . . 0.0 109.732 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.462 -179.957 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.449 HD13 HD13 ' A' ' 51' ' ' ILE . 26.5 mt . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 74.1 mt-10 -133.82 134.69 43.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.268 -0.895 . . . . 0.0 109.441 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -139.7 157.09 25.1 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.705 -1.358 . . . . 0.0 109.705 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.413 ' NZ ' ' OE2' ' A' ' 21' ' ' GLU . 69.6 mttt -111.21 133.69 53.37 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.435 -1.038 . . . . 0.0 108.438 179.189 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.5 ' HA ' HG12 ' A' ' 18' ' ' ILE . 16.2 t -64.05 115.18 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.113 -0.992 . . . . 0.0 110.118 -179.328 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.474 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 14.9 tptp -78.12 -42.04 33.16 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 179.508 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.612 ' O ' ' CE3' ' A' ' 8' ' ' TRP . 0.0 OUTLIER -162.29 156.07 21.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.499 -0.751 . . . . 0.0 109.093 179.99 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.641 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 10.6 p90 -154.16 140.53 18.68 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.13 -0.981 . . . . 0.0 109.041 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 54.5 t-20 . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.13 -0.981 . . . . 0.0 109.499 -179.989 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.621 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.627 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 . . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.562 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -155.41 176.85 32.88 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 109.531 -1.427 . . . . 0.0 109.531 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.527 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 43.6 m-85 -113.79 133.3 55.47 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.248 -1.148 . . . . 0.0 109.187 179.789 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.627 HD11 ' CG2' ' A' ' 47' ' ' VAL . 61.7 mt -116.18 145.43 21.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.388 -0.82 . . . . 0.0 109.722 -179.669 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.536 ' N ' HG23 ' A' ' 18' ' ' ILE . 28.7 tt0 -108.09 116.5 32.07 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.415 -0.803 . . . . 0.0 109.495 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.452 HG22 HG23 ' A' ' 26' ' ' VAL . 2.8 t -87.96 125.93 41.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.295 -0.878 . . . . 0.0 109.422 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.413 ' OE2' ' NZ ' ' A' ' 5' ' ' LYS . 93.3 mt-10 -69.85 101.62 1.77 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.293 -0.879 . . . . 0.0 109.221 179.849 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.22 -22.97 6.97 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 -179.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.434 ' NE2' HG12 ' A' ' 51' ' ' ILE . 12.6 mt-30 -123.28 158.81 30.12 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.364 -1.08 . . . . 0.0 109.322 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.429 ' O ' ' O ' ' A' ' 23' ' ' GLN . 44.8 m-20 -54.81 -171.24 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.19 -0.944 . . . . 0.0 109.452 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.54 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 88.6 m-20 -73.73 133.25 43.3 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.196 -0.94 . . . . 0.0 109.533 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.541 HG23 ' CG1' ' A' ' 51' ' ' ILE . 96.0 t -111.06 125.24 68.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.256 -0.903 . . . . 0.0 109.234 -179.882 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.573 ' CE1' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER -79.28 159.64 27.16 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.052 -1.03 . . . . 0.0 109.747 -179.716 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.609 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 57.8 t -133.95 137.95 51.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.432 -0.792 . . . . 0.0 109.419 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.572 ' O ' ' CD1' ' A' ' 33' ' ' ILE . 21.7 t-80 -111.23 150.59 29.37 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.291 -0.88 . . . . 0.0 108.899 179.593 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.713 ' CG ' ' N ' ' A' ' 31' ' ' SER . 1.3 p90 -48.09 -54.21 13.94 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.046 -1.034 . . . . 0.0 109.298 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.713 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 19.2 t -55.96 -30.55 61.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.025 -1.047 . . . . 0.0 109.899 -179.441 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.563 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -63.66 -17.56 63.06 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.021 -1.049 . . . . 0.0 108.544 179.505 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.582 HD12 ' CD1' ' A' ' 41' ' ' LEU . 0.6 OUTLIER . . . . . 0 C--N 1.302 -1.492 0 O-C-N 121.607 -0.683 . . . . 0.0 109.434 -179.86 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.641 ' O ' ' CD2' ' A' ' 9' ' ' PHE . 5.2 mp . . . . . 0 N--CA 1.489 1.497 0 CA-C-O 121.345 0.593 . . . . 0.0 109.745 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.424 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.2 tt0 -96.98 132.28 42.95 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.237 -0.914 . . . . 0.0 109.528 -179.852 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.474 ' OE2' ' O ' ' A' ' 7' ' ' LYS . 75.1 tt0 -59.51 129.01 39.88 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.318 -0.864 . . . . 0.0 109.343 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 93.74 -8.06 74.0 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.46 ' O ' HG21 ' A' ' 6' ' ' VAL . 70.6 tp60 -78.41 126.33 30.62 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.162 -1.199 . . . . 0.0 109.596 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.47 ' O ' HG11 ' A' ' 47' ' ' VAL . . . -82.88 143.26 30.87 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.251 -0.905 . . . . 0.0 109.344 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.627 ' CG2' HD11 ' A' ' 18' ' ' ILE . 34.4 m -144.41 167.04 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.908 . . . . 0.0 109.597 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.469 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 22.3 t -109.72 154.67 22.56 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.376 -0.827 . . . . 0.0 108.839 179.502 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.623 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 4.2 p90 172.79 166.03 0.13 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.959 -1.088 . . . . 0.0 110.312 -179.759 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.421 ' HA ' ' OE1' ' A' ' 50' ' ' GLU . 67.5 mm-40 -96.09 159.68 14.84 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 178.581 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.541 ' CG1' HG23 ' A' ' 26' ' ' VAL . 1.1 mp -100.52 127.5 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.939 -1.101 . . . . 0.0 110.044 -179.431 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.597 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 27.5 m -115.86 124.18 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 178.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 22.0 mt-10 -95.74 97.16 9.48 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.127 -0.983 . . . . 0.0 109.703 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.19 -179.35 42.77 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.436 ' CG ' ' N ' ' A' ' 56' ' ' ARG . 16.0 p-10 -53.97 -50.31 66.8 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.159 -1.201 . . . . 0.0 109.514 -179.87 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.436 ' N ' ' CG ' ' A' ' 55' ' ' ASN . 33.3 mtp85 -61.31 -42.19 98.25 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.052 -1.03 . . . . 0.0 109.793 -179.726 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 158.79 -164.64 33.75 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 110.016 -1.233 . . . . 0.0 110.016 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.54 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 44.1 Cg_endo -68.55 139.78 45.73 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 123.198 2.598 . . . . 0.0 112.637 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.597 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 68.5 mt-30 -135.58 165.41 25.6 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.301 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.554 ' N ' ' O ' ' A' ' 27' ' ' PHE . . . -99.17 141.96 31.26 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.976 -1.077 . . . . 0.0 110.467 -179.031 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.526 ' O ' ' C ' ' A' ' 62' ' ' ASN . . . -124.22 155.7 38.1 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 179.128 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.526 ' C ' ' O ' ' A' ' 61' ' ' ALA . 0.3 OUTLIER 37.58 66.72 0.43 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.172 -0.955 . . . . 0.0 109.003 -179.798 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.623 ' HA ' ' HB3' ' A' ' 49' ' ' PHE . 2.0 t -79.01 130.99 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.337 -0.852 . . . . 0.0 110.073 -179.048 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.523 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 25.2 m -117.15 123.4 46.63 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.328 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.559 ' HE2' HG21 ' A' ' 33' ' ' ILE . 47.4 mttm -74.97 115.49 14.64 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.203 -0.935 . . . . 0.0 109.939 -179.56 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.455 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 47.2 mt-10 -99.79 169.17 9.43 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.278 -0.889 . . . . 0.0 109.413 179.837 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 118.062 -0.971 . . . . 0.0 109.547 179.827 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.492 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 61.9 mt . . . . . 0 N--CA 1.489 1.508 0 CA-C-O 121.361 0.6 . . . . 0.0 109.672 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -123.45 140.31 53.13 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.323 -0.861 . . . . 0.0 108.901 179.639 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.418 ' HA3' HG21 ' A' ' 18' ' ' ILE . . . -144.39 148.53 20.34 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.893 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 50.0 mttp -101.77 142.63 32.8 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.353 -1.086 . . . . 0.0 108.771 179.288 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.459 HG23 ' O ' ' A' ' 45' ' ' GLN . 21.5 t -73.8 113.47 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.112 -0.993 . . . . 0.0 109.642 -179.64 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.425 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 27.2 tttm -78.65 -41.73 30.61 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.777 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.682 ' CZ3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -160.39 156.51 26.25 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.454 -0.779 . . . . 0.0 108.986 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.595 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 12.5 p90 -155.33 142.95 19.71 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.129 -0.982 . . . . 0.0 109.299 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 58.7 t-20 . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.063 -1.023 . . . . 0.0 109.518 -179.946 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.6 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.338 0.59 . . . . 0.0 109.654 . . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.55 ' O ' HG11 ' A' ' 28' ' ' VAL . . . -144.07 170.28 25.97 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.682 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 30.3 m-85 -111.23 128.67 56.0 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.393 -1.063 . . . . 0.0 108.968 179.798 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.545 HD11 ' CG1' ' A' ' 28' ' ' VAL . 67.8 mt -111.37 145.45 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.184 -0.947 . . . . 0.0 109.699 -179.801 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 5.3 tt0 -108.16 110.83 22.57 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.399 -0.813 . . . . 0.0 109.087 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.526 ' CG2' HG22 ' A' ' 26' ' ' VAL . 2.7 t -89.62 118.09 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.317 -0.864 . . . . 0.0 109.488 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -68.01 109.61 3.55 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.278 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.78 -21.78 6.58 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.5 ' OE1' ' CD1' ' A' ' 51' ' ' ILE . 50.2 mt-30 -135.47 168.8 18.54 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.197 -1.178 . . . . 0.0 109.596 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -55.19 -173.7 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.285 -0.884 . . . . 0.0 109.443 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -77.83 141.6 39.07 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.166 -0.959 . . . . 0.0 109.997 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.526 HG22 ' CG2' ' A' ' 20' ' ' VAL . 63.5 t -111.0 114.04 45.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.231 -0.918 . . . . 0.0 109.355 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.508 ' HE1' ' HB2' ' A' ' 15' ' ' PHE . 0.2 OUTLIER -84.48 106.85 16.38 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.254 -0.904 . . . . 0.0 109.276 179.812 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.55 HG11 ' O ' ' A' ' 16' ' ' GLY . 0.2 OUTLIER -86.41 143.74 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 O-C-N 121.128 -0.982 . . . . 0.0 109.712 -179.308 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.7 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 15.6 t-80 -113.86 157.99 21.62 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.653 -0.655 . . . . 0.0 109.272 -179.606 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.7 ' CD2' ' CE1' ' A' ' 29' ' ' HIS . 0.8 OUTLIER -46.37 -54.89 8.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.881 -1.137 . . . . 0.0 108.761 -179.787 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.699 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 94.1 p -50.82 -37.56 43.56 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.212 -0.93 . . . . 0.0 109.918 -179.791 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.479 ' HB1' ' O ' ' A' ' 29' ' ' HIS . . . -56.43 -29.02 61.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.036 -1.04 . . . . 0.0 109.341 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.582 HG12 HD11 ' A' ' 41' ' ' LEU . 1.9 mp . . . . . 0 C--N 1.302 -1.462 0 O-C-N 121.397 -0.814 . . . . 0.0 109.317 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.595 ' O ' ' CD2' ' A' ' 9' ' ' PHE . 3.6 mp . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 121.402 0.62 . . . . 0.0 109.861 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.439 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 85.1 tt0 -106.72 149.51 27.23 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.475 -0.766 . . . . 0.0 109.192 179.614 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.425 ' HG3' ' O ' ' A' ' 7' ' ' LYS . 70.2 tt0 -72.35 124.23 24.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.19 -0.943 . . . . 0.0 109.499 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 96.16 -7.5 66.89 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.459 ' O ' HG23 ' A' ' 6' ' ' VAL . 60.5 tt0 -81.31 127.64 32.95 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.209 -1.171 . . . . 0.0 109.651 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.438 ' O ' HG13 ' A' ' 47' ' ' VAL . . . -74.56 145.22 43.59 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.338 -0.851 . . . . 0.0 109.444 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.512 HG22 ' CD1' ' A' ' 18' ' ' ILE . 34.6 m -145.88 160.86 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.095 -1.003 . . . . 0.0 110.017 -179.747 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.55 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 9.6 p -113.7 158.46 20.88 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.25 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.601 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 8.8 p90 169.25 169.3 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.999 -1.063 . . . . 0.0 109.996 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.461 ' HA ' ' OE1' ' A' ' 50' ' ' GLU . 65.3 mm-40 -104.97 157.84 16.95 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 178.826 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.5 ' CD1' ' OE1' ' A' ' 23' ' ' GLN . 1.9 mt -95.66 130.64 44.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 120.922 -1.111 . . . . 0.0 110.105 -179.41 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.515 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 3.6 m -112.7 122.57 67.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.306 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -90.77 88.85 7.24 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.039 -1.038 . . . . 0.0 109.755 -179.414 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -93.41 -175.36 40.37 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.7 t30 -54.51 -63.1 1.26 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.2 -1.176 . . . . 0.0 109.639 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 72.5 mtp180 -46.75 -38.9 10.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.125 -0.985 . . . . 0.0 109.033 179.827 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.77 -158.85 27.85 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.481 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 49.2 Cg_endo -70.71 142.48 43.85 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.565 2.177 . . . . 0.0 111.747 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.515 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 67.7 mt-30 -139.17 169.15 18.31 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.342 -0.849 . . . . 0.0 109.133 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.532 ' CB ' ' HB ' ' A' ' 28' ' ' VAL . . . -89.92 134.07 34.42 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.972 -1.08 . . . . 0.0 110.14 -179.463 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.565 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -121.56 153.09 38.47 Favored 'General case' 0 N--CA 1.491 1.601 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.541 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.497 ' C ' ' O ' ' A' ' 61' ' ' ALA . 83.6 m-20 41.13 72.74 0.15 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.033 -1.042 . . . . 0.0 108.577 -179.475 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.601 ' HA ' ' HB3' ' A' ' 49' ' ' PHE . 2.2 t -92.98 130.39 42.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.218 -0.926 . . . . 0.0 110.517 -178.724 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.3 m -120.08 125.23 47.77 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.493 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.532 ' HE3' HD13 ' A' ' 41' ' ' LEU . 29.6 mttp -74.36 112.1 10.19 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.067 -1.021 . . . . 0.0 109.702 -179.606 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -88.89 163.78 15.46 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.318 -0.864 . . . . 0.0 109.605 -179.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 118.004 -0.998 . . . . 0.0 109.439 179.88 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.567 ' CD1' ' N ' ' A' ' 2' ' ' LEU . 5.6 mp . . . . . 0 N--CA 1.489 1.502 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 58.6 mt-10 -132.28 127.97 36.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.147 -0.97 . . . . 0.0 109.446 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.431 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -127.51 155.25 19.95 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.408 ' O ' HG21 ' A' ' 18' ' ' ILE . 43.2 mttt -103.99 138.48 40.47 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.299 -1.118 . . . . 0.0 108.874 179.578 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.495 ' HA ' HG12 ' A' ' 18' ' ' ILE . 18.9 t -71.28 113.24 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.213 -0.929 . . . . 0.0 110.045 -179.469 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 13.0 ttpt -80.08 -40.71 27.06 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.588 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.41 155.4 28.57 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.397 -0.814 . . . . 0.0 109.018 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 9.6 p90 -156.22 137.96 14.25 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.128 -0.983 . . . . 0.0 109.242 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.456 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 52.3 t-20 . . . . . 0 N--CA 1.489 1.492 0 O-C-N 121.233 -0.917 . . . . 0.0 109.437 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.499 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 . . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.588 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -140.37 172.41 23.53 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.424 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 27.6 m-85 -113.9 132.86 55.77 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.341 -1.094 . . . . 0.0 108.986 179.786 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.572 ' CD1' ' CG2' ' A' ' 47' ' ' VAL . 13.9 mt -116.22 151.52 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.252 -0.905 . . . . 0.0 109.717 -179.646 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -115.57 116.91 28.95 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.365 -0.834 . . . . 0.0 109.21 179.863 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.442 HG23 ' CG2' ' A' ' 26' ' ' VAL . 2.3 t -94.3 119.82 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.364 -0.835 . . . . 0.0 109.395 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -69.21 110.55 4.64 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.24 -0.913 . . . . 0.0 109.351 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 125.78 -37.77 2.42 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.525 ' OE1' ' CD1' ' A' ' 51' ' ' ILE . 56.4 mt-30 -120.45 166.31 13.76 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.366 -1.079 . . . . 0.0 109.381 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.422 ' O ' ' O ' ' A' ' 23' ' ' GLN . 49.5 m-20 -52.53 -176.83 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.206 -0.934 . . . . 0.0 109.562 -179.862 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.489 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 81.0 m-20 -74.31 141.93 45.22 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.346 -0.846 . . . . 0.0 109.629 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.464 HG21 ' CG1' ' A' ' 51' ' ' ILE . 98.2 t -115.08 117.95 57.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.242 -0.911 . . . . 0.0 109.31 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.555 ' O ' ' N ' ' A' ' 60' ' ' ALA . 0.1 OUTLIER -76.73 161.12 28.76 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.103 -0.998 . . . . 0.0 109.388 -179.879 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.588 ' CG1' HG22 ' A' ' 63' ' ' VAL . 14.6 t -133.75 134.13 56.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.287 -0.883 . . . . 0.0 109.602 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.642 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 15.2 t-80 -104.66 151.33 23.82 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.217 -0.927 . . . . 0.0 109.19 179.652 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.685 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -44.92 -53.96 7.03 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.106 -0.996 . . . . 0.0 109.549 -179.529 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.685 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 90.3 p -60.35 -18.49 50.42 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.06 -1.025 . . . . 0.0 109.956 -179.544 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.466 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -67.36 -24.54 65.72 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.075 -1.016 . . . . 0.0 109.356 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.565 ' CG1' HD12 ' A' ' 41' ' ' LEU . 3.1 mp . . . . . 0 N--CA 1.489 1.514 0 O-C-N 121.303 -0.873 . . . . 0.0 109.468 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.584 ' O ' ' CD2' ' A' ' 9' ' ' PHE . 5.8 mp . . . . . 0 N--CA 1.489 1.5 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.467 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.1 tt0 -120.25 138.53 53.61 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.238 -0.914 . . . . 0.0 109.619 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.453 ' HA ' HG12 ' A' ' 6' ' ' VAL . 57.4 tt0 -67.65 129.7 40.72 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.261 -0.899 . . . . 0.0 109.454 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 90.64 -5.88 82.25 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.467 ' HB2' ' HB3' ' A' ' 42' ' ' GLU . 60.4 tt0 -81.12 126.11 31.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.215 -1.168 . . . . 0.0 109.371 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.497 ' O ' HG11 ' A' ' 47' ' ' VAL . . . -79.18 142.49 36.28 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.228 -0.92 . . . . 0.0 109.31 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.572 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 28.2 m -143.96 168.65 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.246 -0.909 . . . . 0.0 109.438 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.5 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 9.4 t -114.51 155.26 26.76 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.324 -0.86 . . . . 0.0 108.859 179.65 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.591 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 5.6 p90 173.38 165.88 0.16 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.041 -1.037 . . . . 0.0 110.099 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 90.8 mt-10 -100.6 150.36 22.79 Favored 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.815 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.525 ' CD1' ' OE1' ' A' ' 23' ' ' GLN . 0.5 OUTLIER -87.13 123.05 39.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.029 -1.044 . . . . 0.0 109.837 -179.574 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.622 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.6 m -107.03 120.87 59.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.385 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -88.41 85.18 6.82 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.259 -0.901 . . . . 0.0 109.633 -179.544 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.39 -177.05 43.18 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 18.4 p-10 -55.27 -55.89 26.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.097 -1.237 . . . . 0.0 109.701 -179.743 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 43.3 mtp180 -52.43 -41.27 63.11 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.992 -1.068 . . . . 0.0 109.285 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 146.34 -150.85 23.14 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.489 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 47.6 Cg_endo -70.24 129.25 16.78 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.817 2.345 . . . . 0.0 112.292 -179.851 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.622 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 53.7 mt-30 -131.04 164.23 25.85 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 179.138 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.555 ' N ' ' O ' ' A' ' 27' ' ' PHE . . . -90.52 127.08 36.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.098 -1.001 . . . . 0.0 110.401 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.535 ' O ' ' C ' ' A' ' 62' ' ' ASN . . . -109.86 147.71 32.85 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.034 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.535 ' C ' ' O ' ' A' ' 61' ' ' ALA . 59.2 t30 38.17 73.73 0.1 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.049 -1.032 . . . . 0.0 108.816 -179.686 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.591 ' HA ' ' HB3' ' A' ' 49' ' ' PHE . 1.4 t -84.8 129.62 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.321 -0.862 . . . . 0.0 110.331 -178.767 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.457 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 13.0 m -115.28 121.37 42.68 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.459 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.51 ' HA ' ' CG1' ' A' ' 47' ' ' VAL . 20.2 mttt -74.12 114.83 12.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.154 -0.966 . . . . 0.0 109.742 -179.67 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.439 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 50.8 mt-10 -98.99 168.05 10.35 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.354 -0.841 . . . . 0.0 109.616 -179.818 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.495 0 CA-C-O 117.944 -1.027 . . . . 0.0 109.444 179.989 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 21.1 mt . . . . . 0 N--CA 1.488 1.448 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -134.19 127.9 32.91 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.209 -0.932 . . . . 0.0 109.297 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.41 ' C ' ' CG2' ' A' ' 18' ' ' ILE . . . -126.49 158.63 20.64 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 -179.735 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.476 ' NZ ' ' OE2' ' A' ' 21' ' ' GLU . 38.8 mttp -103.7 133.64 48.37 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.394 -1.063 . . . . 0.0 108.823 179.561 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.45 HG21 ' O ' ' A' ' 45' ' ' GLN . 18.3 t -66.49 113.73 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.151 -0.968 . . . . 0.0 110.055 -179.344 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -79.12 -39.93 32.36 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.34 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.642 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -159.11 155.01 26.51 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.807 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.646 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 9.1 p90 -155.57 140.55 17.32 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.056 -1.028 . . . . 0.0 109.347 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.463 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.2 t-20 . . . . . 0 N--CA 1.489 1.504 0 O-C-N 121.117 -0.989 . . . . 0.0 109.727 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.554 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 1.2 p90 . . . . . 0 N--CA 1.491 1.614 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.642 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -140.88 171.69 23.99 Favored Glycine 0 N--CA 1.492 2.378 0 C-N-CA 119.654 -1.26 . . . . 0.0 110.067 -179.491 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.558 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 43.1 m-85 -114.02 139.4 49.29 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.319 -1.107 . . . . 0.0 109.195 179.751 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.602 HD11 ' CG2' ' A' ' 47' ' ' VAL . 16.7 mt -124.1 150.91 28.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.272 -0.892 . . . . 0.0 109.691 -179.485 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.509 ' N ' HG21 ' A' ' 18' ' ' ILE . 38.3 tt0 -113.48 119.47 37.7 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.384 -0.823 . . . . 0.0 109.448 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.439 HG21 HG23 ' A' ' 26' ' ' VAL . 2.6 t -90.46 124.13 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.329 -0.857 . . . . 0.0 109.655 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.476 ' OE2' ' NZ ' ' A' ' 5' ' ' LYS . 80.1 mt-10 -71.45 109.34 5.37 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.309 -0.869 . . . . 0.0 109.512 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 117.81 -26.1 8.15 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.471 ' OE1' HD12 ' A' ' 51' ' ' ILE . 43.2 mt-30 -122.95 161.31 24.45 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.259 -1.142 . . . . 0.0 109.482 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 58.9 m-20 -52.84 -178.96 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.274 -0.891 . . . . 0.0 109.659 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -71.65 141.37 49.92 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.268 -0.895 . . . . 0.0 109.506 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.439 HG23 HG21 ' A' ' 20' ' ' VAL . 97.3 t -117.99 117.7 55.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.171 -0.956 . . . . 0.0 109.656 -179.582 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.539 ' CE1' ' HB3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -76.56 157.16 32.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.2 -0.937 . . . . 0.0 108.997 179.684 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.59 ' CG2' HD13 ' A' ' 18' ' ' ILE . 34.1 t -133.01 137.38 53.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.205 -0.935 . . . . 0.0 109.763 -179.525 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.629 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 12.8 t-80 -114.97 152.45 32.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.429 -0.794 . . . . 0.0 108.993 179.696 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.68 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -44.31 -53.53 6.63 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.093 -1.004 . . . . 0.0 109.502 -179.631 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.68 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 27.3 t -54.29 -27.35 34.75 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.101 -1.0 . . . . 0.0 110.068 -179.452 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.621 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -66.9 -12.63 60.03 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.04 -1.037 . . . . 0.0 109.002 179.71 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.57 ' CG2' HG11 ' A' ' 63' ' ' VAL . 0.9 OUTLIER . . . . . 0 C--N 1.304 -1.396 0 O-C-N 121.503 -0.748 . . . . 0.0 109.589 -179.581 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.646 ' O ' ' CD2' ' A' ' 9' ' ' PHE . 4.9 mp . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.433 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 96.8 mt-10 -109.28 155.04 21.62 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.316 -0.865 . . . . 0.0 109.305 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -70.41 127.67 33.54 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.29 -0.881 . . . . 0.0 109.593 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 88.51 -3.12 85.2 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.45 ' O ' HG21 ' A' ' 6' ' ' VAL . 51.1 tt0 -81.71 130.24 34.99 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.198 -1.178 . . . . 0.0 109.603 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.471 ' O ' HG12 ' A' ' 47' ' ' VAL . . . -78.21 141.87 38.32 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.235 -0.916 . . . . 0.0 109.383 179.731 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.602 ' CG2' HD11 ' A' ' 18' ' ' ILE . 34.7 m -141.52 153.21 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.136 -0.977 . . . . 0.0 109.781 -179.746 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.522 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 17.8 t -97.57 148.65 23.05 Favored 'General case' 0 N--CA 1.488 1.459 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 179.075 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.59 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 7.8 p90 176.09 162.47 0.35 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.874 -1.141 . . . . 0.0 110.272 -179.546 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.438 ' HA ' ' OE1' ' A' ' 50' ' ' GLU . 67.0 mm-40 -99.92 160.37 14.37 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 178.908 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.471 HD12 ' OE1' ' A' ' 23' ' ' GLN . 0.9 OUTLIER -99.6 127.38 52.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 120.917 -1.114 . . . . 0.0 109.91 -179.524 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.613 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.9 m -114.32 124.81 71.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 179.197 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -93.6 93.31 7.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 110.241 -179.087 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -95.15 -175.8 37.72 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -53.17 -59.22 4.83 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.104 -1.233 . . . . 0.0 109.462 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 53.0 mtp180 -49.3 -40.47 34.93 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.087 -1.008 . . . . 0.0 109.215 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 149.18 -158.12 27.53 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -70.46 139.96 38.98 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.723 2.282 . . . . 0.0 111.849 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.613 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 76.9 mt-30 -136.26 167.81 20.6 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.324 -0.86 . . . . 0.0 109.13 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -95.22 139.31 31.72 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.136 -0.978 . . . . 0.0 110.184 -179.286 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.59 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -124.3 156.02 37.68 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.378 -0.826 . . . . 0.0 108.826 179.605 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.481 ' C ' ' O ' ' A' ' 61' ' ' ALA . 78.8 m-20 42.2 72.59 0.16 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.968 -1.083 . . . . 0.0 108.952 -179.821 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.621 ' HB ' ' O ' ' A' ' 32' ' ' ALA . 3.9 t -86.76 125.93 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.234 -0.916 . . . . 0.0 110.088 -179.17 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.429 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 60.6 m -119.0 125.51 49.56 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.379 -0.825 . . . . 0.0 109.256 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 87.9 mttt -67.52 106.97 2.32 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.2 -0.937 . . . . 0.0 109.479 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.415 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 89.6 mt-10 -87.04 162.0 17.85 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.227 -0.921 . . . . 0.0 109.497 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 117.973 -1.013 . . . . 0.0 109.487 -179.939 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 49.4 mt . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.431 ' O ' HG12 ' A' ' 20' ' ' VAL . 86.9 mt-10 -131.48 135.83 47.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.28 -0.888 . . . . 0.0 109.171 179.772 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.481 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -136.15 157.94 23.7 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 -179.684 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.494 ' N ' HG23 ' A' ' 18' ' ' ILE . 12.5 mttp -103.65 142.26 34.63 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.341 -1.094 . . . . 0.0 108.817 179.51 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.492 HG13 ' HA ' ' A' ' 43' ' ' GLU . 22.1 t -75.22 116.96 18.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.073 -1.017 . . . . 0.0 109.935 -179.51 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.8 -32.73 17.71 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.465 -0.772 . . . . 0.0 108.933 179.693 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.683 ' CE3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -159.44 153.98 24.2 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.381 -0.824 . . . . 0.0 109.023 179.792 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.457 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 9.1 p90 -157.54 139.03 13.81 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.173 -0.954 . . . . 0.0 109.282 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.419 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 63.5 t-20 . . . . . 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 109.618 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.597 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.663 0 CA-C-O 121.42 0.628 . . . . 0.0 109.695 . . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.508 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -135.99 167.49 24.33 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.683 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 22.1 m-85 -115.05 130.12 56.86 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.184 -1.186 . . . . 0.0 109.289 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.546 ' CD1' ' CG2' ' A' ' 47' ' ' VAL . 56.4 mt -114.23 151.42 16.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.44 -0.787 . . . . 0.0 109.654 -179.79 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.426 ' N ' HG21 ' A' ' 18' ' ' ILE . 40.6 tt0 -114.2 104.29 11.95 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.361 -0.837 . . . . 0.0 108.915 179.518 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.544 HG21 ' CG2' ' A' ' 26' ' ' VAL . 2.8 t -78.63 120.64 30.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.264 -0.897 . . . . 0.0 109.428 -179.702 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 74.0 mm-40 -67.93 108.89 3.2 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.206 -0.933 . . . . 0.0 109.135 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.59 -24.46 6.82 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.422 ' OE1' HD11 ' A' ' 51' ' ' ILE . 36.0 mt-30 -128.18 165.92 19.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.298 -1.119 . . . . 0.0 109.6 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 48.9 m-20 -56.93 -169.08 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.292 -0.88 . . . . 0.0 109.729 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.497 ' OD1' ' N ' ' A' ' 25' ' ' ASP . 7.7 p30 -78.45 141.47 38.25 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.254 -0.904 . . . . 0.0 110.003 -179.543 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.544 ' CG2' HG21 ' A' ' 20' ' ' VAL . 57.4 t -116.23 115.09 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.212 -0.93 . . . . 0.0 109.305 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.706 ' O ' ' CG ' ' A' ' 27' ' ' PHE . 0.1 OUTLIER -83.5 107.72 16.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.047 -1.033 . . . . 0.0 109.39 179.979 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.59 ' CG2' HG21 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -85.48 146.92 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.061 -1.024 . . . . 0.0 109.632 -179.167 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.691 ' CE1' ' CE2' ' A' ' 30' ' ' PHE . 11.8 t-160 -116.2 155.05 28.99 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.283 -0.886 . . . . 0.0 109.336 -179.772 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.769 ' CD1' ' N ' ' A' ' 31' ' ' SER . 1.9 p90 -47.75 -54.11 13.21 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.092 -1.005 . . . . 0.0 109.607 -179.481 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.769 ' N ' ' CD1' ' A' ' 30' ' ' PHE . 19.9 t -53.41 -21.22 5.6 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.872 -1.142 . . . . 0.0 109.517 -179.771 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.464 ' HB2' HG23 ' A' ' 28' ' ' VAL . . . -66.84 -38.81 87.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.273 -0.892 . . . . 0.0 109.635 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.547 ' CG1' ' CG1' ' A' ' 63' ' ' VAL . 1.8 mp . . . . . 0 N--CA 1.491 1.577 0 O-C-N 121.168 -0.958 . . . . 0.0 109.966 -179.74 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.47 HD11 HD11 ' A' ' 33' ' ' ILE . 3.1 mp . . . . . 0 N--CA 1.492 1.626 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.462 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 97.0 mt-10 -115.8 151.27 35.51 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.302 -0.874 . . . . 0.0 109.373 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.492 ' HA ' HG13 ' A' ' 6' ' ' VAL . 46.5 tt0 -67.84 125.37 26.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.227 -0.92 . . . . 0.0 109.426 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 92.7 -6.63 77.29 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.883 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.455 ' O ' HG23 ' A' ' 6' ' ' VAL . 61.5 tp60 -82.28 135.05 35.29 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.185 -1.185 . . . . 0.0 109.762 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.508 ' O ' HG13 ' A' ' 47' ' ' VAL . . . -85.87 144.62 27.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.318 -0.864 . . . . 0.0 109.293 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.546 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 30.6 m -144.55 166.46 12.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.198 -0.939 . . . . 0.0 109.717 -179.838 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.533 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 3.3 t -112.87 157.21 21.7 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 179.338 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.558 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 10.0 p90 170.32 167.97 0.06 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.092 -1.005 . . . . 0.0 110.076 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 92.1 mt-10 -102.34 162.2 13.1 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 178.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.422 HD11 ' OE1' ' A' ' 23' ' ' GLN . 1.5 mt -99.91 127.75 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.008 -1.058 . . . . 0.0 109.75 -179.615 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.561 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 0.8 OUTLIER -109.17 120.82 61.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.62 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -88.53 85.89 6.92 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.194 -0.941 . . . . 0.0 109.713 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.14 -179.51 45.55 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 19.3 p-10 -54.49 -53.27 56.57 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.298 -1.119 . . . . 0.0 109.895 -179.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 20.3 mtm180 -57.13 -38.56 73.66 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.017 -1.052 . . . . 0.0 109.389 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.96 -158.81 27.99 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.493 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 52.3 Cg_endo -73.01 141.48 33.08 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.725 2.283 . . . . 0.0 112.006 179.898 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.561 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 31.8 mt-30 -137.03 168.45 19.56 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.37 -0.831 . . . . 0.0 108.894 179.543 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.497 ' CB ' ' HB ' ' A' ' 28' ' ' VAL . . . -94.13 139.93 30.38 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.015 -1.053 . . . . 0.0 110.332 -179.253 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.536 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -126.53 155.65 42.02 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.44 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.49 ' C ' ' O ' ' A' ' 61' ' ' ALA . 57.6 t30 40.88 63.06 1.25 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.958 -1.089 . . . . 0.0 108.849 -179.708 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.59 HG21 ' CG2' ' A' ' 28' ' ' VAL . 1.8 t -79.46 128.75 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.291 -0.881 . . . . 0.0 110.421 -179.011 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 56.4 m -119.6 125.59 49.14 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 69.6 mttt -65.51 110.6 2.76 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.21 -0.932 . . . . 0.0 109.531 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.447 ' HG3' ' HA ' ' A' ' 47' ' ' VAL . 90.4 mt-10 -89.6 159.38 17.2 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.321 -0.862 . . . . 0.0 109.628 -179.845 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.551 0 CA-C-O 117.99 -1.005 . . . . 0.0 109.469 179.942 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.5 ' CD1' ' N ' ' A' ' 2' ' ' LEU . 6.4 mp . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.282 0.563 . . . . 0.0 109.569 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.403 ' O ' HG11 ' A' ' 20' ' ' VAL . 61.0 mt-10 -132.87 139.55 47.48 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.36 -0.838 . . . . 0.0 109.213 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -139.64 157.41 25.18 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.45 ' C ' HG22 ' A' ' 18' ' ' ILE . 63.6 mttm -102.57 142.95 32.89 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.418 -1.048 . . . . 0.0 108.831 179.561 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.466 HG21 ' O ' ' A' ' 45' ' ' GLN . 18.7 t -76.61 112.09 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.173 -0.954 . . . . 0.0 110.047 -179.447 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.465 ' CG ' ' N ' ' A' ' 8' ' ' TRP . 3.3 pttt -79.94 -37.7 33.94 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.622 ' CE3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -159.75 155.01 25.18 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 -179.941 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.463 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 10.5 p90 -155.88 138.87 15.41 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.156 -0.965 . . . . 0.0 109.196 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.472 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.3 t-20 . . . . . 0 N--CA 1.489 1.521 0 O-C-N 121.097 -1.002 . . . . 0.0 109.633 -179.745 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.605 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 . . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.593 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -140.43 170.26 24.48 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 -179.65 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.622 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 27.5 m-85 -114.66 131.5 56.71 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.387 -1.066 . . . . 0.0 108.997 179.812 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.619 HD12 ' CG2' ' A' ' 47' ' ' VAL . 26.9 mt -120.27 149.29 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.164 -0.96 . . . . 0.0 109.433 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.564 ' N ' HG23 ' A' ' 18' ' ' ILE . 18.1 tp10 -108.75 123.76 49.52 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.244 -0.91 . . . . 0.0 109.504 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.536 HG21 ' CG2' ' A' ' 26' ' ' VAL . 2.3 t -102.11 120.25 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.215 -0.928 . . . . 0.0 109.25 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -66.98 109.39 2.95 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.247 -0.908 . . . . 0.0 109.772 -179.701 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.14 -29.34 3.71 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.505 ' O ' ' O ' ' A' ' 24' ' ' ASP . 38.2 mt-30 -131.41 166.26 21.68 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.227 -1.161 . . . . 0.0 109.23 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.505 ' O ' ' O ' ' A' ' 23' ' ' GLN . 0.0 OUTLIER -52.8 -169.17 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.173 -0.954 . . . . 0.0 109.683 -179.777 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.447 ' OD1' ' OE1' ' A' ' 19' ' ' GLU . 42.2 m-20 -75.36 141.65 43.27 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.236 -0.915 . . . . 0.0 109.742 -179.77 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.536 ' CG2' HG21 ' A' ' 20' ' ' VAL . 87.0 t -112.11 119.73 60.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.259 -0.9 . . . . 0.0 109.385 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.498 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.1 OUTLIER -79.53 154.71 28.62 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.244 -0.91 . . . . 0.0 109.127 -179.94 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.596 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 5.0 t -129.64 133.04 65.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.292 -0.88 . . . . 0.0 109.27 -179.729 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.626 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 13.4 t-80 -105.61 150.2 25.62 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.157 -0.964 . . . . 0.0 109.219 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.689 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.9 OUTLIER -43.1 -52.56 5.35 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.197 -0.939 . . . . 0.0 109.198 -179.818 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.689 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 23.0 t -56.25 -23.06 33.68 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.912 . . . . 0.0 109.856 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.509 ' N ' ' O ' ' A' ' 29' ' ' HIS . . . -65.38 -23.76 67.05 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.075 -1.015 . . . . 0.0 109.446 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.535 ' CD1' HD11 ' A' ' 41' ' ' LEU . 3.2 mp . . . . . 0 N--CA 1.489 1.494 0 O-C-N 121.286 -0.883 . . . . 0.0 109.337 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.535 HD11 ' CD1' ' A' ' 33' ' ' ILE . 4.7 mp . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 121.319 0.58 . . . . 0.0 109.578 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . 0.445 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 95.7 mt-10 -111.67 151.43 28.87 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.376 -0.827 . . . . 0.0 109.329 179.788 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 76.6 tt0 -69.13 126.44 29.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.282 -0.886 . . . . 0.0 109.626 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 89.94 -3.2 82.7 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.466 ' O ' HG21 ' A' ' 6' ' ' VAL . 56.7 tt0 -82.16 131.03 35.24 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.197 -1.178 . . . . 0.0 109.701 179.822 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.464 ' O ' HG12 ' A' ' 47' ' ' VAL . . . -76.82 142.69 40.18 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.211 -0.93 . . . . 0.0 109.226 179.755 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.619 ' CG2' HD12 ' A' ' 18' ' ' ILE . 30.1 m -145.39 159.36 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.233 -0.917 . . . . 0.0 110.093 -179.637 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.551 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 39.7 t -110.94 154.32 24.26 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.601 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 14.0 p90 173.37 163.87 0.15 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.817 -1.177 . . . . 0.0 110.508 -179.659 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -99.58 158.71 15.57 Favored 'General case' 0 N--CA 1.488 1.455 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 3.1 mt -102.13 131.77 49.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 120.928 -1.107 . . . . 0.0 110.244 -179.409 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.546 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 5.6 m -114.19 123.62 70.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 178.703 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -91.55 90.36 7.58 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.187 -0.946 . . . . 0.0 109.937 -178.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.6 -177.47 42.76 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -53.16 -59.81 4.08 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.169 -1.195 . . . . 0.0 109.533 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 20.9 mtp180 -49.82 -39.07 37.47 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.189 -0.944 . . . . 0.0 109.201 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.09 -161.91 29.25 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.502 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 52.6 Cg_endo -72.31 144.9 42.25 Favored 'Trans proline' 0 C--O 1.216 -0.613 0 C-N-CA 122.7 2.267 . . . . 0.0 111.828 179.772 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.546 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 71.1 mt-30 -137.37 169.47 17.72 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.276 -0.89 . . . . 0.0 109.232 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.42 ' N ' ' O ' ' A' ' 27' ' ' PHE . . . -94.0 139.73 30.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.216 -0.927 . . . . 0.0 110.232 -179.407 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.583 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -127.98 157.74 39.79 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.514 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.49 ' C ' ' O ' ' A' ' 61' ' ' ALA . 85.7 m-20 41.4 68.57 0.43 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.857 -1.152 . . . . 0.0 108.816 -179.761 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.601 ' HA ' ' HB3' ' A' ' 49' ' ' PHE . 2.3 t -87.13 126.3 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.239 -0.913 . . . . 0.0 110.315 -178.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 82.3 m -117.99 124.26 47.74 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 50.3 mttt -68.39 110.97 4.37 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.291 -0.881 . . . . 0.0 109.614 -179.814 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.459 ' O ' ' O ' ' A' ' 67' ' ' ALA . 64.2 mt-10 -90.05 161.46 15.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.901 . . . . 0.0 109.604 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . 0.459 ' O ' ' O ' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.52 0 CA-C-O 117.989 -1.005 . . . . 0.0 109.466 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.492 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 27.2 mt . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 121.339 0.59 . . . . 0.0 109.503 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -129.24 141.33 51.16 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -0.916 . . . . 0.0 109.061 179.753 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.524 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -146.66 156.71 27.13 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -179.719 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.511 ' N ' HG22 ' A' ' 18' ' ' ILE . 16.0 mttt -102.2 136.01 42.78 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.382 -1.069 . . . . 0.0 108.836 179.48 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.532 ' HA ' HG12 ' A' ' 18' ' ' ILE . 40.3 t -68.59 115.71 7.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.161 -0.962 . . . . 0.0 110.095 -179.53 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 17' ' ' PHE . 5.9 tttm -79.06 -35.11 43.02 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.476 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' TRP . . . . . 0.654 ' CD2' ' N ' ' A' ' 9' ' ' PHE . 0.4 OUTLIER -160.36 168.55 24.99 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.486 -0.759 . . . . 0.0 109.047 179.755 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.654 ' N ' ' CD2' ' A' ' 8' ' ' TRP . 21.4 p90 -163.44 141.23 7.65 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.885 -1.135 . . . . 0.0 110.312 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.595 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 20.5 t-20 . . . . . 0 N--CA 1.493 1.7 0 O-C-N 121.491 -0.755 . . . . 0.0 109.338 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.538 ' HB2' ' HA ' ' A' ' 29' ' ' HIS . 10.8 p90 . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.612 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -157.77 165.61 33.63 Favored Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.497 -1.335 . . . . 0.0 110.146 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.523 ' O ' ' N ' ' A' ' 7' ' ' LYS . 92.6 m-85 -96.43 138.63 33.73 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.457 -1.026 . . . . 0.0 108.909 179.726 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.635 HD13 ' CG2' ' A' ' 28' ' ' VAL . 63.2 mt -121.53 160.07 23.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.561 -0.712 . . . . 0.0 109.647 -179.715 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.454 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 39.6 tt0 -120.4 119.09 32.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.35 -0.844 . . . . 0.0 109.46 -179.737 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.411 HG23 HG21 ' A' ' 26' ' ' VAL . 2.2 t -95.28 111.73 26.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.265 -0.897 . . . . 0.0 109.214 179.832 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.41 ' HA ' ' OE1' ' A' ' 21' ' ' GLU . 72.5 mm-40 -61.43 110.3 1.41 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.234 -0.916 . . . . 0.0 109.474 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.9 -33.97 3.56 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLN . . . . . 0.474 ' O ' ' O ' ' A' ' 24' ' ' ASP . 36.1 mt-30 -124.28 163.39 21.75 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.248 -1.148 . . . . 0.0 109.365 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.474 ' O ' ' O ' ' A' ' 23' ' ' GLN . 57.9 m-20 -50.76 -176.81 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.304 -0.873 . . . . 0.0 109.652 -179.866 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.409 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 90.0 m-20 -74.02 140.88 45.74 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.336 -0.853 . . . . 0.0 109.728 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.547 HG23 ' CG1' ' A' ' 51' ' ' ILE . 88.9 t -113.42 115.75 50.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.319 -0.863 . . . . 0.0 109.411 -179.895 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' PHE . . . . . 0.585 ' CE2' ' HB3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -70.75 156.72 39.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.057 -1.027 . . . . 0.0 109.355 -179.937 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.635 ' CG2' HD13 ' A' ' 18' ' ' ILE . 21.9 t -134.49 133.87 54.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.117 -0.989 . . . . 0.0 109.871 -179.472 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.672 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 14.3 t-80 -114.47 151.12 33.75 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.355 -0.841 . . . . 0.0 109.192 179.588 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.677 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.7 OUTLIER -42.63 -51.5 5.18 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.091 -1.006 . . . . 0.0 109.353 -179.858 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.677 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 86.6 p -53.69 -29.61 39.74 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.178 -0.952 . . . . 0.0 109.925 -179.618 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.585 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -64.91 -10.31 27.8 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.107 -0.995 . . . . 0.0 109.217 179.744 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.556 ' CG2' HG13 ' A' ' 63' ' ' VAL . 0.8 OUTLIER . . . . . 0 C--N 1.303 -1.442 0 O-C-N 121.487 -0.758 . . . . 0.0 109.726 -179.415 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.569 ' CD1' ' N ' ' A' ' 41' ' ' LEU . 3.5 mp . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 121.464 0.649 . . . . 0.0 109.756 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -103.92 144.14 31.92 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.285 -0.884 . . . . 0.0 109.319 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.448 ' HA ' HG13 ' A' ' 6' ' ' VAL . 53.3 tt0 -63.11 130.34 44.23 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.293 -0.88 . . . . 0.0 109.477 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.97 -3.12 85.91 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 46.8 tt0 -81.29 128.19 33.54 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.201 -1.176 . . . . 0.0 109.602 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.489 ' O ' HG11 ' A' ' 47' ' ' VAL . . . -77.54 140.71 39.78 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.215 -0.928 . . . . 0.0 109.085 179.614 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.6 ' CG2' HD11 ' A' ' 18' ' ' ILE . 32.1 m -142.43 160.78 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.158 -0.964 . . . . 0.0 109.832 -179.825 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.536 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 24.0 t -107.3 152.06 24.64 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 178.827 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.542 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 35.3 p90 174.81 164.16 0.24 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.807 -1.183 . . . . 0.0 110.215 -179.426 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -100.31 172.28 7.25 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.547 ' CG1' HG23 ' A' ' 26' ' ' VAL . 1.0 OUTLIER -111.52 125.46 68.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 120.867 -1.146 . . . . 0.0 109.901 -179.819 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.586 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.7 m -109.16 123.48 65.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 179.138 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.4 mt-10 -91.52 83.75 5.43 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 109.645 -179.533 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.79 -172.06 42.28 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 179.789 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.433 ' O ' ' C ' ' A' ' 56' ' ' ARG . 3.8 t30 -56.73 -63.55 1.16 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.14 -1.212 . . . . 0.0 109.212 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.433 ' C ' ' O ' ' A' ' 55' ' ' ASN . 36.2 mtp180 -42.0 -46.9 4.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.171 -0.955 . . . . 0.0 109.325 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.01 -149.33 21.46 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.409 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 46.2 Cg_endo -70.13 125.5 12.02 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.654 2.236 . . . . 0.0 112.128 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.586 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 33.2 mt-30 -125.56 158.62 34.13 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.335 -0.853 . . . . 0.0 108.875 179.389 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.457 ' N ' ' O ' ' A' ' 27' ' ' PHE . . . -91.47 134.86 34.27 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.019 -1.051 . . . . 0.0 109.767 -179.545 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.542 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -122.72 156.37 34.56 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.388 -0.82 . . . . 0.0 108.9 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.473 ' C ' ' O ' ' A' ' 61' ' ' ALA . 82.9 m-20 41.72 66.01 0.77 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.084 -1.01 . . . . 0.0 109.045 -179.727 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.585 ' HB ' ' O ' ' A' ' 32' ' ' ALA . 4.5 t -83.03 125.85 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.234 -0.916 . . . . 0.0 109.93 -179.381 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' THR . . . . . 0.475 HG22 ' OE2' ' A' ' 66' ' ' GLU . 92.4 m -118.35 125.02 49.15 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.53 -0.731 . . . . 0.0 109.211 179.766 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 32.4 mttp -65.41 110.5 2.68 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.338 -0.851 . . . . 0.0 109.438 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.475 ' OE2' HG22 ' A' ' 64' ' ' THR . 73.3 mm-40 -100.67 166.71 10.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.283 -0.885 . . . . 0.0 109.504 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 118.001 -1.0 . . . . 0.0 109.452 -179.991 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 81.9 mtp . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.452 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 59.6 mt -98.8 160.53 14.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.386 -0.821 . . . . 0.0 109.46 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 78.1 mt-10 -130.62 143.52 50.81 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.283 -0.886 . . . . 0.0 109.203 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.524 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -152.06 156.09 26.5 Favored Glycine 0 N--CA 1.488 2.123 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -100.99 135.21 42.81 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.312 -1.111 . . . . 0.0 108.744 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.407 HG11 ' HA ' ' A' ' 43' ' ' GLU . 33.9 t -66.55 119.22 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.123 -0.986 . . . . 0.0 110.01 -179.424 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.502 ' N ' ' O ' ' A' ' 17' ' ' PHE . 5.9 tptm -79.48 -40.96 28.53 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.425 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.652 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -159.98 166.95 29.03 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 179.785 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.643 ' N ' ' CD2' ' A' ' 8' ' ' TRP . 17.1 p90 -158.76 147.39 18.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.943 -1.098 . . . . 0.0 110.574 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.622 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 13.9 t-20 -103.6 135.85 44.41 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.412 -0.805 . . . . 0.0 109.353 179.662 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.8 p -83.24 -15.08 51.73 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.089 -1.007 . . . . 0.0 109.442 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 41.0 tp10 -59.98 -63.42 1.31 Allowed 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.27 -0.894 . . . . 0.0 109.604 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.647 ' HB2' ' CD1' ' A' ' 15' ' ' PHE . 19.9 mttm -98.68 -10.73 22.8 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.355 -0.841 . . . . 0.0 109.745 -179.526 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.508 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 77.23 68.86 1.46 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.002 -1.239 . . . . 0.0 110.002 179.477 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.647 ' CD1' ' HB2' ' A' ' 13' ' ' LYS . 3.1 p90 -156.21 161.41 40.28 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.151 -1.205 . . . . 0.0 109.005 179.299 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.652 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -161.07 160.86 32.45 Favored Glycine 0 N--CA 1.486 2.018 0 C-N-CA 119.598 -1.286 . . . . 0.0 110.044 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.504 ' CD1' ' HB2' ' A' ' 27' ' ' PHE . 98.0 m-85 -90.74 139.37 30.79 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.488 -1.007 . . . . 0.0 108.719 179.492 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.583 ' CD1' ' CG2' ' A' ' 47' ' ' VAL . 19.7 mt -113.25 159.28 13.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.582 -0.699 . . . . 0.0 109.222 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.467 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 65.7 tt0 -114.27 109.52 18.51 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.225 -0.922 . . . . 0.0 109.464 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.439 HG22 HG23 ' A' ' 26' ' ' VAL . 2.7 t -90.74 109.48 20.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.199 -0.938 . . . . 0.0 109.206 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 74.3 mm-40 -59.22 108.87 0.75 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.214 -0.929 . . . . 0.0 109.267 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.9 -35.62 3.48 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.496 ' OE1' HD13 ' A' ' 51' ' ' ILE . 46.7 mt-30 -117.95 160.92 20.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -1.155 . . . . 0.0 109.362 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.447 ' O ' ' O ' ' A' ' 23' ' ' GLN . 44.5 m-20 -52.92 -174.19 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.253 -0.904 . . . . 0.0 109.514 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.479 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 80.8 m-20 -74.31 139.45 44.21 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.299 -0.876 . . . . 0.0 109.647 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.439 HG23 HG22 ' A' ' 20' ' ' VAL . 91.8 t -114.39 119.87 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.306 -0.871 . . . . 0.0 109.529 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.514 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.0 OUTLIER -77.17 155.75 32.05 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.111 -0.993 . . . . 0.0 109.396 -179.965 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.561 ' O ' ' HB2' ' A' ' 15' ' ' PHE . 10.8 t -131.09 138.5 53.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.294 -0.879 . . . . 0.0 109.434 -179.652 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.58 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 12.9 t-80 -112.21 149.93 31.58 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.094 -1.004 . . . . 0.0 109.581 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.699 ' CG ' ' N ' ' A' ' 31' ' ' SER . 1.2 p90 -46.88 -53.99 10.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.152 -0.968 . . . . 0.0 109.672 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.699 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 21.0 t -59.56 -20.85 58.58 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.024 -1.048 . . . . 0.0 109.907 -179.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.551 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -77.77 -12.66 60.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.157 -0.964 . . . . 0.0 109.414 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.656 ' CG2' HG13 ' A' ' 63' ' ' VAL . 3.0 mt -110.36 146.07 16.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.435 -0.79 . . . . 0.0 109.82 -179.66 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 65.2 mt-30 -97.08 128.08 43.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.387 -0.821 . . . . 0.0 109.685 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.607 ' CA ' ' HE1' ' A' ' 38' ' ' PHE . . . 146.17 80.48 0.04 OUTLIER Glycine 0 N--CA 1.484 1.889 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.458 ' HG2' ' NZ ' ' A' ' 39' ' ' LYS . 94.4 mt-10 -61.69 -21.63 64.63 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.247 -1.149 . . . . 0.0 109.465 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.509 ' C ' ' CG ' ' A' ' 38' ' ' PHE . . . -94.08 17.13 59.42 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 179.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.607 ' HE1' ' CA ' ' A' ' 35' ' ' GLY . 0.1 OUTLIER 168.96 54.48 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.24 -1.153 . . . . 0.0 109.774 179.952 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.525 ' HG3' ' O ' ' A' ' 35' ' ' GLY . 29.1 mttt -73.73 -21.47 60.2 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.107 -0.995 . . . . 0.0 109.397 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.3 p -69.71 116.09 9.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.243 -0.91 . . . . 0.0 109.528 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.613 ' CD1' ' CD1' ' A' ' 33' ' ' ILE . 4.3 mp -73.85 144.98 45.25 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.244 -0.91 . . . . 0.0 109.84 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.451 ' O ' ' C ' ' A' ' 43' ' ' GLU . 58.5 tt0 -93.91 119.72 33.21 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.407 -0.808 . . . . 0.0 109.084 179.629 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.451 ' C ' ' O ' ' A' ' 42' ' ' GLU . 53.4 tt0 -41.13 131.38 2.65 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.284 -0.885 . . . . 0.0 109.553 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 89.69 -3.95 83.47 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 52.1 tt0 -80.81 128.18 33.37 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.171 -1.194 . . . . 0.0 109.466 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.503 ' O ' HG11 ' A' ' 47' ' ' VAL . . . -79.9 143.36 34.33 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.27 -0.894 . . . . 0.0 109.055 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.583 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 28.9 m -147.84 171.41 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.196 -0.94 . . . . 0.0 109.678 -179.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.64 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 34.7 t -116.3 156.46 26.61 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.308 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.583 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 17.0 p90 172.81 166.78 0.13 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.894 -1.129 . . . . 0.0 110.488 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -108.82 154.28 22.32 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.496 HD13 ' OE1' ' A' ' 23' ' ' GLN . 1.9 mt -87.73 122.85 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 120.863 -1.148 . . . . 0.0 110.069 -179.433 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.608 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 26.8 m -110.72 128.29 67.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 178.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -68.63 120.05 14.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.084 -1.01 . . . . 0.0 109.838 -179.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -128.02 162.57 21.81 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.761 -1.335 . . . . 0.0 109.761 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -51.78 -60.22 3.42 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.241 -1.153 . . . . 0.0 109.493 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 82.2 mtp180 -51.0 -33.16 23.65 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.274 -0.891 . . . . 0.0 109.184 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 144.84 -146.12 16.18 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.434 -1.466 . . . . 0.0 109.434 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.479 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 45.8 Cg_endo -69.35 127.99 15.74 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.781 2.321 . . . . 0.0 111.793 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.608 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 84.8 mt-30 -121.99 156.21 33.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.188 -0.945 . . . . 0.0 109.265 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.464 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -88.35 127.76 35.49 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.159 -0.963 . . . . 0.0 110.088 -179.336 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.515 ' HB3' ' CG1' ' A' ' 52' ' ' VAL . . . -108.71 150.47 27.52 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.322 -0.861 . . . . 0.0 108.887 179.37 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.487 ' C ' ' O ' ' A' ' 61' ' ' ALA . 36.8 t-20 40.64 67.22 0.53 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.213 -0.93 . . . . 0.0 109.013 -179.67 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.656 HG13 ' CG2' ' A' ' 33' ' ' ILE . 1.2 t -82.14 127.25 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.329 -0.857 . . . . 0.0 110.21 -179.175 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 35.3 m -115.63 117.56 30.63 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.146 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.499 ' NZ ' ' O ' ' A' ' 38' ' ' PHE . 18.1 mttm -65.34 117.01 7.26 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.279 -0.888 . . . . 0.0 109.663 -179.66 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 82.8 mt-10 -108.87 167.67 9.91 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.375 -0.828 . . . . 0.0 109.661 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.506 -179.956 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.413 ' C ' HD12 ' A' ' 2' ' ' LEU . 82.3 mtp . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.606 ' CD1' ' N ' ' A' ' 2' ' ' LEU . 5.1 mp -116.22 160.95 19.69 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.287 -0.883 . . . . 0.0 109.327 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.479 ' O ' HG12 ' A' ' 20' ' ' VAL . 2.7 tt0 -127.68 140.27 52.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.227 -0.921 . . . . 0.0 109.208 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.0 155.22 24.91 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.784 -1.326 . . . . 0.0 109.784 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.476 ' HE3' ' OE2' ' A' ' 21' ' ' GLU . 54.5 mttt -108.88 137.86 46.13 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.406 -1.055 . . . . 0.0 108.645 179.46 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.521 ' HB ' ' O ' ' A' ' 42' ' ' GLU . 15.0 t -70.16 112.56 5.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.054 -1.029 . . . . 0.0 109.983 -179.301 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.475 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 14.7 tttm -78.5 -40.87 34.04 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.592 ' O ' ' CE3' ' A' ' 8' ' ' TRP . 0.0 OUTLIER -161.44 155.78 22.73 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.923 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.434 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 11.0 p90 -154.31 139.77 17.76 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.054 -1.029 . . . . 0.0 109.07 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.532 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 3.1 t-20 -114.46 118.25 33.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.052 -1.03 . . . . 0.0 109.869 -179.601 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 82.7 p -63.82 -17.08 62.75 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.311 -0.868 . . . . 0.0 109.562 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.482 ' HB3' ' OD1' ' A' ' 10' ' ' ASN . 76.2 tt0 -85.67 -39.56 17.12 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.256 -0.902 . . . . 0.0 109.253 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.632 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 27.0 mttp -66.6 -42.75 86.4 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.363 -0.836 . . . . 0.0 109.326 179.816 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.453 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 103.26 1.02 47.67 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.369 -1.492 . . . . 0.0 109.369 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.632 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 0.8 OUTLIER -145.54 179.61 7.3 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -1.131 . . . . 0.0 109.322 179.858 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.533 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -148.57 173.85 28.41 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.564 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 29.2 m-85 -113.25 132.3 55.58 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.402 -1.058 . . . . 0.0 109.011 179.767 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.603 ' CD1' ' CG2' ' A' ' 28' ' ' VAL . 58.8 mt -119.07 149.5 21.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.239 -0.913 . . . . 0.0 109.681 -179.615 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.47 ' N ' HG23 ' A' ' 18' ' ' ILE . 46.8 tt0 -112.09 122.15 46.95 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.353 -0.842 . . . . 0.0 109.415 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.521 HG23 ' CG2' ' A' ' 26' ' ' VAL . 3.2 t -91.32 124.88 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.246 -0.909 . . . . 0.0 109.647 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.476 ' OE2' ' HE3' ' A' ' 5' ' ' LYS . 91.6 mt-10 -70.4 103.76 2.52 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.236 -0.915 . . . . 0.0 109.367 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 120.83 -19.13 8.99 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 49.0 mt-30 -129.82 162.6 28.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.263 -1.139 . . . . 0.0 109.578 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -54.46 -176.44 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.317 -0.864 . . . . 0.0 109.689 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.494 ' OD1' ' N ' ' A' ' 25' ' ' ASP . 11.3 p30 -73.39 136.32 44.33 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.29 -0.881 . . . . 0.0 109.413 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.521 ' CG2' HG23 ' A' ' 20' ' ' VAL . 72.3 t -113.03 122.31 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.235 -0.916 . . . . 0.0 109.569 -179.753 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.518 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.4 OUTLIER -78.12 157.29 29.51 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.164 -0.96 . . . . 0.0 109.223 179.837 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.603 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 21.9 t -132.27 131.24 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.296 -0.877 . . . . 0.0 109.243 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.679 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 13.9 t-80 -105.83 154.64 20.25 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.124 -0.985 . . . . 0.0 109.267 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.685 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -46.52 -53.46 11.26 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.159 -0.963 . . . . 0.0 109.246 -179.683 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.685 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 86.7 p -55.96 -24.37 37.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.096 -1.003 . . . . 0.0 109.979 -179.692 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.493 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -66.32 -19.97 65.96 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.114 -0.991 . . . . 0.0 109.577 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.553 HD13 ' CD1' ' A' ' 41' ' ' LEU . 2.9 mp -110.84 132.34 59.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.229 -0.92 . . . . 0.0 109.443 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 79.6 mt-30 -110.73 146.22 36.68 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.291 -0.881 . . . . 0.0 109.411 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.661 ' HA3' ' CZ ' ' A' ' 38' ' ' PHE . . . 174.25 -176.21 46.63 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 -179.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -73.32 -36.59 66.23 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.352 -1.087 . . . . 0.0 109.363 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -175.94 30.0 0.08 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.661 ' CZ ' ' HA3' ' A' ' 35' ' ' GLY . 43.5 p90 -122.69 28.23 7.41 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.164 -1.198 . . . . 0.0 109.64 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 82.3 mttt -49.94 -32.78 15.64 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.243 -0.911 . . . . 0.0 109.546 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.425 ' O ' ' CE ' ' A' ' 65' ' ' LYS . 27.4 m -62.0 136.75 58.09 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.199 -0.938 . . . . 0.0 109.526 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.553 ' CD1' HD13 ' A' ' 33' ' ' ILE . 5.2 mp -92.98 170.94 9.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.261 -0.899 . . . . 0.0 109.629 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.521 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 84.9 tt0 -116.11 149.26 39.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.297 -0.877 . . . . 0.0 109.008 179.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.478 ' HA ' HG13 ' A' ' 6' ' ' VAL . 77.5 tt0 -71.0 124.46 24.41 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.15 -0.969 . . . . 0.0 109.769 -179.788 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 92.01 -6.88 79.15 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.901 -1.28 . . . . 0.0 109.901 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.463 ' HB2' ' HB3' ' A' ' 42' ' ' GLU . 48.6 tp60 -82.04 133.19 35.27 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.131 -1.217 . . . . 0.0 109.732 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.485 ' O ' HG12 ' A' ' 47' ' ' VAL . . . -84.34 144.95 28.51 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.899 . . . . 0.0 109.415 179.8 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.594 ' CG2' HD11 ' A' ' 18' ' ' ILE . 23.2 m -144.78 163.61 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.232 -0.917 . . . . 0.0 109.795 -179.725 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.498 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 1.0 OUTLIER -108.19 153.23 23.48 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 179.342 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.516 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 7.8 p90 174.63 165.82 0.25 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.99 -1.069 . . . . 0.0 110.055 -179.76 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -102.84 165.14 11.21 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.14 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.0 mt -102.44 125.74 56.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 120.936 -1.102 . . . . 0.0 109.854 -179.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.569 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 32.0 m -114.3 126.29 71.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.413 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 178.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -66.18 118.64 10.2 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.158 -0.964 . . . . 0.0 109.727 -179.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -122.07 157.44 16.8 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.496 ' CG ' ' N ' ' A' ' 56' ' ' ARG . 7.9 p30 -48.05 -49.66 30.6 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.319 -1.106 . . . . 0.0 109.654 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.496 ' N ' ' CG ' ' A' ' 55' ' ' ASN . 84.0 mtp180 -64.47 -25.23 67.91 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.109 -0.994 . . . . 0.0 109.012 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 142.63 -152.63 23.99 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.475 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 49.2 Cg_endo -70.72 137.25 32.28 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.631 2.22 . . . . 0.0 111.782 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.569 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 79.1 mt-30 -127.53 163.83 23.29 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.228 -0.92 . . . . 0.0 109.207 179.641 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -96.6 142.65 28.4 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.154 -0.966 . . . . 0.0 110.103 -179.324 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.514 ' HB3' HG12 ' A' ' 52' ' ' VAL . . . -124.65 154.06 41.34 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.387 -0.821 . . . . 0.0 108.881 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.476 ' C ' ' O ' ' A' ' 61' ' ' ALA . 58.3 t30 42.54 64.24 1.2 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.103 -0.998 . . . . 0.0 108.784 -179.65 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.564 HG21 ' CG1' ' A' ' 28' ' ' VAL . 1.8 t -78.38 128.91 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.337 -0.852 . . . . 0.0 109.944 -179.122 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.467 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 93.4 m -119.56 126.32 50.95 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.484 -0.76 . . . . 0.0 109.082 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.468 ' NZ ' HG21 ' A' ' 33' ' ' ILE . 38.2 mttp -73.39 114.78 12.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.219 -0.925 . . . . 0.0 109.771 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.439 ' HG3' ' HA ' ' A' ' 47' ' ' VAL . 97.1 mt-10 -92.44 161.98 14.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.251 -0.905 . . . . 0.0 109.452 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.392 179.884 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.7 mtt . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.432 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 57.5 mt -106.2 158.99 16.44 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.305 -0.872 . . . . 0.0 109.435 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.483 ' O ' HG12 ' A' ' 20' ' ' VAL . 3.5 tt0 -128.43 137.76 51.99 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.266 -0.896 . . . . 0.0 109.208 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.05 154.33 24.41 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.776 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.448 ' O ' HG21 ' A' ' 18' ' ' ILE . 58.0 mttp -104.16 140.46 37.77 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.434 -1.039 . . . . 0.0 108.829 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.46 HG11 ' HA ' ' A' ' 43' ' ' GLU . 18.8 t -72.85 114.36 11.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.009 -1.057 . . . . 0.0 109.963 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 10.7 tptt -78.76 -42.24 28.54 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.581 ' O ' ' CE3' ' A' ' 8' ' ' TRP . 0.0 OUTLIER -160.1 156.12 26.3 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.452 -0.78 . . . . 0.0 109.009 179.96 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.498 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 10.4 p90 -154.96 139.08 16.5 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.124 -0.985 . . . . 0.0 109.021 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.481 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 58.7 t-20 -115.02 121.17 42.29 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.01 -1.056 . . . . 0.0 109.836 -179.517 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 70.7 p -66.0 -16.41 63.87 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.317 -0.865 . . . . 0.0 109.407 179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 78.5 mm-40 -85.9 -41.3 15.07 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.257 -0.902 . . . . 0.0 109.264 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.636 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 16.0 mttt -65.76 -41.13 92.45 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.352 -0.842 . . . . 0.0 109.261 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.475 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 102.02 0.17 51.53 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.636 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 0.9 OUTLIER -145.6 176.89 9.28 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.2 -1.176 . . . . 0.0 109.321 179.775 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.566 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -145.12 175.4 24.73 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.564 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 32.8 m-85 -115.54 133.29 56.18 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.265 -1.138 . . . . 0.0 109.022 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.617 HD13 ' CG2' ' A' ' 47' ' ' VAL . 20.2 mt -119.88 155.08 22.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.226 -0.921 . . . . 0.0 109.402 -179.807 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 32.4 tp10 -117.83 123.92 47.1 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.315 -0.866 . . . . 0.0 109.588 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.483 HG12 ' O ' ' A' ' 3' ' ' GLU . 2.3 t -97.94 119.98 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.314 -0.866 . . . . 0.0 109.47 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -69.11 109.61 4.11 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.27 -0.894 . . . . 0.0 109.556 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 126.46 -30.68 4.19 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.491 ' OE1' ' CD1' ' A' ' 51' ' ' ILE . 57.1 mt-30 -128.6 166.85 18.07 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.322 -1.105 . . . . 0.0 109.41 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.46 ' O ' ' O ' ' A' ' 23' ' ' GLN . 55.4 m-20 -51.13 -177.38 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.251 -0.906 . . . . 0.0 109.411 179.898 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.493 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 20.3 p30 -75.27 147.28 40.37 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.232 -0.917 . . . . 0.0 109.308 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.455 HG21 HG23 ' A' ' 20' ' ' VAL . 81.6 t -118.14 120.44 64.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.121 -0.987 . . . . 0.0 109.676 -179.556 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.529 ' CE1' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER -76.81 158.27 30.96 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.127 -0.983 . . . . 0.0 109.11 179.696 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.582 ' CG2' HD12 ' A' ' 18' ' ' ILE . 7.7 t -131.64 134.08 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.187 -0.946 . . . . 0.0 109.299 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.632 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 12.9 t-80 -109.32 152.63 25.01 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.193 -0.942 . . . . 0.0 109.15 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.682 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.9 OUTLIER -45.43 -53.04 9.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.199 -0.938 . . . . 0.0 109.176 -179.592 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.682 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 22.7 t -54.96 -28.94 55.31 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.243 -0.911 . . . . 0.0 110.051 -179.587 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.487 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -62.83 -21.58 66.03 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.048 -1.032 . . . . 0.0 109.352 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.527 ' CD1' HD11 ' A' ' 41' ' ' LEU . 3.3 mp -111.18 132.19 60.38 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.298 -0.876 . . . . 0.0 109.256 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 82.9 mt-30 -113.97 148.72 36.42 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.161 -0.962 . . . . 0.0 109.562 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.654 ' HA3' ' CZ ' ' A' ' 38' ' ' PHE . . . 174.23 -176.92 46.61 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -71.02 -31.94 68.56 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.335 -1.097 . . . . 0.0 109.404 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 178.02 32.43 0.05 OUTLIER Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.654 ' CZ ' ' HA3' ' A' ' 35' ' ' GLY . 40.4 p90 -126.12 30.08 5.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.132 -1.217 . . . . 0.0 109.571 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 18.2 mttt -51.48 -34.73 36.88 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.123 -0.986 . . . . 0.0 109.522 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.521 ' O ' ' NZ ' ' A' ' 65' ' ' LYS . 36.8 m -62.28 130.87 47.33 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.19 -0.944 . . . . 0.0 109.469 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.527 HD11 ' CD1' ' A' ' 33' ' ' ILE . 5.4 mp -86.97 175.0 8.35 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.266 -0.896 . . . . 0.0 109.699 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.49 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 85.2 tt0 -117.57 152.07 35.87 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.415 -0.803 . . . . 0.0 109.042 179.546 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.46 ' HA ' HG11 ' A' ' 6' ' ' VAL . 67.4 tt0 -72.85 124.57 25.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.207 -0.933 . . . . 0.0 109.6 -179.729 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.7 -4.44 79.17 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.49 ' HB2' ' HB3' ' A' ' 42' ' ' GLU . 55.9 tp60 -82.05 132.81 35.26 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.189 -1.183 . . . . 0.0 109.877 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.489 ' O ' HG13 ' A' ' 47' ' ' VAL . . . -80.45 141.06 35.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.289 -0.882 . . . . 0.0 109.169 179.669 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.617 ' CG2' HD13 ' A' ' 18' ' ' ILE . 30.1 m -141.69 159.04 21.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 109.902 -179.614 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.499 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 28.9 t -109.66 153.11 24.7 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.048 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.527 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 8.5 p90 173.39 165.67 0.16 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.913 -1.117 . . . . 0.0 110.178 -179.764 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -100.05 162.89 12.69 Favored 'General case' 0 N--CA 1.487 1.382 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.491 ' CD1' ' OE1' ' A' ' 23' ' ' GLN . 0.9 OUTLIER -102.25 125.46 56.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 120.927 -1.108 . . . . 0.0 110.022 -179.571 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.6 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 26.7 m -109.9 121.98 63.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.7 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.418 ' OE2' ' HB3' ' A' ' 58' ' ' PRO . 39.9 mm-40 -91.47 89.9 7.42 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.144 -0.973 . . . . 0.0 109.945 -179.001 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.05 -169.96 32.23 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 56' ' ' ARG . 4.1 t30 -58.05 -66.17 0.52 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.236 -1.155 . . . . 0.0 109.837 -179.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.428 ' C ' ' O ' ' A' ' 55' ' ' ASN . 15.2 mtm180 -41.82 -46.29 3.88 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.282 -0.886 . . . . 0.0 109.501 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 150.65 -153.97 25.34 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.493 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 47.9 Cg_endo -69.64 129.42 17.69 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.682 2.255 . . . . 0.0 112.024 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.6 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 61.2 mt-30 -127.19 161.14 29.23 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.334 -0.854 . . . . 0.0 108.976 179.506 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.422 ' N ' ' O ' ' A' ' 27' ' ' PHE . . . -90.02 136.52 32.99 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.032 -1.043 . . . . 0.0 110.296 -179.154 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.521 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -118.79 149.57 41.28 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 179.442 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.488 ' C ' ' O ' ' A' ' 61' ' ' ALA . 38.6 t-20 41.34 67.77 0.51 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.033 -1.042 . . . . 0.0 108.875 -179.57 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.527 ' HA ' ' HB3' ' A' ' 49' ' ' PHE . 2.1 t -81.57 127.85 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.404 -0.81 . . . . 0.0 110.161 -179.176 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 91.8 m -118.1 123.84 46.57 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.472 -0.768 . . . . 0.0 109.082 179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.521 ' NZ ' ' O ' ' A' ' 40' ' ' THR . 74.1 mttt -70.75 112.63 7.11 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.199 -0.938 . . . . 0.0 109.737 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -92.75 162.7 14.02 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.326 -0.859 . . . . 0.0 109.584 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.995 -1.002 . . . . 0.0 109.491 179.997 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.413 ' C ' HD13 ' A' ' 2' ' ' LEU . 75.1 mtm . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.628 ' CD1' ' N ' ' A' ' 2' ' ' LEU . 4.6 mp -115.89 162.02 17.94 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.24 -0.913 . . . . 0.0 109.117 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.477 ' O ' HG12 ' A' ' 20' ' ' VAL . 2.4 tt0 -128.73 143.67 50.98 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.205 -0.935 . . . . 0.0 109.163 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -144.34 157.08 27.07 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.428 ' C ' HG21 ' A' ' 18' ' ' ILE . 43.2 mttm -108.23 137.1 46.79 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.423 -1.045 . . . . 0.0 108.576 179.383 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.417 ' HA ' HG12 ' A' ' 18' ' ' ILE . 16.1 t -68.28 114.45 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.128 -0.983 . . . . 0.0 109.85 -179.341 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.46 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 29.7 tttt -79.33 -38.07 36.03 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 179.601 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.608 ' CZ3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -166.37 157.39 12.89 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.476 -0.765 . . . . 0.0 109.035 -179.893 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.432 ' N ' ' CG ' ' A' ' 8' ' ' TRP . 16.1 p90 -152.75 139.89 19.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.203 -0.936 . . . . 0.0 108.847 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.499 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 55.1 t-20 -117.11 121.54 41.58 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.045 -1.034 . . . . 0.0 109.971 -179.408 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 88.0 p -66.45 -17.94 65.07 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.387 -0.82 . . . . 0.0 109.443 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -83.7 -40.58 18.73 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.231 -0.918 . . . . 0.0 109.373 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.635 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 24.9 mttp -68.76 -43.52 75.63 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.29 -0.882 . . . . 0.0 109.367 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.467 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 104.53 -0.4 42.94 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.635 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 0.4 OUTLIER -142.33 179.8 6.72 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.112 -1.228 . . . . 0.0 109.529 179.88 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.516 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -145.3 172.17 26.16 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.679 -1.368 . . . . 0.0 109.679 -179.834 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.608 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 28.4 m-85 -114.79 131.94 56.64 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.22 -1.164 . . . . 0.0 109.021 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.606 HD13 ' CG2' ' A' ' 47' ' ' VAL . 37.3 mt -119.25 149.54 21.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.146 -0.971 . . . . 0.0 109.647 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 46.3 tt0 -112.28 120.3 41.27 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.406 -0.809 . . . . 0.0 109.413 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.484 HG22 ' CG2' ' A' ' 26' ' ' VAL . 2.6 t -90.85 125.1 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.312 -0.868 . . . . 0.0 109.428 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.459 ' HA ' ' OE1' ' A' ' 21' ' ' GLU . 67.0 mm-40 -73.57 106.05 5.18 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.318 -0.864 . . . . 0.0 109.25 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.53 -17.54 8.89 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 46.5 mt-30 -133.9 164.62 26.86 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.276 -1.132 . . . . 0.0 109.648 -179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 50.5 m-20 -55.02 -176.6 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.207 -0.933 . . . . 0.0 109.607 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.499 ' OD1' ' N ' ' A' ' 25' ' ' ASP . 11.4 p30 -73.33 139.96 46.39 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.29 -0.881 . . . . 0.0 109.477 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.484 ' CG2' HG22 ' A' ' 20' ' ' VAL . 56.1 t -115.74 122.02 68.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.196 -0.94 . . . . 0.0 109.44 -179.796 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.503 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.3 OUTLIER -79.78 157.53 27.06 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.13 -0.981 . . . . 0.0 109.192 179.977 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.602 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 13.0 t -132.31 130.18 60.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.303 -0.873 . . . . 0.0 109.373 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.667 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 13.4 t-80 -103.65 154.41 19.55 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.148 -0.97 . . . . 0.0 109.089 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.689 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.7 OUTLIER -45.98 -53.44 10.02 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.082 -1.011 . . . . 0.0 109.188 -179.682 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.689 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 93.0 p -55.55 -30.26 60.45 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.154 -0.966 . . . . 0.0 110.236 -179.555 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -58.03 -27.9 63.99 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.996 -1.065 . . . . 0.0 109.331 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.621 HG12 HD11 ' A' ' 41' ' ' LEU . 2.6 mp -108.13 142.56 20.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.355 -0.841 . . . . 0.0 109.52 -179.844 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -105.22 145.99 29.87 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.201 -0.937 . . . . 0.0 109.486 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.641 ' CA ' ' CZ ' ' A' ' 38' ' ' PHE . . . 161.43 149.99 5.79 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -68.12 -46.55 70.59 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.209 -1.171 . . . . 0.0 109.44 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -143.93 -11.72 0.34 Allowed Glycine 0 N--CA 1.491 2.345 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.641 ' CZ ' ' CA ' ' A' ' 35' ' ' GLY . 53.5 p90 -86.9 16.61 4.73 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.91 -1.347 . . . . 0.0 109.642 -179.763 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.512 ' O ' ' CD1' ' A' ' 41' ' ' LEU . 43.3 mtmt -63.0 -18.45 63.31 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.22 -0.925 . . . . 0.0 109.487 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 21.2 m -67.19 120.29 13.52 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.277 -0.89 . . . . 0.0 109.3 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.621 HD11 HG12 ' A' ' 33' ' ' ILE . 4.4 mp -81.21 139.99 35.19 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.266 -0.896 . . . . 0.0 109.837 -179.669 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.433 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.5 tt0 -91.75 134.4 34.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.43 -0.794 . . . . 0.0 109.401 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.46 ' HG3' ' O ' ' A' ' 7' ' ' LYS . 76.1 tt0 -59.44 128.28 36.27 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.239 -0.913 . . . . 0.0 109.638 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.406 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 91.99 -5.13 78.8 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.726 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.433 ' HB2' ' HB3' ' A' ' 42' ' ' GLU . 63.3 tt0 -81.37 131.48 35.29 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.269 -1.136 . . . . 0.0 109.758 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.465 ' O ' HG12 ' A' ' 47' ' ' VAL . . . -79.14 141.4 37.29 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.247 -0.908 . . . . 0.0 109.22 179.681 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.606 ' CG2' HD13 ' A' ' 18' ' ' ILE . 33.2 m -141.83 159.19 21.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.127 -0.983 . . . . 0.0 109.907 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.495 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 27.5 t -106.08 151.26 24.91 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 179.017 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.578 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 11.7 p90 175.13 165.39 0.29 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.943 -1.098 . . . . 0.0 110.317 -179.707 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -100.05 166.26 11.12 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 178.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.415 HG12 HG21 ' A' ' 26' ' ' VAL . 0.6 OUTLIER -104.16 125.72 58.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.917 -1.114 . . . . 0.0 109.804 -179.66 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.59 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 33.1 m -114.03 125.57 71.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.173 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.446 ' HA ' ' HA ' ' A' ' 58' ' ' PRO . 19.8 mt-10 -96.66 93.61 6.84 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.196 -0.94 . . . . 0.0 109.923 -179.35 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.61 -176.62 44.33 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.407 ' CG ' ' N ' ' A' ' 56' ' ' ARG . 18.5 p-10 -53.17 -50.77 63.92 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.219 -1.165 . . . . 0.0 109.715 -179.674 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.407 ' N ' ' CG ' ' A' ' 55' ' ' ASN . 20.1 mtm180 -58.96 -37.5 76.93 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.081 -1.012 . . . . 0.0 109.381 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.05 -159.21 28.07 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.446 ' HA ' ' HA ' ' A' ' 53' ' ' GLU . 53.7 Cg_endo -72.59 142.28 35.99 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.728 2.285 . . . . 0.0 111.903 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.59 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 72.8 mt-30 -138.97 169.89 16.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.384 -0.822 . . . . 0.0 108.945 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.427 ' HB2' HG11 ' A' ' 26' ' ' VAL . . . -95.03 138.17 33.11 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.047 -1.033 . . . . 0.0 110.383 -179.132 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.578 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -125.42 156.33 39.01 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.34 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 73.5 m-20 45.39 69.18 0.47 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.893 -1.13 . . . . 0.0 108.665 -179.647 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.56 ' CG1' ' CG1' ' A' ' 33' ' ' ILE . 2.2 t -88.14 125.83 41.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.326 -0.859 . . . . 0.0 110.17 -179.033 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 98.1 m -118.16 121.23 39.99 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.505 -0.747 . . . . 0.0 109.025 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.51 ' NZ ' ' O ' ' A' ' 38' ' ' PHE . 28.7 mttp -71.49 112.26 7.47 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.229 -0.919 . . . . 0.0 109.361 -179.805 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.461 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 96.2 mt-10 -94.03 166.89 11.93 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.313 -0.867 . . . . 0.0 109.642 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . 0.414 ' O ' ' O ' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 117.998 -1.001 . . . . 0.0 109.548 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 77.1 mtp . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 121.283 0.564 . . . . 0.0 109.54 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.614 ' CD1' ' N ' ' A' ' 2' ' ' LEU . 3.6 mp -109.35 161.79 14.95 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.351 -0.843 . . . . 0.0 109.366 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.481 ' O ' HG11 ' A' ' 20' ' ' VAL . 83.0 mt-10 -127.96 144.27 51.1 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.274 -0.891 . . . . 0.0 109.185 179.671 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.475 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -140.06 153.43 23.32 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.485 ' N ' HG21 ' A' ' 18' ' ' ILE . 58.4 mttm -104.03 139.26 39.39 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.315 -1.109 . . . . 0.0 108.841 179.482 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.554 ' CG1' ' HA ' ' A' ' 43' ' ' GLU . 38.7 t -71.63 109.94 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.166 -0.958 . . . . 0.0 109.899 -179.43 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.67 -32.83 27.94 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.371 -0.831 . . . . 0.0 108.977 179.42 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.686 ' CE3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -158.63 159.28 35.22 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 -179.837 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.505 ' N ' ' CG ' ' A' ' 8' ' ' TRP . 22.4 p90 -161.16 132.5 5.5 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.029 -1.044 . . . . 0.0 109.283 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.498 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.1 t-20 -128.19 123.6 34.69 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.197 -0.939 . . . . 0.0 109.539 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -76.64 -18.05 58.81 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.293 -0.88 . . . . 0.0 108.805 179.616 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.436 ' HB2' ' ND2' ' A' ' 10' ' ' ASN . 95.3 mt-10 -59.86 -56.08 26.21 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 178.557 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.682 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 13.8 mttp -67.15 -42.3 84.61 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 178.353 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.415 ' C ' ' CD1' ' A' ' 15' ' ' PHE . . . 106.56 7.0 35.02 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 179.345 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.703 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 0.0 OUTLIER -137.14 173.08 12.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.0 -1.294 . . . . 0.0 109.22 179.102 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.598 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -136.96 172.57 22.56 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.686 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 17.0 m-85 -119.37 133.74 55.56 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.226 -1.161 . . . . 0.0 109.306 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.574 ' CD1' ' CG2' ' A' ' 28' ' ' VAL . 15.4 mt -120.82 154.41 24.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.342 -0.849 . . . . 0.0 109.46 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.455 ' N ' HG22 ' A' ' 18' ' ' ILE . 24.9 tp10 -117.65 122.91 44.82 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.307 -0.871 . . . . 0.0 109.38 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.526 HG23 ' CG2' ' A' ' 26' ' ' VAL . 2.9 t -93.58 120.16 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.228 -0.92 . . . . 0.0 109.553 -179.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -67.14 109.18 2.94 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.295 -0.878 . . . . 0.0 109.286 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.22 -23.1 7.75 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.533 ' OE1' ' CD1' ' A' ' 51' ' ' ILE . 65.0 mt-30 -130.79 164.79 24.38 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.304 -1.115 . . . . 0.0 109.51 -179.77 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 41.0 m-20 -55.28 -175.02 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.33 -0.856 . . . . 0.0 109.924 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.475 ' OD1' ' N ' ' A' ' 25' ' ' ASP . 15.2 p30 -74.18 141.99 45.46 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.301 -0.875 . . . . 0.0 109.737 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.526 ' CG2' HG23 ' A' ' 20' ' ' VAL . 90.6 t -117.87 118.13 57.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.207 -0.933 . . . . 0.0 109.353 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.452 ' CE1' ' HB3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -75.13 156.06 36.37 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.231 -0.918 . . . . 0.0 109.021 179.771 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.574 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 6.9 t -133.57 139.95 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.89 . . . . 0.0 109.607 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.703 ' HA ' ' HB3' ' A' ' 15' ' ' PHE . 13.6 t-80 -114.42 150.3 34.91 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.26 -0.9 . . . . 0.0 109.25 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.668 ' CG ' ' N ' ' A' ' 31' ' ' SER . 1.0 OUTLIER -43.75 -52.66 6.44 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.174 -0.954 . . . . 0.0 109.396 -179.642 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.668 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 22.8 t -57.61 -20.84 35.51 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.17 -0.956 . . . . 0.0 109.863 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.465 ' N ' ' O ' ' A' ' 29' ' ' HIS . . . -69.42 -22.75 63.66 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.115 -0.991 . . . . 0.0 109.735 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.594 ' CG1' ' CG1' ' A' ' 63' ' ' VAL . 2.9 mp -103.08 143.45 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.207 -0.933 . . . . 0.0 109.716 -179.852 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.455 ' C ' ' O ' ' A' ' 33' ' ' ILE . 59.6 mt-30 -40.68 -59.03 1.48 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.326 -0.859 . . . . 0.0 109.602 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.501 ' HA3' ' HE3' ' A' ' 39' ' ' LYS . . . 92.24 2.75 68.07 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.433 ' C ' ' O ' ' A' ' 35' ' ' GLY . 81.9 tt0 -44.05 -27.5 0.39 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.187 -1.184 . . . . 0.0 109.322 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 174.23 40.29 0.04 OUTLIER Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.505 ' HB2' ' HE2' ' A' ' 65' ' ' LYS . 5.7 p90 -175.42 46.94 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.201 -1.176 . . . . 0.0 109.56 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.501 ' HE3' ' HA3' ' A' ' 35' ' ' GLY . 17.8 mttp -62.15 -32.13 72.7 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.183 -0.948 . . . . 0.0 109.332 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 30.0 m -73.66 108.24 6.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.245 -0.909 . . . . 0.0 109.492 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.567 HD11 HG12 ' A' ' 33' ' ' ILE . 5.5 mp -74.49 147.31 42.0 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.244 -0.91 . . . . 0.0 109.787 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.426 ' O ' ' CB ' ' A' ' 6' ' ' VAL . 94.5 mt-10 -105.47 146.29 29.73 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.44 -0.787 . . . . 0.0 109.36 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.554 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 52.6 tt0 -70.06 130.72 42.91 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.184 -0.947 . . . . 0.0 109.613 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 93.11 -5.96 75.75 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.726 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.403 ' HB3' HG23 ' A' ' 6' ' ' VAL . 60.2 tp60 -81.86 125.68 30.99 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.26 -1.141 . . . . 0.0 109.73 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -73.25 143.94 46.88 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.199 -0.938 . . . . 0.0 109.223 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.567 ' CG2' HD12 ' A' ' 18' ' ' ILE . 33.4 m -145.39 158.92 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.109 -0.994 . . . . 0.0 110.188 -179.576 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.523 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 4.6 p -110.49 154.53 23.52 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.115 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.566 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 7.9 p90 171.29 167.66 0.08 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.93 -1.106 . . . . 0.0 110.035 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -103.67 165.09 11.25 Favored 'General case' 0 C--N 1.303 -1.436 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.212 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.533 ' CD1' ' OE1' ' A' ' 23' ' ' GLN . 3.9 mt -106.25 132.22 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 120.997 -1.064 . . . . 0.0 109.685 -179.897 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.54 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 20.5 m -121.28 133.12 68.87 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.557 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 -84.97 82.66 8.35 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.213 -0.929 . . . . 0.0 109.604 -179.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -84.32 176.64 51.56 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 20.2 p-10 -49.47 -51.69 34.13 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.241 -1.152 . . . . 0.0 109.65 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 23.2 mtm180 -62.38 -31.98 72.72 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.095 -1.003 . . . . 0.0 109.549 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 142.93 -148.22 19.89 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 50.0 Cg_endo -71.24 133.59 23.17 Favored 'Trans proline' 0 C--O 1.214 -0.688 0 C-N-CA 122.802 2.334 . . . . 0.0 112.034 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.54 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 42.6 mt-30 -127.87 161.32 29.34 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.38 -0.825 . . . . 0.0 109.359 179.726 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -92.16 110.49 21.87 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.217 -0.927 . . . . 0.0 110.134 -179.508 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.559 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -93.48 152.07 19.31 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.327 -0.858 . . . . 0.0 109.061 179.633 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.494 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 79.0 m-20 43.63 78.23 0.06 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.043 -1.036 . . . . 0.0 109.029 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.594 ' CG1' ' CG1' ' A' ' 33' ' ' ILE . 2.1 t -92.87 125.87 45.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.182 -0.949 . . . . 0.0 110.003 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.457 HG23 ' OE2' ' A' ' 66' ' ' GLU . 56.9 m -120.48 130.22 54.19 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.655 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.505 ' HE2' ' HB2' ' A' ' 38' ' ' PHE . 44.3 mttp -76.81 114.04 15.13 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.277 -0.889 . . . . 0.0 109.72 -179.697 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.457 ' OE2' HG23 ' A' ' 64' ' ' THR . 57.5 mm-40 -101.02 172.02 7.28 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.284 -0.885 . . . . 0.0 109.635 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 117.993 -1.003 . . . . 0.0 109.471 179.893 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.426 ' HB3' HD13 ' A' ' 2' ' ' LEU . 73.1 mtp . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.604 ' CD1' ' N ' ' A' ' 2' ' ' LEU . 5.2 mp -112.93 165.72 12.06 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.322 -0.861 . . . . 0.0 109.319 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.485 ' O ' HG11 ' A' ' 20' ' ' VAL . 2.4 tt0 -132.39 139.99 48.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.179 -0.951 . . . . 0.0 109.461 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -140.4 158.75 26.09 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.507 ' O ' HG23 ' A' ' 18' ' ' ILE . 85.6 mttt -106.96 139.69 40.97 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.32 -1.106 . . . . 0.0 108.895 179.78 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.485 ' HB ' ' O ' ' A' ' 42' ' ' GLU . 22.6 t -72.88 111.56 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.109 -0.994 . . . . 0.0 110.127 -179.34 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 19.1 tttt -79.16 -40.6 30.52 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.615 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.7 154.76 26.88 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.765 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.436 ' N ' ' CG ' ' A' ' 8' ' ' TRP . 13.6 p90 -154.9 141.0 18.43 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.058 -1.026 . . . . 0.0 109.424 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.46 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.7 t-20 -132.76 128.92 37.89 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.253 -0.904 . . . . 0.0 109.677 -179.746 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.3 p -78.46 -20.03 51.83 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.208 -0.933 . . . . 0.0 108.831 179.564 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.437 ' HA ' ' OE1' ' A' ' 12' ' ' GLU . 69.9 mm-40 -64.45 -45.69 86.36 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 178.092 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.629 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 10.3 mttm -73.86 -34.98 64.71 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 178.449 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.503 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 92.84 0.93 68.26 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 179.191 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.629 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 5.6 p90 -138.78 171.94 13.61 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.044 -1.268 . . . . 0.0 108.883 178.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.615 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -138.43 172.11 23.15 Favored Glycine 0 N--CA 1.49 2.27 0 C-N-CA 119.634 -1.27 . . . . 0.0 110.024 -179.452 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.514 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 27.1 m-85 -115.17 133.0 56.42 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.339 -1.095 . . . . 0.0 108.789 179.569 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.595 HD13 ' CG2' ' A' ' 47' ' ' VAL . 13.1 mt -120.92 155.29 24.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.151 -0.968 . . . . 0.0 109.873 -179.518 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.4 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 23.4 tp10 -116.92 123.47 47.06 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.398 -0.814 . . . . 0.0 109.369 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.485 HG11 ' O ' ' A' ' 3' ' ' GLU . 2.3 t -98.15 123.0 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.17 -0.956 . . . . 0.0 109.317 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.455 ' HA ' ' OE1' ' A' ' 21' ' ' GLU . 68.7 mm-40 -72.24 108.83 5.6 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 0.0 109.3 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 125.44 -22.68 6.17 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.226 -1.55 . . . . 0.0 109.226 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.538 ' OE1' ' CD1' ' A' ' 51' ' ' ILE . 73.1 mt-30 -135.73 167.54 20.96 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.28 -1.13 . . . . 0.0 109.548 -179.78 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -53.52 -177.12 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.262 -0.899 . . . . 0.0 109.587 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.479 ' OD1' ' N ' ' A' ' 25' ' ' ASP . 11.8 p30 -74.61 143.18 44.48 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.937 . . . . 0.0 109.426 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.472 HG21 HG21 ' A' ' 20' ' ' VAL . 97.9 t -116.33 119.36 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.16 -0.962 . . . . 0.0 109.425 -179.813 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.518 ' CG ' ' N ' ' A' ' 28' ' ' VAL . 0.4 OUTLIER -77.84 158.8 29.32 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.172 -0.955 . . . . 0.0 109.207 179.916 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.583 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 4.4 t -133.09 125.71 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.476 -0.765 . . . . 0.0 109.144 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.676 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 14.6 t-80 -98.46 153.93 18.24 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.355 -0.84 . . . . 0.0 109.091 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.687 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -45.13 -53.68 7.75 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.07 -1.019 . . . . 0.0 109.203 -179.65 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.687 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 62.8 p -54.27 -25.13 21.69 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.189 -0.945 . . . . 0.0 109.921 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.461 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -62.34 -24.52 67.38 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.126 -0.984 . . . . 0.0 109.439 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.538 ' CD1' HD12 ' A' ' 41' ' ' LEU . 3.0 mp -109.25 136.0 46.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.238 -0.914 . . . . 0.0 109.544 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 61.5 tt0 -101.44 113.95 27.52 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.315 -0.865 . . . . 0.0 109.447 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.586 ' HA3' ' CE1' ' A' ' 38' ' ' PHE . . . -176.81 162.07 30.25 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 86.1 mt-10 -118.04 87.57 2.74 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.23 -1.159 . . . . 0.0 109.356 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.03 -24.81 7.72 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.586 ' CE1' ' HA3' ' A' ' 35' ' ' GLY . 49.0 p90 -123.65 25.36 8.17 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.336 -1.096 . . . . 0.0 109.242 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.467 ' HG3' ' O ' ' A' ' 35' ' ' GLY . 89.1 mttt -55.31 -36.8 66.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.336 -0.852 . . . . 0.0 109.662 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.52 ' O ' ' NZ ' ' A' ' 65' ' ' LYS . 20.7 m -72.17 138.43 47.64 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.209 -0.932 . . . . 0.0 109.522 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.538 HD12 ' CD1' ' A' ' 33' ' ' ILE . 5.1 mp -80.52 178.68 8.17 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.348 -0.845 . . . . 0.0 109.788 -179.784 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.485 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 20.5 tt0 -116.42 140.24 49.56 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.391 -0.818 . . . . 0.0 109.057 179.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.462 ' HA ' HG13 ' A' ' 6' ' ' VAL . 76.6 tt0 -62.35 125.35 23.6 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.264 -0.898 . . . . 0.0 109.618 -179.76 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 90.67 -7.1 81.82 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.462 ' OE1' ' HB3' ' A' ' 42' ' ' GLU . 66.7 tt0 -81.76 134.39 35.44 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.24 -1.153 . . . . 0.0 109.72 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.459 ' O ' HG13 ' A' ' 47' ' ' VAL . . . -80.07 140.16 36.6 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.271 -0.893 . . . . 0.0 109.155 179.675 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.595 ' CG2' HD13 ' A' ' 18' ' ' ILE . 26.4 m -140.57 151.73 20.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.227 -0.921 . . . . 0.0 109.745 -179.464 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.511 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 33.0 t -100.56 148.94 24.24 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.053 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.581 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 7.2 p90 176.28 164.7 0.42 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.903 -1.123 . . . . 0.0 110.105 -179.63 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.418 ' HG2' ' HB2' ' A' ' 1' ' ' MET . 94.9 mt-10 -103.54 161.41 13.9 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.247 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.538 ' CD1' ' OE1' ' A' ' 23' ' ' GLN . 7.2 mt -104.61 135.78 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.969 -1.082 . . . . 0.0 109.783 -179.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.494 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 32.7 m -122.23 131.41 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.481 -0.762 . . . . 0.0 109.11 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -86.8 84.22 7.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.185 -0.947 . . . . 0.0 109.634 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -85.84 177.16 49.55 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.3 t30 -50.34 -54.33 22.35 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.196 -1.179 . . . . 0.0 109.608 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 71.3 mtm180 -57.38 -35.46 70.01 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.241 -0.912 . . . . 0.0 109.498 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 145.2 -153.28 25.17 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -70.37 137.31 33.41 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.734 2.289 . . . . 0.0 111.987 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.494 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 92.2 mt-30 -135.19 165.99 24.14 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.342 -0.849 . . . . 0.0 109.275 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -94.58 137.15 34.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.198 -0.938 . . . . 0.0 109.777 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.581 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -123.96 155.04 38.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.365 -0.834 . . . . 0.0 108.843 179.717 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.476 ' C ' ' O ' ' A' ' 61' ' ' ALA . 85.8 m-20 43.19 73.91 0.13 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.897 -1.127 . . . . 0.0 108.706 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.543 HG22 ' CG1' ' A' ' 28' ' ' VAL . 2.7 t -89.65 126.96 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.212 -0.93 . . . . 0.0 109.99 -179.108 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.401 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 70.3 m -118.45 124.29 47.27 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.52 ' NZ ' ' O ' ' A' ' 40' ' ' THR . 55.5 mttt -71.73 111.03 6.67 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.181 -0.95 . . . . 0.0 109.528 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -89.78 164.1 14.79 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.364 -0.835 . . . . 0.0 109.566 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.461 -179.922 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 91.8 mtp . . . . . 0 N--CA 1.489 1.475 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.587 ' CD1' ' N ' ' A' ' 2' ' ' LEU . 4.6 mp -107.55 161.91 14.42 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.238 -0.914 . . . . 0.0 109.391 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.474 ' O ' HG11 ' A' ' 20' ' ' VAL . 96.1 mt-10 -129.48 147.36 51.29 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.167 -0.958 . . . . 0.0 109.295 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.45 ' HA3' HG22 ' A' ' 18' ' ' ILE . . . -143.1 153.46 24.77 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.451 ' C ' HG23 ' A' ' 18' ' ' ILE . 27.6 mttp -102.48 141.38 35.39 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.284 -1.127 . . . . 0.0 108.839 179.557 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.517 ' CG1' ' HA ' ' A' ' 43' ' ' GLU . 33.7 t -73.8 110.58 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.247 -0.908 . . . . 0.0 110.126 -179.392 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.471 ' NZ ' ' HB3' ' A' ' 17' ' ' PHE . 2.9 pttt -79.89 -36.46 36.5 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.618 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -159.74 154.26 24.04 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.962 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.627 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 17.0 p90 -156.03 140.33 16.64 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.075 -1.016 . . . . 0.0 109.496 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.429 ' ND2' ' HB2' ' A' ' 12' ' ' GLU . 55.1 t-20 -130.82 121.91 26.16 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.224 -0.923 . . . . 0.0 109.521 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -74.08 -20.04 60.41 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.159 -0.963 . . . . 0.0 108.745 179.637 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.429 ' HB2' ' ND2' ' A' ' 10' ' ' ASN . 95.5 mt-10 -63.19 -47.46 82.5 Favored 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 106.476 -1.675 . . . . 0.0 106.476 177.883 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.696 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 28.8 mttm -70.31 -41.44 73.29 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 178.161 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.488 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 99.15 3.46 56.73 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.386 -1.485 . . . . 0.0 109.386 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.696 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 2.8 p90 -141.85 167.52 21.94 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.274 -1.133 . . . . 0.0 108.85 179.015 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.618 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -136.07 177.22 19.72 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.652 -1.261 . . . . 0.0 110.05 -179.366 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.562 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 19.4 m-85 -119.2 135.49 54.65 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.384 -1.068 . . . . 0.0 109.078 179.834 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.569 HG21 ' N ' ' A' ' 19' ' ' GLU . 37.9 mt -122.34 148.41 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.168 -0.958 . . . . 0.0 109.507 -179.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.569 ' N ' HG21 ' A' ' 18' ' ' ILE . 23.3 tp10 -110.98 121.05 44.37 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.342 -0.849 . . . . 0.0 109.332 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.484 HG23 HG21 ' A' ' 26' ' ' VAL . 2.6 t -91.46 120.59 40.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.211 -0.931 . . . . 0.0 109.664 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.404 ' OE1' ' HA ' ' A' ' 21' ' ' GLU . 73.2 mm-40 -71.9 110.64 6.54 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.202 -0.936 . . . . 0.0 109.246 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.57 -18.38 8.18 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.513 ' OE1' ' CD1' ' A' ' 51' ' ' ILE . 63.9 mt-30 -140.04 170.35 16.01 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.353 -1.086 . . . . 0.0 109.495 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 60.2 m-20 -55.31 -178.35 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.291 -0.88 . . . . 0.0 109.654 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 22.6 p30 -75.01 146.46 41.61 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.236 -0.915 . . . . 0.0 109.438 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.484 HG21 HG23 ' A' ' 20' ' ' VAL . 58.1 t -118.35 119.07 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.242 -0.911 . . . . 0.0 109.401 -179.67 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.54 ' CD1' ' C ' ' A' ' 27' ' ' PHE . 0.0 OUTLIER -76.61 156.31 32.84 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.205 -0.934 . . . . 0.0 109.148 179.855 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.558 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 14.7 t -133.45 132.97 57.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.383 -0.823 . . . . 0.0 109.399 -179.762 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.68 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 15.3 t-80 -111.18 153.5 25.7 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.354 -0.841 . . . . 0.0 109.053 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.682 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -44.47 -53.85 6.55 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.126 -0.984 . . . . 0.0 109.347 -179.605 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.682 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 32.3 t -57.04 -22.81 41.78 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.115 -0.991 . . . . 0.0 110.014 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.413 ' N ' ' O ' ' A' ' 29' ' ' HIS . . . -66.43 -27.53 67.91 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.09 -1.006 . . . . 0.0 109.458 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.589 ' CG1' ' CG1' ' A' ' 63' ' ' VAL . 2.4 mp -100.65 141.52 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.258 -0.901 . . . . 0.0 109.677 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.407 ' C ' ' O ' ' A' ' 33' ' ' ILE . 60.7 mt-30 -42.69 -53.28 4.57 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.276 -0.89 . . . . 0.0 109.63 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.517 ' CA ' ' HG2' ' A' ' 39' ' ' LYS . . . 88.4 11.06 67.17 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.369 -1.492 . . . . 0.0 109.369 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.414 ' C ' ' O ' ' A' ' 35' ' ' GLY . 82.3 tt0 -45.09 -26.44 0.45 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.317 -1.108 . . . . 0.0 109.425 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 172.34 40.57 0.04 OUTLIER Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.503 ' HB2' ' NZ ' ' A' ' 65' ' ' LYS . 0.1 OUTLIER -178.96 40.38 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.203 -1.175 . . . . 0.0 109.643 179.936 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.517 ' HG2' ' CA ' ' A' ' 35' ' ' GLY . 87.0 mttt -47.77 -29.59 3.26 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.191 -0.943 . . . . 0.0 109.351 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 29.9 m -79.15 109.35 13.38 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.278 -0.889 . . . . 0.0 109.449 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.627 ' O ' ' CD2' ' A' ' 9' ' ' PHE . 3.1 mp -75.28 152.73 38.2 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.32 -0.863 . . . . 0.0 109.672 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.468 ' O ' ' CB ' ' A' ' 6' ' ' VAL . 96.0 mt-10 -100.7 149.15 24.09 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.324 -0.86 . . . . 0.0 109.484 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.517 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 69.8 tt0 -71.91 130.01 39.97 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.348 -0.845 . . . . 0.0 109.625 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.463 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 90.52 -4.26 82.17 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.421 ' OE1' ' HG2' ' A' ' 65' ' ' LYS . 49.8 tt0 -80.8 129.57 34.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.271 -1.135 . . . . 0.0 109.638 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.499 ' O ' HG13 ' A' ' 47' ' ' VAL . . . -76.48 139.75 40.94 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.268 -0.895 . . . . 0.0 109.065 179.702 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.544 ' CG2' HD12 ' A' ' 18' ' ' ILE . 31.8 m -142.28 162.24 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.029 -1.044 . . . . 0.0 109.959 -179.651 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.524 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 63.8 m -112.44 153.38 27.47 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.61 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 5.8 p90 172.75 168.56 0.12 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.033 -1.042 . . . . 0.0 109.978 -179.833 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.496 ' HB2' ' HB1' ' A' ' 61' ' ' ALA . 95.1 mt-10 -103.5 160.88 14.34 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.513 ' CD1' ' OE1' ' A' ' 23' ' ' GLN . 3.9 mt -103.5 134.47 44.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.116 -0.99 . . . . 0.0 109.616 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.529 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 33.9 m -122.74 131.74 72.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -85.7 87.2 7.37 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.102 -0.999 . . . . 0.0 109.677 -179.724 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.62 178.07 43.96 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.9 t30 -50.24 -56.75 9.82 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.23 -1.159 . . . . 0.0 109.514 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 21.6 mtm180 -57.11 -34.07 67.96 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.262 -0.898 . . . . 0.0 109.417 -179.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 144.53 -152.18 24.15 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.434 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 51.0 Cg_endo -70.46 136.98 32.43 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.835 2.357 . . . . 0.0 112.052 -179.869 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.529 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 89.9 mt-30 -132.85 165.3 24.93 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.443 -0.786 . . . . 0.0 109.263 179.796 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.435 ' N ' ' CG1' ' A' ' 26' ' ' VAL . . . -90.13 132.19 35.58 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.16 -0.963 . . . . 0.0 109.789 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.529 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -113.7 147.76 37.61 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.528 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.484 ' C ' ' O ' ' A' ' 61' ' ' ALA . 23.9 t-20 41.27 74.41 0.11 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.141 -0.975 . . . . 0.0 108.778 -179.497 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.61 ' HA ' ' HB3' ' A' ' 49' ' ' PHE . 1.4 t -84.38 127.94 39.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.387 -0.821 . . . . 0.0 110.159 -179.068 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 27.7 m -119.68 126.61 51.53 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 179.333 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.503 ' NZ ' ' HB2' ' A' ' 38' ' ' PHE . 57.7 mttt -73.72 108.78 6.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.162 -0.961 . . . . 0.0 109.511 -179.614 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 45.9 mm-40 -99.08 175.8 5.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.338 -0.852 . . . . 0.0 109.689 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.479 179.922 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.433 ' C ' HD13 ' A' ' 2' ' ' LEU . 84.0 mmm . . . . . 0 N--CA 1.491 1.595 0 CA-C-O 121.296 0.569 . . . . 0.0 109.487 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.621 ' CD1' ' N ' ' A' ' 2' ' ' LEU . 5.1 mp -115.88 154.89 28.91 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.209 -0.932 . . . . 0.0 109.33 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.468 ' O ' HG11 ' A' ' 20' ' ' VAL . 2.1 tt0 -124.74 140.45 52.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.276 -0.89 . . . . 0.0 108.993 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -144.63 149.87 21.98 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 19.4 mttm -99.52 139.53 35.05 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.38 -1.071 . . . . 0.0 108.539 179.295 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.469 HG21 ' O ' ' A' ' 45' ' ' GLN . 20.7 t -69.91 115.22 8.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.039 -1.038 . . . . 0.0 109.776 -179.464 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.436 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 40.7 tttt -78.76 -42.13 28.81 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.726 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.63 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -160.14 154.93 24.28 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.43 -0.794 . . . . 0.0 108.888 179.976 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.463 ' CE2' HG23 ' A' ' 40' ' ' THR . 11.3 p90 -154.25 141.74 19.76 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.101 -0.999 . . . . 0.0 109.193 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.456 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 57.9 t-20 -129.79 133.57 47.05 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.151 -0.968 . . . . 0.0 109.832 -179.62 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 12.5 p -78.63 -21.2 48.79 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.125 -0.984 . . . . 0.0 108.906 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.428 ' HB2' ' ND2' ' A' ' 10' ' ' ASN . 92.8 mt-10 -65.52 -44.63 86.34 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 106.657 -1.609 . . . . 0.0 106.657 177.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.655 ' HD3' ' CE2' ' A' ' 15' ' ' PHE . 16.1 mttm -75.36 -37.7 60.5 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.363 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.497 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 91.01 1.47 72.85 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 179.542 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.655 ' CE2' ' HD3' ' A' ' 13' ' ' LYS . 4.0 p90 -138.38 169.95 16.88 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.098 -1.236 . . . . 0.0 108.937 179.118 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.63 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -138.63 175.21 21.61 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 119.625 -1.274 . . . . 0.0 109.97 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.483 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 37.6 m-85 -116.7 132.49 56.67 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.404 -1.057 . . . . 0.0 109.014 179.696 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.583 ' CD1' ' CG2' ' A' ' 28' ' ' VAL . 37.1 mt -116.89 148.7 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.141 -0.974 . . . . 0.0 109.528 -179.827 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 30.6 tp10 -110.29 121.31 44.98 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.332 -0.855 . . . . 0.0 109.448 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.468 HG11 ' O ' ' A' ' 3' ' ' GLU . 2.4 t -96.22 120.02 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.163 -0.961 . . . . 0.0 109.471 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 47.1 mp0 -71.75 109.01 5.36 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.273 -0.892 . . . . 0.0 109.36 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.426 ' C ' ' HG3' ' A' ' 23' ' ' GLN . . . 125.28 -20.46 6.61 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.783 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.426 ' HG3' ' C ' ' A' ' 22' ' ' GLY . 37.3 mt-30 -138.83 169.62 17.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.317 -1.107 . . . . 0.0 109.695 -179.811 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -53.54 -177.4 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.32 -0.862 . . . . 0.0 109.665 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' A' ' 25' ' ' ASP . 11.0 p30 -75.97 143.54 41.49 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.287 -0.883 . . . . 0.0 109.661 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.468 HG21 HG21 ' A' ' 20' ' ' VAL . 79.7 t -116.92 120.87 66.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.23 -0.919 . . . . 0.0 109.527 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.553 ' CG ' ' N ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER -80.26 161.11 25.3 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.373 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.583 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 15.0 t -135.7 125.02 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.428 -0.795 . . . . 0.0 109.4 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.688 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 15.1 t-80 -96.2 154.35 17.3 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.231 -0.918 . . . . 0.0 109.14 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.688 ' CD2' ' CE1' ' A' ' 29' ' ' HIS . 0.7 OUTLIER -45.8 -53.41 9.66 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.105 -0.997 . . . . 0.0 109.245 -179.616 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.685 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 86.8 p -55.66 -27.24 48.84 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.171 -0.956 . . . . 0.0 109.982 -179.618 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -64.41 -35.94 82.52 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.995 -1.066 . . . . 0.0 109.159 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 5.1 mt -91.97 147.85 5.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.228 -0.92 . . . . 0.0 109.349 179.777 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 69.3 mt-30 -125.45 145.51 50.04 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.213 -0.93 . . . . 0.0 109.449 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.605 ' CA ' ' CZ ' ' A' ' 38' ' ' PHE . . . -179.35 161.78 28.09 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -77.34 -36.87 53.41 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.232 -1.158 . . . . 0.0 109.523 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -150.58 17.13 0.98 Allowed Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.605 ' CZ ' ' CA ' ' A' ' 35' ' ' GLY . 44.4 p90 -127.44 49.83 2.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.269 -1.136 . . . . 0.0 109.502 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 46.4 mtpt -66.56 -30.26 70.52 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.2 -0.938 . . . . 0.0 109.567 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.463 HG23 ' CE2' ' A' ' 9' ' ' PHE . 36.6 m -72.89 111.21 7.81 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.283 -0.886 . . . . 0.0 109.642 -179.754 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.48 HD23 HG12 ' A' ' 47' ' ' VAL . 1.1 mt -59.69 174.68 0.43 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.262 -0.899 . . . . 0.0 109.575 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.465 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 46.3 tp10 -123.18 147.13 47.18 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.203 -0.936 . . . . 0.0 109.56 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.466 ' HA ' HG11 ' A' ' 6' ' ' VAL . 76.0 tt0 -73.35 126.01 29.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.196 -0.94 . . . . 0.0 109.739 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.75 -5.45 79.62 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.469 ' O ' HG21 ' A' ' 6' ' ' VAL . 48.4 tp60 -81.22 124.4 29.26 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.196 -1.179 . . . . 0.0 109.601 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.455 ' O ' HG11 ' A' ' 47' ' ' VAL . . . -75.09 144.61 42.84 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.263 -0.898 . . . . 0.0 109.154 179.63 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.546 ' CG2' HD11 ' A' ' 18' ' ' ILE . 21.7 m -148.36 168.11 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.177 -0.952 . . . . 0.0 109.827 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.528 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 4.1 p -112.48 152.76 28.37 Favored 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.325 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.558 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 14.4 p90 175.83 164.42 0.36 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.979 -1.076 . . . . 0.0 110.141 -179.781 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -100.36 164.6 11.86 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 179.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.459 HG12 HG22 ' A' ' 26' ' ' VAL . 0.4 OUTLIER -101.77 124.36 55.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 120.851 -1.156 . . . . 0.0 109.422 -179.903 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.558 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.1 m -111.1 123.57 67.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.401 -0.812 . . . . 0.0 109.011 179.764 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.41 ' HA ' ' HA ' ' A' ' 58' ' ' PRO . 10.2 mt-10 -94.97 91.12 6.23 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.177 -0.952 . . . . 0.0 109.948 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.08 -174.88 42.37 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 179.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -54.37 -62.39 1.69 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.171 -1.194 . . . . 0.0 109.546 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 18.8 mtm180 -46.66 -41.23 14.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.157 -0.964 . . . . 0.0 109.194 179.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 152.99 -161.53 29.65 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.486 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 53.6 Cg_endo -72.09 144.12 41.65 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.712 2.275 . . . . 0.0 111.752 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.558 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 78.8 mt-30 -141.82 172.36 12.79 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.289 -0.882 . . . . 0.0 109.048 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.415 ' N ' ' O ' ' A' ' 27' ' ' PHE . . . -94.23 142.55 27.28 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.139 -0.976 . . . . 0.0 110.236 -179.234 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.512 ' O ' ' C ' ' A' ' 62' ' ' ASN . . . -124.43 152.85 42.77 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.434 -0.791 . . . . 0.0 108.903 179.578 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.512 ' C ' ' O ' ' A' ' 61' ' ' ALA . 44.8 t30 38.62 73.91 0.1 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.07 -1.019 . . . . 0.0 109.186 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.558 ' HA ' ' HB3' ' A' ' 49' ' ' PHE . 1.5 t -86.97 129.22 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.245 -0.909 . . . . 0.0 109.96 -179.313 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.436 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 65.3 m -115.44 119.53 36.54 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.35 -0.843 . . . . 0.0 109.116 179.645 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.534 ' HD2' ' CD2' ' A' ' 38' ' ' PHE . 35.9 mttt -69.73 108.17 3.79 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 109.286 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.437 ' HG3' ' HA ' ' A' ' 47' ' ' VAL . 97.2 mt-10 -87.4 164.09 16.4 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.272 -0.892 . . . . 0.0 109.725 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.562 0 CA-C-O 117.989 -1.005 . . . . 0.0 109.58 -179.955 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 71.2 mtm . . . . . 0 N--CA 1.489 1.51 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 45.5 mt -108.61 166.24 10.94 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.233 -0.917 . . . . 0.0 109.541 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.465 ' O ' HG12 ' A' ' 20' ' ' VAL . 89.1 mt-10 -136.13 136.54 40.17 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.241 -0.912 . . . . 0.0 109.26 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -133.78 159.42 23.7 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.463 ' C ' HG21 ' A' ' 18' ' ' ILE . 77.9 mttt -103.34 140.84 36.9 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.409 -1.053 . . . . 0.0 108.824 179.41 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.487 ' HB ' ' O ' ' A' ' 42' ' ' GLU . 18.9 t -73.73 114.2 12.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.116 -0.99 . . . . 0.0 110.241 -179.111 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.4 tttt -78.44 -41.45 32.79 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.664 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.78 153.89 25.32 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.553 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.629 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 6.2 p90 -156.05 141.65 17.8 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.986 -1.071 . . . . 0.0 109.764 -179.61 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.412 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 50.4 t-20 -127.17 126.03 42.14 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.276 -0.89 . . . . 0.0 108.992 179.528 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 41.5 p -78.54 -12.99 60.04 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.198 -0.939 . . . . 0.0 109.594 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -59.26 -58.78 7.13 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 178.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.584 ' HD2' ' CE2' ' A' ' 15' ' ' PHE . 34.0 mtmt -72.08 -44.94 62.48 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.606 ' O ' ' CB ' ' A' ' 30' ' ' PHE . . . 112.1 19.36 7.24 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 120.035 -1.078 . . . . 0.0 110.651 178.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.592 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 50.2 p90 -148.85 172.64 14.33 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.795 -1.414 . . . . 0.0 109.187 179.518 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.664 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -149.53 174.96 28.92 Favored Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.53 -1.319 . . . . 0.0 110.206 -179.477 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.437 ' CE1' ' HB2' ' A' ' 27' ' ' PHE . 49.6 m-85 -111.9 133.75 53.9 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.446 -1.032 . . . . 0.0 108.834 179.644 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.61 ' CD1' ' CG2' ' A' ' 28' ' ' VAL . 19.7 mt -120.4 149.43 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.207 -0.933 . . . . 0.0 109.489 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.55 ' N ' HG22 ' A' ' 18' ' ' ILE . 20.7 tp10 -113.28 122.44 47.44 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.351 -0.843 . . . . 0.0 109.332 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.532 HG23 ' CG2' ' A' ' 26' ' ' VAL . 2.8 t -91.75 121.9 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.253 -0.904 . . . . 0.0 109.525 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -69.36 108.5 3.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.333 -0.854 . . . . 0.0 109.325 179.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.07 -19.72 8.7 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.469 ' OE1' HD12 ' A' ' 51' ' ' ILE . 49.0 mt-30 -133.47 166.18 23.14 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.289 -1.124 . . . . 0.0 109.487 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 59.5 m-20 -54.79 -175.74 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.235 -0.916 . . . . 0.0 109.45 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.493 ' OD1' ' N ' ' A' ' 25' ' ' ASP . 11.2 p30 -75.84 143.78 41.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.291 -0.881 . . . . 0.0 109.577 -179.832 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.532 ' CG2' HG23 ' A' ' 20' ' ' VAL . 79.3 t -118.85 121.42 66.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.184 -0.947 . . . . 0.0 109.374 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.504 ' O ' ' N ' ' A' ' 60' ' ' ALA . 0.1 OUTLIER -79.03 158.26 27.93 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.266 -0.896 . . . . 0.0 109.392 -179.984 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.61 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 17.3 t -132.85 132.38 59.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.428 -0.795 . . . . 0.0 109.165 -179.76 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.678 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 14.6 t-80 -104.61 154.89 19.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.256 -0.903 . . . . 0.0 109.277 -179.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.693 ' CD1' ' N ' ' A' ' 31' ' ' SER . 0.6 OUTLIER -46.3 -53.01 11.56 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.215 -0.928 . . . . 0.0 109.361 -179.696 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.693 ' N ' ' CD1' ' A' ' 30' ' ' PHE . 91.4 p -60.16 -21.19 61.35 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.095 -1.003 . . . . 0.0 110.025 -179.631 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.466 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -63.19 -23.6 67.5 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.042 -1.036 . . . . 0.0 109.468 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.553 HD11 ' CD1' ' A' ' 41' ' ' LEU . 3.5 mp -111.18 136.47 47.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.206 -0.934 . . . . 0.0 109.605 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 74.7 mt-30 -92.66 145.28 24.54 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.245 -0.909 . . . . 0.0 109.51 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.603 ' CA ' ' CE1' ' A' ' 38' ' ' PHE . . . 161.04 148.74 5.38 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -71.16 -47.68 56.3 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.345 -1.091 . . . . 0.0 109.629 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -141.28 19.95 2.64 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.603 ' CE1' ' CA ' ' A' ' 35' ' ' GLY . 50.7 p90 -129.27 26.95 5.39 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.288 -1.125 . . . . 0.0 109.435 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.436 ' O ' ' HB ' ' A' ' 33' ' ' ILE . 77.3 mttt -60.22 -37.57 80.72 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.211 -0.931 . . . . 0.0 109.654 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 29.5 p -62.54 145.47 54.24 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.228 -0.92 . . . . 0.0 109.634 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.629 ' O ' ' CD2' ' A' ' 9' ' ' PHE . 3.0 mp -98.35 -174.29 2.79 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.259 -0.901 . . . . 0.0 109.281 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.495 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.1 tt0 -121.61 150.63 41.42 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.26 -0.9 . . . . 0.0 109.338 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 61.5 tt0 -67.44 124.23 22.62 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.23 -0.919 . . . . 0.0 109.538 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 90.96 -3.58 80.93 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 179.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.495 ' HB2' ' HB3' ' A' ' 42' ' ' GLU . 61.4 tp60 -81.71 131.6 35.27 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.18 -1.189 . . . . 0.0 109.603 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.467 ' O ' HG12 ' A' ' 47' ' ' VAL . . . -76.54 140.16 41.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.187 -0.946 . . . . 0.0 109.204 179.741 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.589 ' CG2' HD12 ' A' ' 18' ' ' ILE . 33.8 m -141.26 159.96 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.151 -0.968 . . . . 0.0 109.532 -179.84 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.511 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 43.4 m -112.86 155.62 24.36 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.385 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.563 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 3.7 p90 171.69 166.48 0.09 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.037 -1.039 . . . . 0.0 110.144 -179.692 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -97.82 157.53 16.02 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.729 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.469 HD12 ' OE1' ' A' ' 23' ' ' GLN . 1.4 mt -98.12 128.1 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.985 -1.072 . . . . 0.0 110.006 -179.473 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.552 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 0.3 OUTLIER -110.07 119.68 59.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.366 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -89.01 91.44 8.83 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.203 -0.936 . . . . 0.0 109.872 -179.446 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -97.23 -176.2 34.58 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -53.57 -61.59 2.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.178 -1.189 . . . . 0.0 109.663 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 61.3 mtp180 -47.9 -38.88 17.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.232 -0.917 . . . . 0.0 109.049 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.86 -157.3 27.3 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -71.06 140.78 38.54 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.719 2.279 . . . . 0.0 111.692 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.552 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 91.8 mt-30 -135.51 167.78 20.44 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.21 -0.931 . . . . 0.0 109.232 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.504 ' N ' ' O ' ' A' ' 27' ' ' PHE . . . -96.42 137.58 35.28 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.18 -0.95 . . . . 0.0 110.158 -179.354 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.563 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -125.18 156.67 38.06 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.466 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.524 ' C ' ' O ' ' A' ' 61' ' ' ALA . 80.7 m-20 38.68 74.56 0.09 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.075 -1.016 . . . . 0.0 108.927 -179.765 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.541 ' CG1' HG13 ' A' ' 33' ' ' ILE . 2.4 t -89.32 129.62 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.234 -0.916 . . . . 0.0 110.307 -178.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.446 HG21 ' OE2' ' A' ' 66' ' ' GLU . 60.8 m -118.54 124.66 48.07 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.513 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.414 ' HE3' ' O ' ' A' ' 38' ' ' PHE . 53.2 mttt -67.18 107.37 2.31 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.245 -0.91 . . . . 0.0 109.281 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.446 ' OE2' HG21 ' A' ' 64' ' ' THR . 59.4 mm-40 -97.09 170.58 9.03 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.157 -0.964 . . . . 0.0 109.622 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.406 179.989 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 78.2 mtp . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.477 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 71.6 mt -112.98 164.07 13.9 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.254 -0.904 . . . . 0.0 109.539 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.414 ' O ' HG12 ' A' ' 20' ' ' VAL . 1.4 tt0 -130.75 140.89 50.35 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.34 -0.85 . . . . 0.0 109.329 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.49 155.06 25.05 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.474 ' O ' HG22 ' A' ' 18' ' ' ILE . 84.5 mttt -104.14 139.51 39.09 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.317 -1.108 . . . . 0.0 108.764 179.553 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.496 ' HB ' ' O ' ' A' ' 42' ' ' GLU . 16.0 t -72.22 113.16 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.097 -1.002 . . . . 0.0 110.085 -179.223 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.3 tttt -78.85 -40.87 31.49 Favored 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 179.546 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.604 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.96 154.41 25.82 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.812 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.601 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 8.2 p90 -155.59 141.27 17.95 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.026 -1.046 . . . . 0.0 109.315 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.436 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 63.2 t-20 -131.48 129.41 41.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.166 -0.959 . . . . 0.0 109.777 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 59.6 p -77.0 -20.38 56.13 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.285 -0.885 . . . . 0.0 109.083 179.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -62.49 -48.07 81.2 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 106.803 -1.555 . . . . 0.0 106.803 178.128 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.671 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 3.7 mttp -73.33 -39.31 65.35 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.57 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.51 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 97.26 5.06 58.26 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 179.395 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.671 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 5.6 p90 -143.1 165.79 26.44 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.162 -1.199 . . . . 0.0 108.994 179.292 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.604 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -134.71 174.54 21.0 Favored Glycine 0 N--CA 1.491 2.349 0 C-N-CA 119.708 -1.234 . . . . 0.0 110.087 -179.438 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.49 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 26.1 m-85 -115.75 137.94 51.6 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.463 -1.022 . . . . 0.0 109.215 179.755 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.6 ' CD1' ' CG2' ' A' ' 28' ' ' VAL . 12.5 mt -123.69 154.06 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.161 -0.962 . . . . 0.0 109.491 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.46 ' N ' HG23 ' A' ' 18' ' ' ILE . 6.9 tt0 -117.98 116.06 26.15 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.313 -0.867 . . . . 0.0 109.503 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.524 HG23 ' CG2' ' A' ' 26' ' ' VAL . 2.4 t -85.33 118.4 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.276 -0.89 . . . . 0.0 109.353 179.789 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 85.4 mt-10 -68.43 111.08 4.45 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.196 -0.94 . . . . 0.0 109.243 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.444 ' C ' ' HG3' ' A' ' 23' ' ' GLN . . . 120.93 -15.66 9.51 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.444 ' HG3' ' C ' ' A' ' 22' ' ' GLY . 49.5 mt-30 -140.68 169.75 17.05 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.222 -1.164 . . . . 0.0 109.622 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 60.5 m-20 -54.75 -179.21 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.254 -0.904 . . . . 0.0 109.681 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.461 ' OD1' ' N ' ' A' ' 25' ' ' ASP . 18.4 p30 -75.41 144.0 42.44 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.307 -0.871 . . . . 0.0 109.706 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.524 ' CG2' HG23 ' A' ' 20' ' ' VAL . 86.4 t -118.38 118.8 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.224 -0.923 . . . . 0.0 109.263 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.586 ' CD1' ' N ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER -77.31 159.0 29.88 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.152 -0.967 . . . . 0.0 109.154 -179.935 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.6 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 13.6 t -134.08 131.43 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.356 -0.84 . . . . 0.0 109.393 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.664 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 17.4 t-80 -106.97 154.64 20.79 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.313 -0.867 . . . . 0.0 109.027 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.676 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -46.47 -53.36 11.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.023 -1.048 . . . . 0.0 109.205 -179.631 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.676 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 54.6 p -53.91 -30.75 47.57 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.155 -0.966 . . . . 0.0 110.347 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.475 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -61.83 -21.24 64.47 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.029 -1.045 . . . . 0.0 109.465 -179.856 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.536 ' CD1' HD11 ' A' ' 41' ' ' LEU . 3.2 mp -111.79 129.04 67.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.204 -0.935 . . . . 0.0 109.506 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.7 mt-30 -111.52 144.06 41.36 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.193 -0.942 . . . . 0.0 109.267 179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.611 ' HA3' ' CZ ' ' A' ' 38' ' ' PHE . . . 176.3 169.28 37.57 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -56.5 -47.63 78.89 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.285 -1.127 . . . . 0.0 109.354 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -170.77 37.98 0.18 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.611 ' CZ ' ' HA3' ' A' ' 35' ' ' GLY . 18.3 p90 -126.24 14.46 7.78 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.154 -1.204 . . . . 0.0 109.545 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.451 ' C ' ' O ' ' A' ' 38' ' ' PHE . 20.0 mtmm -41.49 -40.93 1.94 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.259 -0.9 . . . . 0.0 109.703 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.412 ' O ' ' HE2' ' A' ' 65' ' ' LYS . 23.9 m -52.89 124.59 14.51 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.234 -0.916 . . . . 0.0 109.527 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.601 ' O ' ' CD2' ' A' ' 9' ' ' PHE . 5.3 mp -85.61 170.49 12.51 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.323 -0.861 . . . . 0.0 109.272 179.828 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.496 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 84.7 tt0 -117.31 149.78 39.9 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.181 -0.949 . . . . 0.0 109.055 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.437 ' HA ' HG13 ' A' ' 6' ' ' VAL . 62.8 tt0 -70.52 123.97 23.08 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.253 -0.904 . . . . 0.0 109.584 -179.778 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 92.89 -3.41 73.79 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 179.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.49 ' HB2' ' HB3' ' A' ' 42' ' ' GLU . 60.7 tt0 -82.74 134.95 35.12 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.119 -1.224 . . . . 0.0 109.906 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.485 ' O ' HG12 ' A' ' 47' ' ' VAL . . . -81.1 141.56 34.17 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.399 -0.813 . . . . 0.0 109.067 179.501 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.591 ' CG2' HD13 ' A' ' 18' ' ' ILE . 28.1 m -141.51 159.57 21.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.131 -0.981 . . . . 0.0 109.922 -179.529 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.503 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 23.0 t -110.89 154.06 24.58 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.424 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.541 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 5.6 p90 172.26 166.14 0.11 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.01 -1.056 . . . . 0.0 110.077 -179.746 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -98.98 160.55 14.18 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.435 HD12 ' OE1' ' A' ' 23' ' ' GLN . 0.8 OUTLIER -97.94 125.41 51.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 120.933 -1.105 . . . . 0.0 109.781 -179.436 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.582 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 0.1 OUTLIER -107.85 118.95 56.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.473 -0.767 . . . . 0.0 109.076 179.852 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -86.76 84.78 7.3 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.314 -0.866 . . . . 0.0 109.704 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.43 -177.31 41.61 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.3 t30 -54.2 -61.98 1.96 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.219 -1.165 . . . . 0.0 109.563 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 39.7 mtp180 -48.32 -39.36 21.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.285 -0.884 . . . . 0.0 109.135 179.794 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 148.81 -158.86 27.82 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.532 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 49.8 Cg_endo -70.23 140.44 40.92 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.686 2.257 . . . . 0.0 111.716 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.582 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 8.5 mt-30 -133.88 166.25 23.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.318 -0.864 . . . . 0.0 109.37 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -87.58 128.4 35.26 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.308 -0.87 . . . . 0.0 109.871 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.541 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -112.74 146.45 38.74 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.35 -0.844 . . . . 0.0 108.812 179.457 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.472 ' C ' ' O ' ' A' ' 61' ' ' ALA . 62.5 t30 42.82 71.9 0.2 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.046 -1.034 . . . . 0.0 108.776 -179.615 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.53 HG12 ' CG1' ' A' ' 33' ' ' ILE . 2.0 t -83.82 127.1 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.365 -0.834 . . . . 0.0 110.162 -178.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 93.9 m -119.79 127.04 52.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.449 -0.782 . . . . 0.0 109.016 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.566 ' HD2' ' CD1' ' A' ' 38' ' ' PHE . 55.1 mttp -77.46 112.78 14.57 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.172 -0.955 . . . . 0.0 109.726 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -89.82 165.11 14.34 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.902 . . . . 0.0 109.428 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 118.009 -0.996 . . . . 0.0 109.41 -179.999 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 90.9 mmm . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 121.275 0.56 . . . . 0.0 109.546 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.499 ' CD1' ' N ' ' A' ' 2' ' ' LEU . 6.2 mp -113.63 156.76 23.12 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.22 -0.925 . . . . 0.0 109.547 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.476 ' HG2' ' O ' ' A' ' 47' ' ' VAL . 3.0 tt0 -133.39 132.53 41.3 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.306 -0.871 . . . . 0.0 109.217 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.515 ' C ' ' CG2' ' A' ' 18' ' ' ILE . . . -135.63 167.6 24.19 Favored Glycine 0 N--CA 1.491 2.342 0 C-N-CA 119.632 -1.27 . . . . 0.0 110.229 -179.602 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.514 ' O ' ' HA ' ' A' ' 18' ' ' ILE . 44.0 mmtm -110.39 135.63 50.81 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.544 -0.974 . . . . 0.0 108.693 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.561 ' HA ' HG12 ' A' ' 18' ' ' ILE . 17.6 t -68.5 116.14 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.19 -0.944 . . . . 0.0 109.973 -179.556 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.422 ' N ' ' O ' ' A' ' 17' ' ' PHE . 11.5 tttm -80.38 -33.69 37.0 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.303 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.671 ' CD2' ' N ' ' A' ' 9' ' ' PHE . 0.4 OUTLIER -162.57 166.41 24.74 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 179.671 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.671 ' N ' ' CD2' ' A' ' 8' ' ' TRP . 9.9 p90 -164.47 145.93 8.32 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.94 -1.1 . . . . 0.0 110.601 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.633 ' HB3' ' CE1' ' A' ' 15' ' ' PHE . 38.0 t-20 -103.14 139.14 39.04 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.391 -0.818 . . . . 0.0 109.615 179.741 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 97.5 p -84.7 -14.07 49.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.184 -0.947 . . . . 0.0 109.934 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 65.5 tt0 -58.61 -63.21 1.36 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.087 -1.008 . . . . 0.0 109.219 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.631 ' HB2' ' CD1' ' A' ' 15' ' ' PHE . 20.1 mttm -96.52 -20.7 18.18 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.347 -0.845 . . . . 0.0 109.542 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.554 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 86.56 68.58 1.34 Allowed Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 179.748 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.633 ' CE1' ' HB3' ' A' ' 10' ' ' ASN . 1.4 p90 -154.3 172.89 16.94 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.219 -1.165 . . . . 0.0 108.725 179.468 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.598 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -176.75 151.18 10.99 Favored Glycine 0 N--CA 1.487 2.076 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.026 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.46 ' HB3' ' OD2' ' A' ' 25' ' ' ASP . 89.4 m-85 -79.08 143.18 35.8 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.369 -1.077 . . . . 0.0 108.803 179.596 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.643 HG21 ' N ' ' A' ' 19' ' ' GLU . 73.3 mt -121.84 149.17 25.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 -179.786 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.643 ' N ' HG21 ' A' ' 18' ' ' ILE . 44.5 tt0 -103.7 118.49 36.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.199 -0.938 . . . . 0.0 109.529 -179.852 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.498 HG21 ' CG2' ' A' ' 26' ' ' VAL . 3.4 t -94.32 123.51 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.255 -0.903 . . . . 0.0 109.417 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -59.08 99.93 0.06 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.303 -0.873 . . . . 0.0 109.674 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.25 -29.04 3.54 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 179.623 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.431 ' OE1' HD11 ' A' ' 51' ' ' ILE . 15.0 mt-30 -127.05 169.86 12.93 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.133 -1.216 . . . . 0.0 109.739 -179.814 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.533 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -60.24 -163.41 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.237 -0.914 . . . . 0.0 109.553 179.753 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.46 ' OD2' ' HB3' ' A' ' 17' ' ' PHE . 2.9 t70 -77.53 143.64 38.25 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.285 -0.884 . . . . 0.0 109.713 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.498 ' CG2' HG21 ' A' ' 20' ' ' VAL . 88.4 t -115.95 127.14 73.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.371 -0.831 . . . . 0.0 109.367 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.523 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.1 OUTLIER -76.47 148.23 37.35 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.118 -0.988 . . . . 0.0 109.636 -179.791 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.606 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 16.5 t -131.14 131.44 63.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 -179.79 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.672 ' CE1' ' CE2' ' A' ' 30' ' ' PHE . 12.1 t-80 -102.68 148.33 25.72 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.083 -1.011 . . . . 0.0 109.924 -179.529 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.672 ' CE2' ' CE1' ' A' ' 29' ' ' HIS . 1.1 p90 -43.57 -51.83 6.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.307 -0.871 . . . . 0.0 109.519 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.672 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 46.5 p -61.27 -13.58 19.9 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.168 -0.957 . . . . 0.0 109.801 -179.701 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.517 ' N ' ' O ' ' A' ' 29' ' ' HIS . . . -66.68 -25.23 66.45 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.265 -0.897 . . . . 0.0 109.642 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.562 HG13 ' CG1' ' A' ' 63' ' ' VAL . 2.2 mp -93.49 141.78 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.257 -0.902 . . . . 0.0 109.725 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.467 ' O ' ' HD2' ' A' ' 39' ' ' LYS . 85.6 mt-30 -43.79 151.37 0.21 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.3 -0.875 . . . . 0.0 109.672 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.561 ' HA3' ' CE1' ' A' ' 38' ' ' PHE . . . 115.11 167.21 15.3 Favored Glycine 0 N--CA 1.486 2.004 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -82.03 6.46 16.1 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.296 -1.12 . . . . 0.0 109.062 179.584 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.44 ' HA2' ' HD1' ' A' ' 30' ' ' PHE . . . 117.72 21.17 4.36 Favored Glycine 0 N--CA 1.487 2.099 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.561 ' CE1' ' HA3' ' A' ' 35' ' ' GLY . 29.7 p90 -94.98 -11.32 28.69 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.362 -1.081 . . . . 0.0 109.685 -179.84 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.533 ' CE ' ' CZ ' ' A' ' 38' ' ' PHE . 61.3 mttt -90.86 129.37 36.91 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.197 -0.94 . . . . 0.0 109.599 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 46.5 m -114.01 127.36 55.91 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.296 -0.878 . . . . 0.0 109.368 179.733 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.536 ' CD1' HD11 ' A' ' 33' ' ' ILE . 1.1 mt -68.36 152.04 46.01 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.278 -0.889 . . . . 0.0 109.614 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.461 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 80.2 tt0 -117.42 150.76 38.35 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.341 -0.85 . . . . 0.0 109.249 179.84 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 68.4 tt0 -68.33 128.07 35.25 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.914 . . . . 0.0 109.571 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 86.77 -2.94 87.33 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 179.733 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.461 ' HB2' ' HB3' ' A' ' 42' ' ' GLU . 51.8 tt0 -80.44 134.62 36.01 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.203 -1.175 . . . . 0.0 109.715 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.514 ' O ' HG13 ' A' ' 47' ' ' VAL . . . -87.55 142.52 27.79 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.299 -0.876 . . . . 0.0 109.169 179.689 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.626 ' CG2' HD11 ' A' ' 18' ' ' ILE . 32.9 m -147.06 167.06 5.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.232 -0.918 . . . . 0.0 109.864 -179.734 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.575 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 24.0 t -109.15 154.77 21.87 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 178.838 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.569 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 8.1 p90 172.15 168.59 0.11 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.003 -1.061 . . . . 0.0 110.034 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 90.2 mt-10 -105.99 169.24 8.61 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 179.173 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.431 HD11 ' OE1' ' A' ' 23' ' ' GLN . 4.2 mt -111.02 136.87 45.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.022 -1.049 . . . . 0.0 109.546 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.416 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 33.7 m -123.04 134.36 66.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.465 -0.772 . . . . 0.0 108.942 179.727 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -90.49 79.64 6.18 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.139 -0.975 . . . . 0.0 109.613 -179.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -81.3 -179.5 53.04 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -52.45 -57.15 10.79 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.177 -1.19 . . . . 0.0 109.559 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 82.1 mtm180 -54.19 -38.17 65.32 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.163 -0.96 . . . . 0.0 109.599 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.08 -153.34 25.29 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.416 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 50.9 Cg_endo -70.76 133.76 24.41 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.867 2.378 . . . . 0.0 112.146 -179.825 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 83.7 mt-30 -133.53 164.66 26.65 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.356 -0.84 . . . . 0.0 109.032 179.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -92.72 136.93 32.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.119 -0.988 . . . . 0.0 110.104 -179.506 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.569 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -121.14 153.06 38.01 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 179.376 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.499 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 85.0 m-20 43.86 79.41 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.962 -1.086 . . . . 0.0 108.702 -179.557 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.575 ' HA ' ' O ' ' A' ' 48' ' ' SER . 2.1 t -94.63 124.34 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.161 -0.962 . . . . 0.0 110.195 -179.059 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.475 ' HB ' ' HB3' ' A' ' 48' ' ' SER . 97.1 m -114.16 114.96 26.74 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.49 -0.756 . . . . 0.0 109.055 179.576 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.485 ' HA ' HG13 ' A' ' 47' ' ' VAL . 56.5 mttt -65.02 118.4 9.07 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.335 -0.853 . . . . 0.0 109.426 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 67.1 mm-40 -102.38 162.56 12.82 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.378 -0.826 . . . . 0.0 109.732 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.462 -179.957 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.437 ' HA ' ' OE2' ' A' ' 50' ' ' GLU . 47.7 mtt . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.25 0.548 . . . . 0.0 109.574 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.449 HD13 HD13 ' A' ' 51' ' ' ILE . 26.5 mt -103.6 173.14 6.43 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.292 -0.88 . . . . 0.0 109.385 179.811 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 74.1 mt-10 -133.82 134.69 43.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.268 -0.895 . . . . 0.0 109.441 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -139.7 157.09 25.1 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.705 -1.358 . . . . 0.0 109.705 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.413 ' NZ ' ' OE2' ' A' ' 21' ' ' GLU . 69.6 mttt -111.21 133.69 53.37 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.435 -1.038 . . . . 0.0 108.438 179.189 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.5 ' HA ' HG12 ' A' ' 18' ' ' ILE . 16.2 t -64.05 115.18 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.113 -0.992 . . . . 0.0 110.118 -179.328 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.474 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 14.9 tptp -78.12 -42.04 33.16 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 179.508 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.612 ' O ' ' CE3' ' A' ' 8' ' ' TRP . 0.0 OUTLIER -162.29 156.07 21.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.499 -0.751 . . . . 0.0 109.093 179.99 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.641 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 10.6 p90 -154.16 140.53 18.68 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.13 -0.981 . . . . 0.0 109.041 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.577 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 54.5 t-20 -109.81 115.54 30.03 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.13 -0.981 . . . . 0.0 109.499 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 82.3 p -59.53 -20.27 54.27 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.222 -0.924 . . . . 0.0 109.485 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.7 tt0 -82.94 -39.18 21.76 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.186 -0.946 . . . . 0.0 109.354 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.618 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 23.7 mttp -68.71 -45.5 71.41 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.285 -0.884 . . . . 0.0 109.486 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.479 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 106.09 0.77 38.66 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.621 ' CD1' ' N ' ' A' ' 15' ' ' PHE . 0.3 OUTLIER -143.78 -176.22 4.89 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.112 -1.228 . . . . 0.0 109.288 179.779 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.562 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -155.41 176.85 32.88 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 109.531 -1.427 . . . . 0.0 109.531 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.527 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 43.6 m-85 -113.79 133.3 55.47 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.248 -1.148 . . . . 0.0 109.187 179.789 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.627 HD11 ' CG2' ' A' ' 47' ' ' VAL . 61.7 mt -116.18 145.43 21.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.388 -0.82 . . . . 0.0 109.722 -179.669 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.536 ' N ' HG23 ' A' ' 18' ' ' ILE . 28.7 tt0 -108.09 116.5 32.07 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.415 -0.803 . . . . 0.0 109.495 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.452 HG22 HG23 ' A' ' 26' ' ' VAL . 2.8 t -87.96 125.93 41.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.295 -0.878 . . . . 0.0 109.422 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.413 ' OE2' ' NZ ' ' A' ' 5' ' ' LYS . 93.3 mt-10 -69.85 101.62 1.77 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.293 -0.879 . . . . 0.0 109.221 179.849 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.22 -22.97 6.97 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 -179.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.434 ' NE2' HG12 ' A' ' 51' ' ' ILE . 12.6 mt-30 -123.28 158.81 30.12 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.364 -1.08 . . . . 0.0 109.322 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.429 ' O ' ' O ' ' A' ' 23' ' ' GLN . 44.8 m-20 -54.81 -171.24 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.19 -0.944 . . . . 0.0 109.452 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.54 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 88.6 m-20 -73.73 133.25 43.3 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.196 -0.94 . . . . 0.0 109.533 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.541 HG23 ' CG1' ' A' ' 51' ' ' ILE . 96.0 t -111.06 125.24 68.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.256 -0.903 . . . . 0.0 109.234 -179.882 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.573 ' CE1' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER -79.28 159.64 27.16 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.052 -1.03 . . . . 0.0 109.747 -179.716 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.609 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 57.8 t -133.95 137.95 51.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.432 -0.792 . . . . 0.0 109.419 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.572 ' O ' ' CD1' ' A' ' 33' ' ' ILE . 21.7 t-80 -111.23 150.59 29.37 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.291 -0.88 . . . . 0.0 108.899 179.593 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.713 ' CG ' ' N ' ' A' ' 31' ' ' SER . 1.3 p90 -48.09 -54.21 13.94 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.046 -1.034 . . . . 0.0 109.298 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.713 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 19.2 t -55.96 -30.55 61.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.025 -1.047 . . . . 0.0 109.899 -179.441 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.563 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -63.66 -17.56 63.06 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.021 -1.049 . . . . 0.0 108.544 179.505 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.582 HD12 ' CD1' ' A' ' 41' ' ' LEU . 0.6 OUTLIER -118.08 145.28 24.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.607 -0.683 . . . . 0.0 109.434 -179.86 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 90.6 mt-30 -123.21 159.47 28.6 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.147 -0.971 . . . . 0.0 109.633 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.719 ' HA3' ' CE1' ' A' ' 38' ' ' PHE . . . 150.06 156.33 7.22 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 90.6 mt-10 -119.92 118.71 31.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.266 -1.138 . . . . 0.0 109.294 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 99.5 -5.46 58.7 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.719 ' CE1' ' HA3' ' A' ' 35' ' ' GLY . 38.0 p90 -152.52 38.33 0.54 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.164 -1.198 . . . . 0.0 109.57 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 7.5 mtpt -63.27 -25.57 68.38 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.18 -0.95 . . . . 0.0 109.444 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 70.1 p -75.11 126.09 30.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.246 -0.909 . . . . 0.0 109.462 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.641 ' O ' ' CD2' ' A' ' 9' ' ' PHE . 5.2 mp -72.25 141.12 48.94 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.249 -0.907 . . . . 0.0 109.745 -179.826 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.424 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.2 tt0 -96.98 132.28 42.95 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.237 -0.914 . . . . 0.0 109.528 -179.852 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.474 ' OE2' ' O ' ' A' ' 7' ' ' LYS . 75.1 tt0 -59.51 129.01 39.88 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.318 -0.864 . . . . 0.0 109.343 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 93.74 -8.06 74.0 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.46 ' O ' HG21 ' A' ' 6' ' ' VAL . 70.6 tp60 -78.41 126.33 30.62 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.162 -1.199 . . . . 0.0 109.596 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.47 ' O ' HG11 ' A' ' 47' ' ' VAL . . . -82.88 143.26 30.87 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.251 -0.905 . . . . 0.0 109.344 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.627 ' CG2' HD11 ' A' ' 18' ' ' ILE . 34.4 m -144.41 167.04 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.908 . . . . 0.0 109.597 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.469 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 22.3 t -109.72 154.67 22.56 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.376 -0.827 . . . . 0.0 108.839 179.502 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.623 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 4.2 p90 172.79 166.03 0.13 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.959 -1.088 . . . . 0.0 110.312 -179.759 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.437 ' OE2' ' HA ' ' A' ' 1' ' ' MET . 67.5 mm-40 -96.09 159.68 14.84 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 178.581 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.541 ' CG1' HG23 ' A' ' 26' ' ' VAL . 1.1 mp -100.52 127.5 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.939 -1.101 . . . . 0.0 110.044 -179.431 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.597 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 27.5 m -115.86 124.18 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 178.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 22.0 mt-10 -95.74 97.16 9.48 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.127 -0.983 . . . . 0.0 109.703 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.19 -179.35 42.77 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.436 ' CG ' ' N ' ' A' ' 56' ' ' ARG . 16.0 p-10 -53.97 -50.31 66.8 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.159 -1.201 . . . . 0.0 109.514 -179.87 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.436 ' N ' ' CG ' ' A' ' 55' ' ' ASN . 33.3 mtp85 -61.31 -42.19 98.25 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.052 -1.03 . . . . 0.0 109.793 -179.726 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 158.79 -164.64 33.75 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 110.016 -1.233 . . . . 0.0 110.016 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.54 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 44.1 Cg_endo -68.55 139.78 45.73 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 123.198 2.598 . . . . 0.0 112.637 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.597 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 68.5 mt-30 -135.58 165.41 25.6 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.301 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.554 ' N ' ' O ' ' A' ' 27' ' ' PHE . . . -99.17 141.96 31.26 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.976 -1.077 . . . . 0.0 110.467 -179.031 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.526 ' O ' ' C ' ' A' ' 62' ' ' ASN . . . -124.22 155.7 38.1 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 179.128 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.526 ' C ' ' O ' ' A' ' 61' ' ' ALA . 0.3 OUTLIER 37.58 66.72 0.43 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.172 -0.955 . . . . 0.0 109.003 -179.798 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.623 ' HA ' ' HB3' ' A' ' 49' ' ' PHE . 2.0 t -79.01 130.99 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.337 -0.852 . . . . 0.0 110.073 -179.048 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.523 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 25.2 m -117.15 123.4 46.63 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.328 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.559 ' HE2' HG21 ' A' ' 33' ' ' ILE . 47.4 mttm -74.97 115.49 14.64 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.203 -0.935 . . . . 0.0 109.939 -179.56 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.455 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 47.2 mt-10 -99.79 169.17 9.43 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.278 -0.889 . . . . 0.0 109.413 179.837 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 118.062 -0.971 . . . . 0.0 109.547 179.827 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.466 ' N ' ' OE2' ' A' ' 50' ' ' GLU . 76.0 mmm . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.492 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 61.9 mt -106.81 161.67 14.47 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.093 -1.004 . . . . 0.0 109.672 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -123.45 140.31 53.13 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.323 -0.861 . . . . 0.0 108.901 179.639 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.418 ' HA3' HG21 ' A' ' 18' ' ' ILE . . . -144.39 148.53 20.34 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.893 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 50.0 mttp -101.77 142.63 32.8 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.353 -1.086 . . . . 0.0 108.771 179.288 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.459 HG23 ' O ' ' A' ' 45' ' ' GLN . 21.5 t -73.8 113.47 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.112 -0.993 . . . . 0.0 109.642 -179.64 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.425 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 27.2 tttm -78.65 -41.73 30.61 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.777 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.682 ' CZ3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -160.39 156.51 26.25 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.454 -0.779 . . . . 0.0 108.986 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.595 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 12.5 p90 -155.33 142.95 19.71 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.129 -0.982 . . . . 0.0 109.299 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.534 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 58.7 t-20 -117.44 118.55 32.5 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.063 -1.023 . . . . 0.0 109.518 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 93.0 p -65.27 -14.32 60.45 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.296 -0.877 . . . . 0.0 109.315 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -88.86 -38.43 14.59 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.2 -0.938 . . . . 0.0 108.882 179.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.654 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 16.4 mttm -67.61 -43.88 79.38 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.429 -0.794 . . . . 0.0 109.212 179.585 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.521 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 104.06 1.01 45.03 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.654 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 0.5 OUTLIER -145.23 176.95 9.16 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.116 -1.226 . . . . 0.0 109.654 179.912 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.55 ' O ' HG11 ' A' ' 28' ' ' VAL . . . -144.07 170.28 25.97 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.682 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 30.3 m-85 -111.23 128.67 56.0 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.393 -1.063 . . . . 0.0 108.968 179.798 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.545 HD11 ' CG1' ' A' ' 28' ' ' VAL . 67.8 mt -111.37 145.45 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.184 -0.947 . . . . 0.0 109.699 -179.801 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 5.3 tt0 -108.16 110.83 22.57 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.399 -0.813 . . . . 0.0 109.087 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.526 ' CG2' HG22 ' A' ' 26' ' ' VAL . 2.7 t -89.62 118.09 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.317 -0.864 . . . . 0.0 109.488 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -68.01 109.61 3.55 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.278 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.78 -21.78 6.58 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.5 ' OE1' ' CD1' ' A' ' 51' ' ' ILE . 50.2 mt-30 -135.47 168.8 18.54 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.197 -1.178 . . . . 0.0 109.596 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -55.19 -173.7 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.285 -0.884 . . . . 0.0 109.443 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -77.83 141.6 39.07 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.166 -0.959 . . . . 0.0 109.997 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.526 HG22 ' CG2' ' A' ' 20' ' ' VAL . 63.5 t -111.0 114.04 45.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.231 -0.918 . . . . 0.0 109.355 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.508 ' HE1' ' HB2' ' A' ' 15' ' ' PHE . 0.2 OUTLIER -84.48 106.85 16.38 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.254 -0.904 . . . . 0.0 109.276 179.812 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.55 HG11 ' O ' ' A' ' 16' ' ' GLY . 0.2 OUTLIER -86.41 143.74 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 O-C-N 121.128 -0.982 . . . . 0.0 109.712 -179.308 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.7 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 15.6 t-80 -113.86 157.99 21.62 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.653 -0.655 . . . . 0.0 109.272 -179.606 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.7 ' CD2' ' CE1' ' A' ' 29' ' ' HIS . 0.8 OUTLIER -46.37 -54.89 8.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.881 -1.137 . . . . 0.0 108.761 -179.787 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.699 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 94.1 p -50.82 -37.56 43.56 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.212 -0.93 . . . . 0.0 109.918 -179.791 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.479 ' HB1' ' O ' ' A' ' 29' ' ' HIS . . . -56.43 -29.02 61.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.036 -1.04 . . . . 0.0 109.341 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.582 HG12 HD11 ' A' ' 41' ' ' LEU . 1.9 mp -103.37 151.26 6.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.397 -0.814 . . . . 0.0 109.317 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 -121.97 145.17 48.38 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.186 -0.947 . . . . 0.0 109.584 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.636 ' HA3' ' CE2' ' A' ' 38' ' ' PHE . . . 145.82 157.26 7.21 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -117.94 100.6 7.67 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.24 -1.153 . . . . 0.0 109.403 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.56 -10.73 9.1 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.813 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.636 ' CE2' ' HA3' ' A' ' 35' ' ' GLY . 11.4 p90 -144.15 30.13 1.29 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.146 -1.208 . . . . 0.0 109.621 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.457 ' HE3' ' O ' ' A' ' 35' ' ' GLY . 19.5 mttp -63.35 -28.36 69.95 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.136 -0.978 . . . . 0.0 109.406 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.5 p -78.12 126.41 30.76 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.197 -0.939 . . . . 0.0 109.408 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.595 ' O ' ' CD2' ' A' ' 9' ' ' PHE . 3.6 mp -78.06 159.02 28.95 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.24 -0.913 . . . . 0.0 109.861 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.439 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 85.1 tt0 -106.72 149.51 27.23 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.475 -0.766 . . . . 0.0 109.192 179.614 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.425 ' HG3' ' O ' ' A' ' 7' ' ' LYS . 70.2 tt0 -72.35 124.23 24.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.19 -0.943 . . . . 0.0 109.499 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 96.16 -7.5 66.89 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.459 ' O ' HG23 ' A' ' 6' ' ' VAL . 60.5 tt0 -81.31 127.64 32.95 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.209 -1.171 . . . . 0.0 109.651 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.438 ' O ' HG13 ' A' ' 47' ' ' VAL . . . -74.56 145.22 43.59 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.338 -0.851 . . . . 0.0 109.444 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.512 HG22 ' CD1' ' A' ' 18' ' ' ILE . 34.6 m -145.88 160.86 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.095 -1.003 . . . . 0.0 110.017 -179.747 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.55 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 9.6 p -113.7 158.46 20.88 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.25 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.601 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 8.8 p90 169.25 169.3 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.999 -1.063 . . . . 0.0 109.996 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.466 ' OE2' ' N ' ' A' ' 1' ' ' MET . 65.3 mm-40 -104.97 157.84 16.95 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 178.826 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.5 ' CD1' ' OE1' ' A' ' 23' ' ' GLN . 1.9 mt -95.66 130.64 44.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 120.922 -1.111 . . . . 0.0 110.105 -179.41 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.515 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 3.6 m -112.7 122.57 67.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.306 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -90.77 88.85 7.24 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.039 -1.038 . . . . 0.0 109.755 -179.414 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -93.41 -175.36 40.37 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.7 t30 -54.51 -63.1 1.26 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.2 -1.176 . . . . 0.0 109.639 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 72.5 mtp180 -46.75 -38.9 10.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.125 -0.985 . . . . 0.0 109.033 179.827 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.77 -158.85 27.85 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.481 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 49.2 Cg_endo -70.71 142.48 43.85 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.565 2.177 . . . . 0.0 111.747 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.515 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 67.7 mt-30 -139.17 169.15 18.31 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.342 -0.849 . . . . 0.0 109.133 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.532 ' CB ' ' HB ' ' A' ' 28' ' ' VAL . . . -89.92 134.07 34.42 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.972 -1.08 . . . . 0.0 110.14 -179.463 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.565 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -121.56 153.09 38.47 Favored 'General case' 0 N--CA 1.491 1.601 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.541 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.497 ' C ' ' O ' ' A' ' 61' ' ' ALA . 83.6 m-20 41.13 72.74 0.15 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.033 -1.042 . . . . 0.0 108.577 -179.475 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.601 ' HA ' ' HB3' ' A' ' 49' ' ' PHE . 2.2 t -92.98 130.39 42.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.218 -0.926 . . . . 0.0 110.517 -178.724 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.3 m -120.08 125.23 47.77 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.493 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.532 ' HE3' HD13 ' A' ' 41' ' ' LEU . 29.6 mttp -74.36 112.1 10.19 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.067 -1.021 . . . . 0.0 109.702 -179.606 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -88.89 163.78 15.46 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.318 -0.864 . . . . 0.0 109.605 -179.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 118.004 -0.998 . . . . 0.0 109.439 179.88 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.4 mtm . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.567 ' CD1' ' N ' ' A' ' 2' ' ' LEU . 5.6 mp -107.18 165.64 11.22 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.285 -0.884 . . . . 0.0 109.329 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 58.6 mt-10 -132.28 127.97 36.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.147 -0.97 . . . . 0.0 109.446 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.431 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -127.51 155.25 19.95 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.408 ' O ' HG21 ' A' ' 18' ' ' ILE . 43.2 mttt -103.99 138.48 40.47 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.299 -1.118 . . . . 0.0 108.874 179.578 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.495 ' HA ' HG12 ' A' ' 18' ' ' ILE . 18.9 t -71.28 113.24 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.213 -0.929 . . . . 0.0 110.045 -179.469 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 13.0 ttpt -80.08 -40.71 27.06 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.588 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.41 155.4 28.57 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.397 -0.814 . . . . 0.0 109.018 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 9.6 p90 -156.22 137.96 14.25 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.128 -0.983 . . . . 0.0 109.242 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.456 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 52.3 t-20 -128.03 129.07 46.11 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.233 -0.917 . . . . 0.0 109.437 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -75.56 -19.74 59.1 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.103 -0.998 . . . . 0.0 108.952 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 76.3 tt0 -66.27 -42.43 88.48 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 106.45 -1.685 . . . . 0.0 106.45 177.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.658 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 8.3 mttp -75.69 -39.34 57.66 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 178.368 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.486 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 93.54 3.49 64.63 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.728 -1.349 . . . . 0.0 109.728 179.561 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.658 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 1.0 OUTLIER -140.11 172.95 12.03 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.229 -1.16 . . . . 0.0 108.779 179.127 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.588 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -140.37 172.41 23.53 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.424 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 27.6 m-85 -113.9 132.86 55.77 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.341 -1.094 . . . . 0.0 108.986 179.786 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.572 ' CD1' ' CG2' ' A' ' 47' ' ' VAL . 13.9 mt -116.22 151.52 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.252 -0.905 . . . . 0.0 109.717 -179.646 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -115.57 116.91 28.95 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.365 -0.834 . . . . 0.0 109.21 179.863 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.442 HG23 ' CG2' ' A' ' 26' ' ' VAL . 2.3 t -94.3 119.82 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.364 -0.835 . . . . 0.0 109.395 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -69.21 110.55 4.64 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.24 -0.913 . . . . 0.0 109.351 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 125.78 -37.77 2.42 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.525 ' OE1' ' CD1' ' A' ' 51' ' ' ILE . 56.4 mt-30 -120.45 166.31 13.76 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.366 -1.079 . . . . 0.0 109.381 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.422 ' O ' ' O ' ' A' ' 23' ' ' GLN . 49.5 m-20 -52.53 -176.83 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.206 -0.934 . . . . 0.0 109.562 -179.862 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.489 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 81.0 m-20 -74.31 141.93 45.22 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.346 -0.846 . . . . 0.0 109.629 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.464 HG21 ' CG1' ' A' ' 51' ' ' ILE . 98.2 t -115.08 117.95 57.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.242 -0.911 . . . . 0.0 109.31 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.555 ' O ' ' N ' ' A' ' 60' ' ' ALA . 0.1 OUTLIER -76.73 161.12 28.76 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.103 -0.998 . . . . 0.0 109.388 -179.879 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.588 ' CG1' HG22 ' A' ' 63' ' ' VAL . 14.6 t -133.75 134.13 56.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.287 -0.883 . . . . 0.0 109.602 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.642 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 15.2 t-80 -104.66 151.33 23.82 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.217 -0.927 . . . . 0.0 109.19 179.652 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.685 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -44.92 -53.96 7.03 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.106 -0.996 . . . . 0.0 109.549 -179.529 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.685 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 90.3 p -60.35 -18.49 50.42 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.06 -1.025 . . . . 0.0 109.956 -179.544 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.466 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -67.36 -24.54 65.72 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.075 -1.016 . . . . 0.0 109.356 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.565 ' CG1' HD12 ' A' ' 41' ' ' LEU . 3.1 mp -109.11 132.58 56.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.303 -0.873 . . . . 0.0 109.468 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.404 ' C ' ' O ' ' A' ' 33' ' ' ILE . 34.4 tt0 -47.45 -53.67 13.5 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.094 -1.004 . . . . 0.0 108.828 179.343 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.638 ' HA3' ' CG ' ' A' ' 39' ' ' LYS . . . 55.34 33.89 58.81 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 110.149 -1.18 . . . . 0.0 110.149 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -46.32 -24.26 0.46 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.045 -1.268 . . . . 0.0 108.761 179.495 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.415 ' N ' ' C ' ' A' ' 35' ' ' GLY . . . -162.19 26.99 0.25 Allowed Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 179.753 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.611 ' CD1' ' HA2' ' A' ' 35' ' ' GLY . 0.4 OUTLIER -169.57 44.85 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.303 -1.116 . . . . 0.0 109.571 -179.885 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.638 ' CG ' ' HA3' ' A' ' 35' ' ' GLY . 90.3 mttt -55.39 -20.84 13.24 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.194 -0.941 . . . . 0.0 109.431 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 21.3 m -67.5 99.7 0.78 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.35 -0.844 . . . . 0.0 109.885 -179.606 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.584 ' O ' ' CD2' ' A' ' 9' ' ' PHE . 5.8 mp -62.6 157.8 19.77 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.2 -0.938 . . . . 0.0 109.263 179.588 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.467 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.1 tt0 -120.25 138.53 53.61 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.238 -0.914 . . . . 0.0 109.619 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.453 ' HA ' HG12 ' A' ' 6' ' ' VAL . 57.4 tt0 -67.65 129.7 40.72 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.261 -0.899 . . . . 0.0 109.454 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 90.64 -5.88 82.25 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.467 ' HB2' ' HB3' ' A' ' 42' ' ' GLU . 60.4 tt0 -81.12 126.11 31.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.215 -1.168 . . . . 0.0 109.371 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.497 ' O ' HG11 ' A' ' 47' ' ' VAL . . . -79.18 142.49 36.28 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.228 -0.92 . . . . 0.0 109.31 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.572 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 28.2 m -143.96 168.65 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.246 -0.909 . . . . 0.0 109.438 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.5 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 9.4 t -114.51 155.26 26.76 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.324 -0.86 . . . . 0.0 108.859 179.65 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.591 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 5.6 p90 173.38 165.88 0.16 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.041 -1.037 . . . . 0.0 110.099 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 90.8 mt-10 -100.6 150.36 22.79 Favored 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.815 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.525 ' CD1' ' OE1' ' A' ' 23' ' ' GLN . 0.5 OUTLIER -87.13 123.05 39.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.029 -1.044 . . . . 0.0 109.837 -179.574 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.622 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.6 m -107.03 120.87 59.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.385 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -88.41 85.18 6.82 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.259 -0.901 . . . . 0.0 109.633 -179.544 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.39 -177.05 43.18 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 18.4 p-10 -55.27 -55.89 26.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.097 -1.237 . . . . 0.0 109.701 -179.743 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 43.3 mtp180 -52.43 -41.27 63.11 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.992 -1.068 . . . . 0.0 109.285 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 146.34 -150.85 23.14 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.489 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 47.6 Cg_endo -70.24 129.25 16.78 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.817 2.345 . . . . 0.0 112.292 -179.851 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.622 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 53.7 mt-30 -131.04 164.23 25.85 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 179.138 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.555 ' N ' ' O ' ' A' ' 27' ' ' PHE . . . -90.52 127.08 36.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.098 -1.001 . . . . 0.0 110.401 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.535 ' O ' ' C ' ' A' ' 62' ' ' ASN . . . -109.86 147.71 32.85 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.034 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.535 ' C ' ' O ' ' A' ' 61' ' ' ALA . 59.2 t30 38.17 73.73 0.1 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.049 -1.032 . . . . 0.0 108.816 -179.686 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.591 ' HA ' ' HB3' ' A' ' 49' ' ' PHE . 1.4 t -84.8 129.62 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.321 -0.862 . . . . 0.0 110.331 -178.767 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.457 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 13.0 m -115.28 121.37 42.68 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.459 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.51 ' HA ' ' CG1' ' A' ' 47' ' ' VAL . 20.2 mttt -74.12 114.83 12.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.154 -0.966 . . . . 0.0 109.742 -179.67 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.439 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 50.8 mt-10 -98.99 168.05 10.35 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.354 -0.841 . . . . 0.0 109.616 -179.818 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.495 0 CA-C-O 117.944 -1.027 . . . . 0.0 109.444 179.989 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 91.6 mtp . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 21.1 mt -103.96 161.84 13.63 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.214 -0.929 . . . . 0.0 109.275 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -134.19 127.9 32.91 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.209 -0.932 . . . . 0.0 109.297 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.41 ' C ' ' CG2' ' A' ' 18' ' ' ILE . . . -126.49 158.63 20.64 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 -179.735 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.476 ' NZ ' ' OE2' ' A' ' 21' ' ' GLU . 38.8 mttp -103.7 133.64 48.37 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.394 -1.063 . . . . 0.0 108.823 179.561 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.45 HG21 ' O ' ' A' ' 45' ' ' GLN . 18.3 t -66.49 113.73 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.151 -0.968 . . . . 0.0 110.055 -179.344 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -79.12 -39.93 32.36 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.34 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.642 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -159.11 155.01 26.51 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.807 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.646 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 9.1 p90 -155.57 140.55 17.32 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.056 -1.028 . . . . 0.0 109.347 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.463 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.2 t-20 -132.59 130.61 40.49 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.117 -0.989 . . . . 0.0 109.727 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 14.6 p -76.95 -19.16 57.69 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.056 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.455 ' HA ' ' OE1' ' A' ' 12' ' ' GLU . 69.7 mm-40 -65.31 -45.52 84.02 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 178.129 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.636 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 8.1 mttp -74.21 -38.59 63.53 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 178.303 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.515 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 94.31 5.98 61.67 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.725 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.636 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 1.2 p90 -143.78 170.08 16.56 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.164 -1.198 . . . . 0.0 109.195 179.358 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.642 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -140.88 171.69 23.99 Favored Glycine 0 N--CA 1.492 2.378 0 C-N-CA 119.654 -1.26 . . . . 0.0 110.067 -179.491 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.558 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 43.1 m-85 -114.02 139.4 49.29 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.319 -1.107 . . . . 0.0 109.195 179.751 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.602 HD11 ' CG2' ' A' ' 47' ' ' VAL . 16.7 mt -124.1 150.91 28.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.272 -0.892 . . . . 0.0 109.691 -179.485 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.509 ' N ' HG21 ' A' ' 18' ' ' ILE . 38.3 tt0 -113.48 119.47 37.7 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.384 -0.823 . . . . 0.0 109.448 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.439 HG21 HG23 ' A' ' 26' ' ' VAL . 2.6 t -90.46 124.13 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.329 -0.857 . . . . 0.0 109.655 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.476 ' OE2' ' NZ ' ' A' ' 5' ' ' LYS . 80.1 mt-10 -71.45 109.34 5.37 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.309 -0.869 . . . . 0.0 109.512 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 117.81 -26.1 8.15 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.471 ' OE1' HD12 ' A' ' 51' ' ' ILE . 43.2 mt-30 -122.95 161.31 24.45 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.259 -1.142 . . . . 0.0 109.482 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 58.9 m-20 -52.84 -178.96 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.274 -0.891 . . . . 0.0 109.659 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -71.65 141.37 49.92 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.268 -0.895 . . . . 0.0 109.506 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.439 HG23 HG21 ' A' ' 20' ' ' VAL . 97.3 t -117.99 117.7 55.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.171 -0.956 . . . . 0.0 109.656 -179.582 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.539 ' CE1' ' HB3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -76.56 157.16 32.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.2 -0.937 . . . . 0.0 108.997 179.684 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.59 ' CG2' HD13 ' A' ' 18' ' ' ILE . 34.1 t -133.01 137.38 53.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.205 -0.935 . . . . 0.0 109.763 -179.525 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.629 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 12.8 t-80 -114.97 152.45 32.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.429 -0.794 . . . . 0.0 108.993 179.696 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.68 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -44.31 -53.53 6.63 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.093 -1.004 . . . . 0.0 109.502 -179.631 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.68 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 27.3 t -54.29 -27.35 34.75 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.101 -1.0 . . . . 0.0 110.068 -179.452 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.621 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -66.9 -12.63 60.03 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.04 -1.037 . . . . 0.0 109.002 179.71 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.57 ' CG2' HG11 ' A' ' 63' ' ' VAL . 0.9 OUTLIER -122.7 126.75 74.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.503 -0.748 . . . . 0.0 109.589 -179.581 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 50.8 tt0 -87.5 133.42 33.77 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.242 -0.911 . . . . 0.0 109.671 -179.79 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.613 ' CA ' ' CZ ' ' A' ' 38' ' ' PHE . . . 173.94 147.6 6.09 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.868 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -65.36 -58.85 4.86 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.255 -1.144 . . . . 0.0 109.471 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -136.03 13.23 4.13 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.613 ' CZ ' ' CA ' ' A' ' 35' ' ' GLY . 44.5 p90 -113.96 17.32 17.96 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.249 -1.148 . . . . 0.0 109.498 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.499 ' CE ' ' O ' ' A' ' 35' ' ' GLY . 86.3 mttt -55.48 -42.16 74.0 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.297 -0.877 . . . . 0.0 109.581 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 32.9 m -56.27 128.51 36.08 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.191 -0.943 . . . . 0.0 109.654 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.646 ' O ' ' CD2' ' A' ' 9' ' ' PHE . 4.9 mp -88.21 171.85 9.91 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.222 -0.924 . . . . 0.0 109.559 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.433 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 96.8 mt-10 -109.28 155.04 21.62 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.316 -0.865 . . . . 0.0 109.305 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -70.41 127.67 33.54 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.29 -0.881 . . . . 0.0 109.593 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 88.51 -3.12 85.2 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.45 ' O ' HG21 ' A' ' 6' ' ' VAL . 51.1 tt0 -81.71 130.24 34.99 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.198 -1.178 . . . . 0.0 109.603 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.471 ' O ' HG12 ' A' ' 47' ' ' VAL . . . -78.21 141.87 38.32 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.235 -0.916 . . . . 0.0 109.383 179.731 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.602 ' CG2' HD11 ' A' ' 18' ' ' ILE . 34.7 m -141.52 153.21 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.136 -0.977 . . . . 0.0 109.781 -179.746 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.522 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 17.8 t -97.57 148.65 23.05 Favored 'General case' 0 N--CA 1.488 1.459 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 179.075 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.59 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 7.8 p90 176.09 162.47 0.35 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.874 -1.141 . . . . 0.0 110.272 -179.546 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.438 ' HA ' ' OE1' ' A' ' 50' ' ' GLU . 67.0 mm-40 -99.92 160.37 14.37 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 178.908 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.471 HD12 ' OE1' ' A' ' 23' ' ' GLN . 0.9 OUTLIER -99.6 127.38 52.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 120.917 -1.114 . . . . 0.0 109.91 -179.524 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.613 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.9 m -114.32 124.81 71.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 179.197 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -93.6 93.31 7.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 110.241 -179.087 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -95.15 -175.8 37.72 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -53.17 -59.22 4.83 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.104 -1.233 . . . . 0.0 109.462 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 53.0 mtp180 -49.3 -40.47 34.93 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.087 -1.008 . . . . 0.0 109.215 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 149.18 -158.12 27.53 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -70.46 139.96 38.98 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.723 2.282 . . . . 0.0 111.849 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.613 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 76.9 mt-30 -136.26 167.81 20.6 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.324 -0.86 . . . . 0.0 109.13 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -95.22 139.31 31.72 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.136 -0.978 . . . . 0.0 110.184 -179.286 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.59 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -124.3 156.02 37.68 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.378 -0.826 . . . . 0.0 108.826 179.605 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.481 ' C ' ' O ' ' A' ' 61' ' ' ALA . 78.8 m-20 42.2 72.59 0.16 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.968 -1.083 . . . . 0.0 108.952 -179.821 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.621 ' HB ' ' O ' ' A' ' 32' ' ' ALA . 3.9 t -86.76 125.93 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.234 -0.916 . . . . 0.0 110.088 -179.17 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.429 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 60.6 m -119.0 125.51 49.56 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.379 -0.825 . . . . 0.0 109.256 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.434 ' NZ ' ' O ' ' A' ' 38' ' ' PHE . 87.9 mttt -67.52 106.97 2.32 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.2 -0.937 . . . . 0.0 109.479 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.415 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 89.6 mt-10 -87.04 162.0 17.85 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.227 -0.921 . . . . 0.0 109.497 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 117.973 -1.013 . . . . 0.0 109.487 -179.939 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 50.3 mtm . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 49.4 mt -99.52 160.21 14.46 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.321 -0.862 . . . . 0.0 109.494 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.431 ' O ' HG12 ' A' ' 20' ' ' VAL . 86.9 mt-10 -131.48 135.83 47.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.28 -0.888 . . . . 0.0 109.171 179.772 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.481 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -136.15 157.94 23.7 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 -179.684 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.494 ' N ' HG23 ' A' ' 18' ' ' ILE . 12.5 mttp -103.65 142.26 34.63 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.341 -1.094 . . . . 0.0 108.817 179.51 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.492 HG13 ' HA ' ' A' ' 43' ' ' GLU . 22.1 t -75.22 116.96 18.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.073 -1.017 . . . . 0.0 109.935 -179.51 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.8 -32.73 17.71 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.465 -0.772 . . . . 0.0 108.933 179.693 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.683 ' CE3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -159.44 153.98 24.2 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.381 -0.824 . . . . 0.0 109.023 179.792 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.457 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 9.1 p90 -157.54 139.03 13.81 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.173 -0.954 . . . . 0.0 109.282 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.419 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 63.5 t-20 -121.6 116.91 25.48 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 109.618 -179.809 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 11.0 t -69.47 -13.75 62.51 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.232 -0.917 . . . . 0.0 109.222 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -81.37 -46.87 14.03 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.369 -0.832 . . . . 0.0 108.964 179.604 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.66 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 21.1 mttp -68.56 -45.3 72.47 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.417 -0.802 . . . . 0.0 108.882 179.507 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.541 ' C ' ' CD1' ' A' ' 15' ' ' PHE . . . 108.96 7.93 28.42 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 179.055 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.66 ' CE2' ' HB3' ' A' ' 13' ' ' LYS . 0.0 OUTLIER -142.58 166.42 24.73 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.81 -1.406 . . . . 0.0 109.695 179.72 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.508 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -135.99 167.49 24.33 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.683 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 22.1 m-85 -115.05 130.12 56.86 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.184 -1.186 . . . . 0.0 109.289 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.546 ' CD1' ' CG2' ' A' ' 47' ' ' VAL . 56.4 mt -114.23 151.42 16.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.44 -0.787 . . . . 0.0 109.654 -179.79 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.426 ' N ' HG21 ' A' ' 18' ' ' ILE . 40.6 tt0 -114.2 104.29 11.95 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.361 -0.837 . . . . 0.0 108.915 179.518 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.544 HG21 ' CG2' ' A' ' 26' ' ' VAL . 2.8 t -78.63 120.64 30.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.264 -0.897 . . . . 0.0 109.428 -179.702 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 74.0 mm-40 -67.93 108.89 3.2 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.206 -0.933 . . . . 0.0 109.135 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.59 -24.46 6.82 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.422 ' OE1' HD11 ' A' ' 51' ' ' ILE . 36.0 mt-30 -128.18 165.92 19.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.298 -1.119 . . . . 0.0 109.6 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 48.9 m-20 -56.93 -169.08 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.292 -0.88 . . . . 0.0 109.729 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.497 ' OD1' ' N ' ' A' ' 25' ' ' ASP . 7.7 p30 -78.45 141.47 38.25 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.254 -0.904 . . . . 0.0 110.003 -179.543 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.544 ' CG2' HG21 ' A' ' 20' ' ' VAL . 57.4 t -116.23 115.09 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.212 -0.93 . . . . 0.0 109.305 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.706 ' O ' ' CG ' ' A' ' 27' ' ' PHE . 0.1 OUTLIER -83.5 107.72 16.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.047 -1.033 . . . . 0.0 109.39 179.979 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.59 ' CG2' HG21 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -85.48 146.92 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.061 -1.024 . . . . 0.0 109.632 -179.167 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.691 ' CE1' ' CE2' ' A' ' 30' ' ' PHE . 11.8 t-160 -116.2 155.05 28.99 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.283 -0.886 . . . . 0.0 109.336 -179.772 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.769 ' CD1' ' N ' ' A' ' 31' ' ' SER . 1.9 p90 -47.75 -54.11 13.21 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.092 -1.005 . . . . 0.0 109.607 -179.481 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.769 ' N ' ' CD1' ' A' ' 30' ' ' PHE . 19.9 t -53.41 -21.22 5.6 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.872 -1.142 . . . . 0.0 109.517 -179.771 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.464 ' HB2' HG23 ' A' ' 28' ' ' VAL . . . -66.84 -38.81 87.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.273 -0.892 . . . . 0.0 109.635 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.547 ' CG1' ' CG1' ' A' ' 63' ' ' VAL . 1.8 mp -80.43 151.67 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.168 -0.958 . . . . 0.0 109.966 -179.74 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 65.9 mt-30 -56.1 134.75 52.94 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.337 -0.852 . . . . 0.0 109.597 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.586 ' HA3' ' CE1' ' A' ' 38' ' ' PHE . . . 120.92 169.9 13.93 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 179.591 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -86.62 10.15 16.41 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.428 -1.042 . . . . 0.0 109.269 179.829 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.31 4.29 10.07 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.586 ' CE1' ' HA3' ' A' ' 35' ' ' GLY . 29.2 p90 -80.79 2.55 25.8 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.289 -1.124 . . . . 0.0 109.489 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.509 ' HG2' ' CE2' ' A' ' 38' ' ' PHE . 21.3 mmtt -113.96 117.91 32.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.189 -0.945 . . . . 0.0 109.355 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 27.3 p -109.0 138.26 45.63 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.286 -0.884 . . . . 0.0 109.508 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.47 HD11 HD11 ' A' ' 33' ' ' ILE . 3.1 mp -78.59 158.31 28.52 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.182 -0.949 . . . . 0.0 109.332 179.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.462 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 97.0 mt-10 -115.8 151.27 35.51 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.302 -0.874 . . . . 0.0 109.373 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.492 ' HA ' HG13 ' A' ' 6' ' ' VAL . 46.5 tt0 -67.84 125.37 26.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.227 -0.92 . . . . 0.0 109.426 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 92.7 -6.63 77.29 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.883 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.455 ' O ' HG23 ' A' ' 6' ' ' VAL . 61.5 tp60 -82.28 135.05 35.29 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.185 -1.185 . . . . 0.0 109.762 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.508 ' O ' HG13 ' A' ' 47' ' ' VAL . . . -85.87 144.62 27.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.318 -0.864 . . . . 0.0 109.293 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.546 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 30.6 m -144.55 166.46 12.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.198 -0.939 . . . . 0.0 109.717 -179.838 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.533 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 3.3 t -112.87 157.21 21.7 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 179.338 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.558 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 10.0 p90 170.32 167.97 0.06 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.092 -1.005 . . . . 0.0 110.076 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 92.1 mt-10 -102.34 162.2 13.1 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 178.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.422 HD11 ' OE1' ' A' ' 23' ' ' GLN . 1.5 mt -99.91 127.75 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.008 -1.058 . . . . 0.0 109.75 -179.615 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.561 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 0.8 OUTLIER -109.17 120.82 61.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.62 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -88.53 85.89 6.92 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.194 -0.941 . . . . 0.0 109.713 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.14 -179.51 45.55 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 19.3 p-10 -54.49 -53.27 56.57 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.298 -1.119 . . . . 0.0 109.895 -179.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 20.3 mtm180 -57.13 -38.56 73.66 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.017 -1.052 . . . . 0.0 109.389 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.96 -158.81 27.99 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.493 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 52.3 Cg_endo -73.01 141.48 33.08 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.725 2.283 . . . . 0.0 112.006 179.898 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.561 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 31.8 mt-30 -137.03 168.45 19.56 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.37 -0.831 . . . . 0.0 108.894 179.543 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.497 ' CB ' ' HB ' ' A' ' 28' ' ' VAL . . . -94.13 139.93 30.38 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.015 -1.053 . . . . 0.0 110.332 -179.253 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.536 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -126.53 155.65 42.02 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.44 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.49 ' C ' ' O ' ' A' ' 61' ' ' ALA . 57.6 t30 40.88 63.06 1.25 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.958 -1.089 . . . . 0.0 108.849 -179.708 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.59 HG21 ' CG2' ' A' ' 28' ' ' VAL . 1.8 t -79.46 128.75 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.291 -0.881 . . . . 0.0 110.421 -179.011 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 56.4 m -119.6 125.59 49.14 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 69.6 mttt -65.51 110.6 2.76 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.21 -0.932 . . . . 0.0 109.531 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.447 ' HG3' ' HA ' ' A' ' 47' ' ' VAL . 90.4 mt-10 -89.6 159.38 17.2 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.321 -0.862 . . . . 0.0 109.628 -179.845 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.551 0 CA-C-O 117.99 -1.005 . . . . 0.0 109.469 179.942 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.3 mtm . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 121.309 0.576 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.5 ' CD1' ' N ' ' A' ' 2' ' ' LEU . 6.4 mp -102.21 166.33 10.65 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.195 -0.94 . . . . 0.0 109.569 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.403 ' O ' HG11 ' A' ' 20' ' ' VAL . 61.0 mt-10 -132.87 139.55 47.48 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.36 -0.838 . . . . 0.0 109.213 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -139.64 157.41 25.18 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.45 ' C ' HG22 ' A' ' 18' ' ' ILE . 63.6 mttm -102.57 142.95 32.89 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.418 -1.048 . . . . 0.0 108.831 179.561 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.466 HG21 ' O ' ' A' ' 45' ' ' GLN . 18.7 t -76.61 112.09 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.173 -0.954 . . . . 0.0 110.047 -179.447 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.465 ' CG ' ' N ' ' A' ' 8' ' ' TRP . 3.3 pttt -79.94 -37.7 33.94 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.622 ' CE3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -159.75 155.01 25.18 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 -179.941 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.463 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 10.5 p90 -155.88 138.87 15.41 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.156 -0.965 . . . . 0.0 109.196 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.472 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.3 t-20 -132.63 133.55 43.77 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.097 -1.002 . . . . 0.0 109.633 -179.745 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 32.7 p -80.11 -18.51 49.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.268 -0.895 . . . . 0.0 108.939 179.456 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -64.77 -47.96 76.24 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 178.111 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.66 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 14.1 mttm -70.9 -40.21 72.32 Favored 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.151 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.477 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 97.08 2.67 59.23 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.681 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.66 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 0.4 OUTLIER -138.98 175.63 9.38 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.207 -1.172 . . . . 0.0 109.145 179.155 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.593 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -140.43 170.26 24.48 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 -179.65 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.622 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 27.5 m-85 -114.66 131.5 56.71 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.387 -1.066 . . . . 0.0 108.997 179.812 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.619 HD12 ' CG2' ' A' ' 47' ' ' VAL . 26.9 mt -120.27 149.29 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.164 -0.96 . . . . 0.0 109.433 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.564 ' N ' HG23 ' A' ' 18' ' ' ILE . 18.1 tp10 -108.75 123.76 49.52 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.244 -0.91 . . . . 0.0 109.504 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.536 HG21 ' CG2' ' A' ' 26' ' ' VAL . 2.3 t -102.11 120.25 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.215 -0.928 . . . . 0.0 109.25 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -66.98 109.39 2.95 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.247 -0.908 . . . . 0.0 109.772 -179.701 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.14 -29.34 3.71 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.505 ' O ' ' O ' ' A' ' 24' ' ' ASP . 38.2 mt-30 -131.41 166.26 21.68 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.227 -1.161 . . . . 0.0 109.23 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.505 ' O ' ' O ' ' A' ' 23' ' ' GLN . 0.0 OUTLIER -52.8 -169.17 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.173 -0.954 . . . . 0.0 109.683 -179.777 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.447 ' OD1' ' OE1' ' A' ' 19' ' ' GLU . 42.2 m-20 -75.36 141.65 43.27 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.236 -0.915 . . . . 0.0 109.742 -179.77 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.536 ' CG2' HG21 ' A' ' 20' ' ' VAL . 87.0 t -112.11 119.73 60.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.259 -0.9 . . . . 0.0 109.385 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.498 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.1 OUTLIER -79.53 154.71 28.62 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.244 -0.91 . . . . 0.0 109.127 -179.94 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.596 ' CG2' ' CD1' ' A' ' 18' ' ' ILE . 5.0 t -129.64 133.04 65.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.292 -0.88 . . . . 0.0 109.27 -179.729 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.626 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 13.4 t-80 -105.61 150.2 25.62 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.157 -0.964 . . . . 0.0 109.219 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.689 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.9 OUTLIER -43.1 -52.56 5.35 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.197 -0.939 . . . . 0.0 109.198 -179.818 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.689 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 23.0 t -56.25 -23.06 33.68 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.912 . . . . 0.0 109.856 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.509 ' N ' ' O ' ' A' ' 29' ' ' HIS . . . -65.38 -23.76 67.05 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.075 -1.015 . . . . 0.0 109.446 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.535 ' CD1' HD11 ' A' ' 41' ' ' LEU . 3.2 mp -108.25 135.72 46.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.286 -0.883 . . . . 0.0 109.337 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 64.4 tt0 -95.76 119.83 34.96 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.136 -0.977 . . . . 0.0 109.419 179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.629 ' CA ' ' CZ ' ' A' ' 38' ' ' PHE . . . -176.02 147.86 8.92 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -64.98 -56.24 14.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.24 -1.153 . . . . 0.0 109.588 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -134.03 12.3 4.75 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.629 ' CZ ' ' CA ' ' A' ' 35' ' ' GLY . 49.8 p90 -117.36 25.68 10.28 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.164 -1.198 . . . . 0.0 109.374 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.467 ' NZ ' ' O ' ' A' ' 35' ' ' GLY . 44.7 mttp -60.88 -42.54 98.15 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.237 -0.915 . . . . 0.0 109.509 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.453 ' O ' ' NZ ' ' A' ' 65' ' ' LYS . 29.5 m -58.66 138.19 57.12 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.297 -0.877 . . . . 0.0 109.479 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.535 HD11 ' CD1' ' A' ' 33' ' ' ILE . 4.7 mp -93.64 175.33 6.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.165 -0.959 . . . . 0.0 109.578 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . 0.445 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 95.7 mt-10 -111.67 151.43 28.87 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.376 -0.827 . . . . 0.0 109.329 179.788 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 76.6 tt0 -69.13 126.44 29.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.282 -0.886 . . . . 0.0 109.626 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 89.94 -3.2 82.7 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.466 ' O ' HG21 ' A' ' 6' ' ' VAL . 56.7 tt0 -82.16 131.03 35.24 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.197 -1.178 . . . . 0.0 109.701 179.822 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.464 ' O ' HG12 ' A' ' 47' ' ' VAL . . . -76.82 142.69 40.18 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.211 -0.93 . . . . 0.0 109.226 179.755 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.619 ' CG2' HD12 ' A' ' 18' ' ' ILE . 30.1 m -145.39 159.36 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.233 -0.917 . . . . 0.0 110.093 -179.637 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.551 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 39.7 t -110.94 154.32 24.26 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.601 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 14.0 p90 173.37 163.87 0.15 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.817 -1.177 . . . . 0.0 110.508 -179.659 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -99.58 158.71 15.57 Favored 'General case' 0 N--CA 1.488 1.455 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 3.1 mt -102.13 131.77 49.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 120.928 -1.107 . . . . 0.0 110.244 -179.409 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.546 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 5.6 m -114.19 123.62 70.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 178.703 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -91.55 90.36 7.58 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.187 -0.946 . . . . 0.0 109.937 -178.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.6 -177.47 42.76 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -53.16 -59.81 4.08 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.169 -1.195 . . . . 0.0 109.533 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 20.9 mtp180 -49.82 -39.07 37.47 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.189 -0.944 . . . . 0.0 109.201 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.09 -161.91 29.25 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.502 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 52.6 Cg_endo -72.31 144.9 42.25 Favored 'Trans proline' 0 C--O 1.216 -0.613 0 C-N-CA 122.7 2.267 . . . . 0.0 111.828 179.772 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.546 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 71.1 mt-30 -137.37 169.47 17.72 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.276 -0.89 . . . . 0.0 109.232 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.42 ' N ' ' O ' ' A' ' 27' ' ' PHE . . . -94.0 139.73 30.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.216 -0.927 . . . . 0.0 110.232 -179.407 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.583 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -127.98 157.74 39.79 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.514 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.49 ' C ' ' O ' ' A' ' 61' ' ' ALA . 85.7 m-20 41.4 68.57 0.43 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.857 -1.152 . . . . 0.0 108.816 -179.761 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.601 ' HA ' ' HB3' ' A' ' 49' ' ' PHE . 2.3 t -87.13 126.3 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.239 -0.913 . . . . 0.0 110.315 -178.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 82.3 m -117.99 124.26 47.74 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.47 ' NZ ' ' O ' ' A' ' 38' ' ' PHE . 50.3 mttt -68.39 110.97 4.37 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.291 -0.881 . . . . 0.0 109.614 -179.814 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.459 ' O ' ' O ' ' A' ' 67' ' ' ALA . 64.2 mt-10 -90.05 161.46 15.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.901 . . . . 0.0 109.604 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . 0.459 ' O ' ' O ' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.52 0 CA-C-O 117.989 -1.005 . . . . 0.0 109.466 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.408 ' HE2' ' HB2' ' A' ' 1' ' ' MET . 54.9 mtm . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.492 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 27.2 mt -100.68 154.39 18.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.271 -0.893 . . . . 0.0 109.503 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -129.24 141.33 51.16 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -0.916 . . . . 0.0 109.061 179.753 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.524 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -146.66 156.71 27.13 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -179.719 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.511 ' N ' HG22 ' A' ' 18' ' ' ILE . 16.0 mttt -102.2 136.01 42.78 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.382 -1.069 . . . . 0.0 108.836 179.48 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.532 ' HA ' HG12 ' A' ' 18' ' ' ILE . 40.3 t -68.59 115.71 7.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.161 -0.962 . . . . 0.0 110.095 -179.53 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 17' ' ' PHE . 5.9 tttm -79.06 -35.11 43.02 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.476 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.654 ' CD2' ' N ' ' A' ' 9' ' ' PHE . 0.4 OUTLIER -160.36 168.55 24.99 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.486 -0.759 . . . . 0.0 109.047 179.755 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.654 ' N ' ' CD2' ' A' ' 8' ' ' TRP . 21.4 p90 -163.44 141.23 7.65 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.885 -1.135 . . . . 0.0 110.312 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.595 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 20.5 t-20 -92.55 131.71 37.45 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.491 -0.755 . . . . 0.0 109.338 179.671 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.7 m -86.83 -21.93 26.13 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.241 -0.912 . . . . 0.0 109.773 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 71.0 mm-40 -74.09 -38.88 63.74 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.178 -0.952 . . . . 0.0 109.382 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.808 ' HB2' ' CE1' ' A' ' 15' ' ' PHE . 25.4 mttm -94.71 -57.43 2.46 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.363 -0.836 . . . . 0.0 109.824 -179.76 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.531 ' O ' ' CB ' ' A' ' 30' ' ' PHE . . . 116.85 48.8 0.44 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 -179.695 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.808 ' CE1' ' HB2' ' A' ' 13' ' ' LYS . 10.8 p90 -151.74 163.5 39.01 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.122 -1.222 . . . . 0.0 109.0 179.306 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.612 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -157.77 165.61 33.63 Favored Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.497 -1.335 . . . . 0.0 110.146 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.523 ' O ' ' N ' ' A' ' 7' ' ' LYS . 92.6 m-85 -96.43 138.63 33.73 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.457 -1.026 . . . . 0.0 108.909 179.726 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.635 HD13 ' CG2' ' A' ' 28' ' ' VAL . 63.2 mt -121.53 160.07 23.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.561 -0.712 . . . . 0.0 109.647 -179.715 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.454 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 39.6 tt0 -120.4 119.09 32.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.35 -0.844 . . . . 0.0 109.46 -179.737 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.411 HG23 HG21 ' A' ' 26' ' ' VAL . 2.2 t -95.28 111.73 26.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.265 -0.897 . . . . 0.0 109.214 179.832 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.41 ' HA ' ' OE1' ' A' ' 21' ' ' GLU . 72.5 mm-40 -61.43 110.3 1.41 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.234 -0.916 . . . . 0.0 109.474 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.9 -33.97 3.56 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.474 ' O ' ' O ' ' A' ' 24' ' ' ASP . 36.1 mt-30 -124.28 163.39 21.75 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.248 -1.148 . . . . 0.0 109.365 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.474 ' O ' ' O ' ' A' ' 23' ' ' GLN . 57.9 m-20 -50.76 -176.81 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.304 -0.873 . . . . 0.0 109.652 -179.866 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.409 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 90.0 m-20 -74.02 140.88 45.74 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.336 -0.853 . . . . 0.0 109.728 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.547 HG23 ' CG1' ' A' ' 51' ' ' ILE . 88.9 t -113.42 115.75 50.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.319 -0.863 . . . . 0.0 109.411 -179.895 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.585 ' CE2' ' HB3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -70.75 156.72 39.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.057 -1.027 . . . . 0.0 109.355 -179.937 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.635 ' CG2' HD13 ' A' ' 18' ' ' ILE . 21.9 t -134.49 133.87 54.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.117 -0.989 . . . . 0.0 109.871 -179.472 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.672 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 14.3 t-80 -114.47 151.12 33.75 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.355 -0.841 . . . . 0.0 109.192 179.588 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.677 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.7 OUTLIER -42.63 -51.5 5.18 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.091 -1.006 . . . . 0.0 109.353 -179.858 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.677 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 86.6 p -53.69 -29.61 39.74 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.178 -0.952 . . . . 0.0 109.925 -179.618 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.585 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -64.91 -10.31 27.8 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.107 -0.995 . . . . 0.0 109.217 179.744 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.556 ' CG2' HG13 ' A' ' 63' ' ' VAL . 0.8 OUTLIER -126.18 132.98 69.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.487 -0.758 . . . . 0.0 109.726 -179.415 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 62.9 tt0 -104.34 133.21 49.61 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.286 -0.884 . . . . 0.0 109.448 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.632 ' CA ' ' CZ ' ' A' ' 38' ' ' PHE . . . -173.54 150.25 11.85 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -179.871 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 46.3 tp10 -57.67 -54.27 48.77 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.289 -1.124 . . . . 0.0 109.427 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -147.31 26.04 1.55 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.559 -1.417 . . . . 0.0 109.559 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.632 ' CZ ' ' CA ' ' A' ' 35' ' ' GLY . 55.0 p90 -124.87 28.43 6.47 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.301 -1.117 . . . . 0.0 109.432 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.521 ' O ' ' CD1' ' A' ' 41' ' ' LEU . 24.3 mttp -64.55 -31.55 72.81 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.286 -0.884 . . . . 0.0 109.736 -179.82 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 33.0 m -64.63 114.23 4.27 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.177 -0.952 . . . . 0.0 109.516 -179.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.569 ' CD1' ' N ' ' A' ' 41' ' ' LEU . 3.5 mp -74.75 155.58 37.49 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.254 -0.904 . . . . 0.0 109.756 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -103.92 144.14 31.92 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.285 -0.884 . . . . 0.0 109.319 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.448 ' HA ' HG13 ' A' ' 6' ' ' VAL . 53.3 tt0 -63.11 130.34 44.23 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.293 -0.88 . . . . 0.0 109.477 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.97 -3.12 85.91 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 46.8 tt0 -81.29 128.19 33.54 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.201 -1.176 . . . . 0.0 109.602 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.489 ' O ' HG11 ' A' ' 47' ' ' VAL . . . -77.54 140.71 39.78 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.215 -0.928 . . . . 0.0 109.085 179.614 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.6 ' CG2' HD11 ' A' ' 18' ' ' ILE . 32.1 m -142.43 160.78 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.158 -0.964 . . . . 0.0 109.832 -179.825 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.536 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 24.0 t -107.3 152.06 24.64 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 178.827 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.542 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 35.3 p90 174.81 164.16 0.24 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.807 -1.183 . . . . 0.0 110.215 -179.426 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -100.31 172.28 7.25 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.547 ' CG1' HG23 ' A' ' 26' ' ' VAL . 1.0 OUTLIER -111.52 125.46 68.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 120.867 -1.146 . . . . 0.0 109.901 -179.819 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.586 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.7 m -109.16 123.48 65.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 179.138 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.4 mt-10 -91.52 83.75 5.43 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 109.645 -179.533 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.79 -172.06 42.28 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 179.789 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.433 ' O ' ' C ' ' A' ' 56' ' ' ARG . 3.8 t30 -56.73 -63.55 1.16 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.14 -1.212 . . . . 0.0 109.212 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.433 ' C ' ' O ' ' A' ' 55' ' ' ASN . 36.2 mtp180 -42.0 -46.9 4.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.171 -0.955 . . . . 0.0 109.325 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.01 -149.33 21.46 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.409 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 46.2 Cg_endo -70.13 125.5 12.02 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.654 2.236 . . . . 0.0 112.128 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.586 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 33.2 mt-30 -125.56 158.62 34.13 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.335 -0.853 . . . . 0.0 108.875 179.389 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.457 ' N ' ' O ' ' A' ' 27' ' ' PHE . . . -91.47 134.86 34.27 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.019 -1.051 . . . . 0.0 109.767 -179.545 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.542 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -122.72 156.37 34.56 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.388 -0.82 . . . . 0.0 108.9 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.473 ' C ' ' O ' ' A' ' 61' ' ' ALA . 82.9 m-20 41.72 66.01 0.77 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.084 -1.01 . . . . 0.0 109.045 -179.727 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.585 ' HB ' ' O ' ' A' ' 32' ' ' ALA . 4.5 t -83.03 125.85 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.234 -0.916 . . . . 0.0 109.93 -179.381 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' THR . . . . . 0.475 HG22 ' OE2' ' A' ' 66' ' ' GLU . 92.4 m -118.35 125.02 49.15 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.53 -0.731 . . . . 0.0 109.211 179.766 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.483 ' NZ ' ' O ' ' A' ' 38' ' ' PHE . 32.4 mttp -65.41 110.5 2.68 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.338 -0.851 . . . . 0.0 109.438 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.475 ' OE2' HG22 ' A' ' 64' ' ' THR . 73.3 mm-40 -100.67 166.71 10.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.283 -0.885 . . . . 0.0 109.504 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 118.001 -1.0 . . . . 0.0 109.452 -179.991 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.445 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 59.6 mt . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 78.1 mt-10 -130.62 143.52 50.81 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.283 -0.886 . . . . 0.0 109.203 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.516 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -152.06 156.09 26.5 Favored Glycine 0 N--CA 1.488 2.123 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.44 ' N ' HG23 ' A' ' 18' ' ' ILE . 96.7 mttt -100.99 135.21 42.81 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.312 -1.111 . . . . 0.0 108.744 179.463 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.703 HG23 ' O ' ' A' ' 45' ' ' GLN . 33.9 t -66.55 119.22 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.123 -0.986 . . . . 0.0 110.01 -179.424 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.432 ' N ' ' O ' ' A' ' 17' ' ' PHE . 5.9 tptm -79.48 -40.96 28.53 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.425 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.656 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -159.98 166.95 29.03 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 179.785 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.643 ' N ' ' CD2' ' A' ' 8' ' ' TRP . 17.1 p90 -158.76 147.39 18.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.943 -1.098 . . . . 0.0 110.574 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.646 ' HB3' ' CE1' ' A' ' 15' ' ' PHE . 13.9 t-20 . . . . . 0 N--CA 1.491 1.618 0 O-C-N 121.412 -0.805 . . . . 0.0 109.353 179.662 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.646 ' CE1' ' HB3' ' A' ' 10' ' ' ASN . 3.1 p90 . . . . . 0 N--CA 1.488 1.452 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.656 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -161.07 160.86 32.45 Favored Glycine 0 N--CA 1.486 2.018 0 C-N-CA 119.598 -1.286 . . . . 0.0 110.044 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.502 ' CD1' ' HB2' ' A' ' 27' ' ' PHE . 98.0 m-85 -90.74 139.37 30.79 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.488 -1.007 . . . . 0.0 108.719 179.492 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.699 HD12 HG21 ' A' ' 28' ' ' VAL . 19.7 mt -113.25 159.28 13.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.582 -0.699 . . . . 0.0 109.222 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.467 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 65.7 tt0 -114.27 109.52 18.51 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.225 -0.922 . . . . 0.0 109.464 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.569 HG21 HG21 ' A' ' 26' ' ' VAL . 2.7 t -90.74 109.48 20.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.199 -0.938 . . . . 0.0 109.206 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 74.3 mm-40 -59.22 108.87 0.75 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.214 -0.929 . . . . 0.0 109.267 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.9 -35.62 3.48 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.465 ' OE1' HD12 ' A' ' 51' ' ' ILE . 46.7 mt-30 -117.95 160.92 20.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -1.155 . . . . 0.0 109.362 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.447 ' O ' ' O ' ' A' ' 23' ' ' GLN . 44.5 m-20 -52.92 -174.19 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.253 -0.904 . . . . 0.0 109.514 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.5 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 80.8 m-20 -74.31 139.45 44.21 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.299 -0.876 . . . . 0.0 109.647 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.569 HG21 HG21 ' A' ' 20' ' ' VAL . 91.8 t -114.39 119.87 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.306 -0.871 . . . . 0.0 109.529 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.512 ' C ' ' CD1' ' A' ' 27' ' ' PHE . 0.0 OUTLIER -77.17 155.75 32.05 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.111 -0.993 . . . . 0.0 109.396 -179.965 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.699 HG21 HD12 ' A' ' 18' ' ' ILE . 10.8 t -131.09 138.5 53.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.294 -0.879 . . . . 0.0 109.434 -179.652 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.509 ' HB2' ' CZ ' ' A' ' 27' ' ' PHE . 47.1 t60 -112.21 149.93 31.58 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.094 -1.004 . . . . 0.0 109.581 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.699 ' CG ' ' N ' ' A' ' 31' ' ' SER . 1.2 p90 -46.88 -53.99 10.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.152 -0.968 . . . . 0.0 109.672 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.699 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 21.0 t -59.56 -20.85 58.58 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.024 -1.048 . . . . 0.0 109.907 -179.527 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.565 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -77.77 -12.66 60.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.157 -0.964 . . . . 0.0 109.414 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.018 HD13 HD13 ' A' ' 41' ' ' LEU . 3.0 mt . . . . . 0 N--CA 1.489 1.491 0 O-C-N 121.435 -0.79 . . . . 0.0 109.82 -179.66 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 1.018 HD13 HD13 ' A' ' 33' ' ' ILE . 4.3 mp . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.331 0.586 . . . . 0.0 109.84 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.451 ' O ' ' C ' ' A' ' 43' ' ' GLU . 58.5 tt0 -93.91 119.72 33.21 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.407 -0.808 . . . . 0.0 109.084 179.629 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.451 ' C ' ' O ' ' A' ' 42' ' ' GLU . 53.4 tt0 -41.13 131.38 2.65 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.284 -0.885 . . . . 0.0 109.553 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 89.69 -3.95 83.47 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.703 ' O ' HG23 ' A' ' 6' ' ' VAL . 52.1 tt0 -80.81 128.18 33.37 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.171 -1.194 . . . . 0.0 109.466 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -79.9 143.36 34.33 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.27 -0.894 . . . . 0.0 109.055 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.915 HG12 ' HA ' ' A' ' 65' ' ' LYS . 28.9 m -147.84 171.41 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.196 -0.94 . . . . 0.0 109.678 -179.824 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.656 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 34.7 t -116.3 156.46 26.61 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.308 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.598 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 17.0 p90 172.81 166.78 0.13 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.894 -1.129 . . . . 0.0 110.488 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -108.82 154.28 22.32 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.725 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.465 HD12 ' OE1' ' A' ' 23' ' ' GLN . 1.9 mt -87.73 122.85 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 120.863 -1.148 . . . . 0.0 110.069 -179.433 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.805 ' CG1' ' HB2' ' A' ' 61' ' ' ALA . 26.8 m -110.72 128.29 67.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 178.859 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -68.63 120.05 14.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.084 -1.01 . . . . 0.0 109.838 -179.249 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -128.02 162.57 21.81 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.761 -1.335 . . . . 0.0 109.761 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -51.78 -60.22 3.42 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.241 -1.153 . . . . 0.0 109.493 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 82.2 mtp180 -51.0 -33.16 23.65 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.274 -0.891 . . . . 0.0 109.184 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 144.84 -146.12 16.18 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.434 -1.466 . . . . 0.0 109.434 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.5 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 45.8 Cg_endo -69.35 127.99 15.74 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.781 2.321 . . . . 0.0 111.793 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.621 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 84.8 mt-30 -121.99 156.21 33.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.188 -0.945 . . . . 0.0 109.265 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.522 ' HB2' HG22 ' A' ' 28' ' ' VAL . . . -88.35 127.76 35.49 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.159 -0.963 . . . . 0.0 110.088 -179.336 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.805 ' HB2' ' CG1' ' A' ' 52' ' ' VAL . . . -108.71 150.47 27.52 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.322 -0.861 . . . . 0.0 108.887 179.37 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.487 ' C ' ' O ' ' A' ' 61' ' ' ALA . 36.8 t-20 40.64 67.22 0.53 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.213 -0.93 . . . . 0.0 109.013 -179.67 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.922 HG11 HG12 ' A' ' 33' ' ' ILE . 1.2 t -82.14 127.25 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.329 -0.857 . . . . 0.0 110.21 -179.175 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.414 ' HB ' ' HB3' ' A' ' 48' ' ' SER . 35.3 m -115.63 117.56 30.63 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.146 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.915 ' HA ' HG12 ' A' ' 47' ' ' VAL . 18.1 mttm -65.34 117.01 7.26 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.279 -0.888 . . . . 0.0 109.663 -179.66 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 82.8 mt-10 -108.87 167.67 9.91 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.375 -0.828 . . . . 0.0 109.661 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.506 -179.956 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.84 ' N ' HD12 ' A' ' 2' ' ' LEU . 5.1 mp . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.764 ' O ' HG13 ' A' ' 20' ' ' VAL . 2.7 tt0 -127.68 140.27 52.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.227 -0.921 . . . . 0.0 109.208 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.0 155.22 24.91 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.784 -1.326 . . . . 0.0 109.784 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.54 ' C ' HG23 ' A' ' 18' ' ' ILE . 54.5 mttt -108.88 137.86 46.13 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.406 -1.055 . . . . 0.0 108.645 179.46 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.86 HG23 ' O ' ' A' ' 45' ' ' GLN . 15.0 t -70.16 112.56 5.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.054 -1.029 . . . . 0.0 109.983 -179.301 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.483 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 14.7 tttm -78.5 -40.87 34.04 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.592 ' CE3' ' O ' ' A' ' 8' ' ' TRP . 0.0 OUTLIER -161.44 155.78 22.73 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.923 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.434 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 11.0 p90 -154.31 139.77 17.76 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.054 -1.029 . . . . 0.0 109.07 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.433 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 36.7 t30 . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.052 -1.03 . . . . 0.0 109.869 -179.601 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.589 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 0.8 OUTLIER . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 . . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.533 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -148.57 173.85 28.41 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.564 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 29.2 m-85 -113.25 132.3 55.58 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.402 -1.058 . . . . 0.0 109.011 179.767 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 1.119 ' CD1' HG21 ' A' ' 28' ' ' VAL . 58.8 mt -119.07 149.5 21.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.239 -0.913 . . . . 0.0 109.681 -179.615 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 46.8 tt0 -112.09 122.15 46.95 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.353 -0.842 . . . . 0.0 109.415 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.764 HG13 ' O ' ' A' ' 3' ' ' GLU . 3.2 t -91.32 124.88 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.246 -0.909 . . . . 0.0 109.647 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.473 ' OE2' ' HE3' ' A' ' 5' ' ' LYS . 91.6 mt-10 -70.4 103.76 2.52 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.236 -0.915 . . . . 0.0 109.367 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 120.83 -19.13 8.99 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.569 ' OE1' HG11 ' A' ' 20' ' ' VAL . 49.0 mt-30 -129.82 162.6 28.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.263 -1.139 . . . . 0.0 109.578 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -54.46 -176.44 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.317 -0.864 . . . . 0.0 109.689 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 11.3 p30 -73.39 136.32 44.33 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.29 -0.881 . . . . 0.0 109.413 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.556 HG21 HG21 ' A' ' 20' ' ' VAL . 72.3 t -113.03 122.31 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.235 -0.916 . . . . 0.0 109.569 -179.753 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.508 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.4 OUTLIER -78.12 157.29 29.51 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.164 -0.96 . . . . 0.0 109.223 179.837 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 1.119 HG21 ' CD1' ' A' ' 18' ' ' ILE . 21.9 t -132.27 131.24 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.296 -0.877 . . . . 0.0 109.243 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.679 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 13.9 t-80 -105.83 154.64 20.25 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.124 -0.985 . . . . 0.0 109.267 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.685 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -46.52 -53.46 11.26 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.159 -0.963 . . . . 0.0 109.246 -179.683 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.685 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 86.7 p -55.96 -24.37 37.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.096 -1.003 . . . . 0.0 109.979 -179.692 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.502 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -66.32 -19.97 65.96 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.114 -0.991 . . . . 0.0 109.577 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.887 HG21 ' NZ ' ' A' ' 65' ' ' LYS . 2.9 mp . . . . . 0 N--CA 1.489 1.49 0 O-C-N 121.229 -0.92 . . . . 0.0 109.443 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.845 HD11 ' CD1' ' A' ' 33' ' ' ILE . 5.2 mp . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.364 0.602 . . . . 0.0 109.629 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.531 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 84.9 tt0 -116.11 149.26 39.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.297 -0.877 . . . . 0.0 109.008 179.68 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.483 ' HG3' ' O ' ' A' ' 7' ' ' LYS . 77.5 tt0 -71.0 124.46 24.41 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.15 -0.969 . . . . 0.0 109.769 -179.788 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 92.01 -6.88 79.15 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.901 -1.28 . . . . 0.0 109.901 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.86 ' O ' HG23 ' A' ' 6' ' ' VAL . 6.6 tp-100 -82.04 133.19 35.27 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.131 -1.217 . . . . 0.0 109.732 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -84.34 144.95 28.51 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.899 . . . . 0.0 109.415 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.697 HG12 ' HA ' ' A' ' 65' ' ' LYS . 23.2 m -144.78 163.61 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.232 -0.917 . . . . 0.0 109.795 -179.725 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.513 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 1.0 OUTLIER -108.19 153.23 23.48 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 179.342 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.535 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 7.8 p90 174.63 165.82 0.25 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.99 -1.069 . . . . 0.0 110.055 -179.76 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.531 ' HA ' HD13 ' A' ' 2' ' ' LEU . 95.1 mt-10 -102.84 165.14 11.21 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.14 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.0 mt -102.44 125.74 56.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 120.936 -1.102 . . . . 0.0 109.854 -179.747 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.579 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 32.0 m -114.3 126.29 71.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.413 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 178.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -66.18 118.64 10.2 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.158 -0.964 . . . . 0.0 109.727 -179.502 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -122.07 157.44 16.8 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.496 ' CG ' ' N ' ' A' ' 56' ' ' ARG . 7.9 p30 -48.05 -49.66 30.6 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.319 -1.106 . . . . 0.0 109.654 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.496 ' N ' ' CG ' ' A' ' 55' ' ' ASN . 84.0 mtp180 -64.47 -25.23 67.91 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.109 -0.994 . . . . 0.0 109.012 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 142.63 -152.63 23.99 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.494 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 49.2 Cg_endo -70.72 137.25 32.28 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.631 2.22 . . . . 0.0 111.782 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.579 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 79.1 mt-30 -127.53 163.83 23.29 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.228 -0.92 . . . . 0.0 109.207 179.641 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.484 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -96.6 142.65 28.4 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.154 -0.966 . . . . 0.0 110.103 -179.324 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.517 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -124.65 154.06 41.34 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.387 -0.821 . . . . 0.0 108.881 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.476 ' C ' ' O ' ' A' ' 61' ' ' ALA . 58.3 t30 42.54 64.24 1.2 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.103 -0.998 . . . . 0.0 108.784 -179.65 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.766 HG12 HG23 ' A' ' 33' ' ' ILE . 1.8 t -78.38 128.91 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.337 -0.852 . . . . 0.0 109.944 -179.122 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.462 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 93.4 m -119.56 126.32 50.95 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.484 -0.76 . . . . 0.0 109.082 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.887 ' NZ ' HG21 ' A' ' 33' ' ' ILE . 38.2 mttp -73.39 114.78 12.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.219 -0.925 . . . . 0.0 109.771 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.449 ' HG3' ' HA ' ' A' ' 47' ' ' VAL . 97.1 mt-10 -92.44 161.98 14.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.251 -0.905 . . . . 0.0 109.452 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.392 179.884 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.427 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 57.5 mt . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.715 ' O ' HG13 ' A' ' 20' ' ' VAL . 3.5 tt0 -128.43 137.76 51.99 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.266 -0.896 . . . . 0.0 109.208 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.05 154.33 24.41 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.776 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.497 ' O ' HG23 ' A' ' 18' ' ' ILE . 58.0 mttp -104.16 140.46 37.77 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.434 -1.039 . . . . 0.0 108.829 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.768 HG23 ' O ' ' A' ' 45' ' ' GLN . 18.8 t -72.85 114.36 11.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.009 -1.057 . . . . 0.0 109.963 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 10.7 tptt -78.76 -42.24 28.54 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.527 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.581 ' CE3' ' O ' ' A' ' 8' ' ' TRP . 0.0 OUTLIER -160.1 156.12 26.3 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.452 -0.78 . . . . 0.0 109.009 179.96 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.498 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 10.4 p90 -154.96 139.08 16.5 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.124 -0.985 . . . . 0.0 109.021 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.445 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.7 t-20 . . . . . 0 N--CA 1.491 1.597 0 O-C-N 121.01 -1.056 . . . . 0.0 109.836 -179.517 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.584 ' N ' ' CD1' ' A' ' 15' ' ' PHE . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 . . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.566 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -145.12 175.4 24.73 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.564 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 32.8 m-85 -115.54 133.29 56.18 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.265 -1.138 . . . . 0.0 109.022 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 1.09 HD12 ' CG2' ' A' ' 28' ' ' VAL . 20.2 mt -119.88 155.08 22.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.226 -0.921 . . . . 0.0 109.402 -179.807 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 32.4 tp10 -117.83 123.92 47.1 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.315 -0.866 . . . . 0.0 109.588 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.715 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.3 t -97.94 119.98 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.314 -0.866 . . . . 0.0 109.47 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -69.11 109.61 4.11 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.27 -0.894 . . . . 0.0 109.556 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 126.46 -30.68 4.19 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.691 ' OE1' HD12 ' A' ' 51' ' ' ILE . 57.1 mt-30 -128.6 166.85 18.07 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.322 -1.105 . . . . 0.0 109.41 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.46 ' O ' ' O ' ' A' ' 23' ' ' GLN . 55.4 m-20 -51.13 -177.38 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.251 -0.906 . . . . 0.0 109.411 179.898 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.512 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 20.3 p30 -75.27 147.28 40.37 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.232 -0.917 . . . . 0.0 109.308 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.538 HG21 HG21 ' A' ' 20' ' ' VAL . 81.6 t -118.14 120.44 64.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.121 -0.987 . . . . 0.0 109.676 -179.556 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.529 ' CE1' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER -76.81 158.27 30.96 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.127 -0.983 . . . . 0.0 109.11 179.696 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 1.09 ' CG2' HD12 ' A' ' 18' ' ' ILE . 7.7 t -131.64 134.08 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.187 -0.946 . . . . 0.0 109.299 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.611 ' O ' HD12 ' A' ' 33' ' ' ILE . 44.0 t60 -109.32 152.63 25.01 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.193 -0.942 . . . . 0.0 109.15 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.682 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.9 OUTLIER -45.43 -53.04 9.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.199 -0.938 . . . . 0.0 109.176 -179.592 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.682 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 22.7 t -54.96 -28.94 55.31 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.243 -0.911 . . . . 0.0 110.051 -179.587 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.499 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -62.83 -21.58 66.03 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.048 -1.032 . . . . 0.0 109.352 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.944 ' CD1' HD11 ' A' ' 41' ' ' LEU . 3.3 mp . . . . . 0 N--CA 1.488 1.474 0 O-C-N 121.298 -0.876 . . . . 0.0 109.256 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.944 HD11 ' CD1' ' A' ' 33' ' ' ILE . 5.4 mp . . . . . 0 N--CA 1.489 1.501 0 CA-C-O 121.397 0.617 . . . . 0.0 109.699 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.515 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 85.2 tt0 -117.57 152.07 35.87 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.415 -0.803 . . . . 0.0 109.042 179.546 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 67.4 tt0 -72.85 124.57 25.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.207 -0.933 . . . . 0.0 109.6 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.7 -4.44 79.17 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.768 ' O ' HG23 ' A' ' 6' ' ' VAL . 8.0 tp-100 -82.05 132.81 35.26 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.189 -1.183 . . . . 0.0 109.877 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -80.45 141.06 35.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.289 -0.882 . . . . 0.0 109.169 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.656 HG21 HD13 ' A' ' 18' ' ' ILE . 30.1 m -141.69 159.04 21.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 109.902 -179.614 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.503 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 28.9 t -109.66 153.11 24.7 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.048 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.552 ' CE2' HG23 ' A' ' 47' ' ' VAL . 8.5 p90 173.39 165.67 0.16 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.913 -1.117 . . . . 0.0 110.178 -179.764 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -100.05 162.89 12.69 Favored 'General case' 0 N--CA 1.487 1.382 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.894 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.691 HD12 ' OE1' ' A' ' 23' ' ' GLN . 0.9 OUTLIER -102.25 125.46 56.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 120.927 -1.108 . . . . 0.0 110.022 -179.571 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.601 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 26.7 m -109.9 121.98 63.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.7 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.408 ' OE2' ' HB3' ' A' ' 58' ' ' PRO . 39.9 mm-40 -91.47 89.9 7.42 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.144 -0.973 . . . . 0.0 109.945 -179.001 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.05 -169.96 32.23 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 56' ' ' ARG . 19.5 t-20 -58.05 -66.17 0.52 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.236 -1.155 . . . . 0.0 109.837 -179.848 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.428 ' C ' ' O ' ' A' ' 55' ' ' ASN . 15.2 mtm180 -41.82 -46.29 3.88 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.282 -0.886 . . . . 0.0 109.501 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 150.65 -153.97 25.34 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.512 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 47.9 Cg_endo -69.64 129.42 17.69 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.682 2.255 . . . . 0.0 112.024 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.601 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 61.2 mt-30 -127.19 161.14 29.23 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.334 -0.854 . . . . 0.0 108.976 179.506 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.547 ' HB2' HG22 ' A' ' 28' ' ' VAL . . . -90.02 136.52 32.99 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.032 -1.043 . . . . 0.0 110.296 -179.154 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.534 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -118.79 149.57 41.28 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 179.442 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.488 ' C ' ' O ' ' A' ' 61' ' ' ALA . 38.6 t-20 41.34 67.77 0.51 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.033 -1.042 . . . . 0.0 108.875 -179.57 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.609 HG21 ' CG1' ' A' ' 28' ' ' VAL . 2.1 t -81.57 127.85 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.404 -0.81 . . . . 0.0 110.161 -179.176 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 91.8 m -118.1 123.84 46.57 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.472 -0.768 . . . . 0.0 109.082 179.8 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.494 ' HE2' ' HA ' ' A' ' 41' ' ' LEU . 74.1 mttt -70.75 112.63 7.11 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.199 -0.938 . . . . 0.0 109.737 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -92.75 162.7 14.02 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.326 -0.859 . . . . 0.0 109.584 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.995 -1.002 . . . . 0.0 109.491 179.997 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.845 ' N ' HD12 ' A' ' 2' ' ' LEU . 4.6 mp . . . . . 0 N--CA 1.488 1.475 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.794 ' O ' HG13 ' A' ' 20' ' ' VAL . 2.4 tt0 -128.73 143.67 50.98 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.205 -0.935 . . . . 0.0 109.163 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -144.34 157.08 27.07 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.445 ' C ' HG23 ' A' ' 18' ' ' ILE . 43.2 mttm -108.23 137.1 46.79 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.423 -1.045 . . . . 0.0 108.576 179.383 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.789 HG23 ' O ' ' A' ' 45' ' ' GLN . 16.1 t -68.28 114.45 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.128 -0.983 . . . . 0.0 109.85 -179.341 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.459 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 29.7 tttt -79.33 -38.07 36.03 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 179.601 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.608 ' CZ3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -166.37 157.39 12.89 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.476 -0.765 . . . . 0.0 109.035 -179.893 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.432 ' N ' ' CG ' ' A' ' 8' ' ' TRP . 16.1 p90 -152.75 139.89 19.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.203 -0.936 . . . . 0.0 108.847 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.487 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 55.1 t-20 . . . . . 0 N--CA 1.49 1.534 0 O-C-N 121.045 -1.034 . . . . 0.0 109.971 -179.408 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.62 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.29 0.567 . . . . 0.0 109.529 . . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.516 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -145.3 172.17 26.16 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.679 -1.368 . . . . 0.0 109.679 -179.834 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.608 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 28.4 m-85 -114.79 131.94 56.64 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.22 -1.164 . . . . 0.0 109.021 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 1.117 HD12 ' CG2' ' A' ' 28' ' ' VAL . 37.3 mt -119.25 149.54 21.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.146 -0.971 . . . . 0.0 109.647 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 46.3 tt0 -112.28 120.3 41.27 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.406 -0.809 . . . . 0.0 109.413 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.794 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.6 t -90.85 125.1 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.312 -0.868 . . . . 0.0 109.428 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.468 ' HA ' ' OE1' ' A' ' 21' ' ' GLU . 67.0 mm-40 -73.57 106.05 5.18 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.318 -0.864 . . . . 0.0 109.25 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.53 -17.54 8.89 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.564 ' OE1' HD12 ' A' ' 51' ' ' ILE . 46.5 mt-30 -133.9 164.62 26.86 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.276 -1.132 . . . . 0.0 109.648 -179.836 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 50.5 m-20 -55.02 -176.6 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.207 -0.933 . . . . 0.0 109.607 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.499 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 11.4 p30 -73.33 139.96 46.39 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.29 -0.881 . . . . 0.0 109.477 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.587 HG12 ' HB2' ' A' ' 60' ' ' ALA . 56.1 t -115.74 122.02 68.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.196 -0.94 . . . . 0.0 109.44 -179.796 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.495 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.3 OUTLIER -79.78 157.53 27.06 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.13 -0.981 . . . . 0.0 109.192 179.977 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 1.117 ' CG2' HD12 ' A' ' 18' ' ' ILE . 13.0 t -132.31 130.18 60.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.303 -0.873 . . . . 0.0 109.373 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.667 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 13.4 t-80 -103.65 154.41 19.55 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.148 -0.97 . . . . 0.0 109.089 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.689 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.7 OUTLIER -45.98 -53.44 10.02 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.082 -1.011 . . . . 0.0 109.188 -179.682 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.689 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 93.0 p -55.55 -30.26 60.45 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.154 -0.966 . . . . 0.0 110.236 -179.555 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.401 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -58.03 -27.9 63.99 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.996 -1.065 . . . . 0.0 109.331 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.821 HG12 HG11 ' A' ' 63' ' ' VAL . 2.6 mp . . . . . 0 C--N 1.302 -1.462 0 O-C-N 121.355 -0.841 . . . . 0.0 109.52 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.643 HD11 HG12 ' A' ' 33' ' ' ILE . 4.4 mp . . . . . 0 N--CA 1.489 1.519 0 CA-C-O 121.489 0.661 . . . . 0.0 109.837 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.451 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.5 tt0 -91.75 134.4 34.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.43 -0.794 . . . . 0.0 109.401 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.459 ' HG3' ' O ' ' A' ' 7' ' ' LYS . 76.1 tt0 -59.44 128.28 36.27 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.239 -0.913 . . . . 0.0 109.638 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.406 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 91.99 -5.13 78.8 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.726 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.789 ' O ' HG23 ' A' ' 6' ' ' VAL . 63.3 tt0 -81.37 131.48 35.29 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.269 -1.136 . . . . 0.0 109.758 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -79.14 141.4 37.29 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.247 -0.908 . . . . 0.0 109.22 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.681 HG21 HD13 ' A' ' 18' ' ' ILE . 33.2 m -141.83 159.19 21.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.127 -0.983 . . . . 0.0 109.907 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.505 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 27.5 t -106.08 151.26 24.91 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 179.017 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.596 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 11.7 p90 175.13 165.39 0.29 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.943 -1.098 . . . . 0.0 110.317 -179.707 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.552 ' HA ' HD13 ' A' ' 2' ' ' LEU . 93.9 mt-10 -100.05 166.26 11.12 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 178.974 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.564 HD12 ' OE1' ' A' ' 23' ' ' GLN . 0.6 OUTLIER -104.16 125.72 58.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.917 -1.114 . . . . 0.0 109.804 -179.66 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.591 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 33.1 m -114.03 125.57 71.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.173 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.464 ' HA ' ' HA ' ' A' ' 58' ' ' PRO . 19.8 mt-10 -96.66 93.61 6.84 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.196 -0.94 . . . . 0.0 109.923 -179.35 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.61 -176.62 44.33 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.407 ' CG ' ' N ' ' A' ' 56' ' ' ARG . 18.5 p-10 -53.17 -50.77 63.92 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.219 -1.165 . . . . 0.0 109.715 -179.674 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.407 ' N ' ' CG ' ' A' ' 55' ' ' ASN . 20.1 mtm180 -58.96 -37.5 76.93 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.081 -1.012 . . . . 0.0 109.381 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.05 -159.21 28.07 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.5 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 53.7 Cg_endo -72.59 142.28 35.99 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.728 2.285 . . . . 0.0 111.903 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.591 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 72.8 mt-30 -138.97 169.89 16.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.384 -0.822 . . . . 0.0 108.945 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.587 ' HB2' HG12 ' A' ' 26' ' ' VAL . . . -95.03 138.17 33.11 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.047 -1.033 . . . . 0.0 110.383 -179.132 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.596 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -125.42 156.33 39.01 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.34 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 73.5 m-20 45.39 69.18 0.47 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.893 -1.13 . . . . 0.0 108.665 -179.647 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.821 HG11 HG12 ' A' ' 33' ' ' ILE . 2.2 t -88.14 125.83 41.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.326 -0.859 . . . . 0.0 110.17 -179.033 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 98.1 m -118.16 121.23 39.99 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.505 -0.747 . . . . 0.0 109.025 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.721 ' NZ ' HG21 ' A' ' 33' ' ' ILE . 28.7 mttp -71.49 112.26 7.47 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.229 -0.919 . . . . 0.0 109.361 -179.805 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.469 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 96.2 mt-10 -94.03 166.89 11.93 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.313 -0.867 . . . . 0.0 109.642 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ALA . . . . . 0.414 ' O ' ' O ' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 117.998 -1.001 . . . . 0.0 109.548 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.876 ' N ' HD12 ' A' ' 2' ' ' LEU . 3.6 mp . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.735 ' O ' HG13 ' A' ' 20' ' ' VAL . 83.0 mt-10 -127.96 144.27 51.1 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.274 -0.891 . . . . 0.0 109.185 179.671 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.471 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -140.06 153.43 23.32 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.499 ' N ' HG23 ' A' ' 18' ' ' ILE . 58.4 mttm -104.03 139.26 39.39 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.315 -1.109 . . . . 0.0 108.841 179.482 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.64 HG23 ' O ' ' A' ' 45' ' ' GLN . 38.7 t -71.63 109.94 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.166 -0.958 . . . . 0.0 109.899 -179.43 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.67 -32.83 27.94 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.371 -0.831 . . . . 0.0 108.977 179.42 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.686 ' CE3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -158.63 159.28 35.22 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 -179.837 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.505 ' N ' ' CG ' ' A' ' 8' ' ' TRP . 22.4 p90 -161.16 132.5 5.5 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.029 -1.044 . . . . 0.0 109.283 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.523 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.1 t-20 . . . . . 0 N--CA 1.49 1.536 0 O-C-N 121.197 -0.939 . . . . 0.0 109.539 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.735 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.654 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 . . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.593 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -136.96 172.57 22.56 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.686 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 17.0 m-85 -119.37 133.74 55.56 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.226 -1.161 . . . . 0.0 109.306 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 1.103 ' CD1' HG21 ' A' ' 28' ' ' VAL . 15.4 mt -120.82 154.41 24.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.342 -0.849 . . . . 0.0 109.46 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 24.9 tp10 -117.65 122.91 44.82 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.307 -0.871 . . . . 0.0 109.38 179.827 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.735 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.9 t -93.58 120.16 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.228 -0.92 . . . . 0.0 109.553 -179.868 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -67.14 109.18 2.94 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.295 -0.878 . . . . 0.0 109.286 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.22 -23.1 7.75 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.68 ' OE1' HD12 ' A' ' 51' ' ' ILE . 65.0 mt-30 -130.79 164.79 24.38 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.304 -1.115 . . . . 0.0 109.51 -179.77 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 41.0 m-20 -55.28 -175.02 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.33 -0.856 . . . . 0.0 109.924 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.475 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 15.2 p30 -74.18 141.99 45.46 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.301 -0.875 . . . . 0.0 109.737 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.478 HG21 HG21 ' A' ' 20' ' ' VAL . 90.6 t -117.87 118.13 57.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.207 -0.933 . . . . 0.0 109.353 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.448 ' CE1' ' HB3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -75.13 156.06 36.37 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.231 -0.918 . . . . 0.0 109.021 179.771 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 1.103 HG21 ' CD1' ' A' ' 18' ' ' ILE . 6.9 t -133.57 139.95 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.89 . . . . 0.0 109.607 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.735 ' HA ' ' HB3' ' A' ' 15' ' ' PHE . 48.0 t60 -114.42 150.3 34.91 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.26 -0.9 . . . . 0.0 109.25 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.668 ' CG ' ' N ' ' A' ' 31' ' ' SER . 1.0 OUTLIER -43.75 -52.66 6.44 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.174 -0.954 . . . . 0.0 109.396 -179.642 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.668 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 22.8 t -57.61 -20.84 35.51 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.17 -0.956 . . . . 0.0 109.863 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.471 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -69.42 -22.75 63.66 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.115 -0.991 . . . . 0.0 109.735 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.639 ' CG1' HG11 ' A' ' 63' ' ' VAL . 2.9 mp . . . . . 0 N--CA 1.488 1.465 0 O-C-N 121.207 -0.933 . . . . 0.0 109.716 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.597 HD11 ' CD1' ' A' ' 33' ' ' ILE . 5.5 mp . . . . . 0 N--CA 1.489 1.493 0 CA-C-O 121.334 0.587 . . . . 0.0 109.787 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.427 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 94.5 mt-10 -105.47 146.29 29.73 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.44 -0.787 . . . . 0.0 109.36 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.574 ' HA ' HG12 ' A' ' 6' ' ' VAL . 52.6 tt0 -70.06 130.72 42.91 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.184 -0.947 . . . . 0.0 109.613 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 93.11 -5.96 75.75 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.726 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.64 ' O ' HG23 ' A' ' 6' ' ' VAL . 60.2 tp60 -81.86 125.68 30.99 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.26 -1.141 . . . . 0.0 109.73 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -73.25 143.94 46.88 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.199 -0.938 . . . . 0.0 109.223 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.853 HG21 HD13 ' A' ' 18' ' ' ILE . 33.4 m -145.39 158.92 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.109 -0.994 . . . . 0.0 110.188 -179.576 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.526 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 4.6 p -110.49 154.53 23.52 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.115 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.584 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 7.9 p90 171.29 167.66 0.08 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.93 -1.106 . . . . 0.0 110.035 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.651 ' HA ' HD13 ' A' ' 2' ' ' LEU . 94.8 mt-10 -103.67 165.09 11.25 Favored 'General case' 0 C--N 1.303 -1.436 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.212 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.68 HD12 ' OE1' ' A' ' 23' ' ' GLN . 3.9 mt -106.25 132.22 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 120.997 -1.064 . . . . 0.0 109.685 -179.897 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.536 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 20.5 m -121.28 133.12 68.87 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.557 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 -84.97 82.66 8.35 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.213 -0.929 . . . . 0.0 109.604 -179.673 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 57' ' ' GLY . . . -84.32 176.64 51.56 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 20.2 p-10 -49.47 -51.69 34.13 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.241 -1.152 . . . . 0.0 109.65 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 23.2 mtm180 -62.38 -31.98 72.72 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.095 -1.003 . . . . 0.0 109.549 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.413 ' O ' ' N ' ' A' ' 54' ' ' GLY . . . 142.93 -148.22 19.89 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.478 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 50.0 Cg_endo -71.24 133.59 23.17 Favored 'Trans proline' 0 C--O 1.214 -0.688 0 C-N-CA 122.802 2.334 . . . . 0.0 112.034 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.536 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 42.6 mt-30 -127.87 161.32 29.34 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.38 -0.825 . . . . 0.0 109.359 179.726 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.615 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -92.16 110.49 21.87 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.217 -0.927 . . . . 0.0 110.134 -179.508 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.575 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -93.48 152.07 19.31 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.327 -0.858 . . . . 0.0 109.061 179.633 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.494 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 79.0 m-20 43.63 78.23 0.06 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.043 -1.036 . . . . 0.0 109.029 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.748 HG21 ' CG1' ' A' ' 28' ' ' VAL . 2.1 t -92.87 125.87 45.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.182 -0.949 . . . . 0.0 110.003 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.402 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 56.9 m -120.48 130.22 54.19 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.655 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.561 ' NZ ' HG21 ' A' ' 33' ' ' ILE . 44.3 mttp -76.81 114.04 15.13 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.277 -0.889 . . . . 0.0 109.72 -179.697 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 57.5 mm-40 -101.02 172.02 7.28 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.284 -0.885 . . . . 0.0 109.635 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 117.993 -1.003 . . . . 0.0 109.471 179.893 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.837 ' N ' HD12 ' A' ' 2' ' ' LEU . 5.2 mp . . . . . 0 N--CA 1.489 1.502 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.779 ' O ' HG13 ' A' ' 20' ' ' VAL . 2.4 tt0 -132.39 139.99 48.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.179 -0.951 . . . . 0.0 109.461 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -140.4 158.75 26.09 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.509 ' O ' HG23 ' A' ' 18' ' ' ILE . 85.6 mttt -106.96 139.69 40.97 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.32 -1.106 . . . . 0.0 108.895 179.78 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.711 HG23 ' O ' ' A' ' 45' ' ' GLN . 22.6 t -72.88 111.56 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.109 -0.994 . . . . 0.0 110.127 -179.34 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 19.1 tttt -79.16 -40.6 30.52 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.563 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.619 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.7 154.76 26.88 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.765 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.436 ' N ' ' CG ' ' A' ' 8' ' ' TRP . 13.6 p90 -154.9 141.0 18.43 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.058 -1.026 . . . . 0.0 109.424 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.483 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.7 t-20 . . . . . 0 N--CA 1.489 1.517 0 O-C-N 121.253 -0.904 . . . . 0.0 109.677 -179.746 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.551 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 5.6 p90 . . . . . 0 N--CA 1.494 1.734 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.619 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -138.43 172.11 23.15 Favored Glycine 0 N--CA 1.49 2.27 0 C-N-CA 119.634 -1.27 . . . . 0.0 110.024 -179.452 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.514 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 27.1 m-85 -115.17 133.0 56.42 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.339 -1.095 . . . . 0.0 108.789 179.569 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 1.113 HD12 ' CG2' ' A' ' 28' ' ' VAL . 13.1 mt -120.92 155.29 24.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.151 -0.968 . . . . 0.0 109.873 -179.518 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.4 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 23.4 tp10 -116.92 123.47 47.06 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.398 -0.814 . . . . 0.0 109.369 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.779 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.3 t -98.15 123.0 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.17 -0.956 . . . . 0.0 109.317 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.463 ' HA ' ' OE1' ' A' ' 21' ' ' GLU . 68.7 mm-40 -72.24 108.83 5.6 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 0.0 109.3 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 125.44 -22.68 6.17 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.226 -1.55 . . . . 0.0 109.226 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.788 ' OE1' HD12 ' A' ' 51' ' ' ILE . 73.1 mt-30 -135.73 167.54 20.96 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.28 -1.13 . . . . 0.0 109.548 -179.78 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -53.52 -177.12 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.262 -0.899 . . . . 0.0 109.587 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.479 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 11.8 p30 -74.61 143.18 44.48 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.937 . . . . 0.0 109.426 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.559 HG21 HD11 ' A' ' 51' ' ' ILE . 97.9 t -116.33 119.36 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.16 -0.962 . . . . 0.0 109.425 -179.813 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.518 ' CG ' ' N ' ' A' ' 28' ' ' VAL . 0.4 OUTLIER -77.84 158.8 29.32 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.172 -0.955 . . . . 0.0 109.207 179.916 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 1.113 ' CG2' HD12 ' A' ' 18' ' ' ILE . 4.4 t -133.09 125.71 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.476 -0.765 . . . . 0.0 109.144 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.676 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 14.6 t-80 -98.46 153.93 18.24 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.355 -0.84 . . . . 0.0 109.091 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.687 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -45.13 -53.68 7.75 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.07 -1.019 . . . . 0.0 109.203 -179.65 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.687 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 62.8 p -54.27 -25.13 21.69 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.189 -0.945 . . . . 0.0 109.921 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.466 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -62.34 -24.52 67.38 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.126 -0.984 . . . . 0.0 109.439 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.776 HD11 HD11 ' A' ' 41' ' ' LEU . 3.0 mp . . . . . 0 N--CA 1.488 1.474 0 O-C-N 121.238 -0.914 . . . . 0.0 109.544 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 1.038 HD23 HG11 ' A' ' 47' ' ' VAL . 5.1 mp . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.396 0.617 . . . . 0.0 109.788 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.492 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 20.5 tt0 -116.42 140.24 49.56 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.391 -0.818 . . . . 0.0 109.057 179.733 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.432 ' HA ' HG12 ' A' ' 6' ' ' VAL . 76.6 tt0 -62.35 125.35 23.6 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.264 -0.898 . . . . 0.0 109.618 -179.76 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 90.67 -7.1 81.82 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.711 ' O ' HG23 ' A' ' 6' ' ' VAL . 66.7 tt0 -81.76 134.39 35.44 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.24 -1.153 . . . . 0.0 109.72 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -80.07 140.16 36.6 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.271 -0.893 . . . . 0.0 109.155 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 1.038 HG11 HD23 ' A' ' 41' ' ' LEU . 26.4 m -140.57 151.73 20.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.227 -0.921 . . . . 0.0 109.745 -179.464 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.527 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 33.0 t -100.56 148.94 24.24 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.053 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.598 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 7.2 p90 176.28 164.7 0.42 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.903 -1.123 . . . . 0.0 110.105 -179.63 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.571 ' HA ' HD13 ' A' ' 2' ' ' LEU . 94.9 mt-10 -103.54 161.41 13.9 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.247 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.788 HD12 ' OE1' ' A' ' 23' ' ' GLN . 7.2 mt -104.61 135.78 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.969 -1.082 . . . . 0.0 109.783 -179.789 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.501 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 32.7 m -122.23 131.41 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.481 -0.762 . . . . 0.0 109.11 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -86.8 84.22 7.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.185 -0.947 . . . . 0.0 109.634 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -85.84 177.16 49.55 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 14.4 t-20 -50.34 -54.33 22.35 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.196 -1.179 . . . . 0.0 109.608 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 71.3 mtm180 -57.38 -35.46 70.01 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.241 -0.912 . . . . 0.0 109.498 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 145.2 -153.28 25.17 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -70.37 137.31 33.41 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.734 2.289 . . . . 0.0 111.987 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.524 ' C ' HG13 ' A' ' 26' ' ' VAL . 92.2 mt-30 -135.19 165.99 24.14 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.342 -0.849 . . . . 0.0 109.275 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.564 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -94.58 137.15 34.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.198 -0.938 . . . . 0.0 109.777 -179.69 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.598 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -123.96 155.04 38.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.365 -0.834 . . . . 0.0 108.843 179.717 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.476 ' C ' ' O ' ' A' ' 61' ' ' ALA . 85.8 m-20 43.19 73.91 0.13 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.897 -1.127 . . . . 0.0 108.706 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.845 HG11 HD21 ' A' ' 41' ' ' LEU . 2.7 t -89.65 126.96 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.212 -0.93 . . . . 0.0 109.99 -179.108 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.422 ' HB ' ' HB3' ' A' ' 48' ' ' SER . 70.3 m -118.45 124.29 47.27 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.487 ' HE2' ' HA ' ' A' ' 41' ' ' LEU . 55.5 mttt -71.73 111.03 6.67 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.181 -0.95 . . . . 0.0 109.528 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -89.78 164.1 14.79 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.364 -0.835 . . . . 0.0 109.566 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.461 -179.922 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.847 ' N ' HD12 ' A' ' 2' ' ' LEU . 4.6 mp . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.765 ' O ' HG13 ' A' ' 20' ' ' VAL . 96.1 mt-10 -129.48 147.36 51.29 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.167 -0.958 . . . . 0.0 109.295 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.444 ' C ' ' CG2' ' A' ' 18' ' ' ILE . . . -143.1 153.46 24.77 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.666 ' C ' HG23 ' A' ' 18' ' ' ILE . 27.6 mttp -102.48 141.38 35.39 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.284 -1.127 . . . . 0.0 108.839 179.557 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 45' ' ' GLN . 33.7 t -73.8 110.58 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.247 -0.908 . . . . 0.0 110.126 -179.392 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.488 ' NZ ' ' HB3' ' A' ' 17' ' ' PHE . 2.9 pttt -79.89 -36.46 36.5 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.615 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -159.74 154.26 24.04 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.962 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.627 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 17.0 p90 -156.03 140.33 16.64 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.075 -1.016 . . . . 0.0 109.496 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.447 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 55.1 t-20 . . . . . 0 N--CA 1.489 1.489 0 O-C-N 121.224 -0.923 . . . . 0.0 109.521 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.596 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 2.8 p90 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.615 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -136.07 177.22 19.72 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.652 -1.261 . . . . 0.0 110.05 -179.366 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.562 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 19.4 m-85 -119.2 135.49 54.65 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.384 -1.068 . . . . 0.0 109.078 179.834 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 1.088 ' CD1' HG21 ' A' ' 28' ' ' VAL . 37.9 mt -122.34 148.41 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.168 -0.958 . . . . 0.0 109.507 -179.673 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 23.3 tp10 -110.98 121.05 44.37 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.342 -0.849 . . . . 0.0 109.332 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.765 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.6 t -91.46 120.59 40.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.211 -0.931 . . . . 0.0 109.664 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.411 ' OE1' ' HA ' ' A' ' 21' ' ' GLU . 73.2 mm-40 -71.9 110.64 6.54 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.202 -0.936 . . . . 0.0 109.246 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.405 ' C ' ' HG3' ' A' ' 23' ' ' GLN . . . 122.57 -18.38 8.18 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.694 ' OE1' HD12 ' A' ' 51' ' ' ILE . 63.9 mt-30 -140.04 170.35 16.01 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.353 -1.086 . . . . 0.0 109.495 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 60.2 m-20 -55.31 -178.35 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.291 -0.88 . . . . 0.0 109.654 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 22.6 p30 -75.01 146.46 41.61 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.236 -0.915 . . . . 0.0 109.438 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.66 HG13 ' C ' ' A' ' 59' ' ' GLN . 58.1 t -118.35 119.07 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.242 -0.911 . . . . 0.0 109.401 -179.67 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.545 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.0 OUTLIER -76.61 156.31 32.84 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.205 -0.934 . . . . 0.0 109.148 179.855 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 1.088 HG21 ' CD1' ' A' ' 18' ' ' ILE . 14.7 t -133.45 132.97 57.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.383 -0.823 . . . . 0.0 109.399 -179.762 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.596 ' HA ' ' HB3' ' A' ' 15' ' ' PHE . 56.4 t60 -111.18 153.5 25.7 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.354 -0.841 . . . . 0.0 109.053 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.682 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -44.47 -53.85 6.55 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.126 -0.984 . . . . 0.0 109.347 -179.605 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.682 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 32.3 t -57.04 -22.81 41.78 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.115 -0.991 . . . . 0.0 110.014 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.454 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -66.43 -27.53 67.91 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.09 -1.006 . . . . 0.0 109.458 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.719 HG12 HG11 ' A' ' 63' ' ' VAL . 2.4 mp . . . . . 0 N--CA 1.489 1.483 0 O-C-N 121.258 -0.901 . . . . 0.0 109.677 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.64 ' CD1' HD13 ' A' ' 33' ' ' ILE . 3.1 mp . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 121.2 0.524 . . . . 0.0 109.672 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.468 ' O ' ' CB ' ' A' ' 6' ' ' VAL . 96.0 mt-10 -100.7 149.15 24.09 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.324 -0.86 . . . . 0.0 109.484 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.525 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 69.8 tt0 -71.91 130.01 39.97 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.348 -0.845 . . . . 0.0 109.625 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.51 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 90.52 -4.26 82.17 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.583 ' O ' HG23 ' A' ' 6' ' ' VAL . 49.8 tt0 -80.8 129.57 34.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.271 -1.135 . . . . 0.0 109.638 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -76.48 139.75 40.94 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.268 -0.895 . . . . 0.0 109.065 179.702 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.822 HG21 HD13 ' A' ' 18' ' ' ILE . 31.8 m -142.28 162.24 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.029 -1.044 . . . . 0.0 109.959 -179.651 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.509 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 63.8 m -112.44 153.38 27.47 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.634 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 5.8 p90 172.75 168.56 0.12 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.033 -1.042 . . . . 0.0 109.978 -179.833 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.528 ' HA ' HD13 ' A' ' 2' ' ' LEU . 95.1 mt-10 -103.5 160.88 14.34 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.694 HD12 ' OE1' ' A' ' 23' ' ' GLN . 3.9 mt -103.5 134.47 44.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.116 -0.99 . . . . 0.0 109.616 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.533 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 33.9 m -122.74 131.74 72.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -85.7 87.2 7.37 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.102 -0.999 . . . . 0.0 109.677 -179.724 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.62 178.07 43.96 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.9 t30 -50.24 -56.75 9.82 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.23 -1.159 . . . . 0.0 109.514 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 21.6 mtm180 -57.11 -34.07 67.96 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.262 -0.898 . . . . 0.0 109.417 -179.895 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 144.53 -152.18 24.15 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.491 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 51.0 Cg_endo -70.46 136.98 32.43 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.835 2.357 . . . . 0.0 112.052 -179.869 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.66 ' C ' HG13 ' A' ' 26' ' ' VAL . 89.9 mt-30 -132.85 165.3 24.93 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.443 -0.786 . . . . 0.0 109.263 179.796 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.549 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -90.13 132.19 35.58 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.16 -0.963 . . . . 0.0 109.789 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.545 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -113.7 147.76 37.61 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.528 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.484 ' C ' ' O ' ' A' ' 61' ' ' ALA . 23.9 t-20 41.27 74.41 0.11 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.141 -0.975 . . . . 0.0 108.778 -179.497 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.719 HG11 HG12 ' A' ' 33' ' ' ILE . 1.4 t -84.38 127.94 39.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.387 -0.821 . . . . 0.0 110.159 -179.068 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.41 ' HB ' ' HB2' ' A' ' 48' ' ' SER . 27.7 m -119.68 126.61 51.53 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 179.333 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.536 ' HA ' HG12 ' A' ' 47' ' ' VAL . 57.7 mttt -73.72 108.78 6.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.162 -0.961 . . . . 0.0 109.511 -179.614 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 45.9 mm-40 -99.08 175.8 5.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.338 -0.852 . . . . 0.0 109.689 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.479 179.922 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.842 ' N ' HD12 ' A' ' 2' ' ' LEU . 5.1 mp . . . . . 0 N--CA 1.488 1.468 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.731 ' O ' HG13 ' A' ' 20' ' ' VAL . 2.1 tt0 -124.74 140.45 52.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.276 -0.89 . . . . 0.0 108.993 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -144.63 149.87 21.98 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.445 ' O ' HG23 ' A' ' 18' ' ' ILE . 19.4 mttm -99.52 139.53 35.05 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.38 -1.071 . . . . 0.0 108.539 179.295 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.738 HG23 ' O ' ' A' ' 45' ' ' GLN . 20.7 t -69.91 115.22 8.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.039 -1.038 . . . . 0.0 109.776 -179.464 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.437 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 40.7 tttt -78.76 -42.13 28.81 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.726 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.63 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -160.14 154.93 24.28 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.43 -0.794 . . . . 0.0 108.888 179.976 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.46 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 11.3 p90 -154.25 141.74 19.76 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.101 -0.999 . . . . 0.0 109.193 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.48 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 57.9 t-20 . . . . . 0 N--CA 1.489 1.507 0 O-C-N 121.151 -0.968 . . . . 0.0 109.832 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.544 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 4.0 p90 . . . . . 0 N--CA 1.491 1.61 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.63 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -138.63 175.21 21.61 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 119.625 -1.274 . . . . 0.0 109.97 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.483 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 37.6 m-85 -116.7 132.49 56.67 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.404 -1.057 . . . . 0.0 109.014 179.696 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 1.066 ' CD1' HG21 ' A' ' 28' ' ' VAL . 37.1 mt -116.89 148.7 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.141 -0.974 . . . . 0.0 109.528 -179.827 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 30.6 tp10 -110.29 121.31 44.98 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.332 -0.855 . . . . 0.0 109.448 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.731 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.4 t -96.22 120.02 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.163 -0.961 . . . . 0.0 109.471 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 47.1 mp0 -71.75 109.01 5.36 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.273 -0.892 . . . . 0.0 109.36 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.428 ' C ' ' HG3' ' A' ' 23' ' ' GLN . . . 125.28 -20.46 6.61 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.783 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.428 ' HG3' ' C ' ' A' ' 22' ' ' GLY . 37.3 mt-30 -138.83 169.62 17.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.317 -1.107 . . . . 0.0 109.695 -179.811 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -53.54 -177.4 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.32 -0.862 . . . . 0.0 109.665 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.516 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 11.0 p30 -75.97 143.54 41.49 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.287 -0.883 . . . . 0.0 109.661 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.631 HG12 ' HB2' ' A' ' 60' ' ' ALA . 79.7 t -116.92 120.87 66.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.23 -0.919 . . . . 0.0 109.527 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.553 ' CG ' ' N ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER -80.26 161.11 25.3 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.373 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 1.066 HG21 ' CD1' ' A' ' 18' ' ' ILE . 15.0 t -135.7 125.02 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.428 -0.795 . . . . 0.0 109.4 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.688 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 15.1 t-80 -96.2 154.35 17.3 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.231 -0.918 . . . . 0.0 109.14 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.688 ' CD2' ' CE1' ' A' ' 29' ' ' HIS . 0.7 OUTLIER -45.8 -53.41 9.66 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.105 -0.997 . . . . 0.0 109.245 -179.616 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.685 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 86.8 p -55.66 -27.24 48.84 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.171 -0.956 . . . . 0.0 109.982 -179.618 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.432 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -64.41 -35.94 82.52 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.995 -1.066 . . . . 0.0 109.159 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.639 HG12 HG11 ' A' ' 63' ' ' VAL . 5.1 mt . . . . . 0 N--CA 1.488 1.47 0 O-C-N 121.228 -0.92 . . . . 0.0 109.349 179.777 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.557 HD21 HG11 ' A' ' 47' ' ' VAL . 1.1 mt . . . . . 0 N--CA 1.488 1.474 0 CA-C-O 121.243 0.544 . . . . 0.0 109.575 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.499 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 46.3 tp10 -123.18 147.13 47.18 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.203 -0.936 . . . . 0.0 109.56 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.437 ' HG3' ' O ' ' A' ' 7' ' ' LYS . 76.0 tt0 -73.35 126.01 29.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.196 -0.94 . . . . 0.0 109.739 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.75 -5.45 79.62 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.803 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.738 ' O ' HG23 ' A' ' 6' ' ' VAL . 6.2 tp-100 -81.22 124.4 29.26 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.196 -1.179 . . . . 0.0 109.601 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -75.09 144.61 42.84 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.263 -0.898 . . . . 0.0 109.154 179.63 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.832 HG12 ' HA ' ' A' ' 65' ' ' LYS . 21.7 m -148.36 168.11 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.177 -0.952 . . . . 0.0 109.827 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.545 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 4.1 p -112.48 152.76 28.37 Favored 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.325 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.579 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 14.4 p90 175.83 164.42 0.36 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.979 -1.076 . . . . 0.0 110.141 -179.781 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.425 ' HA ' HD13 ' A' ' 2' ' ' LEU . 91.9 mt-10 -100.36 164.6 11.86 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 179.016 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.424 ' O ' HG22 ' A' ' 51' ' ' ILE . 0.4 OUTLIER -101.77 124.36 55.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 120.851 -1.156 . . . . 0.0 109.422 -179.903 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.559 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.1 m -111.1 123.57 67.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.401 -0.812 . . . . 0.0 109.011 179.764 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.417 ' HA ' ' HA ' ' A' ' 58' ' ' PRO . 10.2 mt-10 -94.97 91.12 6.23 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.177 -0.952 . . . . 0.0 109.948 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.08 -174.88 42.37 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 179.702 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 -54.37 -62.39 1.69 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.171 -1.194 . . . . 0.0 109.546 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 18.8 mtm180 -46.66 -41.23 14.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.157 -0.964 . . . . 0.0 109.194 179.86 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 152.99 -161.53 29.65 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.552 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 53.6 Cg_endo -72.09 144.12 41.65 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.712 2.275 . . . . 0.0 111.752 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.559 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 78.8 mt-30 -141.82 172.36 12.79 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.289 -0.882 . . . . 0.0 109.048 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.631 ' HB2' HG12 ' A' ' 26' ' ' VAL . . . -94.23 142.55 27.28 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.139 -0.976 . . . . 0.0 110.236 -179.234 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.512 ' O ' ' C ' ' A' ' 62' ' ' ASN . . . -124.43 152.85 42.77 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.434 -0.791 . . . . 0.0 108.903 179.578 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.512 ' C ' ' O ' ' A' ' 61' ' ' ALA . 44.8 t30 38.62 73.91 0.1 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.07 -1.019 . . . . 0.0 109.186 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.639 HG11 HG12 ' A' ' 33' ' ' ILE . 1.5 t -86.97 129.22 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.245 -0.909 . . . . 0.0 109.96 -179.313 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.432 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 65.3 m -115.44 119.53 36.54 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.35 -0.843 . . . . 0.0 109.116 179.645 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.832 ' HA ' HG12 ' A' ' 47' ' ' VAL . 35.9 mttt -69.73 108.17 3.79 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 109.286 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.45 ' HG3' ' HA ' ' A' ' 47' ' ' VAL . 97.2 mt-10 -87.4 164.09 16.4 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.272 -0.892 . . . . 0.0 109.725 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.562 0 CA-C-O 117.989 -1.005 . . . . 0.0 109.58 -179.955 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 45.5 mt . . . . . 0 N--CA 1.489 1.498 0 CA-C-O 121.291 0.567 . . . . 0.0 109.541 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.66 ' O ' HG13 ' A' ' 20' ' ' VAL . 89.1 mt-10 -136.13 136.54 40.17 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.241 -0.912 . . . . 0.0 109.26 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -133.78 159.42 23.7 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.626 ' O ' HG23 ' A' ' 18' ' ' ILE . 77.9 mttt -103.34 140.84 36.9 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.409 -1.053 . . . . 0.0 108.824 179.41 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.761 HG23 ' O ' ' A' ' 45' ' ' GLN . 18.9 t -73.73 114.2 12.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.116 -0.99 . . . . 0.0 110.241 -179.111 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.4 tttt -78.44 -41.45 32.79 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.438 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.671 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.78 153.89 25.32 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.553 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.629 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 6.2 p90 -156.05 141.65 17.8 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.986 -1.071 . . . . 0.0 109.764 -179.61 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.435 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 50.4 t-20 . . . . . 0 N--CA 1.488 1.456 0 O-C-N 121.276 -0.89 . . . . 0.0 108.992 179.528 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.603 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 50.2 p90 . . . . . 0 N--CA 1.491 1.621 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.671 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -149.53 174.96 28.92 Favored Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.53 -1.319 . . . . 0.0 110.206 -179.477 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.433 ' CE1' ' HB2' ' A' ' 27' ' ' PHE . 49.6 m-85 -111.9 133.75 53.9 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.446 -1.032 . . . . 0.0 108.834 179.644 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 1.137 HD12 ' CG2' ' A' ' 28' ' ' VAL . 19.7 mt -120.4 149.43 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.207 -0.933 . . . . 0.0 109.489 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 20.7 tp10 -113.28 122.44 47.44 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.351 -0.843 . . . . 0.0 109.332 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.66 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.8 t -91.75 121.9 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.253 -0.904 . . . . 0.0 109.525 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -69.36 108.5 3.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.333 -0.854 . . . . 0.0 109.325 179.807 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.07 -19.72 8.7 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.403 ' OE1' HG11 ' A' ' 20' ' ' VAL . 49.0 mt-30 -133.47 166.18 23.14 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.289 -1.124 . . . . 0.0 109.487 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 59.5 m-20 -54.79 -175.74 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.235 -0.916 . . . . 0.0 109.45 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.493 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 11.2 p30 -75.84 143.78 41.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.291 -0.881 . . . . 0.0 109.577 -179.832 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.573 HG21 HG21 ' A' ' 20' ' ' VAL . 79.3 t -118.85 121.42 66.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.184 -0.947 . . . . 0.0 109.374 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.504 ' O ' ' N ' ' A' ' 60' ' ' ALA . 0.1 OUTLIER -79.03 158.26 27.93 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.266 -0.896 . . . . 0.0 109.392 -179.984 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 1.137 ' CG2' HD12 ' A' ' 18' ' ' ILE . 17.3 t -132.85 132.38 59.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.428 -0.795 . . . . 0.0 109.165 -179.76 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.678 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 14.6 t-80 -104.61 154.89 19.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.256 -0.903 . . . . 0.0 109.277 -179.846 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.693 ' CD1' ' N ' ' A' ' 31' ' ' SER . 0.6 OUTLIER -46.3 -53.01 11.56 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.215 -0.928 . . . . 0.0 109.361 -179.696 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.693 ' N ' ' CD1' ' A' ' 30' ' ' PHE . 91.4 p -60.16 -21.19 61.35 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.095 -1.003 . . . . 0.0 110.025 -179.631 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.473 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -63.19 -23.6 67.5 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.042 -1.036 . . . . 0.0 109.468 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.782 ' CD1' HD11 ' A' ' 41' ' ' LEU . 3.5 mp . . . . . 0 N--CA 1.489 1.477 0 O-C-N 121.206 -0.934 . . . . 0.0 109.605 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 1.026 HD23 HG11 ' A' ' 47' ' ' VAL . 3.0 mp . . . . . 0 N--CA 1.489 1.486 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.523 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.1 tt0 -121.61 150.63 41.42 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.26 -0.9 . . . . 0.0 109.338 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 61.5 tt0 -67.44 124.23 22.62 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.23 -0.919 . . . . 0.0 109.538 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 90.96 -3.58 80.93 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 179.795 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.761 ' O ' HG23 ' A' ' 6' ' ' VAL . 61.4 tp60 -81.71 131.6 35.27 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.18 -1.189 . . . . 0.0 109.603 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -76.54 140.16 41.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.187 -0.946 . . . . 0.0 109.204 179.741 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 1.026 HG11 HD23 ' A' ' 41' ' ' LEU . 33.8 m -141.26 159.96 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.151 -0.968 . . . . 0.0 109.532 -179.84 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.499 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 43.4 m -112.86 155.62 24.36 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.385 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.585 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 3.7 p90 171.69 166.48 0.09 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.037 -1.039 . . . . 0.0 110.144 -179.692 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -97.82 157.53 16.02 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.729 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.4 mt -98.12 128.1 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.985 -1.072 . . . . 0.0 110.006 -179.473 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.765 HG23 ' HB2' ' A' ' 59' ' ' GLN . 0.3 OUTLIER -110.07 119.68 59.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.366 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -89.01 91.44 8.83 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.203 -0.936 . . . . 0.0 109.872 -179.446 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -97.23 -176.2 34.58 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 14.3 t-20 -53.57 -61.59 2.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.178 -1.189 . . . . 0.0 109.663 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 61.3 mtp180 -47.9 -38.88 17.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.232 -0.917 . . . . 0.0 109.049 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.86 -157.3 27.3 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.447 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 51.3 Cg_endo -71.06 140.78 38.54 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.719 2.279 . . . . 0.0 111.692 179.806 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.765 ' HB2' HG23 ' A' ' 52' ' ' VAL . 91.8 mt-30 -135.51 167.78 20.44 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.21 -0.931 . . . . 0.0 109.232 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.651 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -96.42 137.58 35.28 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.18 -0.95 . . . . 0.0 110.158 -179.354 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.585 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -125.18 156.67 38.06 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.466 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.524 ' C ' ' O ' ' A' ' 61' ' ' ALA . 80.7 m-20 38.68 74.56 0.09 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.075 -1.016 . . . . 0.0 108.927 -179.765 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.971 HG11 HD21 ' A' ' 41' ' ' LEU . 2.4 t -89.32 129.62 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.234 -0.916 . . . . 0.0 110.307 -178.898 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 60.8 m -118.54 124.66 48.07 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.513 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 53.2 mttt -67.18 107.37 2.31 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.245 -0.91 . . . . 0.0 109.281 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.412 ' HG3' ' OG ' ' A' ' 48' ' ' SER . 59.4 mm-40 -97.09 170.58 9.03 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.157 -0.964 . . . . 0.0 109.622 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.406 179.989 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.469 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 71.6 mt . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 121.256 0.55 . . . . 0.0 109.539 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.615 ' O ' HG13 ' A' ' 20' ' ' VAL . 1.4 tt0 -130.75 140.89 50.35 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.34 -0.85 . . . . 0.0 109.329 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.49 155.06 25.05 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.584 ' O ' HG23 ' A' ' 18' ' ' ILE . 84.5 mttt -104.14 139.51 39.09 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.317 -1.108 . . . . 0.0 108.764 179.553 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.86 HG23 ' O ' ' A' ' 45' ' ' GLN . 16.0 t -72.22 113.16 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.097 -1.002 . . . . 0.0 110.085 -179.223 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.3 tttt -78.85 -40.87 31.49 Favored 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 179.546 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.607 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.96 154.41 25.82 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.812 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.601 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 8.2 p90 -155.59 141.27 17.95 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.026 -1.046 . . . . 0.0 109.315 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.46 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 63.2 t-20 . . . . . 0 N--CA 1.49 1.545 0 O-C-N 121.166 -0.959 . . . . 0.0 109.777 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.563 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 5.6 p90 . . . . . 0 N--CA 1.492 1.673 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.607 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -134.71 174.54 21.0 Favored Glycine 0 N--CA 1.491 2.349 0 C-N-CA 119.708 -1.234 . . . . 0.0 110.087 -179.438 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.49 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 26.1 m-85 -115.75 137.94 51.6 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.463 -1.022 . . . . 0.0 109.215 179.755 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 1.129 HD12 ' CG2' ' A' ' 28' ' ' VAL . 12.5 mt -123.69 154.06 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.161 -0.962 . . . . 0.0 109.491 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -117.98 116.06 26.15 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.313 -0.867 . . . . 0.0 109.503 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.622 HG21 HG21 ' A' ' 26' ' ' VAL . 2.4 t -85.33 118.4 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.276 -0.89 . . . . 0.0 109.353 179.789 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 85.4 mt-10 -68.43 111.08 4.45 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.196 -0.94 . . . . 0.0 109.243 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.451 ' C ' ' HG3' ' A' ' 23' ' ' GLN . . . 120.93 -15.66 9.51 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.495 ' OE1' HD12 ' A' ' 51' ' ' ILE . 49.5 mt-30 -140.68 169.75 17.05 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.222 -1.164 . . . . 0.0 109.622 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 60.5 m-20 -54.75 -179.21 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.254 -0.904 . . . . 0.0 109.681 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.461 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 18.4 p30 -75.41 144.0 42.44 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.307 -0.871 . . . . 0.0 109.706 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.622 HG21 HG21 ' A' ' 20' ' ' VAL . 86.4 t -118.38 118.8 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.224 -0.923 . . . . 0.0 109.263 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.586 ' CD1' ' N ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER -77.31 159.0 29.88 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.152 -0.967 . . . . 0.0 109.154 -179.935 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 1.129 ' CG2' HD12 ' A' ' 18' ' ' ILE . 13.6 t -134.08 131.43 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.356 -0.84 . . . . 0.0 109.393 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.621 ' O ' HD12 ' A' ' 33' ' ' ILE . 67.0 t60 -106.97 154.64 20.79 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.313 -0.867 . . . . 0.0 109.027 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.676 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -46.47 -53.36 11.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.023 -1.048 . . . . 0.0 109.205 -179.631 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.676 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 54.6 p -53.91 -30.75 47.57 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.155 -0.966 . . . . 0.0 110.347 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.485 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -61.83 -21.24 64.47 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.029 -1.045 . . . . 0.0 109.465 -179.856 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.932 ' CD1' HD11 ' A' ' 41' ' ' LEU . 3.2 mp . . . . . 0 N--CA 1.489 1.479 0 O-C-N 121.204 -0.935 . . . . 0.0 109.506 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.932 HD11 ' CD1' ' A' ' 33' ' ' ILE . 5.3 mp . . . . . 0 N--CA 1.488 1.441 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.511 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.7 tt0 -117.31 149.78 39.9 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.181 -0.949 . . . . 0.0 109.055 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 62.8 tt0 -70.52 123.97 23.08 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.253 -0.904 . . . . 0.0 109.584 -179.778 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 92.89 -3.41 73.79 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 179.795 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.86 ' O ' HG23 ' A' ' 6' ' ' VAL . 60.7 tt0 -82.74 134.95 35.12 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.119 -1.224 . . . . 0.0 109.906 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -81.1 141.56 34.17 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.399 -0.813 . . . . 0.0 109.067 179.501 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.785 HG21 HD13 ' A' ' 18' ' ' ILE . 28.1 m -141.51 159.57 21.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.131 -0.981 . . . . 0.0 109.922 -179.529 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.506 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 23.0 t -110.89 154.06 24.58 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.424 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.56 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 5.6 p90 172.26 166.14 0.11 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.01 -1.056 . . . . 0.0 110.077 -179.746 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.431 ' HB2' ' HB3' ' A' ' 61' ' ' ALA . 93.6 mt-10 -98.98 160.55 14.18 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.727 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.495 HD12 ' OE1' ' A' ' 23' ' ' GLN . 0.8 OUTLIER -97.94 125.41 51.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 120.933 -1.105 . . . . 0.0 109.781 -179.436 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.595 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 0.1 OUTLIER -107.85 118.95 56.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.473 -0.767 . . . . 0.0 109.076 179.852 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -86.76 84.78 7.3 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.314 -0.866 . . . . 0.0 109.704 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.43 -177.31 41.61 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 14.7 t-20 -54.2 -61.98 1.96 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.219 -1.165 . . . . 0.0 109.563 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 39.7 mtp180 -48.32 -39.36 21.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.285 -0.884 . . . . 0.0 109.135 179.794 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 148.81 -158.86 27.82 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.595 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 49.8 Cg_endo -70.23 140.44 40.92 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.686 2.257 . . . . 0.0 111.716 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.571 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 8.5 mt-30 -133.88 166.25 23.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.318 -0.864 . . . . 0.0 109.37 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.648 ' HB2' HG22 ' A' ' 28' ' ' VAL . . . -87.58 128.4 35.26 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.308 -0.87 . . . . 0.0 109.871 -179.573 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.56 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -112.74 146.45 38.74 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.35 -0.844 . . . . 0.0 108.812 179.457 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.472 ' C ' ' O ' ' A' ' 61' ' ' ALA . 62.5 t30 42.82 71.9 0.2 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.046 -1.034 . . . . 0.0 108.776 -179.615 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.688 HG12 HG23 ' A' ' 33' ' ' ILE . 2.0 t -83.82 127.1 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.365 -0.834 . . . . 0.0 110.162 -178.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 93.9 m -119.79 127.04 52.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.449 -0.782 . . . . 0.0 109.016 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.907 ' NZ ' HG21 ' A' ' 33' ' ' ILE . 55.1 mttp -77.46 112.78 14.57 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.172 -0.955 . . . . 0.0 109.726 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -89.82 165.11 14.34 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.902 . . . . 0.0 109.428 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 118.009 -0.996 . . . . 0.0 109.41 -179.999 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.736 ' N ' HD12 ' A' ' 2' ' ' LEU . 6.2 mp . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.495 ' HG2' ' O ' ' A' ' 47' ' ' VAL . 3.0 tt0 -133.39 132.53 41.3 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.306 -0.871 . . . . 0.0 109.217 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.515 ' C ' ' CG2' ' A' ' 18' ' ' ILE . . . -135.63 167.6 24.19 Favored Glycine 0 N--CA 1.491 2.342 0 C-N-CA 119.632 -1.27 . . . . 0.0 110.229 -179.602 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.682 ' C ' HG23 ' A' ' 18' ' ' ILE . 44.0 mmtm -110.39 135.63 50.81 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.544 -0.974 . . . . 0.0 108.693 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.709 HG23 ' O ' ' A' ' 45' ' ' GLN . 17.6 t -68.5 116.14 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.19 -0.944 . . . . 0.0 109.973 -179.556 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.432 ' N ' ' O ' ' A' ' 17' ' ' PHE . 11.5 tttm -80.38 -33.69 37.0 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.303 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.671 ' CD2' ' N ' ' A' ' 9' ' ' PHE . 0.4 OUTLIER -162.57 166.41 24.74 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 179.671 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.671 ' N ' ' CD2' ' A' ' 8' ' ' TRP . 9.9 p90 -164.47 145.93 8.32 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.94 -1.1 . . . . 0.0 110.601 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.653 ' HB3' ' CE1' ' A' ' 15' ' ' PHE . 38.0 t-20 . . . . . 0 N--CA 1.493 1.679 0 O-C-N 121.391 -0.818 . . . . 0.0 109.615 179.741 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.653 ' CE1' ' HB3' ' A' ' 10' ' ' ASN . 1.4 p90 . . . . . 0 N--CA 1.488 1.458 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.607 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -176.75 151.18 10.99 Favored Glycine 0 N--CA 1.487 2.076 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.026 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.474 ' HB3' ' OD1' ' A' ' 25' ' ' ASP . 89.4 m-85 -79.08 143.18 35.8 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.369 -1.077 . . . . 0.0 108.803 179.596 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 1.143 ' CD1' HG21 ' A' ' 28' ' ' VAL . 73.3 mt -121.84 149.17 25.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 -179.786 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.403 ' N ' ' O ' ' A' ' 5' ' ' LYS . 44.5 tt0 -103.7 118.49 36.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.199 -0.938 . . . . 0.0 109.529 -179.852 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.599 HG21 HG21 ' A' ' 26' ' ' VAL . 3.4 t -94.32 123.51 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.255 -0.903 . . . . 0.0 109.417 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -59.08 99.93 0.06 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.303 -0.873 . . . . 0.0 109.674 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.25 -29.04 3.54 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 179.623 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 15.0 mt-30 -127.05 169.86 12.93 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.133 -1.216 . . . . 0.0 109.739 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.533 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -60.24 -163.41 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.237 -0.914 . . . . 0.0 109.553 179.753 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.474 ' OD1' ' HB3' ' A' ' 17' ' ' PHE . 2.9 t70 -77.53 143.64 38.25 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.285 -0.884 . . . . 0.0 109.713 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.599 HG21 HG21 ' A' ' 20' ' ' VAL . 88.4 t -115.95 127.14 73.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.371 -0.831 . . . . 0.0 109.367 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.1 OUTLIER -76.47 148.23 37.35 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.118 -0.988 . . . . 0.0 109.636 -179.791 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 1.143 HG21 ' CD1' ' A' ' 18' ' ' ILE . 16.5 t -131.14 131.44 63.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 -179.79 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.672 ' CE1' ' CE2' ' A' ' 30' ' ' PHE . 12.1 t-80 -102.68 148.33 25.72 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.083 -1.011 . . . . 0.0 109.924 -179.529 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.688 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.1 p90 -43.57 -51.83 6.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.307 -0.871 . . . . 0.0 109.519 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.672 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 46.5 p -61.27 -13.58 19.9 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.168 -0.957 . . . . 0.0 109.801 -179.701 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.517 ' N ' ' O ' ' A' ' 29' ' ' HIS . . . -66.68 -25.23 66.45 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.265 -0.897 . . . . 0.0 109.642 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.034 HD11 HD11 ' A' ' 41' ' ' LEU . 2.2 mp . . . . . 0 N--CA 1.491 1.607 0 O-C-N 121.257 -0.902 . . . . 0.0 109.725 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 1.034 HD11 HD11 ' A' ' 33' ' ' ILE . 1.1 mt . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.279 0.562 . . . . 0.0 109.614 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.478 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 80.2 tt0 -117.42 150.76 38.35 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.341 -0.85 . . . . 0.0 109.249 179.84 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 68.4 tt0 -68.33 128.07 35.25 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.914 . . . . 0.0 109.571 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 86.77 -2.94 87.33 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 179.733 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.709 ' O ' HG23 ' A' ' 6' ' ' VAL . 51.8 tt0 -80.44 134.62 36.01 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.203 -1.175 . . . . 0.0 109.715 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -87.55 142.52 27.79 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.299 -0.876 . . . . 0.0 109.169 179.689 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.963 HG12 ' HA ' ' A' ' 65' ' ' LYS . 32.9 m -147.06 167.06 5.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.232 -0.918 . . . . 0.0 109.864 -179.734 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.592 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 24.0 t -109.15 154.77 21.87 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 178.838 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.587 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 8.1 p90 172.15 168.59 0.11 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.003 -1.061 . . . . 0.0 110.034 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.491 ' HA ' HD13 ' A' ' 2' ' ' LEU . 90.2 mt-10 -105.99 169.24 8.61 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 179.173 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.449 HD11 HG21 ' A' ' 26' ' ' VAL . 4.2 mt -111.02 136.87 45.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.022 -1.049 . . . . 0.0 109.546 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.487 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 33.7 m -123.04 134.36 66.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.465 -0.772 . . . . 0.0 108.942 179.727 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -90.49 79.64 6.18 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.139 -0.975 . . . . 0.0 109.613 -179.778 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -81.3 -179.5 53.04 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 -52.45 -57.15 10.79 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.177 -1.19 . . . . 0.0 109.559 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 82.1 mtm180 -54.19 -38.17 65.32 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.163 -0.96 . . . . 0.0 109.599 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.08 -153.34 25.29 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.487 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 50.9 Cg_endo -70.76 133.76 24.41 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.867 2.378 . . . . 0.0 112.146 -179.825 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 19.2 mt-30 -133.53 164.66 26.65 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.356 -0.84 . . . . 0.0 109.032 179.759 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.705 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -92.72 136.93 32.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.119 -0.988 . . . . 0.0 110.104 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.587 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -121.14 153.06 38.01 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 179.376 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.499 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 85.0 m-20 43.86 79.41 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.962 -1.086 . . . . 0.0 108.702 -179.557 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.873 HG21 ' CG1' ' A' ' 28' ' ' VAL . 2.1 t -94.63 124.34 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.161 -0.962 . . . . 0.0 110.195 -179.059 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.497 ' HB ' ' HB3' ' A' ' 48' ' ' SER . 97.1 m -114.16 114.96 26.74 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.49 -0.756 . . . . 0.0 109.055 179.576 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.963 ' HA ' HG12 ' A' ' 47' ' ' VAL . 56.5 mttt -65.02 118.4 9.07 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.335 -0.853 . . . . 0.0 109.426 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 67.1 mm-40 -102.38 162.56 12.82 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.378 -0.826 . . . . 0.0 109.732 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.462 -179.957 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.519 HD12 HD13 ' A' ' 51' ' ' ILE . 26.5 mt . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.507 ' O ' HG13 ' A' ' 20' ' ' VAL . 74.1 mt-10 -133.82 134.69 43.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.268 -0.895 . . . . 0.0 109.441 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -139.7 157.09 25.1 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.705 -1.358 . . . . 0.0 109.705 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.414 ' N ' HG23 ' A' ' 18' ' ' ILE . 69.6 mttt -111.21 133.69 53.37 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.435 -1.038 . . . . 0.0 108.438 179.189 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.923 HG23 ' O ' ' A' ' 45' ' ' GLN . 16.2 t -64.05 115.18 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.113 -0.992 . . . . 0.0 110.118 -179.328 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.474 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 14.9 tptp -78.12 -42.04 33.16 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 179.508 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.612 ' CE3' ' O ' ' A' ' 8' ' ' TRP . 0.0 OUTLIER -162.29 156.07 21.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.499 -0.751 . . . . 0.0 109.093 179.99 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.641 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 10.6 p90 -154.16 140.53 18.68 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.13 -0.981 . . . . 0.0 109.041 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 54.5 t-20 . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.13 -0.981 . . . . 0.0 109.499 -179.989 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.621 ' N ' ' CD1' ' A' ' 15' ' ' PHE . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.627 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 . . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.567 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -155.41 176.85 32.88 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 109.531 -1.427 . . . . 0.0 109.531 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.527 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 43.6 m-85 -113.79 133.3 55.47 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.248 -1.148 . . . . 0.0 109.187 179.789 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 1.096 ' CD1' HG21 ' A' ' 28' ' ' VAL . 61.7 mt -116.18 145.43 21.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.388 -0.82 . . . . 0.0 109.722 -179.669 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 28.7 tt0 -108.09 116.5 32.07 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.415 -0.803 . . . . 0.0 109.495 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.621 HG21 HG21 ' A' ' 26' ' ' VAL . 2.8 t -87.96 125.93 41.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.295 -0.878 . . . . 0.0 109.422 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -69.85 101.62 1.77 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.293 -0.879 . . . . 0.0 109.221 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.22 -22.97 6.97 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 -179.733 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.429 ' O ' ' O ' ' A' ' 24' ' ' ASP . 58.2 mt-30 -123.28 158.81 30.12 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.364 -1.08 . . . . 0.0 109.322 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.429 ' O ' ' O ' ' A' ' 23' ' ' GLN . 44.8 m-20 -54.81 -171.24 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.19 -0.944 . . . . 0.0 109.452 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.565 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 88.6 m-20 -73.73 133.25 43.3 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.196 -0.94 . . . . 0.0 109.533 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.664 HG21 HD11 ' A' ' 51' ' ' ILE . 96.0 t -111.06 125.24 68.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.256 -0.903 . . . . 0.0 109.234 -179.882 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.573 ' CE1' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER -79.28 159.64 27.16 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.052 -1.03 . . . . 0.0 109.747 -179.716 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 1.096 HG21 ' CD1' ' A' ' 18' ' ' ILE . 57.8 t -133.95 137.95 51.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.432 -0.792 . . . . 0.0 109.419 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.604 ' O ' HD12 ' A' ' 33' ' ' ILE . 73.3 t60 -111.23 150.59 29.37 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.291 -0.88 . . . . 0.0 108.899 179.593 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.713 ' CG ' ' N ' ' A' ' 31' ' ' SER . 1.3 p90 -48.09 -54.21 13.94 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.046 -1.034 . . . . 0.0 109.298 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.713 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 19.2 t -55.96 -30.55 61.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.025 -1.047 . . . . 0.0 109.899 -179.441 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.58 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -63.66 -17.56 63.06 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.021 -1.049 . . . . 0.0 108.544 179.505 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.026 HG23 HG12 ' A' ' 63' ' ' VAL . 0.6 OUTLIER . . . . . 0 C--N 1.302 -1.492 0 O-C-N 121.607 -0.683 . . . . 0.0 109.434 -179.86 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.681 HD12 ' HZ1' ' A' ' 65' ' ' LYS . 5.2 mp . . . . . 0 N--CA 1.489 1.497 0 CA-C-O 121.345 0.593 . . . . 0.0 109.745 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.444 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.2 tt0 -96.98 132.28 42.95 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.237 -0.914 . . . . 0.0 109.528 -179.852 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.474 ' OE2' ' O ' ' A' ' 7' ' ' LYS . 75.1 tt0 -59.51 129.01 39.88 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.318 -0.864 . . . . 0.0 109.343 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 93.74 -8.06 74.0 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.923 ' O ' HG23 ' A' ' 6' ' ' VAL . 70.6 tp60 -78.41 126.33 30.62 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.162 -1.199 . . . . 0.0 109.596 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -82.88 143.26 30.87 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.251 -0.905 . . . . 0.0 109.344 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.981 HG12 ' HA ' ' A' ' 65' ' ' LYS . 34.4 m -144.41 167.04 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.908 . . . . 0.0 109.597 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.485 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 22.3 t -109.72 154.67 22.56 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.376 -0.827 . . . . 0.0 108.839 179.502 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.645 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 4.2 p90 172.79 166.03 0.13 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.959 -1.088 . . . . 0.0 110.312 -179.759 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.441 ' OE1' ' HA ' ' A' ' 50' ' ' GLU . 67.5 mm-40 -96.09 159.68 14.84 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 178.581 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.664 HD11 HG21 ' A' ' 26' ' ' VAL . 1.1 mp -100.52 127.5 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.939 -1.101 . . . . 0.0 110.044 -179.431 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.6 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 27.5 m -115.86 124.18 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 178.991 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 22.0 mt-10 -95.74 97.16 9.48 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.127 -0.983 . . . . 0.0 109.703 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.19 -179.35 42.77 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.436 ' CG ' ' N ' ' A' ' 56' ' ' ARG . 16.0 p-10 -53.97 -50.31 66.8 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.159 -1.201 . . . . 0.0 109.514 -179.87 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.436 ' N ' ' CG ' ' A' ' 55' ' ' ASN . 33.3 mtp85 -61.31 -42.19 98.25 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.052 -1.03 . . . . 0.0 109.793 -179.726 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 158.79 -164.64 33.75 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 110.016 -1.233 . . . . 0.0 110.016 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.565 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 44.1 Cg_endo -68.55 139.78 45.73 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 123.198 2.598 . . . . 0.0 112.637 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.6 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 68.5 mt-30 -135.58 165.41 25.6 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.301 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.611 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -99.17 141.96 31.26 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.976 -1.077 . . . . 0.0 110.467 -179.031 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.526 ' O ' ' C ' ' A' ' 62' ' ' ASN . . . -124.22 155.7 38.1 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 179.128 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.526 ' C ' ' O ' ' A' ' 61' ' ' ALA . 24.3 t-20 37.58 66.72 0.43 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.172 -0.955 . . . . 0.0 109.003 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 1.026 HG12 HG23 ' A' ' 33' ' ' ILE . 2.0 t -79.01 130.99 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.337 -0.852 . . . . 0.0 110.073 -179.048 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.521 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 25.2 m -117.15 123.4 46.63 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.328 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.981 ' HA ' HG12 ' A' ' 47' ' ' VAL . 47.4 mttm -74.97 115.49 14.64 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.203 -0.935 . . . . 0.0 109.939 -179.56 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.46 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 47.2 mt-10 -99.79 169.17 9.43 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.278 -0.889 . . . . 0.0 109.413 179.837 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 118.062 -0.971 . . . . 0.0 109.547 179.827 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.485 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 61.9 mt . . . . . 0 N--CA 1.489 1.508 0 CA-C-O 121.361 0.6 . . . . 0.0 109.672 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.585 ' O ' HG13 ' A' ' 20' ' ' VAL . 2.2 tt0 -123.45 140.31 53.13 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.323 -0.861 . . . . 0.0 108.901 179.639 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -144.39 148.53 20.34 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.544 ' O ' HG23 ' A' ' 18' ' ' ILE . 50.0 mttp -101.77 142.63 32.8 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.353 -1.086 . . . . 0.0 108.771 179.288 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.853 HG23 ' O ' ' A' ' 45' ' ' GLN . 21.5 t -73.8 113.47 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.112 -0.993 . . . . 0.0 109.642 -179.64 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.425 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 27.2 tttm -78.65 -41.73 30.61 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.777 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.682 ' CZ3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -160.39 156.51 26.25 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.454 -0.779 . . . . 0.0 108.986 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.595 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 12.5 p90 -155.33 142.95 19.71 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.129 -0.982 . . . . 0.0 109.299 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.418 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.7 t-20 . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.063 -1.023 . . . . 0.0 109.518 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.646 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.338 0.59 . . . . 0.0 109.654 . . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.449 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -144.07 170.28 25.97 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.682 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 30.3 m-85 -111.23 128.67 56.0 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.393 -1.063 . . . . 0.0 108.968 179.798 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.839 ' CD1' HG21 ' A' ' 47' ' ' VAL . 67.8 mt -111.37 145.45 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.184 -0.947 . . . . 0.0 109.699 -179.801 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 5.3 tt0 -108.16 110.83 22.57 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.399 -0.813 . . . . 0.0 109.087 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.66 HG21 HG21 ' A' ' 26' ' ' VAL . 2.7 t -89.62 118.09 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.317 -0.864 . . . . 0.0 109.488 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -68.01 109.61 3.55 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.278 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.78 -21.78 6.58 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.567 ' OE1' HD12 ' A' ' 51' ' ' ILE . 50.2 mt-30 -135.47 168.8 18.54 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.197 -1.178 . . . . 0.0 109.596 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -55.19 -173.7 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.285 -0.884 . . . . 0.0 109.443 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -77.83 141.6 39.07 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.166 -0.959 . . . . 0.0 109.997 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.66 HG21 HG21 ' A' ' 20' ' ' VAL . 63.5 t -111.0 114.04 45.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.231 -0.918 . . . . 0.0 109.355 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.521 ' HE1' ' HB2' ' A' ' 15' ' ' PHE . 0.2 OUTLIER -84.48 106.85 16.38 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.254 -0.904 . . . . 0.0 109.276 179.812 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.598 ' CG2' HD11 ' A' ' 33' ' ' ILE . 0.2 OUTLIER -86.41 143.74 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 O-C-N 121.128 -0.982 . . . . 0.0 109.712 -179.308 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.646 ' HA ' ' HB3' ' A' ' 15' ' ' PHE . 58.6 t60 -113.86 157.99 21.62 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.653 -0.655 . . . . 0.0 109.272 -179.606 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.699 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -46.37 -54.89 8.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.881 -1.137 . . . . 0.0 108.761 -179.787 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.699 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 94.1 p -50.82 -37.56 43.56 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.212 -0.93 . . . . 0.0 109.918 -179.791 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.573 ' HB3' HG23 ' A' ' 28' ' ' VAL . . . -56.43 -29.02 61.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.036 -1.04 . . . . 0.0 109.341 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.083 HG21 ' HZ2' ' A' ' 65' ' ' LYS . 1.9 mp . . . . . 0 C--N 1.302 -1.462 0 O-C-N 121.397 -0.814 . . . . 0.0 109.317 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.706 ' CD1' HD13 ' A' ' 33' ' ' ILE . 3.6 mp . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 121.402 0.62 . . . . 0.0 109.861 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.467 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 85.1 tt0 -106.72 149.51 27.23 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.475 -0.766 . . . . 0.0 109.192 179.614 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.425 ' HG3' ' O ' ' A' ' 7' ' ' LYS . 70.2 tt0 -72.35 124.23 24.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.19 -0.943 . . . . 0.0 109.499 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 96.16 -7.5 66.89 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.853 ' O ' HG23 ' A' ' 6' ' ' VAL . 60.5 tt0 -81.31 127.64 32.95 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.209 -1.171 . . . . 0.0 109.651 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -74.56 145.22 43.59 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.338 -0.851 . . . . 0.0 109.444 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.839 HG21 ' CD1' ' A' ' 18' ' ' ILE . 34.6 m -145.88 160.86 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.095 -1.003 . . . . 0.0 110.017 -179.747 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.542 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 9.6 p -113.7 158.46 20.88 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.25 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.615 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 8.8 p90 169.25 169.3 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.999 -1.063 . . . . 0.0 109.996 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.484 ' OE1' ' HA ' ' A' ' 50' ' ' GLU . 65.3 mm-40 -104.97 157.84 16.95 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 178.826 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.567 HD12 ' OE1' ' A' ' 23' ' ' GLN . 1.9 mt -95.66 130.64 44.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 120.922 -1.111 . . . . 0.0 110.105 -179.41 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.538 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 3.6 m -112.7 122.57 67.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.306 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -90.77 88.85 7.24 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.039 -1.038 . . . . 0.0 109.755 -179.414 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -93.41 -175.36 40.37 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.853 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -54.51 -63.1 1.26 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.2 -1.176 . . . . 0.0 109.639 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 72.5 mtp180 -46.75 -38.9 10.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.125 -0.985 . . . . 0.0 109.033 179.827 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.77 -158.85 27.85 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.538 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 49.2 Cg_endo -70.71 142.48 43.85 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.565 2.177 . . . . 0.0 111.747 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.513 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 67.7 mt-30 -139.17 169.15 18.31 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.342 -0.849 . . . . 0.0 109.133 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.546 ' CB ' ' HB ' ' A' ' 28' ' ' VAL . . . -89.92 134.07 34.42 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.972 -1.08 . . . . 0.0 110.14 -179.463 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.585 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -121.56 153.09 38.47 Favored 'General case' 0 N--CA 1.491 1.601 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.541 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.497 ' C ' ' O ' ' A' ' 61' ' ' ALA . 83.6 m-20 41.13 72.74 0.15 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.033 -1.042 . . . . 0.0 108.577 -179.475 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.759 HG11 HG12 ' A' ' 33' ' ' ILE . 2.2 t -92.98 130.39 42.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.218 -0.926 . . . . 0.0 110.517 -178.724 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.3 m -120.08 125.23 47.77 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.493 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 1.083 ' HZ2' HG21 ' A' ' 33' ' ' ILE . 29.6 mttp -74.36 112.1 10.19 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.067 -1.021 . . . . 0.0 109.702 -179.606 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.407 ' OE2' ' HB3' ' A' ' 48' ' ' SER . 93.2 mt-10 -88.89 163.78 15.46 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.318 -0.864 . . . . 0.0 109.605 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 118.004 -0.998 . . . . 0.0 109.439 179.88 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.811 ' N ' HD12 ' A' ' 2' ' ' LEU . 5.6 mp . . . . . 0 N--CA 1.489 1.502 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 58.6 mt-10 -132.28 127.97 36.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.147 -0.97 . . . . 0.0 109.446 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.43 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -127.51 155.25 19.95 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.445 ' N ' HG23 ' A' ' 18' ' ' ILE . 43.2 mttt -103.99 138.48 40.47 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.299 -1.118 . . . . 0.0 108.874 179.578 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.826 HG23 ' O ' ' A' ' 45' ' ' GLN . 18.9 t -71.28 113.24 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.213 -0.929 . . . . 0.0 110.045 -179.469 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 13.0 ttpt -80.08 -40.71 27.06 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.555 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.588 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.41 155.4 28.57 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.397 -0.814 . . . . 0.0 109.018 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 9.6 p90 -156.22 137.96 14.25 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.128 -0.983 . . . . 0.0 109.242 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.479 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 52.3 t-20 . . . . . 0 N--CA 1.489 1.492 0 O-C-N 121.233 -0.917 . . . . 0.0 109.437 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.519 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 . . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.588 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -140.37 172.41 23.53 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.424 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 27.6 m-85 -113.9 132.86 55.77 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.341 -1.094 . . . . 0.0 108.986 179.786 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.661 HD12 HG21 ' A' ' 28' ' ' VAL . 13.9 mt -116.22 151.52 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.252 -0.905 . . . . 0.0 109.717 -179.646 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -115.57 116.91 28.95 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.365 -0.834 . . . . 0.0 109.21 179.863 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.538 HG21 HG21 ' A' ' 26' ' ' VAL . 2.3 t -94.3 119.82 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.364 -0.835 . . . . 0.0 109.395 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -69.21 110.55 4.64 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.24 -0.913 . . . . 0.0 109.351 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 125.78 -37.77 2.42 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.819 ' OE1' HD12 ' A' ' 51' ' ' ILE . 56.4 mt-30 -120.45 166.31 13.76 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.366 -1.079 . . . . 0.0 109.381 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.422 ' O ' ' O ' ' A' ' 23' ' ' GLN . 49.5 m-20 -52.53 -176.83 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.206 -0.934 . . . . 0.0 109.562 -179.862 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.504 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 81.0 m-20 -74.31 141.93 45.22 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.346 -0.846 . . . . 0.0 109.629 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.538 HG21 HG21 ' A' ' 20' ' ' VAL . 98.2 t -115.08 117.95 57.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.242 -0.911 . . . . 0.0 109.31 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.556 ' O ' ' N ' ' A' ' 60' ' ' ALA . 0.1 OUTLIER -76.73 161.12 28.76 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.103 -0.998 . . . . 0.0 109.388 -179.879 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.763 HG22 ' HB2' ' A' ' 60' ' ' ALA . 14.6 t -133.75 134.13 56.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.287 -0.883 . . . . 0.0 109.602 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.642 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 15.2 t-80 -104.66 151.33 23.82 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.217 -0.927 . . . . 0.0 109.19 179.652 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.685 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -44.92 -53.96 7.03 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.106 -0.996 . . . . 0.0 109.549 -179.529 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.685 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 90.3 p -60.35 -18.49 50.42 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.06 -1.025 . . . . 0.0 109.956 -179.544 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.502 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -67.36 -24.54 65.72 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.075 -1.016 . . . . 0.0 109.356 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.833 HG23 HG12 ' A' ' 63' ' ' VAL . 3.1 mp . . . . . 0 N--CA 1.489 1.514 0 O-C-N 121.303 -0.873 . . . . 0.0 109.468 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.703 HD21 HD11 ' A' ' 33' ' ' ILE . 5.8 mp . . . . . 0 N--CA 1.489 1.5 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.488 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.1 tt0 -120.25 138.53 53.61 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.238 -0.914 . . . . 0.0 109.619 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 57.4 tt0 -67.65 129.7 40.72 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.261 -0.899 . . . . 0.0 109.454 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 90.64 -5.88 82.25 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.826 ' O ' HG23 ' A' ' 6' ' ' VAL . 60.4 tt0 -81.12 126.11 31.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.215 -1.168 . . . . 0.0 109.371 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -79.18 142.49 36.28 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.228 -0.92 . . . . 0.0 109.31 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.985 HG12 ' HA ' ' A' ' 65' ' ' LYS . 28.2 m -143.96 168.65 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.246 -0.909 . . . . 0.0 109.438 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.517 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 9.4 t -114.51 155.26 26.76 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.324 -0.86 . . . . 0.0 108.859 179.65 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.611 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 5.6 p90 173.38 165.88 0.16 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.041 -1.037 . . . . 0.0 110.099 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.467 ' HA ' HD13 ' A' ' 2' ' ' LEU . 90.8 mt-10 -100.6 150.36 22.79 Favored 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.815 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.819 HD12 ' OE1' ' A' ' 23' ' ' GLN . 0.5 OUTLIER -87.13 123.05 39.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.029 -1.044 . . . . 0.0 109.837 -179.574 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.623 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.6 m -107.03 120.87 59.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.385 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -88.41 85.18 6.82 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.259 -0.901 . . . . 0.0 109.633 -179.544 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.39 -177.05 43.18 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.876 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 18.4 p-10 -55.27 -55.89 26.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.097 -1.237 . . . . 0.0 109.701 -179.743 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 43.3 mtp180 -52.43 -41.27 63.11 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.992 -1.068 . . . . 0.0 109.285 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 146.34 -150.85 23.14 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.504 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 47.6 Cg_endo -70.24 129.25 16.78 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.817 2.345 . . . . 0.0 112.292 -179.851 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.623 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 53.7 mt-30 -131.04 164.23 25.85 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 179.138 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.763 ' HB2' HG22 ' A' ' 28' ' ' VAL . . . -90.52 127.08 36.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.098 -1.001 . . . . 0.0 110.401 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.535 ' O ' ' C ' ' A' ' 62' ' ' ASN . . . -109.86 147.71 32.85 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.034 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.535 ' C ' ' O ' ' A' ' 61' ' ' ALA . 59.2 t30 38.17 73.73 0.1 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.049 -1.032 . . . . 0.0 108.816 -179.686 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.833 HG12 HG23 ' A' ' 33' ' ' ILE . 1.4 t -84.8 129.62 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.321 -0.862 . . . . 0.0 110.331 -178.767 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.458 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 13.0 m -115.28 121.37 42.68 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.459 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.985 ' HA ' HG12 ' A' ' 47' ' ' VAL . 20.2 mttt -74.12 114.83 12.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.154 -0.966 . . . . 0.0 109.742 -179.67 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.441 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 50.8 mt-10 -98.99 168.05 10.35 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.354 -0.841 . . . . 0.0 109.616 -179.818 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.495 0 CA-C-O 117.944 -1.027 . . . . 0.0 109.444 179.989 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 21.1 mt . . . . . 0 N--CA 1.488 1.448 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -134.19 127.9 32.91 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.209 -0.932 . . . . 0.0 109.297 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.41 ' C ' ' CG2' ' A' ' 18' ' ' ILE . . . -126.49 158.63 20.64 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 -179.735 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.562 ' C ' HG23 ' A' ' 18' ' ' ILE . 38.8 mttp -103.7 133.64 48.37 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.394 -1.063 . . . . 0.0 108.823 179.561 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.856 HG23 ' O ' ' A' ' 45' ' ' GLN . 18.3 t -66.49 113.73 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.151 -0.968 . . . . 0.0 110.055 -179.344 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.402 ' O ' ' HD2' ' A' ' 7' ' ' LYS . 0.7 OUTLIER -79.12 -39.93 32.36 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.34 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.642 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -159.11 155.01 26.51 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.807 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.646 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 9.1 p90 -155.57 140.55 17.32 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.056 -1.028 . . . . 0.0 109.347 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.487 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.2 t-20 . . . . . 0 N--CA 1.489 1.504 0 O-C-N 121.117 -0.989 . . . . 0.0 109.727 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.594 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 1.2 p90 . . . . . 0 N--CA 1.491 1.614 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.642 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -140.88 171.69 23.99 Favored Glycine 0 N--CA 1.492 2.378 0 C-N-CA 119.654 -1.26 . . . . 0.0 110.067 -179.491 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.558 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 43.1 m-85 -114.02 139.4 49.29 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.319 -1.107 . . . . 0.0 109.195 179.751 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 1.122 ' CD1' HG21 ' A' ' 28' ' ' VAL . 16.7 mt -124.1 150.91 28.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.272 -0.892 . . . . 0.0 109.691 -179.485 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -113.48 119.47 37.7 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.384 -0.823 . . . . 0.0 109.448 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.565 HG21 HG21 ' A' ' 26' ' ' VAL . 2.6 t -90.46 124.13 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.329 -0.857 . . . . 0.0 109.655 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.476 ' OE2' ' NZ ' ' A' ' 5' ' ' LYS . 80.1 mt-10 -71.45 109.34 5.37 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.309 -0.869 . . . . 0.0 109.512 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 117.81 -26.1 8.15 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.612 ' NE2' HD12 ' A' ' 51' ' ' ILE . 36.5 mt-30 -122.95 161.31 24.45 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.259 -1.142 . . . . 0.0 109.482 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 58.9 m-20 -52.84 -178.96 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.274 -0.891 . . . . 0.0 109.659 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -71.65 141.37 49.92 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.268 -0.895 . . . . 0.0 109.506 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.584 HG13 ' C ' ' A' ' 59' ' ' GLN . 97.3 t -117.99 117.7 55.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.171 -0.956 . . . . 0.0 109.656 -179.582 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.54 ' CE1' ' HB3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -76.56 157.16 32.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.2 -0.937 . . . . 0.0 108.997 179.684 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 1.122 HG21 ' CD1' ' A' ' 18' ' ' ILE . 34.1 t -133.01 137.38 53.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.205 -0.935 . . . . 0.0 109.763 -179.525 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.594 ' HA ' ' HB3' ' A' ' 15' ' ' PHE . 42.6 t60 -114.97 152.45 32.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.429 -0.794 . . . . 0.0 108.993 179.696 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.68 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -44.31 -53.53 6.63 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.093 -1.004 . . . . 0.0 109.502 -179.631 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.68 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 27.3 t -54.29 -27.35 34.75 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.101 -1.0 . . . . 0.0 110.068 -179.452 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.63 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -66.9 -12.63 60.03 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.04 -1.037 . . . . 0.0 109.002 179.71 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.912 ' CD1' HD11 ' A' ' 41' ' ' LEU . 0.9 OUTLIER . . . . . 0 C--N 1.304 -1.396 0 O-C-N 121.503 -0.748 . . . . 0.0 109.589 -179.581 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 1.034 HD23 HG11 ' A' ' 47' ' ' VAL . 4.9 mp . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.438 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 96.8 mt-10 -109.28 155.04 21.62 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.316 -0.865 . . . . 0.0 109.305 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -70.41 127.67 33.54 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.29 -0.881 . . . . 0.0 109.593 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.445 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 88.51 -3.12 85.2 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.856 ' O ' HG23 ' A' ' 6' ' ' VAL . 51.1 tt0 -81.71 130.24 34.99 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.198 -1.178 . . . . 0.0 109.603 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -78.21 141.87 38.32 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.235 -0.916 . . . . 0.0 109.383 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 1.034 HG11 HD23 ' A' ' 41' ' ' LEU . 34.7 m -141.52 153.21 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.136 -0.977 . . . . 0.0 109.781 -179.746 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.539 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 17.8 t -97.57 148.65 23.05 Favored 'General case' 0 N--CA 1.488 1.459 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 179.075 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.602 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 7.8 p90 176.09 162.47 0.35 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.874 -1.141 . . . . 0.0 110.272 -179.546 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.458 ' OE1' ' HA ' ' A' ' 50' ' ' GLU . 67.0 mm-40 -99.92 160.37 14.37 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 178.908 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.612 HD12 ' NE2' ' A' ' 23' ' ' GLN . 0.9 OUTLIER -99.6 127.38 52.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 120.917 -1.114 . . . . 0.0 109.91 -179.524 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.614 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.9 m -114.32 124.81 71.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 179.197 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -93.6 93.31 7.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 110.241 -179.087 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -95.15 -175.8 37.72 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 11.9 t-20 -53.17 -59.22 4.83 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.104 -1.233 . . . . 0.0 109.462 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 53.0 mtp180 -49.3 -40.47 34.93 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.087 -1.008 . . . . 0.0 109.215 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 149.18 -158.12 27.53 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.411 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 51.5 Cg_endo -70.46 139.96 38.98 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.723 2.282 . . . . 0.0 111.849 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.614 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 76.9 mt-30 -136.26 167.81 20.6 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.324 -0.86 . . . . 0.0 109.13 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.659 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -95.22 139.31 31.72 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.136 -0.978 . . . . 0.0 110.184 -179.286 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.602 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -124.3 156.02 37.68 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.378 -0.826 . . . . 0.0 108.826 179.605 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.481 ' C ' ' O ' ' A' ' 61' ' ' ALA . 78.8 m-20 42.2 72.59 0.16 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.968 -1.083 . . . . 0.0 108.952 -179.821 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.98 HG11 HD21 ' A' ' 41' ' ' LEU . 3.9 t -86.76 125.93 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.234 -0.916 . . . . 0.0 110.088 -179.17 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.45 ' HB ' ' HB3' ' A' ' 48' ' ' SER . 60.6 m -119.0 125.51 49.56 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.379 -0.825 . . . . 0.0 109.256 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 87.9 mttt -67.52 106.97 2.32 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.2 -0.937 . . . . 0.0 109.479 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.405 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 89.6 mt-10 -87.04 162.0 17.85 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.227 -0.921 . . . . 0.0 109.497 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 117.973 -1.013 . . . . 0.0 109.487 -179.939 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 49.4 mt . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.581 ' O ' HG13 ' A' ' 20' ' ' VAL . 86.9 mt-10 -131.48 135.83 47.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.28 -0.888 . . . . 0.0 109.171 179.772 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.475 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -136.15 157.94 23.7 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 -179.684 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.513 ' N ' HG23 ' A' ' 18' ' ' ILE . 12.5 mttp -103.65 142.26 34.63 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.341 -1.094 . . . . 0.0 108.817 179.51 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.839 HG23 ' O ' ' A' ' 45' ' ' GLN . 22.1 t -75.22 116.96 18.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.073 -1.017 . . . . 0.0 109.935 -179.51 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.8 -32.73 17.71 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.465 -0.772 . . . . 0.0 108.933 179.693 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.683 ' CE3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -159.44 153.98 24.2 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.381 -0.824 . . . . 0.0 109.023 179.792 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.489 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 9.1 p90 -157.54 139.03 13.81 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.173 -0.954 . . . . 0.0 109.282 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.444 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 63.5 t-20 . . . . . 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 109.618 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.597 ' N ' ' CD1' ' A' ' 15' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.663 0 CA-C-O 121.42 0.628 . . . . 0.0 109.695 . . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.504 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -135.99 167.49 24.33 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.683 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 22.1 m-85 -115.05 130.12 56.86 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.184 -1.186 . . . . 0.0 109.289 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.744 ' CD1' HG21 ' A' ' 47' ' ' VAL . 56.4 mt -114.23 151.42 16.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.44 -0.787 . . . . 0.0 109.654 -179.79 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -114.2 104.29 11.95 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.361 -0.837 . . . . 0.0 108.915 179.518 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.581 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.8 t -78.63 120.64 30.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.264 -0.897 . . . . 0.0 109.428 -179.702 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 74.0 mm-40 -67.93 108.89 3.2 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.206 -0.933 . . . . 0.0 109.135 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.59 -24.46 6.82 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.562 ' OE1' HG11 ' A' ' 20' ' ' VAL . 36.0 mt-30 -128.18 165.92 19.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.298 -1.119 . . . . 0.0 109.6 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 48.9 m-20 -56.93 -169.08 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.292 -0.88 . . . . 0.0 109.729 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.497 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 7.7 p30 -78.45 141.47 38.25 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.254 -0.904 . . . . 0.0 110.003 -179.543 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.579 HG21 HG21 ' A' ' 20' ' ' VAL . 57.4 t -116.23 115.09 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.212 -0.93 . . . . 0.0 109.305 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.706 ' O ' ' CG ' ' A' ' 27' ' ' PHE . 0.1 OUTLIER -83.5 107.72 16.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.047 -1.033 . . . . 0.0 109.39 179.979 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.628 ' CG2' HG21 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -85.48 146.92 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.061 -1.024 . . . . 0.0 109.632 -179.167 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.777 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 27.6 t60 -116.2 155.05 28.99 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.283 -0.886 . . . . 0.0 109.336 -179.772 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.777 ' CD2' ' CE1' ' A' ' 29' ' ' HIS . 1.9 p90 -47.75 -54.11 13.21 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.092 -1.005 . . . . 0.0 109.607 -179.481 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.769 ' N ' ' CD1' ' A' ' 30' ' ' PHE . 19.9 t -53.41 -21.22 5.6 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.872 -1.142 . . . . 0.0 109.517 -179.771 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.547 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -66.84 -38.81 87.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.273 -0.892 . . . . 0.0 109.635 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.073 HD11 HD11 ' A' ' 41' ' ' LEU . 1.8 mp . . . . . 0 N--CA 1.491 1.577 0 O-C-N 121.168 -0.958 . . . . 0.0 109.966 -179.74 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 1.073 HD11 HD11 ' A' ' 33' ' ' ILE . 3.1 mp . . . . . 0 N--CA 1.492 1.626 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.469 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 97.0 mt-10 -115.8 151.27 35.51 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.302 -0.874 . . . . 0.0 109.373 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 46.5 tt0 -67.84 125.37 26.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.227 -0.92 . . . . 0.0 109.426 -179.866 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 92.7 -6.63 77.29 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.883 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.839 ' O ' HG23 ' A' ' 6' ' ' VAL . 61.5 tp60 -82.28 135.05 35.29 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.185 -1.185 . . . . 0.0 109.762 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -85.87 144.62 27.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.318 -0.864 . . . . 0.0 109.293 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.777 HG12 ' HA ' ' A' ' 65' ' ' LYS . 30.6 m -144.55 166.46 12.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.198 -0.939 . . . . 0.0 109.717 -179.838 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.55 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 3.3 t -112.87 157.21 21.7 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 179.338 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.577 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 10.0 p90 170.32 167.97 0.06 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.092 -1.005 . . . . 0.0 110.076 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 92.1 mt-10 -102.34 162.2 13.1 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 178.823 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.5 mt -99.91 127.75 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.008 -1.058 . . . . 0.0 109.75 -179.615 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.563 HG23 ' HB2' ' A' ' 59' ' ' GLN . 0.8 OUTLIER -109.17 120.82 61.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.62 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -88.53 85.89 6.92 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.194 -0.941 . . . . 0.0 109.713 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.14 -179.51 45.55 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 19.3 p-10 -54.49 -53.27 56.57 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.298 -1.119 . . . . 0.0 109.895 -179.708 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 20.3 mtm180 -57.13 -38.56 73.66 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.017 -1.052 . . . . 0.0 109.389 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.96 -158.81 27.99 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.557 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 52.3 Cg_endo -73.01 141.48 33.08 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.725 2.283 . . . . 0.0 112.006 179.898 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.563 ' HB2' HG23 ' A' ' 52' ' ' VAL . 31.8 mt-30 -137.03 168.45 19.56 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.37 -0.831 . . . . 0.0 108.894 179.543 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.591 ' HB3' ' HA ' ' A' ' 28' ' ' VAL . . . -94.13 139.93 30.38 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.015 -1.053 . . . . 0.0 110.332 -179.253 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.557 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -126.53 155.65 42.02 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.44 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.49 ' C ' ' O ' ' A' ' 61' ' ' ALA . 57.6 t30 40.88 63.06 1.25 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.958 -1.089 . . . . 0.0 108.849 -179.708 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.885 HG11 HD21 ' A' ' 41' ' ' LEU . 1.8 t -79.46 128.75 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.291 -0.881 . . . . 0.0 110.421 -179.011 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 56.4 m -119.6 125.59 49.14 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.777 ' HA ' HG12 ' A' ' 47' ' ' VAL . 69.6 mttt -65.51 110.6 2.76 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.21 -0.932 . . . . 0.0 109.531 -179.831 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.449 ' HG3' ' HA ' ' A' ' 47' ' ' VAL . 90.4 mt-10 -89.6 159.38 17.2 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.321 -0.862 . . . . 0.0 109.628 -179.845 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.551 0 CA-C-O 117.99 -1.005 . . . . 0.0 109.469 179.942 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.735 ' N ' HD12 ' A' ' 2' ' ' LEU . 6.4 mp . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.282 0.563 . . . . 0.0 109.569 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.575 ' O ' HG13 ' A' ' 20' ' ' VAL . 61.0 mt-10 -132.87 139.55 47.48 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.36 -0.838 . . . . 0.0 109.213 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -139.64 157.41 25.18 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.66 ' O ' HG23 ' A' ' 18' ' ' ILE . 63.6 mttm -102.57 142.95 32.89 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.418 -1.048 . . . . 0.0 108.831 179.561 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.799 HG23 ' O ' ' A' ' 45' ' ' GLN . 18.7 t -76.61 112.09 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.173 -0.954 . . . . 0.0 110.047 -179.447 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.465 ' CG ' ' N ' ' A' ' 8' ' ' TRP . 3.3 pttt -79.94 -37.7 33.94 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.622 ' CE3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -159.75 155.01 25.18 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 -179.941 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.463 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 10.5 p90 -155.88 138.87 15.41 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.156 -0.965 . . . . 0.0 109.196 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.493 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.3 t-20 . . . . . 0 N--CA 1.489 1.521 0 O-C-N 121.097 -1.002 . . . . 0.0 109.633 -179.745 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.647 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 . . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.594 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -140.43 170.26 24.48 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 -179.65 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.622 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 27.5 m-85 -114.66 131.5 56.71 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.387 -1.066 . . . . 0.0 108.997 179.812 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 1.132 HD12 ' CG2' ' A' ' 28' ' ' VAL . 26.9 mt -120.27 149.29 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.164 -0.96 . . . . 0.0 109.433 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.447 ' OE1' ' OD1' ' A' ' 25' ' ' ASP . 18.1 tp10 -108.75 123.76 49.52 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.244 -0.91 . . . . 0.0 109.504 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.672 HG21 HG21 ' A' ' 26' ' ' VAL . 2.3 t -102.11 120.25 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.215 -0.928 . . . . 0.0 109.25 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -66.98 109.39 2.95 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.247 -0.908 . . . . 0.0 109.772 -179.701 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.14 -29.34 3.71 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.505 ' O ' ' O ' ' A' ' 24' ' ' ASP . 38.2 mt-30 -131.41 166.26 21.68 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.227 -1.161 . . . . 0.0 109.23 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.505 ' O ' ' O ' ' A' ' 23' ' ' GLN . 0.0 OUTLIER -52.8 -169.17 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.173 -0.954 . . . . 0.0 109.683 -179.777 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.447 ' OD1' ' OE1' ' A' ' 19' ' ' GLU . 42.2 m-20 -75.36 141.65 43.27 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.236 -0.915 . . . . 0.0 109.742 -179.77 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.672 HG21 HG21 ' A' ' 20' ' ' VAL . 87.0 t -112.11 119.73 60.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.259 -0.9 . . . . 0.0 109.385 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.489 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.1 OUTLIER -79.53 154.71 28.62 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.244 -0.91 . . . . 0.0 109.127 -179.94 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 1.132 ' CG2' HD12 ' A' ' 18' ' ' ILE . 5.0 t -129.64 133.04 65.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.292 -0.88 . . . . 0.0 109.27 -179.729 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.647 ' HA ' ' HB3' ' A' ' 15' ' ' PHE . 47.8 t60 -105.61 150.2 25.62 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.157 -0.964 . . . . 0.0 109.219 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.689 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.9 OUTLIER -43.1 -52.56 5.35 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.197 -0.939 . . . . 0.0 109.198 -179.818 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.689 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 23.0 t -56.25 -23.06 33.68 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.912 . . . . 0.0 109.856 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.509 ' N ' ' O ' ' A' ' 29' ' ' HIS . . . -65.38 -23.76 67.05 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.075 -1.015 . . . . 0.0 109.446 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.907 ' CD1' HD11 ' A' ' 41' ' ' LEU . 3.2 mp . . . . . 0 N--CA 1.489 1.494 0 O-C-N 121.286 -0.883 . . . . 0.0 109.337 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.996 HD23 HG11 ' A' ' 47' ' ' VAL . 4.7 mp . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 121.319 0.58 . . . . 0.0 109.578 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.453 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 95.7 mt-10 -111.67 151.43 28.87 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.376 -0.827 . . . . 0.0 109.329 179.788 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 76.6 tt0 -69.13 126.44 29.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.282 -0.886 . . . . 0.0 109.626 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 89.94 -3.2 82.7 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.799 ' O ' HG23 ' A' ' 6' ' ' VAL . 56.7 tt0 -82.16 131.03 35.24 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.197 -1.178 . . . . 0.0 109.701 179.822 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -76.82 142.69 40.18 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.211 -0.93 . . . . 0.0 109.226 179.755 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.996 HG11 HD23 ' A' ' 41' ' ' LEU . 30.1 m -145.39 159.36 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.233 -0.917 . . . . 0.0 110.093 -179.637 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.569 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 39.7 t -110.94 154.32 24.26 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.615 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 14.0 p90 173.37 163.87 0.15 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.817 -1.177 . . . . 0.0 110.508 -179.659 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -99.58 158.71 15.57 Favored 'General case' 0 N--CA 1.488 1.455 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.908 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.533 HD11 HG21 ' A' ' 26' ' ' VAL . 3.1 mt -102.13 131.77 49.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 120.928 -1.107 . . . . 0.0 110.244 -179.409 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.562 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.6 m -114.19 123.62 70.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 178.703 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -91.55 90.36 7.58 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.187 -0.946 . . . . 0.0 109.937 -178.946 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.6 -177.47 42.76 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 14.9 t-20 -53.16 -59.81 4.08 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.169 -1.195 . . . . 0.0 109.533 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 20.9 mtp180 -49.82 -39.07 37.47 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.189 -0.944 . . . . 0.0 109.201 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.09 -161.91 29.25 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.562 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 52.6 Cg_endo -72.31 144.9 42.25 Favored 'Trans proline' 0 C--O 1.216 -0.613 0 C-N-CA 122.7 2.267 . . . . 0.0 111.828 179.772 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.548 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 71.1 mt-30 -137.37 169.47 17.72 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.276 -0.89 . . . . 0.0 109.232 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.56 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -94.0 139.73 30.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.216 -0.927 . . . . 0.0 110.232 -179.407 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.602 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -127.98 157.74 39.79 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.514 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.49 ' C ' ' O ' ' A' ' 61' ' ' ALA . 85.7 m-20 41.4 68.57 0.43 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.857 -1.152 . . . . 0.0 108.816 -179.761 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.934 HG11 HD21 ' A' ' 41' ' ' LEU . 2.3 t -87.13 126.3 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.239 -0.913 . . . . 0.0 110.315 -178.997 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 82.3 m -117.99 124.26 47.74 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.713 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.435 ' HA ' HG12 ' A' ' 47' ' ' VAL . 50.3 mttt -68.39 110.97 4.37 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.291 -0.881 . . . . 0.0 109.614 -179.814 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.473 ' O ' ' HB3' ' A' ' 67' ' ' ALA . 64.2 mt-10 -90.05 161.46 15.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.901 . . . . 0.0 109.604 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ALA . . . . . 0.473 ' HB3' ' O ' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.52 0 CA-C-O 117.989 -1.005 . . . . 0.0 109.466 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.483 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 27.2 mt . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 121.339 0.59 . . . . 0.0 109.503 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -129.24 141.33 51.16 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -0.916 . . . . 0.0 109.061 179.753 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.52 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -146.66 156.71 27.13 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -179.719 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.514 ' N ' HG23 ' A' ' 18' ' ' ILE . 16.0 mttt -102.2 136.01 42.78 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.382 -1.069 . . . . 0.0 108.836 179.48 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.614 HG23 ' O ' ' A' ' 45' ' ' GLN . 40.3 t -68.59 115.71 7.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.161 -0.962 . . . . 0.0 110.095 -179.53 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 17' ' ' PHE . 5.9 tttm -79.06 -35.11 43.02 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.476 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' TRP . . . . . 0.654 ' CD2' ' N ' ' A' ' 9' ' ' PHE . 0.4 OUTLIER -160.36 168.55 24.99 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.486 -0.759 . . . . 0.0 109.047 179.755 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.654 ' N ' ' CD2' ' A' ' 8' ' ' TRP . 21.4 p90 -163.44 141.23 7.65 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.885 -1.135 . . . . 0.0 110.312 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.599 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 20.5 t-20 . . . . . 0 N--CA 1.493 1.7 0 O-C-N 121.491 -0.755 . . . . 0.0 109.338 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.573 ' HB2' ' HA ' ' A' ' 29' ' ' HIS . 10.8 p90 . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.614 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -157.77 165.61 33.63 Favored Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.497 -1.335 . . . . 0.0 110.146 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.523 ' O ' ' N ' ' A' ' 7' ' ' LYS . 92.6 m-85 -96.43 138.63 33.73 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.457 -1.026 . . . . 0.0 108.909 179.726 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 1.048 HD12 HG21 ' A' ' 28' ' ' VAL . 63.2 mt -121.53 160.07 23.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.561 -0.712 . . . . 0.0 109.647 -179.715 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.48 ' N ' HG22 ' A' ' 18' ' ' ILE . 39.6 tt0 -120.4 119.09 32.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.35 -0.844 . . . . 0.0 109.46 -179.737 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.552 HG21 HG21 ' A' ' 26' ' ' VAL . 2.2 t -95.28 111.73 26.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.265 -0.897 . . . . 0.0 109.214 179.832 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.414 ' HA ' ' OE1' ' A' ' 21' ' ' GLU . 72.5 mm-40 -61.43 110.3 1.41 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.234 -0.916 . . . . 0.0 109.474 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.9 -33.97 3.56 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLN . . . . . 0.614 ' OE1' HD12 ' A' ' 51' ' ' ILE . 36.1 mt-30 -124.28 163.39 21.75 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.248 -1.148 . . . . 0.0 109.365 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.474 ' O ' ' O ' ' A' ' 23' ' ' GLN . 57.9 m-20 -50.76 -176.81 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.304 -0.873 . . . . 0.0 109.652 -179.866 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.42 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 90.0 m-20 -74.02 140.88 45.74 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.336 -0.853 . . . . 0.0 109.728 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.552 HG21 HG21 ' A' ' 20' ' ' VAL . 88.9 t -113.42 115.75 50.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.319 -0.863 . . . . 0.0 109.411 -179.895 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' PHE . . . . . 0.579 ' CE2' ' HB3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -70.75 156.72 39.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.057 -1.027 . . . . 0.0 109.355 -179.937 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 1.048 HG21 HD12 ' A' ' 18' ' ' ILE . 21.9 t -134.49 133.87 54.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.117 -0.989 . . . . 0.0 109.871 -179.472 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.672 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 14.3 t-80 -114.47 151.12 33.75 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.355 -0.841 . . . . 0.0 109.192 179.588 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.677 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.7 OUTLIER -42.63 -51.5 5.18 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.091 -1.006 . . . . 0.0 109.353 -179.858 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.677 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 86.6 p -53.69 -29.61 39.74 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.178 -0.952 . . . . 0.0 109.925 -179.618 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.596 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -64.91 -10.31 27.8 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.107 -0.995 . . . . 0.0 109.217 179.744 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.792 HD13 HD13 ' A' ' 41' ' ' LEU . 0.8 OUTLIER . . . . . 0 C--N 1.303 -1.442 0 O-C-N 121.487 -0.758 . . . . 0.0 109.726 -179.415 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.917 HD21 HG11 ' A' ' 63' ' ' VAL . 3.5 mp . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 121.464 0.649 . . . . 0.0 109.756 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' GLU . . . . . 0.408 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 36.6 tt0 -103.92 144.14 31.92 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.285 -0.884 . . . . 0.0 109.319 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 53.3 tt0 -63.11 130.34 44.23 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.293 -0.88 . . . . 0.0 109.477 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.97 -3.12 85.91 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.614 ' O ' HG23 ' A' ' 6' ' ' VAL . 46.8 tt0 -81.29 128.19 33.54 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.201 -1.176 . . . . 0.0 109.602 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -77.54 140.71 39.78 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.215 -0.928 . . . . 0.0 109.085 179.614 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.68 HG21 ' CD1' ' A' ' 18' ' ' ILE . 32.1 m -142.43 160.78 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.158 -0.964 . . . . 0.0 109.832 -179.825 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.55 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 24.0 t -107.3 152.06 24.64 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 178.827 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.559 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 35.3 p90 174.81 164.16 0.24 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.807 -1.183 . . . . 0.0 110.215 -179.426 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -100.31 172.28 7.25 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.907 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.614 HD12 ' OE1' ' A' ' 23' ' ' GLN . 1.0 OUTLIER -111.52 125.46 68.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 120.867 -1.146 . . . . 0.0 109.901 -179.819 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.585 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.7 m -109.16 123.48 65.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 179.138 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.4 mt-10 -91.52 83.75 5.43 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 109.645 -179.533 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.79 -172.06 42.28 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 179.789 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.433 ' O ' ' C ' ' A' ' 56' ' ' ARG . 18.3 t-20 -56.73 -63.55 1.16 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.14 -1.212 . . . . 0.0 109.212 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.433 ' C ' ' O ' ' A' ' 55' ' ' ASN . 36.2 mtp180 -42.0 -46.9 4.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.171 -0.955 . . . . 0.0 109.325 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.01 -149.33 21.46 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.42 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 46.2 Cg_endo -70.13 125.5 12.02 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.654 2.236 . . . . 0.0 112.128 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.585 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 33.2 mt-30 -125.56 158.62 34.13 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.335 -0.853 . . . . 0.0 108.875 179.389 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.812 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -91.47 134.86 34.27 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.019 -1.051 . . . . 0.0 109.767 -179.545 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.559 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -122.72 156.37 34.56 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.388 -0.82 . . . . 0.0 108.9 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.473 ' C ' ' O ' ' A' ' 61' ' ' ALA . 82.9 m-20 41.72 66.01 0.77 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.084 -1.01 . . . . 0.0 109.045 -179.727 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.917 HG11 HD21 ' A' ' 41' ' ' LEU . 4.5 t -83.03 125.85 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.234 -0.916 . . . . 0.0 109.93 -179.381 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.423 ' HB ' ' HB3' ' A' ' 48' ' ' SER . 92.4 m -118.35 125.02 49.15 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.53 -0.731 . . . . 0.0 109.211 179.766 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.408 ' HA ' HG12 ' A' ' 47' ' ' VAL . 32.4 mttp -65.41 110.5 2.68 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.338 -0.851 . . . . 0.0 109.438 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 73.3 mm-40 -100.67 166.71 10.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.283 -0.885 . . . . 0.0 109.504 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 118.001 -1.0 . . . . 0.0 109.452 -179.991 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 81.9 mtp . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.445 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 59.6 mt -98.8 160.53 14.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.386 -0.821 . . . . 0.0 109.46 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 78.1 mt-10 -130.62 143.52 50.81 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.283 -0.886 . . . . 0.0 109.203 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.516 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -152.06 156.09 26.5 Favored Glycine 0 N--CA 1.488 2.123 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.44 ' N ' HG23 ' A' ' 18' ' ' ILE . 96.7 mttt -100.99 135.21 42.81 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.312 -1.111 . . . . 0.0 108.744 179.463 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.703 HG23 ' O ' ' A' ' 45' ' ' GLN . 33.9 t -66.55 119.22 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.123 -0.986 . . . . 0.0 110.01 -179.424 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.432 ' N ' ' O ' ' A' ' 17' ' ' PHE . 5.9 tptm -79.48 -40.96 28.53 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.425 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.656 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -159.98 166.95 29.03 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 179.785 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.643 ' N ' ' CD2' ' A' ' 8' ' ' TRP . 17.1 p90 -158.76 147.39 18.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.943 -1.098 . . . . 0.0 110.574 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.646 ' HB3' ' CE1' ' A' ' 15' ' ' PHE . 13.9 t-20 -103.6 135.85 44.41 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.412 -0.805 . . . . 0.0 109.353 179.662 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.8 p -83.24 -15.08 51.73 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.089 -1.007 . . . . 0.0 109.442 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 41.0 tp10 -59.98 -63.42 1.31 Allowed 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.27 -0.894 . . . . 0.0 109.604 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.65 ' HB2' ' CD1' ' A' ' 15' ' ' PHE . 19.9 mttm -98.68 -10.73 22.8 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.355 -0.841 . . . . 0.0 109.745 -179.526 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.587 ' HA2' HG22 ' A' ' 40' ' ' THR . . . 77.23 68.86 1.46 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.002 -1.239 . . . . 0.0 110.002 179.477 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.65 ' CD1' ' HB2' ' A' ' 13' ' ' LYS . 3.1 p90 -156.21 161.41 40.28 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.151 -1.205 . . . . 0.0 109.005 179.299 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.656 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -161.07 160.86 32.45 Favored Glycine 0 N--CA 1.486 2.018 0 C-N-CA 119.598 -1.286 . . . . 0.0 110.044 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.502 ' CD1' ' HB2' ' A' ' 27' ' ' PHE . 98.0 m-85 -90.74 139.37 30.79 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.488 -1.007 . . . . 0.0 108.719 179.492 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.699 HD12 HG21 ' A' ' 28' ' ' VAL . 19.7 mt -113.25 159.28 13.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.582 -0.699 . . . . 0.0 109.222 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.467 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 65.7 tt0 -114.27 109.52 18.51 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.225 -0.922 . . . . 0.0 109.464 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.569 HG21 HG21 ' A' ' 26' ' ' VAL . 2.7 t -90.74 109.48 20.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.199 -0.938 . . . . 0.0 109.206 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 74.3 mm-40 -59.22 108.87 0.75 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.214 -0.929 . . . . 0.0 109.267 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.9 -35.62 3.48 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.465 ' OE1' HD12 ' A' ' 51' ' ' ILE . 46.7 mt-30 -117.95 160.92 20.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -1.155 . . . . 0.0 109.362 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.447 ' O ' ' O ' ' A' ' 23' ' ' GLN . 44.5 m-20 -52.92 -174.19 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.253 -0.904 . . . . 0.0 109.514 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.5 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 80.8 m-20 -74.31 139.45 44.21 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.299 -0.876 . . . . 0.0 109.647 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.569 HG21 HG21 ' A' ' 20' ' ' VAL . 91.8 t -114.39 119.87 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.306 -0.871 . . . . 0.0 109.529 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.512 ' C ' ' CD1' ' A' ' 27' ' ' PHE . 0.0 OUTLIER -77.17 155.75 32.05 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.111 -0.993 . . . . 0.0 109.396 -179.965 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.699 HG21 HD12 ' A' ' 18' ' ' ILE . 10.8 t -131.09 138.5 53.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.294 -0.879 . . . . 0.0 109.434 -179.652 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.509 ' HB2' ' CZ ' ' A' ' 27' ' ' PHE . 47.1 t60 -112.21 149.93 31.58 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.094 -1.004 . . . . 0.0 109.581 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.699 ' CG ' ' N ' ' A' ' 31' ' ' SER . 1.2 p90 -46.88 -53.99 10.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.152 -0.968 . . . . 0.0 109.672 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.699 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 21.0 t -59.56 -20.85 58.58 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.024 -1.048 . . . . 0.0 109.907 -179.527 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.565 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -77.77 -12.66 60.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.157 -0.964 . . . . 0.0 109.414 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.018 HD13 HD13 ' A' ' 41' ' ' LEU . 3.0 mt -110.36 146.07 16.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.435 -0.79 . . . . 0.0 109.82 -179.66 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 65.2 mt-30 -97.08 128.08 43.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.387 -0.821 . . . . 0.0 109.685 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.608 ' CA ' ' HE1' ' A' ' 38' ' ' PHE . . . 146.17 80.48 0.04 OUTLIER Glycine 0 N--CA 1.484 1.889 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.472 ' HG2' ' NZ ' ' A' ' 39' ' ' LYS . 94.4 mt-10 -61.69 -21.63 64.63 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.247 -1.149 . . . . 0.0 109.465 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.509 ' C ' ' CG ' ' A' ' 38' ' ' PHE . . . -94.08 17.13 59.42 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 179.803 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.608 ' HE1' ' CA ' ' A' ' 35' ' ' GLY . 0.1 OUTLIER 168.96 54.48 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.24 -1.153 . . . . 0.0 109.774 179.952 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.553 ' HG3' ' O ' ' A' ' 35' ' ' GLY . 29.1 mttt -73.73 -21.47 60.2 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.107 -0.995 . . . . 0.0 109.397 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.587 HG22 ' HA2' ' A' ' 14' ' ' GLY . 69.3 p -69.71 116.09 9.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.243 -0.91 . . . . 0.0 109.528 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 1.018 HD13 HD13 ' A' ' 33' ' ' ILE . 4.3 mp -73.85 144.98 45.25 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.244 -0.91 . . . . 0.0 109.84 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.451 ' O ' ' C ' ' A' ' 43' ' ' GLU . 58.5 tt0 -93.91 119.72 33.21 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.407 -0.808 . . . . 0.0 109.084 179.629 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.451 ' C ' ' O ' ' A' ' 42' ' ' GLU . 53.4 tt0 -41.13 131.38 2.65 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.284 -0.885 . . . . 0.0 109.553 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 89.69 -3.95 83.47 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.703 ' O ' HG23 ' A' ' 6' ' ' VAL . 52.1 tt0 -80.81 128.18 33.37 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.171 -1.194 . . . . 0.0 109.466 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -79.9 143.36 34.33 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.27 -0.894 . . . . 0.0 109.055 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.915 HG12 ' HA ' ' A' ' 65' ' ' LYS . 28.9 m -147.84 171.41 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.196 -0.94 . . . . 0.0 109.678 -179.824 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.656 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 34.7 t -116.3 156.46 26.61 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.308 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.598 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 17.0 p90 172.81 166.78 0.13 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.894 -1.129 . . . . 0.0 110.488 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -108.82 154.28 22.32 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.725 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.465 HD12 ' OE1' ' A' ' 23' ' ' GLN . 1.9 mt -87.73 122.85 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 120.863 -1.148 . . . . 0.0 110.069 -179.433 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.805 ' CG1' ' HB2' ' A' ' 61' ' ' ALA . 26.8 m -110.72 128.29 67.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 178.859 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -68.63 120.05 14.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.084 -1.01 . . . . 0.0 109.838 -179.249 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -128.02 162.57 21.81 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.761 -1.335 . . . . 0.0 109.761 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -51.78 -60.22 3.42 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.241 -1.153 . . . . 0.0 109.493 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 82.2 mtp180 -51.0 -33.16 23.65 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.274 -0.891 . . . . 0.0 109.184 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 144.84 -146.12 16.18 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.434 -1.466 . . . . 0.0 109.434 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.5 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 45.8 Cg_endo -69.35 127.99 15.74 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.781 2.321 . . . . 0.0 111.793 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.621 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 84.8 mt-30 -121.99 156.21 33.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.188 -0.945 . . . . 0.0 109.265 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.522 ' HB2' HG22 ' A' ' 28' ' ' VAL . . . -88.35 127.76 35.49 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.159 -0.963 . . . . 0.0 110.088 -179.336 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.805 ' HB2' ' CG1' ' A' ' 52' ' ' VAL . . . -108.71 150.47 27.52 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.322 -0.861 . . . . 0.0 108.887 179.37 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.487 ' C ' ' O ' ' A' ' 61' ' ' ALA . 36.8 t-20 40.64 67.22 0.53 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.213 -0.93 . . . . 0.0 109.013 -179.67 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.922 HG11 HG12 ' A' ' 33' ' ' ILE . 1.2 t -82.14 127.25 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.329 -0.857 . . . . 0.0 110.21 -179.175 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.414 ' HB ' ' HB3' ' A' ' 48' ' ' SER . 35.3 m -115.63 117.56 30.63 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.146 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.915 ' HA ' HG12 ' A' ' 47' ' ' VAL . 18.1 mttm -65.34 117.01 7.26 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.279 -0.888 . . . . 0.0 109.663 -179.66 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 82.8 mt-10 -108.87 167.67 9.91 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.375 -0.828 . . . . 0.0 109.661 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.506 -179.956 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.843 ' C ' HD12 ' A' ' 2' ' ' LEU . 82.3 mtp . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.843 HD12 ' C ' ' A' ' 1' ' ' MET . 5.1 mp -116.22 160.95 19.69 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.287 -0.883 . . . . 0.0 109.327 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.764 ' O ' HG13 ' A' ' 20' ' ' VAL . 2.7 tt0 -127.68 140.27 52.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.227 -0.921 . . . . 0.0 109.208 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.0 155.22 24.91 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.784 -1.326 . . . . 0.0 109.784 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.54 ' C ' HG23 ' A' ' 18' ' ' ILE . 54.5 mttt -108.88 137.86 46.13 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.406 -1.055 . . . . 0.0 108.645 179.46 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.86 HG23 ' O ' ' A' ' 45' ' ' GLN . 15.0 t -70.16 112.56 5.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.054 -1.029 . . . . 0.0 109.983 -179.301 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.483 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 14.7 tttm -78.5 -40.87 34.04 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.592 ' CE3' ' O ' ' A' ' 8' ' ' TRP . 0.0 OUTLIER -161.44 155.78 22.73 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.923 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.434 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 11.0 p90 -154.31 139.77 17.76 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.054 -1.029 . . . . 0.0 109.07 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.538 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 3.1 t-20 -114.46 118.25 33.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.052 -1.03 . . . . 0.0 109.869 -179.601 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 82.7 p -63.82 -17.08 62.75 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.311 -0.868 . . . . 0.0 109.562 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.486 ' HB3' ' OD1' ' A' ' 10' ' ' ASN . 76.2 tt0 -85.67 -39.56 17.12 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.256 -0.902 . . . . 0.0 109.253 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.632 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 27.0 mttp -66.6 -42.75 86.4 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.363 -0.836 . . . . 0.0 109.326 179.816 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.467 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 103.26 1.02 47.67 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.369 -1.492 . . . . 0.0 109.369 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.632 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 0.8 OUTLIER -145.54 179.61 7.3 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -1.131 . . . . 0.0 109.322 179.858 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.533 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -148.57 173.85 28.41 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.564 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 29.2 m-85 -113.25 132.3 55.58 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.402 -1.058 . . . . 0.0 109.011 179.767 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 1.119 ' CD1' HG21 ' A' ' 28' ' ' VAL . 58.8 mt -119.07 149.5 21.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.239 -0.913 . . . . 0.0 109.681 -179.615 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 46.8 tt0 -112.09 122.15 46.95 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.353 -0.842 . . . . 0.0 109.415 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.764 HG13 ' O ' ' A' ' 3' ' ' GLU . 3.2 t -91.32 124.88 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.246 -0.909 . . . . 0.0 109.647 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.473 ' OE2' ' HE3' ' A' ' 5' ' ' LYS . 91.6 mt-10 -70.4 103.76 2.52 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.236 -0.915 . . . . 0.0 109.367 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 120.83 -19.13 8.99 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.569 ' OE1' HG11 ' A' ' 20' ' ' VAL . 49.0 mt-30 -129.82 162.6 28.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.263 -1.139 . . . . 0.0 109.578 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -54.46 -176.44 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.317 -0.864 . . . . 0.0 109.689 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 11.3 p30 -73.39 136.32 44.33 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.29 -0.881 . . . . 0.0 109.413 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.556 HG21 HG21 ' A' ' 20' ' ' VAL . 72.3 t -113.03 122.31 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.235 -0.916 . . . . 0.0 109.569 -179.753 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.508 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.4 OUTLIER -78.12 157.29 29.51 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.164 -0.96 . . . . 0.0 109.223 179.837 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 1.119 HG21 ' CD1' ' A' ' 18' ' ' ILE . 21.9 t -132.27 131.24 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.296 -0.877 . . . . 0.0 109.243 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.679 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 13.9 t-80 -105.83 154.64 20.25 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.124 -0.985 . . . . 0.0 109.267 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.685 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -46.52 -53.46 11.26 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.159 -0.963 . . . . 0.0 109.246 -179.683 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.685 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 86.7 p -55.96 -24.37 37.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.096 -1.003 . . . . 0.0 109.979 -179.692 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.502 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -66.32 -19.97 65.96 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.114 -0.991 . . . . 0.0 109.577 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.887 HG21 ' NZ ' ' A' ' 65' ' ' LYS . 2.9 mp -110.84 132.34 59.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.229 -0.92 . . . . 0.0 109.443 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 79.6 mt-30 -110.73 146.22 36.68 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.291 -0.881 . . . . 0.0 109.411 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.688 ' HA3' ' CZ ' ' A' ' 38' ' ' PHE . . . 174.25 -176.21 46.63 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 -179.865 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -73.32 -36.59 66.23 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.352 -1.087 . . . . 0.0 109.363 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -175.94 30.0 0.08 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.688 ' CZ ' ' HA3' ' A' ' 35' ' ' GLY . 43.5 p90 -122.69 28.23 7.41 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.164 -1.198 . . . . 0.0 109.64 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.437 ' O ' HD13 ' A' ' 33' ' ' ILE . 82.3 mttt -49.94 -32.78 15.64 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.243 -0.911 . . . . 0.0 109.546 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.425 ' O ' ' CE ' ' A' ' 65' ' ' LYS . 27.4 m -62.0 136.75 58.09 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.199 -0.938 . . . . 0.0 109.526 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.845 HD11 ' CD1' ' A' ' 33' ' ' ILE . 5.2 mp -92.98 170.94 9.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.261 -0.899 . . . . 0.0 109.629 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.531 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 84.9 tt0 -116.11 149.26 39.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.297 -0.877 . . . . 0.0 109.008 179.68 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.483 ' HG3' ' O ' ' A' ' 7' ' ' LYS . 77.5 tt0 -71.0 124.46 24.41 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.15 -0.969 . . . . 0.0 109.769 -179.788 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 92.01 -6.88 79.15 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.901 -1.28 . . . . 0.0 109.901 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.86 ' O ' HG23 ' A' ' 6' ' ' VAL . 6.6 tp-100 -82.04 133.19 35.27 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.131 -1.217 . . . . 0.0 109.732 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -84.34 144.95 28.51 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.899 . . . . 0.0 109.415 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.697 HG12 ' HA ' ' A' ' 65' ' ' LYS . 23.2 m -144.78 163.61 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.232 -0.917 . . . . 0.0 109.795 -179.725 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.513 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 1.0 OUTLIER -108.19 153.23 23.48 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 179.342 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.535 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 7.8 p90 174.63 165.82 0.25 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.99 -1.069 . . . . 0.0 110.055 -179.76 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.531 ' HA ' HD13 ' A' ' 2' ' ' LEU . 95.1 mt-10 -102.84 165.14 11.21 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.14 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.0 mt -102.44 125.74 56.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 120.936 -1.102 . . . . 0.0 109.854 -179.747 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.579 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 32.0 m -114.3 126.29 71.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.413 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 178.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -66.18 118.64 10.2 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.158 -0.964 . . . . 0.0 109.727 -179.502 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -122.07 157.44 16.8 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.496 ' CG ' ' N ' ' A' ' 56' ' ' ARG . 7.9 p30 -48.05 -49.66 30.6 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.319 -1.106 . . . . 0.0 109.654 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.496 ' N ' ' CG ' ' A' ' 55' ' ' ASN . 84.0 mtp180 -64.47 -25.23 67.91 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.109 -0.994 . . . . 0.0 109.012 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 142.63 -152.63 23.99 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.494 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 49.2 Cg_endo -70.72 137.25 32.28 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.631 2.22 . . . . 0.0 111.782 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.579 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 79.1 mt-30 -127.53 163.83 23.29 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.228 -0.92 . . . . 0.0 109.207 179.641 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.484 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -96.6 142.65 28.4 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.154 -0.966 . . . . 0.0 110.103 -179.324 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.517 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -124.65 154.06 41.34 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.387 -0.821 . . . . 0.0 108.881 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.476 ' C ' ' O ' ' A' ' 61' ' ' ALA . 58.3 t30 42.54 64.24 1.2 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.103 -0.998 . . . . 0.0 108.784 -179.65 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.766 HG12 HG23 ' A' ' 33' ' ' ILE . 1.8 t -78.38 128.91 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.337 -0.852 . . . . 0.0 109.944 -179.122 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.462 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 93.4 m -119.56 126.32 50.95 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.484 -0.76 . . . . 0.0 109.082 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.887 ' NZ ' HG21 ' A' ' 33' ' ' ILE . 38.2 mttp -73.39 114.78 12.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.219 -0.925 . . . . 0.0 109.771 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.449 ' HG3' ' HA ' ' A' ' 47' ' ' VAL . 97.1 mt-10 -92.44 161.98 14.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.251 -0.905 . . . . 0.0 109.452 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.392 179.884 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.7 mtt . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.427 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 57.5 mt -106.2 158.99 16.44 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.305 -0.872 . . . . 0.0 109.435 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.715 ' O ' HG13 ' A' ' 20' ' ' VAL . 3.5 tt0 -128.43 137.76 51.99 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.266 -0.896 . . . . 0.0 109.208 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.05 154.33 24.41 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.776 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.497 ' O ' HG23 ' A' ' 18' ' ' ILE . 58.0 mttp -104.16 140.46 37.77 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.434 -1.039 . . . . 0.0 108.829 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.768 HG23 ' O ' ' A' ' 45' ' ' GLN . 18.8 t -72.85 114.36 11.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.009 -1.057 . . . . 0.0 109.963 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 10.7 tptt -78.76 -42.24 28.54 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.527 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.581 ' CE3' ' O ' ' A' ' 8' ' ' TRP . 0.0 OUTLIER -160.1 156.12 26.3 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.452 -0.78 . . . . 0.0 109.009 179.96 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.498 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 10.4 p90 -154.96 139.08 16.5 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.124 -0.985 . . . . 0.0 109.021 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.486 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 58.7 t-20 -115.02 121.17 42.29 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.01 -1.056 . . . . 0.0 109.836 -179.517 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 70.7 p -66.0 -16.41 63.87 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.317 -0.865 . . . . 0.0 109.407 179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 78.5 mm-40 -85.9 -41.3 15.07 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.257 -0.902 . . . . 0.0 109.264 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.636 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 16.0 mttt -65.76 -41.13 92.45 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.352 -0.842 . . . . 0.0 109.261 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.491 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 102.02 0.17 51.53 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.636 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 0.9 OUTLIER -145.6 176.89 9.28 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.2 -1.176 . . . . 0.0 109.321 179.775 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.566 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -145.12 175.4 24.73 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.564 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 32.8 m-85 -115.54 133.29 56.18 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.265 -1.138 . . . . 0.0 109.022 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 1.09 HD12 ' CG2' ' A' ' 28' ' ' VAL . 20.2 mt -119.88 155.08 22.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.226 -0.921 . . . . 0.0 109.402 -179.807 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 32.4 tp10 -117.83 123.92 47.1 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.315 -0.866 . . . . 0.0 109.588 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.715 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.3 t -97.94 119.98 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.314 -0.866 . . . . 0.0 109.47 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -69.11 109.61 4.11 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.27 -0.894 . . . . 0.0 109.556 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 126.46 -30.68 4.19 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.691 ' OE1' HD12 ' A' ' 51' ' ' ILE . 57.1 mt-30 -128.6 166.85 18.07 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.322 -1.105 . . . . 0.0 109.41 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.46 ' O ' ' O ' ' A' ' 23' ' ' GLN . 55.4 m-20 -51.13 -177.38 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.251 -0.906 . . . . 0.0 109.411 179.898 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.512 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 20.3 p30 -75.27 147.28 40.37 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.232 -0.917 . . . . 0.0 109.308 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.538 HG21 HG21 ' A' ' 20' ' ' VAL . 81.6 t -118.14 120.44 64.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.121 -0.987 . . . . 0.0 109.676 -179.556 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.529 ' CE1' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER -76.81 158.27 30.96 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.127 -0.983 . . . . 0.0 109.11 179.696 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 1.09 ' CG2' HD12 ' A' ' 18' ' ' ILE . 7.7 t -131.64 134.08 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.187 -0.946 . . . . 0.0 109.299 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.611 ' O ' HD12 ' A' ' 33' ' ' ILE . 44.0 t60 -109.32 152.63 25.01 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.193 -0.942 . . . . 0.0 109.15 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.682 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.9 OUTLIER -45.43 -53.04 9.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.199 -0.938 . . . . 0.0 109.176 -179.592 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.682 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 22.7 t -54.96 -28.94 55.31 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.243 -0.911 . . . . 0.0 110.051 -179.587 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.499 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -62.83 -21.58 66.03 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.048 -1.032 . . . . 0.0 109.352 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.944 ' CD1' HD11 ' A' ' 41' ' ' LEU . 3.3 mp -111.18 132.19 60.38 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.298 -0.876 . . . . 0.0 109.256 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 82.9 mt-30 -113.97 148.72 36.42 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.161 -0.962 . . . . 0.0 109.562 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.681 ' HA3' ' CZ ' ' A' ' 38' ' ' PHE . . . 174.23 -176.92 46.61 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -71.02 -31.94 68.56 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.335 -1.097 . . . . 0.0 109.404 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 178.02 32.43 0.05 OUTLIER Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.681 ' CZ ' ' HA3' ' A' ' 35' ' ' GLY . 40.4 p90 -126.12 30.08 5.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.132 -1.217 . . . . 0.0 109.571 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 18.2 mttt -51.48 -34.73 36.88 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.123 -0.986 . . . . 0.0 109.522 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.521 ' O ' ' NZ ' ' A' ' 65' ' ' LYS . 36.8 m -62.28 130.87 47.33 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.19 -0.944 . . . . 0.0 109.469 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.944 HD11 ' CD1' ' A' ' 33' ' ' ILE . 5.4 mp -86.97 175.0 8.35 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.266 -0.896 . . . . 0.0 109.699 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.515 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 85.2 tt0 -117.57 152.07 35.87 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.415 -0.803 . . . . 0.0 109.042 179.546 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 67.4 tt0 -72.85 124.57 25.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.207 -0.933 . . . . 0.0 109.6 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.7 -4.44 79.17 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.768 ' O ' HG23 ' A' ' 6' ' ' VAL . 8.0 tp-100 -82.05 132.81 35.26 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.189 -1.183 . . . . 0.0 109.877 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -80.45 141.06 35.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.289 -0.882 . . . . 0.0 109.169 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.656 HG21 HD13 ' A' ' 18' ' ' ILE . 30.1 m -141.69 159.04 21.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 109.902 -179.614 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.503 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 28.9 t -109.66 153.11 24.7 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.048 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.552 ' CE2' HG23 ' A' ' 47' ' ' VAL . 8.5 p90 173.39 165.67 0.16 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.913 -1.117 . . . . 0.0 110.178 -179.764 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -100.05 162.89 12.69 Favored 'General case' 0 N--CA 1.487 1.382 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.894 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.691 HD12 ' OE1' ' A' ' 23' ' ' GLN . 0.9 OUTLIER -102.25 125.46 56.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 120.927 -1.108 . . . . 0.0 110.022 -179.571 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.601 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 26.7 m -109.9 121.98 63.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.7 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.408 ' OE2' ' HB3' ' A' ' 58' ' ' PRO . 39.9 mm-40 -91.47 89.9 7.42 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.144 -0.973 . . . . 0.0 109.945 -179.001 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.05 -169.96 32.23 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 56' ' ' ARG . 19.5 t-20 -58.05 -66.17 0.52 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.236 -1.155 . . . . 0.0 109.837 -179.848 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.428 ' C ' ' O ' ' A' ' 55' ' ' ASN . 15.2 mtm180 -41.82 -46.29 3.88 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.282 -0.886 . . . . 0.0 109.501 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 150.65 -153.97 25.34 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.512 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 47.9 Cg_endo -69.64 129.42 17.69 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.682 2.255 . . . . 0.0 112.024 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.601 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 61.2 mt-30 -127.19 161.14 29.23 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.334 -0.854 . . . . 0.0 108.976 179.506 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.547 ' HB2' HG22 ' A' ' 28' ' ' VAL . . . -90.02 136.52 32.99 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.032 -1.043 . . . . 0.0 110.296 -179.154 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.534 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -118.79 149.57 41.28 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 179.442 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.488 ' C ' ' O ' ' A' ' 61' ' ' ALA . 38.6 t-20 41.34 67.77 0.51 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.033 -1.042 . . . . 0.0 108.875 -179.57 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.609 HG21 ' CG1' ' A' ' 28' ' ' VAL . 2.1 t -81.57 127.85 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.404 -0.81 . . . . 0.0 110.161 -179.176 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 91.8 m -118.1 123.84 46.57 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.472 -0.768 . . . . 0.0 109.082 179.8 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.521 ' NZ ' ' O ' ' A' ' 40' ' ' THR . 74.1 mttt -70.75 112.63 7.11 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.199 -0.938 . . . . 0.0 109.737 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -92.75 162.7 14.02 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.326 -0.859 . . . . 0.0 109.584 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.995 -1.002 . . . . 0.0 109.491 179.997 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.819 ' C ' HD12 ' A' ' 2' ' ' LEU . 75.1 mtm . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.845 ' N ' HD12 ' A' ' 2' ' ' LEU . 4.6 mp -115.89 162.02 17.94 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.24 -0.913 . . . . 0.0 109.117 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.794 ' O ' HG13 ' A' ' 20' ' ' VAL . 2.4 tt0 -128.73 143.67 50.98 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.205 -0.935 . . . . 0.0 109.163 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -144.34 157.08 27.07 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.445 ' C ' HG23 ' A' ' 18' ' ' ILE . 43.2 mttm -108.23 137.1 46.79 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.423 -1.045 . . . . 0.0 108.576 179.383 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.789 HG23 ' O ' ' A' ' 45' ' ' GLN . 16.1 t -68.28 114.45 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.128 -0.983 . . . . 0.0 109.85 -179.341 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.459 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 29.7 tttt -79.33 -38.07 36.03 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 179.601 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.608 ' CZ3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -166.37 157.39 12.89 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.476 -0.765 . . . . 0.0 109.035 -179.893 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.432 ' N ' ' CG ' ' A' ' 8' ' ' TRP . 16.1 p90 -152.75 139.89 19.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.203 -0.936 . . . . 0.0 108.847 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.502 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 55.1 t-20 -117.11 121.54 41.58 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.045 -1.034 . . . . 0.0 109.971 -179.408 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 88.0 p -66.45 -17.94 65.07 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.387 -0.82 . . . . 0.0 109.443 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -83.7 -40.58 18.73 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.231 -0.918 . . . . 0.0 109.373 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.625 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 24.9 mttp -68.76 -43.52 75.63 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.29 -0.882 . . . . 0.0 109.367 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.485 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 104.53 -0.4 42.94 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.625 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 0.4 OUTLIER -142.33 179.8 6.72 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.112 -1.228 . . . . 0.0 109.529 179.88 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.516 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -145.3 172.17 26.16 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.679 -1.368 . . . . 0.0 109.679 -179.834 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.608 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 28.4 m-85 -114.79 131.94 56.64 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.22 -1.164 . . . . 0.0 109.021 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 1.117 HD12 ' CG2' ' A' ' 28' ' ' VAL . 37.3 mt -119.25 149.54 21.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.146 -0.971 . . . . 0.0 109.647 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 46.3 tt0 -112.28 120.3 41.27 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.406 -0.809 . . . . 0.0 109.413 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.794 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.6 t -90.85 125.1 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.312 -0.868 . . . . 0.0 109.428 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.468 ' HA ' ' OE1' ' A' ' 21' ' ' GLU . 67.0 mm-40 -73.57 106.05 5.18 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.318 -0.864 . . . . 0.0 109.25 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.53 -17.54 8.89 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.564 ' OE1' HD12 ' A' ' 51' ' ' ILE . 46.5 mt-30 -133.9 164.62 26.86 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.276 -1.132 . . . . 0.0 109.648 -179.836 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 50.5 m-20 -55.02 -176.6 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.207 -0.933 . . . . 0.0 109.607 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.499 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 11.4 p30 -73.33 139.96 46.39 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.29 -0.881 . . . . 0.0 109.477 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.587 HG12 ' HB2' ' A' ' 60' ' ' ALA . 56.1 t -115.74 122.02 68.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.196 -0.94 . . . . 0.0 109.44 -179.796 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.495 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.3 OUTLIER -79.78 157.53 27.06 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.13 -0.981 . . . . 0.0 109.192 179.977 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 1.117 ' CG2' HD12 ' A' ' 18' ' ' ILE . 13.0 t -132.31 130.18 60.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.303 -0.873 . . . . 0.0 109.373 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.667 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 13.4 t-80 -103.65 154.41 19.55 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.148 -0.97 . . . . 0.0 109.089 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.689 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.7 OUTLIER -45.98 -53.44 10.02 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.082 -1.011 . . . . 0.0 109.188 -179.682 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.689 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 93.0 p -55.55 -30.26 60.45 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.154 -0.966 . . . . 0.0 110.236 -179.555 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.401 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -58.03 -27.9 63.99 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.996 -1.065 . . . . 0.0 109.331 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.821 HG12 HG11 ' A' ' 63' ' ' VAL . 2.6 mp -108.13 142.56 20.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.355 -0.841 . . . . 0.0 109.52 -179.844 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -105.22 145.99 29.87 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.201 -0.937 . . . . 0.0 109.486 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.641 ' CA ' ' CZ ' ' A' ' 38' ' ' PHE . . . 161.43 149.99 5.79 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -68.12 -46.55 70.59 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.209 -1.171 . . . . 0.0 109.44 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -143.93 -11.72 0.34 Allowed Glycine 0 N--CA 1.491 2.345 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.641 ' CZ ' ' CA ' ' A' ' 35' ' ' GLY . 53.5 p90 -86.9 16.61 4.73 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.91 -1.347 . . . . 0.0 109.642 -179.763 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.512 ' O ' ' CD1' ' A' ' 41' ' ' LEU . 43.3 mtmt -63.0 -18.45 63.31 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.22 -0.925 . . . . 0.0 109.487 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 21.2 m -67.19 120.29 13.52 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.277 -0.89 . . . . 0.0 109.3 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.643 HD11 HG12 ' A' ' 33' ' ' ILE . 4.4 mp -81.21 139.99 35.19 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.266 -0.896 . . . . 0.0 109.837 -179.669 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.451 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.5 tt0 -91.75 134.4 34.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.43 -0.794 . . . . 0.0 109.401 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.459 ' HG3' ' O ' ' A' ' 7' ' ' LYS . 76.1 tt0 -59.44 128.28 36.27 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.239 -0.913 . . . . 0.0 109.638 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.406 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 91.99 -5.13 78.8 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.726 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.789 ' O ' HG23 ' A' ' 6' ' ' VAL . 63.3 tt0 -81.37 131.48 35.29 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.269 -1.136 . . . . 0.0 109.758 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -79.14 141.4 37.29 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.247 -0.908 . . . . 0.0 109.22 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.681 HG21 HD13 ' A' ' 18' ' ' ILE . 33.2 m -141.83 159.19 21.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.127 -0.983 . . . . 0.0 109.907 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.505 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 27.5 t -106.08 151.26 24.91 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 179.017 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.596 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 11.7 p90 175.13 165.39 0.29 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.943 -1.098 . . . . 0.0 110.317 -179.707 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.552 ' HA ' HD13 ' A' ' 2' ' ' LEU . 93.9 mt-10 -100.05 166.26 11.12 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 178.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.564 HD12 ' OE1' ' A' ' 23' ' ' GLN . 0.6 OUTLIER -104.16 125.72 58.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.917 -1.114 . . . . 0.0 109.804 -179.66 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.591 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 33.1 m -114.03 125.57 71.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.173 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.464 ' HA ' ' HA ' ' A' ' 58' ' ' PRO . 19.8 mt-10 -96.66 93.61 6.84 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.196 -0.94 . . . . 0.0 109.923 -179.35 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.61 -176.62 44.33 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.407 ' CG ' ' N ' ' A' ' 56' ' ' ARG . 18.5 p-10 -53.17 -50.77 63.92 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.219 -1.165 . . . . 0.0 109.715 -179.674 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.407 ' N ' ' CG ' ' A' ' 55' ' ' ASN . 20.1 mtm180 -58.96 -37.5 76.93 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.081 -1.012 . . . . 0.0 109.381 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.05 -159.21 28.07 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.5 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 53.7 Cg_endo -72.59 142.28 35.99 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.728 2.285 . . . . 0.0 111.903 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.591 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 72.8 mt-30 -138.97 169.89 16.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.384 -0.822 . . . . 0.0 108.945 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.587 ' HB2' HG12 ' A' ' 26' ' ' VAL . . . -95.03 138.17 33.11 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.047 -1.033 . . . . 0.0 110.383 -179.132 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.596 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -125.42 156.33 39.01 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.34 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 73.5 m-20 45.39 69.18 0.47 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.893 -1.13 . . . . 0.0 108.665 -179.647 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.821 HG11 HG12 ' A' ' 33' ' ' ILE . 2.2 t -88.14 125.83 41.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.326 -0.859 . . . . 0.0 110.17 -179.033 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 98.1 m -118.16 121.23 39.99 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.505 -0.747 . . . . 0.0 109.025 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.721 ' NZ ' HG21 ' A' ' 33' ' ' ILE . 28.7 mttp -71.49 112.26 7.47 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.229 -0.919 . . . . 0.0 109.361 -179.805 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.469 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 96.2 mt-10 -94.03 166.89 11.93 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.313 -0.867 . . . . 0.0 109.642 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ALA . . . . . 0.414 ' O ' ' O ' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 117.998 -1.001 . . . . 0.0 109.548 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.6 ' C ' HD12 ' A' ' 2' ' ' LEU . 77.1 mtp . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 121.283 0.564 . . . . 0.0 109.54 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.876 ' N ' HD12 ' A' ' 2' ' ' LEU . 3.6 mp -109.35 161.79 14.95 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.351 -0.843 . . . . 0.0 109.366 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.735 ' O ' HG13 ' A' ' 20' ' ' VAL . 83.0 mt-10 -127.96 144.27 51.1 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.274 -0.891 . . . . 0.0 109.185 179.671 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.471 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -140.06 153.43 23.32 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.499 ' N ' HG23 ' A' ' 18' ' ' ILE . 58.4 mttm -104.03 139.26 39.39 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.315 -1.109 . . . . 0.0 108.841 179.482 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.64 HG23 ' O ' ' A' ' 45' ' ' GLN . 38.7 t -71.63 109.94 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.166 -0.958 . . . . 0.0 109.899 -179.43 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.67 -32.83 27.94 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.371 -0.831 . . . . 0.0 108.977 179.42 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.686 ' CE3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -158.63 159.28 35.22 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 -179.837 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.505 ' N ' ' CG ' ' A' ' 8' ' ' TRP . 22.4 p90 -161.16 132.5 5.5 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.029 -1.044 . . . . 0.0 109.283 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.523 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.1 t-20 -128.19 123.6 34.69 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.197 -0.939 . . . . 0.0 109.539 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -76.64 -18.05 58.81 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.293 -0.88 . . . . 0.0 108.805 179.616 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.439 ' HB2' ' ND2' ' A' ' 10' ' ' ASN . 95.3 mt-10 -59.86 -56.08 26.21 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 178.557 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.692 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 13.8 mttp -67.15 -42.3 84.61 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 178.353 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.415 ' C ' ' CD1' ' A' ' 15' ' ' PHE . . . 106.56 7.0 35.02 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 179.345 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.735 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 0.0 OUTLIER -137.14 173.08 12.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.0 -1.294 . . . . 0.0 109.22 179.102 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.593 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -136.96 172.57 22.56 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.686 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 17.0 m-85 -119.37 133.74 55.56 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.226 -1.161 . . . . 0.0 109.306 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 1.103 ' CD1' HG21 ' A' ' 28' ' ' VAL . 15.4 mt -120.82 154.41 24.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.342 -0.849 . . . . 0.0 109.46 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 24.9 tp10 -117.65 122.91 44.82 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.307 -0.871 . . . . 0.0 109.38 179.827 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.735 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.9 t -93.58 120.16 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.228 -0.92 . . . . 0.0 109.553 -179.868 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -67.14 109.18 2.94 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.295 -0.878 . . . . 0.0 109.286 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.22 -23.1 7.75 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.68 ' OE1' HD12 ' A' ' 51' ' ' ILE . 65.0 mt-30 -130.79 164.79 24.38 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.304 -1.115 . . . . 0.0 109.51 -179.77 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 41.0 m-20 -55.28 -175.02 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.33 -0.856 . . . . 0.0 109.924 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.475 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 15.2 p30 -74.18 141.99 45.46 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.301 -0.875 . . . . 0.0 109.737 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.478 HG21 HG21 ' A' ' 20' ' ' VAL . 90.6 t -117.87 118.13 57.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.207 -0.933 . . . . 0.0 109.353 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.448 ' CE1' ' HB3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -75.13 156.06 36.37 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.231 -0.918 . . . . 0.0 109.021 179.771 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 1.103 HG21 ' CD1' ' A' ' 18' ' ' ILE . 6.9 t -133.57 139.95 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.89 . . . . 0.0 109.607 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.735 ' HA ' ' HB3' ' A' ' 15' ' ' PHE . 48.0 t60 -114.42 150.3 34.91 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.26 -0.9 . . . . 0.0 109.25 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.668 ' CG ' ' N ' ' A' ' 31' ' ' SER . 1.0 OUTLIER -43.75 -52.66 6.44 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.174 -0.954 . . . . 0.0 109.396 -179.642 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.668 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 22.8 t -57.61 -20.84 35.51 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.17 -0.956 . . . . 0.0 109.863 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.471 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -69.42 -22.75 63.66 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.115 -0.991 . . . . 0.0 109.735 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.639 ' CG1' HG11 ' A' ' 63' ' ' VAL . 2.9 mp -103.08 143.45 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.207 -0.933 . . . . 0.0 109.716 -179.852 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.455 ' C ' ' O ' ' A' ' 33' ' ' ILE . 59.6 mt-30 -40.68 -59.03 1.48 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.326 -0.859 . . . . 0.0 109.602 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.524 ' HA3' ' HE3' ' A' ' 39' ' ' LYS . . . 92.24 2.75 68.07 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.433 ' C ' ' O ' ' A' ' 35' ' ' GLY . 81.9 tt0 -44.05 -27.5 0.39 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.187 -1.184 . . . . 0.0 109.322 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 174.23 40.29 0.04 OUTLIER Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.495 ' HB2' ' HE2' ' A' ' 65' ' ' LYS . 5.7 p90 -175.42 46.94 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.201 -1.176 . . . . 0.0 109.56 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.524 ' HE3' ' HA3' ' A' ' 35' ' ' GLY . 17.8 mttp -62.15 -32.13 72.7 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.183 -0.948 . . . . 0.0 109.332 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 30.0 m -73.66 108.24 6.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.245 -0.909 . . . . 0.0 109.492 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.597 HD11 ' CD1' ' A' ' 33' ' ' ILE . 5.5 mp -74.49 147.31 42.0 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.244 -0.91 . . . . 0.0 109.787 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.427 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 94.5 mt-10 -105.47 146.29 29.73 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.44 -0.787 . . . . 0.0 109.36 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.574 ' HA ' HG12 ' A' ' 6' ' ' VAL . 52.6 tt0 -70.06 130.72 42.91 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.184 -0.947 . . . . 0.0 109.613 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 93.11 -5.96 75.75 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.726 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.64 ' O ' HG23 ' A' ' 6' ' ' VAL . 60.2 tp60 -81.86 125.68 30.99 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.26 -1.141 . . . . 0.0 109.73 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -73.25 143.94 46.88 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.199 -0.938 . . . . 0.0 109.223 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.853 HG21 HD13 ' A' ' 18' ' ' ILE . 33.4 m -145.39 158.92 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.109 -0.994 . . . . 0.0 110.188 -179.576 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.526 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 4.6 p -110.49 154.53 23.52 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.115 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.584 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 7.9 p90 171.29 167.66 0.08 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.93 -1.106 . . . . 0.0 110.035 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.651 ' HA ' HD13 ' A' ' 2' ' ' LEU . 94.8 mt-10 -103.67 165.09 11.25 Favored 'General case' 0 C--N 1.303 -1.436 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.212 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.68 HD12 ' OE1' ' A' ' 23' ' ' GLN . 3.9 mt -106.25 132.22 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 120.997 -1.064 . . . . 0.0 109.685 -179.897 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.536 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 20.5 m -121.28 133.12 68.87 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.557 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 -84.97 82.66 8.35 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.213 -0.929 . . . . 0.0 109.604 -179.673 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 57' ' ' GLY . . . -84.32 176.64 51.56 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 20.2 p-10 -49.47 -51.69 34.13 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.241 -1.152 . . . . 0.0 109.65 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 23.2 mtm180 -62.38 -31.98 72.72 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.095 -1.003 . . . . 0.0 109.549 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.413 ' O ' ' N ' ' A' ' 54' ' ' GLY . . . 142.93 -148.22 19.89 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.478 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 50.0 Cg_endo -71.24 133.59 23.17 Favored 'Trans proline' 0 C--O 1.214 -0.688 0 C-N-CA 122.802 2.334 . . . . 0.0 112.034 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.536 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 42.6 mt-30 -127.87 161.32 29.34 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.38 -0.825 . . . . 0.0 109.359 179.726 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.615 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -92.16 110.49 21.87 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.217 -0.927 . . . . 0.0 110.134 -179.508 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.575 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -93.48 152.07 19.31 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.327 -0.858 . . . . 0.0 109.061 179.633 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.494 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 79.0 m-20 43.63 78.23 0.06 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.043 -1.036 . . . . 0.0 109.029 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.748 HG21 ' CG1' ' A' ' 28' ' ' VAL . 2.1 t -92.87 125.87 45.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.182 -0.949 . . . . 0.0 110.003 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.402 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 56.9 m -120.48 130.22 54.19 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.655 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.561 ' NZ ' HG21 ' A' ' 33' ' ' ILE . 44.3 mttp -76.81 114.04 15.13 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.277 -0.889 . . . . 0.0 109.72 -179.697 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 57.5 mm-40 -101.02 172.02 7.28 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.284 -0.885 . . . . 0.0 109.635 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 117.993 -1.003 . . . . 0.0 109.471 179.893 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.749 ' C ' HD12 ' A' ' 2' ' ' LEU . 73.1 mtp . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.837 ' N ' HD12 ' A' ' 2' ' ' LEU . 5.2 mp -112.93 165.72 12.06 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.322 -0.861 . . . . 0.0 109.319 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.779 ' O ' HG13 ' A' ' 20' ' ' VAL . 2.4 tt0 -132.39 139.99 48.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.179 -0.951 . . . . 0.0 109.461 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -140.4 158.75 26.09 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.509 ' O ' HG23 ' A' ' 18' ' ' ILE . 85.6 mttt -106.96 139.69 40.97 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.32 -1.106 . . . . 0.0 108.895 179.78 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.711 HG23 ' O ' ' A' ' 45' ' ' GLN . 22.6 t -72.88 111.56 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.109 -0.994 . . . . 0.0 110.127 -179.34 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 19.1 tttt -79.16 -40.6 30.52 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.563 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.619 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.7 154.76 26.88 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.765 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.436 ' N ' ' CG ' ' A' ' 8' ' ' TRP . 13.6 p90 -154.9 141.0 18.43 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.058 -1.026 . . . . 0.0 109.424 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.483 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.7 t-20 -132.76 128.92 37.89 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.253 -0.904 . . . . 0.0 109.677 -179.746 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.3 p -78.46 -20.03 51.83 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.208 -0.933 . . . . 0.0 108.831 179.564 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.479 ' HA ' ' OE1' ' A' ' 12' ' ' GLU . 69.9 mm-40 -64.45 -45.69 86.36 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 178.092 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.631 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 10.3 mttm -73.86 -34.98 64.71 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 178.449 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.521 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 92.84 0.93 68.26 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 179.191 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.631 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 5.6 p90 -138.78 171.94 13.61 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.044 -1.268 . . . . 0.0 108.883 178.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.619 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -138.43 172.11 23.15 Favored Glycine 0 N--CA 1.49 2.27 0 C-N-CA 119.634 -1.27 . . . . 0.0 110.024 -179.452 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.514 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 27.1 m-85 -115.17 133.0 56.42 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.339 -1.095 . . . . 0.0 108.789 179.569 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 1.113 HD12 ' CG2' ' A' ' 28' ' ' VAL . 13.1 mt -120.92 155.29 24.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.151 -0.968 . . . . 0.0 109.873 -179.518 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.4 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 23.4 tp10 -116.92 123.47 47.06 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.398 -0.814 . . . . 0.0 109.369 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.779 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.3 t -98.15 123.0 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.17 -0.956 . . . . 0.0 109.317 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.463 ' HA ' ' OE1' ' A' ' 21' ' ' GLU . 68.7 mm-40 -72.24 108.83 5.6 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 0.0 109.3 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 125.44 -22.68 6.17 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.226 -1.55 . . . . 0.0 109.226 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.788 ' OE1' HD12 ' A' ' 51' ' ' ILE . 73.1 mt-30 -135.73 167.54 20.96 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.28 -1.13 . . . . 0.0 109.548 -179.78 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -53.52 -177.12 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.262 -0.899 . . . . 0.0 109.587 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.479 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 11.8 p30 -74.61 143.18 44.48 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.937 . . . . 0.0 109.426 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.559 HG21 HD11 ' A' ' 51' ' ' ILE . 97.9 t -116.33 119.36 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.16 -0.962 . . . . 0.0 109.425 -179.813 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.518 ' CG ' ' N ' ' A' ' 28' ' ' VAL . 0.4 OUTLIER -77.84 158.8 29.32 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.172 -0.955 . . . . 0.0 109.207 179.916 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 1.113 ' CG2' HD12 ' A' ' 18' ' ' ILE . 4.4 t -133.09 125.71 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.476 -0.765 . . . . 0.0 109.144 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.676 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 14.6 t-80 -98.46 153.93 18.24 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.355 -0.84 . . . . 0.0 109.091 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.687 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -45.13 -53.68 7.75 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.07 -1.019 . . . . 0.0 109.203 -179.65 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.687 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 62.8 p -54.27 -25.13 21.69 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.189 -0.945 . . . . 0.0 109.921 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.466 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -62.34 -24.52 67.38 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.126 -0.984 . . . . 0.0 109.439 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.776 HD11 HD11 ' A' ' 41' ' ' LEU . 3.0 mp -109.25 136.0 46.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.238 -0.914 . . . . 0.0 109.544 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 61.5 tt0 -101.44 113.95 27.52 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.315 -0.865 . . . . 0.0 109.447 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.608 ' HA3' ' CE1' ' A' ' 38' ' ' PHE . . . -176.81 162.07 30.25 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 86.1 mt-10 -118.04 87.57 2.74 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.23 -1.159 . . . . 0.0 109.356 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.03 -24.81 7.72 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.608 ' CE1' ' HA3' ' A' ' 35' ' ' GLY . 49.0 p90 -123.65 25.36 8.17 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.336 -1.096 . . . . 0.0 109.242 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.49 ' HG3' ' O ' ' A' ' 35' ' ' GLY . 89.1 mttt -55.31 -36.8 66.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.336 -0.852 . . . . 0.0 109.662 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.52 ' O ' ' NZ ' ' A' ' 65' ' ' LYS . 20.7 m -72.17 138.43 47.64 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.209 -0.932 . . . . 0.0 109.522 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 1.038 HD23 HG11 ' A' ' 47' ' ' VAL . 5.1 mp -80.52 178.68 8.17 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.348 -0.845 . . . . 0.0 109.788 -179.784 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.492 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 20.5 tt0 -116.42 140.24 49.56 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.391 -0.818 . . . . 0.0 109.057 179.733 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.432 ' HA ' HG12 ' A' ' 6' ' ' VAL . 76.6 tt0 -62.35 125.35 23.6 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.264 -0.898 . . . . 0.0 109.618 -179.76 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 90.67 -7.1 81.82 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.711 ' O ' HG23 ' A' ' 6' ' ' VAL . 66.7 tt0 -81.76 134.39 35.44 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.24 -1.153 . . . . 0.0 109.72 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -80.07 140.16 36.6 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.271 -0.893 . . . . 0.0 109.155 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 1.038 HG11 HD23 ' A' ' 41' ' ' LEU . 26.4 m -140.57 151.73 20.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.227 -0.921 . . . . 0.0 109.745 -179.464 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.527 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 33.0 t -100.56 148.94 24.24 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.053 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.598 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 7.2 p90 176.28 164.7 0.42 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.903 -1.123 . . . . 0.0 110.105 -179.63 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.571 ' HA ' HD13 ' A' ' 2' ' ' LEU . 94.9 mt-10 -103.54 161.41 13.9 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.247 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.788 HD12 ' OE1' ' A' ' 23' ' ' GLN . 7.2 mt -104.61 135.78 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.969 -1.082 . . . . 0.0 109.783 -179.789 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.501 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 32.7 m -122.23 131.41 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.481 -0.762 . . . . 0.0 109.11 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -86.8 84.22 7.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.185 -0.947 . . . . 0.0 109.634 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -85.84 177.16 49.55 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 14.4 t-20 -50.34 -54.33 22.35 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.196 -1.179 . . . . 0.0 109.608 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 71.3 mtm180 -57.38 -35.46 70.01 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.241 -0.912 . . . . 0.0 109.498 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 145.2 -153.28 25.17 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -70.37 137.31 33.41 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.734 2.289 . . . . 0.0 111.987 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.524 ' C ' HG13 ' A' ' 26' ' ' VAL . 92.2 mt-30 -135.19 165.99 24.14 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.342 -0.849 . . . . 0.0 109.275 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.564 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -94.58 137.15 34.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.198 -0.938 . . . . 0.0 109.777 -179.69 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.598 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -123.96 155.04 38.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.365 -0.834 . . . . 0.0 108.843 179.717 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.476 ' C ' ' O ' ' A' ' 61' ' ' ALA . 85.8 m-20 43.19 73.91 0.13 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.897 -1.127 . . . . 0.0 108.706 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.845 HG11 HD21 ' A' ' 41' ' ' LEU . 2.7 t -89.65 126.96 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.212 -0.93 . . . . 0.0 109.99 -179.108 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.422 ' HB ' ' HB3' ' A' ' 48' ' ' SER . 70.3 m -118.45 124.29 47.27 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.52 ' NZ ' ' O ' ' A' ' 40' ' ' THR . 55.5 mttt -71.73 111.03 6.67 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.181 -0.95 . . . . 0.0 109.528 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -89.78 164.1 14.79 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.364 -0.835 . . . . 0.0 109.566 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.461 -179.922 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.582 ' C ' HD12 ' A' ' 2' ' ' LEU . 91.8 mtp . . . . . 0 N--CA 1.489 1.475 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.847 ' N ' HD12 ' A' ' 2' ' ' LEU . 4.6 mp -107.55 161.91 14.42 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.238 -0.914 . . . . 0.0 109.391 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.765 ' O ' HG13 ' A' ' 20' ' ' VAL . 96.1 mt-10 -129.48 147.36 51.29 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.167 -0.958 . . . . 0.0 109.295 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.444 ' C ' ' CG2' ' A' ' 18' ' ' ILE . . . -143.1 153.46 24.77 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.666 ' C ' HG23 ' A' ' 18' ' ' ILE . 27.6 mttp -102.48 141.38 35.39 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.284 -1.127 . . . . 0.0 108.839 179.557 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 45' ' ' GLN . 33.7 t -73.8 110.58 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.247 -0.908 . . . . 0.0 110.126 -179.392 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.488 ' NZ ' ' HB3' ' A' ' 17' ' ' PHE . 2.9 pttt -79.89 -36.46 36.5 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.615 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -159.74 154.26 24.04 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.962 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.627 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 17.0 p90 -156.03 140.33 16.64 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.075 -1.016 . . . . 0.0 109.496 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.447 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 55.1 t-20 -130.82 121.91 26.16 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.224 -0.923 . . . . 0.0 109.521 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -74.08 -20.04 60.41 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.159 -0.963 . . . . 0.0 108.745 179.637 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.435 ' HB2' ' ND2' ' A' ' 10' ' ' ASN . 95.5 mt-10 -63.19 -47.46 82.5 Favored 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 106.476 -1.675 . . . . 0.0 106.476 177.883 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.693 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 28.8 mttm -70.31 -41.44 73.29 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 178.161 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.504 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 99.15 3.46 56.73 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.386 -1.485 . . . . 0.0 109.386 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.693 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 2.8 p90 -141.85 167.52 21.94 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.274 -1.133 . . . . 0.0 108.85 179.015 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.615 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -136.07 177.22 19.72 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.652 -1.261 . . . . 0.0 110.05 -179.366 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.562 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 19.4 m-85 -119.2 135.49 54.65 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.384 -1.068 . . . . 0.0 109.078 179.834 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 1.088 ' CD1' HG21 ' A' ' 28' ' ' VAL . 37.9 mt -122.34 148.41 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.168 -0.958 . . . . 0.0 109.507 -179.673 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 23.3 tp10 -110.98 121.05 44.37 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.342 -0.849 . . . . 0.0 109.332 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.765 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.6 t -91.46 120.59 40.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.211 -0.931 . . . . 0.0 109.664 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.411 ' OE1' ' HA ' ' A' ' 21' ' ' GLU . 73.2 mm-40 -71.9 110.64 6.54 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.202 -0.936 . . . . 0.0 109.246 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.405 ' C ' ' HG3' ' A' ' 23' ' ' GLN . . . 122.57 -18.38 8.18 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.694 ' OE1' HD12 ' A' ' 51' ' ' ILE . 63.9 mt-30 -140.04 170.35 16.01 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.353 -1.086 . . . . 0.0 109.495 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 60.2 m-20 -55.31 -178.35 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.291 -0.88 . . . . 0.0 109.654 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 22.6 p30 -75.01 146.46 41.61 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.236 -0.915 . . . . 0.0 109.438 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.66 HG13 ' C ' ' A' ' 59' ' ' GLN . 58.1 t -118.35 119.07 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.242 -0.911 . . . . 0.0 109.401 -179.67 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.545 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.0 OUTLIER -76.61 156.31 32.84 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.205 -0.934 . . . . 0.0 109.148 179.855 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 1.088 HG21 ' CD1' ' A' ' 18' ' ' ILE . 14.7 t -133.45 132.97 57.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.383 -0.823 . . . . 0.0 109.399 -179.762 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.596 ' HA ' ' HB3' ' A' ' 15' ' ' PHE . 56.4 t60 -111.18 153.5 25.7 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.354 -0.841 . . . . 0.0 109.053 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.682 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -44.47 -53.85 6.55 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.126 -0.984 . . . . 0.0 109.347 -179.605 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.682 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 32.3 t -57.04 -22.81 41.78 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.115 -0.991 . . . . 0.0 110.014 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.454 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -66.43 -27.53 67.91 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.09 -1.006 . . . . 0.0 109.458 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.719 HG12 HG11 ' A' ' 63' ' ' VAL . 2.4 mp -100.65 141.52 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.258 -0.901 . . . . 0.0 109.677 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.407 ' C ' ' O ' ' A' ' 33' ' ' ILE . 60.7 mt-30 -42.69 -53.28 4.57 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.276 -0.89 . . . . 0.0 109.63 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.54 ' CA ' ' HG2' ' A' ' 39' ' ' LYS . . . 88.4 11.06 67.17 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.369 -1.492 . . . . 0.0 109.369 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.414 ' C ' ' O ' ' A' ' 35' ' ' GLY . 82.3 tt0 -45.09 -26.44 0.45 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.317 -1.108 . . . . 0.0 109.425 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 172.34 40.57 0.04 OUTLIER Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.526 ' HB2' ' HZ2' ' A' ' 65' ' ' LYS . 0.1 OUTLIER -178.96 40.38 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.203 -1.175 . . . . 0.0 109.643 179.936 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.54 ' HG2' ' CA ' ' A' ' 35' ' ' GLY . 87.0 mttt -47.77 -29.59 3.26 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.191 -0.943 . . . . 0.0 109.351 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 29.9 m -79.15 109.35 13.38 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.278 -0.889 . . . . 0.0 109.449 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.64 ' CD1' HD13 ' A' ' 33' ' ' ILE . 3.1 mp -75.28 152.73 38.2 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.32 -0.863 . . . . 0.0 109.672 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.468 ' O ' ' CB ' ' A' ' 6' ' ' VAL . 96.0 mt-10 -100.7 149.15 24.09 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.324 -0.86 . . . . 0.0 109.484 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.525 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 69.8 tt0 -71.91 130.01 39.97 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.348 -0.845 . . . . 0.0 109.625 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.51 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 90.52 -4.26 82.17 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.583 ' O ' HG23 ' A' ' 6' ' ' VAL . 49.8 tt0 -80.8 129.57 34.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.271 -1.135 . . . . 0.0 109.638 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -76.48 139.75 40.94 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.268 -0.895 . . . . 0.0 109.065 179.702 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.822 HG21 HD13 ' A' ' 18' ' ' ILE . 31.8 m -142.28 162.24 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.029 -1.044 . . . . 0.0 109.959 -179.651 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.509 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 63.8 m -112.44 153.38 27.47 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.634 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 5.8 p90 172.75 168.56 0.12 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.033 -1.042 . . . . 0.0 109.978 -179.833 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.528 ' HA ' HD13 ' A' ' 2' ' ' LEU . 95.1 mt-10 -103.5 160.88 14.34 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.694 HD12 ' OE1' ' A' ' 23' ' ' GLN . 3.9 mt -103.5 134.47 44.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.116 -0.99 . . . . 0.0 109.616 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.533 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 33.9 m -122.74 131.74 72.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -85.7 87.2 7.37 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.102 -0.999 . . . . 0.0 109.677 -179.724 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.62 178.07 43.96 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.9 t30 -50.24 -56.75 9.82 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.23 -1.159 . . . . 0.0 109.514 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 21.6 mtm180 -57.11 -34.07 67.96 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.262 -0.898 . . . . 0.0 109.417 -179.895 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 144.53 -152.18 24.15 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.491 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 51.0 Cg_endo -70.46 136.98 32.43 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.835 2.357 . . . . 0.0 112.052 -179.869 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.66 ' C ' HG13 ' A' ' 26' ' ' VAL . 89.9 mt-30 -132.85 165.3 24.93 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.443 -0.786 . . . . 0.0 109.263 179.796 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.549 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -90.13 132.19 35.58 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.16 -0.963 . . . . 0.0 109.789 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.545 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -113.7 147.76 37.61 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.528 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.484 ' C ' ' O ' ' A' ' 61' ' ' ALA . 23.9 t-20 41.27 74.41 0.11 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.141 -0.975 . . . . 0.0 108.778 -179.497 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.719 HG11 HG12 ' A' ' 33' ' ' ILE . 1.4 t -84.38 127.94 39.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.387 -0.821 . . . . 0.0 110.159 -179.068 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.41 ' HB ' ' HB2' ' A' ' 48' ' ' SER . 27.7 m -119.68 126.61 51.53 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 179.333 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.536 ' HA ' HG12 ' A' ' 47' ' ' VAL . 57.7 mttt -73.72 108.78 6.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.162 -0.961 . . . . 0.0 109.511 -179.614 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 45.9 mm-40 -99.08 175.8 5.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.338 -0.852 . . . . 0.0 109.689 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.479 179.922 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.87 ' C ' HD12 ' A' ' 2' ' ' LEU . 84.0 mmm . . . . . 0 N--CA 1.491 1.595 0 CA-C-O 121.296 0.569 . . . . 0.0 109.487 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.87 HD12 ' C ' ' A' ' 1' ' ' MET . 5.1 mp -115.88 154.89 28.91 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.209 -0.932 . . . . 0.0 109.33 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.731 ' O ' HG13 ' A' ' 20' ' ' VAL . 2.1 tt0 -124.74 140.45 52.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.276 -0.89 . . . . 0.0 108.993 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -144.63 149.87 21.98 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.445 ' O ' HG23 ' A' ' 18' ' ' ILE . 19.4 mttm -99.52 139.53 35.05 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.38 -1.071 . . . . 0.0 108.539 179.295 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.738 HG23 ' O ' ' A' ' 45' ' ' GLN . 20.7 t -69.91 115.22 8.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.039 -1.038 . . . . 0.0 109.776 -179.464 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.437 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 40.7 tttt -78.76 -42.13 28.81 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.726 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.63 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -160.14 154.93 24.28 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.43 -0.794 . . . . 0.0 108.888 179.976 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.46 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 11.3 p90 -154.25 141.74 19.76 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.101 -0.999 . . . . 0.0 109.193 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.48 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 57.9 t-20 -129.79 133.57 47.05 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.151 -0.968 . . . . 0.0 109.832 -179.62 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 12.5 p -78.63 -21.2 48.79 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.125 -0.984 . . . . 0.0 108.906 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.429 ' HB2' ' ND2' ' A' ' 10' ' ' ASN . 92.8 mt-10 -65.52 -44.63 86.34 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 106.657 -1.609 . . . . 0.0 106.657 177.926 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.67 ' HD3' ' CE2' ' A' ' 15' ' ' PHE . 16.1 mttm -75.36 -37.7 60.5 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.363 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.513 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 91.01 1.47 72.85 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 179.542 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.67 ' CE2' ' HD3' ' A' ' 13' ' ' LYS . 4.0 p90 -138.38 169.95 16.88 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.098 -1.236 . . . . 0.0 108.937 179.118 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.63 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -138.63 175.21 21.61 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 119.625 -1.274 . . . . 0.0 109.97 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.483 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 37.6 m-85 -116.7 132.49 56.67 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.404 -1.057 . . . . 0.0 109.014 179.696 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 1.066 ' CD1' HG21 ' A' ' 28' ' ' VAL . 37.1 mt -116.89 148.7 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.141 -0.974 . . . . 0.0 109.528 -179.827 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 30.6 tp10 -110.29 121.31 44.98 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.332 -0.855 . . . . 0.0 109.448 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.731 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.4 t -96.22 120.02 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.163 -0.961 . . . . 0.0 109.471 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 47.1 mp0 -71.75 109.01 5.36 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.273 -0.892 . . . . 0.0 109.36 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.428 ' C ' ' HG3' ' A' ' 23' ' ' GLN . . . 125.28 -20.46 6.61 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.783 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.428 ' HG3' ' C ' ' A' ' 22' ' ' GLY . 37.3 mt-30 -138.83 169.62 17.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.317 -1.107 . . . . 0.0 109.695 -179.811 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -53.54 -177.4 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.32 -0.862 . . . . 0.0 109.665 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.516 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 11.0 p30 -75.97 143.54 41.49 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.287 -0.883 . . . . 0.0 109.661 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.631 HG12 ' HB2' ' A' ' 60' ' ' ALA . 79.7 t -116.92 120.87 66.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.23 -0.919 . . . . 0.0 109.527 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.553 ' CG ' ' N ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER -80.26 161.11 25.3 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.373 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 1.066 HG21 ' CD1' ' A' ' 18' ' ' ILE . 15.0 t -135.7 125.02 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.428 -0.795 . . . . 0.0 109.4 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.688 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 15.1 t-80 -96.2 154.35 17.3 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.231 -0.918 . . . . 0.0 109.14 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.688 ' CD2' ' CE1' ' A' ' 29' ' ' HIS . 0.7 OUTLIER -45.8 -53.41 9.66 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.105 -0.997 . . . . 0.0 109.245 -179.616 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.685 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 86.8 p -55.66 -27.24 48.84 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.171 -0.956 . . . . 0.0 109.982 -179.618 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.432 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -64.41 -35.94 82.52 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.995 -1.066 . . . . 0.0 109.159 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.639 HG12 HG11 ' A' ' 63' ' ' VAL . 5.1 mt -91.97 147.85 5.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.228 -0.92 . . . . 0.0 109.349 179.777 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 69.3 mt-30 -125.45 145.51 50.04 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.213 -0.93 . . . . 0.0 109.449 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.605 ' CA ' ' CZ ' ' A' ' 38' ' ' PHE . . . -179.35 161.78 28.09 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -77.34 -36.87 53.41 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.232 -1.158 . . . . 0.0 109.523 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -150.58 17.13 0.98 Allowed Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.605 ' CZ ' ' CA ' ' A' ' 35' ' ' GLY . 44.4 p90 -127.44 49.83 2.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.269 -1.136 . . . . 0.0 109.502 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 46.4 mtpt -66.56 -30.26 70.52 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.2 -0.938 . . . . 0.0 109.567 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.405 HG22 ' CD2' ' A' ' 9' ' ' PHE . 36.6 m -72.89 111.21 7.81 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.283 -0.886 . . . . 0.0 109.642 -179.754 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.557 HD21 HG11 ' A' ' 47' ' ' VAL . 1.1 mt -59.69 174.68 0.43 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.262 -0.899 . . . . 0.0 109.575 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.499 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 46.3 tp10 -123.18 147.13 47.18 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.203 -0.936 . . . . 0.0 109.56 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.437 ' HG3' ' O ' ' A' ' 7' ' ' LYS . 76.0 tt0 -73.35 126.01 29.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.196 -0.94 . . . . 0.0 109.739 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.75 -5.45 79.62 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.803 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.738 ' O ' HG23 ' A' ' 6' ' ' VAL . 6.2 tp-100 -81.22 124.4 29.26 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.196 -1.179 . . . . 0.0 109.601 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -75.09 144.61 42.84 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.263 -0.898 . . . . 0.0 109.154 179.63 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.832 HG12 ' HA ' ' A' ' 65' ' ' LYS . 21.7 m -148.36 168.11 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.177 -0.952 . . . . 0.0 109.827 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.545 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 4.1 p -112.48 152.76 28.37 Favored 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.325 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.579 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 14.4 p90 175.83 164.42 0.36 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.979 -1.076 . . . . 0.0 110.141 -179.781 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.425 ' HA ' HD13 ' A' ' 2' ' ' LEU . 91.9 mt-10 -100.36 164.6 11.86 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 179.016 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.424 ' O ' HG22 ' A' ' 51' ' ' ILE . 0.4 OUTLIER -101.77 124.36 55.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 120.851 -1.156 . . . . 0.0 109.422 -179.903 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.559 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.1 m -111.1 123.57 67.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.401 -0.812 . . . . 0.0 109.011 179.764 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.417 ' HA ' ' HA ' ' A' ' 58' ' ' PRO . 10.2 mt-10 -94.97 91.12 6.23 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.177 -0.952 . . . . 0.0 109.948 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.08 -174.88 42.37 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 179.702 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 -54.37 -62.39 1.69 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.171 -1.194 . . . . 0.0 109.546 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 18.8 mtm180 -46.66 -41.23 14.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.157 -0.964 . . . . 0.0 109.194 179.86 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 152.99 -161.53 29.65 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.552 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 53.6 Cg_endo -72.09 144.12 41.65 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.712 2.275 . . . . 0.0 111.752 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.559 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 78.8 mt-30 -141.82 172.36 12.79 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.289 -0.882 . . . . 0.0 109.048 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.631 ' HB2' HG12 ' A' ' 26' ' ' VAL . . . -94.23 142.55 27.28 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.139 -0.976 . . . . 0.0 110.236 -179.234 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.512 ' O ' ' C ' ' A' ' 62' ' ' ASN . . . -124.43 152.85 42.77 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.434 -0.791 . . . . 0.0 108.903 179.578 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.512 ' C ' ' O ' ' A' ' 61' ' ' ALA . 44.8 t30 38.62 73.91 0.1 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.07 -1.019 . . . . 0.0 109.186 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.639 HG11 HG12 ' A' ' 33' ' ' ILE . 1.5 t -86.97 129.22 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.245 -0.909 . . . . 0.0 109.96 -179.313 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.432 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 65.3 m -115.44 119.53 36.54 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.35 -0.843 . . . . 0.0 109.116 179.645 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.832 ' HA ' HG12 ' A' ' 47' ' ' VAL . 35.9 mttt -69.73 108.17 3.79 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 109.286 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.45 ' HG3' ' HA ' ' A' ' 47' ' ' VAL . 97.2 mt-10 -87.4 164.09 16.4 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.272 -0.892 . . . . 0.0 109.725 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.562 0 CA-C-O 117.989 -1.005 . . . . 0.0 109.58 -179.955 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 71.2 mtm . . . . . 0 N--CA 1.489 1.51 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 45.5 mt -108.61 166.24 10.94 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.233 -0.917 . . . . 0.0 109.541 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.66 ' O ' HG13 ' A' ' 20' ' ' VAL . 89.1 mt-10 -136.13 136.54 40.17 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.241 -0.912 . . . . 0.0 109.26 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -133.78 159.42 23.7 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.626 ' O ' HG23 ' A' ' 18' ' ' ILE . 77.9 mttt -103.34 140.84 36.9 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.409 -1.053 . . . . 0.0 108.824 179.41 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.761 HG23 ' O ' ' A' ' 45' ' ' GLN . 18.9 t -73.73 114.2 12.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.116 -0.99 . . . . 0.0 110.241 -179.111 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.4 tttt -78.44 -41.45 32.79 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.438 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.671 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.78 153.89 25.32 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.553 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.629 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 6.2 p90 -156.05 141.65 17.8 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.986 -1.071 . . . . 0.0 109.764 -179.61 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.435 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 50.4 t-20 -127.17 126.03 42.14 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.276 -0.89 . . . . 0.0 108.992 179.528 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 41.5 p -78.54 -12.99 60.04 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.198 -0.939 . . . . 0.0 109.594 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -59.26 -58.78 7.13 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 178.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.573 ' HD2' ' CE2' ' A' ' 15' ' ' PHE . 34.0 mtmt -72.08 -44.94 62.48 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.606 ' O ' ' CB ' ' A' ' 30' ' ' PHE . . . 112.1 19.36 7.24 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 120.035 -1.078 . . . . 0.0 110.651 178.94 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.603 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 50.2 p90 -148.85 172.64 14.33 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.795 -1.414 . . . . 0.0 109.187 179.518 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.671 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -149.53 174.96 28.92 Favored Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.53 -1.319 . . . . 0.0 110.206 -179.477 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.433 ' CE1' ' HB2' ' A' ' 27' ' ' PHE . 49.6 m-85 -111.9 133.75 53.9 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.446 -1.032 . . . . 0.0 108.834 179.644 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 1.137 HD12 ' CG2' ' A' ' 28' ' ' VAL . 19.7 mt -120.4 149.43 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.207 -0.933 . . . . 0.0 109.489 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 20.7 tp10 -113.28 122.44 47.44 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.351 -0.843 . . . . 0.0 109.332 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.66 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.8 t -91.75 121.9 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.253 -0.904 . . . . 0.0 109.525 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -69.36 108.5 3.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.333 -0.854 . . . . 0.0 109.325 179.807 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.07 -19.72 8.7 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.403 ' OE1' HG11 ' A' ' 20' ' ' VAL . 49.0 mt-30 -133.47 166.18 23.14 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.289 -1.124 . . . . 0.0 109.487 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 59.5 m-20 -54.79 -175.74 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.235 -0.916 . . . . 0.0 109.45 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.493 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 11.2 p30 -75.84 143.78 41.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.291 -0.881 . . . . 0.0 109.577 -179.832 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.573 HG21 HG21 ' A' ' 20' ' ' VAL . 79.3 t -118.85 121.42 66.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.184 -0.947 . . . . 0.0 109.374 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.504 ' O ' ' N ' ' A' ' 60' ' ' ALA . 0.1 OUTLIER -79.03 158.26 27.93 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.266 -0.896 . . . . 0.0 109.392 -179.984 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 1.137 ' CG2' HD12 ' A' ' 18' ' ' ILE . 17.3 t -132.85 132.38 59.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.428 -0.795 . . . . 0.0 109.165 -179.76 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.678 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 14.6 t-80 -104.61 154.89 19.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.256 -0.903 . . . . 0.0 109.277 -179.846 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.693 ' CD1' ' N ' ' A' ' 31' ' ' SER . 0.6 OUTLIER -46.3 -53.01 11.56 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.215 -0.928 . . . . 0.0 109.361 -179.696 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.693 ' N ' ' CD1' ' A' ' 30' ' ' PHE . 91.4 p -60.16 -21.19 61.35 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.095 -1.003 . . . . 0.0 110.025 -179.631 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.473 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -63.19 -23.6 67.5 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.042 -1.036 . . . . 0.0 109.468 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.782 ' CD1' HD11 ' A' ' 41' ' ' LEU . 3.5 mp -111.18 136.47 47.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.206 -0.934 . . . . 0.0 109.605 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 74.7 mt-30 -92.66 145.28 24.54 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.245 -0.909 . . . . 0.0 109.51 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.603 ' HA2' ' CE1' ' A' ' 38' ' ' PHE . . . 161.04 148.74 5.38 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.908 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -71.16 -47.68 56.3 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.345 -1.091 . . . . 0.0 109.629 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -141.28 19.95 2.64 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.603 ' CE1' ' HA2' ' A' ' 35' ' ' GLY . 50.7 p90 -129.27 26.95 5.39 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.288 -1.125 . . . . 0.0 109.435 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.443 ' O ' ' HB ' ' A' ' 33' ' ' ILE . 77.3 mttt -60.22 -37.57 80.72 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.211 -0.931 . . . . 0.0 109.654 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 29.5 p -62.54 145.47 54.24 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.228 -0.92 . . . . 0.0 109.634 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 1.026 HD23 HG11 ' A' ' 47' ' ' VAL . 3.0 mp -98.35 -174.29 2.79 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.259 -0.901 . . . . 0.0 109.281 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.523 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.1 tt0 -121.61 150.63 41.42 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.26 -0.9 . . . . 0.0 109.338 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 61.5 tt0 -67.44 124.23 22.62 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.23 -0.919 . . . . 0.0 109.538 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 90.96 -3.58 80.93 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 179.795 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.761 ' O ' HG23 ' A' ' 6' ' ' VAL . 61.4 tp60 -81.71 131.6 35.27 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.18 -1.189 . . . . 0.0 109.603 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -76.54 140.16 41.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.187 -0.946 . . . . 0.0 109.204 179.741 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 1.026 HG11 HD23 ' A' ' 41' ' ' LEU . 33.8 m -141.26 159.96 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.151 -0.968 . . . . 0.0 109.532 -179.84 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.499 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 43.4 m -112.86 155.62 24.36 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.385 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.585 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 3.7 p90 171.69 166.48 0.09 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.037 -1.039 . . . . 0.0 110.144 -179.692 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -97.82 157.53 16.02 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.729 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.4 mt -98.12 128.1 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.985 -1.072 . . . . 0.0 110.006 -179.473 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.765 HG23 ' HB2' ' A' ' 59' ' ' GLN . 0.3 OUTLIER -110.07 119.68 59.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.366 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -89.01 91.44 8.83 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.203 -0.936 . . . . 0.0 109.872 -179.446 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -97.23 -176.2 34.58 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 14.3 t-20 -53.57 -61.59 2.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.178 -1.189 . . . . 0.0 109.663 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 61.3 mtp180 -47.9 -38.88 17.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.232 -0.917 . . . . 0.0 109.049 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.86 -157.3 27.3 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.447 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 51.3 Cg_endo -71.06 140.78 38.54 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.719 2.279 . . . . 0.0 111.692 179.806 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.765 ' HB2' HG23 ' A' ' 52' ' ' VAL . 91.8 mt-30 -135.51 167.78 20.44 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.21 -0.931 . . . . 0.0 109.232 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.651 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -96.42 137.58 35.28 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.18 -0.95 . . . . 0.0 110.158 -179.354 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.585 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -125.18 156.67 38.06 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.466 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.524 ' C ' ' O ' ' A' ' 61' ' ' ALA . 80.7 m-20 38.68 74.56 0.09 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.075 -1.016 . . . . 0.0 108.927 -179.765 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.971 HG11 HD21 ' A' ' 41' ' ' LEU . 2.4 t -89.32 129.62 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.234 -0.916 . . . . 0.0 110.307 -178.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 60.8 m -118.54 124.66 48.07 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.513 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.411 ' HE3' ' O ' ' A' ' 38' ' ' PHE . 53.2 mttt -67.18 107.37 2.31 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.245 -0.91 . . . . 0.0 109.281 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.412 ' HG3' ' OG ' ' A' ' 48' ' ' SER . 59.4 mm-40 -97.09 170.58 9.03 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.157 -0.964 . . . . 0.0 109.622 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.406 179.989 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 78.2 mtp . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.469 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 71.6 mt -112.98 164.07 13.9 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.254 -0.904 . . . . 0.0 109.539 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.615 ' O ' HG13 ' A' ' 20' ' ' VAL . 1.4 tt0 -130.75 140.89 50.35 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.34 -0.85 . . . . 0.0 109.329 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.49 155.06 25.05 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.584 ' O ' HG23 ' A' ' 18' ' ' ILE . 84.5 mttt -104.14 139.51 39.09 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.317 -1.108 . . . . 0.0 108.764 179.553 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.86 HG23 ' O ' ' A' ' 45' ' ' GLN . 16.0 t -72.22 113.16 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.097 -1.002 . . . . 0.0 110.085 -179.223 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.3 tttt -78.85 -40.87 31.49 Favored 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 179.546 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.607 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.96 154.41 25.82 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.812 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.601 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 8.2 p90 -155.59 141.27 17.95 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.026 -1.046 . . . . 0.0 109.315 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.46 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 63.2 t-20 -131.48 129.41 41.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.166 -0.959 . . . . 0.0 109.777 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 59.6 p -77.0 -20.38 56.13 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.285 -0.885 . . . . 0.0 109.083 179.604 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -62.49 -48.07 81.2 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 106.803 -1.555 . . . . 0.0 106.803 178.128 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.669 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 3.7 mttp -73.33 -39.31 65.35 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.57 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.529 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 97.26 5.06 58.26 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 179.395 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.669 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 5.6 p90 -143.1 165.79 26.44 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.162 -1.199 . . . . 0.0 108.994 179.292 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.607 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -134.71 174.54 21.0 Favored Glycine 0 N--CA 1.491 2.349 0 C-N-CA 119.708 -1.234 . . . . 0.0 110.087 -179.438 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.49 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 26.1 m-85 -115.75 137.94 51.6 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.463 -1.022 . . . . 0.0 109.215 179.755 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 1.129 HD12 ' CG2' ' A' ' 28' ' ' VAL . 12.5 mt -123.69 154.06 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.161 -0.962 . . . . 0.0 109.491 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -117.98 116.06 26.15 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.313 -0.867 . . . . 0.0 109.503 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.622 HG21 HG21 ' A' ' 26' ' ' VAL . 2.4 t -85.33 118.4 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.276 -0.89 . . . . 0.0 109.353 179.789 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 85.4 mt-10 -68.43 111.08 4.45 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.196 -0.94 . . . . 0.0 109.243 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.451 ' C ' ' HG3' ' A' ' 23' ' ' GLN . . . 120.93 -15.66 9.51 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.495 ' OE1' HD12 ' A' ' 51' ' ' ILE . 49.5 mt-30 -140.68 169.75 17.05 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.222 -1.164 . . . . 0.0 109.622 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 60.5 m-20 -54.75 -179.21 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.254 -0.904 . . . . 0.0 109.681 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.461 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 18.4 p30 -75.41 144.0 42.44 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.307 -0.871 . . . . 0.0 109.706 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.622 HG21 HG21 ' A' ' 20' ' ' VAL . 86.4 t -118.38 118.8 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.224 -0.923 . . . . 0.0 109.263 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.586 ' CD1' ' N ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER -77.31 159.0 29.88 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.152 -0.967 . . . . 0.0 109.154 -179.935 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 1.129 ' CG2' HD12 ' A' ' 18' ' ' ILE . 13.6 t -134.08 131.43 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.356 -0.84 . . . . 0.0 109.393 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.621 ' O ' HD12 ' A' ' 33' ' ' ILE . 67.0 t60 -106.97 154.64 20.79 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.313 -0.867 . . . . 0.0 109.027 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.676 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -46.47 -53.36 11.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.023 -1.048 . . . . 0.0 109.205 -179.631 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.676 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 54.6 p -53.91 -30.75 47.57 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.155 -0.966 . . . . 0.0 110.347 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.485 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -61.83 -21.24 64.47 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.029 -1.045 . . . . 0.0 109.465 -179.856 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.932 ' CD1' HD11 ' A' ' 41' ' ' LEU . 3.2 mp -111.79 129.04 67.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.204 -0.935 . . . . 0.0 109.506 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.7 mt-30 -111.52 144.06 41.36 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.193 -0.942 . . . . 0.0 109.267 179.772 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.639 ' HA3' ' CZ ' ' A' ' 38' ' ' PHE . . . 176.3 169.28 37.57 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -56.5 -47.63 78.89 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.285 -1.127 . . . . 0.0 109.354 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -170.77 37.98 0.18 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.639 ' CZ ' ' HA3' ' A' ' 35' ' ' GLY . 18.3 p90 -126.24 14.46 7.78 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.154 -1.204 . . . . 0.0 109.545 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.451 ' C ' ' O ' ' A' ' 38' ' ' PHE . 20.0 mtmm -41.49 -40.93 1.94 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.259 -0.9 . . . . 0.0 109.703 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.43 ' O ' ' HE2' ' A' ' 65' ' ' LYS . 23.9 m -52.89 124.59 14.51 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.234 -0.916 . . . . 0.0 109.527 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.932 HD11 ' CD1' ' A' ' 33' ' ' ILE . 5.3 mp -85.61 170.49 12.51 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.323 -0.861 . . . . 0.0 109.272 179.828 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.511 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.7 tt0 -117.31 149.78 39.9 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.181 -0.949 . . . . 0.0 109.055 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 62.8 tt0 -70.52 123.97 23.08 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.253 -0.904 . . . . 0.0 109.584 -179.778 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 92.89 -3.41 73.79 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 179.795 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.86 ' O ' HG23 ' A' ' 6' ' ' VAL . 60.7 tt0 -82.74 134.95 35.12 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.119 -1.224 . . . . 0.0 109.906 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -81.1 141.56 34.17 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.399 -0.813 . . . . 0.0 109.067 179.501 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.785 HG21 HD13 ' A' ' 18' ' ' ILE . 28.1 m -141.51 159.57 21.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.131 -0.981 . . . . 0.0 109.922 -179.529 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.506 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 23.0 t -110.89 154.06 24.58 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.424 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.56 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 5.6 p90 172.26 166.14 0.11 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.01 -1.056 . . . . 0.0 110.077 -179.746 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.431 ' HB2' ' HB3' ' A' ' 61' ' ' ALA . 93.6 mt-10 -98.98 160.55 14.18 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.727 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.495 HD12 ' OE1' ' A' ' 23' ' ' GLN . 0.8 OUTLIER -97.94 125.41 51.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 120.933 -1.105 . . . . 0.0 109.781 -179.436 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.595 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 0.1 OUTLIER -107.85 118.95 56.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.473 -0.767 . . . . 0.0 109.076 179.852 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -86.76 84.78 7.3 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.314 -0.866 . . . . 0.0 109.704 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.43 -177.31 41.61 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 14.7 t-20 -54.2 -61.98 1.96 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.219 -1.165 . . . . 0.0 109.563 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 39.7 mtp180 -48.32 -39.36 21.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.285 -0.884 . . . . 0.0 109.135 179.794 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 148.81 -158.86 27.82 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.595 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 49.8 Cg_endo -70.23 140.44 40.92 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.686 2.257 . . . . 0.0 111.716 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.571 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 8.5 mt-30 -133.88 166.25 23.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.318 -0.864 . . . . 0.0 109.37 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.648 ' HB2' HG22 ' A' ' 28' ' ' VAL . . . -87.58 128.4 35.26 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.308 -0.87 . . . . 0.0 109.871 -179.573 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.56 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -112.74 146.45 38.74 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.35 -0.844 . . . . 0.0 108.812 179.457 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.472 ' C ' ' O ' ' A' ' 61' ' ' ALA . 62.5 t30 42.82 71.9 0.2 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.046 -1.034 . . . . 0.0 108.776 -179.615 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.688 HG12 HG23 ' A' ' 33' ' ' ILE . 2.0 t -83.82 127.1 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.365 -0.834 . . . . 0.0 110.162 -178.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 93.9 m -119.79 127.04 52.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.449 -0.782 . . . . 0.0 109.016 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.907 ' NZ ' HG21 ' A' ' 33' ' ' ILE . 55.1 mttp -77.46 112.78 14.57 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.172 -0.955 . . . . 0.0 109.726 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -89.82 165.11 14.34 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.902 . . . . 0.0 109.428 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 118.009 -0.996 . . . . 0.0 109.41 -179.999 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.625 ' C ' HD12 ' A' ' 2' ' ' LEU . 90.9 mmm . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 121.275 0.56 . . . . 0.0 109.546 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.736 ' N ' HD12 ' A' ' 2' ' ' LEU . 6.2 mp -113.63 156.76 23.12 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.22 -0.925 . . . . 0.0 109.547 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.495 ' HG2' ' O ' ' A' ' 47' ' ' VAL . 3.0 tt0 -133.39 132.53 41.3 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.306 -0.871 . . . . 0.0 109.217 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.515 ' C ' ' CG2' ' A' ' 18' ' ' ILE . . . -135.63 167.6 24.19 Favored Glycine 0 N--CA 1.491 2.342 0 C-N-CA 119.632 -1.27 . . . . 0.0 110.229 -179.602 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.682 ' C ' HG23 ' A' ' 18' ' ' ILE . 44.0 mmtm -110.39 135.63 50.81 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.544 -0.974 . . . . 0.0 108.693 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.709 HG23 ' O ' ' A' ' 45' ' ' GLN . 17.6 t -68.5 116.14 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.19 -0.944 . . . . 0.0 109.973 -179.556 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.432 ' N ' ' O ' ' A' ' 17' ' ' PHE . 11.5 tttm -80.38 -33.69 37.0 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.303 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.671 ' CD2' ' N ' ' A' ' 9' ' ' PHE . 0.4 OUTLIER -162.57 166.41 24.74 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 179.671 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.671 ' N ' ' CD2' ' A' ' 8' ' ' TRP . 9.9 p90 -164.47 145.93 8.32 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.94 -1.1 . . . . 0.0 110.601 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.653 ' HB3' ' CE1' ' A' ' 15' ' ' PHE . 38.0 t-20 -103.14 139.14 39.04 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.391 -0.818 . . . . 0.0 109.615 179.741 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 97.5 p -84.7 -14.07 49.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.184 -0.947 . . . . 0.0 109.934 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 65.5 tt0 -58.61 -63.21 1.36 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.087 -1.008 . . . . 0.0 109.219 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.636 ' HB2' ' CD1' ' A' ' 15' ' ' PHE . 20.1 mttm -96.52 -20.7 18.18 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.347 -0.845 . . . . 0.0 109.542 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.567 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 86.56 68.58 1.34 Allowed Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 179.748 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.653 ' CE1' ' HB3' ' A' ' 10' ' ' ASN . 1.4 p90 -154.3 172.89 16.94 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.219 -1.165 . . . . 0.0 108.725 179.468 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.607 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -176.75 151.18 10.99 Favored Glycine 0 N--CA 1.487 2.076 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.026 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.474 ' HB3' ' OD1' ' A' ' 25' ' ' ASP . 89.4 m-85 -79.08 143.18 35.8 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.369 -1.077 . . . . 0.0 108.803 179.596 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 1.143 ' CD1' HG21 ' A' ' 28' ' ' VAL . 73.3 mt -121.84 149.17 25.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 -179.786 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.403 ' N ' ' O ' ' A' ' 5' ' ' LYS . 44.5 tt0 -103.7 118.49 36.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.199 -0.938 . . . . 0.0 109.529 -179.852 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.599 HG21 HG21 ' A' ' 26' ' ' VAL . 3.4 t -94.32 123.51 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.255 -0.903 . . . . 0.0 109.417 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -59.08 99.93 0.06 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.303 -0.873 . . . . 0.0 109.674 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.25 -29.04 3.54 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 179.623 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 15.0 mt-30 -127.05 169.86 12.93 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.133 -1.216 . . . . 0.0 109.739 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.533 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -60.24 -163.41 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.237 -0.914 . . . . 0.0 109.553 179.753 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.474 ' OD1' ' HB3' ' A' ' 17' ' ' PHE . 2.9 t70 -77.53 143.64 38.25 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.285 -0.884 . . . . 0.0 109.713 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.599 HG21 HG21 ' A' ' 20' ' ' VAL . 88.4 t -115.95 127.14 73.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.371 -0.831 . . . . 0.0 109.367 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.1 OUTLIER -76.47 148.23 37.35 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.118 -0.988 . . . . 0.0 109.636 -179.791 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 1.143 HG21 ' CD1' ' A' ' 18' ' ' ILE . 16.5 t -131.14 131.44 63.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 -179.79 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.672 ' CE1' ' CE2' ' A' ' 30' ' ' PHE . 12.1 t-80 -102.68 148.33 25.72 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.083 -1.011 . . . . 0.0 109.924 -179.529 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.688 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.1 p90 -43.57 -51.83 6.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.307 -0.871 . . . . 0.0 109.519 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.672 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 46.5 p -61.27 -13.58 19.9 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.168 -0.957 . . . . 0.0 109.801 -179.701 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.517 ' N ' ' O ' ' A' ' 29' ' ' HIS . . . -66.68 -25.23 66.45 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.265 -0.897 . . . . 0.0 109.642 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.034 HD11 HD11 ' A' ' 41' ' ' LEU . 2.2 mp -93.49 141.78 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.257 -0.902 . . . . 0.0 109.725 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.458 ' O ' ' HD2' ' A' ' 39' ' ' LYS . 85.6 mt-30 -43.79 151.37 0.21 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.3 -0.875 . . . . 0.0 109.672 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.59 ' HA3' ' CE1' ' A' ' 38' ' ' PHE . . . 115.11 167.21 15.3 Favored Glycine 0 N--CA 1.486 2.004 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -82.03 6.46 16.1 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.296 -1.12 . . . . 0.0 109.062 179.584 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.467 ' HA2' ' HD1' ' A' ' 30' ' ' PHE . . . 117.72 21.17 4.36 Favored Glycine 0 N--CA 1.487 2.099 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.59 ' CE1' ' HA3' ' A' ' 35' ' ' GLY . 29.7 p90 -94.98 -11.32 28.69 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.362 -1.081 . . . . 0.0 109.685 -179.84 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.533 ' CE ' ' CZ ' ' A' ' 38' ' ' PHE . 61.3 mttt -90.86 129.37 36.91 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.197 -0.94 . . . . 0.0 109.599 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 46.5 m -114.01 127.36 55.91 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.296 -0.878 . . . . 0.0 109.368 179.733 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 1.034 HD11 HD11 ' A' ' 33' ' ' ILE . 1.1 mt -68.36 152.04 46.01 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.278 -0.889 . . . . 0.0 109.614 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.478 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 80.2 tt0 -117.42 150.76 38.35 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.341 -0.85 . . . . 0.0 109.249 179.84 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 68.4 tt0 -68.33 128.07 35.25 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.914 . . . . 0.0 109.571 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 86.77 -2.94 87.33 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 179.733 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.709 ' O ' HG23 ' A' ' 6' ' ' VAL . 51.8 tt0 -80.44 134.62 36.01 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.203 -1.175 . . . . 0.0 109.715 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -87.55 142.52 27.79 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.299 -0.876 . . . . 0.0 109.169 179.689 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.963 HG12 ' HA ' ' A' ' 65' ' ' LYS . 32.9 m -147.06 167.06 5.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.232 -0.918 . . . . 0.0 109.864 -179.734 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.592 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 24.0 t -109.15 154.77 21.87 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 178.838 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.587 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 8.1 p90 172.15 168.59 0.11 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.003 -1.061 . . . . 0.0 110.034 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.491 ' HA ' HD13 ' A' ' 2' ' ' LEU . 90.2 mt-10 -105.99 169.24 8.61 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 179.173 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.449 HD11 HG21 ' A' ' 26' ' ' VAL . 4.2 mt -111.02 136.87 45.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.022 -1.049 . . . . 0.0 109.546 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.487 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 33.7 m -123.04 134.36 66.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.465 -0.772 . . . . 0.0 108.942 179.727 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -90.49 79.64 6.18 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.139 -0.975 . . . . 0.0 109.613 -179.778 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -81.3 -179.5 53.04 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 -52.45 -57.15 10.79 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.177 -1.19 . . . . 0.0 109.559 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 82.1 mtm180 -54.19 -38.17 65.32 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.163 -0.96 . . . . 0.0 109.599 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.08 -153.34 25.29 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.487 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 50.9 Cg_endo -70.76 133.76 24.41 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.867 2.378 . . . . 0.0 112.146 -179.825 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 19.2 mt-30 -133.53 164.66 26.65 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.356 -0.84 . . . . 0.0 109.032 179.759 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.705 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -92.72 136.93 32.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.119 -0.988 . . . . 0.0 110.104 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.587 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -121.14 153.06 38.01 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 179.376 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.499 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 85.0 m-20 43.86 79.41 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.962 -1.086 . . . . 0.0 108.702 -179.557 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.873 HG21 ' CG1' ' A' ' 28' ' ' VAL . 2.1 t -94.63 124.34 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.161 -0.962 . . . . 0.0 110.195 -179.059 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.497 ' HB ' ' HB3' ' A' ' 48' ' ' SER . 97.1 m -114.16 114.96 26.74 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.49 -0.756 . . . . 0.0 109.055 179.576 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.963 ' HA ' HG12 ' A' ' 47' ' ' VAL . 56.5 mttt -65.02 118.4 9.07 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.335 -0.853 . . . . 0.0 109.426 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 67.1 mm-40 -102.38 162.56 12.82 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.378 -0.826 . . . . 0.0 109.732 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.462 -179.957 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.447 ' HA ' ' OE2' ' A' ' 50' ' ' GLU . 47.7 mtt . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.25 0.548 . . . . 0.0 109.574 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.519 HD12 HD13 ' A' ' 51' ' ' ILE . 26.5 mt -103.6 173.14 6.43 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.292 -0.88 . . . . 0.0 109.385 179.811 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.507 ' O ' HG13 ' A' ' 20' ' ' VAL . 74.1 mt-10 -133.82 134.69 43.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.268 -0.895 . . . . 0.0 109.441 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -139.7 157.09 25.1 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.705 -1.358 . . . . 0.0 109.705 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.414 ' N ' HG23 ' A' ' 18' ' ' ILE . 69.6 mttt -111.21 133.69 53.37 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.435 -1.038 . . . . 0.0 108.438 179.189 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.923 HG23 ' O ' ' A' ' 45' ' ' GLN . 16.2 t -64.05 115.18 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.113 -0.992 . . . . 0.0 110.118 -179.328 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.474 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 14.9 tptp -78.12 -42.04 33.16 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 179.508 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.612 ' CE3' ' O ' ' A' ' 8' ' ' TRP . 0.0 OUTLIER -162.29 156.07 21.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.499 -0.751 . . . . 0.0 109.093 179.99 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.641 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 10.6 p90 -154.16 140.53 18.68 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.13 -0.981 . . . . 0.0 109.041 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.58 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 54.5 t-20 -109.81 115.54 30.03 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.13 -0.981 . . . . 0.0 109.499 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 82.3 p -59.53 -20.27 54.27 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.222 -0.924 . . . . 0.0 109.485 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.7 tt0 -82.94 -39.18 21.76 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.186 -0.946 . . . . 0.0 109.354 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.614 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 23.7 mttp -68.71 -45.5 71.41 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.285 -0.884 . . . . 0.0 109.486 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.495 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 106.09 0.77 38.66 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.621 ' N ' ' CD1' ' A' ' 15' ' ' PHE . 0.3 OUTLIER -143.78 -176.22 4.89 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.112 -1.228 . . . . 0.0 109.288 179.779 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.567 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -155.41 176.85 32.88 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 109.531 -1.427 . . . . 0.0 109.531 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.527 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 43.6 m-85 -113.79 133.3 55.47 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.248 -1.148 . . . . 0.0 109.187 179.789 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 1.096 ' CD1' HG21 ' A' ' 28' ' ' VAL . 61.7 mt -116.18 145.43 21.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.388 -0.82 . . . . 0.0 109.722 -179.669 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 28.7 tt0 -108.09 116.5 32.07 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.415 -0.803 . . . . 0.0 109.495 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.621 HG21 HG21 ' A' ' 26' ' ' VAL . 2.8 t -87.96 125.93 41.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.295 -0.878 . . . . 0.0 109.422 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -69.85 101.62 1.77 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.293 -0.879 . . . . 0.0 109.221 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.22 -22.97 6.97 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 -179.733 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.429 ' O ' ' O ' ' A' ' 24' ' ' ASP . 58.2 mt-30 -123.28 158.81 30.12 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.364 -1.08 . . . . 0.0 109.322 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.429 ' O ' ' O ' ' A' ' 23' ' ' GLN . 44.8 m-20 -54.81 -171.24 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.19 -0.944 . . . . 0.0 109.452 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.565 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 88.6 m-20 -73.73 133.25 43.3 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.196 -0.94 . . . . 0.0 109.533 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.664 HG21 HD11 ' A' ' 51' ' ' ILE . 96.0 t -111.06 125.24 68.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.256 -0.903 . . . . 0.0 109.234 -179.882 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.573 ' CE1' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER -79.28 159.64 27.16 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.052 -1.03 . . . . 0.0 109.747 -179.716 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 1.096 HG21 ' CD1' ' A' ' 18' ' ' ILE . 57.8 t -133.95 137.95 51.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.432 -0.792 . . . . 0.0 109.419 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.604 ' O ' HD12 ' A' ' 33' ' ' ILE . 73.3 t60 -111.23 150.59 29.37 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.291 -0.88 . . . . 0.0 108.899 179.593 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.713 ' CG ' ' N ' ' A' ' 31' ' ' SER . 1.3 p90 -48.09 -54.21 13.94 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.046 -1.034 . . . . 0.0 109.298 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.713 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 19.2 t -55.96 -30.55 61.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.025 -1.047 . . . . 0.0 109.899 -179.441 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.58 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -63.66 -17.56 63.06 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.021 -1.049 . . . . 0.0 108.544 179.505 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.026 HG23 HG12 ' A' ' 63' ' ' VAL . 0.6 OUTLIER -118.08 145.28 24.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.607 -0.683 . . . . 0.0 109.434 -179.86 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 90.6 mt-30 -123.21 159.47 28.6 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.147 -0.971 . . . . 0.0 109.633 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.742 ' HA3' ' CE1' ' A' ' 38' ' ' PHE . . . 150.06 156.33 7.22 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 90.6 mt-10 -119.92 118.71 31.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.266 -1.138 . . . . 0.0 109.294 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 99.5 -5.46 58.7 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.875 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.742 ' CE1' ' HA3' ' A' ' 35' ' ' GLY . 38.0 p90 -152.52 38.33 0.54 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.164 -1.198 . . . . 0.0 109.57 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 7.5 mtpt -63.27 -25.57 68.38 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.18 -0.95 . . . . 0.0 109.444 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 70.1 p -75.11 126.09 30.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.246 -0.909 . . . . 0.0 109.462 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.681 HD12 ' HZ1' ' A' ' 65' ' ' LYS . 5.2 mp -72.25 141.12 48.94 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.249 -0.907 . . . . 0.0 109.745 -179.826 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.444 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.2 tt0 -96.98 132.28 42.95 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.237 -0.914 . . . . 0.0 109.528 -179.852 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.474 ' OE2' ' O ' ' A' ' 7' ' ' LYS . 75.1 tt0 -59.51 129.01 39.88 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.318 -0.864 . . . . 0.0 109.343 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 93.74 -8.06 74.0 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.923 ' O ' HG23 ' A' ' 6' ' ' VAL . 70.6 tp60 -78.41 126.33 30.62 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.162 -1.199 . . . . 0.0 109.596 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -82.88 143.26 30.87 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.251 -0.905 . . . . 0.0 109.344 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.981 HG12 ' HA ' ' A' ' 65' ' ' LYS . 34.4 m -144.41 167.04 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.908 . . . . 0.0 109.597 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.485 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 22.3 t -109.72 154.67 22.56 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.376 -0.827 . . . . 0.0 108.839 179.502 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.645 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 4.2 p90 172.79 166.03 0.13 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.959 -1.088 . . . . 0.0 110.312 -179.759 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.447 ' OE2' ' HA ' ' A' ' 1' ' ' MET . 67.5 mm-40 -96.09 159.68 14.84 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 178.581 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.664 HD11 HG21 ' A' ' 26' ' ' VAL . 1.1 mp -100.52 127.5 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.939 -1.101 . . . . 0.0 110.044 -179.431 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.6 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 27.5 m -115.86 124.18 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 178.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 22.0 mt-10 -95.74 97.16 9.48 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.127 -0.983 . . . . 0.0 109.703 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.19 -179.35 42.77 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.436 ' CG ' ' N ' ' A' ' 56' ' ' ARG . 16.0 p-10 -53.97 -50.31 66.8 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.159 -1.201 . . . . 0.0 109.514 -179.87 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.436 ' N ' ' CG ' ' A' ' 55' ' ' ASN . 33.3 mtp85 -61.31 -42.19 98.25 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.052 -1.03 . . . . 0.0 109.793 -179.726 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 158.79 -164.64 33.75 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 110.016 -1.233 . . . . 0.0 110.016 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.565 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 44.1 Cg_endo -68.55 139.78 45.73 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 123.198 2.598 . . . . 0.0 112.637 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.6 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 68.5 mt-30 -135.58 165.41 25.6 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.301 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.611 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -99.17 141.96 31.26 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.976 -1.077 . . . . 0.0 110.467 -179.031 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.526 ' O ' ' C ' ' A' ' 62' ' ' ASN . . . -124.22 155.7 38.1 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 179.128 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.526 ' C ' ' O ' ' A' ' 61' ' ' ALA . 24.3 t-20 37.58 66.72 0.43 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.172 -0.955 . . . . 0.0 109.003 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 1.026 HG12 HG23 ' A' ' 33' ' ' ILE . 2.0 t -79.01 130.99 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.337 -0.852 . . . . 0.0 110.073 -179.048 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.521 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 25.2 m -117.15 123.4 46.63 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.328 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.981 ' HA ' HG12 ' A' ' 47' ' ' VAL . 47.4 mttm -74.97 115.49 14.64 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.203 -0.935 . . . . 0.0 109.939 -179.56 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.46 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 47.2 mt-10 -99.79 169.17 9.43 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.278 -0.889 . . . . 0.0 109.413 179.837 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 118.062 -0.971 . . . . 0.0 109.547 179.827 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.466 ' N ' ' OE2' ' A' ' 50' ' ' GLU . 76.0 mmm . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.485 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 61.9 mt -106.81 161.67 14.47 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.093 -1.004 . . . . 0.0 109.672 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.585 ' O ' HG13 ' A' ' 20' ' ' VAL . 2.2 tt0 -123.45 140.31 53.13 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.323 -0.861 . . . . 0.0 108.901 179.639 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -144.39 148.53 20.34 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.544 ' O ' HG23 ' A' ' 18' ' ' ILE . 50.0 mttp -101.77 142.63 32.8 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.353 -1.086 . . . . 0.0 108.771 179.288 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.853 HG23 ' O ' ' A' ' 45' ' ' GLN . 21.5 t -73.8 113.47 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.112 -0.993 . . . . 0.0 109.642 -179.64 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.425 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 27.2 tttm -78.65 -41.73 30.61 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.777 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.682 ' CZ3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -160.39 156.51 26.25 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.454 -0.779 . . . . 0.0 108.986 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.595 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 12.5 p90 -155.33 142.95 19.71 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.129 -0.982 . . . . 0.0 109.299 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.531 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 58.7 t-20 -117.44 118.55 32.5 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.063 -1.023 . . . . 0.0 109.518 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 93.0 p -65.27 -14.32 60.45 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.296 -0.877 . . . . 0.0 109.315 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -88.86 -38.43 14.59 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.2 -0.938 . . . . 0.0 108.882 179.584 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.653 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 16.4 mttm -67.61 -43.88 79.38 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.429 -0.794 . . . . 0.0 109.212 179.585 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.536 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 104.06 1.01 45.03 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.653 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 0.5 OUTLIER -145.23 176.95 9.16 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.116 -1.226 . . . . 0.0 109.654 179.912 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.449 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -144.07 170.28 25.97 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.682 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 30.3 m-85 -111.23 128.67 56.0 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.393 -1.063 . . . . 0.0 108.968 179.798 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.839 ' CD1' HG21 ' A' ' 47' ' ' VAL . 67.8 mt -111.37 145.45 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.184 -0.947 . . . . 0.0 109.699 -179.801 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 5.3 tt0 -108.16 110.83 22.57 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.399 -0.813 . . . . 0.0 109.087 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.66 HG21 HG21 ' A' ' 26' ' ' VAL . 2.7 t -89.62 118.09 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.317 -0.864 . . . . 0.0 109.488 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -68.01 109.61 3.55 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.278 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.78 -21.78 6.58 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.567 ' OE1' HD12 ' A' ' 51' ' ' ILE . 50.2 mt-30 -135.47 168.8 18.54 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.197 -1.178 . . . . 0.0 109.596 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -55.19 -173.7 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.285 -0.884 . . . . 0.0 109.443 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -77.83 141.6 39.07 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.166 -0.959 . . . . 0.0 109.997 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.66 HG21 HG21 ' A' ' 20' ' ' VAL . 63.5 t -111.0 114.04 45.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.231 -0.918 . . . . 0.0 109.355 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.521 ' HE1' ' HB2' ' A' ' 15' ' ' PHE . 0.2 OUTLIER -84.48 106.85 16.38 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.254 -0.904 . . . . 0.0 109.276 179.812 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.598 ' CG2' HD11 ' A' ' 33' ' ' ILE . 0.2 OUTLIER -86.41 143.74 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 O-C-N 121.128 -0.982 . . . . 0.0 109.712 -179.308 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.646 ' HA ' ' HB3' ' A' ' 15' ' ' PHE . 58.6 t60 -113.86 157.99 21.62 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.653 -0.655 . . . . 0.0 109.272 -179.606 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.699 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -46.37 -54.89 8.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.881 -1.137 . . . . 0.0 108.761 -179.787 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.699 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 94.1 p -50.82 -37.56 43.56 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.212 -0.93 . . . . 0.0 109.918 -179.791 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.573 ' HB3' HG23 ' A' ' 28' ' ' VAL . . . -56.43 -29.02 61.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.036 -1.04 . . . . 0.0 109.341 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.93 HG21 ' NZ ' ' A' ' 65' ' ' LYS . 1.9 mp -103.37 151.26 6.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.397 -0.814 . . . . 0.0 109.317 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 -121.97 145.17 48.38 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.186 -0.947 . . . . 0.0 109.584 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.652 ' HA3' ' CE2' ' A' ' 38' ' ' PHE . . . 145.82 157.26 7.21 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -117.94 100.6 7.67 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.24 -1.153 . . . . 0.0 109.403 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.56 -10.73 9.1 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.813 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.652 ' CE2' ' HA3' ' A' ' 35' ' ' GLY . 11.4 p90 -144.15 30.13 1.29 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.146 -1.208 . . . . 0.0 109.621 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.468 ' HG3' ' O ' ' A' ' 35' ' ' GLY . 19.5 mttp -63.35 -28.36 69.95 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.136 -0.978 . . . . 0.0 109.406 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.5 p -78.12 126.41 30.76 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.197 -0.939 . . . . 0.0 109.408 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.706 ' CD1' HD13 ' A' ' 33' ' ' ILE . 3.6 mp -78.06 159.02 28.95 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.24 -0.913 . . . . 0.0 109.861 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.467 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 85.1 tt0 -106.72 149.51 27.23 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.475 -0.766 . . . . 0.0 109.192 179.614 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.425 ' HG3' ' O ' ' A' ' 7' ' ' LYS . 70.2 tt0 -72.35 124.23 24.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.19 -0.943 . . . . 0.0 109.499 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 96.16 -7.5 66.89 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.853 ' O ' HG23 ' A' ' 6' ' ' VAL . 60.5 tt0 -81.31 127.64 32.95 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.209 -1.171 . . . . 0.0 109.651 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -74.56 145.22 43.59 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.338 -0.851 . . . . 0.0 109.444 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.839 HG21 ' CD1' ' A' ' 18' ' ' ILE . 34.6 m -145.88 160.86 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.095 -1.003 . . . . 0.0 110.017 -179.747 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.542 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 9.6 p -113.7 158.46 20.88 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.25 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.615 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 8.8 p90 169.25 169.3 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.999 -1.063 . . . . 0.0 109.996 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.484 ' OE1' ' HA ' ' A' ' 50' ' ' GLU . 65.3 mm-40 -104.97 157.84 16.95 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 178.826 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.567 HD12 ' OE1' ' A' ' 23' ' ' GLN . 1.9 mt -95.66 130.64 44.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 120.922 -1.111 . . . . 0.0 110.105 -179.41 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.538 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 3.6 m -112.7 122.57 67.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.306 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -90.77 88.85 7.24 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.039 -1.038 . . . . 0.0 109.755 -179.414 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -93.41 -175.36 40.37 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.853 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -54.51 -63.1 1.26 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.2 -1.176 . . . . 0.0 109.639 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 72.5 mtp180 -46.75 -38.9 10.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.125 -0.985 . . . . 0.0 109.033 179.827 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.77 -158.85 27.85 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.538 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 49.2 Cg_endo -70.71 142.48 43.85 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.565 2.177 . . . . 0.0 111.747 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.513 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 67.7 mt-30 -139.17 169.15 18.31 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.342 -0.849 . . . . 0.0 109.133 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.546 ' CB ' ' HB ' ' A' ' 28' ' ' VAL . . . -89.92 134.07 34.42 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.972 -1.08 . . . . 0.0 110.14 -179.463 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.585 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -121.56 153.09 38.47 Favored 'General case' 0 N--CA 1.491 1.601 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.541 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.497 ' C ' ' O ' ' A' ' 61' ' ' ALA . 83.6 m-20 41.13 72.74 0.15 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.033 -1.042 . . . . 0.0 108.577 -179.475 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.759 HG11 HG12 ' A' ' 33' ' ' ILE . 2.2 t -92.98 130.39 42.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.218 -0.926 . . . . 0.0 110.517 -178.724 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.3 m -120.08 125.23 47.77 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.493 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.93 ' NZ ' HG21 ' A' ' 33' ' ' ILE . 29.6 mttp -74.36 112.1 10.19 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.067 -1.021 . . . . 0.0 109.702 -179.606 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.407 ' OE2' ' HB3' ' A' ' 48' ' ' SER . 93.2 mt-10 -88.89 163.78 15.46 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.318 -0.864 . . . . 0.0 109.605 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 118.004 -0.998 . . . . 0.0 109.439 179.88 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.608 ' C ' HD12 ' A' ' 2' ' ' LEU . 70.4 mtm . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.811 ' N ' HD12 ' A' ' 2' ' ' LEU . 5.6 mp -107.18 165.64 11.22 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.285 -0.884 . . . . 0.0 109.329 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 58.6 mt-10 -132.28 127.97 36.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.147 -0.97 . . . . 0.0 109.446 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.43 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -127.51 155.25 19.95 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.445 ' N ' HG23 ' A' ' 18' ' ' ILE . 43.2 mttt -103.99 138.48 40.47 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.299 -1.118 . . . . 0.0 108.874 179.578 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.826 HG23 ' O ' ' A' ' 45' ' ' GLN . 18.9 t -71.28 113.24 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.213 -0.929 . . . . 0.0 110.045 -179.469 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 13.0 ttpt -80.08 -40.71 27.06 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.555 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.588 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.41 155.4 28.57 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.397 -0.814 . . . . 0.0 109.018 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 9.6 p90 -156.22 137.96 14.25 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.128 -0.983 . . . . 0.0 109.242 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.479 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 52.3 t-20 -128.03 129.07 46.11 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.233 -0.917 . . . . 0.0 109.437 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -75.56 -19.74 59.1 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.103 -0.998 . . . . 0.0 108.952 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 76.3 tt0 -66.27 -42.43 88.48 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 106.45 -1.685 . . . . 0.0 106.45 177.923 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.652 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 8.3 mttp -75.69 -39.34 57.66 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 178.368 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.504 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 93.54 3.49 64.63 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.728 -1.349 . . . . 0.0 109.728 179.561 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.652 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 1.0 OUTLIER -140.11 172.95 12.03 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.229 -1.16 . . . . 0.0 108.779 179.127 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.588 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -140.37 172.41 23.53 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.424 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 27.6 m-85 -113.9 132.86 55.77 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.341 -1.094 . . . . 0.0 108.986 179.786 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.661 HD12 HG21 ' A' ' 28' ' ' VAL . 13.9 mt -116.22 151.52 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.252 -0.905 . . . . 0.0 109.717 -179.646 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -115.57 116.91 28.95 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.365 -0.834 . . . . 0.0 109.21 179.863 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.538 HG21 HG21 ' A' ' 26' ' ' VAL . 2.3 t -94.3 119.82 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.364 -0.835 . . . . 0.0 109.395 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -69.21 110.55 4.64 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.24 -0.913 . . . . 0.0 109.351 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 125.78 -37.77 2.42 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.819 ' OE1' HD12 ' A' ' 51' ' ' ILE . 56.4 mt-30 -120.45 166.31 13.76 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.366 -1.079 . . . . 0.0 109.381 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.422 ' O ' ' O ' ' A' ' 23' ' ' GLN . 49.5 m-20 -52.53 -176.83 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.206 -0.934 . . . . 0.0 109.562 -179.862 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.504 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 81.0 m-20 -74.31 141.93 45.22 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.346 -0.846 . . . . 0.0 109.629 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.538 HG21 HG21 ' A' ' 20' ' ' VAL . 98.2 t -115.08 117.95 57.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.242 -0.911 . . . . 0.0 109.31 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.556 ' O ' ' N ' ' A' ' 60' ' ' ALA . 0.1 OUTLIER -76.73 161.12 28.76 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.103 -0.998 . . . . 0.0 109.388 -179.879 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.763 HG22 ' HB2' ' A' ' 60' ' ' ALA . 14.6 t -133.75 134.13 56.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.287 -0.883 . . . . 0.0 109.602 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.642 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 15.2 t-80 -104.66 151.33 23.82 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.217 -0.927 . . . . 0.0 109.19 179.652 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.685 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -44.92 -53.96 7.03 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.106 -0.996 . . . . 0.0 109.549 -179.529 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.685 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 90.3 p -60.35 -18.49 50.42 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.06 -1.025 . . . . 0.0 109.956 -179.544 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.502 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -67.36 -24.54 65.72 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.075 -1.016 . . . . 0.0 109.356 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.833 HG23 HG12 ' A' ' 63' ' ' VAL . 3.1 mp -109.11 132.58 56.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.303 -0.873 . . . . 0.0 109.468 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.404 ' C ' ' O ' ' A' ' 33' ' ' ILE . 34.4 tt0 -47.45 -53.67 13.5 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.094 -1.004 . . . . 0.0 108.828 179.343 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.648 ' HA3' ' CG ' ' A' ' 39' ' ' LYS . . . 55.34 33.89 58.81 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 110.149 -1.18 . . . . 0.0 110.149 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -46.32 -24.26 0.46 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.045 -1.268 . . . . 0.0 108.761 179.495 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.415 ' N ' ' C ' ' A' ' 35' ' ' GLY . . . -162.19 26.99 0.25 Allowed Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 179.753 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.617 ' CD1' ' HA2' ' A' ' 35' ' ' GLY . 0.4 OUTLIER -169.57 44.85 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.303 -1.116 . . . . 0.0 109.571 -179.885 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.648 ' CG ' ' HA3' ' A' ' 35' ' ' GLY . 90.3 mttt -55.39 -20.84 13.24 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.194 -0.941 . . . . 0.0 109.431 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 21.3 m -67.5 99.7 0.78 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.35 -0.844 . . . . 0.0 109.885 -179.606 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.703 HD21 HD11 ' A' ' 33' ' ' ILE . 5.8 mp -62.6 157.8 19.77 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.2 -0.938 . . . . 0.0 109.263 179.588 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.488 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.1 tt0 -120.25 138.53 53.61 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.238 -0.914 . . . . 0.0 109.619 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 57.4 tt0 -67.65 129.7 40.72 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.261 -0.899 . . . . 0.0 109.454 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 90.64 -5.88 82.25 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.826 ' O ' HG23 ' A' ' 6' ' ' VAL . 60.4 tt0 -81.12 126.11 31.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.215 -1.168 . . . . 0.0 109.371 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -79.18 142.49 36.28 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.228 -0.92 . . . . 0.0 109.31 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.985 HG12 ' HA ' ' A' ' 65' ' ' LYS . 28.2 m -143.96 168.65 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.246 -0.909 . . . . 0.0 109.438 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.517 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 9.4 t -114.51 155.26 26.76 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.324 -0.86 . . . . 0.0 108.859 179.65 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.611 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 5.6 p90 173.38 165.88 0.16 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.041 -1.037 . . . . 0.0 110.099 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.467 ' HA ' HD13 ' A' ' 2' ' ' LEU . 90.8 mt-10 -100.6 150.36 22.79 Favored 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.815 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.819 HD12 ' OE1' ' A' ' 23' ' ' GLN . 0.5 OUTLIER -87.13 123.05 39.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.029 -1.044 . . . . 0.0 109.837 -179.574 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.623 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.6 m -107.03 120.87 59.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.385 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -88.41 85.18 6.82 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.259 -0.901 . . . . 0.0 109.633 -179.544 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.39 -177.05 43.18 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.876 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 18.4 p-10 -55.27 -55.89 26.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.097 -1.237 . . . . 0.0 109.701 -179.743 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 43.3 mtp180 -52.43 -41.27 63.11 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.992 -1.068 . . . . 0.0 109.285 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 146.34 -150.85 23.14 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.504 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 47.6 Cg_endo -70.24 129.25 16.78 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.817 2.345 . . . . 0.0 112.292 -179.851 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.623 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 53.7 mt-30 -131.04 164.23 25.85 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 179.138 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.763 ' HB2' HG22 ' A' ' 28' ' ' VAL . . . -90.52 127.08 36.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.098 -1.001 . . . . 0.0 110.401 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.535 ' O ' ' C ' ' A' ' 62' ' ' ASN . . . -109.86 147.71 32.85 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.034 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.535 ' C ' ' O ' ' A' ' 61' ' ' ALA . 59.2 t30 38.17 73.73 0.1 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.049 -1.032 . . . . 0.0 108.816 -179.686 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.833 HG12 HG23 ' A' ' 33' ' ' ILE . 1.4 t -84.8 129.62 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.321 -0.862 . . . . 0.0 110.331 -178.767 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.458 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 13.0 m -115.28 121.37 42.68 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.459 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.985 ' HA ' HG12 ' A' ' 47' ' ' VAL . 20.2 mttt -74.12 114.83 12.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.154 -0.966 . . . . 0.0 109.742 -179.67 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.441 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 50.8 mt-10 -98.99 168.05 10.35 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.354 -0.841 . . . . 0.0 109.616 -179.818 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.495 0 CA-C-O 117.944 -1.027 . . . . 0.0 109.444 179.989 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 91.6 mtp . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 21.1 mt -103.96 161.84 13.63 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.214 -0.929 . . . . 0.0 109.275 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -134.19 127.9 32.91 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.209 -0.932 . . . . 0.0 109.297 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.41 ' C ' ' CG2' ' A' ' 18' ' ' ILE . . . -126.49 158.63 20.64 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 -179.735 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.562 ' C ' HG23 ' A' ' 18' ' ' ILE . 38.8 mttp -103.7 133.64 48.37 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.394 -1.063 . . . . 0.0 108.823 179.561 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.856 HG23 ' O ' ' A' ' 45' ' ' GLN . 18.3 t -66.49 113.73 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.151 -0.968 . . . . 0.0 110.055 -179.344 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.402 ' O ' ' HD2' ' A' ' 7' ' ' LYS . 0.7 OUTLIER -79.12 -39.93 32.36 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.34 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.642 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -159.11 155.01 26.51 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.807 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.646 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 9.1 p90 -155.57 140.55 17.32 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.056 -1.028 . . . . 0.0 109.347 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.487 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.2 t-20 -132.59 130.61 40.49 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.117 -0.989 . . . . 0.0 109.727 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 14.6 p -76.95 -19.16 57.69 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.056 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.494 ' HA ' ' OE1' ' A' ' 12' ' ' GLU . 69.7 mm-40 -65.31 -45.52 84.02 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 178.129 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.629 ' HD3' ' CE2' ' A' ' 15' ' ' PHE . 8.1 mttp -74.21 -38.59 63.53 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 178.303 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.531 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 94.31 5.98 61.67 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.725 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.629 ' CE2' ' HD3' ' A' ' 13' ' ' LYS . 1.2 p90 -143.78 170.08 16.56 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.164 -1.198 . . . . 0.0 109.195 179.358 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.642 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -140.88 171.69 23.99 Favored Glycine 0 N--CA 1.492 2.378 0 C-N-CA 119.654 -1.26 . . . . 0.0 110.067 -179.491 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.558 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 43.1 m-85 -114.02 139.4 49.29 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.319 -1.107 . . . . 0.0 109.195 179.751 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 1.122 ' CD1' HG21 ' A' ' 28' ' ' VAL . 16.7 mt -124.1 150.91 28.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.272 -0.892 . . . . 0.0 109.691 -179.485 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -113.48 119.47 37.7 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.384 -0.823 . . . . 0.0 109.448 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.565 HG21 HG21 ' A' ' 26' ' ' VAL . 2.6 t -90.46 124.13 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.329 -0.857 . . . . 0.0 109.655 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.476 ' OE2' ' NZ ' ' A' ' 5' ' ' LYS . 80.1 mt-10 -71.45 109.34 5.37 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.309 -0.869 . . . . 0.0 109.512 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 117.81 -26.1 8.15 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.612 ' NE2' HD12 ' A' ' 51' ' ' ILE . 36.5 mt-30 -122.95 161.31 24.45 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.259 -1.142 . . . . 0.0 109.482 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 58.9 m-20 -52.84 -178.96 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.274 -0.891 . . . . 0.0 109.659 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -71.65 141.37 49.92 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.268 -0.895 . . . . 0.0 109.506 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.584 HG13 ' C ' ' A' ' 59' ' ' GLN . 97.3 t -117.99 117.7 55.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.171 -0.956 . . . . 0.0 109.656 -179.582 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.54 ' CE1' ' HB3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -76.56 157.16 32.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.2 -0.937 . . . . 0.0 108.997 179.684 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 1.122 HG21 ' CD1' ' A' ' 18' ' ' ILE . 34.1 t -133.01 137.38 53.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.205 -0.935 . . . . 0.0 109.763 -179.525 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.594 ' HA ' ' HB3' ' A' ' 15' ' ' PHE . 42.6 t60 -114.97 152.45 32.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.429 -0.794 . . . . 0.0 108.993 179.696 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.68 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -44.31 -53.53 6.63 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.093 -1.004 . . . . 0.0 109.502 -179.631 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.68 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 27.3 t -54.29 -27.35 34.75 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.101 -1.0 . . . . 0.0 110.068 -179.452 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.63 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -66.9 -12.63 60.03 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.04 -1.037 . . . . 0.0 109.002 179.71 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.912 ' CD1' HD11 ' A' ' 41' ' ' LEU . 0.9 OUTLIER -122.7 126.75 74.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.503 -0.748 . . . . 0.0 109.589 -179.581 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 50.8 tt0 -87.5 133.42 33.77 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.242 -0.911 . . . . 0.0 109.671 -179.79 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.613 ' CA ' ' CZ ' ' A' ' 38' ' ' PHE . . . 173.94 147.6 6.09 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.868 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -65.36 -58.85 4.86 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.255 -1.144 . . . . 0.0 109.471 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -136.03 13.23 4.13 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.613 ' CZ ' ' CA ' ' A' ' 35' ' ' GLY . 44.5 p90 -113.96 17.32 17.96 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.249 -1.148 . . . . 0.0 109.498 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.499 ' CE ' ' O ' ' A' ' 35' ' ' GLY . 86.3 mttt -55.48 -42.16 74.0 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.297 -0.877 . . . . 0.0 109.581 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 32.9 m -56.27 128.51 36.08 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.191 -0.943 . . . . 0.0 109.654 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 1.034 HD23 HG11 ' A' ' 47' ' ' VAL . 4.9 mp -88.21 171.85 9.91 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.222 -0.924 . . . . 0.0 109.559 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.438 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 96.8 mt-10 -109.28 155.04 21.62 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.316 -0.865 . . . . 0.0 109.305 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -70.41 127.67 33.54 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.29 -0.881 . . . . 0.0 109.593 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.445 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 88.51 -3.12 85.2 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.856 ' O ' HG23 ' A' ' 6' ' ' VAL . 51.1 tt0 -81.71 130.24 34.99 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.198 -1.178 . . . . 0.0 109.603 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -78.21 141.87 38.32 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.235 -0.916 . . . . 0.0 109.383 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 1.034 HG11 HD23 ' A' ' 41' ' ' LEU . 34.7 m -141.52 153.21 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.136 -0.977 . . . . 0.0 109.781 -179.746 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.539 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 17.8 t -97.57 148.65 23.05 Favored 'General case' 0 N--CA 1.488 1.459 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 179.075 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.602 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 7.8 p90 176.09 162.47 0.35 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.874 -1.141 . . . . 0.0 110.272 -179.546 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.458 ' OE1' ' HA ' ' A' ' 50' ' ' GLU . 67.0 mm-40 -99.92 160.37 14.37 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 178.908 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.612 HD12 ' NE2' ' A' ' 23' ' ' GLN . 0.9 OUTLIER -99.6 127.38 52.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 120.917 -1.114 . . . . 0.0 109.91 -179.524 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.614 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.9 m -114.32 124.81 71.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 179.197 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -93.6 93.31 7.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 110.241 -179.087 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -95.15 -175.8 37.72 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 11.9 t-20 -53.17 -59.22 4.83 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.104 -1.233 . . . . 0.0 109.462 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 53.0 mtp180 -49.3 -40.47 34.93 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.087 -1.008 . . . . 0.0 109.215 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 149.18 -158.12 27.53 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.411 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 51.5 Cg_endo -70.46 139.96 38.98 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.723 2.282 . . . . 0.0 111.849 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.614 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 76.9 mt-30 -136.26 167.81 20.6 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.324 -0.86 . . . . 0.0 109.13 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.659 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -95.22 139.31 31.72 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.136 -0.978 . . . . 0.0 110.184 -179.286 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.602 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -124.3 156.02 37.68 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.378 -0.826 . . . . 0.0 108.826 179.605 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.481 ' C ' ' O ' ' A' ' 61' ' ' ALA . 78.8 m-20 42.2 72.59 0.16 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.968 -1.083 . . . . 0.0 108.952 -179.821 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.98 HG11 HD21 ' A' ' 41' ' ' LEU . 3.9 t -86.76 125.93 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.234 -0.916 . . . . 0.0 110.088 -179.17 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.45 ' HB ' ' HB3' ' A' ' 48' ' ' SER . 60.6 m -119.0 125.51 49.56 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.379 -0.825 . . . . 0.0 109.256 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.434 ' NZ ' ' O ' ' A' ' 38' ' ' PHE . 87.9 mttt -67.52 106.97 2.32 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.2 -0.937 . . . . 0.0 109.479 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.405 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 89.6 mt-10 -87.04 162.0 17.85 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.227 -0.921 . . . . 0.0 109.497 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 117.973 -1.013 . . . . 0.0 109.487 -179.939 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 50.3 mtm . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 49.4 mt -99.52 160.21 14.46 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.321 -0.862 . . . . 0.0 109.494 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.581 ' O ' HG13 ' A' ' 20' ' ' VAL . 86.9 mt-10 -131.48 135.83 47.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.28 -0.888 . . . . 0.0 109.171 179.772 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.475 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -136.15 157.94 23.7 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 -179.684 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.513 ' N ' HG23 ' A' ' 18' ' ' ILE . 12.5 mttp -103.65 142.26 34.63 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.341 -1.094 . . . . 0.0 108.817 179.51 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.839 HG23 ' O ' ' A' ' 45' ' ' GLN . 22.1 t -75.22 116.96 18.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.073 -1.017 . . . . 0.0 109.935 -179.51 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.8 -32.73 17.71 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.465 -0.772 . . . . 0.0 108.933 179.693 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.683 ' CE3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -159.44 153.98 24.2 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.381 -0.824 . . . . 0.0 109.023 179.792 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.489 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 9.1 p90 -157.54 139.03 13.81 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.173 -0.954 . . . . 0.0 109.282 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.444 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 63.5 t-20 -121.6 116.91 25.48 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 109.618 -179.809 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 11.0 t -69.47 -13.75 62.51 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.232 -0.917 . . . . 0.0 109.222 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -81.37 -46.87 14.03 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.369 -0.832 . . . . 0.0 108.964 179.604 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.671 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 21.1 mttp -68.56 -45.3 72.47 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.417 -0.802 . . . . 0.0 108.882 179.507 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.541 ' C ' ' CD1' ' A' ' 15' ' ' PHE . . . 108.96 7.93 28.42 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 179.055 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.671 ' CE2' ' HB3' ' A' ' 13' ' ' LYS . 0.0 OUTLIER -142.58 166.42 24.73 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.81 -1.406 . . . . 0.0 109.695 179.72 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.504 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -135.99 167.49 24.33 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.683 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 22.1 m-85 -115.05 130.12 56.86 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.184 -1.186 . . . . 0.0 109.289 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.744 ' CD1' HG21 ' A' ' 47' ' ' VAL . 56.4 mt -114.23 151.42 16.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.44 -0.787 . . . . 0.0 109.654 -179.79 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -114.2 104.29 11.95 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.361 -0.837 . . . . 0.0 108.915 179.518 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.581 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.8 t -78.63 120.64 30.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.264 -0.897 . . . . 0.0 109.428 -179.702 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 74.0 mm-40 -67.93 108.89 3.2 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.206 -0.933 . . . . 0.0 109.135 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.59 -24.46 6.82 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.562 ' OE1' HG11 ' A' ' 20' ' ' VAL . 36.0 mt-30 -128.18 165.92 19.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.298 -1.119 . . . . 0.0 109.6 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 48.9 m-20 -56.93 -169.08 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.292 -0.88 . . . . 0.0 109.729 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.497 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 7.7 p30 -78.45 141.47 38.25 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.254 -0.904 . . . . 0.0 110.003 -179.543 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.579 HG21 HG21 ' A' ' 20' ' ' VAL . 57.4 t -116.23 115.09 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.212 -0.93 . . . . 0.0 109.305 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.706 ' O ' ' CG ' ' A' ' 27' ' ' PHE . 0.1 OUTLIER -83.5 107.72 16.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.047 -1.033 . . . . 0.0 109.39 179.979 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.628 ' CG2' HG21 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -85.48 146.92 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.061 -1.024 . . . . 0.0 109.632 -179.167 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.777 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 27.6 t60 -116.2 155.05 28.99 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.283 -0.886 . . . . 0.0 109.336 -179.772 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.777 ' CD2' ' CE1' ' A' ' 29' ' ' HIS . 1.9 p90 -47.75 -54.11 13.21 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.092 -1.005 . . . . 0.0 109.607 -179.481 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.769 ' N ' ' CD1' ' A' ' 30' ' ' PHE . 19.9 t -53.41 -21.22 5.6 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.872 -1.142 . . . . 0.0 109.517 -179.771 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.547 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -66.84 -38.81 87.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.273 -0.892 . . . . 0.0 109.635 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.073 HD11 HD11 ' A' ' 41' ' ' LEU . 1.8 mp -80.43 151.67 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.168 -0.958 . . . . 0.0 109.966 -179.74 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 65.9 mt-30 -56.1 134.75 52.94 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.337 -0.852 . . . . 0.0 109.597 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.612 ' HA3' ' CE1' ' A' ' 38' ' ' PHE . . . 120.92 169.9 13.93 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 179.591 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -86.62 10.15 16.41 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.428 -1.042 . . . . 0.0 109.269 179.829 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.31 4.29 10.07 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.612 ' CE1' ' HA3' ' A' ' 35' ' ' GLY . 29.2 p90 -80.79 2.55 25.8 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.289 -1.124 . . . . 0.0 109.489 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.515 ' HG2' ' CE2' ' A' ' 38' ' ' PHE . 21.3 mmtt -113.96 117.91 32.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.189 -0.945 . . . . 0.0 109.355 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 27.3 p -109.0 138.26 45.63 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.286 -0.884 . . . . 0.0 109.508 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 1.073 HD11 HD11 ' A' ' 33' ' ' ILE . 3.1 mp -78.59 158.31 28.52 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.182 -0.949 . . . . 0.0 109.332 179.798 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.469 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 97.0 mt-10 -115.8 151.27 35.51 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.302 -0.874 . . . . 0.0 109.373 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 46.5 tt0 -67.84 125.37 26.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.227 -0.92 . . . . 0.0 109.426 -179.866 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 92.7 -6.63 77.29 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.883 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.839 ' O ' HG23 ' A' ' 6' ' ' VAL . 61.5 tp60 -82.28 135.05 35.29 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.185 -1.185 . . . . 0.0 109.762 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -85.87 144.62 27.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.318 -0.864 . . . . 0.0 109.293 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.777 HG12 ' HA ' ' A' ' 65' ' ' LYS . 30.6 m -144.55 166.46 12.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.198 -0.939 . . . . 0.0 109.717 -179.838 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.55 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 3.3 t -112.87 157.21 21.7 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 179.338 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.577 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 10.0 p90 170.32 167.97 0.06 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.092 -1.005 . . . . 0.0 110.076 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 92.1 mt-10 -102.34 162.2 13.1 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 178.823 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.5 mt -99.91 127.75 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.008 -1.058 . . . . 0.0 109.75 -179.615 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.563 HG23 ' HB2' ' A' ' 59' ' ' GLN . 0.8 OUTLIER -109.17 120.82 61.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.62 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -88.53 85.89 6.92 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.194 -0.941 . . . . 0.0 109.713 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.14 -179.51 45.55 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 19.3 p-10 -54.49 -53.27 56.57 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.298 -1.119 . . . . 0.0 109.895 -179.708 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 20.3 mtm180 -57.13 -38.56 73.66 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.017 -1.052 . . . . 0.0 109.389 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.96 -158.81 27.99 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.557 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 52.3 Cg_endo -73.01 141.48 33.08 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.725 2.283 . . . . 0.0 112.006 179.898 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.563 ' HB2' HG23 ' A' ' 52' ' ' VAL . 31.8 mt-30 -137.03 168.45 19.56 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.37 -0.831 . . . . 0.0 108.894 179.543 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.591 ' HB3' ' HA ' ' A' ' 28' ' ' VAL . . . -94.13 139.93 30.38 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.015 -1.053 . . . . 0.0 110.332 -179.253 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.557 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -126.53 155.65 42.02 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.44 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.49 ' C ' ' O ' ' A' ' 61' ' ' ALA . 57.6 t30 40.88 63.06 1.25 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.958 -1.089 . . . . 0.0 108.849 -179.708 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.885 HG11 HD21 ' A' ' 41' ' ' LEU . 1.8 t -79.46 128.75 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.291 -0.881 . . . . 0.0 110.421 -179.011 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 56.4 m -119.6 125.59 49.14 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.777 ' HA ' HG12 ' A' ' 47' ' ' VAL . 69.6 mttt -65.51 110.6 2.76 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.21 -0.932 . . . . 0.0 109.531 -179.831 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.449 ' HG3' ' HA ' ' A' ' 47' ' ' VAL . 90.4 mt-10 -89.6 159.38 17.2 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.321 -0.862 . . . . 0.0 109.628 -179.845 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.551 0 CA-C-O 117.99 -1.005 . . . . 0.0 109.469 179.942 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.434 ' C ' HD12 ' A' ' 2' ' ' LEU . 69.3 mtm . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 121.309 0.576 . . . . 0.0 109.511 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.735 ' N ' HD12 ' A' ' 2' ' ' LEU . 6.4 mp -102.21 166.33 10.65 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.195 -0.94 . . . . 0.0 109.569 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.575 ' O ' HG13 ' A' ' 20' ' ' VAL . 61.0 mt-10 -132.87 139.55 47.48 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.36 -0.838 . . . . 0.0 109.213 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -139.64 157.41 25.18 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.66 ' O ' HG23 ' A' ' 18' ' ' ILE . 63.6 mttm -102.57 142.95 32.89 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.418 -1.048 . . . . 0.0 108.831 179.561 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.799 HG23 ' O ' ' A' ' 45' ' ' GLN . 18.7 t -76.61 112.09 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.173 -0.954 . . . . 0.0 110.047 -179.447 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.465 ' CG ' ' N ' ' A' ' 8' ' ' TRP . 3.3 pttt -79.94 -37.7 33.94 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.622 ' CE3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -159.75 155.01 25.18 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 -179.941 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.463 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 10.5 p90 -155.88 138.87 15.41 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.156 -0.965 . . . . 0.0 109.196 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.493 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.3 t-20 -132.63 133.55 43.77 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.097 -1.002 . . . . 0.0 109.633 -179.745 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 32.7 p -80.11 -18.51 49.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.268 -0.895 . . . . 0.0 108.939 179.456 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -64.77 -47.96 76.24 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 178.111 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.657 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 14.1 mttm -70.9 -40.21 72.32 Favored 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.151 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.491 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 97.08 2.67 59.23 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.681 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.657 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 0.4 OUTLIER -138.98 175.63 9.38 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.207 -1.172 . . . . 0.0 109.145 179.155 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.594 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -140.43 170.26 24.48 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 -179.65 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.622 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 27.5 m-85 -114.66 131.5 56.71 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.387 -1.066 . . . . 0.0 108.997 179.812 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 1.132 HD12 ' CG2' ' A' ' 28' ' ' VAL . 26.9 mt -120.27 149.29 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.164 -0.96 . . . . 0.0 109.433 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.447 ' OE1' ' OD1' ' A' ' 25' ' ' ASP . 18.1 tp10 -108.75 123.76 49.52 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.244 -0.91 . . . . 0.0 109.504 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.672 HG21 HG21 ' A' ' 26' ' ' VAL . 2.3 t -102.11 120.25 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.215 -0.928 . . . . 0.0 109.25 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -66.98 109.39 2.95 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.247 -0.908 . . . . 0.0 109.772 -179.701 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.14 -29.34 3.71 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.505 ' O ' ' O ' ' A' ' 24' ' ' ASP . 38.2 mt-30 -131.41 166.26 21.68 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.227 -1.161 . . . . 0.0 109.23 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.505 ' O ' ' O ' ' A' ' 23' ' ' GLN . 0.0 OUTLIER -52.8 -169.17 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.173 -0.954 . . . . 0.0 109.683 -179.777 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.447 ' OD1' ' OE1' ' A' ' 19' ' ' GLU . 42.2 m-20 -75.36 141.65 43.27 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.236 -0.915 . . . . 0.0 109.742 -179.77 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.672 HG21 HG21 ' A' ' 20' ' ' VAL . 87.0 t -112.11 119.73 60.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.259 -0.9 . . . . 0.0 109.385 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.489 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.1 OUTLIER -79.53 154.71 28.62 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.244 -0.91 . . . . 0.0 109.127 -179.94 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 1.132 ' CG2' HD12 ' A' ' 18' ' ' ILE . 5.0 t -129.64 133.04 65.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.292 -0.88 . . . . 0.0 109.27 -179.729 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.647 ' HA ' ' HB3' ' A' ' 15' ' ' PHE . 47.8 t60 -105.61 150.2 25.62 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.157 -0.964 . . . . 0.0 109.219 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.689 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.9 OUTLIER -43.1 -52.56 5.35 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.197 -0.939 . . . . 0.0 109.198 -179.818 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.689 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 23.0 t -56.25 -23.06 33.68 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.912 . . . . 0.0 109.856 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.509 ' N ' ' O ' ' A' ' 29' ' ' HIS . . . -65.38 -23.76 67.05 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.075 -1.015 . . . . 0.0 109.446 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.907 ' CD1' HD11 ' A' ' 41' ' ' LEU . 3.2 mp -108.25 135.72 46.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.286 -0.883 . . . . 0.0 109.337 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 64.4 tt0 -95.76 119.83 34.96 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.136 -0.977 . . . . 0.0 109.419 179.9 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.629 ' CA ' ' CZ ' ' A' ' 38' ' ' PHE . . . -176.02 147.86 8.92 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -64.98 -56.24 14.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.24 -1.153 . . . . 0.0 109.588 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -134.03 12.3 4.75 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.629 ' CZ ' ' CA ' ' A' ' 35' ' ' GLY . 49.8 p90 -117.36 25.68 10.28 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.164 -1.198 . . . . 0.0 109.374 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.467 ' NZ ' ' O ' ' A' ' 35' ' ' GLY . 44.7 mttp -60.88 -42.54 98.15 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.237 -0.915 . . . . 0.0 109.509 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.451 ' O ' ' NZ ' ' A' ' 65' ' ' LYS . 29.5 m -58.66 138.19 57.12 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.297 -0.877 . . . . 0.0 109.479 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.996 HD23 HG11 ' A' ' 47' ' ' VAL . 4.7 mp -93.64 175.33 6.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.165 -0.959 . . . . 0.0 109.578 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.453 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 95.7 mt-10 -111.67 151.43 28.87 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.376 -0.827 . . . . 0.0 109.329 179.788 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 76.6 tt0 -69.13 126.44 29.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.282 -0.886 . . . . 0.0 109.626 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 89.94 -3.2 82.7 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.799 ' O ' HG23 ' A' ' 6' ' ' VAL . 56.7 tt0 -82.16 131.03 35.24 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.197 -1.178 . . . . 0.0 109.701 179.822 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -76.82 142.69 40.18 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.211 -0.93 . . . . 0.0 109.226 179.755 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.996 HG11 HD23 ' A' ' 41' ' ' LEU . 30.1 m -145.39 159.36 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.233 -0.917 . . . . 0.0 110.093 -179.637 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.569 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 39.7 t -110.94 154.32 24.26 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.615 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 14.0 p90 173.37 163.87 0.15 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.817 -1.177 . . . . 0.0 110.508 -179.659 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -99.58 158.71 15.57 Favored 'General case' 0 N--CA 1.488 1.455 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.533 HD11 HG21 ' A' ' 26' ' ' VAL . 3.1 mt -102.13 131.77 49.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 120.928 -1.107 . . . . 0.0 110.244 -179.409 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.562 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.6 m -114.19 123.62 70.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 178.703 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -91.55 90.36 7.58 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.187 -0.946 . . . . 0.0 109.937 -178.946 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.6 -177.47 42.76 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 14.9 t-20 -53.16 -59.81 4.08 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.169 -1.195 . . . . 0.0 109.533 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 20.9 mtp180 -49.82 -39.07 37.47 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.189 -0.944 . . . . 0.0 109.201 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.09 -161.91 29.25 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.562 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 52.6 Cg_endo -72.31 144.9 42.25 Favored 'Trans proline' 0 C--O 1.216 -0.613 0 C-N-CA 122.7 2.267 . . . . 0.0 111.828 179.772 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.548 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 71.1 mt-30 -137.37 169.47 17.72 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.276 -0.89 . . . . 0.0 109.232 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.56 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -94.0 139.73 30.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.216 -0.927 . . . . 0.0 110.232 -179.407 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.602 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -127.98 157.74 39.79 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.514 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.49 ' C ' ' O ' ' A' ' 61' ' ' ALA . 85.7 m-20 41.4 68.57 0.43 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.857 -1.152 . . . . 0.0 108.816 -179.761 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.934 HG11 HD21 ' A' ' 41' ' ' LEU . 2.3 t -87.13 126.3 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.239 -0.913 . . . . 0.0 110.315 -178.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 82.3 m -117.99 124.26 47.74 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.713 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.451 ' NZ ' ' O ' ' A' ' 40' ' ' THR . 50.3 mttt -68.39 110.97 4.37 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.291 -0.881 . . . . 0.0 109.614 -179.814 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.473 ' O ' ' HB3' ' A' ' 67' ' ' ALA . 64.2 mt-10 -90.05 161.46 15.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.901 . . . . 0.0 109.604 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ALA . . . . . 0.473 ' HB3' ' O ' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.52 0 CA-C-O 117.989 -1.005 . . . . 0.0 109.466 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 54.9 mtm . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.483 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 27.2 mt -100.68 154.39 18.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.271 -0.893 . . . . 0.0 109.503 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -129.24 141.33 51.16 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -0.916 . . . . 0.0 109.061 179.753 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.52 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -146.66 156.71 27.13 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -179.719 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.514 ' N ' HG23 ' A' ' 18' ' ' ILE . 16.0 mttt -102.2 136.01 42.78 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.382 -1.069 . . . . 0.0 108.836 179.48 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.614 HG23 ' O ' ' A' ' 45' ' ' GLN . 40.3 t -68.59 115.71 7.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.161 -0.962 . . . . 0.0 110.095 -179.53 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 17' ' ' PHE . 5.9 tttm -79.06 -35.11 43.02 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.476 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.654 ' CD2' ' N ' ' A' ' 9' ' ' PHE . 0.4 OUTLIER -160.36 168.55 24.99 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.486 -0.759 . . . . 0.0 109.047 179.755 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.654 ' N ' ' CD2' ' A' ' 8' ' ' TRP . 21.4 p90 -163.44 141.23 7.65 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.885 -1.135 . . . . 0.0 110.312 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.599 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 20.5 t-20 -92.55 131.71 37.45 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.491 -0.755 . . . . 0.0 109.338 179.671 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.7 m -86.83 -21.93 26.13 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.241 -0.912 . . . . 0.0 109.773 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 71.0 mm-40 -74.09 -38.88 63.74 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.178 -0.952 . . . . 0.0 109.382 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.837 ' HB2' ' CE1' ' A' ' 15' ' ' PHE . 25.4 mttm -94.71 -57.43 2.46 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.363 -0.836 . . . . 0.0 109.824 -179.76 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.531 ' O ' ' CB ' ' A' ' 30' ' ' PHE . . . 116.85 48.8 0.44 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 -179.695 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.837 ' CE1' ' HB2' ' A' ' 13' ' ' LYS . 10.8 p90 -151.74 163.5 39.01 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.122 -1.222 . . . . 0.0 109.0 179.306 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.614 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -157.77 165.61 33.63 Favored Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.497 -1.335 . . . . 0.0 110.146 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.523 ' O ' ' N ' ' A' ' 7' ' ' LYS . 92.6 m-85 -96.43 138.63 33.73 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.457 -1.026 . . . . 0.0 108.909 179.726 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 1.048 HD12 HG21 ' A' ' 28' ' ' VAL . 63.2 mt -121.53 160.07 23.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.561 -0.712 . . . . 0.0 109.647 -179.715 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.48 ' N ' HG22 ' A' ' 18' ' ' ILE . 39.6 tt0 -120.4 119.09 32.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.35 -0.844 . . . . 0.0 109.46 -179.737 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.552 HG21 HG21 ' A' ' 26' ' ' VAL . 2.2 t -95.28 111.73 26.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.265 -0.897 . . . . 0.0 109.214 179.832 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.414 ' HA ' ' OE1' ' A' ' 21' ' ' GLU . 72.5 mm-40 -61.43 110.3 1.41 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.234 -0.916 . . . . 0.0 109.474 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.9 -33.97 3.56 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.614 ' OE1' HD12 ' A' ' 51' ' ' ILE . 36.1 mt-30 -124.28 163.39 21.75 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.248 -1.148 . . . . 0.0 109.365 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.474 ' O ' ' O ' ' A' ' 23' ' ' GLN . 57.9 m-20 -50.76 -176.81 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.304 -0.873 . . . . 0.0 109.652 -179.866 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.42 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 90.0 m-20 -74.02 140.88 45.74 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.336 -0.853 . . . . 0.0 109.728 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.552 HG21 HG21 ' A' ' 20' ' ' VAL . 88.9 t -113.42 115.75 50.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.319 -0.863 . . . . 0.0 109.411 -179.895 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.579 ' CE2' ' HB3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -70.75 156.72 39.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.057 -1.027 . . . . 0.0 109.355 -179.937 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 1.048 HG21 HD12 ' A' ' 18' ' ' ILE . 21.9 t -134.49 133.87 54.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.117 -0.989 . . . . 0.0 109.871 -179.472 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.672 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 14.3 t-80 -114.47 151.12 33.75 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.355 -0.841 . . . . 0.0 109.192 179.588 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.677 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.7 OUTLIER -42.63 -51.5 5.18 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.091 -1.006 . . . . 0.0 109.353 -179.858 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.677 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 86.6 p -53.69 -29.61 39.74 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.178 -0.952 . . . . 0.0 109.925 -179.618 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.596 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -64.91 -10.31 27.8 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.107 -0.995 . . . . 0.0 109.217 179.744 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.792 HD13 HD13 ' A' ' 41' ' ' LEU . 0.8 OUTLIER -126.18 132.98 69.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.487 -0.758 . . . . 0.0 109.726 -179.415 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 62.9 tt0 -104.34 133.21 49.61 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.286 -0.884 . . . . 0.0 109.448 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.632 ' CA ' ' CZ ' ' A' ' 38' ' ' PHE . . . -173.54 150.25 11.85 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -179.871 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 46.3 tp10 -57.67 -54.27 48.77 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.289 -1.124 . . . . 0.0 109.427 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -147.31 26.04 1.55 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.559 -1.417 . . . . 0.0 109.559 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.632 ' CZ ' ' CA ' ' A' ' 35' ' ' GLY . 55.0 p90 -124.87 28.43 6.47 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.301 -1.117 . . . . 0.0 109.432 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.521 ' O ' ' CD1' ' A' ' 41' ' ' LEU . 24.3 mttp -64.55 -31.55 72.81 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.286 -0.884 . . . . 0.0 109.736 -179.82 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 33.0 m -64.63 114.23 4.27 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.177 -0.952 . . . . 0.0 109.516 -179.881 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.917 HD21 HG11 ' A' ' 63' ' ' VAL . 3.5 mp -74.75 155.58 37.49 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.254 -0.904 . . . . 0.0 109.756 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' GLU . . . . . 0.408 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 36.6 tt0 -103.92 144.14 31.92 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.285 -0.884 . . . . 0.0 109.319 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 53.3 tt0 -63.11 130.34 44.23 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.293 -0.88 . . . . 0.0 109.477 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.97 -3.12 85.91 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.614 ' O ' HG23 ' A' ' 6' ' ' VAL . 46.8 tt0 -81.29 128.19 33.54 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.201 -1.176 . . . . 0.0 109.602 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -77.54 140.71 39.78 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.215 -0.928 . . . . 0.0 109.085 179.614 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.68 HG21 ' CD1' ' A' ' 18' ' ' ILE . 32.1 m -142.43 160.78 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.158 -0.964 . . . . 0.0 109.832 -179.825 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.55 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 24.0 t -107.3 152.06 24.64 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 178.827 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.559 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 35.3 p90 174.81 164.16 0.24 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.807 -1.183 . . . . 0.0 110.215 -179.426 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -100.31 172.28 7.25 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.614 HD12 ' OE1' ' A' ' 23' ' ' GLN . 1.0 OUTLIER -111.52 125.46 68.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 120.867 -1.146 . . . . 0.0 109.901 -179.819 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.585 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.7 m -109.16 123.48 65.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 179.138 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.4 mt-10 -91.52 83.75 5.43 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 109.645 -179.533 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.79 -172.06 42.28 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 179.789 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.433 ' O ' ' C ' ' A' ' 56' ' ' ARG . 18.3 t-20 -56.73 -63.55 1.16 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.14 -1.212 . . . . 0.0 109.212 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.433 ' C ' ' O ' ' A' ' 55' ' ' ASN . 36.2 mtp180 -42.0 -46.9 4.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.171 -0.955 . . . . 0.0 109.325 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.01 -149.33 21.46 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.42 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 46.2 Cg_endo -70.13 125.5 12.02 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.654 2.236 . . . . 0.0 112.128 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.585 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 33.2 mt-30 -125.56 158.62 34.13 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.335 -0.853 . . . . 0.0 108.875 179.389 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.812 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -91.47 134.86 34.27 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.019 -1.051 . . . . 0.0 109.767 -179.545 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.559 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -122.72 156.37 34.56 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.388 -0.82 . . . . 0.0 108.9 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.473 ' C ' ' O ' ' A' ' 61' ' ' ALA . 82.9 m-20 41.72 66.01 0.77 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.084 -1.01 . . . . 0.0 109.045 -179.727 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.917 HG11 HD21 ' A' ' 41' ' ' LEU . 4.5 t -83.03 125.85 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.234 -0.916 . . . . 0.0 109.93 -179.381 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.423 ' HB ' ' HB3' ' A' ' 48' ' ' SER . 92.4 m -118.35 125.02 49.15 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.53 -0.731 . . . . 0.0 109.211 179.766 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.483 ' NZ ' ' O ' ' A' ' 38' ' ' PHE . 32.4 mttp -65.41 110.5 2.68 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.338 -0.851 . . . . 0.0 109.438 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 73.3 mm-40 -100.67 166.71 10.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.283 -0.885 . . . . 0.0 109.504 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 118.001 -1.0 . . . . 0.0 109.452 -179.991 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.445 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 59.6 mt . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 78.1 mt-10 -130.62 143.52 50.81 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.283 -0.886 . . . . 0.0 109.203 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.516 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -152.06 156.09 26.5 Favored Glycine 0 N--CA 1.488 2.123 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.44 ' N ' HG23 ' A' ' 18' ' ' ILE . 96.7 mttt -100.99 135.21 42.81 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.312 -1.111 . . . . 0.0 108.744 179.463 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.703 HG23 ' O ' ' A' ' 45' ' ' GLN . 33.9 t -66.55 119.22 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.123 -0.986 . . . . 0.0 110.01 -179.424 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.432 ' N ' ' O ' ' A' ' 17' ' ' PHE . 5.9 tptm -79.48 -40.96 28.53 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.425 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.656 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -159.98 166.95 29.03 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 179.785 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.643 ' N ' ' CD2' ' A' ' 8' ' ' TRP . 17.1 p90 -158.76 147.39 18.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.943 -1.098 . . . . 0.0 110.574 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.646 ' HB3' ' CE1' ' A' ' 15' ' ' PHE . 13.9 t-20 . . . . . 0 N--CA 1.491 1.618 0 O-C-N 121.412 -0.805 . . . . 0.0 109.353 179.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.646 ' CE1' ' HB3' ' A' ' 10' ' ' ASN . 3.1 p90 . . . . . 0 N--CA 1.488 1.452 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.656 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -161.07 160.86 32.45 Favored Glycine 0 N--CA 1.486 2.018 0 C-N-CA 119.598 -1.286 . . . . 0.0 110.044 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.502 ' CD1' ' HB2' ' A' ' 27' ' ' PHE . 98.0 m-85 -90.74 139.37 30.79 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.488 -1.007 . . . . 0.0 108.719 179.492 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.699 HD12 HG21 ' A' ' 28' ' ' VAL . 19.7 mt -113.25 159.28 13.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.582 -0.699 . . . . 0.0 109.222 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.467 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 65.7 tt0 -114.27 109.52 18.51 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.225 -0.922 . . . . 0.0 109.464 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.569 HG21 HG21 ' A' ' 26' ' ' VAL . 2.7 t -90.74 109.48 20.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.199 -0.938 . . . . 0.0 109.206 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 74.3 mm-40 -59.22 108.87 0.75 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.214 -0.929 . . . . 0.0 109.267 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.9 -35.62 3.48 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.465 ' OE1' HD12 ' A' ' 51' ' ' ILE . 46.7 mt-30 -117.95 160.92 20.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -1.155 . . . . 0.0 109.362 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.447 ' O ' ' O ' ' A' ' 23' ' ' GLN . 44.5 m-20 -52.92 -174.19 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.253 -0.904 . . . . 0.0 109.514 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.5 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 80.8 m-20 -74.31 139.45 44.21 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.299 -0.876 . . . . 0.0 109.647 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.569 HG21 HG21 ' A' ' 20' ' ' VAL . 91.8 t -114.39 119.87 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.306 -0.871 . . . . 0.0 109.529 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.512 ' C ' ' CD1' ' A' ' 27' ' ' PHE . 0.0 OUTLIER -77.17 155.75 32.05 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.111 -0.993 . . . . 0.0 109.396 -179.965 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.699 HG21 HD12 ' A' ' 18' ' ' ILE . 10.8 t -131.09 138.5 53.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.294 -0.879 . . . . 0.0 109.434 -179.652 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.58 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 12.9 t-80 -112.21 149.93 31.58 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.094 -1.004 . . . . 0.0 109.581 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.699 ' CG ' ' N ' ' A' ' 31' ' ' SER . 1.2 p90 -46.88 -53.99 10.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.152 -0.968 . . . . 0.0 109.672 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.699 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 21.0 t -59.56 -20.85 58.58 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.024 -1.048 . . . . 0.0 109.907 -179.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.565 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -77.77 -12.66 60.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.157 -0.964 . . . . 0.0 109.414 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.018 HD13 HD13 ' A' ' 41' ' ' LEU . 3.0 mt . . . . . 0 N--CA 1.489 1.491 0 O-C-N 121.435 -0.79 . . . . 0.0 109.82 -179.66 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 1.018 HD13 HD13 ' A' ' 33' ' ' ILE . 4.3 mp . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.331 0.586 . . . . 0.0 109.84 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.451 ' O ' ' C ' ' A' ' 43' ' ' GLU . 58.5 tt0 -93.91 119.72 33.21 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.407 -0.808 . . . . 0.0 109.084 179.629 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.451 ' C ' ' O ' ' A' ' 42' ' ' GLU . 53.4 tt0 -41.13 131.38 2.65 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.284 -0.885 . . . . 0.0 109.553 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 89.69 -3.95 83.47 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.703 ' O ' HG23 ' A' ' 6' ' ' VAL . 52.1 tt0 -80.81 128.18 33.37 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.171 -1.194 . . . . 0.0 109.466 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -79.9 143.36 34.33 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.27 -0.894 . . . . 0.0 109.055 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.915 HG12 ' HA ' ' A' ' 65' ' ' LYS . 28.9 m -147.84 171.41 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.196 -0.94 . . . . 0.0 109.678 -179.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.656 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 34.7 t -116.3 156.46 26.61 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.308 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.598 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 17.0 p90 172.81 166.78 0.13 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.894 -1.129 . . . . 0.0 110.488 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -108.82 154.28 22.32 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.465 HD12 ' OE1' ' A' ' 23' ' ' GLN . 1.9 mt -87.73 122.85 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 120.863 -1.148 . . . . 0.0 110.069 -179.433 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.805 ' CG1' ' HB2' ' A' ' 61' ' ' ALA . 26.8 m -110.72 128.29 67.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 178.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -68.63 120.05 14.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.084 -1.01 . . . . 0.0 109.838 -179.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -128.02 162.57 21.81 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.761 -1.335 . . . . 0.0 109.761 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -51.78 -60.22 3.42 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.241 -1.153 . . . . 0.0 109.493 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 82.2 mtp180 -51.0 -33.16 23.65 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.274 -0.891 . . . . 0.0 109.184 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 144.84 -146.12 16.18 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.434 -1.466 . . . . 0.0 109.434 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.5 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 45.8 Cg_endo -69.35 127.99 15.74 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.781 2.321 . . . . 0.0 111.793 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.621 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 84.8 mt-30 -121.99 156.21 33.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.188 -0.945 . . . . 0.0 109.265 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.522 ' HB2' HG22 ' A' ' 28' ' ' VAL . . . -88.35 127.76 35.49 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.159 -0.963 . . . . 0.0 110.088 -179.336 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.805 ' HB2' ' CG1' ' A' ' 52' ' ' VAL . . . -108.71 150.47 27.52 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.322 -0.861 . . . . 0.0 108.887 179.37 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.487 ' C ' ' O ' ' A' ' 61' ' ' ALA . 36.8 t-20 40.64 67.22 0.53 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.213 -0.93 . . . . 0.0 109.013 -179.67 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.922 HG11 HG12 ' A' ' 33' ' ' ILE . 1.2 t -82.14 127.25 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.329 -0.857 . . . . 0.0 110.21 -179.175 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.414 ' HB ' ' HB3' ' A' ' 48' ' ' SER . 35.3 m -115.63 117.56 30.63 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.146 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.915 ' HA ' HG12 ' A' ' 47' ' ' VAL . 18.1 mttm -65.34 117.01 7.26 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.279 -0.888 . . . . 0.0 109.663 -179.66 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 82.8 mt-10 -108.87 167.67 9.91 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.375 -0.828 . . . . 0.0 109.661 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.506 -179.956 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.84 ' N ' HD12 ' A' ' 2' ' ' LEU . 5.1 mp . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.764 ' O ' HG13 ' A' ' 20' ' ' VAL . 2.7 tt0 -127.68 140.27 52.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.227 -0.921 . . . . 0.0 109.208 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.0 155.22 24.91 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.784 -1.326 . . . . 0.0 109.784 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.54 ' C ' HG23 ' A' ' 18' ' ' ILE . 54.5 mttt -108.88 137.86 46.13 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.406 -1.055 . . . . 0.0 108.645 179.46 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.86 HG23 ' O ' ' A' ' 45' ' ' GLN . 15.0 t -70.16 112.56 5.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.054 -1.029 . . . . 0.0 109.983 -179.301 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.483 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 14.7 tttm -78.5 -40.87 34.04 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.592 ' CE3' ' O ' ' A' ' 8' ' ' TRP . 0.0 OUTLIER -161.44 155.78 22.73 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.923 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.434 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 11.0 p90 -154.31 139.77 17.76 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.054 -1.029 . . . . 0.0 109.07 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.433 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 3.1 t-20 . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.052 -1.03 . . . . 0.0 109.869 -179.601 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.589 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 0.8 OUTLIER . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.533 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -148.57 173.85 28.41 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.564 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 29.2 m-85 -113.25 132.3 55.58 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.402 -1.058 . . . . 0.0 109.011 179.767 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 1.119 ' CD1' HG21 ' A' ' 28' ' ' VAL . 58.8 mt -119.07 149.5 21.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.239 -0.913 . . . . 0.0 109.681 -179.615 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 46.8 tt0 -112.09 122.15 46.95 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.353 -0.842 . . . . 0.0 109.415 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.764 HG13 ' O ' ' A' ' 3' ' ' GLU . 3.2 t -91.32 124.88 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.246 -0.909 . . . . 0.0 109.647 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.473 ' OE2' ' HE3' ' A' ' 5' ' ' LYS . 91.6 mt-10 -70.4 103.76 2.52 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.236 -0.915 . . . . 0.0 109.367 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 120.83 -19.13 8.99 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.569 ' OE1' HG11 ' A' ' 20' ' ' VAL . 49.0 mt-30 -129.82 162.6 28.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.263 -1.139 . . . . 0.0 109.578 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -54.46 -176.44 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.317 -0.864 . . . . 0.0 109.689 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 11.3 p30 -73.39 136.32 44.33 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.29 -0.881 . . . . 0.0 109.413 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.556 HG21 HG21 ' A' ' 20' ' ' VAL . 72.3 t -113.03 122.31 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.235 -0.916 . . . . 0.0 109.569 -179.753 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.508 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.4 OUTLIER -78.12 157.29 29.51 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.164 -0.96 . . . . 0.0 109.223 179.837 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 1.119 HG21 ' CD1' ' A' ' 18' ' ' ILE . 21.9 t -132.27 131.24 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.296 -0.877 . . . . 0.0 109.243 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.679 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 13.9 t-80 -105.83 154.64 20.25 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.124 -0.985 . . . . 0.0 109.267 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.685 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -46.52 -53.46 11.26 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.159 -0.963 . . . . 0.0 109.246 -179.683 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.685 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 86.7 p -55.96 -24.37 37.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.096 -1.003 . . . . 0.0 109.979 -179.692 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.502 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -66.32 -19.97 65.96 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.114 -0.991 . . . . 0.0 109.577 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.887 HG21 ' NZ ' ' A' ' 65' ' ' LYS . 2.9 mp . . . . . 0 N--CA 1.489 1.49 0 O-C-N 121.229 -0.92 . . . . 0.0 109.443 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.845 HD11 ' CD1' ' A' ' 33' ' ' ILE . 5.2 mp . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.364 0.602 . . . . 0.0 109.629 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.531 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 84.9 tt0 -116.11 149.26 39.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.297 -0.877 . . . . 0.0 109.008 179.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.483 ' HG3' ' O ' ' A' ' 7' ' ' LYS . 77.5 tt0 -71.0 124.46 24.41 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.15 -0.969 . . . . 0.0 109.769 -179.788 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 92.01 -6.88 79.15 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.901 -1.28 . . . . 0.0 109.901 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.86 ' O ' HG23 ' A' ' 6' ' ' VAL . 48.6 tp60 -82.04 133.19 35.27 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.131 -1.217 . . . . 0.0 109.732 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -84.34 144.95 28.51 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.899 . . . . 0.0 109.415 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.697 HG12 ' HA ' ' A' ' 65' ' ' LYS . 23.2 m -144.78 163.61 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.232 -0.917 . . . . 0.0 109.795 -179.725 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.513 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 1.0 OUTLIER -108.19 153.23 23.48 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 179.342 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.535 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 7.8 p90 174.63 165.82 0.25 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.99 -1.069 . . . . 0.0 110.055 -179.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.531 ' HA ' HD13 ' A' ' 2' ' ' LEU . 95.1 mt-10 -102.84 165.14 11.21 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.14 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.0 mt -102.44 125.74 56.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 120.936 -1.102 . . . . 0.0 109.854 -179.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.579 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 32.0 m -114.3 126.29 71.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.413 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 178.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -66.18 118.64 10.2 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.158 -0.964 . . . . 0.0 109.727 -179.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -122.07 157.44 16.8 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.496 ' CG ' ' N ' ' A' ' 56' ' ' ARG . 7.9 p30 -48.05 -49.66 30.6 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.319 -1.106 . . . . 0.0 109.654 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.496 ' N ' ' CG ' ' A' ' 55' ' ' ASN . 84.0 mtp180 -64.47 -25.23 67.91 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.109 -0.994 . . . . 0.0 109.012 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 142.63 -152.63 23.99 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.494 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 49.2 Cg_endo -70.72 137.25 32.28 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.631 2.22 . . . . 0.0 111.782 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.579 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 79.1 mt-30 -127.53 163.83 23.29 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.228 -0.92 . . . . 0.0 109.207 179.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.484 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -96.6 142.65 28.4 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.154 -0.966 . . . . 0.0 110.103 -179.324 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.517 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -124.65 154.06 41.34 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.387 -0.821 . . . . 0.0 108.881 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.476 ' C ' ' O ' ' A' ' 61' ' ' ALA . 58.3 t30 42.54 64.24 1.2 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.103 -0.998 . . . . 0.0 108.784 -179.65 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.766 HG12 HG23 ' A' ' 33' ' ' ILE . 1.8 t -78.38 128.91 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.337 -0.852 . . . . 0.0 109.944 -179.122 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.462 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 93.4 m -119.56 126.32 50.95 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.484 -0.76 . . . . 0.0 109.082 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.887 ' NZ ' HG21 ' A' ' 33' ' ' ILE . 38.2 mttp -73.39 114.78 12.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.219 -0.925 . . . . 0.0 109.771 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.449 ' HG3' ' HA ' ' A' ' 47' ' ' VAL . 97.1 mt-10 -92.44 161.98 14.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.251 -0.905 . . . . 0.0 109.452 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.392 179.884 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.427 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 57.5 mt . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.715 ' O ' HG13 ' A' ' 20' ' ' VAL . 3.5 tt0 -128.43 137.76 51.99 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.266 -0.896 . . . . 0.0 109.208 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.05 154.33 24.41 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.776 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.497 ' O ' HG23 ' A' ' 18' ' ' ILE . 58.0 mttp -104.16 140.46 37.77 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.434 -1.039 . . . . 0.0 108.829 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.768 HG23 ' O ' ' A' ' 45' ' ' GLN . 18.8 t -72.85 114.36 11.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.009 -1.057 . . . . 0.0 109.963 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 10.7 tptt -78.76 -42.24 28.54 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.581 ' CE3' ' O ' ' A' ' 8' ' ' TRP . 0.0 OUTLIER -160.1 156.12 26.3 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.452 -0.78 . . . . 0.0 109.009 179.96 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.498 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 10.4 p90 -154.96 139.08 16.5 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.124 -0.985 . . . . 0.0 109.021 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.445 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.7 t-20 . . . . . 0 N--CA 1.491 1.597 0 O-C-N 121.01 -1.056 . . . . 0.0 109.836 -179.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.584 ' N ' ' CD1' ' A' ' 15' ' ' PHE . 0.9 OUTLIER . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.566 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -145.12 175.4 24.73 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.564 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 32.8 m-85 -115.54 133.29 56.18 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.265 -1.138 . . . . 0.0 109.022 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 1.09 HD12 ' CG2' ' A' ' 28' ' ' VAL . 20.2 mt -119.88 155.08 22.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.226 -0.921 . . . . 0.0 109.402 -179.807 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 32.4 tp10 -117.83 123.92 47.1 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.315 -0.866 . . . . 0.0 109.588 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.715 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.3 t -97.94 119.98 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.314 -0.866 . . . . 0.0 109.47 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -69.11 109.61 4.11 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.27 -0.894 . . . . 0.0 109.556 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 126.46 -30.68 4.19 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.691 ' OE1' HD12 ' A' ' 51' ' ' ILE . 57.1 mt-30 -128.6 166.85 18.07 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.322 -1.105 . . . . 0.0 109.41 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.46 ' O ' ' O ' ' A' ' 23' ' ' GLN . 55.4 m-20 -51.13 -177.38 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.251 -0.906 . . . . 0.0 109.411 179.898 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.512 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 20.3 p30 -75.27 147.28 40.37 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.232 -0.917 . . . . 0.0 109.308 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.538 HG21 HG21 ' A' ' 20' ' ' VAL . 81.6 t -118.14 120.44 64.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.121 -0.987 . . . . 0.0 109.676 -179.556 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.529 ' CE1' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER -76.81 158.27 30.96 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.127 -0.983 . . . . 0.0 109.11 179.696 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 1.09 ' CG2' HD12 ' A' ' 18' ' ' ILE . 7.7 t -131.64 134.08 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.187 -0.946 . . . . 0.0 109.299 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.632 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 12.9 t-80 -109.32 152.63 25.01 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.193 -0.942 . . . . 0.0 109.15 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.682 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.9 OUTLIER -45.43 -53.04 9.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.199 -0.938 . . . . 0.0 109.176 -179.592 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.682 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 22.7 t -54.96 -28.94 55.31 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.243 -0.911 . . . . 0.0 110.051 -179.587 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.499 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -62.83 -21.58 66.03 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.048 -1.032 . . . . 0.0 109.352 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.944 ' CD1' HD11 ' A' ' 41' ' ' LEU . 3.3 mp . . . . . 0 N--CA 1.488 1.474 0 O-C-N 121.298 -0.876 . . . . 0.0 109.256 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.944 HD11 ' CD1' ' A' ' 33' ' ' ILE . 5.4 mp . . . . . 0 N--CA 1.489 1.501 0 CA-C-O 121.397 0.617 . . . . 0.0 109.699 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.515 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 85.2 tt0 -117.57 152.07 35.87 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.415 -0.803 . . . . 0.0 109.042 179.546 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 67.4 tt0 -72.85 124.57 25.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.207 -0.933 . . . . 0.0 109.6 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.7 -4.44 79.17 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.768 ' O ' HG23 ' A' ' 6' ' ' VAL . 55.9 tp60 -82.05 132.81 35.26 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.189 -1.183 . . . . 0.0 109.877 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -80.45 141.06 35.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.289 -0.882 . . . . 0.0 109.169 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.656 HG21 HD13 ' A' ' 18' ' ' ILE . 30.1 m -141.69 159.04 21.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 109.902 -179.614 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.503 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 28.9 t -109.66 153.11 24.7 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.048 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.552 ' CE2' HG23 ' A' ' 47' ' ' VAL . 8.5 p90 173.39 165.67 0.16 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.913 -1.117 . . . . 0.0 110.178 -179.764 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -100.05 162.89 12.69 Favored 'General case' 0 N--CA 1.487 1.382 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.691 HD12 ' OE1' ' A' ' 23' ' ' GLN . 0.9 OUTLIER -102.25 125.46 56.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 120.927 -1.108 . . . . 0.0 110.022 -179.571 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.601 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 26.7 m -109.9 121.98 63.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.408 ' OE2' ' HB3' ' A' ' 58' ' ' PRO . 39.9 mm-40 -91.47 89.9 7.42 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.144 -0.973 . . . . 0.0 109.945 -179.001 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.05 -169.96 32.23 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 56' ' ' ARG . 4.1 t30 -58.05 -66.17 0.52 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.236 -1.155 . . . . 0.0 109.837 -179.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.428 ' C ' ' O ' ' A' ' 55' ' ' ASN . 15.2 mtm180 -41.82 -46.29 3.88 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.282 -0.886 . . . . 0.0 109.501 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 150.65 -153.97 25.34 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.512 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 47.9 Cg_endo -69.64 129.42 17.69 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.682 2.255 . . . . 0.0 112.024 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.601 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 61.2 mt-30 -127.19 161.14 29.23 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.334 -0.854 . . . . 0.0 108.976 179.506 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.547 ' HB2' HG22 ' A' ' 28' ' ' VAL . . . -90.02 136.52 32.99 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.032 -1.043 . . . . 0.0 110.296 -179.154 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.534 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -118.79 149.57 41.28 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 179.442 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.488 ' C ' ' O ' ' A' ' 61' ' ' ALA . 38.6 t-20 41.34 67.77 0.51 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.033 -1.042 . . . . 0.0 108.875 -179.57 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.609 HG21 ' CG1' ' A' ' 28' ' ' VAL . 2.1 t -81.57 127.85 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.404 -0.81 . . . . 0.0 110.161 -179.176 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 91.8 m -118.1 123.84 46.57 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.472 -0.768 . . . . 0.0 109.082 179.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.494 ' HE2' ' HA ' ' A' ' 41' ' ' LEU . 74.1 mttt -70.75 112.63 7.11 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.199 -0.938 . . . . 0.0 109.737 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -92.75 162.7 14.02 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.326 -0.859 . . . . 0.0 109.584 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.995 -1.002 . . . . 0.0 109.491 179.997 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.845 ' N ' HD12 ' A' ' 2' ' ' LEU . 4.6 mp . . . . . 0 N--CA 1.488 1.475 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.794 ' O ' HG13 ' A' ' 20' ' ' VAL . 2.4 tt0 -128.73 143.67 50.98 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.205 -0.935 . . . . 0.0 109.163 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -144.34 157.08 27.07 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.445 ' C ' HG23 ' A' ' 18' ' ' ILE . 43.2 mttm -108.23 137.1 46.79 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.423 -1.045 . . . . 0.0 108.576 179.383 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.789 HG23 ' O ' ' A' ' 45' ' ' GLN . 16.1 t -68.28 114.45 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.128 -0.983 . . . . 0.0 109.85 -179.341 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.459 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 29.7 tttt -79.33 -38.07 36.03 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 179.601 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.608 ' CZ3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -166.37 157.39 12.89 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.476 -0.765 . . . . 0.0 109.035 -179.893 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.432 ' N ' ' CG ' ' A' ' 8' ' ' TRP . 16.1 p90 -152.75 139.89 19.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.203 -0.936 . . . . 0.0 108.847 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.487 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 55.1 t-20 . . . . . 0 N--CA 1.49 1.534 0 O-C-N 121.045 -1.034 . . . . 0.0 109.971 -179.408 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.62 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.29 0.567 . . . . 0.0 109.529 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.516 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -145.3 172.17 26.16 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.679 -1.368 . . . . 0.0 109.679 -179.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.608 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 28.4 m-85 -114.79 131.94 56.64 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.22 -1.164 . . . . 0.0 109.021 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 1.117 HD12 ' CG2' ' A' ' 28' ' ' VAL . 37.3 mt -119.25 149.54 21.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.146 -0.971 . . . . 0.0 109.647 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 46.3 tt0 -112.28 120.3 41.27 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.406 -0.809 . . . . 0.0 109.413 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.794 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.6 t -90.85 125.1 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.312 -0.868 . . . . 0.0 109.428 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.468 ' HA ' ' OE1' ' A' ' 21' ' ' GLU . 67.0 mm-40 -73.57 106.05 5.18 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.318 -0.864 . . . . 0.0 109.25 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.53 -17.54 8.89 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.564 ' OE1' HD12 ' A' ' 51' ' ' ILE . 46.5 mt-30 -133.9 164.62 26.86 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.276 -1.132 . . . . 0.0 109.648 -179.836 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 50.5 m-20 -55.02 -176.6 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.207 -0.933 . . . . 0.0 109.607 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.499 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 11.4 p30 -73.33 139.96 46.39 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.29 -0.881 . . . . 0.0 109.477 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.587 HG12 ' HB2' ' A' ' 60' ' ' ALA . 56.1 t -115.74 122.02 68.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.196 -0.94 . . . . 0.0 109.44 -179.796 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.495 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.3 OUTLIER -79.78 157.53 27.06 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.13 -0.981 . . . . 0.0 109.192 179.977 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 1.117 ' CG2' HD12 ' A' ' 18' ' ' ILE . 13.0 t -132.31 130.18 60.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.303 -0.873 . . . . 0.0 109.373 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.667 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 13.4 t-80 -103.65 154.41 19.55 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.148 -0.97 . . . . 0.0 109.089 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.689 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.7 OUTLIER -45.98 -53.44 10.02 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.082 -1.011 . . . . 0.0 109.188 -179.682 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.689 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 93.0 p -55.55 -30.26 60.45 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.154 -0.966 . . . . 0.0 110.236 -179.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.401 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -58.03 -27.9 63.99 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.996 -1.065 . . . . 0.0 109.331 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.821 HG12 HG11 ' A' ' 63' ' ' VAL . 2.6 mp . . . . . 0 C--N 1.302 -1.462 0 O-C-N 121.355 -0.841 . . . . 0.0 109.52 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.643 HD11 HG12 ' A' ' 33' ' ' ILE . 4.4 mp . . . . . 0 N--CA 1.489 1.519 0 CA-C-O 121.489 0.661 . . . . 0.0 109.837 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.451 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.5 tt0 -91.75 134.4 34.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.43 -0.794 . . . . 0.0 109.401 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.459 ' HG3' ' O ' ' A' ' 7' ' ' LYS . 76.1 tt0 -59.44 128.28 36.27 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.239 -0.913 . . . . 0.0 109.638 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.406 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 91.99 -5.13 78.8 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.726 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.789 ' O ' HG23 ' A' ' 6' ' ' VAL . 63.3 tt0 -81.37 131.48 35.29 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.269 -1.136 . . . . 0.0 109.758 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -79.14 141.4 37.29 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.247 -0.908 . . . . 0.0 109.22 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.681 HG21 HD13 ' A' ' 18' ' ' ILE . 33.2 m -141.83 159.19 21.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.127 -0.983 . . . . 0.0 109.907 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.505 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 27.5 t -106.08 151.26 24.91 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 179.017 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.596 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 11.7 p90 175.13 165.39 0.29 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.943 -1.098 . . . . 0.0 110.317 -179.707 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.552 ' HA ' HD13 ' A' ' 2' ' ' LEU . 93.9 mt-10 -100.05 166.26 11.12 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 178.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.564 HD12 ' OE1' ' A' ' 23' ' ' GLN . 0.6 OUTLIER -104.16 125.72 58.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.917 -1.114 . . . . 0.0 109.804 -179.66 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.591 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 33.1 m -114.03 125.57 71.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.173 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.464 ' HA ' ' HA ' ' A' ' 58' ' ' PRO . 19.8 mt-10 -96.66 93.61 6.84 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.196 -0.94 . . . . 0.0 109.923 -179.35 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.61 -176.62 44.33 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.407 ' CG ' ' N ' ' A' ' 56' ' ' ARG . 18.5 p-10 -53.17 -50.77 63.92 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.219 -1.165 . . . . 0.0 109.715 -179.674 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.407 ' N ' ' CG ' ' A' ' 55' ' ' ASN . 20.1 mtm180 -58.96 -37.5 76.93 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.081 -1.012 . . . . 0.0 109.381 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.05 -159.21 28.07 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.5 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 53.7 Cg_endo -72.59 142.28 35.99 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.728 2.285 . . . . 0.0 111.903 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.591 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 72.8 mt-30 -138.97 169.89 16.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.384 -0.822 . . . . 0.0 108.945 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.587 ' HB2' HG12 ' A' ' 26' ' ' VAL . . . -95.03 138.17 33.11 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.047 -1.033 . . . . 0.0 110.383 -179.132 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.596 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -125.42 156.33 39.01 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.34 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 73.5 m-20 45.39 69.18 0.47 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.893 -1.13 . . . . 0.0 108.665 -179.647 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.821 HG11 HG12 ' A' ' 33' ' ' ILE . 2.2 t -88.14 125.83 41.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.326 -0.859 . . . . 0.0 110.17 -179.033 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 98.1 m -118.16 121.23 39.99 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.505 -0.747 . . . . 0.0 109.025 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.721 ' NZ ' HG21 ' A' ' 33' ' ' ILE . 28.7 mttp -71.49 112.26 7.47 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.229 -0.919 . . . . 0.0 109.361 -179.805 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.469 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 96.2 mt-10 -94.03 166.89 11.93 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.313 -0.867 . . . . 0.0 109.642 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . 0.414 ' O ' ' O ' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 117.998 -1.001 . . . . 0.0 109.548 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.876 ' N ' HD12 ' A' ' 2' ' ' LEU . 3.6 mp . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.735 ' O ' HG13 ' A' ' 20' ' ' VAL . 83.0 mt-10 -127.96 144.27 51.1 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.274 -0.891 . . . . 0.0 109.185 179.671 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.471 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -140.06 153.43 23.32 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.499 ' N ' HG23 ' A' ' 18' ' ' ILE . 58.4 mttm -104.03 139.26 39.39 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.315 -1.109 . . . . 0.0 108.841 179.482 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.64 HG23 ' O ' ' A' ' 45' ' ' GLN . 38.7 t -71.63 109.94 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.166 -0.958 . . . . 0.0 109.899 -179.43 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.67 -32.83 27.94 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.371 -0.831 . . . . 0.0 108.977 179.42 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.686 ' CE3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -158.63 159.28 35.22 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 -179.837 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.505 ' N ' ' CG ' ' A' ' 8' ' ' TRP . 22.4 p90 -161.16 132.5 5.5 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.029 -1.044 . . . . 0.0 109.283 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.523 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.1 t-20 . . . . . 0 N--CA 1.49 1.536 0 O-C-N 121.197 -0.939 . . . . 0.0 109.539 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.735 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.654 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.593 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -136.96 172.57 22.56 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.686 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 17.0 m-85 -119.37 133.74 55.56 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.226 -1.161 . . . . 0.0 109.306 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 1.103 ' CD1' HG21 ' A' ' 28' ' ' VAL . 15.4 mt -120.82 154.41 24.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.342 -0.849 . . . . 0.0 109.46 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 24.9 tp10 -117.65 122.91 44.82 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.307 -0.871 . . . . 0.0 109.38 179.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.735 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.9 t -93.58 120.16 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.228 -0.92 . . . . 0.0 109.553 -179.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -67.14 109.18 2.94 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.295 -0.878 . . . . 0.0 109.286 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.22 -23.1 7.75 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.68 ' OE1' HD12 ' A' ' 51' ' ' ILE . 65.0 mt-30 -130.79 164.79 24.38 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.304 -1.115 . . . . 0.0 109.51 -179.77 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 41.0 m-20 -55.28 -175.02 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.33 -0.856 . . . . 0.0 109.924 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.475 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 15.2 p30 -74.18 141.99 45.46 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.301 -0.875 . . . . 0.0 109.737 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.478 HG21 HG21 ' A' ' 20' ' ' VAL . 90.6 t -117.87 118.13 57.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.207 -0.933 . . . . 0.0 109.353 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.448 ' CE1' ' HB3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -75.13 156.06 36.37 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.231 -0.918 . . . . 0.0 109.021 179.771 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 1.103 HG21 ' CD1' ' A' ' 18' ' ' ILE . 6.9 t -133.57 139.95 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.89 . . . . 0.0 109.607 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.735 ' HA ' ' HB3' ' A' ' 15' ' ' PHE . 13.6 t-80 -114.42 150.3 34.91 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.26 -0.9 . . . . 0.0 109.25 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.668 ' CG ' ' N ' ' A' ' 31' ' ' SER . 1.0 OUTLIER -43.75 -52.66 6.44 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.174 -0.954 . . . . 0.0 109.396 -179.642 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.668 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 22.8 t -57.61 -20.84 35.51 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.17 -0.956 . . . . 0.0 109.863 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.471 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -69.42 -22.75 63.66 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.115 -0.991 . . . . 0.0 109.735 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.639 ' CG1' HG11 ' A' ' 63' ' ' VAL . 2.9 mp . . . . . 0 N--CA 1.488 1.465 0 O-C-N 121.207 -0.933 . . . . 0.0 109.716 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.597 HD11 ' CD1' ' A' ' 33' ' ' ILE . 5.5 mp . . . . . 0 N--CA 1.489 1.493 0 CA-C-O 121.334 0.587 . . . . 0.0 109.787 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.427 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 94.5 mt-10 -105.47 146.29 29.73 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.44 -0.787 . . . . 0.0 109.36 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.574 ' HA ' HG12 ' A' ' 6' ' ' VAL . 52.6 tt0 -70.06 130.72 42.91 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.184 -0.947 . . . . 0.0 109.613 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 93.11 -5.96 75.75 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.726 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.64 ' O ' HG23 ' A' ' 6' ' ' VAL . 60.2 tp60 -81.86 125.68 30.99 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.26 -1.141 . . . . 0.0 109.73 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -73.25 143.94 46.88 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.199 -0.938 . . . . 0.0 109.223 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.853 HG21 HD13 ' A' ' 18' ' ' ILE . 33.4 m -145.39 158.92 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.109 -0.994 . . . . 0.0 110.188 -179.576 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.526 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 4.6 p -110.49 154.53 23.52 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.115 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.584 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 7.9 p90 171.29 167.66 0.08 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.93 -1.106 . . . . 0.0 110.035 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.651 ' HA ' HD13 ' A' ' 2' ' ' LEU . 94.8 mt-10 -103.67 165.09 11.25 Favored 'General case' 0 C--N 1.303 -1.436 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.212 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.68 HD12 ' OE1' ' A' ' 23' ' ' GLN . 3.9 mt -106.25 132.22 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 120.997 -1.064 . . . . 0.0 109.685 -179.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.536 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 20.5 m -121.28 133.12 68.87 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.557 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 -84.97 82.66 8.35 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.213 -0.929 . . . . 0.0 109.604 -179.673 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 57' ' ' GLY . . . -84.32 176.64 51.56 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 20.2 p-10 -49.47 -51.69 34.13 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.241 -1.152 . . . . 0.0 109.65 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 23.2 mtm180 -62.38 -31.98 72.72 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.095 -1.003 . . . . 0.0 109.549 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.413 ' O ' ' N ' ' A' ' 54' ' ' GLY . . . 142.93 -148.22 19.89 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.478 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 50.0 Cg_endo -71.24 133.59 23.17 Favored 'Trans proline' 0 C--O 1.214 -0.688 0 C-N-CA 122.802 2.334 . . . . 0.0 112.034 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.536 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 42.6 mt-30 -127.87 161.32 29.34 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.38 -0.825 . . . . 0.0 109.359 179.726 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.615 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -92.16 110.49 21.87 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.217 -0.927 . . . . 0.0 110.134 -179.508 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.575 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -93.48 152.07 19.31 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.327 -0.858 . . . . 0.0 109.061 179.633 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.494 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 79.0 m-20 43.63 78.23 0.06 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.043 -1.036 . . . . 0.0 109.029 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.748 HG21 ' CG1' ' A' ' 28' ' ' VAL . 2.1 t -92.87 125.87 45.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.182 -0.949 . . . . 0.0 110.003 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.402 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 56.9 m -120.48 130.22 54.19 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.655 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.561 ' NZ ' HG21 ' A' ' 33' ' ' ILE . 44.3 mttp -76.81 114.04 15.13 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.277 -0.889 . . . . 0.0 109.72 -179.697 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 57.5 mm-40 -101.02 172.02 7.28 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.284 -0.885 . . . . 0.0 109.635 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 117.993 -1.003 . . . . 0.0 109.471 179.893 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.837 ' N ' HD12 ' A' ' 2' ' ' LEU . 5.2 mp . . . . . 0 N--CA 1.489 1.502 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.779 ' O ' HG13 ' A' ' 20' ' ' VAL . 2.4 tt0 -132.39 139.99 48.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.179 -0.951 . . . . 0.0 109.461 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -140.4 158.75 26.09 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.509 ' O ' HG23 ' A' ' 18' ' ' ILE . 85.6 mttt -106.96 139.69 40.97 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.32 -1.106 . . . . 0.0 108.895 179.78 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.711 HG23 ' O ' ' A' ' 45' ' ' GLN . 22.6 t -72.88 111.56 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.109 -0.994 . . . . 0.0 110.127 -179.34 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 19.1 tttt -79.16 -40.6 30.52 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.619 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.7 154.76 26.88 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.765 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.436 ' N ' ' CG ' ' A' ' 8' ' ' TRP . 13.6 p90 -154.9 141.0 18.43 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.058 -1.026 . . . . 0.0 109.424 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.483 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.7 t-20 . . . . . 0 N--CA 1.489 1.517 0 O-C-N 121.253 -0.904 . . . . 0.0 109.677 -179.746 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.551 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 5.6 p90 . . . . . 0 N--CA 1.494 1.734 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.619 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -138.43 172.11 23.15 Favored Glycine 0 N--CA 1.49 2.27 0 C-N-CA 119.634 -1.27 . . . . 0.0 110.024 -179.452 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.514 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 27.1 m-85 -115.17 133.0 56.42 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.339 -1.095 . . . . 0.0 108.789 179.569 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 1.113 HD12 ' CG2' ' A' ' 28' ' ' VAL . 13.1 mt -120.92 155.29 24.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.151 -0.968 . . . . 0.0 109.873 -179.518 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.4 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 23.4 tp10 -116.92 123.47 47.06 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.398 -0.814 . . . . 0.0 109.369 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.779 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.3 t -98.15 123.0 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.17 -0.956 . . . . 0.0 109.317 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.463 ' HA ' ' OE1' ' A' ' 21' ' ' GLU . 68.7 mm-40 -72.24 108.83 5.6 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 0.0 109.3 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 125.44 -22.68 6.17 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.226 -1.55 . . . . 0.0 109.226 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.788 ' OE1' HD12 ' A' ' 51' ' ' ILE . 73.1 mt-30 -135.73 167.54 20.96 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.28 -1.13 . . . . 0.0 109.548 -179.78 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -53.52 -177.12 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.262 -0.899 . . . . 0.0 109.587 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.479 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 11.8 p30 -74.61 143.18 44.48 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.937 . . . . 0.0 109.426 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.559 HG21 HD11 ' A' ' 51' ' ' ILE . 97.9 t -116.33 119.36 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.16 -0.962 . . . . 0.0 109.425 -179.813 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.518 ' CG ' ' N ' ' A' ' 28' ' ' VAL . 0.4 OUTLIER -77.84 158.8 29.32 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.172 -0.955 . . . . 0.0 109.207 179.916 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 1.113 ' CG2' HD12 ' A' ' 18' ' ' ILE . 4.4 t -133.09 125.71 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.476 -0.765 . . . . 0.0 109.144 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.676 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 14.6 t-80 -98.46 153.93 18.24 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.355 -0.84 . . . . 0.0 109.091 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.687 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -45.13 -53.68 7.75 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.07 -1.019 . . . . 0.0 109.203 -179.65 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.687 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 62.8 p -54.27 -25.13 21.69 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.189 -0.945 . . . . 0.0 109.921 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.466 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -62.34 -24.52 67.38 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.126 -0.984 . . . . 0.0 109.439 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.776 HD11 HD11 ' A' ' 41' ' ' LEU . 3.0 mp . . . . . 0 N--CA 1.488 1.474 0 O-C-N 121.238 -0.914 . . . . 0.0 109.544 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 1.038 HD23 HG11 ' A' ' 47' ' ' VAL . 5.1 mp . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.396 0.617 . . . . 0.0 109.788 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.492 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 20.5 tt0 -116.42 140.24 49.56 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.391 -0.818 . . . . 0.0 109.057 179.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.432 ' HA ' HG12 ' A' ' 6' ' ' VAL . 76.6 tt0 -62.35 125.35 23.6 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.264 -0.898 . . . . 0.0 109.618 -179.76 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 90.67 -7.1 81.82 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.711 ' O ' HG23 ' A' ' 6' ' ' VAL . 66.7 tt0 -81.76 134.39 35.44 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.24 -1.153 . . . . 0.0 109.72 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -80.07 140.16 36.6 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.271 -0.893 . . . . 0.0 109.155 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 1.038 HG11 HD23 ' A' ' 41' ' ' LEU . 26.4 m -140.57 151.73 20.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.227 -0.921 . . . . 0.0 109.745 -179.464 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.527 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 33.0 t -100.56 148.94 24.24 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.053 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.598 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 7.2 p90 176.28 164.7 0.42 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.903 -1.123 . . . . 0.0 110.105 -179.63 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.571 ' HA ' HD13 ' A' ' 2' ' ' LEU . 94.9 mt-10 -103.54 161.41 13.9 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.247 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.788 HD12 ' OE1' ' A' ' 23' ' ' GLN . 7.2 mt -104.61 135.78 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.969 -1.082 . . . . 0.0 109.783 -179.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.501 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 32.7 m -122.23 131.41 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.481 -0.762 . . . . 0.0 109.11 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -86.8 84.22 7.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.185 -0.947 . . . . 0.0 109.634 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -85.84 177.16 49.55 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.3 t30 -50.34 -54.33 22.35 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.196 -1.179 . . . . 0.0 109.608 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 71.3 mtm180 -57.38 -35.46 70.01 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.241 -0.912 . . . . 0.0 109.498 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 145.2 -153.28 25.17 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -70.37 137.31 33.41 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.734 2.289 . . . . 0.0 111.987 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.524 ' C ' HG13 ' A' ' 26' ' ' VAL . 92.2 mt-30 -135.19 165.99 24.14 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.342 -0.849 . . . . 0.0 109.275 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.564 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -94.58 137.15 34.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.198 -0.938 . . . . 0.0 109.777 -179.69 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.598 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -123.96 155.04 38.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.365 -0.834 . . . . 0.0 108.843 179.717 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.476 ' C ' ' O ' ' A' ' 61' ' ' ALA . 85.8 m-20 43.19 73.91 0.13 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.897 -1.127 . . . . 0.0 108.706 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.845 HG11 HD21 ' A' ' 41' ' ' LEU . 2.7 t -89.65 126.96 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.212 -0.93 . . . . 0.0 109.99 -179.108 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.422 ' HB ' ' HB3' ' A' ' 48' ' ' SER . 70.3 m -118.45 124.29 47.27 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.487 ' HE2' ' HA ' ' A' ' 41' ' ' LEU . 55.5 mttt -71.73 111.03 6.67 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.181 -0.95 . . . . 0.0 109.528 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -89.78 164.1 14.79 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.364 -0.835 . . . . 0.0 109.566 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.461 -179.922 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.847 ' N ' HD12 ' A' ' 2' ' ' LEU . 4.6 mp . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.765 ' O ' HG13 ' A' ' 20' ' ' VAL . 96.1 mt-10 -129.48 147.36 51.29 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.167 -0.958 . . . . 0.0 109.295 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.444 ' C ' ' CG2' ' A' ' 18' ' ' ILE . . . -143.1 153.46 24.77 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.666 ' C ' HG23 ' A' ' 18' ' ' ILE . 27.6 mttp -102.48 141.38 35.39 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.284 -1.127 . . . . 0.0 108.839 179.557 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 45' ' ' GLN . 33.7 t -73.8 110.58 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.247 -0.908 . . . . 0.0 110.126 -179.392 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.488 ' NZ ' ' HB3' ' A' ' 17' ' ' PHE . 2.9 pttt -79.89 -36.46 36.5 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.615 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -159.74 154.26 24.04 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.962 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.627 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 17.0 p90 -156.03 140.33 16.64 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.075 -1.016 . . . . 0.0 109.496 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.447 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 55.1 t-20 . . . . . 0 N--CA 1.489 1.489 0 O-C-N 121.224 -0.923 . . . . 0.0 109.521 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.596 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 2.8 p90 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.615 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -136.07 177.22 19.72 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.652 -1.261 . . . . 0.0 110.05 -179.366 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.562 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 19.4 m-85 -119.2 135.49 54.65 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.384 -1.068 . . . . 0.0 109.078 179.834 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 1.088 ' CD1' HG21 ' A' ' 28' ' ' VAL . 37.9 mt -122.34 148.41 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.168 -0.958 . . . . 0.0 109.507 -179.673 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 23.3 tp10 -110.98 121.05 44.37 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.342 -0.849 . . . . 0.0 109.332 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.765 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.6 t -91.46 120.59 40.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.211 -0.931 . . . . 0.0 109.664 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.411 ' OE1' ' HA ' ' A' ' 21' ' ' GLU . 73.2 mm-40 -71.9 110.64 6.54 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.202 -0.936 . . . . 0.0 109.246 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.405 ' C ' ' HG3' ' A' ' 23' ' ' GLN . . . 122.57 -18.38 8.18 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.694 ' OE1' HD12 ' A' ' 51' ' ' ILE . 63.9 mt-30 -140.04 170.35 16.01 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.353 -1.086 . . . . 0.0 109.495 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 60.2 m-20 -55.31 -178.35 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.291 -0.88 . . . . 0.0 109.654 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 22.6 p30 -75.01 146.46 41.61 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.236 -0.915 . . . . 0.0 109.438 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.66 HG13 ' C ' ' A' ' 59' ' ' GLN . 58.1 t -118.35 119.07 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.242 -0.911 . . . . 0.0 109.401 -179.67 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.545 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.0 OUTLIER -76.61 156.31 32.84 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.205 -0.934 . . . . 0.0 109.148 179.855 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 1.088 HG21 ' CD1' ' A' ' 18' ' ' ILE . 14.7 t -133.45 132.97 57.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.383 -0.823 . . . . 0.0 109.399 -179.762 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.68 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 15.3 t-80 -111.18 153.5 25.7 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.354 -0.841 . . . . 0.0 109.053 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.682 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -44.47 -53.85 6.55 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.126 -0.984 . . . . 0.0 109.347 -179.605 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.682 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 32.3 t -57.04 -22.81 41.78 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.115 -0.991 . . . . 0.0 110.014 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.454 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -66.43 -27.53 67.91 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.09 -1.006 . . . . 0.0 109.458 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.719 HG12 HG11 ' A' ' 63' ' ' VAL . 2.4 mp . . . . . 0 N--CA 1.489 1.483 0 O-C-N 121.258 -0.901 . . . . 0.0 109.677 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.64 ' CD1' HD13 ' A' ' 33' ' ' ILE . 3.1 mp . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 121.2 0.524 . . . . 0.0 109.672 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.468 ' O ' ' CB ' ' A' ' 6' ' ' VAL . 96.0 mt-10 -100.7 149.15 24.09 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.324 -0.86 . . . . 0.0 109.484 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.525 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 69.8 tt0 -71.91 130.01 39.97 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.348 -0.845 . . . . 0.0 109.625 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.51 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 90.52 -4.26 82.17 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.583 ' O ' HG23 ' A' ' 6' ' ' VAL . 49.8 tt0 -80.8 129.57 34.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.271 -1.135 . . . . 0.0 109.638 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -76.48 139.75 40.94 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.268 -0.895 . . . . 0.0 109.065 179.702 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.822 HG21 HD13 ' A' ' 18' ' ' ILE . 31.8 m -142.28 162.24 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.029 -1.044 . . . . 0.0 109.959 -179.651 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.509 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 63.8 m -112.44 153.38 27.47 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.634 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 5.8 p90 172.75 168.56 0.12 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.033 -1.042 . . . . 0.0 109.978 -179.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.528 ' HA ' HD13 ' A' ' 2' ' ' LEU . 95.1 mt-10 -103.5 160.88 14.34 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.694 HD12 ' OE1' ' A' ' 23' ' ' GLN . 3.9 mt -103.5 134.47 44.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.116 -0.99 . . . . 0.0 109.616 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.533 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 33.9 m -122.74 131.74 72.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -85.7 87.2 7.37 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.102 -0.999 . . . . 0.0 109.677 -179.724 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.62 178.07 43.96 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.9 t30 -50.24 -56.75 9.82 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.23 -1.159 . . . . 0.0 109.514 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 21.6 mtm180 -57.11 -34.07 67.96 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.262 -0.898 . . . . 0.0 109.417 -179.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 144.53 -152.18 24.15 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.491 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 51.0 Cg_endo -70.46 136.98 32.43 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.835 2.357 . . . . 0.0 112.052 -179.869 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.66 ' C ' HG13 ' A' ' 26' ' ' VAL . 89.9 mt-30 -132.85 165.3 24.93 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.443 -0.786 . . . . 0.0 109.263 179.796 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.549 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -90.13 132.19 35.58 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.16 -0.963 . . . . 0.0 109.789 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.545 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -113.7 147.76 37.61 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.528 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.484 ' C ' ' O ' ' A' ' 61' ' ' ALA . 23.9 t-20 41.27 74.41 0.11 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.141 -0.975 . . . . 0.0 108.778 -179.497 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.719 HG11 HG12 ' A' ' 33' ' ' ILE . 1.4 t -84.38 127.94 39.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.387 -0.821 . . . . 0.0 110.159 -179.068 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.41 ' HB ' ' HB2' ' A' ' 48' ' ' SER . 27.7 m -119.68 126.61 51.53 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 179.333 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.536 ' HA ' HG12 ' A' ' 47' ' ' VAL . 57.7 mttt -73.72 108.78 6.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.162 -0.961 . . . . 0.0 109.511 -179.614 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 45.9 mm-40 -99.08 175.8 5.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.338 -0.852 . . . . 0.0 109.689 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.479 179.922 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.842 ' N ' HD12 ' A' ' 2' ' ' LEU . 5.1 mp . . . . . 0 N--CA 1.488 1.468 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.731 ' O ' HG13 ' A' ' 20' ' ' VAL . 2.1 tt0 -124.74 140.45 52.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.276 -0.89 . . . . 0.0 108.993 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -144.63 149.87 21.98 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.445 ' O ' HG23 ' A' ' 18' ' ' ILE . 19.4 mttm -99.52 139.53 35.05 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.38 -1.071 . . . . 0.0 108.539 179.295 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.738 HG23 ' O ' ' A' ' 45' ' ' GLN . 20.7 t -69.91 115.22 8.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.039 -1.038 . . . . 0.0 109.776 -179.464 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.437 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 40.7 tttt -78.76 -42.13 28.81 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.726 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.63 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -160.14 154.93 24.28 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.43 -0.794 . . . . 0.0 108.888 179.976 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.46 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 11.3 p90 -154.25 141.74 19.76 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.101 -0.999 . . . . 0.0 109.193 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.48 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 57.9 t-20 . . . . . 0 N--CA 1.489 1.507 0 O-C-N 121.151 -0.968 . . . . 0.0 109.832 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.544 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 4.0 p90 . . . . . 0 N--CA 1.491 1.61 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.63 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -138.63 175.21 21.61 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 119.625 -1.274 . . . . 0.0 109.97 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.483 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 37.6 m-85 -116.7 132.49 56.67 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.404 -1.057 . . . . 0.0 109.014 179.696 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 1.066 ' CD1' HG21 ' A' ' 28' ' ' VAL . 37.1 mt -116.89 148.7 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.141 -0.974 . . . . 0.0 109.528 -179.827 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 30.6 tp10 -110.29 121.31 44.98 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.332 -0.855 . . . . 0.0 109.448 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.731 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.4 t -96.22 120.02 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.163 -0.961 . . . . 0.0 109.471 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 47.1 mp0 -71.75 109.01 5.36 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.273 -0.892 . . . . 0.0 109.36 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.428 ' C ' ' HG3' ' A' ' 23' ' ' GLN . . . 125.28 -20.46 6.61 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.783 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.428 ' HG3' ' C ' ' A' ' 22' ' ' GLY . 37.3 mt-30 -138.83 169.62 17.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.317 -1.107 . . . . 0.0 109.695 -179.811 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -53.54 -177.4 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.32 -0.862 . . . . 0.0 109.665 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.516 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 11.0 p30 -75.97 143.54 41.49 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.287 -0.883 . . . . 0.0 109.661 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.631 HG12 ' HB2' ' A' ' 60' ' ' ALA . 79.7 t -116.92 120.87 66.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.23 -0.919 . . . . 0.0 109.527 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.553 ' CG ' ' N ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER -80.26 161.11 25.3 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.373 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 1.066 HG21 ' CD1' ' A' ' 18' ' ' ILE . 15.0 t -135.7 125.02 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.428 -0.795 . . . . 0.0 109.4 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.688 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 15.1 t-80 -96.2 154.35 17.3 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.231 -0.918 . . . . 0.0 109.14 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.688 ' CD2' ' CE1' ' A' ' 29' ' ' HIS . 0.7 OUTLIER -45.8 -53.41 9.66 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.105 -0.997 . . . . 0.0 109.245 -179.616 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.685 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 86.8 p -55.66 -27.24 48.84 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.171 -0.956 . . . . 0.0 109.982 -179.618 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.432 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -64.41 -35.94 82.52 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.995 -1.066 . . . . 0.0 109.159 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.639 HG12 HG11 ' A' ' 63' ' ' VAL . 5.1 mt . . . . . 0 N--CA 1.488 1.47 0 O-C-N 121.228 -0.92 . . . . 0.0 109.349 179.777 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.557 HD21 HG11 ' A' ' 47' ' ' VAL . 1.1 mt . . . . . 0 N--CA 1.488 1.474 0 CA-C-O 121.243 0.544 . . . . 0.0 109.575 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.499 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 46.3 tp10 -123.18 147.13 47.18 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.203 -0.936 . . . . 0.0 109.56 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.437 ' HG3' ' O ' ' A' ' 7' ' ' LYS . 76.0 tt0 -73.35 126.01 29.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.196 -0.94 . . . . 0.0 109.739 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.75 -5.45 79.62 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.738 ' O ' HG23 ' A' ' 6' ' ' VAL . 48.4 tp60 -81.22 124.4 29.26 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.196 -1.179 . . . . 0.0 109.601 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -75.09 144.61 42.84 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.263 -0.898 . . . . 0.0 109.154 179.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.832 HG12 ' HA ' ' A' ' 65' ' ' LYS . 21.7 m -148.36 168.11 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.177 -0.952 . . . . 0.0 109.827 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.545 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 4.1 p -112.48 152.76 28.37 Favored 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.325 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.579 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 14.4 p90 175.83 164.42 0.36 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.979 -1.076 . . . . 0.0 110.141 -179.781 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.425 ' HA ' HD13 ' A' ' 2' ' ' LEU . 91.9 mt-10 -100.36 164.6 11.86 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 179.016 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.424 ' O ' HG22 ' A' ' 51' ' ' ILE . 0.4 OUTLIER -101.77 124.36 55.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 120.851 -1.156 . . . . 0.0 109.422 -179.903 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.559 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.1 m -111.1 123.57 67.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.401 -0.812 . . . . 0.0 109.011 179.764 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.417 ' HA ' ' HA ' ' A' ' 58' ' ' PRO . 10.2 mt-10 -94.97 91.12 6.23 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.177 -0.952 . . . . 0.0 109.948 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.08 -174.88 42.37 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 179.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -54.37 -62.39 1.69 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.171 -1.194 . . . . 0.0 109.546 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 18.8 mtm180 -46.66 -41.23 14.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.157 -0.964 . . . . 0.0 109.194 179.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 152.99 -161.53 29.65 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.552 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 53.6 Cg_endo -72.09 144.12 41.65 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.712 2.275 . . . . 0.0 111.752 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.559 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 78.8 mt-30 -141.82 172.36 12.79 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.289 -0.882 . . . . 0.0 109.048 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.631 ' HB2' HG12 ' A' ' 26' ' ' VAL . . . -94.23 142.55 27.28 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.139 -0.976 . . . . 0.0 110.236 -179.234 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.512 ' O ' ' C ' ' A' ' 62' ' ' ASN . . . -124.43 152.85 42.77 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.434 -0.791 . . . . 0.0 108.903 179.578 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.512 ' C ' ' O ' ' A' ' 61' ' ' ALA . 44.8 t30 38.62 73.91 0.1 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.07 -1.019 . . . . 0.0 109.186 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.639 HG11 HG12 ' A' ' 33' ' ' ILE . 1.5 t -86.97 129.22 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.245 -0.909 . . . . 0.0 109.96 -179.313 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.432 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 65.3 m -115.44 119.53 36.54 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.35 -0.843 . . . . 0.0 109.116 179.645 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.832 ' HA ' HG12 ' A' ' 47' ' ' VAL . 35.9 mttt -69.73 108.17 3.79 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 109.286 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.45 ' HG3' ' HA ' ' A' ' 47' ' ' VAL . 97.2 mt-10 -87.4 164.09 16.4 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.272 -0.892 . . . . 0.0 109.725 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.562 0 CA-C-O 117.989 -1.005 . . . . 0.0 109.58 -179.955 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 45.5 mt . . . . . 0 N--CA 1.489 1.498 0 CA-C-O 121.291 0.567 . . . . 0.0 109.541 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.66 ' O ' HG13 ' A' ' 20' ' ' VAL . 89.1 mt-10 -136.13 136.54 40.17 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.241 -0.912 . . . . 0.0 109.26 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -133.78 159.42 23.7 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.626 ' O ' HG23 ' A' ' 18' ' ' ILE . 77.9 mttt -103.34 140.84 36.9 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.409 -1.053 . . . . 0.0 108.824 179.41 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.761 HG23 ' O ' ' A' ' 45' ' ' GLN . 18.9 t -73.73 114.2 12.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.116 -0.99 . . . . 0.0 110.241 -179.111 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.4 tttt -78.44 -41.45 32.79 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.671 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.78 153.89 25.32 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.553 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.629 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 6.2 p90 -156.05 141.65 17.8 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.986 -1.071 . . . . 0.0 109.764 -179.61 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.435 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 50.4 t-20 . . . . . 0 N--CA 1.488 1.456 0 O-C-N 121.276 -0.89 . . . . 0.0 108.992 179.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.603 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 50.2 p90 . . . . . 0 N--CA 1.491 1.621 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.671 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -149.53 174.96 28.92 Favored Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.53 -1.319 . . . . 0.0 110.206 -179.477 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.433 ' CE1' ' HB2' ' A' ' 27' ' ' PHE . 49.6 m-85 -111.9 133.75 53.9 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.446 -1.032 . . . . 0.0 108.834 179.644 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 1.137 HD12 ' CG2' ' A' ' 28' ' ' VAL . 19.7 mt -120.4 149.43 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.207 -0.933 . . . . 0.0 109.489 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 20.7 tp10 -113.28 122.44 47.44 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.351 -0.843 . . . . 0.0 109.332 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.66 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.8 t -91.75 121.9 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.253 -0.904 . . . . 0.0 109.525 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -69.36 108.5 3.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.333 -0.854 . . . . 0.0 109.325 179.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.07 -19.72 8.7 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.403 ' OE1' HG11 ' A' ' 20' ' ' VAL . 49.0 mt-30 -133.47 166.18 23.14 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.289 -1.124 . . . . 0.0 109.487 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 59.5 m-20 -54.79 -175.74 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.235 -0.916 . . . . 0.0 109.45 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.493 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 11.2 p30 -75.84 143.78 41.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.291 -0.881 . . . . 0.0 109.577 -179.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.573 HG21 HG21 ' A' ' 20' ' ' VAL . 79.3 t -118.85 121.42 66.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.184 -0.947 . . . . 0.0 109.374 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.504 ' O ' ' N ' ' A' ' 60' ' ' ALA . 0.1 OUTLIER -79.03 158.26 27.93 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.266 -0.896 . . . . 0.0 109.392 -179.984 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 1.137 ' CG2' HD12 ' A' ' 18' ' ' ILE . 17.3 t -132.85 132.38 59.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.428 -0.795 . . . . 0.0 109.165 -179.76 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.678 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 14.6 t-80 -104.61 154.89 19.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.256 -0.903 . . . . 0.0 109.277 -179.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.693 ' CD1' ' N ' ' A' ' 31' ' ' SER . 0.6 OUTLIER -46.3 -53.01 11.56 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.215 -0.928 . . . . 0.0 109.361 -179.696 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.693 ' N ' ' CD1' ' A' ' 30' ' ' PHE . 91.4 p -60.16 -21.19 61.35 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.095 -1.003 . . . . 0.0 110.025 -179.631 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.473 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -63.19 -23.6 67.5 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.042 -1.036 . . . . 0.0 109.468 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.782 ' CD1' HD11 ' A' ' 41' ' ' LEU . 3.5 mp . . . . . 0 N--CA 1.489 1.477 0 O-C-N 121.206 -0.934 . . . . 0.0 109.605 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 1.026 HD23 HG11 ' A' ' 47' ' ' VAL . 3.0 mp . . . . . 0 N--CA 1.489 1.486 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.523 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.1 tt0 -121.61 150.63 41.42 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.26 -0.9 . . . . 0.0 109.338 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 61.5 tt0 -67.44 124.23 22.62 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.23 -0.919 . . . . 0.0 109.538 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 90.96 -3.58 80.93 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 179.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.761 ' O ' HG23 ' A' ' 6' ' ' VAL . 61.4 tp60 -81.71 131.6 35.27 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.18 -1.189 . . . . 0.0 109.603 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -76.54 140.16 41.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.187 -0.946 . . . . 0.0 109.204 179.741 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 1.026 HG11 HD23 ' A' ' 41' ' ' LEU . 33.8 m -141.26 159.96 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.151 -0.968 . . . . 0.0 109.532 -179.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.499 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 43.4 m -112.86 155.62 24.36 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.385 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.585 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 3.7 p90 171.69 166.48 0.09 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.037 -1.039 . . . . 0.0 110.144 -179.692 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -97.82 157.53 16.02 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.729 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.4 mt -98.12 128.1 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.985 -1.072 . . . . 0.0 110.006 -179.473 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.765 HG23 ' HB2' ' A' ' 59' ' ' GLN . 0.3 OUTLIER -110.07 119.68 59.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.366 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -89.01 91.44 8.83 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.203 -0.936 . . . . 0.0 109.872 -179.446 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -97.23 -176.2 34.58 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -53.57 -61.59 2.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.178 -1.189 . . . . 0.0 109.663 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 61.3 mtp180 -47.9 -38.88 17.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.232 -0.917 . . . . 0.0 109.049 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.86 -157.3 27.3 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.447 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 51.3 Cg_endo -71.06 140.78 38.54 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.719 2.279 . . . . 0.0 111.692 179.806 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.765 ' HB2' HG23 ' A' ' 52' ' ' VAL . 91.8 mt-30 -135.51 167.78 20.44 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.21 -0.931 . . . . 0.0 109.232 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.651 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -96.42 137.58 35.28 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.18 -0.95 . . . . 0.0 110.158 -179.354 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.585 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -125.18 156.67 38.06 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.466 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.524 ' C ' ' O ' ' A' ' 61' ' ' ALA . 80.7 m-20 38.68 74.56 0.09 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.075 -1.016 . . . . 0.0 108.927 -179.765 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.971 HG11 HD21 ' A' ' 41' ' ' LEU . 2.4 t -89.32 129.62 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.234 -0.916 . . . . 0.0 110.307 -178.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 60.8 m -118.54 124.66 48.07 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.513 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 53.2 mttt -67.18 107.37 2.31 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.245 -0.91 . . . . 0.0 109.281 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.412 ' HG3' ' OG ' ' A' ' 48' ' ' SER . 59.4 mm-40 -97.09 170.58 9.03 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.157 -0.964 . . . . 0.0 109.622 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.406 179.989 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.469 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 71.6 mt . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 121.256 0.55 . . . . 0.0 109.539 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.615 ' O ' HG13 ' A' ' 20' ' ' VAL . 1.4 tt0 -130.75 140.89 50.35 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.34 -0.85 . . . . 0.0 109.329 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.49 155.06 25.05 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.584 ' O ' HG23 ' A' ' 18' ' ' ILE . 84.5 mttt -104.14 139.51 39.09 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.317 -1.108 . . . . 0.0 108.764 179.553 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.86 HG23 ' O ' ' A' ' 45' ' ' GLN . 16.0 t -72.22 113.16 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.097 -1.002 . . . . 0.0 110.085 -179.223 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.3 tttt -78.85 -40.87 31.49 Favored 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 179.546 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.607 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.96 154.41 25.82 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.812 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.601 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 8.2 p90 -155.59 141.27 17.95 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.026 -1.046 . . . . 0.0 109.315 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.46 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 63.2 t-20 . . . . . 0 N--CA 1.49 1.545 0 O-C-N 121.166 -0.959 . . . . 0.0 109.777 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.563 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 5.6 p90 . . . . . 0 N--CA 1.492 1.673 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.607 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -134.71 174.54 21.0 Favored Glycine 0 N--CA 1.491 2.349 0 C-N-CA 119.708 -1.234 . . . . 0.0 110.087 -179.438 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.49 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 26.1 m-85 -115.75 137.94 51.6 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.463 -1.022 . . . . 0.0 109.215 179.755 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 1.129 HD12 ' CG2' ' A' ' 28' ' ' VAL . 12.5 mt -123.69 154.06 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.161 -0.962 . . . . 0.0 109.491 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -117.98 116.06 26.15 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.313 -0.867 . . . . 0.0 109.503 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.622 HG21 HG21 ' A' ' 26' ' ' VAL . 2.4 t -85.33 118.4 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.276 -0.89 . . . . 0.0 109.353 179.789 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 85.4 mt-10 -68.43 111.08 4.45 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.196 -0.94 . . . . 0.0 109.243 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.451 ' C ' ' HG3' ' A' ' 23' ' ' GLN . . . 120.93 -15.66 9.51 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.495 ' OE1' HD12 ' A' ' 51' ' ' ILE . 49.5 mt-30 -140.68 169.75 17.05 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.222 -1.164 . . . . 0.0 109.622 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 60.5 m-20 -54.75 -179.21 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.254 -0.904 . . . . 0.0 109.681 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.461 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 18.4 p30 -75.41 144.0 42.44 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.307 -0.871 . . . . 0.0 109.706 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.622 HG21 HG21 ' A' ' 20' ' ' VAL . 86.4 t -118.38 118.8 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.224 -0.923 . . . . 0.0 109.263 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.586 ' CD1' ' N ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER -77.31 159.0 29.88 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.152 -0.967 . . . . 0.0 109.154 -179.935 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 1.129 ' CG2' HD12 ' A' ' 18' ' ' ILE . 13.6 t -134.08 131.43 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.356 -0.84 . . . . 0.0 109.393 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.664 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 17.4 t-80 -106.97 154.64 20.79 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.313 -0.867 . . . . 0.0 109.027 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.676 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -46.47 -53.36 11.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.023 -1.048 . . . . 0.0 109.205 -179.631 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.676 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 54.6 p -53.91 -30.75 47.57 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.155 -0.966 . . . . 0.0 110.347 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.485 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -61.83 -21.24 64.47 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.029 -1.045 . . . . 0.0 109.465 -179.856 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.932 ' CD1' HD11 ' A' ' 41' ' ' LEU . 3.2 mp . . . . . 0 N--CA 1.489 1.479 0 O-C-N 121.204 -0.935 . . . . 0.0 109.506 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.932 HD11 ' CD1' ' A' ' 33' ' ' ILE . 5.3 mp . . . . . 0 N--CA 1.488 1.441 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.511 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.7 tt0 -117.31 149.78 39.9 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.181 -0.949 . . . . 0.0 109.055 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 62.8 tt0 -70.52 123.97 23.08 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.253 -0.904 . . . . 0.0 109.584 -179.778 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 92.89 -3.41 73.79 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 179.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.86 ' O ' HG23 ' A' ' 6' ' ' VAL . 60.7 tt0 -82.74 134.95 35.12 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.119 -1.224 . . . . 0.0 109.906 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -81.1 141.56 34.17 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.399 -0.813 . . . . 0.0 109.067 179.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.785 HG21 HD13 ' A' ' 18' ' ' ILE . 28.1 m -141.51 159.57 21.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.131 -0.981 . . . . 0.0 109.922 -179.529 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.506 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 23.0 t -110.89 154.06 24.58 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.424 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.56 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 5.6 p90 172.26 166.14 0.11 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.01 -1.056 . . . . 0.0 110.077 -179.746 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.431 ' HB2' ' HB3' ' A' ' 61' ' ' ALA . 93.6 mt-10 -98.98 160.55 14.18 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.495 HD12 ' OE1' ' A' ' 23' ' ' GLN . 0.8 OUTLIER -97.94 125.41 51.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 120.933 -1.105 . . . . 0.0 109.781 -179.436 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.595 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 0.1 OUTLIER -107.85 118.95 56.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.473 -0.767 . . . . 0.0 109.076 179.852 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -86.76 84.78 7.3 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.314 -0.866 . . . . 0.0 109.704 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.43 -177.31 41.61 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.3 t30 -54.2 -61.98 1.96 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.219 -1.165 . . . . 0.0 109.563 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 39.7 mtp180 -48.32 -39.36 21.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.285 -0.884 . . . . 0.0 109.135 179.794 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 148.81 -158.86 27.82 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.595 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 49.8 Cg_endo -70.23 140.44 40.92 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.686 2.257 . . . . 0.0 111.716 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.571 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 8.5 mt-30 -133.88 166.25 23.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.318 -0.864 . . . . 0.0 109.37 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.648 ' HB2' HG22 ' A' ' 28' ' ' VAL . . . -87.58 128.4 35.26 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.308 -0.87 . . . . 0.0 109.871 -179.573 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.56 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -112.74 146.45 38.74 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.35 -0.844 . . . . 0.0 108.812 179.457 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.472 ' C ' ' O ' ' A' ' 61' ' ' ALA . 62.5 t30 42.82 71.9 0.2 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.046 -1.034 . . . . 0.0 108.776 -179.615 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.688 HG12 HG23 ' A' ' 33' ' ' ILE . 2.0 t -83.82 127.1 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.365 -0.834 . . . . 0.0 110.162 -178.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 93.9 m -119.79 127.04 52.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.449 -0.782 . . . . 0.0 109.016 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.907 ' NZ ' HG21 ' A' ' 33' ' ' ILE . 55.1 mttp -77.46 112.78 14.57 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.172 -0.955 . . . . 0.0 109.726 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -89.82 165.11 14.34 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.902 . . . . 0.0 109.428 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 118.009 -0.996 . . . . 0.0 109.41 -179.999 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.736 ' N ' HD12 ' A' ' 2' ' ' LEU . 6.2 mp . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.495 ' HG2' ' O ' ' A' ' 47' ' ' VAL . 3.0 tt0 -133.39 132.53 41.3 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.306 -0.871 . . . . 0.0 109.217 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.515 ' C ' ' CG2' ' A' ' 18' ' ' ILE . . . -135.63 167.6 24.19 Favored Glycine 0 N--CA 1.491 2.342 0 C-N-CA 119.632 -1.27 . . . . 0.0 110.229 -179.602 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.682 ' C ' HG23 ' A' ' 18' ' ' ILE . 44.0 mmtm -110.39 135.63 50.81 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.544 -0.974 . . . . 0.0 108.693 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.709 HG23 ' O ' ' A' ' 45' ' ' GLN . 17.6 t -68.5 116.14 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.19 -0.944 . . . . 0.0 109.973 -179.556 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.432 ' N ' ' O ' ' A' ' 17' ' ' PHE . 11.5 tttm -80.38 -33.69 37.0 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.303 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.671 ' CD2' ' N ' ' A' ' 9' ' ' PHE . 0.4 OUTLIER -162.57 166.41 24.74 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 179.671 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.671 ' N ' ' CD2' ' A' ' 8' ' ' TRP . 9.9 p90 -164.47 145.93 8.32 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.94 -1.1 . . . . 0.0 110.601 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.653 ' HB3' ' CE1' ' A' ' 15' ' ' PHE . 38.0 t-20 . . . . . 0 N--CA 1.493 1.679 0 O-C-N 121.391 -0.818 . . . . 0.0 109.615 179.741 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.653 ' CE1' ' HB3' ' A' ' 10' ' ' ASN . 1.4 p90 . . . . . 0 N--CA 1.488 1.458 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.607 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -176.75 151.18 10.99 Favored Glycine 0 N--CA 1.487 2.076 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.026 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.474 ' HB3' ' OD1' ' A' ' 25' ' ' ASP . 89.4 m-85 -79.08 143.18 35.8 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.369 -1.077 . . . . 0.0 108.803 179.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 1.143 ' CD1' HG21 ' A' ' 28' ' ' VAL . 73.3 mt -121.84 149.17 25.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 -179.786 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.403 ' N ' ' O ' ' A' ' 5' ' ' LYS . 44.5 tt0 -103.7 118.49 36.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.199 -0.938 . . . . 0.0 109.529 -179.852 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.599 HG21 HG21 ' A' ' 26' ' ' VAL . 3.4 t -94.32 123.51 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.255 -0.903 . . . . 0.0 109.417 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -59.08 99.93 0.06 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.303 -0.873 . . . . 0.0 109.674 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.25 -29.04 3.54 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 179.623 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 15.0 mt-30 -127.05 169.86 12.93 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.133 -1.216 . . . . 0.0 109.739 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.533 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -60.24 -163.41 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.237 -0.914 . . . . 0.0 109.553 179.753 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.474 ' OD1' ' HB3' ' A' ' 17' ' ' PHE . 2.9 t70 -77.53 143.64 38.25 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.285 -0.884 . . . . 0.0 109.713 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.599 HG21 HG21 ' A' ' 20' ' ' VAL . 88.4 t -115.95 127.14 73.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.371 -0.831 . . . . 0.0 109.367 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.1 OUTLIER -76.47 148.23 37.35 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.118 -0.988 . . . . 0.0 109.636 -179.791 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 1.143 HG21 ' CD1' ' A' ' 18' ' ' ILE . 16.5 t -131.14 131.44 63.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 -179.79 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.672 ' CE1' ' CE2' ' A' ' 30' ' ' PHE . 12.1 t-80 -102.68 148.33 25.72 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.083 -1.011 . . . . 0.0 109.924 -179.529 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.688 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.1 p90 -43.57 -51.83 6.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.307 -0.871 . . . . 0.0 109.519 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.672 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 46.5 p -61.27 -13.58 19.9 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.168 -0.957 . . . . 0.0 109.801 -179.701 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.517 ' N ' ' O ' ' A' ' 29' ' ' HIS . . . -66.68 -25.23 66.45 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.265 -0.897 . . . . 0.0 109.642 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.034 HD11 HD11 ' A' ' 41' ' ' LEU . 2.2 mp . . . . . 0 N--CA 1.491 1.607 0 O-C-N 121.257 -0.902 . . . . 0.0 109.725 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 1.034 HD11 HD11 ' A' ' 33' ' ' ILE . 1.1 mt . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.279 0.562 . . . . 0.0 109.614 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.478 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 80.2 tt0 -117.42 150.76 38.35 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.341 -0.85 . . . . 0.0 109.249 179.84 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 68.4 tt0 -68.33 128.07 35.25 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.914 . . . . 0.0 109.571 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 86.77 -2.94 87.33 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 179.733 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.709 ' O ' HG23 ' A' ' 6' ' ' VAL . 51.8 tt0 -80.44 134.62 36.01 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.203 -1.175 . . . . 0.0 109.715 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -87.55 142.52 27.79 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.299 -0.876 . . . . 0.0 109.169 179.689 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.963 HG12 ' HA ' ' A' ' 65' ' ' LYS . 32.9 m -147.06 167.06 5.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.232 -0.918 . . . . 0.0 109.864 -179.734 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.592 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 24.0 t -109.15 154.77 21.87 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 178.838 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.587 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 8.1 p90 172.15 168.59 0.11 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.003 -1.061 . . . . 0.0 110.034 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.491 ' HA ' HD13 ' A' ' 2' ' ' LEU . 90.2 mt-10 -105.99 169.24 8.61 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 179.173 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.449 HD11 HG21 ' A' ' 26' ' ' VAL . 4.2 mt -111.02 136.87 45.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.022 -1.049 . . . . 0.0 109.546 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.487 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 33.7 m -123.04 134.36 66.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.465 -0.772 . . . . 0.0 108.942 179.727 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -90.49 79.64 6.18 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.139 -0.975 . . . . 0.0 109.613 -179.778 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -81.3 -179.5 53.04 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -52.45 -57.15 10.79 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.177 -1.19 . . . . 0.0 109.559 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 82.1 mtm180 -54.19 -38.17 65.32 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.163 -0.96 . . . . 0.0 109.599 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.08 -153.34 25.29 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.487 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 50.9 Cg_endo -70.76 133.76 24.41 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.867 2.378 . . . . 0.0 112.146 -179.825 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 83.7 mt-30 -133.53 164.66 26.65 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.356 -0.84 . . . . 0.0 109.032 179.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.705 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -92.72 136.93 32.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.119 -0.988 . . . . 0.0 110.104 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.587 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -121.14 153.06 38.01 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 179.376 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.499 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 85.0 m-20 43.86 79.41 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.962 -1.086 . . . . 0.0 108.702 -179.557 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.873 HG21 ' CG1' ' A' ' 28' ' ' VAL . 2.1 t -94.63 124.34 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.161 -0.962 . . . . 0.0 110.195 -179.059 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.497 ' HB ' ' HB3' ' A' ' 48' ' ' SER . 97.1 m -114.16 114.96 26.74 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.49 -0.756 . . . . 0.0 109.055 179.576 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.963 ' HA ' HG12 ' A' ' 47' ' ' VAL . 56.5 mttt -65.02 118.4 9.07 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.335 -0.853 . . . . 0.0 109.426 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 67.1 mm-40 -102.38 162.56 12.82 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.378 -0.826 . . . . 0.0 109.732 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.462 -179.957 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.519 HD12 HD13 ' A' ' 51' ' ' ILE . 26.5 mt . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.507 ' O ' HG13 ' A' ' 20' ' ' VAL . 74.1 mt-10 -133.82 134.69 43.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.268 -0.895 . . . . 0.0 109.441 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -139.7 157.09 25.1 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.705 -1.358 . . . . 0.0 109.705 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.414 ' N ' HG23 ' A' ' 18' ' ' ILE . 69.6 mttt -111.21 133.69 53.37 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.435 -1.038 . . . . 0.0 108.438 179.189 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.923 HG23 ' O ' ' A' ' 45' ' ' GLN . 16.2 t -64.05 115.18 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.113 -0.992 . . . . 0.0 110.118 -179.328 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.474 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 14.9 tptp -78.12 -42.04 33.16 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 179.508 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.612 ' CE3' ' O ' ' A' ' 8' ' ' TRP . 0.0 OUTLIER -162.29 156.07 21.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.499 -0.751 . . . . 0.0 109.093 179.99 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.641 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 10.6 p90 -154.16 140.53 18.68 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.13 -0.981 . . . . 0.0 109.041 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 54.5 t-20 . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.13 -0.981 . . . . 0.0 109.499 -179.989 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.621 ' N ' ' CD1' ' A' ' 15' ' ' PHE . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.627 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 . . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.567 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -155.41 176.85 32.88 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 109.531 -1.427 . . . . 0.0 109.531 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.527 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 43.6 m-85 -113.79 133.3 55.47 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.248 -1.148 . . . . 0.0 109.187 179.789 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 1.096 ' CD1' HG21 ' A' ' 28' ' ' VAL . 61.7 mt -116.18 145.43 21.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.388 -0.82 . . . . 0.0 109.722 -179.669 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 28.7 tt0 -108.09 116.5 32.07 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.415 -0.803 . . . . 0.0 109.495 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.621 HG21 HG21 ' A' ' 26' ' ' VAL . 2.8 t -87.96 125.93 41.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.295 -0.878 . . . . 0.0 109.422 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -69.85 101.62 1.77 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.293 -0.879 . . . . 0.0 109.221 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.22 -22.97 6.97 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 -179.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.429 ' O ' ' O ' ' A' ' 24' ' ' ASP . 12.6 mt-30 -123.28 158.81 30.12 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.364 -1.08 . . . . 0.0 109.322 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.429 ' O ' ' O ' ' A' ' 23' ' ' GLN . 44.8 m-20 -54.81 -171.24 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.19 -0.944 . . . . 0.0 109.452 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.565 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 88.6 m-20 -73.73 133.25 43.3 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.196 -0.94 . . . . 0.0 109.533 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.664 HG21 HD11 ' A' ' 51' ' ' ILE . 96.0 t -111.06 125.24 68.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.256 -0.903 . . . . 0.0 109.234 -179.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.573 ' CE1' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER -79.28 159.64 27.16 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.052 -1.03 . . . . 0.0 109.747 -179.716 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 1.096 HG21 ' CD1' ' A' ' 18' ' ' ILE . 57.8 t -133.95 137.95 51.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.432 -0.792 . . . . 0.0 109.419 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.604 ' O ' HD12 ' A' ' 33' ' ' ILE . 21.7 t-80 -111.23 150.59 29.37 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.291 -0.88 . . . . 0.0 108.899 179.593 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.713 ' CG ' ' N ' ' A' ' 31' ' ' SER . 1.3 p90 -48.09 -54.21 13.94 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.046 -1.034 . . . . 0.0 109.298 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.713 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 19.2 t -55.96 -30.55 61.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.025 -1.047 . . . . 0.0 109.899 -179.441 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.58 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -63.66 -17.56 63.06 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.021 -1.049 . . . . 0.0 108.544 179.505 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.026 HG23 HG12 ' A' ' 63' ' ' VAL . 0.6 OUTLIER . . . . . 0 C--N 1.302 -1.492 0 O-C-N 121.607 -0.683 . . . . 0.0 109.434 -179.86 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.681 HD12 ' HZ1' ' A' ' 65' ' ' LYS . 5.2 mp . . . . . 0 N--CA 1.489 1.497 0 CA-C-O 121.345 0.593 . . . . 0.0 109.745 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.444 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.2 tt0 -96.98 132.28 42.95 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.237 -0.914 . . . . 0.0 109.528 -179.852 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.474 ' OE2' ' O ' ' A' ' 7' ' ' LYS . 75.1 tt0 -59.51 129.01 39.88 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.318 -0.864 . . . . 0.0 109.343 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 93.74 -8.06 74.0 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.923 ' O ' HG23 ' A' ' 6' ' ' VAL . 70.6 tp60 -78.41 126.33 30.62 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.162 -1.199 . . . . 0.0 109.596 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -82.88 143.26 30.87 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.251 -0.905 . . . . 0.0 109.344 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.981 HG12 ' HA ' ' A' ' 65' ' ' LYS . 34.4 m -144.41 167.04 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.908 . . . . 0.0 109.597 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.485 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 22.3 t -109.72 154.67 22.56 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.376 -0.827 . . . . 0.0 108.839 179.502 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.645 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 4.2 p90 172.79 166.03 0.13 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.959 -1.088 . . . . 0.0 110.312 -179.759 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.441 ' OE1' ' HA ' ' A' ' 50' ' ' GLU . 67.5 mm-40 -96.09 159.68 14.84 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 178.581 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.664 HD11 HG21 ' A' ' 26' ' ' VAL . 1.1 mp -100.52 127.5 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.939 -1.101 . . . . 0.0 110.044 -179.431 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.6 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 27.5 m -115.86 124.18 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 178.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 22.0 mt-10 -95.74 97.16 9.48 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.127 -0.983 . . . . 0.0 109.703 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.19 -179.35 42.77 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.436 ' CG ' ' N ' ' A' ' 56' ' ' ARG . 16.0 p-10 -53.97 -50.31 66.8 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.159 -1.201 . . . . 0.0 109.514 -179.87 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.436 ' N ' ' CG ' ' A' ' 55' ' ' ASN . 33.3 mtp85 -61.31 -42.19 98.25 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.052 -1.03 . . . . 0.0 109.793 -179.726 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 158.79 -164.64 33.75 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 110.016 -1.233 . . . . 0.0 110.016 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.565 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 44.1 Cg_endo -68.55 139.78 45.73 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 123.198 2.598 . . . . 0.0 112.637 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.6 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 68.5 mt-30 -135.58 165.41 25.6 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.301 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.611 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -99.17 141.96 31.26 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.976 -1.077 . . . . 0.0 110.467 -179.031 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.526 ' O ' ' C ' ' A' ' 62' ' ' ASN . . . -124.22 155.7 38.1 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 179.128 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.526 ' C ' ' O ' ' A' ' 61' ' ' ALA . 0.3 OUTLIER 37.58 66.72 0.43 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.172 -0.955 . . . . 0.0 109.003 -179.798 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 1.026 HG12 HG23 ' A' ' 33' ' ' ILE . 2.0 t -79.01 130.99 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.337 -0.852 . . . . 0.0 110.073 -179.048 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.521 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 25.2 m -117.15 123.4 46.63 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.328 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.981 ' HA ' HG12 ' A' ' 47' ' ' VAL . 47.4 mttm -74.97 115.49 14.64 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.203 -0.935 . . . . 0.0 109.939 -179.56 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.46 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 47.2 mt-10 -99.79 169.17 9.43 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.278 -0.889 . . . . 0.0 109.413 179.837 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 118.062 -0.971 . . . . 0.0 109.547 179.827 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.485 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 61.9 mt . . . . . 0 N--CA 1.489 1.508 0 CA-C-O 121.361 0.6 . . . . 0.0 109.672 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.585 ' O ' HG13 ' A' ' 20' ' ' VAL . 2.2 tt0 -123.45 140.31 53.13 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.323 -0.861 . . . . 0.0 108.901 179.639 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -144.39 148.53 20.34 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.544 ' O ' HG23 ' A' ' 18' ' ' ILE . 50.0 mttp -101.77 142.63 32.8 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.353 -1.086 . . . . 0.0 108.771 179.288 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.853 HG23 ' O ' ' A' ' 45' ' ' GLN . 21.5 t -73.8 113.47 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.112 -0.993 . . . . 0.0 109.642 -179.64 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.425 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 27.2 tttm -78.65 -41.73 30.61 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.777 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.682 ' CZ3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -160.39 156.51 26.25 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.454 -0.779 . . . . 0.0 108.986 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.595 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 12.5 p90 -155.33 142.95 19.71 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.129 -0.982 . . . . 0.0 109.299 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.418 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.7 t-20 . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.063 -1.023 . . . . 0.0 109.518 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.646 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.338 0.59 . . . . 0.0 109.654 . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.449 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -144.07 170.28 25.97 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.682 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 30.3 m-85 -111.23 128.67 56.0 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.393 -1.063 . . . . 0.0 108.968 179.798 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.839 ' CD1' HG21 ' A' ' 47' ' ' VAL . 67.8 mt -111.37 145.45 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.184 -0.947 . . . . 0.0 109.699 -179.801 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 5.3 tt0 -108.16 110.83 22.57 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.399 -0.813 . . . . 0.0 109.087 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.66 HG21 HG21 ' A' ' 26' ' ' VAL . 2.7 t -89.62 118.09 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.317 -0.864 . . . . 0.0 109.488 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -68.01 109.61 3.55 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.278 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.78 -21.78 6.58 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.567 ' OE1' HD12 ' A' ' 51' ' ' ILE . 50.2 mt-30 -135.47 168.8 18.54 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.197 -1.178 . . . . 0.0 109.596 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -55.19 -173.7 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.285 -0.884 . . . . 0.0 109.443 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -77.83 141.6 39.07 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.166 -0.959 . . . . 0.0 109.997 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.66 HG21 HG21 ' A' ' 20' ' ' VAL . 63.5 t -111.0 114.04 45.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.231 -0.918 . . . . 0.0 109.355 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.521 ' HE1' ' HB2' ' A' ' 15' ' ' PHE . 0.2 OUTLIER -84.48 106.85 16.38 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.254 -0.904 . . . . 0.0 109.276 179.812 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.598 ' CG2' HD11 ' A' ' 33' ' ' ILE . 0.2 OUTLIER -86.41 143.74 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 O-C-N 121.128 -0.982 . . . . 0.0 109.712 -179.308 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.7 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 15.6 t-80 -113.86 157.99 21.62 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.653 -0.655 . . . . 0.0 109.272 -179.606 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.7 ' CD2' ' CE1' ' A' ' 29' ' ' HIS . 0.8 OUTLIER -46.37 -54.89 8.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.881 -1.137 . . . . 0.0 108.761 -179.787 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.699 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 94.1 p -50.82 -37.56 43.56 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.212 -0.93 . . . . 0.0 109.918 -179.791 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.573 ' HB3' HG23 ' A' ' 28' ' ' VAL . . . -56.43 -29.02 61.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.036 -1.04 . . . . 0.0 109.341 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.083 HG21 ' HZ2' ' A' ' 65' ' ' LYS . 1.9 mp . . . . . 0 C--N 1.302 -1.462 0 O-C-N 121.397 -0.814 . . . . 0.0 109.317 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.706 ' CD1' HD13 ' A' ' 33' ' ' ILE . 3.6 mp . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 121.402 0.62 . . . . 0.0 109.861 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.467 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 85.1 tt0 -106.72 149.51 27.23 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.475 -0.766 . . . . 0.0 109.192 179.614 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.425 ' HG3' ' O ' ' A' ' 7' ' ' LYS . 70.2 tt0 -72.35 124.23 24.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.19 -0.943 . . . . 0.0 109.499 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 96.16 -7.5 66.89 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.853 ' O ' HG23 ' A' ' 6' ' ' VAL . 60.5 tt0 -81.31 127.64 32.95 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.209 -1.171 . . . . 0.0 109.651 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -74.56 145.22 43.59 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.338 -0.851 . . . . 0.0 109.444 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.839 HG21 ' CD1' ' A' ' 18' ' ' ILE . 34.6 m -145.88 160.86 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.095 -1.003 . . . . 0.0 110.017 -179.747 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.542 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 9.6 p -113.7 158.46 20.88 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.25 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.615 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 8.8 p90 169.25 169.3 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.999 -1.063 . . . . 0.0 109.996 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.484 ' OE1' ' HA ' ' A' ' 50' ' ' GLU . 65.3 mm-40 -104.97 157.84 16.95 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 178.826 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.567 HD12 ' OE1' ' A' ' 23' ' ' GLN . 1.9 mt -95.66 130.64 44.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 120.922 -1.111 . . . . 0.0 110.105 -179.41 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.538 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 3.6 m -112.7 122.57 67.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.306 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -90.77 88.85 7.24 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.039 -1.038 . . . . 0.0 109.755 -179.414 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -93.41 -175.36 40.37 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.7 t30 -54.51 -63.1 1.26 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.2 -1.176 . . . . 0.0 109.639 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 72.5 mtp180 -46.75 -38.9 10.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.125 -0.985 . . . . 0.0 109.033 179.827 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.77 -158.85 27.85 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.538 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 49.2 Cg_endo -70.71 142.48 43.85 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.565 2.177 . . . . 0.0 111.747 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.513 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 67.7 mt-30 -139.17 169.15 18.31 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.342 -0.849 . . . . 0.0 109.133 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.546 ' CB ' ' HB ' ' A' ' 28' ' ' VAL . . . -89.92 134.07 34.42 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.972 -1.08 . . . . 0.0 110.14 -179.463 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.585 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -121.56 153.09 38.47 Favored 'General case' 0 N--CA 1.491 1.601 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.541 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.497 ' C ' ' O ' ' A' ' 61' ' ' ALA . 83.6 m-20 41.13 72.74 0.15 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.033 -1.042 . . . . 0.0 108.577 -179.475 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.759 HG11 HG12 ' A' ' 33' ' ' ILE . 2.2 t -92.98 130.39 42.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.218 -0.926 . . . . 0.0 110.517 -178.724 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.3 m -120.08 125.23 47.77 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.493 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 1.083 ' HZ2' HG21 ' A' ' 33' ' ' ILE . 29.6 mttp -74.36 112.1 10.19 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.067 -1.021 . . . . 0.0 109.702 -179.606 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.407 ' OE2' ' HB3' ' A' ' 48' ' ' SER . 93.2 mt-10 -88.89 163.78 15.46 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.318 -0.864 . . . . 0.0 109.605 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 118.004 -0.998 . . . . 0.0 109.439 179.88 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.811 ' N ' HD12 ' A' ' 2' ' ' LEU . 5.6 mp . . . . . 0 N--CA 1.489 1.502 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 58.6 mt-10 -132.28 127.97 36.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.147 -0.97 . . . . 0.0 109.446 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.43 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -127.51 155.25 19.95 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.445 ' N ' HG23 ' A' ' 18' ' ' ILE . 43.2 mttt -103.99 138.48 40.47 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.299 -1.118 . . . . 0.0 108.874 179.578 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.826 HG23 ' O ' ' A' ' 45' ' ' GLN . 18.9 t -71.28 113.24 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.213 -0.929 . . . . 0.0 110.045 -179.469 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 13.0 ttpt -80.08 -40.71 27.06 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.555 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.588 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.41 155.4 28.57 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.397 -0.814 . . . . 0.0 109.018 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 9.6 p90 -156.22 137.96 14.25 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.128 -0.983 . . . . 0.0 109.242 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.479 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 52.3 t-20 . . . . . 0 N--CA 1.489 1.492 0 O-C-N 121.233 -0.917 . . . . 0.0 109.437 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.519 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 . . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.588 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -140.37 172.41 23.53 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.424 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 27.6 m-85 -113.9 132.86 55.77 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.341 -1.094 . . . . 0.0 108.986 179.786 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.661 HD12 HG21 ' A' ' 28' ' ' VAL . 13.9 mt -116.22 151.52 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.252 -0.905 . . . . 0.0 109.717 -179.646 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -115.57 116.91 28.95 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.365 -0.834 . . . . 0.0 109.21 179.863 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.538 HG21 HG21 ' A' ' 26' ' ' VAL . 2.3 t -94.3 119.82 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.364 -0.835 . . . . 0.0 109.395 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -69.21 110.55 4.64 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.24 -0.913 . . . . 0.0 109.351 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 125.78 -37.77 2.42 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.819 ' OE1' HD12 ' A' ' 51' ' ' ILE . 56.4 mt-30 -120.45 166.31 13.76 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.366 -1.079 . . . . 0.0 109.381 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.422 ' O ' ' O ' ' A' ' 23' ' ' GLN . 49.5 m-20 -52.53 -176.83 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.206 -0.934 . . . . 0.0 109.562 -179.862 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.504 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 81.0 m-20 -74.31 141.93 45.22 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.346 -0.846 . . . . 0.0 109.629 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.538 HG21 HG21 ' A' ' 20' ' ' VAL . 98.2 t -115.08 117.95 57.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.242 -0.911 . . . . 0.0 109.31 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.556 ' O ' ' N ' ' A' ' 60' ' ' ALA . 0.1 OUTLIER -76.73 161.12 28.76 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.103 -0.998 . . . . 0.0 109.388 -179.879 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.763 HG22 ' HB2' ' A' ' 60' ' ' ALA . 14.6 t -133.75 134.13 56.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.287 -0.883 . . . . 0.0 109.602 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.642 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 15.2 t-80 -104.66 151.33 23.82 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.217 -0.927 . . . . 0.0 109.19 179.652 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.685 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -44.92 -53.96 7.03 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.106 -0.996 . . . . 0.0 109.549 -179.529 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.685 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 90.3 p -60.35 -18.49 50.42 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.06 -1.025 . . . . 0.0 109.956 -179.544 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.502 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -67.36 -24.54 65.72 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.075 -1.016 . . . . 0.0 109.356 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.833 HG23 HG12 ' A' ' 63' ' ' VAL . 3.1 mp . . . . . 0 N--CA 1.489 1.514 0 O-C-N 121.303 -0.873 . . . . 0.0 109.468 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.703 HD21 HD11 ' A' ' 33' ' ' ILE . 5.8 mp . . . . . 0 N--CA 1.489 1.5 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.488 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.1 tt0 -120.25 138.53 53.61 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.238 -0.914 . . . . 0.0 109.619 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 57.4 tt0 -67.65 129.7 40.72 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.261 -0.899 . . . . 0.0 109.454 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 90.64 -5.88 82.25 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.826 ' O ' HG23 ' A' ' 6' ' ' VAL . 60.4 tt0 -81.12 126.11 31.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.215 -1.168 . . . . 0.0 109.371 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -79.18 142.49 36.28 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.228 -0.92 . . . . 0.0 109.31 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.985 HG12 ' HA ' ' A' ' 65' ' ' LYS . 28.2 m -143.96 168.65 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.246 -0.909 . . . . 0.0 109.438 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.517 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 9.4 t -114.51 155.26 26.76 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.324 -0.86 . . . . 0.0 108.859 179.65 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.611 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 5.6 p90 173.38 165.88 0.16 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.041 -1.037 . . . . 0.0 110.099 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.467 ' HA ' HD13 ' A' ' 2' ' ' LEU . 90.8 mt-10 -100.6 150.36 22.79 Favored 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.815 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.819 HD12 ' OE1' ' A' ' 23' ' ' GLN . 0.5 OUTLIER -87.13 123.05 39.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.029 -1.044 . . . . 0.0 109.837 -179.574 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.623 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.6 m -107.03 120.87 59.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.385 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -88.41 85.18 6.82 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.259 -0.901 . . . . 0.0 109.633 -179.544 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.39 -177.05 43.18 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 18.4 p-10 -55.27 -55.89 26.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.097 -1.237 . . . . 0.0 109.701 -179.743 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 43.3 mtp180 -52.43 -41.27 63.11 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.992 -1.068 . . . . 0.0 109.285 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 146.34 -150.85 23.14 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.504 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 47.6 Cg_endo -70.24 129.25 16.78 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.817 2.345 . . . . 0.0 112.292 -179.851 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.623 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 53.7 mt-30 -131.04 164.23 25.85 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 179.138 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.763 ' HB2' HG22 ' A' ' 28' ' ' VAL . . . -90.52 127.08 36.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.098 -1.001 . . . . 0.0 110.401 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.535 ' O ' ' C ' ' A' ' 62' ' ' ASN . . . -109.86 147.71 32.85 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.034 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.535 ' C ' ' O ' ' A' ' 61' ' ' ALA . 59.2 t30 38.17 73.73 0.1 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.049 -1.032 . . . . 0.0 108.816 -179.686 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.833 HG12 HG23 ' A' ' 33' ' ' ILE . 1.4 t -84.8 129.62 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.321 -0.862 . . . . 0.0 110.331 -178.767 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.458 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 13.0 m -115.28 121.37 42.68 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.459 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.985 ' HA ' HG12 ' A' ' 47' ' ' VAL . 20.2 mttt -74.12 114.83 12.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.154 -0.966 . . . . 0.0 109.742 -179.67 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.441 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 50.8 mt-10 -98.99 168.05 10.35 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.354 -0.841 . . . . 0.0 109.616 -179.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.495 0 CA-C-O 117.944 -1.027 . . . . 0.0 109.444 179.989 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.498 HD13 HE22 ' A' ' 23' ' ' GLN . 21.1 mt . . . . . 0 N--CA 1.488 1.448 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -134.19 127.9 32.91 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.209 -0.932 . . . . 0.0 109.297 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.41 ' C ' ' CG2' ' A' ' 18' ' ' ILE . . . -126.49 158.63 20.64 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 -179.735 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.562 ' C ' HG23 ' A' ' 18' ' ' ILE . 38.8 mttp -103.7 133.64 48.37 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.394 -1.063 . . . . 0.0 108.823 179.561 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.856 HG23 ' O ' ' A' ' 45' ' ' GLN . 18.3 t -66.49 113.73 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.151 -0.968 . . . . 0.0 110.055 -179.344 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.402 ' O ' ' HD2' ' A' ' 7' ' ' LYS . 0.7 OUTLIER -79.12 -39.93 32.36 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.34 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.642 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -159.11 155.01 26.51 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.807 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.646 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 9.1 p90 -155.57 140.55 17.32 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.056 -1.028 . . . . 0.0 109.347 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.487 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.2 t-20 . . . . . 0 N--CA 1.489 1.504 0 O-C-N 121.117 -0.989 . . . . 0.0 109.727 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.594 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 1.2 p90 . . . . . 0 N--CA 1.491 1.614 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.642 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -140.88 171.69 23.99 Favored Glycine 0 N--CA 1.492 2.378 0 C-N-CA 119.654 -1.26 . . . . 0.0 110.067 -179.491 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.558 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 43.1 m-85 -114.02 139.4 49.29 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.319 -1.107 . . . . 0.0 109.195 179.751 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 1.122 ' CD1' HG21 ' A' ' 28' ' ' VAL . 16.7 mt -124.1 150.91 28.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.272 -0.892 . . . . 0.0 109.691 -179.485 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -113.48 119.47 37.7 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.384 -0.823 . . . . 0.0 109.448 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.565 HG21 HG21 ' A' ' 26' ' ' VAL . 2.6 t -90.46 124.13 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.329 -0.857 . . . . 0.0 109.655 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.476 ' OE2' ' NZ ' ' A' ' 5' ' ' LYS . 80.1 mt-10 -71.45 109.34 5.37 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.309 -0.869 . . . . 0.0 109.512 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 117.81 -26.1 8.15 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.498 HE22 HD13 ' A' ' 2' ' ' LEU . 43.2 mt-30 -122.95 161.31 24.45 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.259 -1.142 . . . . 0.0 109.482 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 58.9 m-20 -52.84 -178.96 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.274 -0.891 . . . . 0.0 109.659 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -71.65 141.37 49.92 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.268 -0.895 . . . . 0.0 109.506 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.584 HG13 ' C ' ' A' ' 59' ' ' GLN . 97.3 t -117.99 117.7 55.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.171 -0.956 . . . . 0.0 109.656 -179.582 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.54 ' CE1' ' HB3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -76.56 157.16 32.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.2 -0.937 . . . . 0.0 108.997 179.684 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 1.122 HG21 ' CD1' ' A' ' 18' ' ' ILE . 34.1 t -133.01 137.38 53.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.205 -0.935 . . . . 0.0 109.763 -179.525 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.629 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 12.8 t-80 -114.97 152.45 32.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.429 -0.794 . . . . 0.0 108.993 179.696 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.68 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -44.31 -53.53 6.63 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.093 -1.004 . . . . 0.0 109.502 -179.631 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.68 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 27.3 t -54.29 -27.35 34.75 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.101 -1.0 . . . . 0.0 110.068 -179.452 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.63 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -66.9 -12.63 60.03 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.04 -1.037 . . . . 0.0 109.002 179.71 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.912 ' CD1' HD11 ' A' ' 41' ' ' LEU . 0.9 OUTLIER . . . . . 0 C--N 1.304 -1.396 0 O-C-N 121.503 -0.748 . . . . 0.0 109.589 -179.581 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 1.034 HD23 HG11 ' A' ' 47' ' ' VAL . 4.9 mp . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.438 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 96.8 mt-10 -109.28 155.04 21.62 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.316 -0.865 . . . . 0.0 109.305 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -70.41 127.67 33.54 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.29 -0.881 . . . . 0.0 109.593 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.445 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 88.51 -3.12 85.2 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.856 ' O ' HG23 ' A' ' 6' ' ' VAL . 51.1 tt0 -81.71 130.24 34.99 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.198 -1.178 . . . . 0.0 109.603 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -78.21 141.87 38.32 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.235 -0.916 . . . . 0.0 109.383 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 1.034 HG11 HD23 ' A' ' 41' ' ' LEU . 34.7 m -141.52 153.21 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.136 -0.977 . . . . 0.0 109.781 -179.746 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.539 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 17.8 t -97.57 148.65 23.05 Favored 'General case' 0 N--CA 1.488 1.459 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 179.075 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.602 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 7.8 p90 176.09 162.47 0.35 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.874 -1.141 . . . . 0.0 110.272 -179.546 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.458 ' OE1' ' HA ' ' A' ' 50' ' ' GLU . 67.0 mm-40 -99.92 160.37 14.37 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 178.908 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.462 HD12 ' OE1' ' A' ' 23' ' ' GLN . 0.9 OUTLIER -99.6 127.38 52.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 120.917 -1.114 . . . . 0.0 109.91 -179.524 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.614 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.9 m -114.32 124.81 71.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 179.197 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -93.6 93.31 7.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 110.241 -179.087 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -95.15 -175.8 37.72 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -53.17 -59.22 4.83 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.104 -1.233 . . . . 0.0 109.462 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 53.0 mtp180 -49.3 -40.47 34.93 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.087 -1.008 . . . . 0.0 109.215 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 149.18 -158.12 27.53 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.411 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 51.5 Cg_endo -70.46 139.96 38.98 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.723 2.282 . . . . 0.0 111.849 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.614 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 76.9 mt-30 -136.26 167.81 20.6 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.324 -0.86 . . . . 0.0 109.13 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.659 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -95.22 139.31 31.72 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.136 -0.978 . . . . 0.0 110.184 -179.286 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.602 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -124.3 156.02 37.68 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.378 -0.826 . . . . 0.0 108.826 179.605 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.481 ' C ' ' O ' ' A' ' 61' ' ' ALA . 78.8 m-20 42.2 72.59 0.16 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.968 -1.083 . . . . 0.0 108.952 -179.821 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.98 HG11 HD21 ' A' ' 41' ' ' LEU . 3.9 t -86.76 125.93 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.234 -0.916 . . . . 0.0 110.088 -179.17 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.45 ' HB ' ' HB3' ' A' ' 48' ' ' SER . 60.6 m -119.0 125.51 49.56 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.379 -0.825 . . . . 0.0 109.256 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 87.9 mttt -67.52 106.97 2.32 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.2 -0.937 . . . . 0.0 109.479 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.405 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 89.6 mt-10 -87.04 162.0 17.85 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.227 -0.921 . . . . 0.0 109.497 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 117.973 -1.013 . . . . 0.0 109.487 -179.939 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 49.4 mt . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.581 ' O ' HG13 ' A' ' 20' ' ' VAL . 86.9 mt-10 -131.48 135.83 47.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.28 -0.888 . . . . 0.0 109.171 179.772 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.475 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -136.15 157.94 23.7 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 -179.684 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.513 ' N ' HG23 ' A' ' 18' ' ' ILE . 12.5 mttp -103.65 142.26 34.63 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.341 -1.094 . . . . 0.0 108.817 179.51 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.839 HG23 ' O ' ' A' ' 45' ' ' GLN . 22.1 t -75.22 116.96 18.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.073 -1.017 . . . . 0.0 109.935 -179.51 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.8 -32.73 17.71 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.465 -0.772 . . . . 0.0 108.933 179.693 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.683 ' CE3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -159.44 153.98 24.2 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.381 -0.824 . . . . 0.0 109.023 179.792 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.489 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 9.1 p90 -157.54 139.03 13.81 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.173 -0.954 . . . . 0.0 109.282 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.444 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 63.5 t-20 . . . . . 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 109.618 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.597 ' N ' ' CD1' ' A' ' 15' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.663 0 CA-C-O 121.42 0.628 . . . . 0.0 109.695 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.504 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -135.99 167.49 24.33 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.683 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 22.1 m-85 -115.05 130.12 56.86 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.184 -1.186 . . . . 0.0 109.289 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.744 ' CD1' HG21 ' A' ' 47' ' ' VAL . 56.4 mt -114.23 151.42 16.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.44 -0.787 . . . . 0.0 109.654 -179.79 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -114.2 104.29 11.95 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.361 -0.837 . . . . 0.0 108.915 179.518 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.581 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.8 t -78.63 120.64 30.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.264 -0.897 . . . . 0.0 109.428 -179.702 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 74.0 mm-40 -67.93 108.89 3.2 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.206 -0.933 . . . . 0.0 109.135 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.59 -24.46 6.82 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.562 ' OE1' HG11 ' A' ' 20' ' ' VAL . 36.0 mt-30 -128.18 165.92 19.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.298 -1.119 . . . . 0.0 109.6 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 48.9 m-20 -56.93 -169.08 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.292 -0.88 . . . . 0.0 109.729 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.497 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 7.7 p30 -78.45 141.47 38.25 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.254 -0.904 . . . . 0.0 110.003 -179.543 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.579 HG21 HG21 ' A' ' 20' ' ' VAL . 57.4 t -116.23 115.09 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.212 -0.93 . . . . 0.0 109.305 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.706 ' O ' ' CG ' ' A' ' 27' ' ' PHE . 0.1 OUTLIER -83.5 107.72 16.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.047 -1.033 . . . . 0.0 109.39 179.979 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.628 ' CG2' HG21 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -85.48 146.92 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.061 -1.024 . . . . 0.0 109.632 -179.167 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.691 ' CE1' ' CE2' ' A' ' 30' ' ' PHE . 11.8 t-160 -116.2 155.05 28.99 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.283 -0.886 . . . . 0.0 109.336 -179.772 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.769 ' CD1' ' N ' ' A' ' 31' ' ' SER . 1.9 p90 -47.75 -54.11 13.21 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.092 -1.005 . . . . 0.0 109.607 -179.481 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.769 ' N ' ' CD1' ' A' ' 30' ' ' PHE . 19.9 t -53.41 -21.22 5.6 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.872 -1.142 . . . . 0.0 109.517 -179.771 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.547 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -66.84 -38.81 87.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.273 -0.892 . . . . 0.0 109.635 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.073 HD11 HD11 ' A' ' 41' ' ' LEU . 1.8 mp . . . . . 0 N--CA 1.491 1.577 0 O-C-N 121.168 -0.958 . . . . 0.0 109.966 -179.74 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 1.073 HD11 HD11 ' A' ' 33' ' ' ILE . 3.1 mp . . . . . 0 N--CA 1.492 1.626 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.469 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 97.0 mt-10 -115.8 151.27 35.51 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.302 -0.874 . . . . 0.0 109.373 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 46.5 tt0 -67.84 125.37 26.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.227 -0.92 . . . . 0.0 109.426 -179.866 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 92.7 -6.63 77.29 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.883 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.839 ' O ' HG23 ' A' ' 6' ' ' VAL . 61.5 tp60 -82.28 135.05 35.29 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.185 -1.185 . . . . 0.0 109.762 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -85.87 144.62 27.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.318 -0.864 . . . . 0.0 109.293 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.777 HG12 ' HA ' ' A' ' 65' ' ' LYS . 30.6 m -144.55 166.46 12.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.198 -0.939 . . . . 0.0 109.717 -179.838 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.55 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 3.3 t -112.87 157.21 21.7 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 179.338 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.577 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 10.0 p90 170.32 167.97 0.06 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.092 -1.005 . . . . 0.0 110.076 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 92.1 mt-10 -102.34 162.2 13.1 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 178.823 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.5 mt -99.91 127.75 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.008 -1.058 . . . . 0.0 109.75 -179.615 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.563 HG23 ' HB2' ' A' ' 59' ' ' GLN . 0.8 OUTLIER -109.17 120.82 61.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.62 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -88.53 85.89 6.92 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.194 -0.941 . . . . 0.0 109.713 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.14 -179.51 45.55 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 19.3 p-10 -54.49 -53.27 56.57 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.298 -1.119 . . . . 0.0 109.895 -179.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 20.3 mtm180 -57.13 -38.56 73.66 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.017 -1.052 . . . . 0.0 109.389 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.96 -158.81 27.99 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.557 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 52.3 Cg_endo -73.01 141.48 33.08 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.725 2.283 . . . . 0.0 112.006 179.898 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.563 ' HB2' HG23 ' A' ' 52' ' ' VAL . 31.8 mt-30 -137.03 168.45 19.56 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.37 -0.831 . . . . 0.0 108.894 179.543 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.591 ' HB3' ' HA ' ' A' ' 28' ' ' VAL . . . -94.13 139.93 30.38 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.015 -1.053 . . . . 0.0 110.332 -179.253 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.557 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -126.53 155.65 42.02 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.44 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.49 ' C ' ' O ' ' A' ' 61' ' ' ALA . 57.6 t30 40.88 63.06 1.25 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.958 -1.089 . . . . 0.0 108.849 -179.708 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.885 HG11 HD21 ' A' ' 41' ' ' LEU . 1.8 t -79.46 128.75 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.291 -0.881 . . . . 0.0 110.421 -179.011 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 56.4 m -119.6 125.59 49.14 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.777 ' HA ' HG12 ' A' ' 47' ' ' VAL . 69.6 mttt -65.51 110.6 2.76 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.21 -0.932 . . . . 0.0 109.531 -179.831 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.449 ' HG3' ' HA ' ' A' ' 47' ' ' VAL . 90.4 mt-10 -89.6 159.38 17.2 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.321 -0.862 . . . . 0.0 109.628 -179.845 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.551 0 CA-C-O 117.99 -1.005 . . . . 0.0 109.469 179.942 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.735 ' N ' HD12 ' A' ' 2' ' ' LEU . 6.4 mp . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.282 0.563 . . . . 0.0 109.569 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.575 ' O ' HG13 ' A' ' 20' ' ' VAL . 61.0 mt-10 -132.87 139.55 47.48 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.36 -0.838 . . . . 0.0 109.213 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -139.64 157.41 25.18 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.66 ' O ' HG23 ' A' ' 18' ' ' ILE . 63.6 mttm -102.57 142.95 32.89 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.418 -1.048 . . . . 0.0 108.831 179.561 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.799 HG23 ' O ' ' A' ' 45' ' ' GLN . 18.7 t -76.61 112.09 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.173 -0.954 . . . . 0.0 110.047 -179.447 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.465 ' CG ' ' N ' ' A' ' 8' ' ' TRP . 3.3 pttt -79.94 -37.7 33.94 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.622 ' CE3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -159.75 155.01 25.18 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 -179.941 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.463 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 10.5 p90 -155.88 138.87 15.41 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.156 -0.965 . . . . 0.0 109.196 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.493 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.3 t-20 . . . . . 0 N--CA 1.489 1.521 0 O-C-N 121.097 -1.002 . . . . 0.0 109.633 -179.745 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.647 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.594 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -140.43 170.26 24.48 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 -179.65 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.622 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 27.5 m-85 -114.66 131.5 56.71 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.387 -1.066 . . . . 0.0 108.997 179.812 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 1.132 HD12 ' CG2' ' A' ' 28' ' ' VAL . 26.9 mt -120.27 149.29 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.164 -0.96 . . . . 0.0 109.433 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.447 ' OE1' ' OD1' ' A' ' 25' ' ' ASP . 18.1 tp10 -108.75 123.76 49.52 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.244 -0.91 . . . . 0.0 109.504 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.672 HG21 HG21 ' A' ' 26' ' ' VAL . 2.3 t -102.11 120.25 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.215 -0.928 . . . . 0.0 109.25 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -66.98 109.39 2.95 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.247 -0.908 . . . . 0.0 109.772 -179.701 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.14 -29.34 3.71 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.505 ' O ' ' O ' ' A' ' 24' ' ' ASP . 38.2 mt-30 -131.41 166.26 21.68 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.227 -1.161 . . . . 0.0 109.23 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.505 ' O ' ' O ' ' A' ' 23' ' ' GLN . 0.0 OUTLIER -52.8 -169.17 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.173 -0.954 . . . . 0.0 109.683 -179.777 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.447 ' OD1' ' OE1' ' A' ' 19' ' ' GLU . 42.2 m-20 -75.36 141.65 43.27 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.236 -0.915 . . . . 0.0 109.742 -179.77 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.672 HG21 HG21 ' A' ' 20' ' ' VAL . 87.0 t -112.11 119.73 60.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.259 -0.9 . . . . 0.0 109.385 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.489 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.1 OUTLIER -79.53 154.71 28.62 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.244 -0.91 . . . . 0.0 109.127 -179.94 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 1.132 ' CG2' HD12 ' A' ' 18' ' ' ILE . 5.0 t -129.64 133.04 65.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.292 -0.88 . . . . 0.0 109.27 -179.729 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.647 ' HA ' ' HB3' ' A' ' 15' ' ' PHE . 13.4 t-80 -105.61 150.2 25.62 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.157 -0.964 . . . . 0.0 109.219 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.689 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.9 OUTLIER -43.1 -52.56 5.35 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.197 -0.939 . . . . 0.0 109.198 -179.818 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.689 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 23.0 t -56.25 -23.06 33.68 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.912 . . . . 0.0 109.856 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.509 ' N ' ' O ' ' A' ' 29' ' ' HIS . . . -65.38 -23.76 67.05 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.075 -1.015 . . . . 0.0 109.446 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.907 ' CD1' HD11 ' A' ' 41' ' ' LEU . 3.2 mp . . . . . 0 N--CA 1.489 1.494 0 O-C-N 121.286 -0.883 . . . . 0.0 109.337 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.996 HD23 HG11 ' A' ' 47' ' ' VAL . 4.7 mp . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 121.319 0.58 . . . . 0.0 109.578 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.453 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 95.7 mt-10 -111.67 151.43 28.87 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.376 -0.827 . . . . 0.0 109.329 179.788 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 76.6 tt0 -69.13 126.44 29.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.282 -0.886 . . . . 0.0 109.626 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 89.94 -3.2 82.7 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.799 ' O ' HG23 ' A' ' 6' ' ' VAL . 56.7 tt0 -82.16 131.03 35.24 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.197 -1.178 . . . . 0.0 109.701 179.822 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -76.82 142.69 40.18 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.211 -0.93 . . . . 0.0 109.226 179.755 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.996 HG11 HD23 ' A' ' 41' ' ' LEU . 30.1 m -145.39 159.36 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.233 -0.917 . . . . 0.0 110.093 -179.637 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.569 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 39.7 t -110.94 154.32 24.26 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.615 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 14.0 p90 173.37 163.87 0.15 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.817 -1.177 . . . . 0.0 110.508 -179.659 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -99.58 158.71 15.57 Favored 'General case' 0 N--CA 1.488 1.455 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.533 HD11 HG21 ' A' ' 26' ' ' VAL . 3.1 mt -102.13 131.77 49.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 120.928 -1.107 . . . . 0.0 110.244 -179.409 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.562 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.6 m -114.19 123.62 70.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 178.703 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -91.55 90.36 7.58 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.187 -0.946 . . . . 0.0 109.937 -178.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.6 -177.47 42.76 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -53.16 -59.81 4.08 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.169 -1.195 . . . . 0.0 109.533 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 20.9 mtp180 -49.82 -39.07 37.47 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.189 -0.944 . . . . 0.0 109.201 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.09 -161.91 29.25 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.562 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 52.6 Cg_endo -72.31 144.9 42.25 Favored 'Trans proline' 0 C--O 1.216 -0.613 0 C-N-CA 122.7 2.267 . . . . 0.0 111.828 179.772 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.548 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 71.1 mt-30 -137.37 169.47 17.72 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.276 -0.89 . . . . 0.0 109.232 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.56 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -94.0 139.73 30.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.216 -0.927 . . . . 0.0 110.232 -179.407 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.602 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -127.98 157.74 39.79 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.514 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.49 ' C ' ' O ' ' A' ' 61' ' ' ALA . 85.7 m-20 41.4 68.57 0.43 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.857 -1.152 . . . . 0.0 108.816 -179.761 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.934 HG11 HD21 ' A' ' 41' ' ' LEU . 2.3 t -87.13 126.3 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.239 -0.913 . . . . 0.0 110.315 -178.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 82.3 m -117.99 124.26 47.74 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.435 ' HA ' HG12 ' A' ' 47' ' ' VAL . 50.3 mttt -68.39 110.97 4.37 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.291 -0.881 . . . . 0.0 109.614 -179.814 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.473 ' O ' ' HB3' ' A' ' 67' ' ' ALA . 64.2 mt-10 -90.05 161.46 15.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.901 . . . . 0.0 109.604 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . 0.473 ' HB3' ' O ' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.52 0 CA-C-O 117.989 -1.005 . . . . 0.0 109.466 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.483 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 27.2 mt . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 121.339 0.59 . . . . 0.0 109.503 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -129.24 141.33 51.16 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -0.916 . . . . 0.0 109.061 179.753 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.52 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -146.66 156.71 27.13 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -179.719 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.514 ' N ' HG23 ' A' ' 18' ' ' ILE . 16.0 mttt -102.2 136.01 42.78 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.382 -1.069 . . . . 0.0 108.836 179.48 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.614 HG23 ' O ' ' A' ' 45' ' ' GLN . 40.3 t -68.59 115.71 7.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.161 -0.962 . . . . 0.0 110.095 -179.53 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 17' ' ' PHE . 5.9 tttm -79.06 -35.11 43.02 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.476 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' TRP . . . . . 0.654 ' CD2' ' N ' ' A' ' 9' ' ' PHE . 0.4 OUTLIER -160.36 168.55 24.99 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.486 -0.759 . . . . 0.0 109.047 179.755 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.654 ' N ' ' CD2' ' A' ' 8' ' ' TRP . 21.4 p90 -163.44 141.23 7.65 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.885 -1.135 . . . . 0.0 110.312 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.599 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 20.5 t-20 . . . . . 0 N--CA 1.493 1.7 0 O-C-N 121.491 -0.755 . . . . 0.0 109.338 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.573 ' HB2' ' HA ' ' A' ' 29' ' ' HIS . 10.8 p90 . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.614 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -157.77 165.61 33.63 Favored Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.497 -1.335 . . . . 0.0 110.146 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.523 ' O ' ' N ' ' A' ' 7' ' ' LYS . 92.6 m-85 -96.43 138.63 33.73 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.457 -1.026 . . . . 0.0 108.909 179.726 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 1.048 HD12 HG21 ' A' ' 28' ' ' VAL . 63.2 mt -121.53 160.07 23.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.561 -0.712 . . . . 0.0 109.647 -179.715 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.48 ' N ' HG22 ' A' ' 18' ' ' ILE . 39.6 tt0 -120.4 119.09 32.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.35 -0.844 . . . . 0.0 109.46 -179.737 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.552 HG21 HG21 ' A' ' 26' ' ' VAL . 2.2 t -95.28 111.73 26.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.265 -0.897 . . . . 0.0 109.214 179.832 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.414 ' HA ' ' OE1' ' A' ' 21' ' ' GLU . 72.5 mm-40 -61.43 110.3 1.41 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.234 -0.916 . . . . 0.0 109.474 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.9 -33.97 3.56 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLN . . . . . 0.614 ' OE1' HD12 ' A' ' 51' ' ' ILE . 36.1 mt-30 -124.28 163.39 21.75 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.248 -1.148 . . . . 0.0 109.365 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.474 ' O ' ' O ' ' A' ' 23' ' ' GLN . 57.9 m-20 -50.76 -176.81 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.304 -0.873 . . . . 0.0 109.652 -179.866 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.42 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 90.0 m-20 -74.02 140.88 45.74 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.336 -0.853 . . . . 0.0 109.728 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.552 HG21 HG21 ' A' ' 20' ' ' VAL . 88.9 t -113.42 115.75 50.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.319 -0.863 . . . . 0.0 109.411 -179.895 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' PHE . . . . . 0.579 ' CE2' ' HB3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -70.75 156.72 39.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.057 -1.027 . . . . 0.0 109.355 -179.937 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 1.048 HG21 HD12 ' A' ' 18' ' ' ILE . 21.9 t -134.49 133.87 54.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.117 -0.989 . . . . 0.0 109.871 -179.472 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.672 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 14.3 t-80 -114.47 151.12 33.75 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.355 -0.841 . . . . 0.0 109.192 179.588 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.677 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.7 OUTLIER -42.63 -51.5 5.18 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.091 -1.006 . . . . 0.0 109.353 -179.858 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.677 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 86.6 p -53.69 -29.61 39.74 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.178 -0.952 . . . . 0.0 109.925 -179.618 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.596 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -64.91 -10.31 27.8 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.107 -0.995 . . . . 0.0 109.217 179.744 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.792 HD13 HD13 ' A' ' 41' ' ' LEU . 0.8 OUTLIER . . . . . 0 C--N 1.303 -1.442 0 O-C-N 121.487 -0.758 . . . . 0.0 109.726 -179.415 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.917 HD21 HG11 ' A' ' 63' ' ' VAL . 3.5 mp . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 121.464 0.649 . . . . 0.0 109.756 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' GLU . . . . . 0.408 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 36.6 tt0 -103.92 144.14 31.92 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.285 -0.884 . . . . 0.0 109.319 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 53.3 tt0 -63.11 130.34 44.23 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.293 -0.88 . . . . 0.0 109.477 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.97 -3.12 85.91 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.614 ' O ' HG23 ' A' ' 6' ' ' VAL . 46.8 tt0 -81.29 128.19 33.54 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.201 -1.176 . . . . 0.0 109.602 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -77.54 140.71 39.78 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.215 -0.928 . . . . 0.0 109.085 179.614 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.68 HG21 ' CD1' ' A' ' 18' ' ' ILE . 32.1 m -142.43 160.78 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.158 -0.964 . . . . 0.0 109.832 -179.825 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.55 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 24.0 t -107.3 152.06 24.64 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 178.827 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.559 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 35.3 p90 174.81 164.16 0.24 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.807 -1.183 . . . . 0.0 110.215 -179.426 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -100.31 172.28 7.25 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.614 HD12 ' OE1' ' A' ' 23' ' ' GLN . 1.0 OUTLIER -111.52 125.46 68.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 120.867 -1.146 . . . . 0.0 109.901 -179.819 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.585 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.7 m -109.16 123.48 65.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 179.138 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.4 mt-10 -91.52 83.75 5.43 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 109.645 -179.533 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.79 -172.06 42.28 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 179.789 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.433 ' O ' ' C ' ' A' ' 56' ' ' ARG . 3.8 t30 -56.73 -63.55 1.16 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.14 -1.212 . . . . 0.0 109.212 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.433 ' C ' ' O ' ' A' ' 55' ' ' ASN . 36.2 mtp180 -42.0 -46.9 4.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.171 -0.955 . . . . 0.0 109.325 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.01 -149.33 21.46 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.42 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 46.2 Cg_endo -70.13 125.5 12.02 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.654 2.236 . . . . 0.0 112.128 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.585 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 33.2 mt-30 -125.56 158.62 34.13 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.335 -0.853 . . . . 0.0 108.875 179.389 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.812 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -91.47 134.86 34.27 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.019 -1.051 . . . . 0.0 109.767 -179.545 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.559 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -122.72 156.37 34.56 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.388 -0.82 . . . . 0.0 108.9 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.473 ' C ' ' O ' ' A' ' 61' ' ' ALA . 82.9 m-20 41.72 66.01 0.77 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.084 -1.01 . . . . 0.0 109.045 -179.727 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.917 HG11 HD21 ' A' ' 41' ' ' LEU . 4.5 t -83.03 125.85 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.234 -0.916 . . . . 0.0 109.93 -179.381 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.423 ' HB ' ' HB3' ' A' ' 48' ' ' SER . 92.4 m -118.35 125.02 49.15 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.53 -0.731 . . . . 0.0 109.211 179.766 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.408 ' HA ' HG12 ' A' ' 47' ' ' VAL . 32.4 mttp -65.41 110.5 2.68 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.338 -0.851 . . . . 0.0 109.438 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 73.3 mm-40 -100.67 166.71 10.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.283 -0.885 . . . . 0.0 109.504 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 118.001 -1.0 . . . . 0.0 109.452 -179.991 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 81.9 mtp . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.445 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 59.6 mt -98.8 160.53 14.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.386 -0.821 . . . . 0.0 109.46 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 78.1 mt-10 -130.62 143.52 50.81 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.283 -0.886 . . . . 0.0 109.203 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.516 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -152.06 156.09 26.5 Favored Glycine 0 N--CA 1.488 2.123 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.44 ' N ' HG23 ' A' ' 18' ' ' ILE . 96.7 mttt -100.99 135.21 42.81 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.312 -1.111 . . . . 0.0 108.744 179.463 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.703 HG23 ' O ' ' A' ' 45' ' ' GLN . 33.9 t -66.55 119.22 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.123 -0.986 . . . . 0.0 110.01 -179.424 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.432 ' N ' ' O ' ' A' ' 17' ' ' PHE . 5.9 tptm -79.48 -40.96 28.53 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.425 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.656 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -159.98 166.95 29.03 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 179.785 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.643 ' N ' ' CD2' ' A' ' 8' ' ' TRP . 17.1 p90 -158.76 147.39 18.52 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.943 -1.098 . . . . 0.0 110.574 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.646 ' HB3' ' CE1' ' A' ' 15' ' ' PHE . 13.9 t-20 -103.6 135.85 44.41 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.412 -0.805 . . . . 0.0 109.353 179.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.8 p -83.24 -15.08 51.73 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.089 -1.007 . . . . 0.0 109.442 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 41.0 tp10 -59.98 -63.42 1.31 Allowed 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.27 -0.894 . . . . 0.0 109.604 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.65 ' HB2' ' CD1' ' A' ' 15' ' ' PHE . 19.9 mttm -98.68 -10.73 22.8 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.355 -0.841 . . . . 0.0 109.745 -179.526 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.587 ' HA2' HG22 ' A' ' 40' ' ' THR . . . 77.23 68.86 1.46 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.002 -1.239 . . . . 0.0 110.002 179.477 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.65 ' CD1' ' HB2' ' A' ' 13' ' ' LYS . 3.1 p90 -156.21 161.41 40.28 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.151 -1.205 . . . . 0.0 109.005 179.299 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.656 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -161.07 160.86 32.45 Favored Glycine 0 N--CA 1.486 2.018 0 C-N-CA 119.598 -1.286 . . . . 0.0 110.044 -179.704 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.502 ' CD1' ' HB2' ' A' ' 27' ' ' PHE . 98.0 m-85 -90.74 139.37 30.79 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.488 -1.007 . . . . 0.0 108.719 179.492 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.699 HD12 HG21 ' A' ' 28' ' ' VAL . 19.7 mt -113.25 159.28 13.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.582 -0.699 . . . . 0.0 109.222 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.467 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 65.7 tt0 -114.27 109.52 18.51 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.225 -0.922 . . . . 0.0 109.464 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.569 HG21 HG21 ' A' ' 26' ' ' VAL . 2.7 t -90.74 109.48 20.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.199 -0.938 . . . . 0.0 109.206 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 74.3 mm-40 -59.22 108.87 0.75 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.214 -0.929 . . . . 0.0 109.267 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.9 -35.62 3.48 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.465 ' OE1' HD12 ' A' ' 51' ' ' ILE . 46.7 mt-30 -117.95 160.92 20.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -1.155 . . . . 0.0 109.362 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.447 ' O ' ' O ' ' A' ' 23' ' ' GLN . 44.5 m-20 -52.92 -174.19 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.253 -0.904 . . . . 0.0 109.514 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.5 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 80.8 m-20 -74.31 139.45 44.21 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.299 -0.876 . . . . 0.0 109.647 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.569 HG21 HG21 ' A' ' 20' ' ' VAL . 91.8 t -114.39 119.87 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.306 -0.871 . . . . 0.0 109.529 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.512 ' C ' ' CD1' ' A' ' 27' ' ' PHE . 0.0 OUTLIER -77.17 155.75 32.05 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.111 -0.993 . . . . 0.0 109.396 -179.965 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.699 HG21 HD12 ' A' ' 18' ' ' ILE . 10.8 t -131.09 138.5 53.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.294 -0.879 . . . . 0.0 109.434 -179.652 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.58 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 12.9 t-80 -112.21 149.93 31.58 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.094 -1.004 . . . . 0.0 109.581 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.699 ' CG ' ' N ' ' A' ' 31' ' ' SER . 1.2 p90 -46.88 -53.99 10.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.152 -0.968 . . . . 0.0 109.672 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.699 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 21.0 t -59.56 -20.85 58.58 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.024 -1.048 . . . . 0.0 109.907 -179.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.565 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -77.77 -12.66 60.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.157 -0.964 . . . . 0.0 109.414 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.018 HD13 HD13 ' A' ' 41' ' ' LEU . 3.0 mt -110.36 146.07 16.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.435 -0.79 . . . . 0.0 109.82 -179.66 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 65.2 mt-30 -97.08 128.08 43.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.387 -0.821 . . . . 0.0 109.685 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.608 ' CA ' ' HE1' ' A' ' 38' ' ' PHE . . . 146.17 80.48 0.04 OUTLIER Glycine 0 N--CA 1.484 1.889 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.472 ' HG2' ' NZ ' ' A' ' 39' ' ' LYS . 94.4 mt-10 -61.69 -21.63 64.63 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.247 -1.149 . . . . 0.0 109.465 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.509 ' C ' ' CG ' ' A' ' 38' ' ' PHE . . . -94.08 17.13 59.42 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 179.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.608 ' HE1' ' CA ' ' A' ' 35' ' ' GLY . 0.1 OUTLIER 168.96 54.48 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.24 -1.153 . . . . 0.0 109.774 179.952 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.553 ' HG3' ' O ' ' A' ' 35' ' ' GLY . 29.1 mttt -73.73 -21.47 60.2 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.107 -0.995 . . . . 0.0 109.397 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.587 HG22 ' HA2' ' A' ' 14' ' ' GLY . 69.3 p -69.71 116.09 9.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.243 -0.91 . . . . 0.0 109.528 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 1.018 HD13 HD13 ' A' ' 33' ' ' ILE . 4.3 mp -73.85 144.98 45.25 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.244 -0.91 . . . . 0.0 109.84 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.451 ' O ' ' C ' ' A' ' 43' ' ' GLU . 58.5 tt0 -93.91 119.72 33.21 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.407 -0.808 . . . . 0.0 109.084 179.629 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.451 ' C ' ' O ' ' A' ' 42' ' ' GLU . 53.4 tt0 -41.13 131.38 2.65 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.284 -0.885 . . . . 0.0 109.553 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 89.69 -3.95 83.47 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.703 ' O ' HG23 ' A' ' 6' ' ' VAL . 52.1 tt0 -80.81 128.18 33.37 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.171 -1.194 . . . . 0.0 109.466 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -79.9 143.36 34.33 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.27 -0.894 . . . . 0.0 109.055 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.915 HG12 ' HA ' ' A' ' 65' ' ' LYS . 28.9 m -147.84 171.41 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.196 -0.94 . . . . 0.0 109.678 -179.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.656 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 34.7 t -116.3 156.46 26.61 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.308 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.598 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 17.0 p90 172.81 166.78 0.13 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.894 -1.129 . . . . 0.0 110.488 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -108.82 154.28 22.32 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.465 HD12 ' OE1' ' A' ' 23' ' ' GLN . 1.9 mt -87.73 122.85 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 120.863 -1.148 . . . . 0.0 110.069 -179.433 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.805 ' CG1' ' HB2' ' A' ' 61' ' ' ALA . 26.8 m -110.72 128.29 67.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 178.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -68.63 120.05 14.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.084 -1.01 . . . . 0.0 109.838 -179.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -128.02 162.57 21.81 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.761 -1.335 . . . . 0.0 109.761 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -51.78 -60.22 3.42 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.241 -1.153 . . . . 0.0 109.493 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 82.2 mtp180 -51.0 -33.16 23.65 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.274 -0.891 . . . . 0.0 109.184 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 144.84 -146.12 16.18 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.434 -1.466 . . . . 0.0 109.434 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.5 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 45.8 Cg_endo -69.35 127.99 15.74 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.781 2.321 . . . . 0.0 111.793 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.621 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 84.8 mt-30 -121.99 156.21 33.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.188 -0.945 . . . . 0.0 109.265 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.522 ' HB2' HG22 ' A' ' 28' ' ' VAL . . . -88.35 127.76 35.49 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.159 -0.963 . . . . 0.0 110.088 -179.336 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.805 ' HB2' ' CG1' ' A' ' 52' ' ' VAL . . . -108.71 150.47 27.52 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.322 -0.861 . . . . 0.0 108.887 179.37 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.487 ' C ' ' O ' ' A' ' 61' ' ' ALA . 36.8 t-20 40.64 67.22 0.53 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.213 -0.93 . . . . 0.0 109.013 -179.67 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.922 HG11 HG12 ' A' ' 33' ' ' ILE . 1.2 t -82.14 127.25 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.329 -0.857 . . . . 0.0 110.21 -179.175 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.414 ' HB ' ' HB3' ' A' ' 48' ' ' SER . 35.3 m -115.63 117.56 30.63 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.146 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.915 ' HA ' HG12 ' A' ' 47' ' ' VAL . 18.1 mttm -65.34 117.01 7.26 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.279 -0.888 . . . . 0.0 109.663 -179.66 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 82.8 mt-10 -108.87 167.67 9.91 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.375 -0.828 . . . . 0.0 109.661 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.506 -179.956 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.843 ' C ' HD12 ' A' ' 2' ' ' LEU . 82.3 mtp . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.843 HD12 ' C ' ' A' ' 1' ' ' MET . 5.1 mp -116.22 160.95 19.69 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.287 -0.883 . . . . 0.0 109.327 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.764 ' O ' HG13 ' A' ' 20' ' ' VAL . 2.7 tt0 -127.68 140.27 52.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.227 -0.921 . . . . 0.0 109.208 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.0 155.22 24.91 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.784 -1.326 . . . . 0.0 109.784 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.54 ' C ' HG23 ' A' ' 18' ' ' ILE . 54.5 mttt -108.88 137.86 46.13 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.406 -1.055 . . . . 0.0 108.645 179.46 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.86 HG23 ' O ' ' A' ' 45' ' ' GLN . 15.0 t -70.16 112.56 5.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 O-C-N 121.054 -1.029 . . . . 0.0 109.983 -179.301 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.483 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 14.7 tttm -78.5 -40.87 34.04 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.592 ' CE3' ' O ' ' A' ' 8' ' ' TRP . 0.0 OUTLIER -161.44 155.78 22.73 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.923 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.434 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 11.0 p90 -154.31 139.77 17.76 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.054 -1.029 . . . . 0.0 109.07 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.538 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 3.1 t-20 -114.46 118.25 33.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.052 -1.03 . . . . 0.0 109.869 -179.601 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 82.7 p -63.82 -17.08 62.75 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.311 -0.868 . . . . 0.0 109.562 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.486 ' HB3' ' OD1' ' A' ' 10' ' ' ASN . 76.2 tt0 -85.67 -39.56 17.12 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.256 -0.902 . . . . 0.0 109.253 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.632 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 27.0 mttp -66.6 -42.75 86.4 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.363 -0.836 . . . . 0.0 109.326 179.816 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.467 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 103.26 1.02 47.67 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.369 -1.492 . . . . 0.0 109.369 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.632 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 0.8 OUTLIER -145.54 179.61 7.3 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -1.131 . . . . 0.0 109.322 179.858 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.533 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -148.57 173.85 28.41 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.564 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 29.2 m-85 -113.25 132.3 55.58 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.402 -1.058 . . . . 0.0 109.011 179.767 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 1.119 ' CD1' HG21 ' A' ' 28' ' ' VAL . 58.8 mt -119.07 149.5 21.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.239 -0.913 . . . . 0.0 109.681 -179.615 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 46.8 tt0 -112.09 122.15 46.95 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.353 -0.842 . . . . 0.0 109.415 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.764 HG13 ' O ' ' A' ' 3' ' ' GLU . 3.2 t -91.32 124.88 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.246 -0.909 . . . . 0.0 109.647 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.473 ' OE2' ' HE3' ' A' ' 5' ' ' LYS . 91.6 mt-10 -70.4 103.76 2.52 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.236 -0.915 . . . . 0.0 109.367 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 120.83 -19.13 8.99 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.569 ' OE1' HG11 ' A' ' 20' ' ' VAL . 49.0 mt-30 -129.82 162.6 28.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.263 -1.139 . . . . 0.0 109.578 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -54.46 -176.44 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.317 -0.864 . . . . 0.0 109.689 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 11.3 p30 -73.39 136.32 44.33 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.29 -0.881 . . . . 0.0 109.413 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.556 HG21 HG21 ' A' ' 20' ' ' VAL . 72.3 t -113.03 122.31 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.235 -0.916 . . . . 0.0 109.569 -179.753 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.508 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.4 OUTLIER -78.12 157.29 29.51 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.164 -0.96 . . . . 0.0 109.223 179.837 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 1.119 HG21 ' CD1' ' A' ' 18' ' ' ILE . 21.9 t -132.27 131.24 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.296 -0.877 . . . . 0.0 109.243 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.679 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 13.9 t-80 -105.83 154.64 20.25 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.124 -0.985 . . . . 0.0 109.267 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.685 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -46.52 -53.46 11.26 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.159 -0.963 . . . . 0.0 109.246 -179.683 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.685 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 86.7 p -55.96 -24.37 37.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.096 -1.003 . . . . 0.0 109.979 -179.692 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.502 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -66.32 -19.97 65.96 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.114 -0.991 . . . . 0.0 109.577 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.887 HG21 ' NZ ' ' A' ' 65' ' ' LYS . 2.9 mp -110.84 132.34 59.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.229 -0.92 . . . . 0.0 109.443 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 79.6 mt-30 -110.73 146.22 36.68 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.291 -0.881 . . . . 0.0 109.411 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.688 ' HA3' ' CZ ' ' A' ' 38' ' ' PHE . . . 174.25 -176.21 46.63 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 -179.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -73.32 -36.59 66.23 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.352 -1.087 . . . . 0.0 109.363 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -175.94 30.0 0.08 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.688 ' CZ ' ' HA3' ' A' ' 35' ' ' GLY . 43.5 p90 -122.69 28.23 7.41 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.164 -1.198 . . . . 0.0 109.64 179.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.437 ' O ' HD13 ' A' ' 33' ' ' ILE . 82.3 mttt -49.94 -32.78 15.64 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.243 -0.911 . . . . 0.0 109.546 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.425 ' O ' ' CE ' ' A' ' 65' ' ' LYS . 27.4 m -62.0 136.75 58.09 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.199 -0.938 . . . . 0.0 109.526 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.845 HD11 ' CD1' ' A' ' 33' ' ' ILE . 5.2 mp -92.98 170.94 9.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.261 -0.899 . . . . 0.0 109.629 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.531 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 84.9 tt0 -116.11 149.26 39.28 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.297 -0.877 . . . . 0.0 109.008 179.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.483 ' HG3' ' O ' ' A' ' 7' ' ' LYS . 77.5 tt0 -71.0 124.46 24.41 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.15 -0.969 . . . . 0.0 109.769 -179.788 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 92.01 -6.88 79.15 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.901 -1.28 . . . . 0.0 109.901 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.86 ' O ' HG23 ' A' ' 6' ' ' VAL . 48.6 tp60 -82.04 133.19 35.27 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.131 -1.217 . . . . 0.0 109.732 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -84.34 144.95 28.51 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.261 -0.899 . . . . 0.0 109.415 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.697 HG12 ' HA ' ' A' ' 65' ' ' LYS . 23.2 m -144.78 163.61 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.232 -0.917 . . . . 0.0 109.795 -179.725 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.513 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 1.0 OUTLIER -108.19 153.23 23.48 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 179.342 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.535 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 7.8 p90 174.63 165.82 0.25 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.99 -1.069 . . . . 0.0 110.055 -179.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.531 ' HA ' HD13 ' A' ' 2' ' ' LEU . 95.1 mt-10 -102.84 165.14 11.21 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.14 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.0 mt -102.44 125.74 56.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 120.936 -1.102 . . . . 0.0 109.854 -179.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.579 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 32.0 m -114.3 126.29 71.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.413 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 178.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -66.18 118.64 10.2 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.158 -0.964 . . . . 0.0 109.727 -179.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -122.07 157.44 16.8 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.496 ' CG ' ' N ' ' A' ' 56' ' ' ARG . 7.9 p30 -48.05 -49.66 30.6 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.319 -1.106 . . . . 0.0 109.654 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.496 ' N ' ' CG ' ' A' ' 55' ' ' ASN . 84.0 mtp180 -64.47 -25.23 67.91 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.109 -0.994 . . . . 0.0 109.012 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 142.63 -152.63 23.99 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.494 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 49.2 Cg_endo -70.72 137.25 32.28 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.631 2.22 . . . . 0.0 111.782 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.579 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 79.1 mt-30 -127.53 163.83 23.29 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.228 -0.92 . . . . 0.0 109.207 179.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.484 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -96.6 142.65 28.4 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.154 -0.966 . . . . 0.0 110.103 -179.324 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.517 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -124.65 154.06 41.34 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.387 -0.821 . . . . 0.0 108.881 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.476 ' C ' ' O ' ' A' ' 61' ' ' ALA . 58.3 t30 42.54 64.24 1.2 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.103 -0.998 . . . . 0.0 108.784 -179.65 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.766 HG12 HG23 ' A' ' 33' ' ' ILE . 1.8 t -78.38 128.91 38.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.337 -0.852 . . . . 0.0 109.944 -179.122 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.462 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 93.4 m -119.56 126.32 50.95 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.484 -0.76 . . . . 0.0 109.082 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.887 ' NZ ' HG21 ' A' ' 33' ' ' ILE . 38.2 mttp -73.39 114.78 12.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.219 -0.925 . . . . 0.0 109.771 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.449 ' HG3' ' HA ' ' A' ' 47' ' ' VAL . 97.1 mt-10 -92.44 161.98 14.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.251 -0.905 . . . . 0.0 109.452 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.392 179.884 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.7 mtt . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.427 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 57.5 mt -106.2 158.99 16.44 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.305 -0.872 . . . . 0.0 109.435 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.715 ' O ' HG13 ' A' ' 20' ' ' VAL . 3.5 tt0 -128.43 137.76 51.99 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.266 -0.896 . . . . 0.0 109.208 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.05 154.33 24.41 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.776 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.497 ' O ' HG23 ' A' ' 18' ' ' ILE . 58.0 mttp -104.16 140.46 37.77 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.434 -1.039 . . . . 0.0 108.829 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.768 HG23 ' O ' ' A' ' 45' ' ' GLN . 18.8 t -72.85 114.36 11.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.009 -1.057 . . . . 0.0 109.963 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 10.7 tptt -78.76 -42.24 28.54 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.581 ' CE3' ' O ' ' A' ' 8' ' ' TRP . 0.0 OUTLIER -160.1 156.12 26.3 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.452 -0.78 . . . . 0.0 109.009 179.96 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.498 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 10.4 p90 -154.96 139.08 16.5 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.124 -0.985 . . . . 0.0 109.021 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.486 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 58.7 t-20 -115.02 121.17 42.29 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.01 -1.056 . . . . 0.0 109.836 -179.517 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 70.7 p -66.0 -16.41 63.87 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.317 -0.865 . . . . 0.0 109.407 179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 78.5 mm-40 -85.9 -41.3 15.07 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.257 -0.902 . . . . 0.0 109.264 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.636 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 16.0 mttt -65.76 -41.13 92.45 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.352 -0.842 . . . . 0.0 109.261 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.491 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 102.02 0.17 51.53 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.636 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 0.9 OUTLIER -145.6 176.89 9.28 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.2 -1.176 . . . . 0.0 109.321 179.775 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.566 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -145.12 175.4 24.73 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.564 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 32.8 m-85 -115.54 133.29 56.18 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.265 -1.138 . . . . 0.0 109.022 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 1.09 HD12 ' CG2' ' A' ' 28' ' ' VAL . 20.2 mt -119.88 155.08 22.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.226 -0.921 . . . . 0.0 109.402 -179.807 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 32.4 tp10 -117.83 123.92 47.1 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.315 -0.866 . . . . 0.0 109.588 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.715 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.3 t -97.94 119.98 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.314 -0.866 . . . . 0.0 109.47 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -69.11 109.61 4.11 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.27 -0.894 . . . . 0.0 109.556 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 126.46 -30.68 4.19 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.691 ' OE1' HD12 ' A' ' 51' ' ' ILE . 57.1 mt-30 -128.6 166.85 18.07 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.322 -1.105 . . . . 0.0 109.41 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.46 ' O ' ' O ' ' A' ' 23' ' ' GLN . 55.4 m-20 -51.13 -177.38 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.251 -0.906 . . . . 0.0 109.411 179.898 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.512 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 20.3 p30 -75.27 147.28 40.37 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.232 -0.917 . . . . 0.0 109.308 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.538 HG21 HG21 ' A' ' 20' ' ' VAL . 81.6 t -118.14 120.44 64.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.121 -0.987 . . . . 0.0 109.676 -179.556 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.529 ' CE1' ' O ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER -76.81 158.27 30.96 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.127 -0.983 . . . . 0.0 109.11 179.696 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 1.09 ' CG2' HD12 ' A' ' 18' ' ' ILE . 7.7 t -131.64 134.08 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.187 -0.946 . . . . 0.0 109.299 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.632 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 12.9 t-80 -109.32 152.63 25.01 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.193 -0.942 . . . . 0.0 109.15 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.682 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.9 OUTLIER -45.43 -53.04 9.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.199 -0.938 . . . . 0.0 109.176 -179.592 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.682 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 22.7 t -54.96 -28.94 55.31 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.243 -0.911 . . . . 0.0 110.051 -179.587 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.499 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -62.83 -21.58 66.03 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.048 -1.032 . . . . 0.0 109.352 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.944 ' CD1' HD11 ' A' ' 41' ' ' LEU . 3.3 mp -111.18 132.19 60.38 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.298 -0.876 . . . . 0.0 109.256 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 82.9 mt-30 -113.97 148.72 36.42 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.161 -0.962 . . . . 0.0 109.562 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.681 ' HA3' ' CZ ' ' A' ' 38' ' ' PHE . . . 174.23 -176.92 46.61 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -71.02 -31.94 68.56 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.335 -1.097 . . . . 0.0 109.404 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 178.02 32.43 0.05 OUTLIER Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.681 ' CZ ' ' HA3' ' A' ' 35' ' ' GLY . 40.4 p90 -126.12 30.08 5.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.132 -1.217 . . . . 0.0 109.571 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 18.2 mttt -51.48 -34.73 36.88 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.123 -0.986 . . . . 0.0 109.522 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.521 ' O ' ' NZ ' ' A' ' 65' ' ' LYS . 36.8 m -62.28 130.87 47.33 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.19 -0.944 . . . . 0.0 109.469 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.944 HD11 ' CD1' ' A' ' 33' ' ' ILE . 5.4 mp -86.97 175.0 8.35 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.266 -0.896 . . . . 0.0 109.699 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.515 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 85.2 tt0 -117.57 152.07 35.87 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.415 -0.803 . . . . 0.0 109.042 179.546 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 67.4 tt0 -72.85 124.57 25.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.207 -0.933 . . . . 0.0 109.6 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.7 -4.44 79.17 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.768 ' O ' HG23 ' A' ' 6' ' ' VAL . 55.9 tp60 -82.05 132.81 35.26 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.189 -1.183 . . . . 0.0 109.877 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -80.45 141.06 35.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.289 -0.882 . . . . 0.0 109.169 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.656 HG21 HD13 ' A' ' 18' ' ' ILE . 30.1 m -141.69 159.04 21.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 109.902 -179.614 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.503 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 28.9 t -109.66 153.11 24.7 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.048 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.552 ' CE2' HG23 ' A' ' 47' ' ' VAL . 8.5 p90 173.39 165.67 0.16 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.913 -1.117 . . . . 0.0 110.178 -179.764 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -100.05 162.89 12.69 Favored 'General case' 0 N--CA 1.487 1.382 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.691 HD12 ' OE1' ' A' ' 23' ' ' GLN . 0.9 OUTLIER -102.25 125.46 56.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 120.927 -1.108 . . . . 0.0 110.022 -179.571 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.601 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 26.7 m -109.9 121.98 63.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.408 ' OE2' ' HB3' ' A' ' 58' ' ' PRO . 39.9 mm-40 -91.47 89.9 7.42 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.144 -0.973 . . . . 0.0 109.945 -179.001 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.05 -169.96 32.23 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.428 ' O ' ' C ' ' A' ' 56' ' ' ARG . 4.1 t30 -58.05 -66.17 0.52 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.236 -1.155 . . . . 0.0 109.837 -179.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.428 ' C ' ' O ' ' A' ' 55' ' ' ASN . 15.2 mtm180 -41.82 -46.29 3.88 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.282 -0.886 . . . . 0.0 109.501 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 150.65 -153.97 25.34 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.512 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 47.9 Cg_endo -69.64 129.42 17.69 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.682 2.255 . . . . 0.0 112.024 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.601 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 61.2 mt-30 -127.19 161.14 29.23 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.334 -0.854 . . . . 0.0 108.976 179.506 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.547 ' HB2' HG22 ' A' ' 28' ' ' VAL . . . -90.02 136.52 32.99 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.032 -1.043 . . . . 0.0 110.296 -179.154 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.534 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -118.79 149.57 41.28 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 179.442 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.488 ' C ' ' O ' ' A' ' 61' ' ' ALA . 38.6 t-20 41.34 67.77 0.51 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.033 -1.042 . . . . 0.0 108.875 -179.57 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.609 HG21 ' CG1' ' A' ' 28' ' ' VAL . 2.1 t -81.57 127.85 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.404 -0.81 . . . . 0.0 110.161 -179.176 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 91.8 m -118.1 123.84 46.57 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.472 -0.768 . . . . 0.0 109.082 179.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.521 ' NZ ' ' O ' ' A' ' 40' ' ' THR . 74.1 mttt -70.75 112.63 7.11 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.199 -0.938 . . . . 0.0 109.737 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -92.75 162.7 14.02 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.326 -0.859 . . . . 0.0 109.584 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.995 -1.002 . . . . 0.0 109.491 179.997 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.819 ' C ' HD12 ' A' ' 2' ' ' LEU . 75.1 mtm . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.845 ' N ' HD12 ' A' ' 2' ' ' LEU . 4.6 mp -115.89 162.02 17.94 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.24 -0.913 . . . . 0.0 109.117 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.794 ' O ' HG13 ' A' ' 20' ' ' VAL . 2.4 tt0 -128.73 143.67 50.98 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.205 -0.935 . . . . 0.0 109.163 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -144.34 157.08 27.07 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.445 ' C ' HG23 ' A' ' 18' ' ' ILE . 43.2 mttm -108.23 137.1 46.79 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.423 -1.045 . . . . 0.0 108.576 179.383 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.789 HG23 ' O ' ' A' ' 45' ' ' GLN . 16.1 t -68.28 114.45 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.128 -0.983 . . . . 0.0 109.85 -179.341 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.459 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 29.7 tttt -79.33 -38.07 36.03 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 179.601 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.608 ' CZ3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -166.37 157.39 12.89 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.476 -0.765 . . . . 0.0 109.035 -179.893 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.432 ' N ' ' CG ' ' A' ' 8' ' ' TRP . 16.1 p90 -152.75 139.89 19.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.203 -0.936 . . . . 0.0 108.847 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.502 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 55.1 t-20 -117.11 121.54 41.58 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.045 -1.034 . . . . 0.0 109.971 -179.408 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 88.0 p -66.45 -17.94 65.07 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.387 -0.82 . . . . 0.0 109.443 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -83.7 -40.58 18.73 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.231 -0.918 . . . . 0.0 109.373 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.625 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 24.9 mttp -68.76 -43.52 75.63 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.29 -0.882 . . . . 0.0 109.367 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.485 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 104.53 -0.4 42.94 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.625 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 0.4 OUTLIER -142.33 179.8 6.72 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.112 -1.228 . . . . 0.0 109.529 179.88 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.516 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -145.3 172.17 26.16 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.679 -1.368 . . . . 0.0 109.679 -179.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.608 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 28.4 m-85 -114.79 131.94 56.64 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.22 -1.164 . . . . 0.0 109.021 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 1.117 HD12 ' CG2' ' A' ' 28' ' ' VAL . 37.3 mt -119.25 149.54 21.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.146 -0.971 . . . . 0.0 109.647 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 46.3 tt0 -112.28 120.3 41.27 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.406 -0.809 . . . . 0.0 109.413 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.794 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.6 t -90.85 125.1 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.312 -0.868 . . . . 0.0 109.428 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.468 ' HA ' ' OE1' ' A' ' 21' ' ' GLU . 67.0 mm-40 -73.57 106.05 5.18 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.318 -0.864 . . . . 0.0 109.25 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.53 -17.54 8.89 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.564 ' OE1' HD12 ' A' ' 51' ' ' ILE . 46.5 mt-30 -133.9 164.62 26.86 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.276 -1.132 . . . . 0.0 109.648 -179.836 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 50.5 m-20 -55.02 -176.6 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.207 -0.933 . . . . 0.0 109.607 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.499 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 11.4 p30 -73.33 139.96 46.39 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.29 -0.881 . . . . 0.0 109.477 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.587 HG12 ' HB2' ' A' ' 60' ' ' ALA . 56.1 t -115.74 122.02 68.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.196 -0.94 . . . . 0.0 109.44 -179.796 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.495 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.3 OUTLIER -79.78 157.53 27.06 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.13 -0.981 . . . . 0.0 109.192 179.977 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 1.117 ' CG2' HD12 ' A' ' 18' ' ' ILE . 13.0 t -132.31 130.18 60.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.303 -0.873 . . . . 0.0 109.373 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.667 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 13.4 t-80 -103.65 154.41 19.55 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.148 -0.97 . . . . 0.0 109.089 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.689 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.7 OUTLIER -45.98 -53.44 10.02 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.082 -1.011 . . . . 0.0 109.188 -179.682 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.689 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 93.0 p -55.55 -30.26 60.45 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.154 -0.966 . . . . 0.0 110.236 -179.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.401 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -58.03 -27.9 63.99 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.996 -1.065 . . . . 0.0 109.331 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.821 HG12 HG11 ' A' ' 63' ' ' VAL . 2.6 mp -108.13 142.56 20.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.355 -0.841 . . . . 0.0 109.52 -179.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -105.22 145.99 29.87 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.201 -0.937 . . . . 0.0 109.486 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.641 ' CA ' ' CZ ' ' A' ' 38' ' ' PHE . . . 161.43 149.99 5.79 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -68.12 -46.55 70.59 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.209 -1.171 . . . . 0.0 109.44 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -143.93 -11.72 0.34 Allowed Glycine 0 N--CA 1.491 2.345 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.641 ' CZ ' ' CA ' ' A' ' 35' ' ' GLY . 53.5 p90 -86.9 16.61 4.73 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.91 -1.347 . . . . 0.0 109.642 -179.763 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.512 ' O ' ' CD1' ' A' ' 41' ' ' LEU . 43.3 mtmt -63.0 -18.45 63.31 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.22 -0.925 . . . . 0.0 109.487 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 21.2 m -67.19 120.29 13.52 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.277 -0.89 . . . . 0.0 109.3 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.643 HD11 HG12 ' A' ' 33' ' ' ILE . 4.4 mp -81.21 139.99 35.19 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.266 -0.896 . . . . 0.0 109.837 -179.669 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.451 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.5 tt0 -91.75 134.4 34.77 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.43 -0.794 . . . . 0.0 109.401 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.459 ' HG3' ' O ' ' A' ' 7' ' ' LYS . 76.1 tt0 -59.44 128.28 36.27 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.239 -0.913 . . . . 0.0 109.638 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.406 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 91.99 -5.13 78.8 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 179.726 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.789 ' O ' HG23 ' A' ' 6' ' ' VAL . 63.3 tt0 -81.37 131.48 35.29 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.269 -1.136 . . . . 0.0 109.758 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -79.14 141.4 37.29 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.247 -0.908 . . . . 0.0 109.22 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.681 HG21 HD13 ' A' ' 18' ' ' ILE . 33.2 m -141.83 159.19 21.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.127 -0.983 . . . . 0.0 109.907 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.505 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 27.5 t -106.08 151.26 24.91 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 179.017 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.596 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 11.7 p90 175.13 165.39 0.29 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.943 -1.098 . . . . 0.0 110.317 -179.707 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.552 ' HA ' HD13 ' A' ' 2' ' ' LEU . 93.9 mt-10 -100.05 166.26 11.12 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 178.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.564 HD12 ' OE1' ' A' ' 23' ' ' GLN . 0.6 OUTLIER -104.16 125.72 58.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.917 -1.114 . . . . 0.0 109.804 -179.66 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.591 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 33.1 m -114.03 125.57 71.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.173 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.464 ' HA ' ' HA ' ' A' ' 58' ' ' PRO . 19.8 mt-10 -96.66 93.61 6.84 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.196 -0.94 . . . . 0.0 109.923 -179.35 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.61 -176.62 44.33 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.407 ' CG ' ' N ' ' A' ' 56' ' ' ARG . 18.5 p-10 -53.17 -50.77 63.92 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.219 -1.165 . . . . 0.0 109.715 -179.674 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.407 ' N ' ' CG ' ' A' ' 55' ' ' ASN . 20.1 mtm180 -58.96 -37.5 76.93 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.081 -1.012 . . . . 0.0 109.381 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.05 -159.21 28.07 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.5 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 53.7 Cg_endo -72.59 142.28 35.99 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.728 2.285 . . . . 0.0 111.903 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.591 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 72.8 mt-30 -138.97 169.89 16.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.384 -0.822 . . . . 0.0 108.945 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.587 ' HB2' HG12 ' A' ' 26' ' ' VAL . . . -95.03 138.17 33.11 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.047 -1.033 . . . . 0.0 110.383 -179.132 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.596 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -125.42 156.33 39.01 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.34 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 73.5 m-20 45.39 69.18 0.47 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.893 -1.13 . . . . 0.0 108.665 -179.647 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.821 HG11 HG12 ' A' ' 33' ' ' ILE . 2.2 t -88.14 125.83 41.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.326 -0.859 . . . . 0.0 110.17 -179.033 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 98.1 m -118.16 121.23 39.99 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.505 -0.747 . . . . 0.0 109.025 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.721 ' NZ ' HG21 ' A' ' 33' ' ' ILE . 28.7 mttp -71.49 112.26 7.47 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.229 -0.919 . . . . 0.0 109.361 -179.805 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.469 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 96.2 mt-10 -94.03 166.89 11.93 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.313 -0.867 . . . . 0.0 109.642 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . 0.414 ' O ' ' O ' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 117.998 -1.001 . . . . 0.0 109.548 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.6 ' C ' HD12 ' A' ' 2' ' ' LEU . 77.1 mtp . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 121.283 0.564 . . . . 0.0 109.54 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.876 ' N ' HD12 ' A' ' 2' ' ' LEU . 3.6 mp -109.35 161.79 14.95 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.351 -0.843 . . . . 0.0 109.366 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.735 ' O ' HG13 ' A' ' 20' ' ' VAL . 83.0 mt-10 -127.96 144.27 51.1 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.274 -0.891 . . . . 0.0 109.185 179.671 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.471 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -140.06 153.43 23.32 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.499 ' N ' HG23 ' A' ' 18' ' ' ILE . 58.4 mttm -104.03 139.26 39.39 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.315 -1.109 . . . . 0.0 108.841 179.482 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.64 HG23 ' O ' ' A' ' 45' ' ' GLN . 38.7 t -71.63 109.94 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.166 -0.958 . . . . 0.0 109.899 -179.43 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.67 -32.83 27.94 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.371 -0.831 . . . . 0.0 108.977 179.42 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.686 ' CE3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -158.63 159.28 35.22 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 -179.837 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.505 ' N ' ' CG ' ' A' ' 8' ' ' TRP . 22.4 p90 -161.16 132.5 5.5 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.029 -1.044 . . . . 0.0 109.283 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.523 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.1 t-20 -128.19 123.6 34.69 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.197 -0.939 . . . . 0.0 109.539 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -76.64 -18.05 58.81 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.293 -0.88 . . . . 0.0 108.805 179.616 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.439 ' HB2' ' ND2' ' A' ' 10' ' ' ASN . 95.3 mt-10 -59.86 -56.08 26.21 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 178.557 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.692 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 13.8 mttp -67.15 -42.3 84.61 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 178.353 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.415 ' C ' ' CD1' ' A' ' 15' ' ' PHE . . . 106.56 7.0 35.02 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 179.345 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.735 ' HB3' ' HA ' ' A' ' 29' ' ' HIS . 0.0 OUTLIER -137.14 173.08 12.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.0 -1.294 . . . . 0.0 109.22 179.102 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.593 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -136.96 172.57 22.56 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.686 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 17.0 m-85 -119.37 133.74 55.56 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.226 -1.161 . . . . 0.0 109.306 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 1.103 ' CD1' HG21 ' A' ' 28' ' ' VAL . 15.4 mt -120.82 154.41 24.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.342 -0.849 . . . . 0.0 109.46 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 24.9 tp10 -117.65 122.91 44.82 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.307 -0.871 . . . . 0.0 109.38 179.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.735 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.9 t -93.58 120.16 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.228 -0.92 . . . . 0.0 109.553 -179.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -67.14 109.18 2.94 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.295 -0.878 . . . . 0.0 109.286 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.22 -23.1 7.75 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.68 ' OE1' HD12 ' A' ' 51' ' ' ILE . 65.0 mt-30 -130.79 164.79 24.38 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.304 -1.115 . . . . 0.0 109.51 -179.77 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 41.0 m-20 -55.28 -175.02 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.33 -0.856 . . . . 0.0 109.924 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.475 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 15.2 p30 -74.18 141.99 45.46 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.301 -0.875 . . . . 0.0 109.737 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.478 HG21 HG21 ' A' ' 20' ' ' VAL . 90.6 t -117.87 118.13 57.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.207 -0.933 . . . . 0.0 109.353 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.448 ' CE1' ' HB3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -75.13 156.06 36.37 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.231 -0.918 . . . . 0.0 109.021 179.771 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 1.103 HG21 ' CD1' ' A' ' 18' ' ' ILE . 6.9 t -133.57 139.95 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.89 . . . . 0.0 109.607 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.735 ' HA ' ' HB3' ' A' ' 15' ' ' PHE . 13.6 t-80 -114.42 150.3 34.91 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.26 -0.9 . . . . 0.0 109.25 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.668 ' CG ' ' N ' ' A' ' 31' ' ' SER . 1.0 OUTLIER -43.75 -52.66 6.44 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.174 -0.954 . . . . 0.0 109.396 -179.642 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.668 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 22.8 t -57.61 -20.84 35.51 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.17 -0.956 . . . . 0.0 109.863 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.471 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -69.42 -22.75 63.66 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.115 -0.991 . . . . 0.0 109.735 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.639 ' CG1' HG11 ' A' ' 63' ' ' VAL . 2.9 mp -103.08 143.45 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.207 -0.933 . . . . 0.0 109.716 -179.852 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.455 ' C ' ' O ' ' A' ' 33' ' ' ILE . 59.6 mt-30 -40.68 -59.03 1.48 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.326 -0.859 . . . . 0.0 109.602 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.524 ' HA3' ' HE3' ' A' ' 39' ' ' LYS . . . 92.24 2.75 68.07 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.433 ' C ' ' O ' ' A' ' 35' ' ' GLY . 81.9 tt0 -44.05 -27.5 0.39 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.187 -1.184 . . . . 0.0 109.322 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 174.23 40.29 0.04 OUTLIER Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.495 ' HB2' ' HE2' ' A' ' 65' ' ' LYS . 5.7 p90 -175.42 46.94 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.201 -1.176 . . . . 0.0 109.56 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.524 ' HE3' ' HA3' ' A' ' 35' ' ' GLY . 17.8 mttp -62.15 -32.13 72.7 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.183 -0.948 . . . . 0.0 109.332 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 30.0 m -73.66 108.24 6.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.245 -0.909 . . . . 0.0 109.492 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.597 HD11 ' CD1' ' A' ' 33' ' ' ILE . 5.5 mp -74.49 147.31 42.0 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.244 -0.91 . . . . 0.0 109.787 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.427 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 94.5 mt-10 -105.47 146.29 29.73 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.44 -0.787 . . . . 0.0 109.36 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.574 ' HA ' HG12 ' A' ' 6' ' ' VAL . 52.6 tt0 -70.06 130.72 42.91 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.184 -0.947 . . . . 0.0 109.613 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 93.11 -5.96 75.75 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 179.726 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.64 ' O ' HG23 ' A' ' 6' ' ' VAL . 60.2 tp60 -81.86 125.68 30.99 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.26 -1.141 . . . . 0.0 109.73 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -73.25 143.94 46.88 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.199 -0.938 . . . . 0.0 109.223 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.853 HG21 HD13 ' A' ' 18' ' ' ILE . 33.4 m -145.39 158.92 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.109 -0.994 . . . . 0.0 110.188 -179.576 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.526 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 4.6 p -110.49 154.53 23.52 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.115 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.584 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 7.9 p90 171.29 167.66 0.08 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.93 -1.106 . . . . 0.0 110.035 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.651 ' HA ' HD13 ' A' ' 2' ' ' LEU . 94.8 mt-10 -103.67 165.09 11.25 Favored 'General case' 0 C--N 1.303 -1.436 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.212 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.68 HD12 ' OE1' ' A' ' 23' ' ' GLN . 3.9 mt -106.25 132.22 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 120.997 -1.064 . . . . 0.0 109.685 -179.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.536 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 20.5 m -121.28 133.12 68.87 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.557 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 87.3 tt0 -84.97 82.66 8.35 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.213 -0.929 . . . . 0.0 109.604 -179.673 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 57' ' ' GLY . . . -84.32 176.64 51.56 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 20.2 p-10 -49.47 -51.69 34.13 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.241 -1.152 . . . . 0.0 109.65 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 23.2 mtm180 -62.38 -31.98 72.72 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.095 -1.003 . . . . 0.0 109.549 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.413 ' O ' ' N ' ' A' ' 54' ' ' GLY . . . 142.93 -148.22 19.89 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.478 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 50.0 Cg_endo -71.24 133.59 23.17 Favored 'Trans proline' 0 C--O 1.214 -0.688 0 C-N-CA 122.802 2.334 . . . . 0.0 112.034 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.536 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 42.6 mt-30 -127.87 161.32 29.34 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.38 -0.825 . . . . 0.0 109.359 179.726 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.615 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -92.16 110.49 21.87 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.217 -0.927 . . . . 0.0 110.134 -179.508 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.575 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -93.48 152.07 19.31 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.327 -0.858 . . . . 0.0 109.061 179.633 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.494 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 79.0 m-20 43.63 78.23 0.06 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.043 -1.036 . . . . 0.0 109.029 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.748 HG21 ' CG1' ' A' ' 28' ' ' VAL . 2.1 t -92.87 125.87 45.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.182 -0.949 . . . . 0.0 110.003 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.402 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 56.9 m -120.48 130.22 54.19 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.655 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.561 ' NZ ' HG21 ' A' ' 33' ' ' ILE . 44.3 mttp -76.81 114.04 15.13 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.277 -0.889 . . . . 0.0 109.72 -179.697 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 57.5 mm-40 -101.02 172.02 7.28 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.284 -0.885 . . . . 0.0 109.635 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 117.993 -1.003 . . . . 0.0 109.471 179.893 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.749 ' C ' HD12 ' A' ' 2' ' ' LEU . 73.1 mtp . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.837 ' N ' HD12 ' A' ' 2' ' ' LEU . 5.2 mp -112.93 165.72 12.06 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.322 -0.861 . . . . 0.0 109.319 -179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.779 ' O ' HG13 ' A' ' 20' ' ' VAL . 2.4 tt0 -132.39 139.99 48.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.179 -0.951 . . . . 0.0 109.461 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -140.4 158.75 26.09 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.509 ' O ' HG23 ' A' ' 18' ' ' ILE . 85.6 mttt -106.96 139.69 40.97 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.32 -1.106 . . . . 0.0 108.895 179.78 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.711 HG23 ' O ' ' A' ' 45' ' ' GLN . 22.6 t -72.88 111.56 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.109 -0.994 . . . . 0.0 110.127 -179.34 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 19.1 tttt -79.16 -40.6 30.52 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.619 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.7 154.76 26.88 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 179.765 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.436 ' N ' ' CG ' ' A' ' 8' ' ' TRP . 13.6 p90 -154.9 141.0 18.43 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.058 -1.026 . . . . 0.0 109.424 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.483 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.7 t-20 -132.76 128.92 37.89 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.253 -0.904 . . . . 0.0 109.677 -179.746 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.3 p -78.46 -20.03 51.83 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.208 -0.933 . . . . 0.0 108.831 179.564 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.479 ' HA ' ' OE1' ' A' ' 12' ' ' GLU . 69.9 mm-40 -64.45 -45.69 86.36 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 178.092 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.631 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 10.3 mttm -73.86 -34.98 64.71 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 178.449 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.521 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 92.84 0.93 68.26 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 179.191 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.631 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 5.6 p90 -138.78 171.94 13.61 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.044 -1.268 . . . . 0.0 108.883 178.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.619 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -138.43 172.11 23.15 Favored Glycine 0 N--CA 1.49 2.27 0 C-N-CA 119.634 -1.27 . . . . 0.0 110.024 -179.452 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.514 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 27.1 m-85 -115.17 133.0 56.42 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.339 -1.095 . . . . 0.0 108.789 179.569 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 1.113 HD12 ' CG2' ' A' ' 28' ' ' VAL . 13.1 mt -120.92 155.29 24.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.151 -0.968 . . . . 0.0 109.873 -179.518 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.4 ' N ' ' CG2' ' A' ' 18' ' ' ILE . 23.4 tp10 -116.92 123.47 47.06 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.398 -0.814 . . . . 0.0 109.369 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.779 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.3 t -98.15 123.0 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.17 -0.956 . . . . 0.0 109.317 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.463 ' HA ' ' OE1' ' A' ' 21' ' ' GLU . 68.7 mm-40 -72.24 108.83 5.6 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.228 -0.92 . . . . 0.0 109.3 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 125.44 -22.68 6.17 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.226 -1.55 . . . . 0.0 109.226 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.788 ' OE1' HD12 ' A' ' 51' ' ' ILE . 73.1 mt-30 -135.73 167.54 20.96 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.28 -1.13 . . . . 0.0 109.548 -179.78 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -53.52 -177.12 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.262 -0.899 . . . . 0.0 109.587 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.479 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 11.8 p30 -74.61 143.18 44.48 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.937 . . . . 0.0 109.426 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.559 HG21 HD11 ' A' ' 51' ' ' ILE . 97.9 t -116.33 119.36 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.16 -0.962 . . . . 0.0 109.425 -179.813 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.518 ' CG ' ' N ' ' A' ' 28' ' ' VAL . 0.4 OUTLIER -77.84 158.8 29.32 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.172 -0.955 . . . . 0.0 109.207 179.916 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 1.113 ' CG2' HD12 ' A' ' 18' ' ' ILE . 4.4 t -133.09 125.71 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.476 -0.765 . . . . 0.0 109.144 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.676 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 14.6 t-80 -98.46 153.93 18.24 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.355 -0.84 . . . . 0.0 109.091 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.687 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -45.13 -53.68 7.75 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.07 -1.019 . . . . 0.0 109.203 -179.65 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.687 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 62.8 p -54.27 -25.13 21.69 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.189 -0.945 . . . . 0.0 109.921 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.466 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -62.34 -24.52 67.38 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.126 -0.984 . . . . 0.0 109.439 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.776 HD11 HD11 ' A' ' 41' ' ' LEU . 3.0 mp -109.25 136.0 46.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.238 -0.914 . . . . 0.0 109.544 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 61.5 tt0 -101.44 113.95 27.52 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.315 -0.865 . . . . 0.0 109.447 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.608 ' HA3' ' CE1' ' A' ' 38' ' ' PHE . . . -176.81 162.07 30.25 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 86.1 mt-10 -118.04 87.57 2.74 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.23 -1.159 . . . . 0.0 109.356 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.03 -24.81 7.72 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.608 ' CE1' ' HA3' ' A' ' 35' ' ' GLY . 49.0 p90 -123.65 25.36 8.17 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.336 -1.096 . . . . 0.0 109.242 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.49 ' HG3' ' O ' ' A' ' 35' ' ' GLY . 89.1 mttt -55.31 -36.8 66.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.336 -0.852 . . . . 0.0 109.662 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.52 ' O ' ' NZ ' ' A' ' 65' ' ' LYS . 20.7 m -72.17 138.43 47.64 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.209 -0.932 . . . . 0.0 109.522 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 1.038 HD23 HG11 ' A' ' 47' ' ' VAL . 5.1 mp -80.52 178.68 8.17 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.348 -0.845 . . . . 0.0 109.788 -179.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.492 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 20.5 tt0 -116.42 140.24 49.56 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.391 -0.818 . . . . 0.0 109.057 179.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.432 ' HA ' HG12 ' A' ' 6' ' ' VAL . 76.6 tt0 -62.35 125.35 23.6 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.264 -0.898 . . . . 0.0 109.618 -179.76 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 90.67 -7.1 81.82 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.711 ' O ' HG23 ' A' ' 6' ' ' VAL . 66.7 tt0 -81.76 134.39 35.44 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.24 -1.153 . . . . 0.0 109.72 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -80.07 140.16 36.6 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.271 -0.893 . . . . 0.0 109.155 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 1.038 HG11 HD23 ' A' ' 41' ' ' LEU . 26.4 m -140.57 151.73 20.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.227 -0.921 . . . . 0.0 109.745 -179.464 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.527 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 33.0 t -100.56 148.94 24.24 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.053 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.598 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 7.2 p90 176.28 164.7 0.42 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.903 -1.123 . . . . 0.0 110.105 -179.63 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.571 ' HA ' HD13 ' A' ' 2' ' ' LEU . 94.9 mt-10 -103.54 161.41 13.9 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.247 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.788 HD12 ' OE1' ' A' ' 23' ' ' GLN . 7.2 mt -104.61 135.78 41.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.969 -1.082 . . . . 0.0 109.783 -179.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.501 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 32.7 m -122.23 131.41 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.481 -0.762 . . . . 0.0 109.11 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -86.8 84.22 7.4 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.185 -0.947 . . . . 0.0 109.634 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -85.84 177.16 49.55 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.3 t30 -50.34 -54.33 22.35 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.196 -1.179 . . . . 0.0 109.608 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 71.3 mtm180 -57.38 -35.46 70.01 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.241 -0.912 . . . . 0.0 109.498 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 145.2 -153.28 25.17 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -70.37 137.31 33.41 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.734 2.289 . . . . 0.0 111.987 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.524 ' C ' HG13 ' A' ' 26' ' ' VAL . 92.2 mt-30 -135.19 165.99 24.14 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.342 -0.849 . . . . 0.0 109.275 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.564 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -94.58 137.15 34.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.198 -0.938 . . . . 0.0 109.777 -179.69 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.598 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -123.96 155.04 38.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.365 -0.834 . . . . 0.0 108.843 179.717 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.476 ' C ' ' O ' ' A' ' 61' ' ' ALA . 85.8 m-20 43.19 73.91 0.13 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.897 -1.127 . . . . 0.0 108.706 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.845 HG11 HD21 ' A' ' 41' ' ' LEU . 2.7 t -89.65 126.96 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.212 -0.93 . . . . 0.0 109.99 -179.108 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.422 ' HB ' ' HB3' ' A' ' 48' ' ' SER . 70.3 m -118.45 124.29 47.27 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 179.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.52 ' NZ ' ' O ' ' A' ' 40' ' ' THR . 55.5 mttt -71.73 111.03 6.67 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.181 -0.95 . . . . 0.0 109.528 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -89.78 164.1 14.79 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.364 -0.835 . . . . 0.0 109.566 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.461 -179.922 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.582 ' C ' HD12 ' A' ' 2' ' ' LEU . 91.8 mtp . . . . . 0 N--CA 1.489 1.475 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.847 ' N ' HD12 ' A' ' 2' ' ' LEU . 4.6 mp -107.55 161.91 14.42 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.238 -0.914 . . . . 0.0 109.391 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.765 ' O ' HG13 ' A' ' 20' ' ' VAL . 96.1 mt-10 -129.48 147.36 51.29 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.167 -0.958 . . . . 0.0 109.295 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.444 ' C ' ' CG2' ' A' ' 18' ' ' ILE . . . -143.1 153.46 24.77 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.666 ' C ' HG23 ' A' ' 18' ' ' ILE . 27.6 mttp -102.48 141.38 35.39 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.284 -1.127 . . . . 0.0 108.839 179.557 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 45' ' ' GLN . 33.7 t -73.8 110.58 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.247 -0.908 . . . . 0.0 110.126 -179.392 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.488 ' NZ ' ' HB3' ' A' ' 17' ' ' PHE . 2.9 pttt -79.89 -36.46 36.5 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.615 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -159.74 154.26 24.04 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.962 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.627 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 17.0 p90 -156.03 140.33 16.64 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.075 -1.016 . . . . 0.0 109.496 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.447 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 55.1 t-20 -130.82 121.91 26.16 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.224 -0.923 . . . . 0.0 109.521 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -74.08 -20.04 60.41 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.159 -0.963 . . . . 0.0 108.745 179.637 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.435 ' HB2' ' ND2' ' A' ' 10' ' ' ASN . 95.5 mt-10 -63.19 -47.46 82.5 Favored 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 106.476 -1.675 . . . . 0.0 106.476 177.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.693 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 28.8 mttm -70.31 -41.44 73.29 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 178.161 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.504 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 99.15 3.46 56.73 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.386 -1.485 . . . . 0.0 109.386 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.693 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 2.8 p90 -141.85 167.52 21.94 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.274 -1.133 . . . . 0.0 108.85 179.015 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.615 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -136.07 177.22 19.72 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.652 -1.261 . . . . 0.0 110.05 -179.366 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.562 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 19.4 m-85 -119.2 135.49 54.65 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.384 -1.068 . . . . 0.0 109.078 179.834 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 1.088 ' CD1' HG21 ' A' ' 28' ' ' VAL . 37.9 mt -122.34 148.41 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.168 -0.958 . . . . 0.0 109.507 -179.673 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 23.3 tp10 -110.98 121.05 44.37 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.342 -0.849 . . . . 0.0 109.332 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.765 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.6 t -91.46 120.59 40.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.211 -0.931 . . . . 0.0 109.664 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.411 ' OE1' ' HA ' ' A' ' 21' ' ' GLU . 73.2 mm-40 -71.9 110.64 6.54 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.202 -0.936 . . . . 0.0 109.246 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.405 ' C ' ' HG3' ' A' ' 23' ' ' GLN . . . 122.57 -18.38 8.18 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.694 ' OE1' HD12 ' A' ' 51' ' ' ILE . 63.9 mt-30 -140.04 170.35 16.01 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.353 -1.086 . . . . 0.0 109.495 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 60.2 m-20 -55.31 -178.35 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.291 -0.88 . . . . 0.0 109.654 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 22.6 p30 -75.01 146.46 41.61 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.236 -0.915 . . . . 0.0 109.438 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.66 HG13 ' C ' ' A' ' 59' ' ' GLN . 58.1 t -118.35 119.07 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.242 -0.911 . . . . 0.0 109.401 -179.67 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.545 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.0 OUTLIER -76.61 156.31 32.84 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.205 -0.934 . . . . 0.0 109.148 179.855 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 1.088 HG21 ' CD1' ' A' ' 18' ' ' ILE . 14.7 t -133.45 132.97 57.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.383 -0.823 . . . . 0.0 109.399 -179.762 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.68 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 15.3 t-80 -111.18 153.5 25.7 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.354 -0.841 . . . . 0.0 109.053 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.682 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -44.47 -53.85 6.55 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.126 -0.984 . . . . 0.0 109.347 -179.605 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.682 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 32.3 t -57.04 -22.81 41.78 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.115 -0.991 . . . . 0.0 110.014 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.454 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -66.43 -27.53 67.91 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.09 -1.006 . . . . 0.0 109.458 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.719 HG12 HG11 ' A' ' 63' ' ' VAL . 2.4 mp -100.65 141.52 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.258 -0.901 . . . . 0.0 109.677 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.407 ' C ' ' O ' ' A' ' 33' ' ' ILE . 60.7 mt-30 -42.69 -53.28 4.57 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.276 -0.89 . . . . 0.0 109.63 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.54 ' CA ' ' HG2' ' A' ' 39' ' ' LYS . . . 88.4 11.06 67.17 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.369 -1.492 . . . . 0.0 109.369 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.414 ' C ' ' O ' ' A' ' 35' ' ' GLY . 82.3 tt0 -45.09 -26.44 0.45 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.317 -1.108 . . . . 0.0 109.425 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 172.34 40.57 0.04 OUTLIER Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.526 ' HB2' ' HZ2' ' A' ' 65' ' ' LYS . 0.1 OUTLIER -178.96 40.38 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.203 -1.175 . . . . 0.0 109.643 179.936 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.54 ' HG2' ' CA ' ' A' ' 35' ' ' GLY . 87.0 mttt -47.77 -29.59 3.26 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.191 -0.943 . . . . 0.0 109.351 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 29.9 m -79.15 109.35 13.38 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.278 -0.889 . . . . 0.0 109.449 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.64 ' CD1' HD13 ' A' ' 33' ' ' ILE . 3.1 mp -75.28 152.73 38.2 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.32 -0.863 . . . . 0.0 109.672 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.468 ' O ' ' CB ' ' A' ' 6' ' ' VAL . 96.0 mt-10 -100.7 149.15 24.09 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.324 -0.86 . . . . 0.0 109.484 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.525 ' HA ' ' CG1' ' A' ' 6' ' ' VAL . 69.8 tt0 -71.91 130.01 39.97 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.348 -0.845 . . . . 0.0 109.625 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.51 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 90.52 -4.26 82.17 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.583 ' O ' HG23 ' A' ' 6' ' ' VAL . 49.8 tt0 -80.8 129.57 34.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.271 -1.135 . . . . 0.0 109.638 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -76.48 139.75 40.94 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.268 -0.895 . . . . 0.0 109.065 179.702 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.822 HG21 HD13 ' A' ' 18' ' ' ILE . 31.8 m -142.28 162.24 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.029 -1.044 . . . . 0.0 109.959 -179.651 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.509 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 63.8 m -112.44 153.38 27.47 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.634 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 5.8 p90 172.75 168.56 0.12 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.033 -1.042 . . . . 0.0 109.978 -179.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.528 ' HA ' HD13 ' A' ' 2' ' ' LEU . 95.1 mt-10 -103.5 160.88 14.34 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.694 HD12 ' OE1' ' A' ' 23' ' ' GLN . 3.9 mt -103.5 134.47 44.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.116 -0.99 . . . . 0.0 109.616 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.533 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 33.9 m -122.74 131.74 72.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -85.7 87.2 7.37 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.102 -0.999 . . . . 0.0 109.677 -179.724 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.62 178.07 43.96 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 5.9 t30 -50.24 -56.75 9.82 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.23 -1.159 . . . . 0.0 109.514 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 21.6 mtm180 -57.11 -34.07 67.96 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.262 -0.898 . . . . 0.0 109.417 -179.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 144.53 -152.18 24.15 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.491 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 51.0 Cg_endo -70.46 136.98 32.43 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.835 2.357 . . . . 0.0 112.052 -179.869 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.66 ' C ' HG13 ' A' ' 26' ' ' VAL . 89.9 mt-30 -132.85 165.3 24.93 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.443 -0.786 . . . . 0.0 109.263 179.796 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.549 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -90.13 132.19 35.58 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.16 -0.963 . . . . 0.0 109.789 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.545 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -113.7 147.76 37.61 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.528 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.484 ' C ' ' O ' ' A' ' 61' ' ' ALA . 23.9 t-20 41.27 74.41 0.11 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.141 -0.975 . . . . 0.0 108.778 -179.497 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.719 HG11 HG12 ' A' ' 33' ' ' ILE . 1.4 t -84.38 127.94 39.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.387 -0.821 . . . . 0.0 110.159 -179.068 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.41 ' HB ' ' HB2' ' A' ' 48' ' ' SER . 27.7 m -119.68 126.61 51.53 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 179.333 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.536 ' HA ' HG12 ' A' ' 47' ' ' VAL . 57.7 mttt -73.72 108.78 6.76 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.162 -0.961 . . . . 0.0 109.511 -179.614 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 45.9 mm-40 -99.08 175.8 5.78 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.338 -0.852 . . . . 0.0 109.689 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.479 179.922 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.87 ' C ' HD12 ' A' ' 2' ' ' LEU . 84.0 mmm . . . . . 0 N--CA 1.491 1.595 0 CA-C-O 121.296 0.569 . . . . 0.0 109.487 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.87 HD12 ' C ' ' A' ' 1' ' ' MET . 5.1 mp -115.88 154.89 28.91 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.209 -0.932 . . . . 0.0 109.33 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.731 ' O ' HG13 ' A' ' 20' ' ' VAL . 2.1 tt0 -124.74 140.45 52.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.276 -0.89 . . . . 0.0 108.993 179.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -144.63 149.87 21.98 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.445 ' O ' HG23 ' A' ' 18' ' ' ILE . 19.4 mttm -99.52 139.53 35.05 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.38 -1.071 . . . . 0.0 108.539 179.295 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.738 HG23 ' O ' ' A' ' 45' ' ' GLN . 20.7 t -69.91 115.22 8.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.039 -1.038 . . . . 0.0 109.776 -179.464 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.437 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 40.7 tttt -78.76 -42.13 28.81 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.726 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.63 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -160.14 154.93 24.28 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.43 -0.794 . . . . 0.0 108.888 179.976 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.46 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 11.3 p90 -154.25 141.74 19.76 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.101 -0.999 . . . . 0.0 109.193 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.48 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 57.9 t-20 -129.79 133.57 47.05 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.151 -0.968 . . . . 0.0 109.832 -179.62 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 12.5 p -78.63 -21.2 48.79 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.125 -0.984 . . . . 0.0 108.906 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.429 ' HB2' ' ND2' ' A' ' 10' ' ' ASN . 92.8 mt-10 -65.52 -44.63 86.34 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 106.657 -1.609 . . . . 0.0 106.657 177.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.67 ' HD3' ' CE2' ' A' ' 15' ' ' PHE . 16.1 mttm -75.36 -37.7 60.5 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.363 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.513 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 91.01 1.47 72.85 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 179.542 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.67 ' CE2' ' HD3' ' A' ' 13' ' ' LYS . 4.0 p90 -138.38 169.95 16.88 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.098 -1.236 . . . . 0.0 108.937 179.118 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.63 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -138.63 175.21 21.61 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 119.625 -1.274 . . . . 0.0 109.97 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.483 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 37.6 m-85 -116.7 132.49 56.67 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.404 -1.057 . . . . 0.0 109.014 179.696 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 1.066 ' CD1' HG21 ' A' ' 28' ' ' VAL . 37.1 mt -116.89 148.7 19.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.141 -0.974 . . . . 0.0 109.528 -179.827 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 30.6 tp10 -110.29 121.31 44.98 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.332 -0.855 . . . . 0.0 109.448 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.731 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.4 t -96.22 120.02 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.163 -0.961 . . . . 0.0 109.471 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 47.1 mp0 -71.75 109.01 5.36 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.273 -0.892 . . . . 0.0 109.36 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.428 ' C ' ' HG3' ' A' ' 23' ' ' GLN . . . 125.28 -20.46 6.61 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.783 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.428 ' HG3' ' C ' ' A' ' 22' ' ' GLY . 37.3 mt-30 -138.83 169.62 17.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.317 -1.107 . . . . 0.0 109.695 -179.811 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -53.54 -177.4 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.32 -0.862 . . . . 0.0 109.665 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.516 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 11.0 p30 -75.97 143.54 41.49 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.287 -0.883 . . . . 0.0 109.661 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.631 HG12 ' HB2' ' A' ' 60' ' ' ALA . 79.7 t -116.92 120.87 66.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.23 -0.919 . . . . 0.0 109.527 -179.845 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.553 ' CG ' ' N ' ' A' ' 28' ' ' VAL . 0.3 OUTLIER -80.26 161.11 25.3 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.373 179.953 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 1.066 HG21 ' CD1' ' A' ' 18' ' ' ILE . 15.0 t -135.7 125.02 40.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.428 -0.795 . . . . 0.0 109.4 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.688 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 15.1 t-80 -96.2 154.35 17.3 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.231 -0.918 . . . . 0.0 109.14 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.688 ' CD2' ' CE1' ' A' ' 29' ' ' HIS . 0.7 OUTLIER -45.8 -53.41 9.66 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.105 -0.997 . . . . 0.0 109.245 -179.616 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.685 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 86.8 p -55.66 -27.24 48.84 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.171 -0.956 . . . . 0.0 109.982 -179.618 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.432 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -64.41 -35.94 82.52 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.995 -1.066 . . . . 0.0 109.159 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.639 HG12 HG11 ' A' ' 63' ' ' VAL . 5.1 mt -91.97 147.85 5.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.228 -0.92 . . . . 0.0 109.349 179.777 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 69.3 mt-30 -125.45 145.51 50.04 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.213 -0.93 . . . . 0.0 109.449 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.605 ' CA ' ' CZ ' ' A' ' 38' ' ' PHE . . . -179.35 161.78 28.09 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -77.34 -36.87 53.41 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.232 -1.158 . . . . 0.0 109.523 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -150.58 17.13 0.98 Allowed Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.605 ' CZ ' ' CA ' ' A' ' 35' ' ' GLY . 44.4 p90 -127.44 49.83 2.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.269 -1.136 . . . . 0.0 109.502 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 46.4 mtpt -66.56 -30.26 70.52 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.2 -0.938 . . . . 0.0 109.567 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.405 HG22 ' CD2' ' A' ' 9' ' ' PHE . 36.6 m -72.89 111.21 7.81 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.283 -0.886 . . . . 0.0 109.642 -179.754 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.557 HD21 HG11 ' A' ' 47' ' ' VAL . 1.1 mt -59.69 174.68 0.43 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.262 -0.899 . . . . 0.0 109.575 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.499 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 46.3 tp10 -123.18 147.13 47.18 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.203 -0.936 . . . . 0.0 109.56 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.437 ' HG3' ' O ' ' A' ' 7' ' ' LYS . 76.0 tt0 -73.35 126.01 29.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.196 -0.94 . . . . 0.0 109.739 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.75 -5.45 79.62 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.738 ' O ' HG23 ' A' ' 6' ' ' VAL . 48.4 tp60 -81.22 124.4 29.26 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.196 -1.179 . . . . 0.0 109.601 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -75.09 144.61 42.84 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.263 -0.898 . . . . 0.0 109.154 179.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.832 HG12 ' HA ' ' A' ' 65' ' ' LYS . 21.7 m -148.36 168.11 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.177 -0.952 . . . . 0.0 109.827 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.545 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 4.1 p -112.48 152.76 28.37 Favored 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.325 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.579 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 14.4 p90 175.83 164.42 0.36 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.979 -1.076 . . . . 0.0 110.141 -179.781 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.425 ' HA ' HD13 ' A' ' 2' ' ' LEU . 91.9 mt-10 -100.36 164.6 11.86 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 179.016 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.424 ' O ' HG22 ' A' ' 51' ' ' ILE . 0.4 OUTLIER -101.77 124.36 55.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 120.851 -1.156 . . . . 0.0 109.422 -179.903 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.559 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.1 m -111.1 123.57 67.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.401 -0.812 . . . . 0.0 109.011 179.764 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.417 ' HA ' ' HA ' ' A' ' 58' ' ' PRO . 10.2 mt-10 -94.97 91.12 6.23 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.177 -0.952 . . . . 0.0 109.948 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.08 -174.88 42.37 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 179.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -54.37 -62.39 1.69 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.171 -1.194 . . . . 0.0 109.546 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 18.8 mtm180 -46.66 -41.23 14.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.157 -0.964 . . . . 0.0 109.194 179.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 152.99 -161.53 29.65 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.552 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 53.6 Cg_endo -72.09 144.12 41.65 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.712 2.275 . . . . 0.0 111.752 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.559 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 78.8 mt-30 -141.82 172.36 12.79 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.289 -0.882 . . . . 0.0 109.048 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.631 ' HB2' HG12 ' A' ' 26' ' ' VAL . . . -94.23 142.55 27.28 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.139 -0.976 . . . . 0.0 110.236 -179.234 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.512 ' O ' ' C ' ' A' ' 62' ' ' ASN . . . -124.43 152.85 42.77 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.434 -0.791 . . . . 0.0 108.903 179.578 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.512 ' C ' ' O ' ' A' ' 61' ' ' ALA . 44.8 t30 38.62 73.91 0.1 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.07 -1.019 . . . . 0.0 109.186 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.639 HG11 HG12 ' A' ' 33' ' ' ILE . 1.5 t -86.97 129.22 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.245 -0.909 . . . . 0.0 109.96 -179.313 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.432 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 65.3 m -115.44 119.53 36.54 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.35 -0.843 . . . . 0.0 109.116 179.645 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.832 ' HA ' HG12 ' A' ' 47' ' ' VAL . 35.9 mttt -69.73 108.17 3.79 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 109.286 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.45 ' HG3' ' HA ' ' A' ' 47' ' ' VAL . 97.2 mt-10 -87.4 164.09 16.4 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.272 -0.892 . . . . 0.0 109.725 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.562 0 CA-C-O 117.989 -1.005 . . . . 0.0 109.58 -179.955 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 71.2 mtm . . . . . 0 N--CA 1.489 1.51 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 45.5 mt -108.61 166.24 10.94 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.233 -0.917 . . . . 0.0 109.541 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.66 ' O ' HG13 ' A' ' 20' ' ' VAL . 89.1 mt-10 -136.13 136.54 40.17 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.241 -0.912 . . . . 0.0 109.26 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -133.78 159.42 23.7 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.626 ' O ' HG23 ' A' ' 18' ' ' ILE . 77.9 mttt -103.34 140.84 36.9 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.409 -1.053 . . . . 0.0 108.824 179.41 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.761 HG23 ' O ' ' A' ' 45' ' ' GLN . 18.9 t -73.73 114.2 12.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.116 -0.99 . . . . 0.0 110.241 -179.111 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.4 tttt -78.44 -41.45 32.79 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.671 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.78 153.89 25.32 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.553 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.629 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 6.2 p90 -156.05 141.65 17.8 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.986 -1.071 . . . . 0.0 109.764 -179.61 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.435 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 50.4 t-20 -127.17 126.03 42.14 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.276 -0.89 . . . . 0.0 108.992 179.528 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 41.5 p -78.54 -12.99 60.04 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.198 -0.939 . . . . 0.0 109.594 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -59.26 -58.78 7.13 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 178.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.573 ' HD2' ' CE2' ' A' ' 15' ' ' PHE . 34.0 mtmt -72.08 -44.94 62.48 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.606 ' O ' ' CB ' ' A' ' 30' ' ' PHE . . . 112.1 19.36 7.24 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 120.035 -1.078 . . . . 0.0 110.651 178.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.603 ' HB2' ' O ' ' A' ' 28' ' ' VAL . 50.2 p90 -148.85 172.64 14.33 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.795 -1.414 . . . . 0.0 109.187 179.518 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.671 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -149.53 174.96 28.92 Favored Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.53 -1.319 . . . . 0.0 110.206 -179.477 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.433 ' CE1' ' HB2' ' A' ' 27' ' ' PHE . 49.6 m-85 -111.9 133.75 53.9 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.446 -1.032 . . . . 0.0 108.834 179.644 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 1.137 HD12 ' CG2' ' A' ' 28' ' ' VAL . 19.7 mt -120.4 149.43 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.207 -0.933 . . . . 0.0 109.489 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 20.7 tp10 -113.28 122.44 47.44 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.351 -0.843 . . . . 0.0 109.332 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.66 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.8 t -91.75 121.9 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.253 -0.904 . . . . 0.0 109.525 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -69.36 108.5 3.74 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.333 -0.854 . . . . 0.0 109.325 179.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.07 -19.72 8.7 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.403 ' OE1' HG11 ' A' ' 20' ' ' VAL . 49.0 mt-30 -133.47 166.18 23.14 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.289 -1.124 . . . . 0.0 109.487 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 59.5 m-20 -54.79 -175.74 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.235 -0.916 . . . . 0.0 109.45 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.493 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 11.2 p30 -75.84 143.78 41.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.291 -0.881 . . . . 0.0 109.577 -179.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.573 HG21 HG21 ' A' ' 20' ' ' VAL . 79.3 t -118.85 121.42 66.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.184 -0.947 . . . . 0.0 109.374 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.504 ' O ' ' N ' ' A' ' 60' ' ' ALA . 0.1 OUTLIER -79.03 158.26 27.93 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.266 -0.896 . . . . 0.0 109.392 -179.984 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 1.137 ' CG2' HD12 ' A' ' 18' ' ' ILE . 17.3 t -132.85 132.38 59.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.428 -0.795 . . . . 0.0 109.165 -179.76 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.678 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 14.6 t-80 -104.61 154.89 19.37 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.256 -0.903 . . . . 0.0 109.277 -179.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.693 ' CD1' ' N ' ' A' ' 31' ' ' SER . 0.6 OUTLIER -46.3 -53.01 11.56 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.215 -0.928 . . . . 0.0 109.361 -179.696 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.693 ' N ' ' CD1' ' A' ' 30' ' ' PHE . 91.4 p -60.16 -21.19 61.35 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.095 -1.003 . . . . 0.0 110.025 -179.631 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.473 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -63.19 -23.6 67.5 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.042 -1.036 . . . . 0.0 109.468 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.782 ' CD1' HD11 ' A' ' 41' ' ' LEU . 3.5 mp -111.18 136.47 47.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.206 -0.934 . . . . 0.0 109.605 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 74.7 mt-30 -92.66 145.28 24.54 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.245 -0.909 . . . . 0.0 109.51 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.603 ' HA2' ' CE1' ' A' ' 38' ' ' PHE . . . 161.04 148.74 5.38 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -71.16 -47.68 56.3 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.345 -1.091 . . . . 0.0 109.629 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -141.28 19.95 2.64 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.603 ' CE1' ' HA2' ' A' ' 35' ' ' GLY . 50.7 p90 -129.27 26.95 5.39 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.288 -1.125 . . . . 0.0 109.435 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.443 ' O ' ' HB ' ' A' ' 33' ' ' ILE . 77.3 mttt -60.22 -37.57 80.72 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.211 -0.931 . . . . 0.0 109.654 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 29.5 p -62.54 145.47 54.24 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.228 -0.92 . . . . 0.0 109.634 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 1.026 HD23 HG11 ' A' ' 47' ' ' VAL . 3.0 mp -98.35 -174.29 2.79 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.259 -0.901 . . . . 0.0 109.281 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.523 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.1 tt0 -121.61 150.63 41.42 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.26 -0.9 . . . . 0.0 109.338 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 61.5 tt0 -67.44 124.23 22.62 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.23 -0.919 . . . . 0.0 109.538 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 90.96 -3.58 80.93 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 179.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.761 ' O ' HG23 ' A' ' 6' ' ' VAL . 61.4 tp60 -81.71 131.6 35.27 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.18 -1.189 . . . . 0.0 109.603 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -76.54 140.16 41.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.187 -0.946 . . . . 0.0 109.204 179.741 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 1.026 HG11 HD23 ' A' ' 41' ' ' LEU . 33.8 m -141.26 159.96 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.151 -0.968 . . . . 0.0 109.532 -179.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.499 ' O ' ' HB3' ' A' ' 49' ' ' PHE . 43.4 m -112.86 155.62 24.36 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.385 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.585 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 3.7 p90 171.69 166.48 0.09 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.037 -1.039 . . . . 0.0 110.144 -179.692 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -97.82 157.53 16.02 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 178.729 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.4 mt -98.12 128.1 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.985 -1.072 . . . . 0.0 110.006 -179.473 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.765 HG23 ' HB2' ' A' ' 59' ' ' GLN . 0.3 OUTLIER -110.07 119.68 59.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.366 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -89.01 91.44 8.83 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.203 -0.936 . . . . 0.0 109.872 -179.446 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -97.23 -176.2 34.58 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -53.57 -61.59 2.2 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.178 -1.189 . . . . 0.0 109.663 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 61.3 mtp180 -47.9 -38.88 17.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.232 -0.917 . . . . 0.0 109.049 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.86 -157.3 27.3 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.447 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 51.3 Cg_endo -71.06 140.78 38.54 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.719 2.279 . . . . 0.0 111.692 179.806 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.765 ' HB2' HG23 ' A' ' 52' ' ' VAL . 91.8 mt-30 -135.51 167.78 20.44 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.21 -0.931 . . . . 0.0 109.232 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.651 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -96.42 137.58 35.28 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.18 -0.95 . . . . 0.0 110.158 -179.354 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.585 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -125.18 156.67 38.06 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.466 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.524 ' C ' ' O ' ' A' ' 61' ' ' ALA . 80.7 m-20 38.68 74.56 0.09 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.075 -1.016 . . . . 0.0 108.927 -179.765 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.971 HG11 HD21 ' A' ' 41' ' ' LEU . 2.4 t -89.32 129.62 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.234 -0.916 . . . . 0.0 110.307 -178.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 60.8 m -118.54 124.66 48.07 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.513 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.411 ' HE3' ' O ' ' A' ' 38' ' ' PHE . 53.2 mttt -67.18 107.37 2.31 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.245 -0.91 . . . . 0.0 109.281 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.412 ' HG3' ' OG ' ' A' ' 48' ' ' SER . 59.4 mm-40 -97.09 170.58 9.03 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.157 -0.964 . . . . 0.0 109.622 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.406 179.989 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 78.2 mtp . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.469 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 71.6 mt -112.98 164.07 13.9 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.254 -0.904 . . . . 0.0 109.539 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.615 ' O ' HG13 ' A' ' 20' ' ' VAL . 1.4 tt0 -130.75 140.89 50.35 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.34 -0.85 . . . . 0.0 109.329 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.49 155.06 25.05 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.584 ' O ' HG23 ' A' ' 18' ' ' ILE . 84.5 mttt -104.14 139.51 39.09 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.317 -1.108 . . . . 0.0 108.764 179.553 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.86 HG23 ' O ' ' A' ' 45' ' ' GLN . 16.0 t -72.22 113.16 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.097 -1.002 . . . . 0.0 110.085 -179.223 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.3 tttt -78.85 -40.87 31.49 Favored 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 179.546 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.607 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.96 154.41 25.82 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.812 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.601 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 8.2 p90 -155.59 141.27 17.95 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.026 -1.046 . . . . 0.0 109.315 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.46 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 63.2 t-20 -131.48 129.41 41.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.166 -0.959 . . . . 0.0 109.777 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 59.6 p -77.0 -20.38 56.13 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.285 -0.885 . . . . 0.0 109.083 179.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -62.49 -48.07 81.2 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 106.803 -1.555 . . . . 0.0 106.803 178.128 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.669 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 3.7 mttp -73.33 -39.31 65.35 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.57 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.529 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 97.26 5.06 58.26 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 179.395 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.669 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 5.6 p90 -143.1 165.79 26.44 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.162 -1.199 . . . . 0.0 108.994 179.292 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.607 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -134.71 174.54 21.0 Favored Glycine 0 N--CA 1.491 2.349 0 C-N-CA 119.708 -1.234 . . . . 0.0 110.087 -179.438 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.49 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 26.1 m-85 -115.75 137.94 51.6 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.463 -1.022 . . . . 0.0 109.215 179.755 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 1.129 HD12 ' CG2' ' A' ' 28' ' ' VAL . 12.5 mt -123.69 154.06 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.161 -0.962 . . . . 0.0 109.491 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -117.98 116.06 26.15 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.313 -0.867 . . . . 0.0 109.503 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.622 HG21 HG21 ' A' ' 26' ' ' VAL . 2.4 t -85.33 118.4 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.276 -0.89 . . . . 0.0 109.353 179.789 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 85.4 mt-10 -68.43 111.08 4.45 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.196 -0.94 . . . . 0.0 109.243 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.451 ' C ' ' HG3' ' A' ' 23' ' ' GLN . . . 120.93 -15.66 9.51 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.495 ' OE1' HD12 ' A' ' 51' ' ' ILE . 49.5 mt-30 -140.68 169.75 17.05 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.222 -1.164 . . . . 0.0 109.622 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 60.5 m-20 -54.75 -179.21 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.254 -0.904 . . . . 0.0 109.681 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.461 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 18.4 p30 -75.41 144.0 42.44 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.307 -0.871 . . . . 0.0 109.706 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.622 HG21 HG21 ' A' ' 20' ' ' VAL . 86.4 t -118.38 118.8 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.224 -0.923 . . . . 0.0 109.263 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.586 ' CD1' ' N ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER -77.31 159.0 29.88 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.152 -0.967 . . . . 0.0 109.154 -179.935 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 1.129 ' CG2' HD12 ' A' ' 18' ' ' ILE . 13.6 t -134.08 131.43 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.356 -0.84 . . . . 0.0 109.393 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.664 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 17.4 t-80 -106.97 154.64 20.79 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.313 -0.867 . . . . 0.0 109.027 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.676 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -46.47 -53.36 11.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.023 -1.048 . . . . 0.0 109.205 -179.631 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.676 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 54.6 p -53.91 -30.75 47.57 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.155 -0.966 . . . . 0.0 110.347 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.485 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -61.83 -21.24 64.47 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.029 -1.045 . . . . 0.0 109.465 -179.856 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.932 ' CD1' HD11 ' A' ' 41' ' ' LEU . 3.2 mp -111.79 129.04 67.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.204 -0.935 . . . . 0.0 109.506 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.7 mt-30 -111.52 144.06 41.36 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.193 -0.942 . . . . 0.0 109.267 179.772 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.639 ' HA3' ' CZ ' ' A' ' 38' ' ' PHE . . . 176.3 169.28 37.57 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -56.5 -47.63 78.89 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.285 -1.127 . . . . 0.0 109.354 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -170.77 37.98 0.18 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.639 ' CZ ' ' HA3' ' A' ' 35' ' ' GLY . 18.3 p90 -126.24 14.46 7.78 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.154 -1.204 . . . . 0.0 109.545 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.451 ' C ' ' O ' ' A' ' 38' ' ' PHE . 20.0 mtmm -41.49 -40.93 1.94 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.259 -0.9 . . . . 0.0 109.703 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.43 ' O ' ' HE2' ' A' ' 65' ' ' LYS . 23.9 m -52.89 124.59 14.51 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.234 -0.916 . . . . 0.0 109.527 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.932 HD11 ' CD1' ' A' ' 33' ' ' ILE . 5.3 mp -85.61 170.49 12.51 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.323 -0.861 . . . . 0.0 109.272 179.828 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.511 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.7 tt0 -117.31 149.78 39.9 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.181 -0.949 . . . . 0.0 109.055 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 62.8 tt0 -70.52 123.97 23.08 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.253 -0.904 . . . . 0.0 109.584 -179.778 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 92.89 -3.41 73.79 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 179.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.86 ' O ' HG23 ' A' ' 6' ' ' VAL . 60.7 tt0 -82.74 134.95 35.12 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.119 -1.224 . . . . 0.0 109.906 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -81.1 141.56 34.17 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.399 -0.813 . . . . 0.0 109.067 179.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.785 HG21 HD13 ' A' ' 18' ' ' ILE . 28.1 m -141.51 159.57 21.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.131 -0.981 . . . . 0.0 109.922 -179.529 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.506 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 23.0 t -110.89 154.06 24.58 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.424 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.56 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 5.6 p90 172.26 166.14 0.11 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.01 -1.056 . . . . 0.0 110.077 -179.746 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.431 ' HB2' ' HB3' ' A' ' 61' ' ' ALA . 93.6 mt-10 -98.98 160.55 14.18 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.495 HD12 ' OE1' ' A' ' 23' ' ' GLN . 0.8 OUTLIER -97.94 125.41 51.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 120.933 -1.105 . . . . 0.0 109.781 -179.436 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.595 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 0.1 OUTLIER -107.85 118.95 56.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.473 -0.767 . . . . 0.0 109.076 179.852 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -86.76 84.78 7.3 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.314 -0.866 . . . . 0.0 109.704 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.43 -177.31 41.61 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.3 t30 -54.2 -61.98 1.96 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.219 -1.165 . . . . 0.0 109.563 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 39.7 mtp180 -48.32 -39.36 21.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.285 -0.884 . . . . 0.0 109.135 179.794 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 148.81 -158.86 27.82 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.595 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 49.8 Cg_endo -70.23 140.44 40.92 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.686 2.257 . . . . 0.0 111.716 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.571 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 8.5 mt-30 -133.88 166.25 23.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.318 -0.864 . . . . 0.0 109.37 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.648 ' HB2' HG22 ' A' ' 28' ' ' VAL . . . -87.58 128.4 35.26 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.308 -0.87 . . . . 0.0 109.871 -179.573 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.56 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -112.74 146.45 38.74 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.35 -0.844 . . . . 0.0 108.812 179.457 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.472 ' C ' ' O ' ' A' ' 61' ' ' ALA . 62.5 t30 42.82 71.9 0.2 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.046 -1.034 . . . . 0.0 108.776 -179.615 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.688 HG12 HG23 ' A' ' 33' ' ' ILE . 2.0 t -83.82 127.1 40.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.365 -0.834 . . . . 0.0 110.162 -178.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 93.9 m -119.79 127.04 52.42 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.449 -0.782 . . . . 0.0 109.016 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.907 ' NZ ' HG21 ' A' ' 33' ' ' ILE . 55.1 mttp -77.46 112.78 14.57 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.172 -0.955 . . . . 0.0 109.726 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -89.82 165.11 14.34 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.902 . . . . 0.0 109.428 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 118.009 -0.996 . . . . 0.0 109.41 -179.999 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.625 ' C ' HD12 ' A' ' 2' ' ' LEU . 90.9 mmm . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 121.275 0.56 . . . . 0.0 109.546 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.736 ' N ' HD12 ' A' ' 2' ' ' LEU . 6.2 mp -113.63 156.76 23.12 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.22 -0.925 . . . . 0.0 109.547 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.495 ' HG2' ' O ' ' A' ' 47' ' ' VAL . 3.0 tt0 -133.39 132.53 41.3 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.306 -0.871 . . . . 0.0 109.217 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.515 ' C ' ' CG2' ' A' ' 18' ' ' ILE . . . -135.63 167.6 24.19 Favored Glycine 0 N--CA 1.491 2.342 0 C-N-CA 119.632 -1.27 . . . . 0.0 110.229 -179.602 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.682 ' C ' HG23 ' A' ' 18' ' ' ILE . 44.0 mmtm -110.39 135.63 50.81 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.544 -0.974 . . . . 0.0 108.693 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.709 HG23 ' O ' ' A' ' 45' ' ' GLN . 17.6 t -68.5 116.14 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.19 -0.944 . . . . 0.0 109.973 -179.556 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.432 ' N ' ' O ' ' A' ' 17' ' ' PHE . 11.5 tttm -80.38 -33.69 37.0 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 179.303 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.671 ' CD2' ' N ' ' A' ' 9' ' ' PHE . 0.4 OUTLIER -162.57 166.41 24.74 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 179.671 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.671 ' N ' ' CD2' ' A' ' 8' ' ' TRP . 9.9 p90 -164.47 145.93 8.32 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.94 -1.1 . . . . 0.0 110.601 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.653 ' HB3' ' CE1' ' A' ' 15' ' ' PHE . 38.0 t-20 -103.14 139.14 39.04 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.391 -0.818 . . . . 0.0 109.615 179.741 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 97.5 p -84.7 -14.07 49.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.184 -0.947 . . . . 0.0 109.934 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 65.5 tt0 -58.61 -63.21 1.36 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.087 -1.008 . . . . 0.0 109.219 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.636 ' HB2' ' CD1' ' A' ' 15' ' ' PHE . 20.1 mttm -96.52 -20.7 18.18 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.347 -0.845 . . . . 0.0 109.542 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.567 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 86.56 68.58 1.34 Allowed Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 179.748 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.653 ' CE1' ' HB3' ' A' ' 10' ' ' ASN . 1.4 p90 -154.3 172.89 16.94 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.219 -1.165 . . . . 0.0 108.725 179.468 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.607 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -176.75 151.18 10.99 Favored Glycine 0 N--CA 1.487 2.076 0 C-N-CA 119.447 -1.359 . . . . 0.0 110.026 -179.871 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.474 ' HB3' ' OD1' ' A' ' 25' ' ' ASP . 89.4 m-85 -79.08 143.18 35.8 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.369 -1.077 . . . . 0.0 108.803 179.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 1.143 ' CD1' HG21 ' A' ' 28' ' ' VAL . 73.3 mt -121.84 149.17 25.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 -179.786 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.403 ' N ' ' O ' ' A' ' 5' ' ' LYS . 44.5 tt0 -103.7 118.49 36.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.199 -0.938 . . . . 0.0 109.529 -179.852 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.599 HG21 HG21 ' A' ' 26' ' ' VAL . 3.4 t -94.32 123.51 46.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.255 -0.903 . . . . 0.0 109.417 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -59.08 99.93 0.06 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.303 -0.873 . . . . 0.0 109.674 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.25 -29.04 3.54 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 179.623 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 15.0 mt-30 -127.05 169.86 12.93 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.133 -1.216 . . . . 0.0 109.739 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.533 ' N ' ' OD1' ' A' ' 24' ' ' ASP . 0.0 OUTLIER -60.24 -163.41 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.237 -0.914 . . . . 0.0 109.553 179.753 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.474 ' OD1' ' HB3' ' A' ' 17' ' ' PHE . 2.9 t70 -77.53 143.64 38.25 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.285 -0.884 . . . . 0.0 109.713 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.599 HG21 HG21 ' A' ' 20' ' ' VAL . 88.4 t -115.95 127.14 73.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.371 -0.831 . . . . 0.0 109.367 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.1 OUTLIER -76.47 148.23 37.35 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.118 -0.988 . . . . 0.0 109.636 -179.791 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 1.143 HG21 ' CD1' ' A' ' 18' ' ' ILE . 16.5 t -131.14 131.44 63.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 -179.79 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.672 ' CE1' ' CE2' ' A' ' 30' ' ' PHE . 12.1 t-80 -102.68 148.33 25.72 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.083 -1.011 . . . . 0.0 109.924 -179.529 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.688 ' O ' HD12 ' A' ' 33' ' ' ILE . 1.1 p90 -43.57 -51.83 6.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.307 -0.871 . . . . 0.0 109.519 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.672 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 46.5 p -61.27 -13.58 19.9 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.168 -0.957 . . . . 0.0 109.801 -179.701 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.517 ' N ' ' O ' ' A' ' 29' ' ' HIS . . . -66.68 -25.23 66.45 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.265 -0.897 . . . . 0.0 109.642 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.034 HD11 HD11 ' A' ' 41' ' ' LEU . 2.2 mp -93.49 141.78 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.257 -0.902 . . . . 0.0 109.725 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.458 ' O ' ' HD2' ' A' ' 39' ' ' LYS . 85.6 mt-30 -43.79 151.37 0.21 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.3 -0.875 . . . . 0.0 109.672 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.59 ' HA3' ' CE1' ' A' ' 38' ' ' PHE . . . 115.11 167.21 15.3 Favored Glycine 0 N--CA 1.486 2.004 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -82.03 6.46 16.1 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.296 -1.12 . . . . 0.0 109.062 179.584 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.467 ' HA2' ' HD1' ' A' ' 30' ' ' PHE . . . 117.72 21.17 4.36 Favored Glycine 0 N--CA 1.487 2.099 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 -179.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.59 ' CE1' ' HA3' ' A' ' 35' ' ' GLY . 29.7 p90 -94.98 -11.32 28.69 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.362 -1.081 . . . . 0.0 109.685 -179.84 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.533 ' CE ' ' CZ ' ' A' ' 38' ' ' PHE . 61.3 mttt -90.86 129.37 36.91 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.197 -0.94 . . . . 0.0 109.599 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 46.5 m -114.01 127.36 55.91 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.296 -0.878 . . . . 0.0 109.368 179.733 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 1.034 HD11 HD11 ' A' ' 33' ' ' ILE . 1.1 mt -68.36 152.04 46.01 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.278 -0.889 . . . . 0.0 109.614 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.478 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 80.2 tt0 -117.42 150.76 38.35 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.341 -0.85 . . . . 0.0 109.249 179.84 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 68.4 tt0 -68.33 128.07 35.25 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.914 . . . . 0.0 109.571 -179.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 86.77 -2.94 87.33 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 179.733 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.709 ' O ' HG23 ' A' ' 6' ' ' VAL . 51.8 tt0 -80.44 134.62 36.01 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.203 -1.175 . . . . 0.0 109.715 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -87.55 142.52 27.79 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.299 -0.876 . . . . 0.0 109.169 179.689 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.963 HG12 ' HA ' ' A' ' 65' ' ' LYS . 32.9 m -147.06 167.06 5.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.232 -0.918 . . . . 0.0 109.864 -179.734 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.592 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 24.0 t -109.15 154.77 21.87 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 178.838 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.587 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 8.1 p90 172.15 168.59 0.11 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.003 -1.061 . . . . 0.0 110.034 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.491 ' HA ' HD13 ' A' ' 2' ' ' LEU . 90.2 mt-10 -105.99 169.24 8.61 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 179.173 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.449 HD11 HG21 ' A' ' 26' ' ' VAL . 4.2 mt -111.02 136.87 45.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.022 -1.049 . . . . 0.0 109.546 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.487 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 33.7 m -123.04 134.36 66.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.465 -0.772 . . . . 0.0 108.942 179.727 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -90.49 79.64 6.18 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.139 -0.975 . . . . 0.0 109.613 -179.778 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -81.3 -179.5 53.04 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -52.45 -57.15 10.79 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.177 -1.19 . . . . 0.0 109.559 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 82.1 mtm180 -54.19 -38.17 65.32 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.163 -0.96 . . . . 0.0 109.599 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.08 -153.34 25.29 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.487 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 50.9 Cg_endo -70.76 133.76 24.41 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.867 2.378 . . . . 0.0 112.146 -179.825 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 83.7 mt-30 -133.53 164.66 26.65 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.356 -0.84 . . . . 0.0 109.032 179.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.705 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -92.72 136.93 32.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.119 -0.988 . . . . 0.0 110.104 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.587 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -121.14 153.06 38.01 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 179.376 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.499 ' O ' ' HA ' ' A' ' 49' ' ' PHE . 85.0 m-20 43.86 79.41 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.962 -1.086 . . . . 0.0 108.702 -179.557 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.873 HG21 ' CG1' ' A' ' 28' ' ' VAL . 2.1 t -94.63 124.34 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.161 -0.962 . . . . 0.0 110.195 -179.059 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.497 ' HB ' ' HB3' ' A' ' 48' ' ' SER . 97.1 m -114.16 114.96 26.74 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.49 -0.756 . . . . 0.0 109.055 179.576 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.963 ' HA ' HG12 ' A' ' 47' ' ' VAL . 56.5 mttt -65.02 118.4 9.07 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.335 -0.853 . . . . 0.0 109.426 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 67.1 mm-40 -102.38 162.56 12.82 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.378 -0.826 . . . . 0.0 109.732 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.462 -179.957 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.447 ' HA ' ' OE2' ' A' ' 50' ' ' GLU . 47.7 mtt . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.25 0.548 . . . . 0.0 109.574 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.519 HD12 HD13 ' A' ' 51' ' ' ILE . 26.5 mt -103.6 173.14 6.43 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.292 -0.88 . . . . 0.0 109.385 179.811 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.507 ' O ' HG13 ' A' ' 20' ' ' VAL . 74.1 mt-10 -133.82 134.69 43.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.268 -0.895 . . . . 0.0 109.441 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -139.7 157.09 25.1 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.705 -1.358 . . . . 0.0 109.705 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.414 ' N ' HG23 ' A' ' 18' ' ' ILE . 69.6 mttt -111.21 133.69 53.37 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.435 -1.038 . . . . 0.0 108.438 179.189 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.923 HG23 ' O ' ' A' ' 45' ' ' GLN . 16.2 t -64.05 115.18 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.113 -0.992 . . . . 0.0 110.118 -179.328 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.474 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 14.9 tptp -78.12 -42.04 33.16 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 179.508 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.612 ' CE3' ' O ' ' A' ' 8' ' ' TRP . 0.0 OUTLIER -162.29 156.07 21.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.499 -0.751 . . . . 0.0 109.093 179.99 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.641 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 10.6 p90 -154.16 140.53 18.68 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.13 -0.981 . . . . 0.0 109.041 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.58 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 54.5 t-20 -109.81 115.54 30.03 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.13 -0.981 . . . . 0.0 109.499 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 82.3 p -59.53 -20.27 54.27 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.222 -0.924 . . . . 0.0 109.485 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.7 tt0 -82.94 -39.18 21.76 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.186 -0.946 . . . . 0.0 109.354 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.614 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 23.7 mttp -68.71 -45.5 71.41 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.285 -0.884 . . . . 0.0 109.486 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.495 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 106.09 0.77 38.66 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.621 ' N ' ' CD1' ' A' ' 15' ' ' PHE . 0.3 OUTLIER -143.78 -176.22 4.89 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.112 -1.228 . . . . 0.0 109.288 179.779 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.567 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -155.41 176.85 32.88 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 109.531 -1.427 . . . . 0.0 109.531 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.527 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 43.6 m-85 -113.79 133.3 55.47 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.248 -1.148 . . . . 0.0 109.187 179.789 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 1.096 ' CD1' HG21 ' A' ' 28' ' ' VAL . 61.7 mt -116.18 145.43 21.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.388 -0.82 . . . . 0.0 109.722 -179.669 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 28.7 tt0 -108.09 116.5 32.07 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.415 -0.803 . . . . 0.0 109.495 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.621 HG21 HG21 ' A' ' 26' ' ' VAL . 2.8 t -87.96 125.93 41.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.295 -0.878 . . . . 0.0 109.422 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -69.85 101.62 1.77 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.293 -0.879 . . . . 0.0 109.221 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.22 -22.97 6.97 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 -179.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.429 ' O ' ' O ' ' A' ' 24' ' ' ASP . 12.6 mt-30 -123.28 158.81 30.12 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.364 -1.08 . . . . 0.0 109.322 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.429 ' O ' ' O ' ' A' ' 23' ' ' GLN . 44.8 m-20 -54.81 -171.24 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.19 -0.944 . . . . 0.0 109.452 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.565 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 88.6 m-20 -73.73 133.25 43.3 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.196 -0.94 . . . . 0.0 109.533 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.664 HG21 HD11 ' A' ' 51' ' ' ILE . 96.0 t -111.06 125.24 68.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.256 -0.903 . . . . 0.0 109.234 -179.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.573 ' CE1' ' O ' ' A' ' 28' ' ' VAL . 0.1 OUTLIER -79.28 159.64 27.16 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.052 -1.03 . . . . 0.0 109.747 -179.716 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 1.096 HG21 ' CD1' ' A' ' 18' ' ' ILE . 57.8 t -133.95 137.95 51.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.432 -0.792 . . . . 0.0 109.419 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.604 ' O ' HD12 ' A' ' 33' ' ' ILE . 21.7 t-80 -111.23 150.59 29.37 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.291 -0.88 . . . . 0.0 108.899 179.593 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.713 ' CG ' ' N ' ' A' ' 31' ' ' SER . 1.3 p90 -48.09 -54.21 13.94 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.046 -1.034 . . . . 0.0 109.298 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.713 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 19.2 t -55.96 -30.55 61.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.025 -1.047 . . . . 0.0 109.899 -179.441 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.58 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -63.66 -17.56 63.06 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.021 -1.049 . . . . 0.0 108.544 179.505 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.026 HG23 HG12 ' A' ' 63' ' ' VAL . 0.6 OUTLIER -118.08 145.28 24.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.607 -0.683 . . . . 0.0 109.434 -179.86 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 90.6 mt-30 -123.21 159.47 28.6 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.147 -0.971 . . . . 0.0 109.633 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.742 ' HA3' ' CE1' ' A' ' 38' ' ' PHE . . . 150.06 156.33 7.22 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 90.6 mt-10 -119.92 118.71 31.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.266 -1.138 . . . . 0.0 109.294 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 99.5 -5.46 58.7 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.875 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.742 ' CE1' ' HA3' ' A' ' 35' ' ' GLY . 38.0 p90 -152.52 38.33 0.54 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.164 -1.198 . . . . 0.0 109.57 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 7.5 mtpt -63.27 -25.57 68.38 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.18 -0.95 . . . . 0.0 109.444 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 70.1 p -75.11 126.09 30.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.246 -0.909 . . . . 0.0 109.462 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.681 HD12 ' HZ1' ' A' ' 65' ' ' LYS . 5.2 mp -72.25 141.12 48.94 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.249 -0.907 . . . . 0.0 109.745 -179.826 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.444 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.2 tt0 -96.98 132.28 42.95 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.237 -0.914 . . . . 0.0 109.528 -179.852 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.474 ' OE2' ' O ' ' A' ' 7' ' ' LYS . 75.1 tt0 -59.51 129.01 39.88 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.318 -0.864 . . . . 0.0 109.343 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 93.74 -8.06 74.0 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.923 ' O ' HG23 ' A' ' 6' ' ' VAL . 70.6 tp60 -78.41 126.33 30.62 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.162 -1.199 . . . . 0.0 109.596 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -82.88 143.26 30.87 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.251 -0.905 . . . . 0.0 109.344 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.981 HG12 ' HA ' ' A' ' 65' ' ' LYS . 34.4 m -144.41 167.04 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.908 . . . . 0.0 109.597 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.485 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 22.3 t -109.72 154.67 22.56 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.376 -0.827 . . . . 0.0 108.839 179.502 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.645 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 4.2 p90 172.79 166.03 0.13 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.959 -1.088 . . . . 0.0 110.312 -179.759 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.447 ' OE2' ' HA ' ' A' ' 1' ' ' MET . 67.5 mm-40 -96.09 159.68 14.84 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 178.581 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.664 HD11 HG21 ' A' ' 26' ' ' VAL . 1.1 mp -100.52 127.5 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.939 -1.101 . . . . 0.0 110.044 -179.431 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.6 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 27.5 m -115.86 124.18 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 178.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 22.0 mt-10 -95.74 97.16 9.48 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.127 -0.983 . . . . 0.0 109.703 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.19 -179.35 42.77 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.246 -1.541 . . . . 0.0 109.246 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.436 ' CG ' ' N ' ' A' ' 56' ' ' ARG . 16.0 p-10 -53.97 -50.31 66.8 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.159 -1.201 . . . . 0.0 109.514 -179.87 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.436 ' N ' ' CG ' ' A' ' 55' ' ' ASN . 33.3 mtp85 -61.31 -42.19 98.25 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.052 -1.03 . . . . 0.0 109.793 -179.726 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 158.79 -164.64 33.75 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 110.016 -1.233 . . . . 0.0 110.016 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.565 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 44.1 Cg_endo -68.55 139.78 45.73 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 123.198 2.598 . . . . 0.0 112.637 -179.758 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.6 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 68.5 mt-30 -135.58 165.41 25.6 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 179.301 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.611 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -99.17 141.96 31.26 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.976 -1.077 . . . . 0.0 110.467 -179.031 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.526 ' O ' ' C ' ' A' ' 62' ' ' ASN . . . -124.22 155.7 38.1 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 179.128 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.526 ' C ' ' O ' ' A' ' 61' ' ' ALA . 0.3 OUTLIER 37.58 66.72 0.43 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.172 -0.955 . . . . 0.0 109.003 -179.798 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 1.026 HG12 HG23 ' A' ' 33' ' ' ILE . 2.0 t -79.01 130.99 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.337 -0.852 . . . . 0.0 110.073 -179.048 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.521 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 25.2 m -117.15 123.4 46.63 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.328 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.981 ' HA ' HG12 ' A' ' 47' ' ' VAL . 47.4 mttm -74.97 115.49 14.64 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.203 -0.935 . . . . 0.0 109.939 -179.56 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.46 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 47.2 mt-10 -99.79 169.17 9.43 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.278 -0.889 . . . . 0.0 109.413 179.837 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 118.062 -0.971 . . . . 0.0 109.547 179.827 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.466 ' N ' ' OE2' ' A' ' 50' ' ' GLU . 76.0 mmm . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.485 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 61.9 mt -106.81 161.67 14.47 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.093 -1.004 . . . . 0.0 109.672 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.585 ' O ' HG13 ' A' ' 20' ' ' VAL . 2.2 tt0 -123.45 140.31 53.13 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.323 -0.861 . . . . 0.0 108.901 179.639 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -144.39 148.53 20.34 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.544 ' O ' HG23 ' A' ' 18' ' ' ILE . 50.0 mttp -101.77 142.63 32.8 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.353 -1.086 . . . . 0.0 108.771 179.288 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.853 HG23 ' O ' ' A' ' 45' ' ' GLN . 21.5 t -73.8 113.47 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.112 -0.993 . . . . 0.0 109.642 -179.64 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.425 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 27.2 tttm -78.65 -41.73 30.61 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.777 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.682 ' CZ3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -160.39 156.51 26.25 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.454 -0.779 . . . . 0.0 108.986 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.595 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 12.5 p90 -155.33 142.95 19.71 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.129 -0.982 . . . . 0.0 109.299 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.531 ' HB3' ' HB2' ' A' ' 13' ' ' LYS . 58.7 t-20 -117.44 118.55 32.5 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.063 -1.023 . . . . 0.0 109.518 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 93.0 p -65.27 -14.32 60.45 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.296 -0.877 . . . . 0.0 109.315 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -88.86 -38.43 14.59 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.2 -0.938 . . . . 0.0 108.882 179.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.653 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 16.4 mttm -67.61 -43.88 79.38 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.429 -0.794 . . . . 0.0 109.212 179.585 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.536 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 104.06 1.01 45.03 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.653 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 0.5 OUTLIER -145.23 176.95 9.16 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.116 -1.226 . . . . 0.0 109.654 179.912 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.449 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -144.07 170.28 25.97 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.682 ' CD2' ' CZ3' ' A' ' 8' ' ' TRP . 30.3 m-85 -111.23 128.67 56.0 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.393 -1.063 . . . . 0.0 108.968 179.798 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.839 ' CD1' HG21 ' A' ' 47' ' ' VAL . 67.8 mt -111.37 145.45 17.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.184 -0.947 . . . . 0.0 109.699 -179.801 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 5.3 tt0 -108.16 110.83 22.57 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.399 -0.813 . . . . 0.0 109.087 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.66 HG21 HG21 ' A' ' 26' ' ' VAL . 2.7 t -89.62 118.09 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.317 -0.864 . . . . 0.0 109.488 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -68.01 109.61 3.55 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.278 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.78 -21.78 6.58 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.567 ' OE1' HD12 ' A' ' 51' ' ' ILE . 50.2 mt-30 -135.47 168.8 18.54 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.197 -1.178 . . . . 0.0 109.596 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -55.19 -173.7 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.285 -0.884 . . . . 0.0 109.443 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -77.83 141.6 39.07 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.166 -0.959 . . . . 0.0 109.997 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.66 HG21 HG21 ' A' ' 20' ' ' VAL . 63.5 t -111.0 114.04 45.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.231 -0.918 . . . . 0.0 109.355 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.521 ' HE1' ' HB2' ' A' ' 15' ' ' PHE . 0.2 OUTLIER -84.48 106.85 16.38 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.254 -0.904 . . . . 0.0 109.276 179.812 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.598 ' CG2' HD11 ' A' ' 33' ' ' ILE . 0.2 OUTLIER -86.41 143.74 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 O-C-N 121.128 -0.982 . . . . 0.0 109.712 -179.308 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.7 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 15.6 t-80 -113.86 157.99 21.62 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.653 -0.655 . . . . 0.0 109.272 -179.606 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.7 ' CD2' ' CE1' ' A' ' 29' ' ' HIS . 0.8 OUTLIER -46.37 -54.89 8.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.881 -1.137 . . . . 0.0 108.761 -179.787 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.699 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 94.1 p -50.82 -37.56 43.56 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.212 -0.93 . . . . 0.0 109.918 -179.791 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.573 ' HB3' HG23 ' A' ' 28' ' ' VAL . . . -56.43 -29.02 61.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.036 -1.04 . . . . 0.0 109.341 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.93 HG21 ' NZ ' ' A' ' 65' ' ' LYS . 1.9 mp -103.37 151.26 6.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.397 -0.814 . . . . 0.0 109.317 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 -121.97 145.17 48.38 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.186 -0.947 . . . . 0.0 109.584 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.652 ' HA3' ' CE2' ' A' ' 38' ' ' PHE . . . 145.82 157.26 7.21 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -117.94 100.6 7.67 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.24 -1.153 . . . . 0.0 109.403 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.56 -10.73 9.1 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.813 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.652 ' CE2' ' HA3' ' A' ' 35' ' ' GLY . 11.4 p90 -144.15 30.13 1.29 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.146 -1.208 . . . . 0.0 109.621 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.468 ' HG3' ' O ' ' A' ' 35' ' ' GLY . 19.5 mttp -63.35 -28.36 69.95 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.136 -0.978 . . . . 0.0 109.406 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.5 p -78.12 126.41 30.76 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.197 -0.939 . . . . 0.0 109.408 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.706 ' CD1' HD13 ' A' ' 33' ' ' ILE . 3.6 mp -78.06 159.02 28.95 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.24 -0.913 . . . . 0.0 109.861 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.467 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 85.1 tt0 -106.72 149.51 27.23 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.475 -0.766 . . . . 0.0 109.192 179.614 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.425 ' HG3' ' O ' ' A' ' 7' ' ' LYS . 70.2 tt0 -72.35 124.23 24.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.19 -0.943 . . . . 0.0 109.499 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 96.16 -7.5 66.89 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.853 ' O ' HG23 ' A' ' 6' ' ' VAL . 60.5 tt0 -81.31 127.64 32.95 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.209 -1.171 . . . . 0.0 109.651 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -74.56 145.22 43.59 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.338 -0.851 . . . . 0.0 109.444 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.839 HG21 ' CD1' ' A' ' 18' ' ' ILE . 34.6 m -145.88 160.86 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.095 -1.003 . . . . 0.0 110.017 -179.747 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.542 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 9.6 p -113.7 158.46 20.88 Favored 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.25 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.615 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 8.8 p90 169.25 169.3 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.999 -1.063 . . . . 0.0 109.996 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.484 ' OE1' ' HA ' ' A' ' 50' ' ' GLU . 65.3 mm-40 -104.97 157.84 16.95 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 178.826 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.567 HD12 ' OE1' ' A' ' 23' ' ' GLN . 1.9 mt -95.66 130.64 44.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 120.922 -1.111 . . . . 0.0 110.105 -179.41 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.538 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 3.6 m -112.7 122.57 67.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.306 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -90.77 88.85 7.24 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.039 -1.038 . . . . 0.0 109.755 -179.414 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -93.41 -175.36 40.37 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.7 t30 -54.51 -63.1 1.26 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.2 -1.176 . . . . 0.0 109.639 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 72.5 mtp180 -46.75 -38.9 10.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.125 -0.985 . . . . 0.0 109.033 179.827 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.77 -158.85 27.85 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.538 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 49.2 Cg_endo -70.71 142.48 43.85 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.565 2.177 . . . . 0.0 111.747 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.513 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 67.7 mt-30 -139.17 169.15 18.31 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.342 -0.849 . . . . 0.0 109.133 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.546 ' CB ' ' HB ' ' A' ' 28' ' ' VAL . . . -89.92 134.07 34.42 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.972 -1.08 . . . . 0.0 110.14 -179.463 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.585 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -121.56 153.09 38.47 Favored 'General case' 0 N--CA 1.491 1.601 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.541 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.497 ' C ' ' O ' ' A' ' 61' ' ' ALA . 83.6 m-20 41.13 72.74 0.15 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.033 -1.042 . . . . 0.0 108.577 -179.475 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.759 HG11 HG12 ' A' ' 33' ' ' ILE . 2.2 t -92.98 130.39 42.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.218 -0.926 . . . . 0.0 110.517 -178.724 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 11.3 m -120.08 125.23 47.77 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.493 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.93 ' NZ ' HG21 ' A' ' 33' ' ' ILE . 29.6 mttp -74.36 112.1 10.19 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.067 -1.021 . . . . 0.0 109.702 -179.606 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.407 ' OE2' ' HB3' ' A' ' 48' ' ' SER . 93.2 mt-10 -88.89 163.78 15.46 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.318 -0.864 . . . . 0.0 109.605 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 118.004 -0.998 . . . . 0.0 109.439 179.88 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.608 ' C ' HD12 ' A' ' 2' ' ' LEU . 70.4 mtm . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.811 ' N ' HD12 ' A' ' 2' ' ' LEU . 5.6 mp -107.18 165.64 11.22 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.285 -0.884 . . . . 0.0 109.329 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 58.6 mt-10 -132.28 127.97 36.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.147 -0.97 . . . . 0.0 109.446 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.43 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -127.51 155.25 19.95 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.445 ' N ' HG23 ' A' ' 18' ' ' ILE . 43.2 mttt -103.99 138.48 40.47 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.299 -1.118 . . . . 0.0 108.874 179.578 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.826 HG23 ' O ' ' A' ' 45' ' ' GLN . 18.9 t -71.28 113.24 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.213 -0.929 . . . . 0.0 110.045 -179.469 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 13.0 ttpt -80.08 -40.71 27.06 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.555 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.588 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -158.41 155.4 28.57 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.397 -0.814 . . . . 0.0 109.018 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.584 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 9.6 p90 -156.22 137.96 14.25 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.128 -0.983 . . . . 0.0 109.242 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.479 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 52.3 t-20 -128.03 129.07 46.11 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.233 -0.917 . . . . 0.0 109.437 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -75.56 -19.74 59.1 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.103 -0.998 . . . . 0.0 108.952 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 76.3 tt0 -66.27 -42.43 88.48 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 106.45 -1.685 . . . . 0.0 106.45 177.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.652 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 8.3 mttp -75.69 -39.34 57.66 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 178.368 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.504 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 93.54 3.49 64.63 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.728 -1.349 . . . . 0.0 109.728 179.561 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.652 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 1.0 OUTLIER -140.11 172.95 12.03 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.229 -1.16 . . . . 0.0 108.779 179.127 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.588 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -140.37 172.41 23.53 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.424 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 27.6 m-85 -113.9 132.86 55.77 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.341 -1.094 . . . . 0.0 108.986 179.786 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.661 HD12 HG21 ' A' ' 28' ' ' VAL . 13.9 mt -116.22 151.52 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.252 -0.905 . . . . 0.0 109.717 -179.646 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -115.57 116.91 28.95 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.365 -0.834 . . . . 0.0 109.21 179.863 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.538 HG21 HG21 ' A' ' 26' ' ' VAL . 2.3 t -94.3 119.82 42.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.364 -0.835 . . . . 0.0 109.395 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -69.21 110.55 4.64 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.24 -0.913 . . . . 0.0 109.351 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 125.78 -37.77 2.42 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.819 ' OE1' HD12 ' A' ' 51' ' ' ILE . 56.4 mt-30 -120.45 166.31 13.76 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.366 -1.079 . . . . 0.0 109.381 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.422 ' O ' ' O ' ' A' ' 23' ' ' GLN . 49.5 m-20 -52.53 -176.83 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.206 -0.934 . . . . 0.0 109.562 -179.862 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.504 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 81.0 m-20 -74.31 141.93 45.22 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.346 -0.846 . . . . 0.0 109.629 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.538 HG21 HG21 ' A' ' 20' ' ' VAL . 98.2 t -115.08 117.95 57.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.242 -0.911 . . . . 0.0 109.31 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.556 ' O ' ' N ' ' A' ' 60' ' ' ALA . 0.1 OUTLIER -76.73 161.12 28.76 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.103 -0.998 . . . . 0.0 109.388 -179.879 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.763 HG22 ' HB2' ' A' ' 60' ' ' ALA . 14.6 t -133.75 134.13 56.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.287 -0.883 . . . . 0.0 109.602 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.642 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 15.2 t-80 -104.66 151.33 23.82 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.217 -0.927 . . . . 0.0 109.19 179.652 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.685 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -44.92 -53.96 7.03 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.106 -0.996 . . . . 0.0 109.549 -179.529 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.685 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 90.3 p -60.35 -18.49 50.42 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.06 -1.025 . . . . 0.0 109.956 -179.544 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.502 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -67.36 -24.54 65.72 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.075 -1.016 . . . . 0.0 109.356 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.833 HG23 HG12 ' A' ' 63' ' ' VAL . 3.1 mp -109.11 132.58 56.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.303 -0.873 . . . . 0.0 109.468 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.404 ' C ' ' O ' ' A' ' 33' ' ' ILE . 34.4 tt0 -47.45 -53.67 13.5 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.094 -1.004 . . . . 0.0 108.828 179.343 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.648 ' HA3' ' CG ' ' A' ' 39' ' ' LYS . . . 55.34 33.89 58.81 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 110.149 -1.18 . . . . 0.0 110.149 179.515 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -46.32 -24.26 0.46 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.045 -1.268 . . . . 0.0 108.761 179.495 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.415 ' N ' ' C ' ' A' ' 35' ' ' GLY . . . -162.19 26.99 0.25 Allowed Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 179.753 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.617 ' CD1' ' HA2' ' A' ' 35' ' ' GLY . 0.4 OUTLIER -169.57 44.85 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.303 -1.116 . . . . 0.0 109.571 -179.885 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.648 ' CG ' ' HA3' ' A' ' 35' ' ' GLY . 90.3 mttt -55.39 -20.84 13.24 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.194 -0.941 . . . . 0.0 109.431 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 21.3 m -67.5 99.7 0.78 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.35 -0.844 . . . . 0.0 109.885 -179.606 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.703 HD21 HD11 ' A' ' 33' ' ' ILE . 5.8 mp -62.6 157.8 19.77 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.2 -0.938 . . . . 0.0 109.263 179.588 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.488 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 84.1 tt0 -120.25 138.53 53.61 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.238 -0.914 . . . . 0.0 109.619 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 57.4 tt0 -67.65 129.7 40.72 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.261 -0.899 . . . . 0.0 109.454 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 90.64 -5.88 82.25 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.826 ' O ' HG23 ' A' ' 6' ' ' VAL . 60.4 tt0 -81.12 126.11 31.06 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.215 -1.168 . . . . 0.0 109.371 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -79.18 142.49 36.28 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.228 -0.92 . . . . 0.0 109.31 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.985 HG12 ' HA ' ' A' ' 65' ' ' LYS . 28.2 m -143.96 168.65 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.246 -0.909 . . . . 0.0 109.438 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.517 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 9.4 t -114.51 155.26 26.76 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.324 -0.86 . . . . 0.0 108.859 179.65 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.611 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 5.6 p90 173.38 165.88 0.16 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.041 -1.037 . . . . 0.0 110.099 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.467 ' HA ' HD13 ' A' ' 2' ' ' LEU . 90.8 mt-10 -100.6 150.36 22.79 Favored 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.815 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.819 HD12 ' OE1' ' A' ' 23' ' ' GLN . 0.5 OUTLIER -87.13 123.05 39.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.029 -1.044 . . . . 0.0 109.837 -179.574 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.623 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.6 m -107.03 120.87 59.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.385 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -88.41 85.18 6.82 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.259 -0.901 . . . . 0.0 109.633 -179.544 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.39 -177.05 43.18 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 18.4 p-10 -55.27 -55.89 26.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.097 -1.237 . . . . 0.0 109.701 -179.743 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 43.3 mtp180 -52.43 -41.27 63.11 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.992 -1.068 . . . . 0.0 109.285 179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 146.34 -150.85 23.14 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.504 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 47.6 Cg_endo -70.24 129.25 16.78 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.817 2.345 . . . . 0.0 112.292 -179.851 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.623 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 53.7 mt-30 -131.04 164.23 25.85 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 179.138 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.763 ' HB2' HG22 ' A' ' 28' ' ' VAL . . . -90.52 127.08 36.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.098 -1.001 . . . . 0.0 110.401 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.535 ' O ' ' C ' ' A' ' 62' ' ' ASN . . . -109.86 147.71 32.85 Favored 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.034 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.535 ' C ' ' O ' ' A' ' 61' ' ' ALA . 59.2 t30 38.17 73.73 0.1 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.049 -1.032 . . . . 0.0 108.816 -179.686 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.833 HG12 HG23 ' A' ' 33' ' ' ILE . 1.4 t -84.8 129.62 37.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.321 -0.862 . . . . 0.0 110.331 -178.767 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.458 ' O ' ' HA ' ' A' ' 47' ' ' VAL . 13.0 m -115.28 121.37 42.68 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.459 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.985 ' HA ' HG12 ' A' ' 47' ' ' VAL . 20.2 mttt -74.12 114.83 12.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.154 -0.966 . . . . 0.0 109.742 -179.67 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.441 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 50.8 mt-10 -98.99 168.05 10.35 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.354 -0.841 . . . . 0.0 109.616 -179.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.495 0 CA-C-O 117.944 -1.027 . . . . 0.0 109.444 179.989 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 91.6 mtp . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.498 HD13 HE22 ' A' ' 23' ' ' GLN . 21.1 mt -103.96 161.84 13.63 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.214 -0.929 . . . . 0.0 109.275 179.813 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -134.19 127.9 32.91 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.209 -0.932 . . . . 0.0 109.297 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.41 ' C ' ' CG2' ' A' ' 18' ' ' ILE . . . -126.49 158.63 20.64 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 -179.735 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.562 ' C ' HG23 ' A' ' 18' ' ' ILE . 38.8 mttp -103.7 133.64 48.37 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.394 -1.063 . . . . 0.0 108.823 179.561 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.856 HG23 ' O ' ' A' ' 45' ' ' GLN . 18.3 t -66.49 113.73 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.151 -0.968 . . . . 0.0 110.055 -179.344 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.402 ' O ' ' HD2' ' A' ' 7' ' ' LYS . 0.7 OUTLIER -79.12 -39.93 32.36 Favored 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 179.34 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.642 ' CZ3' ' HA2' ' A' ' 16' ' ' GLY . 0.0 OUTLIER -159.11 155.01 26.51 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.807 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.646 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 9.1 p90 -155.57 140.55 17.32 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.056 -1.028 . . . . 0.0 109.347 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.487 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.2 t-20 -132.59 130.61 40.49 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.117 -0.989 . . . . 0.0 109.727 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 14.6 p -76.95 -19.16 57.69 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.056 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.494 ' HA ' ' OE1' ' A' ' 12' ' ' GLU . 69.7 mm-40 -65.31 -45.52 84.02 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 178.129 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.629 ' HD3' ' CE2' ' A' ' 15' ' ' PHE . 8.1 mttp -74.21 -38.59 63.53 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 178.303 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.531 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 94.31 5.98 61.67 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.725 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.629 ' CE2' ' HD3' ' A' ' 13' ' ' LYS . 1.2 p90 -143.78 170.08 16.56 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.164 -1.198 . . . . 0.0 109.195 179.358 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.642 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -140.88 171.69 23.99 Favored Glycine 0 N--CA 1.492 2.378 0 C-N-CA 119.654 -1.26 . . . . 0.0 110.067 -179.491 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.558 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 43.1 m-85 -114.02 139.4 49.29 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.319 -1.107 . . . . 0.0 109.195 179.751 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 1.122 ' CD1' HG21 ' A' ' 28' ' ' VAL . 16.7 mt -124.1 150.91 28.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.272 -0.892 . . . . 0.0 109.691 -179.485 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -113.48 119.47 37.7 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.384 -0.823 . . . . 0.0 109.448 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.565 HG21 HG21 ' A' ' 26' ' ' VAL . 2.6 t -90.46 124.13 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.329 -0.857 . . . . 0.0 109.655 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.476 ' OE2' ' NZ ' ' A' ' 5' ' ' LYS . 80.1 mt-10 -71.45 109.34 5.37 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.309 -0.869 . . . . 0.0 109.512 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 117.81 -26.1 8.15 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.498 HE22 HD13 ' A' ' 2' ' ' LEU . 43.2 mt-30 -122.95 161.31 24.45 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.259 -1.142 . . . . 0.0 109.482 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 58.9 m-20 -52.84 -178.96 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.274 -0.891 . . . . 0.0 109.659 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -71.65 141.37 49.92 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.268 -0.895 . . . . 0.0 109.506 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.584 HG13 ' C ' ' A' ' 59' ' ' GLN . 97.3 t -117.99 117.7 55.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.171 -0.956 . . . . 0.0 109.656 -179.582 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.54 ' CE1' ' HB3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -76.56 157.16 32.25 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.2 -0.937 . . . . 0.0 108.997 179.684 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 1.122 HG21 ' CD1' ' A' ' 18' ' ' ILE . 34.1 t -133.01 137.38 53.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.205 -0.935 . . . . 0.0 109.763 -179.525 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.629 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 12.8 t-80 -114.97 152.45 32.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.429 -0.794 . . . . 0.0 108.993 179.696 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.68 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.8 OUTLIER -44.31 -53.53 6.63 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.093 -1.004 . . . . 0.0 109.502 -179.631 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.68 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 27.3 t -54.29 -27.35 34.75 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.101 -1.0 . . . . 0.0 110.068 -179.452 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.63 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -66.9 -12.63 60.03 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.04 -1.037 . . . . 0.0 109.002 179.71 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.912 ' CD1' HD11 ' A' ' 41' ' ' LEU . 0.9 OUTLIER -122.7 126.75 74.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.503 -0.748 . . . . 0.0 109.589 -179.581 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 50.8 tt0 -87.5 133.42 33.77 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.242 -0.911 . . . . 0.0 109.671 -179.79 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.613 ' CA ' ' CZ ' ' A' ' 38' ' ' PHE . . . 173.94 147.6 6.09 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.868 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -65.36 -58.85 4.86 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.255 -1.144 . . . . 0.0 109.471 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -136.03 13.23 4.13 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.613 ' CZ ' ' CA ' ' A' ' 35' ' ' GLY . 44.5 p90 -113.96 17.32 17.96 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.249 -1.148 . . . . 0.0 109.498 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.499 ' CE ' ' O ' ' A' ' 35' ' ' GLY . 86.3 mttt -55.48 -42.16 74.0 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.297 -0.877 . . . . 0.0 109.581 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 32.9 m -56.27 128.51 36.08 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.191 -0.943 . . . . 0.0 109.654 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 1.034 HD23 HG11 ' A' ' 47' ' ' VAL . 4.9 mp -88.21 171.85 9.91 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.222 -0.924 . . . . 0.0 109.559 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.438 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 96.8 mt-10 -109.28 155.04 21.62 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.316 -0.865 . . . . 0.0 109.305 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -70.41 127.67 33.54 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.29 -0.881 . . . . 0.0 109.593 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.445 ' N ' ' O ' ' A' ' 6' ' ' VAL . . . 88.51 -3.12 85.2 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.856 ' O ' HG23 ' A' ' 6' ' ' VAL . 51.1 tt0 -81.71 130.24 34.99 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.198 -1.178 . . . . 0.0 109.603 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -78.21 141.87 38.32 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.235 -0.916 . . . . 0.0 109.383 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 1.034 HG11 HD23 ' A' ' 41' ' ' LEU . 34.7 m -141.52 153.21 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.136 -0.977 . . . . 0.0 109.781 -179.746 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.539 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 17.8 t -97.57 148.65 23.05 Favored 'General case' 0 N--CA 1.488 1.459 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 179.075 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.602 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 7.8 p90 176.09 162.47 0.35 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.874 -1.141 . . . . 0.0 110.272 -179.546 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.458 ' OE1' ' HA ' ' A' ' 50' ' ' GLU . 67.0 mm-40 -99.92 160.37 14.37 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 178.908 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.462 HD12 ' OE1' ' A' ' 23' ' ' GLN . 0.9 OUTLIER -99.6 127.38 52.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 120.917 -1.114 . . . . 0.0 109.91 -179.524 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.614 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.9 m -114.32 124.81 71.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 179.197 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -93.6 93.31 7.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 110.241 -179.087 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -95.15 -175.8 37.72 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -53.17 -59.22 4.83 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.104 -1.233 . . . . 0.0 109.462 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 53.0 mtp180 -49.3 -40.47 34.93 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.087 -1.008 . . . . 0.0 109.215 179.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 149.18 -158.12 27.53 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.278 -1.529 . . . . 0.0 109.278 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.411 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 51.5 Cg_endo -70.46 139.96 38.98 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.723 2.282 . . . . 0.0 111.849 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.614 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 76.9 mt-30 -136.26 167.81 20.6 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.324 -0.86 . . . . 0.0 109.13 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.659 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -95.22 139.31 31.72 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.136 -0.978 . . . . 0.0 110.184 -179.286 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.602 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -124.3 156.02 37.68 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.378 -0.826 . . . . 0.0 108.826 179.605 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.481 ' C ' ' O ' ' A' ' 61' ' ' ALA . 78.8 m-20 42.2 72.59 0.16 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.968 -1.083 . . . . 0.0 108.952 -179.821 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.98 HG11 HD21 ' A' ' 41' ' ' LEU . 3.9 t -86.76 125.93 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.234 -0.916 . . . . 0.0 110.088 -179.17 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.45 ' HB ' ' HB3' ' A' ' 48' ' ' SER . 60.6 m -119.0 125.51 49.56 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.379 -0.825 . . . . 0.0 109.256 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.434 ' NZ ' ' O ' ' A' ' 38' ' ' PHE . 87.9 mttt -67.52 106.97 2.32 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.2 -0.937 . . . . 0.0 109.479 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.405 ' OE2' ' HB2' ' A' ' 48' ' ' SER . 89.6 mt-10 -87.04 162.0 17.85 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.227 -0.921 . . . . 0.0 109.497 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 117.973 -1.013 . . . . 0.0 109.487 -179.939 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 50.3 mtm . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 49.4 mt -99.52 160.21 14.46 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.321 -0.862 . . . . 0.0 109.494 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.581 ' O ' HG13 ' A' ' 20' ' ' VAL . 86.9 mt-10 -131.48 135.83 47.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.28 -0.888 . . . . 0.0 109.171 179.772 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.475 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -136.15 157.94 23.7 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 -179.684 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.513 ' N ' HG23 ' A' ' 18' ' ' ILE . 12.5 mttp -103.65 142.26 34.63 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.341 -1.094 . . . . 0.0 108.817 179.51 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.839 HG23 ' O ' ' A' ' 45' ' ' GLN . 22.1 t -75.22 116.96 18.75 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.073 -1.017 . . . . 0.0 109.935 -179.51 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.8 -32.73 17.71 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.465 -0.772 . . . . 0.0 108.933 179.693 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.683 ' CE3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -159.44 153.98 24.2 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.381 -0.824 . . . . 0.0 109.023 179.792 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.489 ' HA ' ' HA2' ' A' ' 16' ' ' GLY . 9.1 p90 -157.54 139.03 13.81 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.173 -0.954 . . . . 0.0 109.282 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.444 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 63.5 t-20 -121.6 116.91 25.48 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 109.618 -179.809 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 11.0 t -69.47 -13.75 62.51 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.232 -0.917 . . . . 0.0 109.222 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -81.37 -46.87 14.03 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.369 -0.832 . . . . 0.0 108.964 179.604 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.671 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 21.1 mttp -68.56 -45.3 72.47 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.417 -0.802 . . . . 0.0 108.882 179.507 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.541 ' C ' ' CD1' ' A' ' 15' ' ' PHE . . . 108.96 7.93 28.42 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 179.055 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.671 ' CE2' ' HB3' ' A' ' 13' ' ' LYS . 0.0 OUTLIER -142.58 166.42 24.73 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.81 -1.406 . . . . 0.0 109.695 179.72 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.504 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -135.99 167.49 24.33 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.683 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 22.1 m-85 -115.05 130.12 56.86 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.184 -1.186 . . . . 0.0 109.289 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.744 ' CD1' HG21 ' A' ' 47' ' ' VAL . 56.4 mt -114.23 151.42 16.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.44 -0.787 . . . . 0.0 109.654 -179.79 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -114.2 104.29 11.95 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.361 -0.837 . . . . 0.0 108.915 179.518 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.581 HG13 ' O ' ' A' ' 3' ' ' GLU . 2.8 t -78.63 120.64 30.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.264 -0.897 . . . . 0.0 109.428 -179.702 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 74.0 mm-40 -67.93 108.89 3.2 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.206 -0.933 . . . . 0.0 109.135 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.59 -24.46 6.82 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.562 ' OE1' HG11 ' A' ' 20' ' ' VAL . 36.0 mt-30 -128.18 165.92 19.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.298 -1.119 . . . . 0.0 109.6 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 48.9 m-20 -56.93 -169.08 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.292 -0.88 . . . . 0.0 109.729 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.497 ' N ' ' OD1' ' A' ' 25' ' ' ASP . 7.7 p30 -78.45 141.47 38.25 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.254 -0.904 . . . . 0.0 110.003 -179.543 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.579 HG21 HG21 ' A' ' 20' ' ' VAL . 57.4 t -116.23 115.09 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.212 -0.93 . . . . 0.0 109.305 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.706 ' O ' ' CG ' ' A' ' 27' ' ' PHE . 0.1 OUTLIER -83.5 107.72 16.16 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.047 -1.033 . . . . 0.0 109.39 179.979 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.628 ' CG2' HG21 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -85.48 146.92 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.061 -1.024 . . . . 0.0 109.632 -179.167 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.691 ' CE1' ' CE2' ' A' ' 30' ' ' PHE . 11.8 t-160 -116.2 155.05 28.99 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.283 -0.886 . . . . 0.0 109.336 -179.772 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.769 ' CD1' ' N ' ' A' ' 31' ' ' SER . 1.9 p90 -47.75 -54.11 13.21 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.092 -1.005 . . . . 0.0 109.607 -179.481 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.769 ' N ' ' CD1' ' A' ' 30' ' ' PHE . 19.9 t -53.41 -21.22 5.6 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.872 -1.142 . . . . 0.0 109.517 -179.771 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.547 ' HB3' ' O ' ' A' ' 29' ' ' HIS . . . -66.84 -38.81 87.12 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.273 -0.892 . . . . 0.0 109.635 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.073 HD11 HD11 ' A' ' 41' ' ' LEU . 1.8 mp -80.43 151.67 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.168 -0.958 . . . . 0.0 109.966 -179.74 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 65.9 mt-30 -56.1 134.75 52.94 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.337 -0.852 . . . . 0.0 109.597 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.612 ' HA3' ' CE1' ' A' ' 38' ' ' PHE . . . 120.92 169.9 13.93 Favored Glycine 0 N--CA 1.488 2.138 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 179.591 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -86.62 10.15 16.41 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.428 -1.042 . . . . 0.0 109.269 179.829 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 121.31 4.29 10.07 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.612 ' CE1' ' HA3' ' A' ' 35' ' ' GLY . 29.2 p90 -80.79 2.55 25.8 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.289 -1.124 . . . . 0.0 109.489 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.515 ' HG2' ' CE2' ' A' ' 38' ' ' PHE . 21.3 mmtt -113.96 117.91 32.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.189 -0.945 . . . . 0.0 109.355 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 27.3 p -109.0 138.26 45.63 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.286 -0.884 . . . . 0.0 109.508 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 1.073 HD11 HD11 ' A' ' 33' ' ' ILE . 3.1 mp -78.59 158.31 28.52 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.182 -0.949 . . . . 0.0 109.332 179.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.469 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 97.0 mt-10 -115.8 151.27 35.51 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.302 -0.874 . . . . 0.0 109.373 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 46.5 tt0 -67.84 125.37 26.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.227 -0.92 . . . . 0.0 109.426 -179.866 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 92.7 -6.63 77.29 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.883 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.839 ' O ' HG23 ' A' ' 6' ' ' VAL . 61.5 tp60 -82.28 135.05 35.29 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.185 -1.185 . . . . 0.0 109.762 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -85.87 144.62 27.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.318 -0.864 . . . . 0.0 109.293 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.777 HG12 ' HA ' ' A' ' 65' ' ' LYS . 30.6 m -144.55 166.46 12.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.198 -0.939 . . . . 0.0 109.717 -179.838 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.55 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 3.3 t -112.87 157.21 21.7 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 179.338 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.577 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 10.0 p90 170.32 167.97 0.06 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.092 -1.005 . . . . 0.0 110.076 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 92.1 mt-10 -102.34 162.2 13.1 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 178.823 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.5 mt -99.91 127.75 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.008 -1.058 . . . . 0.0 109.75 -179.615 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.563 HG23 ' HB2' ' A' ' 59' ' ' GLN . 0.8 OUTLIER -109.17 120.82 61.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.62 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -88.53 85.89 6.92 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.194 -0.941 . . . . 0.0 109.713 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.14 -179.51 45.55 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 19.3 p-10 -54.49 -53.27 56.57 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.298 -1.119 . . . . 0.0 109.895 -179.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 20.3 mtm180 -57.13 -38.56 73.66 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.017 -1.052 . . . . 0.0 109.389 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.96 -158.81 27.99 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.557 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 52.3 Cg_endo -73.01 141.48 33.08 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.725 2.283 . . . . 0.0 112.006 179.898 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.563 ' HB2' HG23 ' A' ' 52' ' ' VAL . 31.8 mt-30 -137.03 168.45 19.56 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.37 -0.831 . . . . 0.0 108.894 179.543 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.591 ' HB3' ' HA ' ' A' ' 28' ' ' VAL . . . -94.13 139.93 30.38 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.015 -1.053 . . . . 0.0 110.332 -179.253 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.557 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -126.53 155.65 42.02 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.44 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.49 ' C ' ' O ' ' A' ' 61' ' ' ALA . 57.6 t30 40.88 63.06 1.25 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.958 -1.089 . . . . 0.0 108.849 -179.708 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.885 HG11 HD21 ' A' ' 41' ' ' LEU . 1.8 t -79.46 128.75 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.291 -0.881 . . . . 0.0 110.421 -179.011 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 56.4 m -119.6 125.59 49.14 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.777 ' HA ' HG12 ' A' ' 47' ' ' VAL . 69.6 mttt -65.51 110.6 2.76 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.21 -0.932 . . . . 0.0 109.531 -179.831 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.449 ' HG3' ' HA ' ' A' ' 47' ' ' VAL . 90.4 mt-10 -89.6 159.38 17.2 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.321 -0.862 . . . . 0.0 109.628 -179.845 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.551 0 CA-C-O 117.99 -1.005 . . . . 0.0 109.469 179.942 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.434 ' C ' HD12 ' A' ' 2' ' ' LEU . 69.3 mtm . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 121.309 0.576 . . . . 0.0 109.511 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.735 ' N ' HD12 ' A' ' 2' ' ' LEU . 6.4 mp -102.21 166.33 10.65 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.195 -0.94 . . . . 0.0 109.569 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.575 ' O ' HG13 ' A' ' 20' ' ' VAL . 61.0 mt-10 -132.87 139.55 47.48 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.36 -0.838 . . . . 0.0 109.213 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -139.64 157.41 25.18 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.66 ' O ' HG23 ' A' ' 18' ' ' ILE . 63.6 mttm -102.57 142.95 32.89 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.418 -1.048 . . . . 0.0 108.831 179.561 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.799 HG23 ' O ' ' A' ' 45' ' ' GLN . 18.7 t -76.61 112.09 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.173 -0.954 . . . . 0.0 110.047 -179.447 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.465 ' CG ' ' N ' ' A' ' 8' ' ' TRP . 3.3 pttt -79.94 -37.7 33.94 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.622 ' CE3' ' CD2' ' A' ' 17' ' ' PHE . 0.0 OUTLIER -159.75 155.01 25.18 Favored 'General case' 0 N--CA 1.488 1.466 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 -179.941 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.463 ' CD2' ' O ' ' A' ' 41' ' ' LEU . 10.5 p90 -155.88 138.87 15.41 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.156 -0.965 . . . . 0.0 109.196 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.493 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 58.3 t-20 -132.63 133.55 43.77 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.097 -1.002 . . . . 0.0 109.633 -179.745 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 32.7 p -80.11 -18.51 49.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.268 -0.895 . . . . 0.0 108.939 179.456 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -64.77 -47.96 76.24 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 178.111 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.657 ' HB3' ' CZ ' ' A' ' 15' ' ' PHE . 14.1 mttm -70.9 -40.21 72.32 Favored 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.151 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.491 ' O ' ' HB3' ' A' ' 30' ' ' PHE . . . 97.08 2.67 59.23 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.681 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.657 ' CZ ' ' HB3' ' A' ' 13' ' ' LYS . 0.4 OUTLIER -138.98 175.63 9.38 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.207 -1.172 . . . . 0.0 109.145 179.155 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.594 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -140.43 170.26 24.48 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 -179.65 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.622 ' CD2' ' CE3' ' A' ' 8' ' ' TRP . 27.5 m-85 -114.66 131.5 56.71 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.387 -1.066 . . . . 0.0 108.997 179.812 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 1.132 HD12 ' CG2' ' A' ' 28' ' ' VAL . 26.9 mt -120.27 149.29 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.164 -0.96 . . . . 0.0 109.433 -179.825 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.447 ' OE1' ' OD1' ' A' ' 25' ' ' ASP . 18.1 tp10 -108.75 123.76 49.52 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.244 -0.91 . . . . 0.0 109.504 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.672 HG21 HG21 ' A' ' 26' ' ' VAL . 2.3 t -102.11 120.25 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.215 -0.928 . . . . 0.0 109.25 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -66.98 109.39 2.95 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.247 -0.908 . . . . 0.0 109.772 -179.701 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.14 -29.34 3.71 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.505 ' O ' ' O ' ' A' ' 24' ' ' ASP . 38.2 mt-30 -131.41 166.26 21.68 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.227 -1.161 . . . . 0.0 109.23 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.505 ' O ' ' O ' ' A' ' 23' ' ' GLN . 0.0 OUTLIER -52.8 -169.17 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.173 -0.954 . . . . 0.0 109.683 -179.777 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.447 ' OD1' ' OE1' ' A' ' 19' ' ' GLU . 42.2 m-20 -75.36 141.65 43.27 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.236 -0.915 . . . . 0.0 109.742 -179.77 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.672 HG21 HG21 ' A' ' 20' ' ' VAL . 87.0 t -112.11 119.73 60.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.259 -0.9 . . . . 0.0 109.385 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.489 ' CZ ' ' HB2' ' A' ' 29' ' ' HIS . 0.1 OUTLIER -79.53 154.71 28.62 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.244 -0.91 . . . . 0.0 109.127 -179.94 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 1.132 ' CG2' HD12 ' A' ' 18' ' ' ILE . 5.0 t -129.64 133.04 65.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.292 -0.88 . . . . 0.0 109.27 -179.729 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.647 ' HA ' ' HB3' ' A' ' 15' ' ' PHE . 13.4 t-80 -105.61 150.2 25.62 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.157 -0.964 . . . . 0.0 109.219 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.689 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.9 OUTLIER -43.1 -52.56 5.35 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.197 -0.939 . . . . 0.0 109.198 -179.818 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.689 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 23.0 t -56.25 -23.06 33.68 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.912 . . . . 0.0 109.856 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.509 ' N ' ' O ' ' A' ' 29' ' ' HIS . . . -65.38 -23.76 67.05 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.075 -1.015 . . . . 0.0 109.446 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.907 ' CD1' HD11 ' A' ' 41' ' ' LEU . 3.2 mp -108.25 135.72 46.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.286 -0.883 . . . . 0.0 109.337 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 64.4 tt0 -95.76 119.83 34.96 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.136 -0.977 . . . . 0.0 109.419 179.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.629 ' CA ' ' CZ ' ' A' ' 38' ' ' PHE . . . -176.02 147.86 8.92 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -64.98 -56.24 14.33 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.24 -1.153 . . . . 0.0 109.588 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -134.03 12.3 4.75 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.629 ' CZ ' ' CA ' ' A' ' 35' ' ' GLY . 49.8 p90 -117.36 25.68 10.28 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.164 -1.198 . . . . 0.0 109.374 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.467 ' NZ ' ' O ' ' A' ' 35' ' ' GLY . 44.7 mttp -60.88 -42.54 98.15 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.237 -0.915 . . . . 0.0 109.509 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.451 ' O ' ' NZ ' ' A' ' 65' ' ' LYS . 29.5 m -58.66 138.19 57.12 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.297 -0.877 . . . . 0.0 109.479 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.996 HD23 HG11 ' A' ' 47' ' ' VAL . 4.7 mp -93.64 175.33 6.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.165 -0.959 . . . . 0.0 109.578 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.453 ' O ' ' HB ' ' A' ' 6' ' ' VAL . 95.7 mt-10 -111.67 151.43 28.87 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.376 -0.827 . . . . 0.0 109.329 179.788 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 76.6 tt0 -69.13 126.44 29.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.282 -0.886 . . . . 0.0 109.626 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 89.94 -3.2 82.7 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.799 ' O ' HG23 ' A' ' 6' ' ' VAL . 56.7 tt0 -82.16 131.03 35.24 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.197 -1.178 . . . . 0.0 109.701 179.822 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -76.82 142.69 40.18 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.211 -0.93 . . . . 0.0 109.226 179.755 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.996 HG11 HD23 ' A' ' 41' ' ' LEU . 30.1 m -145.39 159.36 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.233 -0.917 . . . . 0.0 110.093 -179.637 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.569 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 39.7 t -110.94 154.32 24.26 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.615 ' HB3' ' HA ' ' A' ' 63' ' ' VAL . 14.0 p90 173.37 163.87 0.15 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.817 -1.177 . . . . 0.0 110.508 -179.659 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -99.58 158.71 15.57 Favored 'General case' 0 N--CA 1.488 1.455 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.533 HD11 HG21 ' A' ' 26' ' ' VAL . 3.1 mt -102.13 131.77 49.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 120.928 -1.107 . . . . 0.0 110.244 -179.409 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.562 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 5.6 m -114.19 123.62 70.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 178.703 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -91.55 90.36 7.58 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.187 -0.946 . . . . 0.0 109.937 -178.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.6 -177.47 42.76 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -53.16 -59.81 4.08 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.169 -1.195 . . . . 0.0 109.533 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 20.9 mtp180 -49.82 -39.07 37.47 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.189 -0.944 . . . . 0.0 109.201 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.09 -161.91 29.25 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.562 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 52.6 Cg_endo -72.31 144.9 42.25 Favored 'Trans proline' 0 C--O 1.216 -0.613 0 C-N-CA 122.7 2.267 . . . . 0.0 111.828 179.772 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.548 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 71.1 mt-30 -137.37 169.47 17.72 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.276 -0.89 . . . . 0.0 109.232 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.56 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -94.0 139.73 30.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.216 -0.927 . . . . 0.0 110.232 -179.407 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.602 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -127.98 157.74 39.79 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.514 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.49 ' C ' ' O ' ' A' ' 61' ' ' ALA . 85.7 m-20 41.4 68.57 0.43 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.857 -1.152 . . . . 0.0 108.816 -179.761 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.934 HG11 HD21 ' A' ' 41' ' ' LEU . 2.3 t -87.13 126.3 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.239 -0.913 . . . . 0.0 110.315 -178.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 82.3 m -117.99 124.26 47.74 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.451 ' NZ ' ' O ' ' A' ' 40' ' ' THR . 50.3 mttt -68.39 110.97 4.37 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.291 -0.881 . . . . 0.0 109.614 -179.814 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.473 ' O ' ' HB3' ' A' ' 67' ' ' ALA . 64.2 mt-10 -90.05 161.46 15.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.901 . . . . 0.0 109.604 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . 0.473 ' HB3' ' O ' ' A' ' 66' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.52 0 CA-C-O 117.989 -1.005 . . . . 0.0 109.466 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 54.9 mtm . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.483 ' HB2' ' O ' ' A' ' 49' ' ' PHE . 27.2 mt -100.68 154.39 18.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.271 -0.893 . . . . 0.0 109.503 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -129.24 141.33 51.16 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -0.916 . . . . 0.0 109.061 179.753 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.52 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -146.66 156.71 27.13 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 -179.719 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.514 ' N ' HG23 ' A' ' 18' ' ' ILE . 16.0 mttt -102.2 136.01 42.78 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.382 -1.069 . . . . 0.0 108.836 179.48 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.614 HG23 ' O ' ' A' ' 45' ' ' GLN . 40.3 t -68.59 115.71 7.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.161 -0.962 . . . . 0.0 110.095 -179.53 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 17' ' ' PHE . 5.9 tttm -79.06 -35.11 43.02 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.476 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.654 ' CD2' ' N ' ' A' ' 9' ' ' PHE . 0.4 OUTLIER -160.36 168.55 24.99 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.486 -0.759 . . . . 0.0 109.047 179.755 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.654 ' N ' ' CD2' ' A' ' 8' ' ' TRP . 21.4 p90 -163.44 141.23 7.65 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.885 -1.135 . . . . 0.0 110.312 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.599 ' HB2' ' CZ2' ' A' ' 8' ' ' TRP . 20.5 t-20 -92.55 131.71 37.45 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.491 -0.755 . . . . 0.0 109.338 179.671 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.7 m -86.83 -21.93 26.13 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.241 -0.912 . . . . 0.0 109.773 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 71.0 mm-40 -74.09 -38.88 63.74 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.178 -0.952 . . . . 0.0 109.382 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.837 ' HB2' ' CE1' ' A' ' 15' ' ' PHE . 25.4 mttm -94.71 -57.43 2.46 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.363 -0.836 . . . . 0.0 109.824 -179.76 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.531 ' O ' ' CB ' ' A' ' 30' ' ' PHE . . . 116.85 48.8 0.44 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 -179.695 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.837 ' CE1' ' HB2' ' A' ' 13' ' ' LYS . 10.8 p90 -151.74 163.5 39.01 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.122 -1.222 . . . . 0.0 109.0 179.306 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.614 ' HA2' ' CZ3' ' A' ' 8' ' ' TRP . . . -157.77 165.61 33.63 Favored Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.497 -1.335 . . . . 0.0 110.146 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.523 ' O ' ' N ' ' A' ' 7' ' ' LYS . 92.6 m-85 -96.43 138.63 33.73 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.457 -1.026 . . . . 0.0 108.909 179.726 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 1.048 HD12 HG21 ' A' ' 28' ' ' VAL . 63.2 mt -121.53 160.07 23.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.561 -0.712 . . . . 0.0 109.647 -179.715 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.48 ' N ' HG22 ' A' ' 18' ' ' ILE . 39.6 tt0 -120.4 119.09 32.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.35 -0.844 . . . . 0.0 109.46 -179.737 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.552 HG21 HG21 ' A' ' 26' ' ' VAL . 2.2 t -95.28 111.73 26.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.265 -0.897 . . . . 0.0 109.214 179.832 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.414 ' HA ' ' OE1' ' A' ' 21' ' ' GLU . 72.5 mm-40 -61.43 110.3 1.41 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.234 -0.916 . . . . 0.0 109.474 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 124.9 -33.97 3.56 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.614 ' OE1' HD12 ' A' ' 51' ' ' ILE . 36.1 mt-30 -124.28 163.39 21.75 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.248 -1.148 . . . . 0.0 109.365 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.474 ' O ' ' O ' ' A' ' 23' ' ' GLN . 57.9 m-20 -50.76 -176.81 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.304 -0.873 . . . . 0.0 109.652 -179.866 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.42 ' O ' ' HG2' ' A' ' 58' ' ' PRO . 90.0 m-20 -74.02 140.88 45.74 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.336 -0.853 . . . . 0.0 109.728 -179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.552 HG21 HG21 ' A' ' 20' ' ' VAL . 88.9 t -113.42 115.75 50.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.319 -0.863 . . . . 0.0 109.411 -179.895 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.579 ' CE2' ' HB3' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -70.75 156.72 39.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.057 -1.027 . . . . 0.0 109.355 -179.937 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 1.048 HG21 HD12 ' A' ' 18' ' ' ILE . 21.9 t -134.49 133.87 54.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.117 -0.989 . . . . 0.0 109.871 -179.472 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.672 ' CE1' ' CD2' ' A' ' 30' ' ' PHE . 14.3 t-80 -114.47 151.12 33.75 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.355 -0.841 . . . . 0.0 109.192 179.588 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.677 ' CG ' ' N ' ' A' ' 31' ' ' SER . 0.7 OUTLIER -42.63 -51.5 5.18 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.091 -1.006 . . . . 0.0 109.353 -179.858 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.677 ' N ' ' CG ' ' A' ' 30' ' ' PHE . 86.6 p -53.69 -29.61 39.74 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.178 -0.952 . . . . 0.0 109.925 -179.618 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.596 ' O ' ' HB ' ' A' ' 63' ' ' VAL . . . -64.91 -10.31 27.8 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.107 -0.995 . . . . 0.0 109.217 179.744 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.792 HD13 HD13 ' A' ' 41' ' ' LEU . 0.8 OUTLIER -126.18 132.98 69.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.487 -0.758 . . . . 0.0 109.726 -179.415 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 62.9 tt0 -104.34 133.21 49.61 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.286 -0.884 . . . . 0.0 109.448 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.632 ' CA ' ' CZ ' ' A' ' 38' ' ' PHE . . . -173.54 150.25 11.85 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 -179.871 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 46.3 tp10 -57.67 -54.27 48.77 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.289 -1.124 . . . . 0.0 109.427 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -147.31 26.04 1.55 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.559 -1.417 . . . . 0.0 109.559 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.632 ' CZ ' ' CA ' ' A' ' 35' ' ' GLY . 55.0 p90 -124.87 28.43 6.47 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.301 -1.117 . . . . 0.0 109.432 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.521 ' O ' ' CD1' ' A' ' 41' ' ' LEU . 24.3 mttp -64.55 -31.55 72.81 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.286 -0.884 . . . . 0.0 109.736 -179.82 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 33.0 m -64.63 114.23 4.27 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.177 -0.952 . . . . 0.0 109.516 -179.881 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.917 HD21 HG11 ' A' ' 63' ' ' VAL . 3.5 mp -74.75 155.58 37.49 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.254 -0.904 . . . . 0.0 109.756 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . 0.408 ' HB3' ' HB2' ' A' ' 45' ' ' GLN . 36.6 tt0 -103.92 144.14 31.92 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.285 -0.884 . . . . 0.0 109.319 179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 53.3 tt0 -63.11 130.34 44.23 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.293 -0.88 . . . . 0.0 109.477 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.97 -3.12 85.91 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.614 ' O ' HG23 ' A' ' 6' ' ' VAL . 46.8 tt0 -81.29 128.19 33.54 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.201 -1.176 . . . . 0.0 109.602 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -77.54 140.71 39.78 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.215 -0.928 . . . . 0.0 109.085 179.614 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.68 HG21 ' CD1' ' A' ' 18' ' ' ILE . 32.1 m -142.43 160.78 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.158 -0.964 . . . . 0.0 109.832 -179.825 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.55 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 24.0 t -107.3 152.06 24.64 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 178.827 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.559 ' HB2' ' O ' ' A' ' 61' ' ' ALA . 35.3 p90 174.81 164.16 0.24 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.807 -1.183 . . . . 0.0 110.215 -179.426 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -100.31 172.28 7.25 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.614 HD12 ' OE1' ' A' ' 23' ' ' GLN . 1.0 OUTLIER -111.52 125.46 68.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 120.867 -1.146 . . . . 0.0 109.901 -179.819 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.585 ' CG2' ' HB2' ' A' ' 59' ' ' GLN . 35.7 m -109.16 123.48 65.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 179.138 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.4 mt-10 -91.52 83.75 5.43 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 109.645 -179.533 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.79 -172.06 42.28 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 179.789 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.433 ' O ' ' C ' ' A' ' 56' ' ' ARG . 3.8 t30 -56.73 -63.55 1.16 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.14 -1.212 . . . . 0.0 109.212 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.433 ' C ' ' O ' ' A' ' 55' ' ' ASN . 36.2 mtp180 -42.0 -46.9 4.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.171 -0.955 . . . . 0.0 109.325 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 147.01 -149.33 21.46 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.42 ' HG2' ' O ' ' A' ' 25' ' ' ASP . 46.2 Cg_endo -70.13 125.5 12.02 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.654 2.236 . . . . 0.0 112.128 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.585 ' HB2' ' CG2' ' A' ' 52' ' ' VAL . 33.2 mt-30 -125.56 158.62 34.13 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.335 -0.853 . . . . 0.0 108.875 179.389 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.812 ' CB ' HG22 ' A' ' 28' ' ' VAL . . . -91.47 134.86 34.27 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.019 -1.051 . . . . 0.0 109.767 -179.545 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.559 ' O ' ' HB2' ' A' ' 49' ' ' PHE . . . -122.72 156.37 34.56 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.388 -0.82 . . . . 0.0 108.9 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.473 ' C ' ' O ' ' A' ' 61' ' ' ALA . 82.9 m-20 41.72 66.01 0.77 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.084 -1.01 . . . . 0.0 109.045 -179.727 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.917 HG11 HD21 ' A' ' 41' ' ' LEU . 4.5 t -83.03 125.85 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.234 -0.916 . . . . 0.0 109.93 -179.381 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.423 ' HB ' ' HB3' ' A' ' 48' ' ' SER . 92.4 m -118.35 125.02 49.15 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.53 -0.731 . . . . 0.0 109.211 179.766 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.483 ' NZ ' ' O ' ' A' ' 38' ' ' PHE . 32.4 mttp -65.41 110.5 2.68 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.338 -0.851 . . . . 0.0 109.438 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 73.3 mm-40 -100.67 166.71 10.75 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.283 -0.885 . . . . 0.0 109.504 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 118.001 -1.0 . . . . 0.0 109.452 -179.991 . . . . . . . . 0 0 . 1 stop_ save_